(navigation image)
Home American Libraries | Canadian Libraries | Universal Library | Community Texts | Project Gutenberg | Children's Library | Biodiversity Heritage Library | Additional Collections
Search: Advanced Search
Anonymous User (login or join us)
Upload
See other formats

Full text of "Psychopharmacology abstracts"

U-vC-£X TASLr, 



MOT To pr r. 



■"''SeON(.y""-'S«AW... 



liVi'Xv:- 



'''' ' /H:. 





PSYCHOPHARMACOLOGY ABSTRACTS is a pubUcation of the National Clearinghouse 
for Mental Health Information of the National Institute of Mental Health. It is a 
speciahzed information medium designed to assist the Institute in meeting its obligation 
to foster and support laboratory and clinical research into the nature and causes of 
mental disorders and methods of treatment and prevention. Specifically, this information 
service is designed to meet the needs of investigators in the field of psychopharmacology 
for rapid and comprehensive information about new developments and research results. 
For information or correspondence with the National Institute of Mental Health 
concerning Psychopharmacology Abstracts, changes of address, or removal of names from 
the mailing list see the inside back cover page. 



The Secretary of Health, Education, and Welfare has determined that the publication of 
this periodical is necessary in the transaction of the public business required by law of this 
Department. Use of funds for printing this periodical has been approved by the Director 
of the Office of Management and Budget through December 31 , 1976. 



NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION 
PSYCHOPHARMACOLOGY ABSTRACTS 



Volume 14 



Cumulative Index 



June 1977 



Page 

Author Index Al 

Subject Index SI 



Carrie Lee Rothgeb,£'<izYo/' 

Bette L. Shannon, Managing Editor 



U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE 

Public Health Service 

Alcohol, Drug Abuse and Mental Health Administration 

National Institute of Mental Health 

National Clearinghouse for Mental Health Information 

5600 Fishers Lane 

Rockville, Maryland 20857 



Publication No. (ADM) 78-150 
Printed 1978 



For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 
20402. Subscription price per year in the United States, Canada, and Mexico: $16.90; other 
countries, $21.15. Single copy $3.70. Cumulative Index issue $2.25. The Clearinghouse does not sell 
copies of Psvchopharmacology Abstracts. Persons wishing to subscribe by the year or to purchase smgle 
copies should send their orders, accompanied by check or money order, directly to the Supermtendent 
of Documents. 



AUTHOR INDEX 



I The 6 digit number is the abstract occes 






nbcr The nexf two digits are the issue number, digits after hyphen ore the category number. I 



AADAMSOOA 226900 01-13 
AALBERSJA 236667 02-15 

ABBOTT D 240278 03-17 

ABBRUZZESE G 244589 04-09 

ABOALA EN 240839 03-09 

ABDALLAH AH 238846 03-03, 248284 04-03 

ABE K 22714101-10,239346 03-11 

ABET 227806 01-1) 

ABEL EL 231227 01 17. 234626 02-14, 238766 
03-03 

ABRAMS R 253617 04-09 

ABREU LA 237924 02-03 

ABREU RR 237924 02-03 

ABUZZAHAB FS 239681 03-17, 253048 04-08 

ACETO MD 248009 04-03 

ACHTE KA 244023 04-17 

ACKEJ 237026 02- n 

ACKENHEIL M 240218 03-08, 240219 03-1 1 
240220 03-14 

ACKER/WANN RF 239272 03-04 

ACOSTA-URQUIDI J 239261 03-03 

ADACHI Y 241297 03-03 

ADAM K 239059 03- 1 4, 24 1 753 03- 1 7 

ADAMS AJ 235759 02-14 

ADAMS CBT 230739 01-13 

ADAMS MD 238809 03-03, 243800 04-03 2494 U 
04-03 

ADAMS PM 235564 02-03 

ADAMSON L 239059 03- 1 4, 24 1 753 03- 1 7 

ADDABBO A 244588 04-09 

ADLERJE 238157 02-03 

ADRIANOV OS 236261 02-03 

AEBERLI P 248539 04 02 

AGEEL AM 251989 04-04 

AGHAJANIAN GK 226400 01-03, 227126 01-04 
229431 01-03, 236519 02-03, 239957 03-03 
240073 03-03, 243882 04-03, 244072 04-03' 
246846 04-03, 247211 04-03 

AGID Y 230854 01-03, 249899 04-03 

AGNATI L 229462 01-03, 232507 01-03 248288 
04-03 

AGRANOFF BW 235320 02-04 

AGRUP-ANDERSSON L 226408 01-08 

AGUILAR SJ 227821 01-08 

AGURELL S 246891 04-11 

AHLFORS U 246623 04-09 

AHMAD S 225890 01-15 

AIBA H 245986 04-11 

AITKEN WC 226305 01-04 

AKAMATSU T 227808 01-15, 244779 04-15 

AKERA T 231006 01-03 

AKIYAMA R 241405 03-03 

AKPINAR S 229038 01-07,229473 01-13 241275 
03-10 

ALSHALTCHIB 241759 03-10 

ALARCON RD 252941 04-09 

ALBANO C 244589 04-09 

ALBELDA SM 242743 03-04, 250984 04-04 

ALBERT J 237901 02-13, 245650 04-08 

ALBERT JM 228225 01-08 

ALBERTSON TE 249241 04-06 

ALBRECHT J 251417 04-15 

ALECU C 22635101-13 

ALEKSANDROVA GM 228552 01-03 

ALEKSANDROWICZ JW 230640 0117 

ALEVIZOS PN 228224 01-08 

ALEXANDER KS 238487 02-01 

ALEXANDER PE 238489 02-08 

ALEXIANU D 229118 01-15 

ALFORD GS 252674 04-04 

ALFORD HF 252674 04-04 

ALHAVA E 239043 03-05, 241414 03-03 

ALI B 239662 03-03 

ALIVISATOS SGA 250081 04-03 

ALKANA RL 238748 03-13 

ALKER PC 233377 02-12 

ALLAM M 251004 04-10 

ALLEN D 236529 02-06 

ALLEN GS 243797 04-03 

ALLEN JE 251827 04-14 

ALLEN MD 252656 04-15 

ALLEN RP 247377 04-15 



ALLIKMETS LK 242544 03-03, 244455 04-04 

ALMEIDA MP 236526 02-06 

ALPERN HP 237731 02-04 

ALPERT M 253036 04-15 

ALTAMURA AC 238988 03-11, 249673 04-13 

ALTMANJL 23994103-11 

ALTMAN N 245840 04-13 

ALTSHULER H 237755 02-04, 238787 03-04 

249004 04-06 
ALTURA BM 229474 01-03, 251905 04-03 

253113 04-03 
ALTURA BT 251905 04-03, 2531 13 04-03 
ALVAN G 245653 04-13 
AMADUCCI L 227219 01-07 
AMAMOTO H 229761 01-08 
AMAN MG 247378 04-15 
AMATRUDA TT 226405 01-04 
AMBUEL JP 240538 03-11 
AMDISEN A 236806 02-16 
AMICARELLA-BOYLE R 238771 03-03 
AMICO DJD 239685 03-03 
AMIN M 253057 04-11 
AMIN MM 235356 02-07, 235361 02-09 
ANANTH J 228242 01-11, 230012 01-15, 230780 
01-08, 235358 02-07, 235360 02-07, 235826 
02-10, 237896 02- 10 
ANCONA L 229529 01-14 
ANDEN N 249669 04-04, 249670 04-04 251226 

04-02, 251227 04-02 
ANDERMANN F 226737 01-13 
ANDERSEN H 247875 04-04, 253643 04-04 
ANDERSEN P 232606 02-03 
ANDERSON AD 237920 02-03 
ANDERSON DJ 245596 04-05 
ANDERSON EG 23261 1 02-03 
ANDERSON JAD 252381 04 1 1 
ANDERSON M 249783 04-01 
ANDERSON MH 234826 02- 1 7 
ANDERSON PF 227130 01-04 
ANDERSON TR 243779 04-03, 2531 10 04-03 
ANDERSON WH 242269 03-17 
ANDERSSON BE 250941 04-04 
AN DO F 241381 03-03 
AN DO K 237701 02-04 
ANDRADE NM 253051 04-08 
ANDREW RJ 245712 04-04, 245713 04-04 
ANDREYEVA Nl 236369 02-03 
ANDRY DEK 238159 02-03 
ANGELINI F 246665 04-03 
ANGRIST B 233961 02-13, 237725 02-08 
ANGST J 23199101-15,237992 02-08 238864 

03-08, 251118 04-09 
ANISIMOVVN 241983 03-05 
ANISMAN H 237703 02 04, 237778 02-04 

245486 04-04, 250074 04-04 
ANLEZARK G 228050 01-03, 241934 03-05 
ANNABLE L 228225 01-08, 231037 01 08, 251828 

04-08 
ANNAU Z 238722 03-04 
ANSARI AN 248537 04 01 
ANTELMAN SM 227343 01-03, 229475 01-04 
ANTONACCIO AAJ 231039 01-03 
ANTONIJEVIC S 250943 04-07 
ANUMONYEA 237775 02-10 
ANZIVINO F 244476 04-11 
APPEL JB 230876 01-04, 242750 04-04 
APPLETON WS 247880 04- 1 7 
APRISON MH 241205 03-04, 250067 04-04 
ARAI E 251990 04-04 
ARAKI Y 245597 04-03 
ARCHER RA 249276 04-02 
ARCIOLI I 231367 01-08 
AREFOLOV VA 228551 01-03, 236233 02-03 

236713 02-03, 241982 03-05 
ARENDSEN D 248648 04-02 
ARGENTAG 230827 01-09 
ARGUELLES AE 229369 01-15 
ARGYROPOULOS G 243198 04-1 1 
ARIKAWA K 229026 01-07 
ARISON BH 238684 03-03 
ARNOLD LE 227571 01 11, 238825 03-03, 239932 

03-11 
ARNONE A 231368 01-09 
ARONY AJ 246425 04-09 



ARSENIC 229118 01-15,239089 03-05 
ARUSHANYAN EB 231248 01-04 
ARUSHANYAN Y8 228546 01-03, 231071 01-03 
ARY M 250078 04-03, 2501 14 04-03 
ASBERG M 240216 03-09 
ASHFORD J 241918 03-04, 243758 04-04 
ASHFORD JR 232519 01-14, 232520 01-13 

232521 01-14 
ASHMORE J 238683 03-06 
ASNINA W 236369 02 03 
ASPER H 239862 03-03 
ASSAEL BM 246993 04-13, 246994 04-13 
ASSAF RAE 238531 02-13 
ASSELAAAN P 251239 04-11 
ATANASIO G 230991 01 11 
ATIN J 245612 04-02 
ATKINS HL 248537 04-01 
ATTEWELL PA 240074 03-14 
AUBERT C 237709 02-03, 237710 02-03 
AUTORE A 244476 04 1 1 
AUYONG TK 239662 03-03 
AVADHANI NG 237871 02-03 
AVAKYAN RM 231071 01 03 
AVIS HH 230865 01-04 
AVNI J 247777 04 03 
AXELRAD AD 252006 04-08 
AXELRODJ 234919 02-03,237170 02-03 243795 

04-03 
AXELSSON R 237902 02-13, 238552 02-13 
AXELSSON S 251119 04-08 
AYALA GF 241805 03 03 
AYD FJ 232937 02-17 
AYHAN H 241224 03-04 
AYNSLEY-GREEN A 247715 04-15 
AYVAZOV KG 228546 0103 
AZARNOFF DL 231003 01-03 
AZCARATE CL 246184 04 15 
AZZARO AJ 238700 03-03 

B 

BAG 233815 02-08 

BAAR H 238866 03 11 

BAASTRUP P 236361 02 08, 240217 03-09 
248955 04-10 

BAB Bl N I M 232530 1 07, 237 1 06 02-04, 245602 
04-04, 248959 04-04, 249623 04-02 

BACH D 244725 04-03 

BACK G 252222 04-03 

BADINAND A 245116 04-05 

BADZINSKI S 229439 01-16 

BAEKELAND F 229091 01-11 

BAER R 226777 01-09 

BAEZ LA 250084 04-03 

BAHERSJ 237890 02-03 

BAHRKE G 238320 02-03 

BAILEY J 230742 0115 

BAILEY PT 226943 0104 

BAILEE AM 229906 0116 

BAIN G 238755 03-04, 249271 04-02 

BAIOCCHI L 235367 02-09 

BAK IJ 239834 03 04 

BAKER J 226349 0114 

BAKER M 239058 03-14 

BAKER TO 237717 02-04, 237718 02-04 

BALDESSARINI RJ 226405 01-04, 237244 02-03, 
246150 04 04, 250928 04-17, 251699 04-04 

BALESTRA V 244591 04- 13 

BALLARD JE 253041 04-15 

BALLETTO AJ 238684 03-03 

BALLINGER BR 235545 02-17, 243716 04-15 

BALSTER RL 238794 03-04, 238813 03-04, 250066 
04-04, 251976 04 04 

BAN TA 227820 01 14, 229459 01-11, 230780 
01-08, 230812 01-08, 231034 01-08, 231035 
01-09, 231607 01 17. 235355 02-17. 235356 
02-07, 235357 02-07, 235359 02-07. 235361 
02-09, 235363 02-09. 235369 02-07, 235370 
02-09. 242249 03-09, 253053 04-07, 253054 
04 1 1 , 253055 04 11 , 253059 04- 1 1 
BANERJEE SP 248701 04 03 
BARASI S 241923 03 03 

BAR BEAU A 226932 1 -04, 25 1 648 04 1 1 253695 
04-03 



e 
S 

i 

> 
I 

s 

I 

•e 
2 



A-l 



Author Index 



Psychopharmacology Abstracts 



BARBOUR BH 240843 0315 

BARCHAS JD 238729 03-03, 241902 03-17 

BAREGGI SR 246993 04- 1 3, 246994 04-13 

BARFKNECHT CF 239660 03-01 

BARKAI A 238681 03-03 

BARKER E 245001 04-14 

BARKER JL 226398 0103 

BARKER K 244686 04-11 

BARKER LA 245594 04-04 

BARKER P 245621 04-14 

BARKOV NK 241987 03-03, 244352 04-04 

BARLOW TS 250110 04-03 ' 

BARNES CD 238823 03-03, 239982 03-03 

BARNES SE 245344 04-11 

BARON J 244874 04-03 

BARON M 246629 04-09 

BARR GA 243346 04-04 

BARR M 252825 04-13 

BARRACO RA 239673 03-04 

BARRATT ES 235564 02-03 

BARRETT 249144 04-11 

BARRETT AM 237745 02-04 

BARRETT JE 250111 04-04 

BARRETT RJ 239850 03-04 

BARRY H 230840 01-03, 238756 03-04, 239086 

03-03 
BARRY HI 248283 04-02 
BARRY WU 234711 02-09 
BARTEN H 235628 02-17 
BARTHWAL JP 238712 03-03, 239661 03-03 
BARTLETT JR 241210 03-13 
BARTOLETTI M 232530 01-07, 237106 02-04, 
245602 04-04, 248959 04-04, 249623 04-02 
BARTOLI JF 241350 03-01 
BARTOLOMEJ 253110 04-03 
BARTRAM SF 226763 01-03 
BARZAGHI F 252030 04-04 
BASKER MA 252381 04-11 
BATAILLE M 237015 02-17 
BATTENBERG ELF 236875 02-06 
BATTISTAA 251649 04-07 
BAUDIS P 234420 02-14 

BAUDRY M 226651 01-02 

BAUER RH 228160 01-04 

BAUGHN RL 246286 04-03 

BAUM MJ 244343 04-04 

BAUMANN P 237700 02-03 

BAUMANN PA 251394 04-03 

BAUMEL IP 237758 02-03 

BAUMLER G 240644 03-14 

BAUST W 240260 03 11 

BAYLISS PFC 227210 01-07, 227225 01-09 

BAYLOR MR 238700 03-03 

BEAR ES 237813 02-15 

BEAROSLEY P 227128 01-04 

BEAUBIEN AR 249929 04-05, 250655 04-03 

BEAUMONT G 245468 04-09, 252142 04-17 

BEAUNE P 241350 03-01 

BEAUTRAIS AL 239853 03-14 

BECH P 240055 03-09, 241425 03-15, 243089 
04-13, 249927 04-15 

BECHTEL P 240762 03-11 

BECK L 238727 03-03 

BECKER BA 230007 01-04 

BECKER CE 247089 04-15 

BECKER M 245301 04-04 

BECKER RA 240977 03-11 

BECKETT AH 237980 02-01, 237981 02-02 

BECKNER JS 237753 02-03, 238813 03-04 

BEDA E 244467 04-10 

BEDERKAJP 238696 03-04 

BEECHER MD 251988 04-04 

BEER B 231112 01-17 

BEJ AJ 233361 02-01 

BELEGAUD J 244874 04-03 

BELENDIUK KT 247021 04-03 

BELL JA 238704 03-04 

BELL-MIDURA M 237253 02-11 

BELLAMY G 238683 03-06 

BELLEAU R 229034 01-04 

BELLUZZI JD 232508 01-03 

BELLVILLE JW 226828 01-15, 237734 02-14, 
251825 04-14 

BELMAKER R 239728 03-09 

BELOZERTSEV YA 228546 01-03, 236371 02-04 

BELPAIRE FM 244131 04-13 

BELSEY RE 245806 04-15 

BEMPORADJR 241990 03-15 

BENASSI P 229550 01-11 



BENDER AD 246970 04-13 

BENDER DA 227712 01-03,235629 02-08 

BENESOVA 242732 03-04, 251991 04-04 

BENGTSSON A 226408 01-08 

BENINGTON F 227692 01-03, 230453 01-03 

BENKERT 233684 02-17 

BENNETT EL 237264 02-04 

BENNETT JP 226936 01-12 

BENNIE FH 252653 04-09 

BENOITO 22809101-11 

BENOWITZ NL 247089 04-15, 252327 04-13, 

252825 04-13, 253609 04-13 
BENSEMANA D 233336 02-03 
BENSON R 23161101-09 
BENTLEY RG 252520 04-05 
BENZI G 247012 04-03 
BEREGI L 237118 02-03 
BERESEWICZM 236429 02-10 
BERGANDE F 241232 03-03 
BERGER FM 245646 04-09 
BERGER PA 250417 04-13 
BERGERT BJ 2371 55 02-03 
BERGEY B 227826 01-09 
BERGAAANN F 239860 03-04 
BERGNER PE 245842 04-08 
BERGOFSKY EH 251820 04-03 
BERGONZI P 229557 01-14 
BERL S 237140 02-03 
BERLIN A 246891 04-11 
BERNARD BK 250068 04-02 
BERNARD P 249304 04-03 
BERNARDO DL 244701 04-15 

BERNASCONI S 237240 02-03, 237742 02-03, 
237743 02-03, 241235 03-03 

BERNER P 244043 04-03 

BERNHEIM-CHALTELAIN C 240657 03-1 1 

BERRY DG 230862 01-03 

BERTEAU P 242898 04-11 

BERTILSSON L 226430 01-07, 232325 01-03, 
237863 02-03, 241253 03-03, 245653 04-13 

BERTOLINO A 229551 01-11, 252220 04-03 

BERTOLLINI A 246665 04-03 

BERTONCELLI R 244476 04-1 1 

BERTRAND M 245650 04-08 

BESSON JM 232328 01-03 

8ESS0N M 241247 03-03, 252217 04-03 

BESZTERCZY A 235358 02-07 

BEVAN P 251705 04-03 

BEYEL V 233829 02-08 

BHAGAVAN HN 232639 02-04 

BHARGAVA HN 250079 04-04 

BHATNAGAR RK 238826 03-03, 248408 04-03 

BHATNAGAR SP 238484 02-06 

BHATTACHARYA P 241343 03-03 

BIAMINOG 231317 01-15 

BIANCHETTI A 237834 02-02 

BIANCHI L 246148 04-04 

BIANCHI S 248410 04-03 

BIASCI G 230993 01-11 

BIBLE HH 250984 04-04 

BICKEL MH 230820 01-15, 247129 04-03 

BICKFORD RG 238507 02-14 

BIEL JH 233946 02-01 

BIERNER R 225932 01-08, 229446 01-08 

BIGELOWA 227826 01-09 

BIGELOW G 240831 03-14 

BIGELOW LB 233817 02-08 

BIGGINS JG 247209 04-04 

BIGGS JT 231318 01-13, 238486 02-16, 253314 
04-09 

BIGLER ED 231719 01-03, 239858 03-03 

BILLEWICZ-STANKIEWICZ J 227635 01-03 

BILLINGS RE 238683 03-06 

BINITIE A 237730 02-15 

BIRCH H 225932 01-08, 238748 03-13 

BIRCH NJ 250725 04-13 

BIRKAMYER W 23391 7 02-1 1 

BIRKETT DJ 226829 01-13 

BISCHEL MD 240843 03-15 

BISOGNI A 23099101-11 

BISSETTE G 232618 02-03 

BITHELL V 226871 01-03 

BIXLER EO 245652 04-11,252230 04-11 

BJARNASON DF 232865 02-15 

BLACK IB 226935 01-03 

BLACKMAN DE 226852 01-04, 226854 01-04, 
246306 04-04, 250070 04-04, 251670 04-04 

BLACKMAN JG 232333 01-03 

BLACKWELL B 248976 04-08, 252991 04-17 



SLAIN S 237728 02 04 

BLAKIS M 239943 03-15 

BLASBERG RG 231002 01-03 

BLASIG J 239854 03-03, 24 1 223 03-04, 25 1 400 

04-03 
BLATCHLEY RJ 226902 01-16 
BLAUSTEIN MP 237751 02-03 
BLAZER DG 225873 01-15 
BLEULERM 251118 04-09 
BLEVINS RD 251420 04-13 
BLOOM AS 238769 03-03 
BLOOM F 229318 01-03, 232512 01-03 
BLOOM FE 236875 02-06, 238471 02-03, 243183 

04-17, 252012 04-03 
BLOOM W 247483 04-08 
BLOSSER J 249484 04-03 
BLUM K 238789 03-03 
BLUMBERG H 249269 04-04 
BLUMER D 245863 04-08 
BLUNDELL JE 250938 04-03, 253315 04-11 
BOAL D 233974 02-1 1, 251649 04-07 
BOARETTI AC 228241 01-11 
BOSON DP 227769 01-17, 250266 04-1 7 
BODNAR RJ 239272 03-04 
BODOG G 244355 04-15 
BOECKLER W 238846 03-03, 248284 04-03 
BOEGMAN RJ 253407 04-03 
BOERNER U 247089 04-15 
BOGAERT MG 237160 02-03, 244131 04-13 
BOGDANOWICZ E 234046 02-09, 234047 02-1 1 
SOGLIOLO C 229552 01-17 
BOHN E 238320 02-03 
BOIARDI A 246992 04-13 
BOILEAU R 253041 04-15 
BOISSIER JR 227207 01-06, 237708 02-04, 
249677 04-04, 249678 04-04, 251216 04-04, 
251217 04-03, 252032 04-04 
BOISSL KW 242503 03-08 
BOJDECKI K 234047 02-11 
BOKSAY IJE 251407 04-17 
BOLLA K 252444 04-1 7, 252446 04-14, 252448 

04-07, 252450 04-11 
BOLLER F 233295 02-14 
BOLME P 229462 01-03, 232507 01-03 
BOND NW 226852 01-04 
BONESE K 250066 04-04 
BONFIGLI L 229553 01-17 
BONFITTO M 230860 01-03 
BONKOWSKI L 244199 04-03 
BONTA IL 245599 04-03 
BORALESSA H 250932 04-07 
BORBELY AA 246388 04-04 
BORGAONKAR D 248222 04-10 
BORGMAN RJ 246150 04-04, 251699 04-04 
BORISON HL 232333 01-03 
BORISON R 249309 04-03, 249310 04-03 
BORISON RL 238077 02-03, 238820 03-03, 

238841 03-03, 248162 04-01, 249311 04-03 
BORROMEI A 239700 03-11 
BORZELLECAJF 238815 03-03 
BOS ERH 235630 02-09 
BOS IN TR 243798 04-03 
BOSSLE PC 248538 04-02 
BOSSONI G 237834 02-02 
BOSZORMENYI Z 252447 04-10 
BOTHWELL S 238981 03-10 
BOTTER PA 229370 01-11 
BOTWINICK CY 245614 04-02 
BOUDENE C 244874 04-03 
BOUDIER HS 238321 02-03 
BOULANGER M 237118 02-03, 237119 02-03 
BOULAYM 244638 04-03 
BOULLIN DJ 230739 01-13 
SOU LOS BM 238745 03-03 
BOULTON AA 250379 04-03 
BOURDOIS PS 227391 01-05 
BOURGOIN S 247213 04-03, 249512 04-03 
BOUSQUET WF 226865 01-03 
BOUVIERJ 242898 04-11 
BOWER BD 245344 04-11 
BOWERS MB 230010 01-11,240076 03-12 
BOWMAN FJ 238769 03-03 
BOWAMN RE 228139 01-04 
BOYD EH 244693 04-03 
BOYD ES 244693 04-03 
BOYKO SS 228547 01-04 
BOYNOVA II 236714 02-04 
BRACKBILL RM 241521 03-04 
BRACS P 230856 01-03 



A-2 



VOLUME 14, AUTHOR INDEX 



Author Index 



BRADEN DH 227746 01-09 

BRADFORD HF 241206 0303 

BRADSHAW CM 251 705 04-03 

BRADY JV 227137 01 04, 240014 03-04 

BRAESTRUP C 247875 04-04, 250361 04-04, 
253643 0404 

BRAGAJC 241870 03-17 

BRAHEN LS 244298 04-11 

BRALET J 243777 0403 

BRAMBILLA F 230839 01-08 

BRANCH MN 245303 04-04 

BRANCHEY MH 237696 0214. 244501 04-08 

BRANCONNIER RJ 226478 01 -1 1 

BRANDES D 247032 04-03 

BRANDMAN ES 241133 03-14 

BRANISTEANU DD 226855 01-03 

ERASE DA 237891 02-03, 241245 03-04, 249316 
04-03, 253112 04-04 

BRASSEUR R 240032 03-09 

BRAUDE MC 235671 02-05, 238807 03-05, 
243181 04-04, 249267 04-04, 249268 04-03 
249270 04-04, 249290 04-03 

BREBBIAAF 237696 02-14 

BREBBIA DR 237696 0214 

BREESE GR 230841 01-03, 232609 02-04, 232618 
02-03, 233970 02-03, 246149 04-03, 2501 10 
04-03 

BREMKAMP H 230866 01-16 

BRESSLER R 238715 03-03 

BREZENOFF HE 241346 03-03 

BRIANT RH 238316 02-03 

BRIDGER WH 234811 02-12, 237732 02-04 

BRIDGERS WF 229476 01-03 

BRIDGES PK 241210 03-13 

BRIESCH ST 243878 04-04 

BRIGGS AH 238789 03-03 

BRIGGS FN 237245 02-03 

BRINKMANN R 244896 04-14 

BRION S 227217 01-09 

BRIZZEE KR 239832 03-03 

BROCCO MJ 238694 0304, 249268 04-03 
249270 04-04, 249290 04-03 

BROCHIER F 240166 03-11, 242899 04-11 

BRODIE NH 247030 04-11 

BRODY TM 230919 01-03, 231006 01-03 

BROEKKAMP CL 252033 04-03 

BROMHAM BM 238975 03-08 

BRONAUGH RL 238758 03-03, 247212 04-03 
249232 04-15 

BROOKS DC 237780 02-04 

BROOKSHIRE KH 241521 03-04 

BROPHY PD 227106 01-04 

BROSNAN RD 251003 04-15 

BROWN AL 250414 04-11 

BROWN B 235759 02-14 

BROWN CP 251982 04-04 

BROWN CR 232622 02-14 

BROWN EC 225869 01-17 

BROWN JE 238720 03-04 

BROWN JGE 227550 0111 

BROWN LE 244693 04-03 

BROWN PJ 232622 02-14 

BROWN TCK 243064 04-15 

BROWN WT 251712 04-15 

BROWNE RC 238843 03-04 

BROWNE RG 241573 03-03 

BRUCK J 233718 02-15 

BRUCKNER S 232503 01-13 

BRUDZYNSKI S 232483 01-04 

BRUGMANS M 244685 04-04 

BRUMBACK RA 233499 02-15 

BRUNSWICK DJ 238775 03-01 

BRUSCHI WC 246123 04 17 

BRUYNOOGHE F 229128 01-14 

BUCHSBAUM M 244664 04-09, 246629 04-09 

BUCKINGHAM RL 231009 01-03 

BUCKLEY JP 229477 01-04, 238810 03-03 

246967 04-04 
BUCZKO W 250936 04-03 
BUDA M 232624 02 03 
BUDAI Z 231008 01-03 
BUDDEBERG C 238855 0315 
BUEGEL D 236663 02-10 
BUEHLER JD 250332 04-06 
BUENO OFA 251977 04-04 
BUNKER P 249671 04 04 
BUNNEY BS 229431 01-03, 236519 02-03, 243882 

04-03, 247211 04-03 
CUNNEY WE 227785 01-09, 243440 04-03 



BURCH LS 23551 1 02-04 

BURCHFIEL JL 249983 04-03 

BURCKHARDT WA 253137 04-13 

BURDOCK GA 227389 01-03 

BURES J 239861 03-04 

BURESOVA 239861 03-04 

SURGE KG 227074 01-04, 239284 03-04 

BURGEL P 251409 04-04 

BURGISON RM 238737 03-03 

BURKED 226960 01-11 

BURKI HR 239862 03-03, 246671 04-03, 250360 

04-02 
BURKS CD 233448 02-04 
BURNETT GB 231609 01-08 
BURNS RS 247147 04-15 
BUROW J 243234 04-04 
BURRELL CD 239679 03-17 
BURROWS GD 250491 0410 
BURSUCK L 237102 02-14 
BURT DR 240077 03-03, 243483 04-03, 247862 

04-03 
BURTON MJ 242748 04-04 
BURY J 246126 04-17 
BUSBY AM 251003 04-15 
BUSCH H 242751 04-17 
BUSH HD 250019 04-04 
BUSH MAF 250019 04-04 
BUSHING JA 246851 04-03 
BUSHNELL PJ 228139 01-04 
BUSSONE G 246992 04-13 
BUSTOS G 251178 04-03 
BUTTAR HS 238710 03-03 
BUTTER HJ 245012 04-14 
BUTTERICK JR 242003 0301 
BUTTERWORTH RF 253695 04-03 
BUTTERY JE 241777 03-16 
BUXBAUM DM 249249 04-03 
BYMASTER FP 238840 03-03, 246848 04-03 
BYRD LD 246854 04-02 



CACCAMO LP 24 1 357 03- 1 5 

CACCIA MR 246992 04-13, 246995 04-1 1 

CACCIA S 238322 02-03 

CADEJFJ 227413 01-09 

CAFFEY E 225718 01-09, 227731 01-17, 236359 

02-08, 252954 04-09 
CAGOSSI M 229529 01-14 
CAILLE G 237901 02-13 
CAIN DP 232905 02-03 
CALDERINI G 237740 02-03, 246993 04-13, 

246994 04-13 
CALDWELL J 250723 04-03 
CALLAHAN EJ 228224 01-08 
CALNE DB 239685 03-03, 245647 04-13, 246699 

04-15 
CALVO JM 238503 02-03 
CAMACHO JG 238349 02-03 
CAMBRIA E 246694 04-11 
CAMERON OG 242750 04-04 
CAMMELLI E 245595 04-03 
CAMPAILLAG 229553 01-17 
CAMPBELL AB 233968 02-04 
CAMPBELL C 250944 04-11 
CAMPBELL M 228224 01-08, 229921 01-1 1, 

247386 04-17, 247480 04-08 
CAMPBELL P 235360 02-07 
CANALE D 246694 04-11 
CANDY JM 241930 03-03 
CANNON E 244195 04-12, 252519 04-03 
CANNON JG 241313 03-03 
CANOJP 229906 01-16 
CANTER JW 235286 02-15 
CANTOR A 252174 04-03 
CANTWELL DP 247385 04-17 
CAPONE T 244298 04-11 
CAPPELL H 233488 02-14 
CARABALLO F 232613 02-03 
CARCHMAN R 238808 03-03, 238816 03-03 
CARDER B 241243 03-04 
CARDO B 237103 02-04, 248964 04-04, 250982 

04-04 
CARENZI A 226851 01-03, 237156 02-04, 244514 

04-03 
CAREY RJ 237777 02-03 
CARINO MA 236524 02-04, 238695 03-03, 

249280 04-04 
CARL J L 230834 01-03 



CARLINI EA 251977 04-04, 251981 04-04 

CARLSON RH 239863 03-04 

CARLSSON A 244037 04-17, 251374 04-08 

CARMEN J S 227785 01-09 

CARMICHAEL FJ 246850 04-03 

CARMONA A 244691 04-03 

CARNASCIALI E 235988 02-15 

CARNEVALE A 24891 5 04-05 

CARNEY JM 249246 04-04 

CARNEY MWP 22771 1 01-1 1, 240663 03-08 

CARNEY PA 249246 04-04 

CAROL M 252209 04-04 

CARPENTER DC 249929 04-05 

CARPENTER DO 235588 02-03 

CARPENTER JA 232517 01-17, 232518 01-14, 

232521 01-14 
CARRARA S 229554 01-16 
CARRUBA MO 240643 03-03, 252030 04-04, 

252201 04-03 
CARRUTHERS M 25116104-10 
CARSON VG 249298 04-03, 251 181 04-03 
CARTER DA 244676 04-04 
CARTER EA 251179 04-03 
CARTER SB 245233 04-13 
CASATI C 230827 01-09 
CASEY DE 227570 01-11 
CASH RJ 230835 01-03 
CASSANO GB 229554 01-16, 253393 04-03 
CASTAGNOLI N 236520 02-03, 249234 04-05 
CASTROGIOVANNI P 229554 01-16 
CATAGNI CF 229552 01-17 
CATALANOA 229550 01-11 
CATANIA AC 240016 03-04 
CATRAVAS G 249484 04-03 
CAT RAVAS J D 227389 1 -03 
CAU SA P 232502 1 -03, 232528 1 -02 
CAUTHEN SE 251180 04-01 
CAVALIERI R 233295 02-14 
CAVERO I 240064 03-03 
CERRETA KV 238763 03-03, 249297 04-03 
CESPUGLIO R 238503 02-03 
CHABOTM 231037 01-08 
CHADWICK D 230855 01 03, 237977 02-13 
CHAIMOVITZ M 239860 03-04 
CHAIT LD 238794 03-04, 243800 04-03, 249418 

04-03 
CHAKRABARTY I 241343 03-03 
CHALHUB E 251654 04-15 
CHAMBERLAIN JH 237718 02-04 
CHAMBERS WR 23727102 14 
CHAN AWK 249261 04-04 
CHAN TL 229445 0108 
CHANCE MRA 225569 01-04, 237715 02-04, 

246310 04-04 
CHANDRA B 231654 01-11 
CHANDRA 246672 04-08 
CHANG BL 233276 02-01 
CHANG C 251698 04-01 
CHANG CC 248409 04-03 
CHANG H 228068 01-08 
CHANG K 253693 04-03 
CHANG KJ 227400 01-03 
CHANGS 238486 02-16 
CHANG SS 231318 01-13 
CHAPEL JL 229037 01-11 
CHAPAAAN CR 238687 03 04 
CHARETTE R 228225 01-08 
CHARUVASTRA CV 239943 03- 1 5 
CHASE R 239261 03-03 
CHASE TN 233975 02-11, 250942 04-11 
CHASIN M 229464 01-03 
CHAUDHURY PC 235348 0209 
CHEMBURKAR PB 250332 04-06 
CHEN C 226532 01-04 
CHEN HT 243951 04-03 
CHEN PC 241378 03-04 
CHEN PO 231316 01-04 
CHENEY DL 241252 03-03, 244514 04 03, 247146 

04-03, 248700 04-03 
CHENG HC 248408 04-03 
CHENG RS 241243 03-04 
CHENOWETH MB 239979 03-04 
CHENPANICH K 239646 03 14 
CHERANYA 244636 04-06 
GHERKIN A 237260 02-04, 239852 03-04 
CHERMAT R 237708 02-04, 251217 04-03 
CHERNOBROVKINA TV 236717 02-03 
CHESAREK W 250078 04-03 



A-3 



Author Index 



Psychopharmacoiogy Abstracts 



CHESHER GB 226764 01 04, 227130 01-04, 

230856 01-03, 239859 0303, 244894 04-04, 

251561 04-13 
CHESSA P 244690 04-04 
CHETANASILPIN P 239646 03-14 
CHIAN CY 226944 01-05 
CHIAPPA KH 236667 02-15 
CHICHKANOV GG 228553 01-03 
CHIEL HJ 238726 03-03 
CHIEN C 252006 04-08 
CHIN L 238706 03-04, 251989 04-04 
CHIOU WL 253693 04-03 
CHIRSTENSEN DE 232807 02-11 
CHITTO G 248291 04-03 
CHIU E 250491 04-10 
CHIU P 231010 01-03 
CHIUEH CC 237154 02-03 
CHLOPOCKA-WGZNIAK AA 243985 04-09 
CHMELAR M 234430 02 13 
CHO AK 229478 0103, 238682 03-03, 246316 

04-03, 248637 04-01, 251181 04-03 
CHODERA A 240237 03-04 
CHOMA P 238845 03-04 
CHOPRA Y 245593 04-05 
CHOTTARD JC 241350 03-01 
CHOU DDT 238702 03-03 
CHOU SN 243797 04-03 
CHOUDHURY PC 231603 0110 
CHOUINARD G 228225 01-08, 231037 01-08, 

251828 04-08 
CHRISTENSEN JA 245296 04-03 
CHRISTENSEN JM 250657 04 13 
CHRISTENSEN S 239046 0305 
CHRISTIAN ST 227692 01-03 
CHRISTIANSEN J 243089 04-13 
CHRISTODOULIDES H 245967 04-08 
CHRISTOFFERSEN T 239044 03-03 

CHRITENSEN S 239041 03-05 

CHRUSCIEL L 229043 01-17 

CHRUSCIEL M 2291120117 

CHRUSCIEL TL 229112 0117 

CHUANG HL 240937 03-02 

CHUN AHC 246968 04-03, 246969 04-17 

CHUNG H 240933 0303 

CHURCH AC 244680 04-04 

CIACCIO El 243793 04-03 

CIARAMITARO DA 238773 03-03 

CICERO TJ 226848 01-05 

CIUREZU T 236794 02-11 

CLAEYS M 237274 02-16 

CLARE A 235429 02 08 

CLARE RA 243085 04-15 

CLARK EL 245649 04-11 

CLARKE 229639 01-04 

CLARK EC 229479 01-04 

CLARK JA 249675 04-03 

CLARK ML 229441 01-16, 229444 01-08, 251777 
04-06, 251778 04-16 

CLARK MSG 249675 04-03 

CLARK R 249459 04-03 

CLARK RE 235356 02-07, 235357 0207 

CLARK S 226903 01-14 

CLAVERIA LE 246699 04-15 

CLAY MM 249278 04-04 

CLAY PM 249536 04-16 

CLEARY PA 237726 02-08 

CLEMENT-CORMIER YC 230600 01 03, 230602 
01-13 

CLEREJ 229083 011! 

CLEVENGERJW 232623 02-13 

CLIMAN M 227820 0114,231034 01-08 

CLINESCHMIDT BV 24491104-04 

CLODY DE 248600 04-03 

CLOUGH JM 241256 0303 

CLOW DJ 251103 04-11 

CLYNE KE 253154 04-15 

COBBY JM 232519 0114,232520 01-13 

COCCHI R 235998 02-10, 239615 03-09 

COCCHIA MA 243865 04 03 

COHEN G 248603 04-03, 248699 04-03 

COHEN HB 238748 03 13 

COHEN MN 248593 0411 

COHEN Y 230450 01-03 

COHN M 238792 03-03, 247514 04-03, 248276 
04-03, 252221 04-03 

COHN ML 227386 01-04, 238792 03-03, 247514 
04-03, 248276 04-03, 252221 04-03 

COLASANTI B 227701 01 03, 230836 01-04, 
230880 01 04 



COLDWELL BB 231007 01 03, 250655 04-03 

COLE AP 230424 01-15 

COLE HF 238735 03-03 

COLE JO 226478 01-11, 230863 01-14, 236307 

02-08, 251830 04-13, 253037 04-15 
COLE SO 244679 04-04, 248394 04-04 
COLEMAN JH 225869 01-17, 246187 04-15 
COLEMAN M 239936 03-13 
COLLARD J 227764 01-06,244433 04-17 
COLLET A 242898 04-11 
COLLICE M 246993 04-13, 246994 04-13 
COLLIER B 248724 04-03 
COLLIER TJ 238757 03-04 
COLLIGNON P 244450 04-1 1, 244451 04-1 1 
COLLINS AC 237731 02-04, 241225 03-04 
COLLINS P 251719 04-07 
COLLINS PJ 247480 04-08 
COLLU R 248275 04-05, 253700 04-03 
COLNER G 239932 03-1! 
COLONNA F 231367 01-08 
COLPAERT EC 237744 02-04, 241228 03-04, 
250355 04-03, 250656 04-03, 251429 04-03, 
253394 04-04 
COMBS DT 247148 04-15 
COMBS LW 232623 02-13 
COMMITTEE ON DRUGS AAP 24581 1 04-15 
CONCHA I 251178 04-03 
CONFORTO C 239641 03-11 
CONNER JT 237734 02-14 
CONNERS CK 247375 04-11, 247379 04-14 
CONNOR JD 239961 03-03 
CONSEILLER C 232328 01-03 
CONSOLO S 232510 01-03, 248291 04-03, 248410 

04-03 
CONSROE PF 244071 04-12 
CONSTANT J 229078 01-16 
CONSTANTINESCU E 252711 04-03 
CONSTANTINIDIS J 226915 01-09 
CONWAY AC 238837 03-03 
CONWAY JL 249983 04-03 
COOKJD 231004 01-03 
COOK L 229461 01-04, 232509 01-04, 238697 

03-04 
COOK RB 238476 02-01 
COOLS A 238321 02-03 
COOLS AR 237104 02-03, 237270 02-06, 237786 

02-03, 244215 04-04, 252033 04-03 
COOMBESJ 252859 04-17 
COOMBES S 252859 04-17 
COONS EE 250278 04-03 
COOPER B 23084! 01-03 
COOPER BR 232609 02-04, 233970 02-03, 246149 

04-03, 250110 04-03 
COOPER J K 238484 02-06 
COOPER SF 237901 02-13, 245650 04-08 
COOPER TB 229438 01-16, 236529 02-06, 245842 

04-08, 247208 04-03 
COPER H 234316 02-03, 237109 02-04, 241242 

03-03, 24896! 04-03 
COPPEN A 226187 01-!0, 230742 01-15, 237994 

02-10 
CORBETT L 246186 04-08 
CORCIA RM 230838 01-04 
CORCORAN ME 230475 01-03, 230478 01-03 
CORKEY RF 237242 02-03 
CORRADO R 247147 04-15 
CORSICO R 237102 02-14 
CORSINI GU 237733 02-1! 
CORSON EO 238825 03-03 
CORSON SA 238825 03-03 
CORYELL MR 237871 02-03 
COSCIA L 232502 01-03,232528 01-02 
COSCINA DV 228142 01-04 
COSGROVE KA 249299 04-03 
COSSIDENTE A 229552 01-17 
COSTA D 242863 04-15 

COSTA E 226185 01-04, 226851 01-03, 226857 
01-03, 226961 01-17, 229463 01-03, 229466 
01-03, 232325 01-03, 232506 01-03, 232513 
01-03, 232514 01-03, 232921 02-03, 236674 
02-03, 237156 02-04, 237172 02-03, 239977 
03-03, 240699 03-03, 241252 03-03, 243041 
04-03, 244514 04-03, 248698 04-05, 248700 
04-03, 250362 04-03 
COSTA J L 22673 1 01-13, 244202 04-04 
COSTALL B 227133 0103, 227135 01-04, 23778! 
02-03, 238319 02-04, 239964 03-04, 240063 
03-03, 248290 04-06, 248407 04-04, 250358 
0404, 25203! 04-03 



COSTELLO CE 247090 04-15 

COSTENTIN J 227996 01-03 

COTE G 229033 01-03 

COTE M 251829 04-08 

COTTJM 250110 04-03 

COTZIAS GC 237253 02-11 

COUCH JR 237138 02-11 

COUGHENOUR LL 238842 03-04 

COULSON GE 236708 02-04 

COURSIN DB 232639 02-04 

COVI L 229449 01-09, 252941 04-09 

COVINGTON J S 234114 02-11 

COWAN A 237100 02-03, 250354 04-04 

COWARD JK 251698 04-01 

COX B 250078 04-03, 250082 04-03, 2501 14 

04-03 
COX CM 238718 03-04 
COXJR 229368 01-11 
COX R 226729 01-04 
COX RD 227703 01-04, 250089 04-04 
COX RH 247729 04-02 
COX VC 239290 03-04 
COY DH 248349 04-03 
COYLE I 237721 02-05, 242744 03-17 
CRADDOCK D 243869 04-1 1 
CRAIG CR 230836 01-04 
CRAIG JC 229442 01-16 
CRAIGMILL AL 249263 04-03 
CRAMER H 240447 03-03, 243023 04-09 
CRAMER MB 238477 02-02 
CRANE AM 245594 04-04 
CRANE G 247209 04-04 
CRAVEN C 231010 01-03 
CRAVISO GL 238686 03-03 
CREESE I 229434 01-03, 240077 03-03, 243483 
04-03, 247862 04-03, 248703 04-03, 250088 
04-03 
CREVELING CR 238798 03-03 
CRISP AH 240423 03-11 
CRISWELL HE 250062 04-04 
CRONHOLM B 239002 03-09 
CROOK TH 250726 04-11 
CROSSET P 247683 04-04, 247730 04-03 
CROSSLAND J 245596 04-05 
CROW TJ 239841 03-04 
CROWDERMK 234713 02-15 
CROWLEY WR 238822 03-03 
CSILLAGM 252450 04-11 
CUATRECASAS P 229436 1 -03 
CUBEDDU XL 246844 04-03 
CUCULIC Z 237828 02-08 
CUDILLO CA 24431 1 04-04, 250012 04-04 
CULLINAN T 237141 02-14 
CULVER B 247207 04-04 
CUMMINS JT 236522 02-03 
CUNNINGHAM RF 249243 04-03 
CUNNINGHAM WL 227385 01-04 
CURRY SH 237750 02-06 
CURTIS DR 241921 03-03 
CURZON G 239959 03-03, 241210 03-13, 241925 

03-03 
CUSHMAN P 229039 01-15, 243088 04-15 
CUTHBERT MF 245233 04-13 
CUTIS DR 243762 04-03 
CUTLER MG 225569 01-04, 237715 02-04, 237727 

02-04, 246310 04-04 
CYGAN D 237778 02-04 



DAMATOMR 230577 01-04 

DELIA G 226410 01-10 

DAFNY N 246145 04-03 

DAHL KE 238347 02-04 

DAHL SG 250422 04-07 

DAHLSTROM A 249669 04-04 

DALEVA L 240205 03-05 

DALLY P 249537 04-16 

DALTON R 252381 04-1 1 

DALTON WS 243087 04-14, 245648 04-14 

DALY J 238798 03-03 

DALY JW 240242 03-03, 253109 04-03 

DALZELL HC 248651 04-02, 248652 0402 

DAMAMME P 242898 04-1 1 

DAMASSA DA 238800 03-04 

DAMICO DJ 237729 02-04 

DANA N 247683 04-04 

DANDIYA PC 245593 04-05 

DANIELL JR 233448 02-04 



A-4 



VOLUME 14, AUTHOR INDEX 

DANIELS JD 226397 01-03 
DANIELS S 226869 01-03 

DANKE F 238862 03-15 

DANKOVA JB 249317 04-05 

DAROEN J 249293 04-03 

DARKEN RA 244113 04-15 

DARLEY CF 230871 01-14 

DARLING M 243085 04-15 

DARNOWSKI RJ 239659 03-01 

DARVAS F 231008 01-03 

DASBERG H 241427 03-10 

OAUL CB 249003 04-05 

DAVANZO JP 244685 04-04 

DAVENPORT JW 228143 01-04 

DAVID J 248649 04-02 

DAVID 251572 04-11 

DAVID R 247480 04-08 

DAVIDSON DL 250944 04-11 

DAVIDSON J 232838 02-17 

DAVIDSON JM 238800 03-04 

DAVIES B 230118 01-17 

DAVIES OS 243085 04-15 

DAVILA D 237739 02-03 

DAVILA T 237739 02-03 

DAVIS DP 238476 02-01 

DAVIS HP 250060 04-14 

DAVIS J 230816 0109 

DAVIS JE 228750 01-11 

DAVIS JM 229440 01-14, 232616 02-04 232827 
02-08, 233967 02-08, 235803 02-08, 236303 
02-17, 236751 02-08, 238696 03-04, 239678 
03-17, 239933 03-08, 252847 04-08, 253018 
04-08 

DAVIS KL 250417 04-13 

DAVIS M 227126 01-04, 240062 03-04, 241754 
03-17 

DAVIS VE 243778 04-03 

DAVIS WM 226766 01-03, 227389 01-03, 230825 
01-04, 250021 0404, 250658 04-04 

DAVISON MA 239963 03-03 

DAW NW 236863 02-03 

DAY T 247206 04-04 

DE ALMEIDA LUIZ AMC 228241 01-1 1 

DEANGELISL 226827 01-03 

DE BELLEROCHE JS 241206 03-03 

DE BELLIS AM 245595 04-03 

DE BERNARDI M 244453 04-15 

DE BOER B 2387 1 2 03-03, 239662 03-03 

DE BUCK R 227771 01-08, 237025 02-10 

DE CAROLIS AS 237707 02-04, 247485 04-04 

DE CROUSAZ G 240762 03-11 

DE GAETANO G 237240 02-03 

DE JONG W 246673 04-03 

DE JONGHE F 252760 04-09 

DE LA VEGA CE 230743 01-11, 239305 03- 1 3 

DE LISIO G 241234 03-13 

DE MAIO D 229555 01-17 

DE MARCHI F 232530 01-07 

DE MOL J 240033 03-11 

DE SOUSA A 235348 02-09 

DE VERA H 243793 04-03 

DE WIED D 239851 03-03, 246853 04-04 

DEBUS G 233683 02-17 

DECKARD BS 241687 0304 

OECSI L 239275 03-04 

DEEN HG 238743 03-03 

DEFEUDIS FV 238349 02-03, 249672 04-04 

DEFEUDIS PA 249672 04-04 

DEGANI N 250779 04-11 

OEGENHARDT T 234289 02-11 

DEHAVEN RN 249074 04-03 

DEKABAN AS 233832 02-13 

DEKIRMENJIAN H 229440 01-14 

DEL CASTILLO J 249783 04-01 

DELPRIOREM 231368 01-09 

DELINI-STULA A 251225 04-03, 251397 04-03 

DELL H 237120 02-05 

DELLA BELLA D 230860 01-03 

DELLARIA S 249765 04-17 

DEILUNTO A 244588 04-09 

DELONG FL 238085 02-14 

DELORENZO RJ 240746 03-03 

DEMEL I 229044 01-11 

DEMETRESCUM 238830 03-03 

DEMETRIADES J 238684 03-03 

OEMIRJIAN C 231304 01-03 

DEMOULIN A 248224 04-13 

DENCKERH 2522310413 



DENCKER SJ 243089 04-13, 246623 04-09 

252231 04-13 
DENCKLAMB 241990 03-15 
DENIKER P 247554 04-09 
DENNEY D 227570 01-11 
DEONNA T 240762 03-11 
DERKERVORKIAN K 253058 04-1 1 
DEROGATIS LR 244063 04-17 
DEROSA ER 232781 0208 
DESMEDT LKC 225571 01-04 
DESOUSAA 231603 01-10 
DETTBARN WD 249295 04-03 
DEUPREE JD 239962 03-03 
DEUTSCH M 235365 02-08, 235366 02-08 
DEVIC M 237096 02-11 
DEVIVO DC 251654 04-15 
OEWEER B 241330 03-04 

DEWEY WL 237753 02-03, 238765 03-03, 238769 
03-03, 238815 03-03, 246852 04-04, 251534 
04-03 
DEWS PB 229429 01-06, 2501 12 04-04 
Dl MASCIO A 244701 04-15 
Dl REDA L 252220 04-03 
DIAL EJ 249278 04-04 
DIAMOND Bl 238725 03-03, 240474 03-03, 

249257 04-03, 249258 04-03 
DIAMOND F 253036 04-15 
DIAZ PM 238753 03-03 
D I C K P 24 1 760 03-08, 24 1 763 03- 1 5, 24 1 765 

03-15, 247711 04-09 
DICK WC 252137 04-17 
DICKINSON WA 238006 02-04 
DIEHL LW 232260 01-15 
DIETZ DD 227387 01-03 
DIEZ JA 239581 03-03 
DILL RE 251143 04-04 
DIL/WAN VM 241983 03-05 
DIMICCO J 237758 02-03 
DINGELL JV 249245 04-03, 249284 04-03 
DINKELKAMP T 237992 02-08 
DINNENDAHL V 241246 03-03, 246389 04-03 

251416 04-03, 251432 04-03 
DINOVO E 229446 01-08, 251776 04-16 
DIONNE R 237758 02-03 
DIPOJONO B 239269 03-1 1 
DISMUKES RK 238798 03-03 
DITTMER TU 251118 04-09 
DITTRICH A 240645 03-14 
DITTRICH VT 238735 03-03 
DJOJODIBROTO RD 230859 01-03 
DOCHERTY JP 231277 01-08, 238491 02-13 

238493 02-17 
DODD KL 251103 04-11 
DODGE P 248648 04-02, 248651 04-02 
DODGE PW 248647 04-02. 248652 04-02 
DODRILL CB 240473 03-15, 240475 03-14 

251937 04-13 
DOEPPS 238855 03-15 
DOGGETT NS 225574 01-03 
DOHERTYJP 238489 02-08 
DOLAN-GUTCHER K 227137 01-04 
DOLEZAL V 234503 02-14 
DOLFINI E 230827 01-09 
DOLLERY CT 2383 1 6 02-03, 243085 04- 1 5 
DOLPHIN A 248289 04-04 
DOMINO EF 238709 03-03, 241872 03-08 248629 

04-13, 252825 04-13 
DONALD JF 245468 04-09 
DONALDSON D 235236 02-14 
DONALDSON I 251239 0-1-11 
DONALDSON IM 241929 03-03, 249076 04-04 
DONELSON AC 238709 03-03 
DONLEY P 245521 04-09 
DONLON M 238736 03-03 
DONLON PJ 228240 01-08 
DONLON PT 252006 04-08 
DOORENBOS H 235630 02-09 
DORAAAN JD 237825 02-11 
DORMER RA 250711 04-17 
DORR M 244687 04-04 
DORRIS RL 238731 03-03, 241919 03-03 243760 

04-03, 251143 04-04 
DOTTI A 229556 01-08 
DOUSTJNL 225935 0108 
DOUSTJWL 225935 01-08 
DOWNES H 230454 01-03 
DOWNS DA 227127 01-04,240018 03-04 241250 

03-04 
DOWRICK PW 247743 04-11 



Author Index 

DOYLE LN 228243 01-11 

DRAF W 238866 03-11 

DRAFFAN GH 243085 04-15 

DRAGHI SC 228037 01-09 

DRAGULEA G 229118 01-15 

DRAPER R 245138 04-10 

DRASKOCZY PR 247777 04-03 

DRAWBAUGH R 227132 01-04, 238713 03-04 

DRAY A 237783 02-03, 252521 04-03 

DREN A 248648 04-02, 248651 04-02 

DREN AT 248647 04-02, 248652 04-02 

DRESSEA 227763 01-04 

DREW GM 252025 04-03 

DREW WG 248008 04 04 

DREWNOWSKI A 230875 01-04 

DREYFUS JF 227216 01-09 

DREYFUSS J 247130 04-03, 253323 04-07 

DRISCOLL P 239865 03-04 

DROLETA 251829 04-08 

DRYBANSKI A 227637 01-04 

DRYDEN WF 244199 04-03 

DUBINSKY B 246967 04-04 

DUBNITSKAYA EB 244349 04-10 

DUBOIS EL 232865 02-15 

DUBOIS J 229078 01-16 

DUCHARME JR 253700 04-03 

DUCHATEAU JC 239576 03-04 

DUDEK BC 244680 04-04 

DUDGEON KL 237759 0203 

DUDLEY GE 248538 04-02 

DUFFY FH 249983 04-03 

DUFRASNE M 237015 02-17 

DUGAL R 237901 02-13, 2-^5650 04-08 

DUGAS M 229081 01-14 

DUGGAN AW 235866 02-03, 244203 04-03 

DUHAULTJ 237118 02-03,237119 02-03 

DUNCAN DL 228160 01-04 

DUNDEE JW 238531 02-13 

DUNN AJ 237155 02-03 

DUNN MJ 246856 04-13 

DUNNER DL 234203 02-09,238977 03-15 244495 

04-09, 247582 04-09 
DUNNIGAN D 248648 04-02 
DUPONT RL 250711 04 17 
DURDEN DA 250379 04-03 
DURHAM HD 238710 03-03 
DUTTA SN 249033 04-03 
DUVHOK C 239042 03-14 
DYER DC 230453 01-03 
DZOUIC MR 245599 04-03 



EARNHARDT JT 238809 03-03, 243800 04-03 

249418 04-03 
EBBUTT AF 252138 04-11 
EBEN E 240218 03-08, 240219 03-1 1, 240220 

03-14 
EBERT MH 244574 04-09 
EBSTEIN R 239728 03-09 
ECCLESTON D 227205 01 09 
ECKMANN F 241736 03-15 
ECOFFET M 240657 03-11 
EDELSON A 237105 02-04, 248956 04-04 
EDGARIAN H 251905 04-03, 2531 13 04-03 
EDNEY SM 230454 01-03 
EDWARDS DA 239284 03-04 
EDWARDS JA 227695 01-02 
EDWARDS SJ 249304 04-03 
EGAN SM 252200 04-03 
EICH JE 243013 04-04 
EICHENBAUM H 235320 02-04 
EICHENBERGER E 246671 04-03 
EICHSTADTKE 238476 02-01 
EINON D 230828 01-04 
EISENSTEIN N 230577 01-04 
EKDAWI MY 227215 01-09 
EKIEL I 234046 02-09 
EKSTRAND R 245653 04-13 
ELCHISAK MA 238768 03-04 
ELITHORN A 230580 01-15 
ELLEN P 226305 01-04 
ELLINWOOD EH 233965 02-03, 251754 04-15 
ELLIOTT GR 241902 03-17, 242002 03-02 
ELLIOTT H 251238 04-17 
ELLIS RD 251180 04-01 
ELLISON G 251063 04 04 
ELLMAN SJ 239272 03-04 
ELMQVIST D 227140 01-14 



A-5 



Author Index 

ELSDONDEW RW 251159 0410 

ELWAN 251004 04-10 

EMSON PC 226399 01-03 

ENDELL W 252222 04-03 

ENDOM 236696 02 15 

ENDO T 231316 01-04 

ENEVER RP 246317 04-01 

ENGEL J 249670 04-04 

ENNA SJ 226407 01-03, 23251 1 0103 

ENULESCU 252713 04-11 

ERCAN ZS 226762 01-03 

ERDAAANN G 244681 04-03 

ERHARDT PW 239660 03-01 

ERHAAANN M 239943 03-15 

ERICKSEN SE 253018 04-08 

ERILL S 248629 04-13 

ERLANDSSON K 226408 01-08 

ERVIN GN 246149 04-03 

ERWIN VG 237920 02-03 

ESCANDE M 234597 02-09 

ESKRIDGE NK 250084 04-03 

ESSMAN WB 229642 01-09,245873 04-17 

ESTLER CJ 248951 04-03 

ETO J 229761 01-08 

EUBANKS EE 226734 01-04 

EVANS BM 235563 02-13 

EVANS CD 252138 04-11 

EVANS HL 231005 01-04 

EVANS J PM 241979 03-04 

EVANS JR 229448 01-08 

EVANS LEJ 229693 01-09 

EVERETT GM 238728 03-03 

EVERETT HC 232864 02-15 

EXTEIN I 230010 01-11 

EZZAT MA 242267 03-15 



FABRE LF 24 1 278 03- 1 0, 248532 04- 1 

FACCHINI G 244476 04-11 

FAHIMM 229037 0111 

FAHNDRICH C 237109 02-04, 241242 03-03, 

248961 04-03 
FAINMAN F 238828 03-03 
FAIRBAIRN JW 237784 02-01 , 237982 02-01 
FALTER H 252149 04-04 
FANG VS 226869 01-03, 23431 1 02-03, 239931 

03-08 
FANIELLE J 250266 04-17 
FARAJ BA 243834 04-06 
FARBERJ 241678 03-03 
FARIELLO RG 233299 02-03 
FARNEBO LO 250937 04-03 
FAURBYE A 240048 03-15 
FECHTER LD 238722 03-04 
FEDAN JS 248413 04-03 
FEDER R 239258 03-14 
FEDERMAN EJ 250175 04-15 
FEDINETS P 252017 04-04 
FEENEY DM 238811 03-04 
FEIGELSON JL 238977 03-15 
FEIGENSON JS 251651 04-07 
FEINBERG AP 250088 04-03 
FEINGLASS SJ 238789 03-03 
FEINSILVER DB 225826 01-08 
FEJER D 236046 02-17 
FELDMAN JM 237927 02-13 
FELDMAN S 228978 01-17 
FELOMULLER F 249785 04-04 
FELIX D 240523 0303 
FELLMAN JH 251185 04-03 
FENNER H 2313170115 
FENOGLIO CM 247208 04-03 
FENSKE M 239828 03-03 
FENSTERMACHER JD 231002 01-03 
FERGUSON CP 248538 04-02 
FERNANDES M 251408 0417 
FERNER UJ 253052 04-08 
FERNGREN H 246891 04-11 
FERNSTROM JD 226873 01-03, 233290 02-03, 

238676 03-03, 241472 03-17 
FERRANDO R 245114 0406 
FERRARI E 239695 03-15 
FERRIS RM 249273 04-03, 249308 04-03 
FFRRO FM 229559 01-10 
FERUTTAAM 231367 01-08 
FIBIGER HC 227134 01-03, 232915 02-03, 241300 

03-04, 244676 04-04 
FIELDING S 249272 0404, 249304 04-03 



FIEVE RR 23081 7 01 -03, 234203 02-09, 234699 
02-09, 244495 04-09, 245416 04-09, 247582 
04-09 
FIGLER MH 242892 04-04 
FILE SE 241932 03-04 
FILLION G 237890 02-03 
FILLION M 237890 02-03 
FILLOUX B 246273 04-15 
FINCH CE 247588 04-03 
FINDLEYJD 227137 01-04 
FINDLEY U 245647 04-13 
FINK M 230781 01-14, 241275 03-10 
FINKELFARB E 251977 04-04 
FINN BW 238347 02-04 
FINNEGAN K 236523 02-04 
FINZEN A 253103 04-17 
FIORIELLO G 237834 02-02 
FIRSOV VK 241982 03-05 
FISCHBACH R 229826 01-13 
FISCHER E 229827 01-09 
FISCHER G 228550 01-03 
FISCHER JF 248637 04-01 
FISCHER P 238516 02-11 
FISCHER R 241428 03-12 
FISCHER-CORNELSSEN KA 253052 04-08 
FISCHMAN MW 250076 04-14 
FISHER JV 248851 04-15 
FISHER LA 238783 03-03, 239958 03-04, 252516 

04-03 
FISHERS 253043 04-16 
FJERDINGSTAD E 241221 03-04 
FJERDINGSTAD EJ 241221 03-04 
FLACH FF 228037 01-09 
FLEISCHHAUER J 239822 03-1 5, 241 762 03-09 
FLEISCHMAN RW 235671 02-05 
FLEISHER LN 231301 01-04 
FLEISSJL 230817 01-03 
FLEMENBAUM A 252955 04-1 7 
FLEMING DE 239858 03-03 
FLOMMC 235759 02-14 
FLOOD JF 237264 02-04 
FLORES-MERCADO F 2451 36 04- 1 1 
FLORIOV 246148 04-04 
FLORU L 239823 03-08 
FLYNN EJ 229480 01-03, 238763 03-03, 249297 

04-03 
FOCK S 241798 03-03 
FOLDES FF 252223 04-03 
FONSECA NM 251981 04-04 
FONTANA AF 234700 02-08 
FORD RD 238813 03-04 
FORDVB 228726 01-11 
FORINO V 229550 01-11 
FORNARO P 253393 04-03 
FORNEY RB 243087 04-14, 245648 04-14 
FORNI PJ 247089 04-15 
FORREST AD 231609 01-08 
FORREST IS 229481 01-03, 238818 03-01, 249328 

04-01 
FORREST WH 232622 02-14 
FORSMAN A 237152 02-16 
FORSTER EB 237774 02-10 
FORTUNE DH 237781 02-03 
FOSSOM LH 248697 04-03 
FOSTER BB 235534 02-17 
FOTHERGILL LA 233300 02-01 
FOURIEZOS G 249749 04-03 
FOWLER JS 248537 04-01 
FOWLER SJ 245608 04-02 
FOWLKES DK 245822 04-13 
FOX KA 243788 04-04 
FRACCHIA J 233829 02-08, 246694 04-1 1 
FRANCHIMONT P 248224 04-13 
FRANCHINI CL 231367 01-08 
FRANCOIS G 247544 04-15 
FRANCOS £ 245967 04-08 
FRANK GB 238710 03-03 
FRANK PI 227223 01-16 
FRANKE K 226840 01-03,237116 02-13 
FRANKEL D 237720 02-04 
FRANKLIN KBJ 246774 04-03 
FRANKOVA S 251991 04-04 
FRANKS HM 249674 04-14 
FRANTZ AG 245840 0413 
FRASSANITO LS 235992 02-11 
FRATTA W 244690 04-04 
FRAZIER SH 243863 04-09 
FREE CA 229464 01-03 



Psychopharmacology Abstracts 

FREEDMAN DX 23431 1 02-03, 246303 04-14, 

247021 04 03 
FREEDMAN R 240242 03-03, 253109 04-03 
FREEAAAN H 237646 02-08 
FREEMAN HS 248650 04-02 
FREESE ML 250516 04-10 
FRENCH SW 237756 02-03 
FRESTON JW 245806 04-15 
FREUDENTHAL J 241359 03-02 
FREY H 233301 02-03, 25301 1 04-07 
FREYBERGER H 226778 01-09 
FRICKE NL 232815 02-15 
FRIEDEL RO 229482 01-03, 244089 04-03 
FRIEDHOFF AJ 249035 04-01 , 253036 04-1 5 
FRIEDMAN E 241254 03-03, 245601 04-04, 
247215 04-03, 247216 04-09, 247480 04-08, 
249002 04-03 
FRIEDMAN Ml 227125 01-04 
FRIEL P 251937 04-13 
FRIOU GJ 232865 02-15 
FROEHLING S 246440 04-14 

FROHWIRTH C 229081 01-14 

FRUENSGAARD K 238551 02-09, 246623 04-09 

FRUMKIN K 251978 04-04 

FU WLH 252757 04-03 

FUENTES JA 227783 01-03, 233947 02-03, 237776 
02-03, 250376 04-03 

FUJIMURAH 241397 03-04 

FUJITAK 233832 02-13 

FUJITATS 251185 04-03 

FUJITANI Y 241375 03-04 

FUJIWARA M 241363 03-04, 241398 03-04 

FUKUDA T 241372 03-04, 245597 04-03 

FUKUDA Y 246319 04-03 

FULLER JL 226532 01 -04, 244680 04-04 

FULLER RW 226765 01-03, 238691 03-03, 241339 
03-03, 246151 04-03, 246847 04-03, 248605 
04-02 

FUNK K 250058 04-03 

FURGESON MD 251 143 04-04 

FURTADOJD 250193 04-14 

FURUKAWA K 241393 03-03 

F U R U KAWA T 24 1 406 03-03 

FUXE K 229462 01-03, 229483 01-03, 232507 
01-03, 248288 04-03, 250937 04-03, 251649 
04-07 

FYRO B 230824 01-09 



GABRY 237117 02-03 

GABRIEL E 237647 02-14, 239835 03-15, 243438 

04-15 
GABRIELLI F 244591 04-13 
GAHWILER BH 232906 02-03, 237880 02-03, 

239836 03-03, 244205 04-03 
GAIARDI M 232530 01-07, 237106 02-04, 245602 

04-04, 248959 04-04 
GAILIS L 229033 01-03 
GAILLARD J 226915 01-09, 239819 03-14 
GAIND R 251158 04-10 
GAIRADI M 249623 04-02 
GAITOJ 251929 04-04 
GAJDZINSKAH 244462 04-06 
GAL EM 232614 02-03, 246151 04-03 
GAL J 238682 03-03, 249234 04-05 
GALE KN 238699 03-03 
GALEA-DEBONO A 251239 04-1 1 
GALEONE F 247969 04-09 
GALEY D 244216 04-04 
GALLAGER DW 226400 01-03, 239957 03-03, 

246846 04-03 
GALLAGHER BB 237758 02-03 
GALLAHER EJ 249264 04-04 
GALLANT DM 237899 02-08, 247483 04-08, 

251718 04-11 
GALLEGOS-TORRES J 245136 04-11 
GALLIC 241276 03-14 
GAL VAN L 235364 02-08 
GAMBI D 229557 01-14, 229559 0110 
GAMBLE JAS 238531 02-13 
GAME CJA 241921 03-03, 243762 04-03 
GANDELMAN R 245406 04-04 
GANDOLFO C 244589 04-09 
GANES T 232606 02-03, 232607 02-03 
CANS P 241350 03-01 
GARATTINI S 232510 01-03, 237240 02-03, 

237740 02-03, 237742 02-03, 237743 02-03, 

248159 04-03, 248291 04-03, 250936 04-03 



A-6 



VOLUME 14, AUTHOR INDEX 



Author Index 



GARAU L 249664 04-03 

GARCIA J 238866 03-1 1, 246661 04 03, 246662 

04-03 
GARDNER M 239980 03-04 
GARDOS G 236307 02-08. 251830 04-13, 253037 

04-15 
GARFINKEL BD 235322 02-11, 245786 04-14, 

252798 04- 11 
GARMAN MW 237260 02-04 
GARVER DL 238696 03-04 
GASCON AL 233336 02-03 
GASSERJC 226828 01-15 
GAUCHY C 244636 04-06 
GAUTIERJ 251829 04-08 
GAY PE 230838 01-04, 244679 04-04, 248394 

04-04, 250008 04-04 
GAYEVYY MD 236234 02-03 
GAYRAL L 234597 02-09 
GAZZANIGAMS 251939 04-14 
GAZZARD BG 241754 03-17 
GEAGEA C 235358 02-07 
GEBHART GF 229484 01-04, 249248 04-03 
GEDDES PG 251776 04 16 
GEDYE JL 250414 04-11 
GEHRMANN JE 249251 04-03 
GEIGER PF 238706 03-04, 238734 03-03 
GEISLERA 251129 04-17 
GEISSBUHLER F 237709 02-03, 237710 02-03 
GELASHVILI DB 236261 02-03 
GELLER I 238750 03-04, 246821 04-05 
GELLERT V 249247 04-04, 249291 04-03 
GENIESER N 247480 04-08 
GENT M 242248 03-09 
GENTIL V 246312 04-13 
GEORGE R 246661 04-03, 246662 04-03, 251238 

04-17 
GEORGIYEV VP 236368 02-07 
GERALD MC 238315 02-03, 238475 02-01, 

241257 03-03, 251983 04-03 
GERBERSHAGEN U 238866 03-1 1 
GEREVICH J 252446 04-14 
GERHAROS HJ 237156 02-04 
GERLACH J 230823 01-08, 237702 02-03, 239023 

03-08 
GERNAM 242212 03 11 
GERNER RH 227785 01-09 
GEROLD M 240064 03-03 
GERSHON ES 246629 04-09 
GERSHON S 227702 01-04, 230816 01-09, 230878 

01-04, 231112 01-17, 232615 02-04, 233961 

02-13, 236528 02-03, 237725 02-08, 237903 

02-08, 237922 02-03, 241241 03-04, 241254 

03-03, 242251 03-09, 245601 04-04. 247215 

04-03, 247216 04-09, 249001 04-04, 249002 

04-03, 249283 04-03, 251720 04-08 
GERSON S 226405 01-04, 247777 04-03 
GESSA GL 237733 02- 1 1 , 2445 1 3 04-03, 244690 

04-04 
GESSNER PK 249317 04-05, 249318 04-03 
GEYER H 241241 03-04 
GEYER HM 238839 03-03 
GEYER MA 248947 04-03, 250377 04-01, 253255 

04-04 
GHONEIM MM 230830 01-14, 237722 02-14 
GHOSE K 226187 01-10,227210 01-07 
GHOSH AK 243782 04-03 
GHOSH JJ 241343 03-03, 243182 04-03, 253406 

04-03 
GHOSH P 238798 03-03 
GHOSH S 243782 04-03 
GIANTURCO D 253061 04-11 
GIANUTSOS G 227132 01 04, 239826 03-04, 

249139 04-04 
GIBB JW 238693 03-03, 252027 04-03 
GIBBINS RJ 232517 01-17,232518 01-14 
GIBBONS JL 243346 04-04 
GIBBONS P 244686 04-11 
GIBBS J 245612 04 02 
GIBBS M 242742 03-04 
GIBBS ME 253290 04 04 
GIBSON JE 249296 04-02 
GIEOT WR 238795 03-03, 249240 04-03 
GIELEN L 244215 04 04 
GIERLICHS HW 251418 04 11 
GIGON PL 226928 01-03 
GIL AD I 240643 03-03 
GILBERT J 240657 03-11 
GILBERT JC 243801 04 03 
GILBERT MM 248975 04 10 



GILDEN L 241328 03-03 

GILL CA 240022 03-04 

GILLIES AHB 245856 04 13 

GILLIES R 241222 03-03 

GILLIN JC 227802 01-04, 232324 01-11, 233817 

02-08, 234798 02-08, 235801 02-15, 236672 

02-04, 236750 02-08, 241474 03-14, 243013 

04-04, 243822 04-14, 244195 04-12, 248160 

04-10, 251 128 04-09, 252519 04-03 
GIMES G 252450 04-11 
GINESTET D 247543 04-09 
GINGRICH RL 245649 04-11 
GINSBORG BL 251703 04-03 
GINSBURG BE 239581 03-03 
GIORDANO J 235286 02-15 
GIORGUIEFF M 241247 03-03, 252217 04-03 
GIOVINE A 252220 04-03 
GIRAROI P 232779 02-09 
GIRTANNER B 229083 01-11 
GISPEN WH 239851 03-03 
GITTELMAN-KLEIN R 229053 01-11, 247381 

04-17, 247382 04-14 
GIULIANI E 232502 01-03, 232528 01-02 
GIUSTI GV 248915 04-05 
GLASER GH 240746 03-03 
GLASSGOLDJM 248163 04-02 
GLASSMAN AH 229443 01-09, 245784 04-09 
GLEES P 246587 04-03 
GLENNON RA 249318 04-03 
GLESER GC 235534 02-17 
GLICK EN 252136 04-11 
GLICK S 226729 01-04 
GLICK SD 227703 01-04, 231301 01-04, 240750 

03-04, 24131 1 03-04, 245594 04-04, 249485 

04-04, 250089 04-04 
GLITTERSTAM K 226411 01-09 
GLOWINSKI J 230854 01-03, 241247 03-03, 

244636 04-06, 249512 04-03, 252217 04-03 
GO K 241397 03-04 
GODSCHALK M 245599 04-03 
GODSE DD 228142 01-04, 238774 03-01 
GOGERTY JH 248539 04-02, 250080 04-03 
GOLABEK M 234047 02-11 
GOLDBERG DM 2501 13 04-04 
GOLDBERG MA 237825 02-11 
GOLDBERG ME 249027 04-03 
GOLDBERG SR 24001 1 03-04, 240012 03-04, 

240017 03-04, 250113 04-04 
GOLDEN GS 251962 04-11 
GOLDFINGER SS 253691 04-03 
GOLDFRANK L 252733 04-15 
GOLDMAN D 253038 04-15 
GOLDMAN H 226874 01-04, 241428 03-12 
GOLDMAN P 245307 04-13 
GOLDMAN R 244725 04-03 
GOLDSMITH RS 245806 04-15 
GOLDSTEIN A 239939 03-11, 241244 03-04 
GOLDSTEIN DB 238701 03-03, 241240 03-17 
GOLDSTEIN JM 253392 04-04 
GOLDSTEIN M 238758 03-03, 247212 04-03, 

247216 04-09, 251649 04-07 
GOLDSTEIN MJ 229448 01-08 
GOLDSTEIN S 248976 04-08 
GOLLUB LR 226853 01-04 
GOLOVANOVA LA 244349 04-10 
GOLUB M 230864 01-04, 234739 02-04 
GOMENI R 241234 03-13 
GOMEZ J 249537 04-16 
GOMEZ L 235360 02-07 
GOMEZ-LOZANO P 242250 03-10 
GONCALVES N 234217 02-08 
GOODALE DB 245598 04-03 
GOODALL EB 237777 02-03, 244214 04-04 
GOODGOLDA 248612 04-11 
GOODLET I 237748 02-03,241924 03-03 
GOODMAN J 228142 01-04 
GOODMAN JM 240843 03-15 
GOODMAN P 251964 04-03 
GOODSON WH 240243 03-15 
GOODWIN BL 227212 01-07 
GOODWIN DW 242947 04 15, 244960 04-13 
GOODWIN FK 233964 02-14, 234797 02 09, 

243023 04 09, 243819 04-13, 244574 04 09, 

250389 04-13 
GOODWIN JC 250725 04-13 
GORDON E 226899 01-09 
GORDON EK 248464 04-13 
GORDON JH 234067 02 03 
GORDON JW 251951 04-04 



GORDON P 231480 01-12 

GORELICK DA 226991 01-12, 237732 02 04 

GORINSON HS 251428 04-05 

GORKIN VZ 236369 02-03 

GORNY D 227635 0103 

GORODETZKY CW 240934 03-03 

GOSENFELD L 252847 04-08 

GOSWAAAI SN 228217 01-09, 240697 03-15 

GOTESTAM KG 245298 04-03, 250941 04-04 

GOTO Y 228322 01-17,229504 01-11 

GOTSICK JE 248008 04-04 

GOTTESFELD Z 237098 02-03, 237105 02-04, 

248956 04-04, 248957 04-03 
GOTTFRIES CG 226408 01-08, 226409 01-08. 

227769 01-17, 227770 01 08 
GOTTSCHALK LA 225932 01 -08, 229446 01 08, 

251776 04-16 
GOTTWALD K 237123 02 13 
GOUDIE AJ 225572 01-03, 226871 01-03, 230829 

01-04, 237713 02-04, 250939 04-02, 252522 

04-03 
GOUJET MA 237708 02-04 
GOVONI S 226406 01 03, 250356 04-03 
GRABOWSKA M 237785 02-03, 251226 04-02, 

251227 04-02 
GRAD B 235368 02-09 
GRAHAM GG 226829 0113 
GRAHAM JDP 252200 04-03 
GRAHAM N 231609 01-08 
GRAHAME-SMITH DG 230739 01-13, 239960 

03-03, 241979 03-04 
GRAM LF 243089 04- 1 3, 2472 1 04- 1 3 
GRAMSCH C 251400 04-03 
GRANCHELLI FE 248646 04-02 
GRANDJEAN EP 253587 04 12 
GRANT I 226922 01-15 
GRANT LD 239856 03-04 
GRASDIJK L 241207 03-03 
GRATTON L 235357 02-07, 235362 02-09 
GRAVES J 248160 04 10 
GRAYJA 230875 01-04, 234918 02-03, 244217 

04-04 
GRAY R 243865 04-03 
GRECH 237981 02-02 
GREEN A 252231 04-13 
GREEN AR 239960 03-03, 241979 03-04, 245600 

04-04, 251704 04-04 
GREEN BL 235534 02-17 
GREEN DE 238818 03-01, 249328 04-01 
GREEN JP 229485 01-04, 238674 03-03 
GREEN JR 239658 03-13 
GREEN L 226409 01-08 
GREEN R 251181 04-03 
GREEN RA 251128 04 09 
GREEN RD 246842 04-03 
GREEN SE 235509 02-04 
GREENAN E 243897 04-15 
GREENBERG AS 239936 03 1 3 
GREENBERG I 230876 01-04 
GREENBERG LM 244932 04-15. 247380 04 14 
GREENBLATT DJ 226840 01-03. 2371 16 02 13. 

237928 02-15. 244701 04-15. 250780 04 17, 

25 1 755 04 1 7, 252656 04- 1 5, 253495 04 1 5 
GREENBLATT M 234378 02-17 
GREENGARD P 226961 01-17, 229318 01-03, 

230600 01-03. 230602 01-13. 231014 01-03. 

231021 01-17. 232506 01-03. 237171 02-03 
GREENSLADE FC 244685 04 04 
GREENSTEIN R 229852 01-17 
GREENSTEIN S 226729 01-04. 240750 03-04 
GREENWALD ES 247978 04-15 
GREENWOOD DT 227208 01-02 
GREENWOOD MH 246312 04-13 
GREER CA 237731 02-04 
GREGERJ 234289 02 11 
GREIL W 233682 02-17 
GREVEN HM 246853 04 04 
GRIECOM 229039 0115 
GRIFFITH FF 226405 01-04 
GRIFFITH JD 231319 01-13. 238797 03 13 
GRIFFITHS R 240831 03 14 
GRIFFITHS RR 227137 01 04, 240014 03 04 
GRIGORYEVA ON 231119 0104 
GRILLY DM 230868 01-04 
GRINGRAS M 252139 04 17 
GRISANTI G 237834 02 02 
GROENEWOUD ET 230859 0103 
GROL CJ 248949 04-01. 252523 04-03 
GRONSKAJ 232483 0104 



A- 7 



Author Index 



Psychophormacology Abstracts 



GROPPETTI A 252030 0404, 252201 04-03 

GROSS CJ 243797 04-03 

GROSS D 238866 03-1! 

GROSS MD 247878 04-11 

GROSSER Bl 237864 02-03 

GROSSMAN J 227330 01 -n 

GROVES JE 245841 04-08 

GRUEN PH 245840 04-13 

GRUENKE LD 229442 01-16, 249234 04-05 

GRUNBERGER J 226612 01-09 

GRUNDIG E 244692 04-03 

GRUNHAUS L 239728 03-09 

GRUZELIER J 235629 02-08 

GSELL S 237458 02-10 

GUASTALLAA 230839 01-08 

GUAZELLI M 241234 03-13 

GUELFI J 227216 01-09 

GUERIOT C 229081 01-14 

GUERRIERO FJ 243788 0404 

GUERRINI A 230839 01-08 

GUHA D 249033 04-03 

GUIDOTTI A 226185 01-04, 226851 01-03, 226857 

01-03, 229466 01-03, 232514 01-03, 232921 

02-03, 237172 02-03, 243041 04-03, 244514 

04-03, 248698 04-05, 250362 04-03 
GUIGNARD JP 246273 04-15 
GUILLAMON A 244217 04-04 
GULATI OD 235670 02-03, 238764 03-03, 246817 

04-03, 246822 04-03 
GULDBERG HC 252173 04-03 
GUMULKA SW 241246 03-03, 251416 04-03, 

251432 04-03 
GUNBY B 227772 01-14 
GUNDERSON JG 225826 01-08 
GUNNE L 250943 04-07 
GUPTAS 229039 01-15 
GUPTA TK 238475 02-01 
GUREVICH Ml 236831 02-03 
GURLAND M 249002 04-03 
GURURAJ VJ 251827 04-14 
GUT I 230007 01-04 
GUZ I 227218 01-09 
GUZEK JW 248952 04-03 
GYE RS 230739 01-13 
GYLYSJA 237717 02-04 
GYSLING E 248909 04-15 
GYSLING K 251178 04-03 



H 



HADA H 228310 01-13 

HADNAGYC 23716102-15 

HAEFELY W 228051 01-03, 229465 01-03, 232515 
01-03, 241315 03-03, 241316 03-03, 241317 
03-03, 241318 03-03, 241319 03-03, 251399 
04-03 

HAEGERSTROM-PORTNOY G 235759 02-14 

HAEUSLER G 240064 03-03 

HAFNERJ 250727 04-10 

HAFNER RJ 240423 03-11 

HAGEDORN H 249674 04-14 

HAGQUIST WW 228143 01-04 

HAHER EJ 245842 04-08 

HAIDVOGL M 233717 02-11 

HAIGLER HJ 240073 03-03 

HAILEY DM 230424 01-15 

HALARIS AE 23431 1 02-03, 247021 04-03 

HALL JG 244203 04-03 

HALL ME 241301 03-04, 241689 0304 

HALL R 229693 01-09 

HALLAS R 248648 04-02 

HALLER L 225873 01-15 

HALLE Y J 231039 0103 

HALPERN LM 251937 04-13 

HAMBERGER B 250937 04-03 

HAMEL AR 229165 01-11 

HAMILL WT 234700 02-08 

HAMILTON LW 241546 03-04 

HAMILTON M 227213 01-16 

HAMMAR WJ 238837 03-03 

HAMMOND C 226960 01-11 

HAMMOND KR 231066 01-14 

HAMMOND N 235629 02-08 

HAMON M 247213 04-03,249512 04-03 

HANBAUER I 239977 03-03 

HANCE AJ 239857 03-04 

HANCOCK JC 238740 03-03 

HANDA T 241374 03-04 

HANDRICK GR 248651 04-02, 248652 04-02 



HANEY WG 233276 02-01 

HANIN I 238708 03-03, 239086 03-03, 241254 

03-03, 246275 04-13, 248700 04-03 
HANLON OP 238762 03-01 
HANLON TE 226901 01-14, 226902 01-16, 239824 

03-11 
HANSEN CE 24021 7 03-09, 248955 04-10 
HANSON K 238507 02-14 
HARAC 241367 03-04 
HARAT 228315 01-11,243092 04-17 
HARBANS L 239826 03-04 
HARBAUER H 236150 02-17 
HARBISON RD 249223 04-03 
HARCLERODE J 226763 01-03 
HARGRAVE R 237897 02-08 
HARMATZJ 227569 01-14,229457 01-11, 

229840 01-11 
HARMATZJS 237116 02-13 
HARRER G 242720 03-17 
HARRI MNE 239091 03-05 
HARRISON 229464 01-03 
HARRIS JE 237244 02-03 
HARRIS LS 233292 02-04, 233293 02-04, 237753 

02-03, 238765 03-03, 238808 03-03, 246852 

04-04, 248646 04-02 
HARRIS PB 249267 04-04 
HARRIS RA 237870 02-03, 238814 03-04, 249275 

04-04 
HARRIS RT 241278 03-10, 248532 04-10 
HARRIS S 240614 03-17 
HART FD 252135 04-17 
HARVEY DJ 243787 04-03 
HARVEY JA 237875 02-03, 241251 03-04, 247214 

04-05 
HASEGAWA K 238566 02-04 
HASEGAWA M 246971 04-03 
HASHIGUCHI K 228325 01-08 
HASKAYNE L 246699 04-15 
HASKELL D 250056 04-15 
HASLAM MT 238975 03-08 
HASSAN MA 251004 04-10 
HASSANEIN R 237138 02-11 
HASSLER R 239834 03-04 
HASSOURI H 251649 04-07 
HATA T 241374 03-04 
HATEGAN D 252711 04-03 
HATOTANI N 249123 04-13 
HATTON DC 231701 01-03 
HAUBRICH DR 248600 04-03 
HAUER B 237705 02-04 
HAUSER OCR 248163 04-02 
HAUSNERM 234503 02-14 
HAVDALA HH 249258 04-03 
HAVDALA HS 238725 03-03 
HAWKINGS JR 251165 04-10 
HAWKINS DF 243085 04-15 
HAWLINAA 251418 04-11 
HAYASHI S 252757 04-03 
HAYDEN D 238807 03-05 
HAYDEN DW 235671 02-05 
HAYES PE 246187 04-15 
HAYES TA 245001 04-14 
HEACOCK A 235320 02-04 
HEADLEY PM 235863 02-03, 235866 02-03 
HEALEYML 252816 04-04 
HEATH RG 249003 04-05 
HECKMATT JZ 251103 04-11 
HEDDEN MP 229264 01-04 
HEER-CARCANO L 251979 04-04 
HEIDRICH R 234291 02-11 
HEIJNEN HJ 252033 04-03 
HEIKKILA RE 248699 04-03, 253691 04-03 
HEILMAN RD 244685 04-04 
HEIMAN MF 247877 04-07 
HEIMANN H 237121 02-17 
HEINEMANN H 241232 0303 
HEINRICH K 239823 03-08, 251 1 18 04-09 
HEISE A 251414 04-03 
HEISERJF 225932 01-08 
HEISLER S 248909 04-15 
HELLER B 229827 01-09, 248515 04-03 
HELLSTROM B 246891 04-11 
HELMCHEN H 235354 02-17 
HENDERSON LM 243797 04-03 
HENDRY lA 244200 04-03 
HENNIES RS 228143 01-04 
HENRICSON S 227140 01-14 
HENRIKSSON BG 245297 04-04 
HENRY GM 244664 04-09 



HENSLEYVR 249674 04-14 

HENSLEY WJ 249674 04-14 

HERBERG K 246932 04-15, 249367 04-13 

HERBERG U 246774 04-03, 250075 04-04 

HERBET A 249899 04-03 

HERCZEG T 237760 02-03 

HERIZAEL 251185 04-03 

HERJANIC BL 233499 02-15 

HERMAN RL 248600 04-03 

HERMAN ZS 227637 01-04, 232484 01-04 

HERMANN W 251408 04-17 

HERNANDEZ L 231700 01-03 

HERR F 245295 04-04 

HERRIDGE CF 239820 0309 

HERRMANN W 229473 01-13 

HERRAAANN WM 229038 01-07, 232532 01 14 

HERTRICH 239782 03-15 

HERVONEN H 235649 02-03 

HERY F 24721 3 04-03, 24951 2 04-03 

HERZ A 237736 02-03, 237737 02-03, 239854 

03-03, 241223 03-04, 251433 04-03 
HESE R 230818 01-10 
HESS SM 229464 01-03 
HIDAKA H 253450 04-04 
HIEB £ 237115 02-14 
HIGSONJE 246970 04-13 
HIGUCHI M 229504 01 -n 
HILEY CR 241248 03-03 
HILL R 241242 03-03 
HILL SE 249535 04-09 
HILL SY 242947 04-1 5, 244960 04-13 
HILLMAN H 25341 1 04-03 
HILLS M 227139 01-03 
HIMBERG JJ 229907 01-14 
HINDMARCH I 237122 02-14 
HINDS CJ 233278 02-01 
HINE B 227702 01-04, 230878 01-04, 232615 

02-04. 245601 04-04, 249001 04-04 
HINGTGEN JN 241205 03-04, 250067 04-04 
HIPPIUS H 233684 02-17, 240218 03-08, 240219 

03- 1 1 , 240220 03- 1 4, 240705 03- 1 7, 25 1 1 1 8 

04-09 
HIPPS PP 238486 02-16 
HIRAI T 229725 01-14 
HI ROM 249253 04-04 
HIROSE K 241388 03-03 
HIRSCH AAJ 226873 01-03, 238676 03-03 
HIRSCHHORN ID 244683 04-04 
HIRSH K 238698 03-04 
HIRST M 248513 0403 
HITRI A 250081 04-03 
HITZEMANN 6A 241245 03-04 
HITZEMANN RJ 241245 03-04 
HIXSON B 238764 03-03 
HIXSON EJ 243798 04-03 
HO B 249310 04-03 
HO IK 238791 03-03, 241338 03-03, 249254 

04-05, 249292 04-03 
HO PPK 238691 03-03 
HOEBEL BG 231 700 01-03, 243878 04-04 
HOEHN MM 249232 04-15 
HOEYJR 227924 01-11 
HOFFER BJ 238471 02-03, 240242 03-03 
HOFFMAN DJ 246968 04-03, 246969 04-17 
HOFFAAAN PF 237813 02-15 
HOFFAAAN WE 251 142 04-03, 252170 04-03 
HOFFMEISTER F 233681 02-06, 240020 03-04, 

246855 04-04, 251414 04-03 
HOFMANN G 226612 01-09,243438 04-15 
HOFMANN HP 246674 04-04 
HOGAN TP 229650 01-14 
HOJER B 243086 04-13 
HOKFELT T 232507 01-03 
HOK IN-NEAVERSON M 253 1 37 04- 1 3 
HOLOEN JMC 227765 01-08 
HOLE K 252173 04-03 
HOLFORT S 250657 04-13 
HOLINKA CF 247588 04-03 
HOLLAND OB 251320 04-17 
HOLLAND RPC 251003 04-15 
HOLLAND WH 238486 0216 
HOLLETT CR 238784 03-03 
HOLLISTER AS 230841 01-03, 246149 04-03 
HOLLISTER LE 229315 01- II, 233514 02-17, 

243861 04-09, 248850 04-15, 250417 04-13 
HOLLSTEIN H 240261 03 15 
HOLLT V 239854 03-03 
HOLMAN RB 241902 03-17 
HOLMES JC 241345 03-03 



A-8 



rOLUME 14, AUTHOR fNDEX 



Author index 



OLMSTEDT BR 229486 01-03 

OLMSTRANO J 250945 04-07 

OLOWIECKI J 230818 01-10 

OLT J 245612 04-02 

OLTZMAN SG 237754 02-04, 241314 03-04, 

251975 04-04 
OLZ RW 236873 0203 
OLZ WC 240022 03-04 
OLZ/VWN PS 246303 04 14 
ONDA F 241382 03-04 
ONECKER H 229041 01-03, 234316 02-03 
ONIG WMM 237704 02-04, 248285 04-02 
ONTELA S 253055 04- 1 1 , 253056 04- 1 1 , 253057 

04-11 

OPKINSON G 239348 03-09 
OPPER M 239943 03-15 
ORIBE M 241378 03-04 
ORIKAWA S 246309 04-07 
ORITA A 228977 01-05, 236524 02-04, 238695 

03-03, 249280 0404 
ORN AS 226761 01-03, 229435 0103, 238317 

02-01, 250357 04-01 
ORNG JS 246848 04-03, 250380 04-03 
ORNYKIEWICZ 233299 02-03, 244039 04-1 7 
OROWSKI R 252028 04-04 
ORVATH L 239089 03-05 
ORWITZ D 232324 01-11 
OTZ M 227330 01-11 
OUGHTON GW 225890 01-15 
OULIHAN WJ 248539 04-02 
OUSE CR 251703 04-03 
OUSE KM 253595 04-09 
OUSER VP 230835 01-03, 240886 03-03, 240916 

03-04, 242894 04-04 
OUSTON AB 251103 04-11 
OWARD JL 249273 04-03, 249308 04-03 
OWARD ML 229650 01-14 
OWES JF 248651 04-02, 248652 04-02 
OWLETT L 230015 01-10 
RACHOVEC JP 246425 04-09 
RDINA PO 246152 04-03, 247131 04-03, 253135 

04-03 
RUSKA RE 238715 03-03, 238773 03-03, 241574 

03-03 

SU LL 250377 04-01 
U J 249254 0405 
UANGA 235286 02-15 
UANG CL 226849 01-03 
UANGJH 237746 02-03 
UBBARD RB 240074 03-14 
UCKER HB 238684 03-03 
UDICK JP 240065 03-03 
UESTIS RD 22757101-11,239932 03-11 
UFFMAN RD 238790 03-03 
UG R 228094 01-14 
UGHES J 227774 01-03, 233300 02-01 
UGHEST JP 245600 04-04 
UGUE M 241275 03-10 
UGUET R 242900 04-11 
UIDOBRO F 249288 04-04 
U1D0BR0-T0R0 JP 249288 04-04 
ULL RC 246300 0410 
ULLIN RP 250725 04-13 
ULSEBUS R 249138 04-04 
UNT HF 251428 04-05 
UNT W 246856 04-13,249293 04-03 
UNTER J 234309 02-03 
UNTER P 229693 01-09 
UPPERT FA 230831 01-04 
URT SW 253018 04-08 
URWIC MJ 229437 01-09 
USSAIN SMA 250414 04-11 
USTONJP 246388 04-04 
USZKA L 225935 01-08 
UTCHINGS DE 251428 04-05 
UTCHISON MT 249242 04-03 
UTTENLOCHER PR 237826 02-03, 251952 04-1 1 
UXTABLE RJ 238715 03-03, 238773 03-03 
UY ND 229033 01-03, 229034 01-04 
VIDBERG EF 240217 03-09, 248955 04-10 
WANG K 248648 0402 
YNESMD 227132 0104 
YTTEL J 241416 03-03 



3SEN 1 243089 04-13 
IHIMARU I 227220 01-09 



IDANPAAN-HEIKKILA J 226927 01-03, 227696 

01-03 
IDZOREK S 236317 02-15 
IGLAUER C 240015 03-04 
IISALO E 253011 04-07 
IKEDA C 249269 04-04 
IKEDA S 241385 03-03 
IKEDA Y 241399 03-04 
ILHAN M 241313 03-03 
ILLIG R 247715 04-15 
ILSON D 248724 04-03 
IMAZ F 235359 02-07 
IMMICH H 241736 03-15 
INABA T 250423 04-13 
I N AN AGA K 229026 01-07, 229064 1 -08, 244528 

04-08, 249120 04-08 
INGALL GB 238693 03-03 
INGVAR DH 227140 01-14, 230867 01-14 
INOKI R 251070 04-03 
INOUE K 229026 01-07, 229064 01-08 
INOUE N 226932 01-04 
lORDANOV Y 236811 02-17 
lORIO LC 248539 04-02, 250080 04-03 
IRVIN CW 229715 01-11 
IRWIN P 230781 01-14 
ISAAC L 238838 03-03 
ISAACSON RL 252148 04-05 
ISERI Y 229504 01-11 
ISHIDA R 241384 03-03 
ISHIDAT 229761 01-08 
ISHll S 241273 03-14 
ISHIKAWA K 241401 03-04 
ISHIKAWA T 246319 04-03 
ISRAEL Y 246850 04-03 
ISSELBACHER KJ 251 179 04-03 
ITIL TM 225721 01-17, 226725 01-16, 227826 

01-09, 229038 01-07, 229470 01-14, 229473 

01-13, 232532 01-14, 232635 02-11, 241275 

03-10 
ITO K 241384 03-03 
ITO N 241405 03-03 
ITO T 241383 03-03,243782 04-03 
ITOH H 228226 01-09, 252181 04-17, 253034 

04-15 
ITOH K 228226 01-09 
ITOH T 241381 03-03 
ITONAGAY 228325 01-08 
ITURRIAN WB 233277 02-06 
IVERSEN LL 226349 01-14, 229435 01-03, 249680 

04-04 
IVERSEN SD 226349 01-14, 226937 01-04, 229434 

01-03, 230831 01-04, 234917 02-04 
IVES JO 239938 03-10 
IWAMOTO ET 237870 02-03, 2531 12 04-04 
IWASAKI T 241399 03-04 
IWASAWA Y 238563 02-03 
I WAT A H 247013 04-03,249253 04-04 
IWINSKA B 229681 01-04 
IZQUIERDO I 227138 01-04, 230570 01-04 
IZQUIERDOJA 237108 02-04 



JAASKELAINEN J 237162 02-17 

JACKLER F 239272 03-04 

JACKSON DE 251988 04-04 

JACKSON DM 226764 01-04, 227130 01-04, 

230856 01-03, 239859 03-03, 244894 04-04, 

249669 04-04, 249670 04-04 
JACKSON J A 238696 03-04 
JACOB J 237890 02-03 
JACOBI P 238516 02-11,239682 03-15 
JACOBOWITZ DM 238673 03-03, 244202 04-04 
JACOBS BL 226734 01-04, 241505 03-12, 249078 

04-03, 250083 04-04 
JACOBS D 251964 04-03 
JACOBS J R 229264 01-04 
JACOBS LS 243822 04-14, 251 128 04-09 
JACOBSON J 249271 04-02 
JACOBSSON L 22641 1 01-09, 226412 01-08, 

244189 04-07 
JACOBY JH 233290 02-03 
JACOUET YF 252209 04-04 
JAGOOA A 238765 03-03 
JAHN U 241231 03-04 
JAILLON P 240657 03-11 
JAIM-ETCHEVERRY G 249666 04-03 
JAIN RC 230780 01-08 
JAISWAL RK 238712 03 03 



JAKIMOW B 236429 02-10 

JAKLINSKA A 234522 02-03 

JALFRE M 241315 03-03, 241316 03-03, 241317 

03-03, 241318 03-03, 241319 03-03 
JAMES DTD 234918 02-03 
JAMES RJ 244113 04-15 
JAMES SH 247147 04-15 
JAMMESJL 251966 04-11 
JANCAR VG 246425 04-09 
J AN DH YALA BS 2388 1 03-03 
JANKEW 233683 02-17 
JANOS A 239992 03-14 
JANOWSKY D 230816 01-09 
JANOWSKY DS 233967 02-08, 239933 03-08 
JANSSEN H 237786 02-03 
JANSSEN HJ 244215 04-04 
JANSSEN PAJ 232529 01-04, 237744 02-04, 

241228 03-04, 250355 04-03, 251429 04-03, 

253394 04-04 
JANZIK H 240692 03-15 
JARBE TUC 241258 03-04, 242737 03-04, 245297 

04-04 
JAROSZYNSKI J 236421 02-08 
JARVIK L 229460 01-11 
JARVIK ME 248583 04-09, 249671 04-04 
JARVISJAE 241249 03-05 
JASINSKI DR 231319 01-13 
JATON AL 241927 03-04, 251405 04-03 
JATSA K 226900 01-13 
JAVOY F 230854 01-03, 249899 04-03 
JEFFERSON JW 237909 02-15, 253137 04-13 
JENDEN DJ 238828 03-03, 249298 04-03, 251 181 

04-03 
JENKINS DG 252138 04-11 
JENNER FA 253593 04-04 
JENNER P 230855 01-03, 237977 02-13, 241929 

03-03, 248289 04-04, 249628 04-03 
JENSEN J 2371 10 02-04, 244651 04 03 
JENSEN K 238551 02-09, 246623 04-09 
JEONG Y 241357 03-15 
JEPPSSONJ 238998 03-15 
JERMINI C 253587 04-12 
JERUSSI TP 241311 03-04 
JHAMANDAS K 252023 04-03 
JIMERSON DC 243440 04-03 
JOBE PC 238706 03-04, 238734 03-03 
JOFFE JM 243789 04-03 
JOFFE P 233377 02-12 
JOH TH 238759 03-03, 246845 04-03 
JOHANNESEN M 251129 04-17 
JOHANSON CE 240013 03-04, 250066 04-04 
JOHANSSON JO 241258 03-04, 242737 03-04, 

245297 04-04 
JOHANSSON R 246387 04-13 
JOHNSON AK 244469 04-04 
JOHNSON AM 249419 04 04 
JOHNSON CA 249671 04-04 
JOHNSON CL 238674 03-03 
JOHNSON DAW 238996 03-08, 252763 04-08 
JOHNSON FN 243804 04-04, 248516 04-03, 

249381 04-04 
JOHNSON G 230119 01-17 
JOHNSON GF 237165 02-10 
JOHNSON K 238765 03-03 
JOHNSON KM 238769 03-03 
JOHNSON L 251215 04-04 
JOHNSON LC 238507 02-14 
JOHNSON R 241730 03-13 
JOHNSON RD 227212 01-07 
JOHNSON WC 227825 01-10 
JOHNSTON M 229693 01-09 
JOHNSTON RE 226865 01-03 
JOHNSTONE EC 228208 01-15, 251985 04-10 
JONAS S 248612 04-11 
JONAS WZ 246629 04 09 
JONES BC 241668 03-04, 251989 04-04 
JONES BE 230879 01-04, 244674 04-06 
JONES BJ 241918 03-04, 243758 04-04 
JONES CN 239856 03-04 
JONES DG 241206 03-03 
JONES DJ 249286 04-03 
JONES GL 237243 02-03 
JONES GR 237980 02-01 
JONES JM 239533 03-04 
JONES JT 229264 01-04 
JONES RF 226960 01-11 
JONES RT 235759 02-14, 252327 04-13, 252825 

04 13, 253609 04-13 
JONSSON G 241196 03-03 



A-9 



Author Index 



Psychopharmacology Abstract 



JONSSON J 250943 04 07, 250945 04 07 

JONSSON S 2511)9 04-08 

JORI A 230827 01-09, 238322 02 03, 250936 

0403 
JOSEPH MH 226399 0103 
JOSHI VG 236665 02-09 
JOSLIN RS 250332 04-06 
JOST M 246388 04 04 
JOUVET M 23531 7 02-04, 2521 71 04-04 
JOVANOVIC UJ 240710 03-11 
JOYCE CRB 231066 01-14 
JOYCE D 235509 02 04 
JUBIZ W 245806 04-15 
JUDD A 253593 04-04 
JUDD LL 226922 01-15, 240074 03-14 
JUHL RP 253154 04-15 
JUHOS E 232638 02-13 
JULIEN RM 249242 04-03 
JUN HW 233277 02-06 
JUNG M 238782 03-03 
JUNG AAJ 238781 03 04 
JUNGE C 230866 01-16 
JUNGHANI J 227391 01-05 
JUS A 244497 04-15, 250991 04-15, 251829 

04-08 
JUS K 244497 04 15, 250991 04-15, 251829 

04-08 
JUST WW 244681 04-03 
JUTKOWITZ R 251960 04-13 
JUVANCZ P 245304 04-04 



KADLETSOVA 244456 04-04 

KADOBAYASHll 251214 04-03 

KAESS H 232503 01-13 

KAFKA MS 236873 02-03 

KAI Y 229026 01-07 

KAISER J 243234 04-04 

KAJARIA SM 230907 01-08 

KAKITAY 229725 01-14 

KALANT H 237720 0204, 242741 03-03 

KALDORA 252990 04-17 

KALES A 245652 04-11,252230 04-11 

KALES JD 245652 04)1,252230 04-11 

KALOTKIN M 252793 04-11 

KAMDAR BV 238478 02-01 

KAAAEI C 241375 03-04, 247039 04 03 

KAMENICKAV 234430 02 13 

KAMENOV G 236363 02-10 

KAMEYAMA T 24)370 03-04, 24)37) 03 04, 

242205 03-04 
KAMP R 237120 02-05 
KANABUS P 244050 04-08 
KANAPA DJ 25)959 04 05 
KANE FJ 233828 02)5 
KANG S 238674 03-03 
KANNER M 236523 02 04 
KANTAMANENI BD 241210 03-13 
KANTO J 229042 0113,237735 02-13 
KANTOR SJ 229443 01 09, 245784 04-09 
KANZLER MB 229437 01-09 
KAPLAN J 236750 02 08 
KAPLAN LJ 242743 03-04 
KAPLAN NM 251320 04-17 
KARASAWA T 241393 03 03 
KARASU TB 245840 04 13 
KARBOWSKI M 238765 03-03 
KARCZMAR AG 249299 04-03 
KARLER R 2310)0 01 03, 238767 03-03 
KARIINERW 249765 04)7 
KARNIOL IG 225570 0)03, 249622 04-07 
KAROBATH M 237244 02-03, 237647 02-14, 

239835 03 15, 244043 04 03 
KAROUM F 238761 03 03 
KARPIAK SE 226)86 0104 
KARPOVVN 231248 0104 
KARR G 226903 01-14 
KASICH AM 241274 03)4 
KASSOUNY ME 238720 03-04 
KASTIN AJ 248349 04-03,250082 04 03 
KATAOKA K 226739 01-03 
KATO AC 248724 04-03 
KATO N 229068 01 03, 234673 02 09, 251214 

04 03 
KATO S 228211 01-17 
KAISUNO 1 228325 01-08 
KA)Z FH 233001 02 13 
KAI/ MM 22572) 01 17 



KATZ RL 237734 02 14 

KATZ S 247381 04-17, 248603 04-03 

KATZMAN R 231304 01-03 

KAUFMAN RD 226828 01-15 

KAUL PN 229441 01-16, 229444 01-08, 251777 

04 06, 251778 04-16 
KAWAJIRI T 229761 01-08 
KAWAKITAY 229504 01-11 
KAWASAKI H 241389 03 03 
KAWASHIMA K 236527 02-03 
KAY DC 246304 04-13 
KAY EJ 249158 04-04 
KAYAAAKCALAN S 226762 01-03 
KAZAMATSURI H 22821101-17 
KEBABIAN JW 229318 01-03, 230600 01-03, 
230602 01-13, 234919 02-03, 237170 02-03 
KEEHN JD 236708 02-04 
KEELER MH 245524 04-17 
KEESEY RR 243790 04-03 
KELFER DA 231533 01-04 
KELLAMS JJ 232840 02-08, 253049 04-08 
KELLEHER RT 229428 01-04, 240010 03-04, 

240012 03-04, 240017 03-04 
KELLER HH 251399 04-03 
KELLER J K 248646 04-02 
KELLETTJM 230742 01-15 
KELLEY M 225572 01-03 
KELLNER R 22822) 0)08, 231992 01-15, 249625 

04-11, 250516 04-10, 253050 04-11 
KELLOGG C 245608 04-02 

KELLY D 251155 04-14 

KELLY JT 236663 02-10 

KELLY PH 226937 01-04, 234918 02-03, 237866 
02-03, 248286 04-03, 248287 04-02, 249680 
04-04, 251704 04-04 

KENNARD 226761 01-03, 23831 7 02-01 , 
250357 04-01 

KENNEDY G 251239 04-11 

KENNY F 239348 03-09 

KENT EW 252017 04-04 

KESSLER C 237899 02-08 

KETAI R 235419 02-17 

KEY BJ 241930 03-03, 24631 1 04-03 

KHACHATURIAN ZS 230840 01-03, 238708 03-03, 
239086 03-03 

KHALSAJH 226766 01-03 

KHANNA JM 237720 02-04 

KHAZAN N 227701 01-03, 230880 01-04, 251533 
04-04 

KHURANA R 243088 04-15 

KICZAK J 232545 01-17,234045 02-15 

KIDD MR 251)80 04-01 

KIDSON MA 227550 01-1) 

KIELHOLZ P 244040 04-10 

KIELY WF 232865 02-15 

KIESSLINGM 240447 03-03 

KILLAM KF 237755 02-04, 239857 03-04, 249251 
04-03, 249267 04-04, 249268 04-03, 249270 
04-04, 249290 04-03 

KILLIAM EK 237755 02-04 

KIM J 237920 02-03 

KIMJS 23983403-04 

KIMISHIMA K 241379 03-04 

KIMURA S 228325 01-08,229626 01-11 

KINDEL GH 249299 04-03 

KING CD 238744 03-04, 249281 04-02 

KING GW 238794 03-04 

KINGJM 239290 03-04 

K I NG LJ 230834 1 03, 24 1 256 03-03 

KING SM 228420 01-14 

KINNARD WJ 246967 04-04 

KIRAN BK 246820 04 04 

KIRBYMJ 240802 03-13 

KIRCHMAN A 227701 01-03 

KIREMITCI N 253641 04-11 

KIRK L 240048 03-15 

KIRMAN B 249525 04-17 

KIRSHNER N 241294 03-13 

KIRSTEIN R 252733 04-15 

KISARA K 241380 03-04,242202 03-03 

KISHI R 241377 03-04 

KISS C 252450 04-11 

KITA T 241374 03-04 

KITAHAMA K 249676 04-04, 252171 04-04 

KITAHARA T 229026 01-07 

KITAMURA S 229725 01-14 

KIYOMOTO A 238563 02 03 

KJELLBERG B 230869 01-04 

KLARA PM 239832 03 03 



KLATZO I 239577 03-03 
KLAWANS HL 237729 02-04, 239685 0303, 
247683 04-04, 247730 04-03, 251959 04-05 
KLEE WA 232960 0203, 2371 75 02-03, 238571 

02-03, 239787 03-03 
KLEIN DF 228223 01-08, 228978 01-17, 229451 
01-10, 239937 03-09, 247381 04-17, 247382 
04-14, 253047 04-08 
KLEIN HE 246672 04-08 
KLEINKNECHT RA 235236 02-14 
KLEINLOGEL H 226728 01-03 
KLEINROK Z 227636 01-04, 237032 02-04 
KLEMM WR 250071 04-06 
KLERAAAN GL 229450 01-09, 241936 03-08 
KLETT CJ 225718 01-09 
KLICH R 240711 03-11 
KLIEB J 236708 02-04 
KLINE NS 226794 01-09, 231991 01-15, 247208 

04-03 
KLING R 227330 01-11 
KLINGNERA 231035 01-09 
KLOPPER JH 251951 04-04 
KLOSAJ 232527 01-01 
KLYGULO TA 244456 04-04 
KLYSNER R 251129 04-17 
KNAPP S 233958 02-03, 234805 02-03, 246849 

04-03, 252514 04-03 
KNAUTH P 229236 01-09 
KNESEVICH JW 253314 04-09 
KNOBDL E 249622 04-07 
KNOBEL M 249772 04-11 
KNOLL B 249787 04-17 
KNOLL J 249787 04-1 7, 252223 04-03 
KOBAYASHI H 238717 03-04 
KOBAYASHI M 251990 04-04 
KOCH M 236663 02-10 
KOCH-BOURDOUXHE S 237013 02-09 
KOCH-WESER J 226840 01-03, 237116 02-13, 
237928 02-15, 250780 04-17, 252656 04- 15 
KOCHANSKYGE 227569 01-14 
KOCURJ 234097 02-12 
KOE BK 237242 02-03, 238738 03-01 
KOEPKE HH 246184 04-15,248975 04-10 
KOGAN FJ 238079 02-03, 238693 03-03, 25202; 

04-03 
KOH S 247013 04-03 
KOHLERC 229083 01-11,252173 04-03 
KOHLER M 249144 04-11 
KOHLMEYER K 240708 03-17 
KOKKINIDIS L 237703 02-04 
KOLAKOWSKA T 246612 04-17 
KOLANSKY H 237651 02-15 
KOLASIEWICZ W 242745 04-04 
KOLODNY E 245863 04-08 
KOMENDANTOVA MV 228552 01-03, 236373 

02-03 
KOMISARUK BR 238822 03-03 
KOMISKEY HL 241255 03-03 
KOMISSAROV IV 231251 01-04, 241980 03-03 
KOMLOS M 246318 04-04 
KONDO H 234673 02-09, 249124 04-14 
KONIG L 240741 03-14, 244188 04-08 
KONIG P 226612 01-09 
KONIG U 251071 04-12 
KONSTORUMMG 231072 01-06 
KOPANDA RT 231771 01-04, 249005 04-04 
KOPELL BS 230871 01-14 
KOPIN IJ 227777 01-03, 238673 03-03, 246843 

04-03, 247028 04-03, 248464 04-13 
KORB RJ 231629 01-14 

KORFJ 226727 01-03, 238997 03-13, 241207 
03-03, 241912 03-08, 245510 04-09, 249984 
04-03 
KORFF FA 242861 04-17 
KORNETSKY C 230864 01-04, 234739 02-04, 

238755 03-04, 249271 04-02 
KOROLENKO TA 228548 01-03 
KORR H 239855 03-03, 239864 03-03 
KORSON L 239938 03-10 
KORTTILA K 232531 01 13 
KOSAJE 230836 01-04 
KOSEKI Y 241381 03-03 
KOSHELEVA OV 236235 02 03, 236712 02-04 
KOSLOW SH 239307 03-03, 241253 03-03 
KOSOCZKY 1 231008 01-03,252445 04-02 
KOSS MC 239963 03-03 
KOSTERLITZ HW 233300 02-01 
KOSTOPOULOS GK 232621 02-03, 248725 04-01 
KOSTREZEWA RM 239832 03-03 



A-10 



>LUME 14, AUTHOR INDEX 




Author Index 


IN J 236318 02 15 


LAFFRANCHINI S 239748 03-14 


LEHMANN HE 227820 01-14, 229459 01-1 1, 


ORII M 246309 04-07 


LAGENDIJKA 245599 04-03 


230780 01-08, 231034 01-08, 231035 01-09, 


ORII T 229064 01-08 


LAGERWEY C 237270 02-06 


235355 02-17, 235356 02-07, 235363 02-09, 


AKIEWICZ R 241328 03-03 


LAIDLAWJ 225890 01-15 


235370 02-09, 235773 02-08, 242249 03-09, 


;ARYN I 240237 03-04 


LAJTHA A 240065 03-03 


253053 04 07, 253054 04 1 1 , 253055 04- 1 1 , 


lOVSKAYA MM 2361 74 02 04 


LAKE CR 239305 03-13 


253059 04 11, 253060 04-11 


,EMER GW 248437 04 04 


LAL H 227132 01-04, 232617 02-03, 238713 


LEHMANN K 240740 03-03 


,GH-SORENSEN P 240217 03-09, 248955 04-10 


03-04, 248274 04-03, 249139 04-04, 249272 


LEHTI H 227136 01 15 


,IKER H 246707 04-15 


04-04, 249289 04-04, 250656 04-03 


LEIBOWITZ M 248612 04-11, 248613 04-11 


■KOWSKI AJ 228244 0117 


LAL S 230743 01-1 1, 237747 02-03, 249785 04-04 


LEIBOWITZ SF 23261 02-03, 245929 04-02, 


1 VA 253062 04-17 


LAMB P 242267 03-15 


245930 04-02 


,MER M 248976 04-08 


LAMBERT GA 249002 04-03 


LEICKERT KH 242502 03-14 


,MP P 239023 03-08 


LAMBERT P 252181 04-17 


LEITH NJ 239850 03-04, 249255 04-03 


,UER B 243085 04-15 


LAMBORN KR 239938 03-10 


LEMBERGER L 243087 04-14, 245648 04-14, 


.YNACK BJ 252221 04-03 


LAMBRECHTS P 237270 02-06 


248628 04-12, 249260 04-07 


BS H 252018 04-03 


LAMON S 230838 01-04 


LEMKE TL 238477 02 02 


ISKOTT H 246674 04-04 


LAMPEN EL 247743 04-11 


LENA B 236118 02-11 


WMER EC 238756 03-04 


LANDSBERG L 241299 03-03 


LENAERTS FM 232529 01-04 


JHNAN G 251160 04-10 


LANEJD 241205 0304 


LENNOX WJ 248538 04-02 


JTJANSEN P 227761 01-17, 239023 03-08 


LANGE E 244188 04-08 


LENTZ S 238819 03 04 


/OBOK GK 231251 01-04, 236257 02-04 


LANGEMANN H 237158 02-03 


LENTZEN H 251392 04 03 


lEGER BK 238080 02-13 


LANGLEY A 238690 03-03 


LENZ G 239835 03-15, 243438 04-15 


IGER E 250209 04-15 


LANKOSZJ 229515 01-10 


LEONARD BE 239849 03-03 


IPER J 244311 04-04 


LANNER G 243198 04-11 


LEONARD DP 227550 01-11 


ISKEMPER G 232364 01-14 


LAO L 230834 0103 


LERERMP 251569 04 14 


ISKEMPER HL 232364 01-14 


LAPIERRE Y 241203 03-03 


LERER RJ 251569 04-14 


ISZEWSKA A 240240 03-03 


LAPIERRE YD 225686 01-15, 231036 01-10, 


LERISSONJ 242898 04-11 


SA G 244050 04-08 


245012 04-14, 247484 04-10, 251431 04-15 


LERNERCB 252327 04-13 


SPIN-EXNER K 229044 01-11 


LAPRADE B 238487 02-01 


LERNERSE 247147 04 15 


« C 227131 01-04, 242739 03-04 


LARKIN RP 231707 01-04 


LESHEM M 250938 04-03 


lA S 227808 1 - 1 5, 244779 04- 1 5 


LARMORE CK 237759 02-03 


LETARTE J 253700 04-03 


lA K 227808 01-15,244779 04-15 


EARNED D 230027 01-15 


LEUTNER V 226778 01-09, 239029 03-14, 240706 


)0Y 241384 03-03 


LAROUCHE B 235357 02-07 


03-17 


HNLEJC 242269 03-17 


LARRISON SB 251180 04-01 


LEVANDER SE 239002 03-09 


FERLE 8 237647 02 14 


LARSEN F 241244 03-04 


LEVANDOWSKYM 248163 04-02 


;E T 241273 03 14 


LASCHKA E 241223 03-04, 251402 04-04 


LEVENSONAJ 241277 03-08 


lAR MJ 226407 01-03, 227400 01-03, 24721 1 


LASSEN JB 227129 01-04, 245296 04-03, 252029 


LEVER JD 237738 02 03 


4-03. 249074 04-03, 249303 04-03, 252219 


04-04 


LEVI G 246665 04-03 


4-03 


LASTG 233079 02-11 


LEVI RN 248543 04-16 


IN D 238764 03-03 


LASTRUCCI P 235988 02-15 


LEVIN BE 243791 04-03 


IN DM 230876 01-04 


LASZLO D 239992 03-14 


LEVIN K 245863 04-08 


INEG 236348 02-17 


LATIMER PR 227746 0109 


LEVIN RM 249287 04-03 


;OPULOS A 232779 02-09 


1 All Rl 2S7R9S 04-13 


LEVINE HD 252061 04-14 


CSAR A 229465 01-03, 232515 01-03 


LAUDER JM 252018 04 03 


LEVINEJ 232902 02 16 


KARNI S 249678 04-04 
LBERGMP 238797 03 13 
MKURA K 226406 01-03 


LAUERJW 251717 04-11 
LAURENT B 229035 01-03 
LAURENT JP 238503 02-03 


LEVINE MS 238716 03 03 
LEVINE TE 238081 02-04 
LEVITT M 230817 0103 


MRS 238712 03-03 
MSHIRO H 243094 04-17 


LAURITSEN B 239023 03-08 
LAVOIEJ 246273 04-15 
LAVRETSKAYA EF 236714 02-04 
LAVRETSKAYA YF 236715 02-03 
LAWSON J 247020 04-03 
LAWSON T 240278 03-17 
LE BARS D 232328 01-03 


LEVITT RA 232938 02 1 7, 238006 02 04 
LEVY DL 246303 04- 1 4 


ABARACHI T 234203 02-09, 244495 04-09 

JO H 241391 03-03 

JZE H 238320 02-03 

IZER W 243194 04-10 

'PER OJ 246275 04-13 

WISHI Y 242204 03-03 


LEVY RH 239658 03 13 

LEVY S 233279 02-03 

LEWANDER T 233962 02 03. 245298 04-03 

LEWI PJ 239683 03 06 

LEWICKA H 244050 04-08 

LEWIN E 251964 04-03 


WMITSU M 228074 01-11 


LE BLANC AE 233488 02-14 


LEWIS BD 232624 02 03 


WMOTO S 245986 04-11 


LE BRUN Y 233974 02-11 


LEWIS BF 232838 02 1 7 


IIBARA H 238564 02-04, 241 376 03 04, 


LE CLECOH G 247151 04-04 


LEWIS DE 238838 03 03 


41400 03-04 


LE FLOCH ML 252217 04 03 


LEWIS AAJ 241 100 03 03, 244202 04-04, 252200 


ilHARA M 228226 01-09 


LE MOAL M 244216 04-04,250982 04 04 


04-03 


[LAND AA 226901 01-14, 226902 01-16, 


LEAF R 230838 01-04 


LEWIS PJ 245647 04 13 


39824 03-11 


LEAKE CD 238814 03 04 


LEWIS VA 249248 04-03 


iOCHKIN IG 236372 02 04 


LEALMAN GT 25110304-11 


LI WAN PO A 246317 04-01 


!OCHKINA Al 236265 02-03 


LEANDER JD 233292 02 04, 233293 02-04, 


LIBET B 238717 03-04 


!OIWA Y 241403 03-03, 242201 03-03 


249266 04-04 


LICHTENSTEIGER W 237158 02-03 


!OSAWA A 2371 72 02-03, 241 388 03-03, 


LEBLANC AE 237720 02-04, 242741 03-03 


LIDBRINK P 232507 01-03 


43041 04-03 


LEBOEUF G 253700 04-03 


LIDEN CB 247090 04-15 


iTZ P 242733 0304 


LECANUETJ 241330 03-04 


LIEB J 23898103 10 


iTZ PD 251149 04-17 


LECRUBIERY 239607 03-17 


LIEBERMAN A 233974 02-11, 248612 04-11, 


;TZMAN S 238757 03-04 


LEE A 231771 01-04, 249005 04-04 


248613 04 11, 251649 04 07 


iSIN D 253057 04-11 


LEE BH 233277 02-06 


LIEBMAN JM 241307 03-04, 249486 04-03 


.UHARAT 228325 01-08 


LEE C 251701 04-01 


LIEBMANN JA 237784 02-01 


SCHER CL 242746 04-04 


LEE CA 230919 01-03 


LIEBSCHUTZJ 238719 03-03 


ICL J 248647 04-02, 248648 04-02 


LEE CR 249535 04-09 


LIEBSON 1 240831 03-14 


ICHUKOVA P 236732 02-09 


LEE CY 244203 04-03 


LIEFF BD 238201 02 03 




LEE GM 238812 03-03 


LIENHART R 237158 02-03 


L 


LEE IP 250109 04 03 


LIIVAMAGI J 226900 01-13 




LEE JH 244501 04-08, 247481 04-07 


LIUEQUIST R 229907 01-14, 246315 04-14 


WURA G 22955101-11 


LEE M 247484 04-10 


LIUEOUIST S 249670 04-04 


ELLA FS 246586 04-03 


LEE T 248466 04-03 


LIN R 249188 04 01 


HANCE R 244497 04-15, 250991 04-15 


LEE Y 248648 04-02 


LIN Y 247846 04-06 


ORBIERE M 243482 04-03 


LEE-SON S 233289 02-03 


LINAUER W 233917 02 11 


OURSIERE RB 251996 04-08 


LEEMING FC 229487 01-04 


LINDBERG D 246623 04 09 


ER M 232704 02-10, 236360 02-08 


LEES P 243759 0403 


LINDLT 240447 03-03 


ER MH 227209 01-17, 241758 03-10, 246312 


LEEUWIN RS 230859 01-03 


LINET 01 248533 04-11 


4-13 


LEFEVER GS 246842 04-03 


LING W 239943 03 15 


INSKY H 232510 01 03, 248291 04-03, 


LEFKOWITZ SS 226944 01-05 


LINNOILAM 229907 01-14,241417 03-15, 


48410 04-03 


LEGROSJJ 248224 04-13 


246315 04 14, 247967 04-11 


URON P 250359 04 03 


LEHMANN H 251546 04-08 
A-11 


LINSEMAN MA 237099 02 03 



Author Index 

LION JR 231610 0109, 245016 0409. 246184 

04 1 5 
I lONEL NOW 250932 04-07 
LIPINSKI JF 250928 04 17 
LIPMAN RS 229449 01 09, 252941 04-09 
LIPPERT B 238781 0304, 238782 0303 
LIPPMANN W 244316 04-02, 244678 04-03 

249313 04-03 
LIPTON MA 232618 02-03 
LIST AF 226763 01-03 
LITKENHOUS EE 240243 03 15 
LITTLE SRCJ 231609 01-08 
LITTLETON JM 241926 03-03 
LIFTMAN P 226840 01-03 
LIU S 226849 01 03, 227390 01-03 
LIVENGOOD D 238736 03-03, 246998 04-03 
LIVREA P 252220 04-03 
UUNGBERG T 243348 04-04, 250086 04-04 
UUNGDAHL A 232507 01-03 
LLEWELLYN ME 240015 03 04 
LLINAS JJ 241435 03-17 
LLOYD KG 233299 02-03 
LODGE D 235863 02-03, 235866 02-03 241921 

03-03, 243762 04-03 
LODGE JW 237787 02-16 
LODGE PATCH IC 246699 04-15 
LOEFFLER KO 238818 03-01, 249328 04-01 
LOEFFLER U 233278 02-01 
LOEW DM 241927 03-04,249419 04-04 249668 

04-04, 251405 04-03 
LOFSTRANDH S 238678 03-03 
LOGAN RW 251103 04-11 
LOH H 250087 04-02 
LOH HH 23)01 1 01 03, 237870 02-03, 237891 

02 03, 238814 03-04, 241245 03-04 241338 

03-03, 249275 04-04, 249316 04-03, 253107 

04-03, 253108 04-04, 253112 04-04 
LOHMANN F 231317 0115 
LOMAX P 250078 04-03, 2501 14 04-03 
LOMEN P 248533 04-11 
LONG JP 241313 03-03, 248408 04-03 
LONGENECKER HE 238743 03-03 
LONGO VG 237707 02-04, 246148 04-04, 247485 

04 04 
LONGUSKI PA 250012 04-04 
lONNQVISTJ 227136 0115 
LONOWSKI DJ 238006 02-04 
LOO H 247554 0409 
LOOMIS TA 249264 04 04 
LOONEY RL 233448 02-04 
lOPEZJB 241777 0316 
LOPEZ 7AN0N A 227221 01-09 
LORENS SA 244214 04-04, 252173 04-03 
LORENZO AV 237873 02-03 
LOSEY EG 248834 04-03, 249930 04-03, 251 184 

0-103 
LOVCHIKOV VA 236249 02-03 
LOVE G 238819 03-04 
LOVEJOY FH 247090 04 15 
LOVERING EG 238485 0202 
LOWE G 245305 04 04 
LOWENSTAM I 228908 01-11 
LU K 237738 02 03 
LU KM 243951 04-03 
LUCIERGW 250109 04 03 
lUrOTJB 249266 04 04 
I IJHDORF K 230823 01-08, 239023 03-08 
LUIIMANN RAUCH R 237153 02-05 
lUMBRERAS N 248515 04 03 
LUNDWALL LK 229091 01-11 
IIJNZERM 230580 0115 
LUSH IE 230870 01-04 
lUlHRA YK 243181 04-04 
LUTZ EG 247784 04-15 
LYDIARD RB 248697 04-03, 249291 04-03 
lYNCHHD 234826 02-17 
tYON WE 237271 02-14 
LYIIf LD 238741 03-03, 239958 03 04, 252516 

0.103 
lYUBIMOV Bl 228547 01 04, 241986 03-03 

24 1 989 03 03 

M 

MAAS JW 229489 0103 
MA(AVOYMG 246305 04 13 
MA((ANNFLI K 226903 01 14 
MA((UIIOtHMJ 239010 03 15 
MA( DONALD Ml 252848 04-08 



Psychopharmocology Abstracts 



MACFARLANE IR 237100 0203 

MACGREGOR RR 248537 04-01 

MAC KAY MC 241990 03-15 

MACKINTOSH JH 225569 01-04, 237715 02-04, 

237727 02-04, 246310 04-04 
MACLEAN Ki 241926 03-03 
MACLEOD SM 250779 04-11 
MACNEILL AL 252137 04-17 
MACPHAIL I 245469 04-11 
MACPHAIL RC 226853 01-04, 230842 01-04, 

238844 03-04, 2531 1 1 04-04 
MACRI J 238828 03-03 
MADLE RA 251149 04-17 
MADSEN JA 245806 04-15 
MADTES P 238349 02-03 
MAEKAWA T 246319 04-03 
MAENGWYN-DAVIES GD 229488 01-04, 238673 

03-03 
MAGIN F 238866 03-11 
MAGNUS RV 245137 04-10 
MAGOS L 241 249 03-05, 250090 04-04 
MAGOUR S 237109 02-04, 241242 03-03, 248961 

04-03 
MAGRINI G 240762 03-11 
MAHAPATRASB 227214 01-09 
MAHON WA 250423 04 13 
MAICKEL RP 243798 04-03, 247729 04-02 
MAINVILLE CA 238485 02-02 
MAITRE L 251225 04-03, 251395 04-03, 251398 

04-03 
MAJOVSKI LV 238510 02-11 
MAKI M 229907 01-14 
MAKMAN MH 231304 01-03, 238739 03-03 
MALEC D 227636 01-04 
MALEN C 237118 02-03,237119 02-03 
MALICK JB 253392 04-04 
MALIK NA 238996 03-08 
MALLACH HJ 237123 02-13 
MALLINGERAG 246275 04-13 
MALLOY KP 2388)0 03-03 
MALOFF P 228139 01-04 
MALOR R 226764 01-04, 227130 01-04, 244894 

04-04 
MALTZMAN I 249798 04-09 
MANBER M 248862 04-15 
MANDEL MR 245841 04-08 
MANDEL P 237723 02-04, 241222 03-03, 241348 

03-03 
MANDELL AJ 233958 02 03, 246849 04-03, 

250377 04-01, 252514 04-03, 253255 04-04 
MANGOLD B 230002 01-11 
MANGONI A 237733 02-11 
MANIAN AA 236521 02-03, 237174 02-01, 

237241 02-03, 238777 03-03, 239582 03-03 

252515 04-05 
MANNING FJ 250061 04-04 
MANNING RA 248880 04-03 
MANOWITZ P 247847 04-03 
MANSUY 241350 03-01 
MANTEGAZZA P 252030 04-04, 252201 0403 
MANTILLA-PLATA 8 249223 04-03 
MANZO L 244453 04-15 
MAO CC 226857 01-03, 229466 01-03, 232514 

0)03 
MAPLE PJ 238820 03-03 
MARCHAND A 247208 04-03 
MARCONCINI-PEPEU I 249664 04-03 
MARCUS RJ 249307 04-03 
MARCUSSON J 226410 0)10 
MARCY R 227694 01-03,248514 04-04 
MARDER JE 244701 04-15 
MARGOLIN Dl 247683 04-04 
MARGOSES N 238864 03-08 
MARGULES DL 244202 04-04 
MARIETTA MP 250107 04-03, 250108 04-03 
MARINIJL 251826 04-15 
MARJERRISON G 243860 04-09 
MARKEY SP 237274 02-16 
MARKINVA 24)989 03-03 
MARKOFF RA 230015 0110 
MARKOMIHELAKIS H 251986 04 14 
MARKOWITZ R 249271 04-02 
MARKS DF 239853 03-14, 246305 04 13 
MARKS I 250727 04-10 
MARKS V 241256 03-03 
MARK/M 249272 04-04 
MARLEY E 241978 03 03, 243848 04-03 
MARQUIS WJ 234810 02-04, 237718 02-04 
MARRIOTT PF 253531 04 15 



MARROSU F 237733 02-11 
MARSDEN CA 239959 03-03, 241925 03-03 
MARSDEN CD 230855 01-03, 237781 02-03 
237977 02-13, 241929 03-03, 241934 03-05, 
248289 04-04, 249076 04-04, 249628 04-03 
249629 04-04, 249679 04-04, 250358 04-04 
250722 04-15, 251239 04-11 
MARSHALL A 248513 04-03 
MARSHALL J A 246300 04-10 
MARSHMAN JA 232517 01-17, 232518 01-14 
MARTENS H 251118 04-09 
MARTENSSON E 237152 02-16, 237902 02-13, 

238552 02-13 
MARTINA 251979 04-04 
MARTIN BR 237753 02-03 
MARTIN GE 239087 03-03, 252024 04-03 
MARTIN GF 226478 01-11 
MARTIN GM 251629 04-05 
MARTIN ICA 238978 03-15 
MARTIN JC 245405 04-05 
MARTIN RL 253595 04-09 
MARTIN WR 237752 02-03, 244674 04-06 
MARTIN YC 233946 02-01 
MARTINEZ G 251178 04-03 
MARTINEZ M 237624 02-1 1 
MARTINI M 235992 02-11 
MARTRES M 226651 01-02 
MARTZ R 243087 04-14, 245648 04-14 
MARUKO K 243094 04-17 
MARUYAMA S 241386 03-03 
MARVOLA M 25 1 1 30 04 02 
MARWAHA J 238710 03-03 
MARX M 227695 01-02 
MARZULLO G 249035 04-01 
MASANES P 249144 04-11 
MASE GB 230990 01-09, 230992 01-09 
MASELLI A 237624 02-11 
MASHKOVSKIY MD 236369 02-03 
MASLANKAA 23884103-03 
MASON AS 251751 04-17 
MASON ST 234917 02-04 
MASSARI VJ 248414 04-05 
MASSERANO JM 238744 03-04 
MASSOTTI M 247485 04-04 
MASTER RS 230907 01-08 
MASUDA K 233077 02-04 
MASUDA Y 241393 03-03, 247039 04-03 
MATHIEU LF 249929 04-05, 250655 04-03 
MATHUR PP 2377o0 02 03, 241344 03-03 
MATHURA CB 241680 03-04 
MATSUBARA I 246971 04-03 
MATSUDA H 231316 01-04, 241378 03-04 
MATSUOA T 243094 04-17 
MATSUMOTO H 244050 04-08 
MATSUNAGA M 24274103-03 
MATSUURA H 227808 0115,244779 04-15 
MATTE AC 237714 02-04 
MATTHEW H 250715 04-15 
MATTHEWS WD 239961 03-03 
MATTHYSSE S 238464 02-08 
MATTILAAAJ 246315 04-14 
MATTSSON B 226410 0110,226413 01-11, 

226414 01-1 1, 226430 01-07 
MATUSSEK N 233682 02-17, 246672 04 08 
MAUGER JW 238487 02-01 
MAWDSLEY C 250944 04-11 
MAXION H 238516 02-11,239682 03-15 
MAXMEN JS 2466)7 04 17 
MAXSON SC 237706 02-03 
MAY J 249257 04-03, 249309 04-03 
MAY PRA 229448 0) -08 
MAY V 239783 03)5 
MAYER B 240692 03-15 
MAYER DY 240251 03 15 
MAYSOV Nl 2363/0 02-03 
MAZAYEVA NA 244349 04-10 
MAZURKIEWICZ KWILECKI IM 230853 01-03 
MCARTHURAW 248172 04-11 
MCBRIDE WJ 250067 04 04 
MCCABE GP 247217 04 14 
MCCABE L 226901 0114 
MCCABE OL 239824 03 11 
MCCALLUM NK 233279 02-03 
MCCARDLE K 238698 03-04 
MCCARTHY K 238736 03-03 
MCCARTY RC 242749 04-04 
MCCLAIN LD 227692 0)03 
MCCONNELL WR 238815 03-03 
MCCOY TH 253106 04 03 



A-12 



HUME 14, AUTHOR INDEX 



Author Index 



CURDY RL 245524 04-17 

DERMEO JO 248650 04-02 

DOWELL FH 250927 04-1), 251651 04-07 

FARLAIN RA 251718 04-11 

GHIE RL 247030 04-11 

GILL TE 242743 03-04, 250984 04 04 

GILVERAY IJ 238484 02-06 

GLAMERY M 251961 04-11 

GLASHAN TH 237726 02-08 

GRATH SD 230104 Ol-n 

GUFFIN JC 244911 04-04 

INOEWAR I 237748 02-03 

KEARNEY JW 240021 03-04 

KFNZIE GM 233969 02-03, 248650 04-02 

KINNEY WT 247889 04-04, 248437 04-04 

LARTY DO 230763 01-13 

LEAN JR 238842 03-04 

WAHON RE 238683 03-06 

WASTER SE 247214 04-05 

WILLAN DE 233292 02-04, 233293 02-04. 

38749 03-04, 247845 04-04, 249266 04-04, 
52816 04-04 

WURTREY KD 243778 04-03 

WURTRY R.J 249232 04-15 

'JAMEE HB 239941 03-11 

^lAUGHTON N 234918 02-03 

»JEILLYAS 240423 03 11 

^UTT B 253041 04-15 

5HARRY L 237745 02-04 

:H0ULAA/\ R 248701 04-03 

)INA E 240850 03-08 

)1NA MA 249286 04-03 

)VEDEV OS 241988 03-03 

)ZIHRADSKY F 252178 04-03 

)ZIHRADSZKY K 248349 04 03 

X R 231278 01-06, 237863 02-03, 238678 

3 03, 241253 03 03 

HILANE L 226900 01-13 

HTA JM 235348 02-09 

ERJP 246970 04 13 

NECKE RO 237260 02-04 

SCH RA 227128 01-04 

TES J 240642 03-03, 243951 04 03 

.ANCON J 231037 01-08 

.DRUM as 241934 03-05 

.TZER HL 238977 03-15 

.TZER HY 226869 01-03, 230826 01-03, 

36523 02-04, 239931 03-08, 243813 04-03 

TZER L 251533 04-04 

JDELSJ 238775 03-01 

JDELSON WB 226848 01-05, 229924 01-14 

12947 04-15, 244960 04-13 

>IDESLON V\/B 243822 04-14 

JDEZ JS 237253 02-1 1, 238347 02-04 

JOLEWICZ J 230817 01 03, 231410 0117 

JDOZA C 252694 04-11 

JDUNI G 231368 0109 

JETREY D 232328 0103 

JKES DB 253255 04-04 

TON MK 253107 04-03,253108 04-04 

<SE S 241798 03-03 

<TASTI M 233917 02 11 

iALI 7 253135 04-03 

!EU GP 244690 04-04 

(LIS S 233829 02-08, 246694 04-1 1 

!RILL DMR 228431 01-11 

ISIHA FS 233296 02-13,238318 02-04, 

38750 03 04, 238836 03-03, 246821 04-05 
;SING RB 238783 03-03, 239958 03 04 
52516 04-03 

CALF B 238782 03-03 

CALF M 247380 04-14 

CALFF M 230742 0115 

IRICE E 227768 01 09 

CORAKH Y 236732 02-09 

VALDf SP 230830 01-14,237722 02 14 

'ENDORF R 240705 03-17 

'FR H 237124 02 08, 240707 03 09 

'fR ME 23170101-03 

'FR RE 239941 03-11 

'ER W 248222 04 10 

'EPSON LR 243778 04-03 

:EY E 247032 04 03 

ZEK KA 244682 04 04 

DAUGH LD 226528 0104 

HA KK 238484 02-06 

-KE DH 231995 0115. 237899 02 08, 247483 

1-08, 251718 04 11 

EON C 248222 04 10 



MIHAILOVA D 237981 02-02 

MIKAMI M 251214 04-03 

MIKKELSEN LI 227572 01-09 

MIKSIC S 238713 03-04 

Ml LEY WM 253485 04-04 

MILIARESSIS E 237862 02-03 

Ml LEAN C 245016 04-09 

MILLARD BJ 246317 04-01 

MILLER AF 242151 03-14 

MILLER I 247130 04-03 

MILLER Jl 248538 04-02 

MILLER MA 2500T9 04-04 

MILLER MH 244684 04-04 

MILLER R 241929 03-03 

MILLER RJ 229435 01-03, 241248 03-03, 241347 

03-03, 248286 04-03, 248287 04-02 
MILLICHAPJG 225783 01-14 
MiLLOY S 241575 03-03 
MILLS L 235676 02-11 
MILMORE JE 250333 04-03 
MILNE JF 229460 01-11 
MILNE RJ 232333 01-03 
MILSON JA 243803 04-04 
MILSTEIN SL 226903 01-14 
MILSTEIN V 232840 02-08, 253049 04-08 
MILSTOC M 244495 04-09 
MINDHAM RHS 242267 03-15, 250722 04-15 
MINDUS P 239002 03-09 
MINN FL 242251 03-09, 251719 04-07 
MIR P 242251 03-09, 251720 04-08 
MIREYLEES SE 241924 03-03 
MIRIN SM 239941 03-11 
MIRSKY AF 239848 03-04 
MISHRA RK 231304 01-03, 238739 03-03, 238784 

03-03 
MISRA PC 225699 01-15 
MISRA RS 239661 03-03 
MISSLIN R 237723 02-04 
MISU Y 242204 03-03 
MISUREC J 234419 02-11,234430 02-13 
MITCHELL CL 238837 03-03 
MITCHELL DN 238697 03-04 
MITRAG 243182 04-03 

MITROFANOV VS 228547 01-04, 241989 03-03 
MITSUMOTO H 233295 02-14 
MITTAG TW 245594 04-04 
MIURA S 228214 01 15, 252181 04-17, 253034 

04-15 
MIXICH G 241231 03-04 
MIYAGAWA K 236696 02-15 
MIYAKE H 229626 01-11 
MIYAMOTO H 228325 01-08 
MIYAMOTO K 228327 01-09 
MIYAUCHl 1 241364 03-04, 246664 04-04 
MIZUSHIMA S 236696 02-15 
MJORNDAL T 226413 01-11, 251131 04-03 
MOAN E 233829 02-08 
MODAK AT 230451 01-03, 253106 04-03 
MODONESI C 231368 01-09 
MOFFAT JA 252023 04-03 
MOFFETT RB 238478 02-01 
MOGILNICKA E 250361 04-04 
MOHAMMED S 238672 03-03 
MOHAMMED YS 237117 02-03 
MOHLER H 229465 01-03, 232515 01-03 
MOISAN D 247544 04-15 

MOIZESZOWICZ J 237102 02-14, 240838 03-1 7 
MOJA EA 236672 02-04,241474 03-14 
MOLANDER L 237107 02-04, 239042 03-14, 

245296 04-03. 248960 04-02 
MOLINOFF PB 244315 04-03 
MOLLER N 227762 01-04 
MOLLOY BB 246151 04-03, 246847 04-03, 246848 

04 03 
MOMOSE T 241273 03-14 
MONACO F 242212 03 11 
MONEY J 248222 04-10 
MONTEL H 248979 04-03, 248980 04-03 
MONTEVERDI T 230990 01-09, 230992 01-09 
MONTGRAIN N 246126 04-17 
MONTI JM 246818 04-04 
MOORE J 232840 02-08 
MOORE JD 251824 04 16 
MOORE KE 233973 02 03, 237154 02-03, 245598 

04 03 
MOORE MS 250073 04-06 
MOORE WT 237651 02-15 
MOOSMAYER A 237123 02-13 
MORA F 242748 04-04 



MO RAN EC 247889 04-04 

MORETON JE 251533 04-04 

MORGAN BA 233300 02-01 

MORGAN DW 245521 04-09 

MORGAN JP 233296 02-13,238672 03-03 

MORGAN M 246821 04-05 

MORGAN WW 238790 03-03 

MORGANTI A 249673 04-13 

MORGENROTH VH 226856 01-03, 233971 02-03, 

241296 03-03 
MORI M 241405 03-03 
MORIHISA JM 249485 04-04 
MORIN AM 236522 02-03 
MORIN RD 227692 01-03, 230453 01-03 
MO R LAND J 239044 03-03 
MORMONT C 245971 04-06 
MORRANTJCA 227750 01-11 
MORRIS HR 233300 02-01 
MORRIS RJ 245649 04-11 
MORRISON HL 248437 04-04 
MORSE WH 240009 03-04, 240019 03-04, 2501 13 

04-04 
MORSELLI PL 237740 02-03, 241234 03-13, 

242212 03-1 1, 246993 04-13, 246994 04-13, 

247131 04-03 
MORTIAUX H 244215 04-04 
MORZORATI SL 238823 03-03 
MOSES F 238675 03-03 
MOSHKOVSKIY YS 236715 02-03 
MOSKOWITZ MA 238719 03 03 
MOSNAIM AD 248162 04-01 
MOSS J 227777 01-03, 247028 04-03 
MOTOMURA H 229760 01-09 
MOYANO CZ 245014 04-08 
MOYER KE 243346 04-04 
MRSUUA BB 239577 03-03 
MRSUUA BJ 239577 03-03 
MUELLER PS 247482 04-09 
MUIZELAARJP 230877 01-06 
MUKAI T 228325 01-08 
MUKHERJEE BP 238754 03 04 
MULAS ML 249664 04-03 
MULDAWER MD 22822101-08 
MULLENIX P 247207 04-04 
MULLER D 250209 04-15 
MULLER E 234291 02-11 
MULLER EE 240643 03-03 
MULLER WE 251176 04-01,251177 04-01 
MULLER OERLINGHAUSEN B 235354 02-17, 

251417 04 15 
MUNKVAD I 239023 03-08 
MONRO A 239014 03-11 
MUNRO HN 238719 03-03 
MONRO JF 250944 04-11 
MURAKAMI E 229504 01-11 
MURASE Y 229068 01-03 
MURATA T 228311 01 11 
MURAVCHICK S 251820 04-03 
MURAYAMA S 241385 03-03 
MURDOCK HR 232623 02-13, 237872 02-13 
MURPHY D 248160 04-10 
MURPHY DL 226731 01 13, 237716 02-14, 

239305 03-13, 244664 04 09 
MURPHY JE 227226 01-09, 227227 01-07, 245468 

04-09 
MURPHY PJ 238683 03-06 
MURRIN LC 250085 04-03 
MUSACCHIOJM 238686 03-03 
MUSCETTOLAG 237274 02-16 
MUSTY RE 246819 04 04, 249622 04-07 
MUTSCHLER E 240704 03-17 
MUZIO M 244591 04-13 
MYCEK AAJ 229490 01-03, 241346 03-03 
MYERS PR 246998 04-03 
MYERS RD 226938 01 04, 227382 01-06. 239087 

03-03, 252024 04 03 
MYLLYLA VV 239090 03-03 
MYSLINSKI NR 238737 03-03 
MYTILINEOU C 248699 04-03 



N 



NABESHIMA T 241370 03-04, 241371 03-04, 

242205 03-04 
NACHON M 229827 01-09 
NADITCH MP 233377 02-12 
NAG AHAMA F 229504 0111 
NAGAMI GT 246316 04-03 
NAGARAJAN K 248649 04-02 



X 

> 

i ^ 

\ ^' 

I S 

■6 
P 

II* 



A-13 



Author Index 



Psychopharmacology Abstracts 



NAGASAKA Y 252757 04-03 

NAGASHI M 228308 01-08 

NAG AT A T 244528 04-08, 249120 04-08 

NAGATSU T 241360 03-03 

NAGY A 243089 04-13, 246387 04 13, 246623 

04 09, 252231 04 13 
NAGY J 239275 03-04 
NAHUNEK K 234419 02-11,234430 02-13 
NAIK SR 243041 04-03 
NAIR NPV 235365 02-08 
NAIR NVP 253055 04-11 
NAITO Y 241388 03-03 
NAITOH F 238565 02 03, 241366 03-03 
NAKAHARA H 241373 03-04 
NAKAHARA T 246314 04-08 
NAKAMURA K 241369 03-03, 241369 03-03 
NAKAAAURA Y 229504 01-11 
NAKANO T 244528 04 08 
NAKANO U 241406 03-03 
NAKAYA S 241381 03 03 
NAKAZAWA Y 229064 01-08, 246309 04-07 
NAMMATHAO B 248514 04-04 
NANDI AR 251006 04-07 
NANDI BR 251776 04 16 
NARASIMHACHARI N 249188 04-01 
NAROD ME 237756 02-03 
NATHAN BA 242882 04-04 
NATHANSON JA 23717102-03 
NAUSIEDA PA 251959 04-05 
NAVA V 244587 04 08 
NAYLOR GJ 247711 04-09 
NAYLOR R 250414 04-11 
NAYLOR RJ 227133 01-03, 227135 01-04, 237781 

02-03, 238319 02-04, 239964 03-04, 240063 

03-03, 248290 04-06, 248407 04-04, 250358 

04-04, 252031 04-03 
NAZAR BL 226763 01-03 
NECKERS L 226401 01-03, 232325 01-03, 238677 

03-03, 241253 03-03 
NEFF NH 227783 01-03, 228032 01-03, 233947 

02-03, 237776 02-03, 238761 03-03, 250376 

04-03 
NEILL DB 251138 04-04 
NEISS ES 229036 01 07, 253323 04-07 
NEISV\/ORTH JT 251149 04-17 
MELIUS D 235336 02 15 
NELSON HL 242248 03 09 
NELSON JF 247588 04 03 
NEMEROFF CB 232618 02-03 
NEMTSOV AV 231070 01-03. 236265 02-03 
NEREANTIU F 239089 03-05 
NESMELOV NB 241987 03-03 
NETTER P 226898 01-09 
NEUMEYER JL 238319 02 04, 248286 04-03 

248287 04-02 
NEVILLE M 238804 03-04 
NEWBERG DC 252024 04-03 
NEWMAN H 228224 01 08 
NEYE J 231317 01-15 
NEZIROGLU FA 233870 02-11 
NG KT 253290 04-04 
NG LKY 226870 01-03 
NICHOLS WK 252027 04-03 
NICKLAS WJ 237140 02-03 
NICOLESCU P 239039 03-05 
NICOLL RA 247513 04 03 
NICOTERA M 247969 04-09 
NiEDERHOFF H 243194 04 10 
NIELSEN NP 244587 04 08 
NIEMEGEERS C 249289 04-04, 250656 04-03 
NIEMEGEERS CJE 225571 01-04, 230452 01 04, 

232529 01-04, 237744 02 04, 241228 03-04, 

241229 03 04, 250355 04-03, 251429 04-03, 

253394 04 04 
NIES A 239938 03-10 
NIESSNER G 244045 04 11 
NIETOD 235364 02-08 
NIGHTINGALE SL 250711 04 1 7 
NIKAIDO RS 235587 02-04 
NIKOLICS K 248349 04-03 
NIKOLOV R 240205 03 05 
NIKOLOVA M 240205 03-05 
NING JL 240850 03 08 
NISHIDA H 228074 01-11 
NISHIKUBOM 249123 04-13 
NISHIMORI T 231316 01-04 
NISS Al 236725 02-08 
NISSEN C 248349 04-03 
NISTICO G 252034 04-03 



NISTRI A 235327 02-08, 241922 03-03, 245595 

04 03 
NITSCH F 239834 03-04 
NIXON RA 241298 03-03 
NOBLE EP 225932 01-08, 238748 03-13, 241222 

03-03 
NOGUCHI T 229760 01-09 
NOMURA J 249123 04-13 
NOMURA Y 241361 03-03, 241366 03-03, 249667 

04-03 
NORDBERGA 251175 04-03 
NORDGREN L 251119 04-08 
NORDQVIST M 238316 02-03 
NOREN M 226412 01-08 
NORTON S 247207 04-04 
NOSAKA H 241379 03-04 
NOTSU Y 241382 03-04 
NOVICK WJ 238839 03-03 
NOVIN D 230872 01-04 
NOWACZYK T 23531 7 02-04, 245304 04-04 
NOWAK JZ 240238 03-03 
NOWAK T 238719 03-03 
NOWLIN JB 246440 04-14 
NOZAKI M 238704 03-04 
NUESSLE NO 233276 02-01 
NUWJAN R 23261 7 02-03, 248274 04-03 
NUNEZ AH 240850 03-08 
NUNN WD 236801 02-13 
NUNZIATA A 232502 01-03 
NURIMOTO S 241384 03-03 
NUROWSKA K 243986 04-08, 244049 04-08 
NUTTJG 231319 01-13 
NYBERG G 237152 02-16, 237902 02-13 



OAKLEY GP 229349 01-17 

OBERINKJI 230877 01-06 

OBOYLEJH 230763 01-13 

OBRIEN CP 229852 01-17 

OBRIEN EMD 236118 02-11 

OCHI Y 249124 04-14 

ODUTOLA A 248725 04-03 

OEHME M 235589 02-06 

OETTINGER L 238510 02-11 

OFFERMEIER J 250940 04-03 

OGAWA H 241400 03-04 

OGAWA N 227818 01-11,229064 01-08 

OGAWA Y 241388 03-03 

OGELTREE AM 227569 01-14 

OGILVIE A 245469 04-11 

OGITA K 252181 04-17 

OGLE CW 251986 04-14 

OGREN S 232507 01-03 

OGREN SO 250937 04-03 

OGRIS E 233718 02-15 

OGURA C 227808 01-15,244779 04-15 

OHARA H 247030 04-11 

OHASHI M 238563 02-03 

OHASHI T 238758 03-03 

OHMAN R 237152 02-16 

OHSHIMA M 246309 04-07, 249120 04-08 

OHTAKA T 232703 02-04 

OJEMANN LM 251937 04-13 

OKA M 241375 03-04, 241388 03-03, 247039 

04-03 
OKA T 241394 03-03, 241395 03-03, 241396 

03-03, 241402 03-03 
OKAGE T 241374 03-04 
OKAMOTO H 247013 04-03 
OKAMOTO M 238770 03-03 
OKUIZUMl K 238564 02-04, 241376 03-04, 

241400 03-04 
OKUMA T 227808 01-15, 228327 01-09, 244779 

04-15 
OLDS ME 232332 01-04, 239980 03-04, 239981 

03-04 
OLDS SW 229295 01-11 
OLEARY MH 246286 04-03 
OLESEN OV 2371 10 02-04, 244651 04-03 
OLESHANSKY MA 228032 01-03, 250376 04-03 
OLIVER J 248464 04-13 
OLKONIEMI J 229907 01-14 
OLLING M 241359 03-02,251419 04-03 
OLMSTED CA 238812 03-03 
OLSEN DM 231010 01-03 
OLSEN JL 237787 02-16 
OLSEN MR 227461 01-17 
OLSEN RW 238779 03-03 



OLSNERV 228550 0103 

OLSON RK 237731 02-04 

OMBRATO M 230993 01-11, 247969 04-09 

ONEILL JJ 236521 02-03, 238777 03-03 

ONOJK 241994 03-04 

ONO N 241406 03-03 

ONO S 243094 04-17 

ONO T 248358 04-03 

ONODERA K 242202 03-03 

OOMURA Y 248358 04-03 

OPMEER FA 241246 03-03 

OPPENHEIM RW 228630 01-04 

OPRESCU M 242863 04-15 

ORBACH L 235361 02-09, 242249 03-09 

ORCUTTJC 244315 04-03 

ORDONEZ LA 232613 02-03 

ORELAND L 226413 01-11 

ORLANSKY H 248699 04-03, 253691 04-03 

ORLOFF ER 237699 02-04 

ORLOV BN 236261 02-03 

ORME AE 237264 02-04 

ORME M 245653 04-13 

OSAWA T 230475 01-03 

OSBORNE NN 243799 04-03 

OSE E 246623 04-09 

OSGOOD PF 238805 03-02 

OSHEAL FE 229715 01-11 

OSHEROFF R 251966 04-11 

OS HI MAM 229064 01-08 

OSMAN MY 237117 02-03 

OSNES J 239044 03-03 

OSTERHOLM KG 249250 04-03 

OSWALD I 239059 03-14 

OTERO JB 239848 03-04 

OTHMER E 229924 01-14 

OTIS LS 241244 03-04 

OTT J 234291 02-11 

OTTEN U 251393 04-03, 251434 04-03 

OUGHOURLIAN JM 247554 04-09 

OURI P 227222 01-09 

OURY M 244450 04-11,24445104-11 

OVERSTREET DH 247209 04-04 

OVERTON DA 249025 04-04 

OYE I 239044 03-03 

OZAKI M 241365 03-03 

OZAWA H 241364 03 04, 246664 04-04 

OZKURTS 246820 04 04 



PAALZOW G 237697 02-04, 252026 04-03 

PAALZOW L 237697 02-04, 252026 04-03 

PAC WS K A A 23404 7 02- 1 1 

PADJEN A 232512 01-03 

PALFAI T 242733 03-04 

PALFREYMAN ES 249675 04-03 

PALFREYMAN MG 249675 04-03 

PALLETTJ 226899 01-09 

PALLIS CA 246699 04-15 

PALM U 226411 01-09 

PALMER DS 237756 02-03 

PALMER GC 237241 02-03, 238680 03-03, 239085 

03-03, 239582 03-03, 249286 04-03 
PALMER L 245653 04-13 
PALUBA M 243986 04-08 
PAMPLIN W 249249 04-03 
PANASYUK LV 228551 01-03, 236233 02-03, 

236713 02-03, 241982 03-05 
PANDHI V 251215 04-04 
PANDINA RJ 246819 04-04 
PANELLJ 239943 03-15 
PANG DC 237245 02-03 
PANITCH ML 245001 04-14 
PAOLINO RM 226865 01-03, 249672 04-04 
PAPAV 235998 02-10 
PAPAVASILIOU PS 237253 02-11 
PAPESCHI R 226726 01-03, 237698 02-03, 237736 

02-03, 237737 02-03, 241224 03-04, 253393 

04-03 
PAPROCKI J 253051 04-08 
PARE CMB 227139 01-03, 245233 04-13 
PARENT A 244638 04-03 
PARENT M 250266 04-17 
PARKER ES 238748 03-13 
PARKER J 253593 04-04 
PARKER LA 252859 04-17 
PARKER RB 238842 03-04 
PARKER T 238828 03-03 
PARKESJD 250722 04-15,251239 04-11 



A-14 



VOLUME 14, AUTHOR INDEX 



Author Index 



PARLI CJ 248605 04-02 

PARMAR SS 238712 03-03, 239661 03-03, 

239662 03 03 
PAROLI E 229549 01-15 
PARRY 241923 03-03 
PARS HC 238805 03-02 
PARS HG 248646 04-02, 248647 04-02, 248651 

04-02 
PARSON N 237734 02-14 
PARUTA AN 238487 02-01 
PASCHELKE G 239854 03-03 
PASHUK LK 236373 02-03 
PASIUD-WANIEK J 234046 02-09 
PASQUALI E 243198 04-11 
PASTERNAK GW 252219 04-03 
PASTERNAK V 239860 03-04 
PATARNELLO L 229558 01-17 
PATAY M 247151 04-04 
PATCH ICL 239001 03-15 
PATEL BC 237729 02-04, 247730 04-03 
PATEL DM 239659 03-01 
PATHAK D 228221 01-08 
PATLAK C 231002 01-03 
PATON WDM 243787 04-03 
PATRICK RL 238729 03-03 
PATTERSON CD 227826 01-09 
'AUL CJ 231007 01-03 
PAULSON GW 241900 03-15 
'AWLOWSKI GJ 237900 02-10 
^AWLOWSKI L 250058 04-03 
^AZDERNIK TL 251700 04-03 
'EARL J 252520 04-05 
'EARLMAN C 245301 04-04 
'ECKNOLD JC 231034 01-08, 231035 01-09, 

235355 021 7, 235359 02-07, 235361 02-09, 

235362 02-09, 235363 0209, 235367 02-09 

235368 02-09, 235369 02-07, 235370 02-09 

242249 03-09, 253053 04 07 
'EDIGO NW 246852 04-04 
'EEKE HVS 230865 01-04 
'EET M 247711 04-09 
'EIRIS JB 250932 04-07 
'EIXOTO MPB 253051 04-08 
'ELC I 237025 02-10 
'ELCHAT G 244497 04-15, 250991 04-15 
'ELET J 246273 04-15 
^ELIKAN EW 238845 03-04 
'ELZER NL 238718 03-04 
'ENNA MW 231610 01-09 
'ENOT C 239829 03-04 
'ENTREATH VW 243799 04-03 
>ENTTILA A 227136 01-15 
'ENTYUK AA 241986 03-03 
'EPEU G 249664 04-03 
'EPPERCORN MA 245307 04-13 
'EREL JM 229437 01-09, 229443 01-09, 238776 

03-01 
>ERERA HV 246715 04-11 
>EREX HC 253049 04-08 
'EREZ DE LA MORA M 232507 01-03 
'EREZ-CRUETJ 226870 01-03 
'EREZ-LOPEZ R 236658 02-10 
'ERI G 248291 04-03 
'ERINGER E 241929 03-03, 249628 04-03 
'ERKINS R 239058 03-14 
'ERLOFF MM 245649 04-11 
'ERRAUD J 227391 01-05 
'ERRIS C 226410 01-10,226412 01-08 
'ERRY KW 226765 01-03, 241339 03-03, 246847 

04-03 
'ERSINGER MA 252149 04-04 
'ERSSON G 226410 01-10 
■ERTA 249138 04-04 
'ERT CB 250378 04-03 
'ETEROVA E 234420 02-14 
'ETERS DAV 230853 0103 
'ETERS HD 251432 04-03 
'ETERS J 249771 04-10 
'ETERS MA 238723 03-03 
'ETERS UH 240709 03-08 
'ETERSEN GO 243089 04-13 
'ETERSEN H 238487 02-01 
'ETERSEN RC 23871103-14 
ETERSON DW 231437 01-04 
ETERSON JM 243789 04-03 
ETIT P 245116 04-05 
ETIT TL 252148 04-05 
ETOCZ L 231008 01-03, 252445 04-02 
ETRIEA 246699 04-15 



PETRUCH F 240692 03-15 

PETTERSON U 230824 01-09 

PETTIGREWJD 226397 01-03 

PETZOLD GL 230600 01-03, 230602 01-13 

PFEIFFER E 253061 04-11 

PFEIFFER K 249798 04-09 

PFLUEGER AB 244911 04-04 

PHEBUS L 238783 03-03, 239958 03-04, 252516 

04-03 
PHILIPPU A 251392 04-03 
PHILIPS SR 250379 04-03 
PHILLIPS AG 235587 02-04, 241300 03-04, 

244676 04-04 
PHILLIPS KC 245305 04-04 
PHILLIPS Ml 251142 04-03, 252170 04-03 
PHILLIPS N 237903 02-08 
PHILLIPS P 249004 04-06 
PHILLIS JW 232621 02-03, 248725 04-03 
PIALL EM 241256 03-03 
PIATEK W 248952 04-03 
PICCHIONI AL 238706 03-04, 251989 04-04 
PICHOT P 227216 01-09, 240444 03-)7 
PICK GR 236801 02-13 
PICKENS R 250010 04-04 
PICKWORTH WB 238703 03-03, 238772 03-03 
PIDEVICH IN 241982 03-05 
PIERI L 228051 01-03, 232515 01-03 
PIERI M 228051 01-03 
PIERS DA 235630 02-09 
PIETRUSZEWSKA I 244050 04-08 
PI CACHE RM 235629 02-08 
PIHKANEN TA 246623 04-09 
PIHL R 247420 04-04 

PIJNENBURG AJJ 237704 02-04, 248285 04-02 
PILC A 240238 03-03 
PILLING JB 226349 01-14 
PINDER RM 239964 03-04 
PINEAU R 244497 04-15, 250991 04-15, 251829 

04-08 
PINES A 251006 04-07 
PINTO A 232781 02-08 
PINTO F 229557 0114,229559 01-10 
PIRCH JH 243953 04-14, 249250 04-03 
PI RES P 244497 04-15, 250991 04-15 
PISARSKI W 229680 01-04 
PISZKIEWICZ FF 237174 02-01 
PITLICK WH 239658 03-13 
PITTNER H 251415 04-03 
PLACIDI GF 229554 01-16, 241234 03-13, 253393 

04-03 
PLAKUN E 246617 04-17 
PLANCHE R 237095 02-11 
PLANCHE S 237095 02-1 1 
PLANZ G 251418 04-11 
PLANZ R 251418 04-11 
PLECH A 227637 01-04 
PLETSCHER A 244038 04-17 
PLEUVRY BJ 237741 02-03 
PLONK JW 237927 02-13 
PLOTNIKOFF N 248647 04-02, 248651 04-02, 

248652 04-02, 251701 04-01 
PLUTCHIK R 227330 01-11 
PODDAR MK 243182 04-03 
POIGNANT J 244899 04-04 
POKORNYA 233828 02-15 
POLC P 232515 01-03 
POLDINGER W 241759 03-10 
POLK A 250332 04-06 
POLLARD GT 249273 04-03 
POLLOCK M 248172 04-11 
POLOSAC 238771 03-03 
POL VAN N 227826 1 -09, 24 1 275 03- 1 
POLYAKOVA AG 236261 02-03 
POLZIN R 239982 03-03 
POMERLEAU G 246126 04-17 
POND SM 226829 01-13 
POOL 247483 04-08 
POPOVA NK 228549 01-04 
POPPING A 251980 04-04 
PORFIRYEVA RP 228547 01-04, 236232 02-03 
PORGES SW 231629 01-14 
PORSOLT RD 249668 04-04 
PORTA M 246993 04-13, 246994 04-13 
POST A 246970 04-13 
POST ML 226761 01-03 

POST RM 227785 01-09, 231771 01-04, 234797 
02-09, 237169 02-04, 240241 03-04, 243023 
04-09, 243024 04-17, 243440 04-03, 243819 



04-13, 243820 04-17, 249005 04-04, 250389 
04-13 
POTGIETER B 250940 04-03 
POTTER JJ 247032 04-03 
POTTER LS 248394 04-04 
POUST Rl 246275 04-13 
PRADA JA 244674 04-06 
PRADHAN SN 226943 01-04, 238754 03-04, 

249033 04-03 
PRANGE AJ 232618 02-03, 2501 10 04-03 
PRASTKA GJ 235678 02-17 
PRAY BJ 227745 01-15 
PREACHE MM 249296 04-02 
PREDESCU V 236794 02-1 1 
PREDOMINATO M 226827 01-03 
PRESLEY R 237738 02-03 
PRESSLICH 226612 0)09 
PRESTON KL 238696 03-04 
PREZIOSI P 252034 04-03 
PRICE MTC 232915 02-03 
PRIEN R 236359 02-08 
PRIEN RF 225718 01-09, 227731 01-17, 229458 

01-11, 252954 04-09 
PRIEST RG 226898 01-09 
PRIVOLNEVA TP 236714 02-04 
PROCACCINI RL 241344 03-03 
PROCOPIU-CONSTANTINESCU T 229113 01-14 
PROCTOR DL 248008 04-04 
PROCTOR LR 246303 04-14 
PROSSER TD 226865 01-03, 244688 04-03 
PROTAIS P 227996 01-03 
PROUDFIT HK 23261 1 02-03 
PROZOROVSKIY VB 231072 01-06 
PRUSKAUER-APOSTOL B 226351 01-13 
PRUSOFF B 229450 01-09, 238981 03-10 
PRYOR GT 241244 03-04 
PRYTZ S 240054 03-13 
PRZEWLOCKI R 237785 02-03 
PUDWILL CR 250107 04-03, 250108 04-03 
PUECH AJ 252032 04-04 
PUERTO A 253255 04-04 
PUGLIESE A 237624 02-11 
PUGSLEY T 244316 04-02, 244678 04-03, 249313 

04-03 
PUJOL J 232624 02-03 
PUOLAKKAJO 226927 01-03 
PURDY RE 249242 04-03 
PURI SK 238845 03-04, 249139 04-04 
PURVIS CR 245469 04-11 
PUTZOLU S 235367 02-09, 235368 02-09, 235369 

02-07 
PUZYNSKI S 234047 02-11, 236429 02-10 
PYCOCK C 228050 01-03, 237781 02-03, 240063 

03-03, 243803 04-04, 249076 04-04, 249629 

04-04, 249679 04-04, 250358 04-04 
PYNE E 237696 02-14 
PYNNONEN S 253011 04-07 
PYSZKO J 242527 03-07 



QUADAGNO DM 242743 03-04 

QUARANTOTTI BP 237707 02-04 

QUARTERMAIN D 245614 04-02 

QUATTRONE A 241235 03-03 

QUENON BA 235320 02-04 

QUERMONNE AAA 227694 01-03, 248514 04-04 

QUIK M 244314 04-03 

QUISMORIO FP 232865 02-15 

QUITKIN F 228223 01 -08, 239937 03-09, 253047 

04-08 
QUOCK RM 240936 03-03 



RAABE W 241805 03-03 

RAAFAT H 251006 04-07 

RABINER CJ 253047 04-08 

RACAGNI G 241252 03-03, 244514 04-03, 247146 

04-03, 250362 04-03 
RACHIDA 22824101-11 
RACK PH 226897 01-15 
RAD A RT 228240 01-08, 249625 04-1 1, 250516 

04-10, 253050 04-11 
RADKO KA 231070 01-03 
RADOJP 232638 02-13 
RADULOVACKI M 231009 01-03 
RAFAELSEN OJ 240055 03-09, 249927 04-15 
RAFT D 232838 02-17 



e 

I 
% 

I 



A-15 



Author Index 



Psychopharmacology Abstracts 



RAHEEM KA 244692 04-03 

RAHEJA S 230907 01-08 

RAHMAN M 251006 04-07 

RAHN KH 251418 04-11 

RAI K HMAN LM 2367 1 5 02-03 

RAINEYJM 234713 02-15 

RAI NOVA L 248551 04-03 

RAITERI M 246665 04-03 

RAJPUT AH 245235 04-11 

RAMDOHR B 231317 01-15 

RAMOS JS 238734 03-03 

RAMSAY AC 235545 0217,243716 0415 

RANDALL PK 226850 01-03 

RANDALL RE 237813 02-15 

RANDRUP A 230869 01-04, 237107 02-04, 

247875 04-04, 248960 04-02, 253643 04-04 
RANE A 243086 04 13 
RAPINJ 230450 01-03 
RAPPW 226412 01-08 
RAPPORT MM 226186 01-04,248604 04-03 
RASKIN A 250726 04-11 
RASMUSSEN K 240048 03-15 
RASTOGI RB 241203 03-03, 243792 04-03, 

246152 04-03 
RATCLIFFE JG 230763 01-13 
RATHBUN RC 248605 0402 
RATTAN S 249278 04-04 
RAU WS AG 24 1 359 03-02, 25 1 4 1 9 04-03 
RAVARIS CL 239938 03-10 
RAYEVSKIY KS 236370 02-03 
RAZ A 244725 04-03 
RAZDAN RK 248646 0402, 248647 04-02, 
248651 04-02, 248652 04-02 

RAZZAK A 241398 03-04 

REA TH 248538 04-02 

REAK CJ 243780 04-03 

REAVEY-CANTWELL NH 237760 02-03, 239659 
03-01, 241344 03-03, 250332 04-06 

RECCHIAM 242212 0311 

RECH RH 234810 02-04, 237718 02-04 

RECHARDT L 235649 02-03 

RECKER RR 245651 04-13 

REEPMEYER JC 238476 02-01 

REGALADO RG 252141 04-07 

REGAN J D 251420 04-13 

REGINALDI D 232779 02-09 

REICHARD G 246970 04-13 

REICHMAN J 229924 01-14 

REICHMAN JD 242947 04-15, 244960 04-13 

REID D 226899 01-09 

REID JL 246843 04-03 

REID LD 250019 04-04 

REIDERER P 233917 02-11 

REINERT H 227391 01-05 

REINIS S 249030 04-03, 249031 04-03, 249032 
04-04 

REIS DJ 229491 01-03, 238759 03-03, 246845 
04-03 

REISBY N 243089 04-13 

REISECKER F 237124 02-08 

REISLER KL 230840 01-03, 238708 03-03 

REITER LW 227384 01-03 

REMY M 241760 03-08 

RENAUD B 232624 02-03 

RENNERT H 236348 02-17 

REUTER CJ 250935 0417 

REVUELTA A 226851 01-03, 236674 02-03, 
248698 04-05 

REVUSKY S 246093 0404, 252859 04-17 

REY-BELLET JJ 241760 03-08 

REYES E 238680 03-03 

REYNOLDS EH 230855 01-03, 237977 02-13 

REYNOLDS GP 237993 02-15 

REZEK M 230872 01-04 

RHEES RW 237864 02-03 

RICCIO A 242212 03-11 

RICCOBONI FA 249251 04-03 

RICH J 252223 04-03 

RICHARDS DJ 241274 0314 

RICHARDS RK 226926 01-04 

RICHARDS WA 228686 01-11 

RICHELSON E 23291 7 0203, 238692 03-03 

RICHENSA 225890 01-15 

RICHTER NA 251983 04-03 

RICKELS K 245649 04-11 

RIDING J 239014 0311 

RIOLON SA 238839 03-03 

RIE ED 240538 03-11 

RIE HE 226069 01 14. 240538 03-11 



RIEBLE R 238866 03-11 

RIEGE WH 239852 03-04 

RIEGER B 238782 03-03 

RIEGLE GD 240642 03-03 

RIFFEE WH 24 1 257 03-03, 24 1 576 03-03 

RIFKIN A 239937 03-09, 253047 04-08 

RIGGENBACH H 240064 03-03 

RIGGI F 230839 01-08 

RIGTER H 251980 04-04 

RIKLAN M 229165 01-11,23714102-14 

RILEY CC 238846 03-03, 248284 04-03 

RILEY PG 238476 02-01 

RIMESTAD S 227766 01-11 

RIMON R 239728 03-09 

RISBERG A 227140 01-14,230867 01-14 

RISBERGJ 230867 01-14 

RISMGNDO N 244899 04-04 

RISNERME 230879 01-04 

RISSE GL 251939 04-14 

RISSO AM 239641 03-11 

RITTER K 238866 03-11 

RITTER RC 238804 03-04 

RITTER S 238718 03-04 

RIVAE 247131 04-03 

RIVA M 237834 02-02 

RIVERA-CALIMLIM L 229492 01-13, 230918 

01-03, 233296 02-13, 238732 03-03, 241920 

03-03 
RIZK MM 238708 03-03 
ROBBINS T 226349 01-14 
ROBBINS TW 23771 1 02-04, 237712 02-04 
ROBERGE AG 244638 04-03 
ROBERTS MHT 241923 03-03 
ROBERTSON L 229840 01-11 
ROBINSON CA 249267 04-04 
ROBINSON DS 239938 03-10 
ROBINSON JA 245521 04-09 
ROBINSON SE 249305 04-06 
ROBINSON WW 227137 01-04 
ROBSON RD 249304 04-03 
ROBY D 248284 04-03 
ROBY DM 238846 03-03 
ROCCA E 246992 04-13 

ROCCATAGLIATA G 231369 01-11, 244589 04-09 
ROCH M 238828 03-03 
ROCHE J 237927 02-13 
ROCHETTE L 243777 04-03 
ROCHFORD J 247482 04-09 
RODDA BE 243087 04-14, 245648 04-14 
RODGERS JR 23831 7 02-01 , 250357 04-01 
RODNICK EH 229448 01-08 
RODOVAA 234419 02-11 
RODRIGUEZ-SIERRA JF 238822 03-03 
ROERIG DL 243780 04-03 
ROFFLER-TARLOV S 249233 04-03 
ROGERS ME 247586 04-01 
ROGERS SC 249536 04-16 
ROHRBACH KW 249273 04-03 
ROIZEN M 227777 01-03. 247028 04-03 
ROLLEMA H 248949 04-01 , 252523 04-03 
ROLLS ET 242748 04-04 
ROLSTEN C 247587 04-02 
ROMAN I 229115 0113,236793 02-14 
ROMANIUK A 232483 01-04 
ROMERO JA 234919 02-03, 2371 70 02-03, 241471 

03-17, 243795 04-03 
ROMILAA 229115 01-13,236793 02-14 
ROMILDO BUENO J 247968 04-08 
ROMMELSPACHER H 249074 04-03 
RONCAGLIONI MC 237240 02-03 
RONIGER JJ 237899 02-08, 247483 04-08 
ROONEY JFF 239010 03-15, 251006 04-07 
ROOS B 251374 04-08 
ROPARTZ P 237723 02-04 
ROPS RH 252033 04-03 
ROSECRANS JA 238768 03-04, 244683 04-04 
ROSEN TS 251428 04-05 

ROSENBAUM AH 227572 01-09, 23471 1 0209 
ROSENBAUM D 251960 04-13 
ROSENBERG FJ 248646 04-02 
ROSENBERG HC 238770 03-03 
ROSENBERGER PB 252793 04-1 1 
ROSENBLOOM MJ 23087101-14 
ROSENFELD H 245649 0411 
ROSENKRANTZ H 235671 02-05, 238807 03-05, 

243181 04-04 
ROSINA PL 231367 01-08 
ROSKOSKI R 238826 03-03 
ROSLOFF BN 231438 01-03 



ROSNERJ 229369 0115 

ROSS A 251149 04-17 

ROSS DC 228978 01-17 

ROSSJJ 247130 0403 

ROSS R 240599 03-17 

ROSS RA 238759 03-03, 246845 04-03 

ROSSANDA M 246993 04- 13, 246994 04-13 

ROSZELL DK 228977 01-05 

ROSZKOWSKI AP 227695 0102 

ROTH ES 251185 04-03 

ROTH RH 226856 01 03. 233971 02-03, 236519 

02-03, 237921 02-03, 241295 03-03, 241296 

03-03, 24721 1 04-03, 250085 04-03 
ROTH T 248976 04-08 
ROTH WT 230871 01-14 
ROTH-SCHECHTER BE 241348 03-03 
ROTHFELD B 240916 03-04 
ROT ROSEN J 247215 04-03, 249002 04-03 
ROUND E 253411 04-03 
ROUSOS AP 237897 02-08 
ROUTTENBERG A 238757 03-04 
ROUZIOUXJM 245116 04-05 
ROVARO E 237102 02-14 
ROVERE C 230839 01-08 
ROWAN MG 237784 02-01,237982 02-01 
ROWE H 248628 04-12, 249260 04-07 
ROWE ML 238485 02-02 
ROY M 251648 04-11 
ROY PE 229033 01 03, 229034 01-04, 229035 

01-03 
ROY VM 229693 01-09 
ROZDILSKY B 245235 0411 
RUBIN DC 238719 03-03 
RUBIN L 227330 01-11 
RUBOTTOM GM 249783 04-01 
RUCH W 239862 03-03 
RUCH-MONACHON MA 241315 03-03. 241316 

03-03, 241317 03-03, 241318 03-03. 241319 

03-03 
RUDOLPH SA 231014 01-03 
RUDY TA 239576 03-04.241255 03-03 
RUDY V 246629 04-09 
RUEST E 246694 04-11 
RUHLANDW 243180 04-11 
RUIZ M 246818 04 04 
RUIZ-NAVARRO JF 235366 02-08 
RUSSELL IS 252209 04-04 
RUSSO RM 251827 04-14 
RUSTERHOLZ DB 239660 03-01 
RUSTIN TA 244107 04-11 
RUTHER E 240218 03-08, 240219 03 1 1, 240220 

03-14 
RUTHVEN CRJ 227212 01-07 
RUTLEDGE CO 238688 03-03, 241345 03-03, 

249232 04-15 
RUWITCH JF 231318 01-13 
RYAN EA 250080 04-03 
RYAN MS 248976 04 08 
RYBAK PG 241986 03-03 
RYBAKOWSKI J 234044 02-09, 243979 04-09, 

243985 04-09 
RYZNARJ 230997 01-11 
RZEWUSKA-SZATKOWSKA M 236421 02-08 



SAARIO I 229907 01-14, 241417 03-15. 246315 

04-14 
SAARMA J 226900 01-13. 235365 02-08 
SAARMA M 226900 01-13 
SAAVEDRAJM 241208 03-03 
SABA P 247969 04-09 
SABBATINI F 229560 01-11 
SABELLI HC 238725 03-03, 240474 03-03. 248162 

0401, 249257 04 03, 249258 04-03, 249309 

04-03, 249310 04-03, 24931 1 04-03 
SACHAR EJ 245840 04 13 
SACHS C 241196 03-03 
SAC K RL 233964 02- 1 4, 234797 0209 
SACKLERAM 251215 04-04 
SACKS C 226737 01-13 
SADOWSKY CH 243791 04-03 
SAELENSJK 249304 04-03 
SAFER DJ 247377 04-15 
SAFRAMJ 229349 01 17 
SAGALES T 248629 04 13 
SAHAKIAN BJ 237712 02-04 
SAITOH 242200 03-03 
SAITO K 241361 03-03 



A-16 



rOLUME 14, AUTHOR INDEX 




Author Index 


AITO M 228226 0109 


SCHEIBJ 239932 03-11 


SENAULT B 241227 03-04 


AITO S 238563 02 03. 241401 03-04 


SCHEIN R 250084 04-03 


SENGUPTA D 241343 03-03 


AKABE T 246319 0403 


SCHELLEKENS KHL 232529 01-04 


SEPINWALL J 229461 01-04, 232509 01-04, 


AKALIS G 229445 0108, 251719 04-07 


SCHELLINGJ 240762 03-11 


238697 03-04 


AKAMOTO K 238565 02-03, 241378 03-04 


SCHENKER S 241730 03-13 


SEPPALAT 246315 04-14 


AKUMAA 228226 01-09 


SCHERBERGERRR 232503 01-13 


SEREGI A 246318 04-04 


AKURAOA S 241380 03-04 


SCHERMANN H 251408 04-17 


SERGEYEV PV 236717 02-03 


AKURADA T 242202 03-03 


SCHEURLEN HR 241736 03-15 


SERRA MT 238818 03-01, 249328 04-01 


AKURAI S 228214 01-15 


SC H 1 AVON M 239022 03- 1 


SERRANO L 243759 04-03 


AKURAI Y 246314 04-08 


SCHIELE BC 225867 01-08 


SERRANO M 228225 01-08 


ALAMA Al 249027 04-03 


SCHIFF AA 238975 03-08, 247030 04-1 1 


SERTEL H 243085 04-15 


ALETU B 232532 01-14 


SCHILDKRAUT JJ 234804 02-03, 241937 03-09, 


SETHI BB 231604 01-05 


ALETU M 232532 01-14 


247777 04-03 


SETHI N 231604 01-05 


ALIMOV RM 231069 01-04 


SCHILKRUT R 240218 03-08, 240219 03-11, 


SETOGAWA T 227808 01-15. 244779 04-15 


ALLER CF 243879 04-04 


240220 03-14 


SETYONEGORO RK 239269 03-1 1 


ALLOU C 244958 04-11 


SCHILLER GD 247209 04-04 


SEVER PS 249633 04-03, 250723 04-03 


ALVADORINI F 247969 04-09 


SCHILLING A 245649 04-11 


SEVIOUR PW 226937 01-04 


ALVENDYG 247217 04-14 


SCHLEMMER RF 238696 03-04 


SHABSHELOWITZ H 233290 02-03 


ALVENMOSER F 244692 04-03 


SCHMALBACH NL 242746 04-04 


SHADER Rl 227569 01-14, 229457 01-11, 229840 


ALZMAN C 227569 01-14,229457 01-11, 


SCHMIDT D 233280 02-13 


01-11, 236300 02-17, 237116 02 13, 237928 


229840 01-11, 236300 02-17 


SCHMIDT DE 239976 03-03, 249295 04-03, 


02-15, 243864 04-09, 250780 04-17, 251755 


ALZMAN PM 226856 01-03 


249300 04-03 


04-17, 252656 04-15 


AM J 247586 04-01 


SCHMIDT RH 238826 03-03 


SHAGASS C 251984 04-13 


AMANIN R 237240 02-03, 237742 02-03, 237743 


SCHMITT H 237118 02-03,237119 02-03 


SHAGSIOR BJ 237787 02-16 


02-03, 241235 03-03, 248159 04-03 


SCHNEIDER E 238516 02-11 


SHAH NS 229264 01-04, 235670 02-03, 238764 


AMBANDHAM R 251961 04-11 


SCHNEIDER PJ 249245 04-03 


03-03, 241349 03-04, 246817 04-03 


AMBROOKS JE 239010 03-15 


SCHNELL RC 226865 01-03, 244688 04-03 


SHAH PB 250332 04-06 


AMORAISKI T 247587 04-02 


SCHNIEDEN H 250082 04-03 


SHAH RK 248649 04-02 


AMOYLOV NN 241986 03-03 


SCHNOLL SH 247147 04-15 


SHAIN W 238736 03-03, 246998 04-03 


AMPSON P 247143 04-17 


SCHOCK G 234289 02 11 


SHANNON PJ 227550 01-11 


AMUEL D 237105 02-04, 248956 04-04 


SCHOENFELD Rl 252824 04-04 


SHAPIRO AK 235628 02 17 


ANCHEZ TE 240850 03-08 


SCHOLFIELD CN 237875 02-03 


SHAPIRO E 235628 02-17 


ANDERS B 241225 03-04, 250284 04 04 


SCHOLTYSIK G 226728 01-03 


SHAPOVAL LN 23683102-03 


ANDERS DG 230562 01-11 


SCHOLTZ J 244043 04-03 


SHARE JB 239074 03-11 


ANDERS-8'JSH E 226400 01-03, 246851 04-03, 


SCHONECKE OW 235782 02-1 1 


SHARMA RP 249265 04-05 


248414 04-05 


SCHONHOFER PS 241246 03-03, 251432 04-03 


SHAROV PA 228547 01-04 


ANDLER M 227212 01-07. 237993 02-15, 245233 


SCHONYW 244896 04-14 


SHARPE LG 238703 03-03. 238772 03-03 


04-13 


SCHOOLER NR 229445 01-08 


SHARPLES D 239684 03-13 


ANGER DJ 226852 01-04, 226854 01-04, 246306 


SCHOU M 253064 04-17 


SHATTUCK D 243865 04-03 


04-04, 250070 04-04, 251670 04-04 


SCHREIBER EC 247130 04-03, 253323 04-07 


SHAW GG 245596 04-05 


ANGHVI 1 236528 02-03, 237903 02-08, 237922 


SCHREIBER HL 239863 03-04 


SHAW JA 245521 04-09 


02-03, 241241 03-04, 249283 04-03 


SCHREINER HC 238977 03-15 


SHAWJM 247130 04-03 


ANNELLAJJ 245806 04-15 


SCHUBERT D 243482 04-03 


SHAW SG 242748 04-04 


ANSONE M 247778 04-02, 249026 04-04 


SCHUFFEL W 235782 02-11 


SHAYWITZ BA 251951 04-04 


ANTER RM 237738 02-03 


SCHULERME 227695 01-02 


SHEARD MH 240062 03-04. 251826 04-15 


ANTINI V 230860 01-03 


SCHULZ H 244896 04-14 


SHELLENBERGER MK 234067 02-03, 238716 03-03 


ANTOS CA 226528 01-04 


SCHULZE G 251409 04-04 


SHELLSHEAR ID 245856 04-13 


ANTOS MOREIRA M 241875 03-09 


SCHUPF N 250278 04-03 


SHEPPARD C 233829 02-08, 246694 04-1 1 


APRONOV NS 236716 02-03 


SCHUREN K 231317 01-15 


SHERMAN A 24615104-03 


ARACENI C 229529 01-14 


SCHUSTER CR 242747 04-04, 250076 04-14 


SHERMAN AD 232614 02-03 


ARAF K 247381 04-17 


SCHUSTER P 237647 02-14, 243438 04-15 


SHERMAN WR 238486 02-16 


ARI A 246319 04-03 


SCHWABACH G 247877 04-07 


SHERWIN AL 226737 01-13 


ARKAR C 253406 04-03 


SCHWARK WS 243790 04-03 


SHIBATAD 229026 01-07 


ATHANANTHAN G 237903 02-08, 242251 03-09, 


SCHWARTZ J 22665101-02 


SHIBUYA T 231316 01-04, 241378 03-04 


251720 04-08 


SCHWARTZ JC 227996 01-03 


SHIGEHISA T 242205 03-04 


ATINOFF E 252174 04-03 


SCORZA-SMERALDI R 250476 04-07 


SHIGENAGAY 251070 04-03 


ATO K 23 1 3 1 6 1 -04, 24 1 378 03-04 


SCOTTOJC 247546 04-17 


SHIH T 230840 01-03, 238708 03-03, 239086 


ATOM 230478 01-03,237782 02-03 


SCOVILLE B 239680 03-17 


03-03 


ATOH H 241382 03-04, 241403 03-03, 242201 


SCUDDER CL 238745 03-03. 249299 04-03 


SHILLADYDD 229493 01-06 


03-03 


SEBO J 252446 04-14, 252448 04-07, 252450 


SHIMAT 229760 01-09 


ATOH M 251433 04-03 


04-11 


SHIMADAA 229725 01-14 


ATOH Y 241382 03-04 


SEDVALL G 230824 01-09 


SHIMIZU M 241375 03-04, 241383 03-03, 241393 


ATTERFIELDJH 247385 04-17 


SEEMAN P 248466 04-03 


03-03, 247039 04-03 


AVAGEC 239824 03-11 


SEGAL DS 234809 02-04, 238843 03-04. 241307 


SHIMIZU S 241377 03-04 


AVIGNANO-BOWMAN J 230863 01-14 


03-04, 248947 04-03, 249486 04-03, 253255 


SHINY 228068 01-08 


AWA A 24 1 396 03-03, 24 1 402 03-03 


04-04 


SHINN B 253485 04-04 


AWADA M 237782 02-03 


SEGAL JL 249243 04-03 


SHIOMI H 241373 03-04 


AWINSKY 1 232638 02-13 


SEGAL M 251072 04-03, 252012 04-03 


SHIRAKAWA 1 249622 04-07 


AXEN 1 229350 01-15 


SEGAWAM 241373 03-04 


SHIROTAM 241376 03 04 


AXEN L 229350 01-15 


SEGAWA T 238565 02-03. 241361 03-03, 241366 


SHOEMAN DW 231003 01-03 


AXENA B 242248 03-09 


03-03, 249667 04-03 


SHOJI T 241380 03-04 


AYED AJ 236754 02-09 


SEGHETTI E 237834 02-02 


SHOPSIN B 230816 01-09, 236528 02-03. 237725 


AYERS AC 226728 01-03, 246671 04-03, 250360 


SEIBEL 1 251118 04-09 


02-08, 247216 04-09 


0402 


SEIDEL G 252222 04-03 


SHORE H 247420 04-04 


CATTON B 226858 01-03 


SEIDEN LS 230842 01-04, 233968 02-04, 238844 


SHORE PA 238730 03-03, 241919 03-03, 243760 


CHACHT U 238839 03-03 


03-04, 253111 04-04 


04-03 


CHAEFERA 246318 04-04 


SEIDLER FJ 253110 04-03 


SHORT PH 249274 04-04 


CHAEFFER JC 246316 04-03, 248637 04-01 


SEIFERT R 230866 01-16 


SHOSTAK M 229443 01-09, 238776 03-01, 


CHAFFNER R 232515 01-03, 251399 04-03 


SEILER N 239855 03-03 


245784 04 09 


CHAIN RJ 250682 04-05, 251949 04-1 1 


SEKERKE HJ 246851 04-03 


SHOTTON E 246317 04-01 


CHAUY AV 248349 04-03 


SELENATI A 246993 04-13, 246994 04-13 


SHOULSON 1 250942 04-n 


CHANBERG SM 231004 01-03, 241294 03-13 


SELIGER DL 246313 04-04 


SHUDO 1 242200 03-03 


CHAPPI R 241763 03 15 


SELIVANOVA AT 23671 1 02-04 


SHULL CM 247847 04-03 


CHARF M 252230 04-11 


SELL AB 251981 04-04 


SHULL HJ 241730 03-13 


CHARFMB 245652 04-11 


SELLERS EM 250779 04-11 


SHUSTER L 249274 04-04 


CHECHTER MD 238768 03-04 


SELLINGER OZ 227387 01-03 


SICE J 252061 04-14 


CHECHTER PJ 238781 03-04 


SELTZER V 237976 02-03 


SICILIANI 239022 03 10 


CHEDL R 244692 04 03 


SEMAL C 233817 02-08 


SIEGEL B 227330 01-11 


CHEFF TJ 239298 03 17 


SEMERARO S 244476 0411 

A-17 


SIEGEL SR 237813 02-15 






Author Index 



Psychopharmacology Abstracts 



SIEMENS AJ 238766 03-03, 249261 0404 

SIEW C 238701 03-03 

SIGGINS GR 238471 02-03 

SIGNORET J 248223 04-04 

SILBERFARB PM 246617 04 17 

SILLANPAA M 253011 04-07 

SILVERSTONE T 240086 03-17, 251156 04-10 

SIMM 226899 01-09 

SIMANTOV R 252219 04-03 

SIMEON J 232635 02-11 

SIMIONESCU L 242863 04-15 

SIMKE JP 249304 04-03 

SIMON G 243794 04-03 

SIMON H 244216 04-04,250982 04-04 

SIMON JR 249074 04-03, 249303 04-03 

SIMON M 246661 04-03, 246662 04-03 

SIMON P 227207 01-06, 237708 02-04, 249677 

0404, 249678 04-04, 251216 04-04, 251217 

04-03, 252032 04-04 
SIMON W 235589 02-06 
SIMOPOULOS AM 232781 02-08 
SIMPSON G 237696 02 14 
SIMPSON GM 229438 01-16, 231993 01-15, 

236529 02-06, 237828 02-08, 244501 04-08, 

245842 04-08, 247481 04-07 
SIMPSON LL 231113 01-17 
SIMS T 226305 01-04 
SINGER G 237721 02-05, 242744 03-17, 251982 

04-04 
SINGH AN 242248 03-09 
SINGH JM 229286 01-04 
SINGH MM 250989 04-15 
SINGH SB 245884 0411 
SINGH SP 239661 03-03, 239662 03-03 
SINGHAL RL 241203 03-03, 243792 04-03, 

246152 04-03, 253135 0403 
SINYUKHIN VN 236369 02-03 
SIOMOPOULOS V 245019 04-15, 250196 04-13 
SIRIS E 238491 02-13 
SIRIS SG 231277 01-08, 238489 02-08, 238491 

02-13, 238493 02-17 
SISHTA SK 252131 04-11 
SITARAM N 232760 02 1 4, 243822 04- 1 4 
SIVARAMAKRISHNA N 246822 04 03 
SIVOKHINA NV 242702 03-14 
SJODEN P 250013 04-04 
SJOERDSMA A 238781 03-04, 238782 03-03 
SJOGREN J 238998 03-15 
SJURSEN EH 241109 03-04 
SKINNER D 247206 04-04 
SKOLNICK P 240242 03-03, 253109 0403 
SKOTT A 251374 04-08 
SKOU M 236806 02-16 
SKOWRONSKAJ 23642102-08 
SKUSE N 226960 01-11 
SKYLER J 243440 04-03 
SLANGEN J 244691 04-03 
SLATER S 239305 03-13 
SLEATOR EK 247376 04-17 
SLIKKER W 238694 03-04, 249251 04-03 
SLOMAN L 235322 02-1 1, 245786 04-14, 252798 

04-11 
SLOTKIN TA 243779 04-03, 243796 04-03, 

253110 0403 
SLOVITER HA 243782 04-03 
SMALL AM 247480 04-08 
SMALL JG 232840 02-08, 253049 04-08 
SMART RG 236046 02-17 
SMEE ML 247206 04-04 
SMELT2ER DJ 227571 01-11, 239932 03-11 
SMERALDI E 250476 04-07 
SMIALOWSKA M 237785 02-03 
SMIDT NA 248172 04-11 
SMILEY KA 238767 03-03 
SMITH DF 225573 01 04, 246673 04-03, 252198 

04-03 
SMITH DH 249459 04-03 
SMITH DJ 243789 04-03 
SMITH ER 238800 03-04 
SMITH GP 245612 04-02 
SMITH HE 246851 04-03 
SMITH J B 229639 01-04 
SMITH JE 241205 03-04 
SMITH N 232617 02-03, 238713 03-04 
SMITH RC 229440 01 14, 232616 02-04, 250076 

04-14 
SMITH RV 239660 03-01 
SMITH SE 228997 01-13,235638 02-17 
SMITH SG 250021 04-04, 250658 04-04 



SMITH SJ 229494 01 -03 

SMITH TP 230825 01-04 

SMITH TW 233300 02-01, 253495 04-15 

SMITH VK 229449 01-09, 252941 04-09 

SMOLEN VF 232623 02-13, 237872 02-13 

SMULEVICH AB 244349 04-10 

SMYTH RD 237760 02-03, 241344 03-03, 250332 

04-06 
SNEAD OC 237826 02-03 
SNELL D 238814 03-04, 249275 04-04 
SNIBBE JR 244875 04-17 
SNIFFIN C 251830 04-13, 253037 04-15 
SNISARENKO AA 244449 04-04 
SNODDY HD 238691 03-03 
SNODGRASS RE 232762 02-1 7, 246033 04-1 7 
SNODGRASS SR 237873 02-03, 249983 04-03 
SNYDER BD 240614 03-17 
SNYDER SH 226407 01-03, 226936 01-12, 227400 

01-03, 235802 02-08, 240077 03-03, 243483 

04-03, 246996 04-03, 247862 04-03, 248701 

04-03, 248703 04-03, 249301 04-03, 250088 

04-03, 250378 04-03, 252219 04-03, 252515 

04-05 
SODERBERG U 250013 04-04 
SOFIA RD 226826 01-03, 248283 04-02 
SOKOL GH 226840 01-03 
SOKOL M 253037 04-15 
SOLARO F 239641 03-11 
SOLDINGER SM 236318 02-15 
SOLIMAN KFA 238751 03-03 
SOLOMON J 243865 04-03 
SOLOMON TA 248283 04-02 
SOLOW C 250856 04-17 
SOLYOM C 235826 02-10 
SOLYOM L 235826 02-10, 237896 02-10 
SOMAN I P 248647 04-02 
SOOKM D 235826 02-10 
SORIAAACHI M 226739 01-03, 237881 02-03 
SOSKIN RA 251752 04-17 
SOSSI N 249284 04-03 
SOTELO C 249899 04-03 
SOUBRIE P 249677 04-04, 249678 04-04, 251216 

04-04 
SOUIEF M 251004 04-10 
SOULAIRAC A 244874 04-03 
SOURKES TL 237747 02-03, 244314 04-03, 

247690 04-17 
SOYKA LF 243789 04-03 
SPANIS CW 250060 04-14 
SPANO PF 226406 01-03, 250356 04-03 
SPARSER SB 238687 03-04, 248697 04-03, 

249247 04-04, 249291 04-03 
SPATZ H 229827 01-09 
SPATZ M 239577 03-03 
SPAULDING TC 251534 04-03 
SPECIALE SG 235317 02-04 
SPECTOR NL 236526 02-06 
SPECTOR S 236526 02-06, 236527 02-03 
SPEHLMANN R 230457 01-03 
SPENCER CA 230763 01-13 
SPENCER PSJ 252134 04-17 
SPENCER RF 232838 02-17 
SPERANSKAYA NP 236372 02-04 
SPETH RC 249295 04-03 
SPIKER DG 231318 01-13 
SPIKER M 238811 03-04 
SPIKER MD 239582 03-03 
SPILKER BA 252520 04-05 
SPIRAKIS C 237890 02-03 
SPISSU A 237733 02-11 
SPOERRI PE 246587 04-03 
SPOHN HE 251996 04-08 
SPOONERJ 241754 03-17 
SPRAGUE GL 249263 04-03 
SPRAGUE RL 231629 01-14, 247376 04-17, 

248593 04-11 
SPRING C 247380 04-14 
SPRINGER NS 232815 02-15 
SQUIRE LR 250060 04-14 
SQUIRES RF 245296 04-03 
SREBRO B 252173 04-03 
STAAK M 237123 02-13 
STAHL JM 226305 01-04 
STAIBAG 228550 01-03 
STALLONE F 234203 02-09, 247582 04-09 
STANCER HC 228142 01-04, 238774 03-01 
STANOEN S 241234 03-13 
STANES MD 251982 04-04 
STANESCU A 252713 04-11 



STANEVA-STOYTCHEVA D 248551 0403 

STANFORD J 241459 03-08 

STANLEY ME 233291 02-03 

STARK P 249276 04-02 

STARKE K 248979 04-03, 248980 04-03 

STARLING LM 230739 01-13 

STARMER GA 239859 03-03, 249674 04-14 

STAVINOHA WB 230451 01-03, 249286 04-03, 

253106 04-03 
STAWARZ RJ 249255 04-03 
STEELE TH 237759 02-03 
STEFAN IK P 234309 02-03 
STEFANKO S 245599 04-03 
STEICHEN FM 238792 03-03 
STEIN L 232508 01-03 
STEINBERG H 244687 04-04 
STEINERAL 229318 01-03 
STEINER FA 240523 03-03 
STEINER SS 239272 03-04 
STELLA B 230818 01-10 
STENBERG VI 239661 03-03 
STENCKA K 244050 04-08 
STEPANIAN K 235305 02-11 
STEPHANYW 251418 04-11 
STEPHENS DN 250075 04-04 
STEPHENSON JBP 251103 04-11 
STEPHENSON JD 252034 04-03 
STEPOCHKINA NA 241988 03-03 
STERLING 227820 01-14 
STERN G 247712 04-17 
STERN JJ 24431 1 04-04, 250012 04-04 
STERNBERG DE 248583 04-09 
STETTNER U 239673 03-04 
STEVENS W 237864 02-03 
STEVENSON J 250491 04-10 
STEWART CN 232639 02-04 
STEWART JA 253053 04-07, 253054 04-1 1, 

253055 04-1 1, 253056 04-1 1, 253059 04-1 1 
STEWART JT 233277 02-06 
STEWART M 24771 1 04-09 
STEWART AAJ 235545 02-17 
STEWARTS 240538 03-11 
STEWART WJ 237728 02-04, 247863 04-04 
STILL CN 249367 04-13 
STILLMAN R 236750 02-08 
STILLMAN RC 243013 04-04 
STIMMEL GL 227560 01-17 
STINUS L 237103 02-04,248964 04-04 
STITZEL RE 238700 03-03 
STITZER ML 237874 02-04 
STJERNHOLMMR 23300102-13 
STOCK G 241232 03-03 
STOCK K 246389 04-03 
STOCKARDJJ 236667 02-15 
STOCKDALE S 2371 15 02-14, 237926 02-1 1 
STOFF DM 227802 01-04, 236672 02-04, 241474 

03-14, 244195 04-12 
STOICAL 252713 04-11 
STOKES JD 238745 03-03 
STOKES PE 236801 02-13 
STOLERMAN IP 249671 04-04 
STOLK JM 229495 01-02, 238762 03-01, 243791 

04-03 
STOLL PM 236801 02-13 
STOLE RE 226865 01-03, 244688 04-03 
STOLLER K 251825 04-14 
STOLMAN S 230919 01-03, 23101 1 01-03 
STOLTMAN WP 232623 02-13 
STONE J 241129 03-03 
STONE R 250423 04-13 
STONE TW 237925 02-03, 243805 04-03 
STONE WN 235534 02-17 
STORES G 230368 01-11 
STORLIEN LH 251629 04-05 
STRAHILEVITZ M 23751102 17 
STRATTEN WP 226945 01-04 
STRAUGHAN DW 252521 04-03 
STRAUMANISJJ 251984 04-13 
STRAUSS ME 245559 04-08 
STRETCH R 237699 02-04 
STRICKER EM 227125 01-04, 243815 04-03, 

243879 04-04 
STRIPLING JS 237731 02-04 
STROMBOM U 251226 04-02 
STRUENING EL 235628 02-17 
STRUMIA E 232530 01-07 
STRZELCZYK M 238674 03-03 
STUBBS DF 248532 04-10 
SU MJ 248409 04-03 



A-18 



VOLUME 14, AUTHOR INDEX 



Author Index 



SUCHANEK-FROHLICH H 233698 02-07 

SUDILOVSKYA 231112 01-17 

SUENAGA N 241372 03-04 

SUENAGE N 245597 04-03 

SUGAWARA K 241365 0303, 246664 04-04 

SUGERMAN AA 231994 01-15, 247482 04-09 

SUGIMORI M 248358 04-03 

SUGRUE MF 237748 02-03, 241924 03-03 

SUH KY 228072 01-15 

SULLIVAN JW 238697 03-04 

SULLIVAN MF 238806 03-03 

SULSER F 226400 01-03, 229497 01-03, 245115 

04-03, 249255 04-03, 249305 04-06 
SULTAN WE 248538 04-02 
SULZBACHER SI 233513 02-17 
SUAAAN A 229552 01-17 
SUMMERFIELD A 235509 02-04 
SUNAMI Y 228327 01-09 
SUNDARESAN PR 230918 01-03, 233296 02-13 
SUNDWALL A 251175 04-03 
SUNG YF 241314 03-04 
SUNGURBEY K 241275 03-10 
SUNIER A 229370 01-11 
SURAN AA 249294 04-03 
SURI AK 251158 04-10 
SURIA A 229463 01-03, 232513 01-03 
SU WAN A AB 24 1 849 03-09 
SUZUKI JS 251977 04-04 
SUZUKI M 241370 03-04, 241371 03-04 
SUZUKI 237923 02-03 
SUZUKI T 228214 01-15 
SVARE B 245406 04-04 
SVENSON TH 227126 01-04 
SVESTKAJ 234419 02-11 
SWANN JW 235588 02-03 
SWANSON GD 251825 04-14 
SWARTZBURG M 247482 04-09 
SWEET RD 250927 04-1 1, 251651 04-07 
SWETT C 225722 01-15, 253661 04-15 
SYMES AL 237747 02-03 
SYNDER SH 232511 01-03 
SYVALAHTI EKG 229042 01-13 
SZABADI E 251705 04-03 
SZCZAWINSKA K 240237 03-04 
SZE PY 226401 01-03, 237706 02-03, 239581 

03-03 
SZECHTMAN H 227343 01-03 
SZOBOR A 252449 04-07 



TABAKOFF B 238675 03-03 

TABET P 249693 04-11 

TACHIBANA H 229064 01-08, 246309 04-07 

TADANO T 242202 03-03 

TADOKORO S 238564 02-04, 241376 03-04, 

241400 03-04 
TAGLIAMONTE A 244513 04-03 
TAHEDL A 237124 02-08 
TAKAGI H 241373 03-04, 242204 03-03 
TAKAHASHI H 233281 02-14 
TAKAHASHI R 225570 01-03, 228226 01-09 

246314 04-08 
TAKAHASHI RN 249622 04-07 
TAKAHASHI S 234673 02-09, 249121 04-08 

249124 04-14 
TAKAI H 246971 04-03 
TAKAMI N 241365 03-03 
TAKANO N 241399 03-04 
TAKIMOTO GS 246316 04-03 
TAKISHITA S 241372 03-04 
TALALAYENKO AN 231251 01-04, 236257 02-04 

236828 02-04, 241980 0303 
TALENS GM 227384 01-03 
TAMAI A 227808 01-15,244779 04-15 
TAMAKI Y 253450 04 04 
TAMIR H 248604 04-03 
TAAAURAA 228334 01-09 
TANABE K 241379 03 04 
TANABE T 242200 0303 
TANAKA A 241361 03-03 
TANAKA M 229064 01-08, 244528 04-08 
TANAKA T 238717 03 04 
TANAKA Y 249667 04-03 
TANG AH 240019 03-04 
TANGHEAJ 229128 0114 
TANI N 249121 04 08 
TANNER NS 229498 01 03, 233361 02-01 
TANSELLA M 239022 03 10 



TARCZYNSKA K 236421 02-08 

TARIKAS H 243482 04-03 

TARISKAJ 252444 04-17 

TARSY D 249629 04-04, 249679 04-04 

TARYAN S 227550 01-11 

TASHKIN DP 237787 02-16 

TASSIN JP 244636 04-06 

TAUBE HD 248979 04-03, 248980 04-03 

TAUKULIS H 246093 04-04 

TAYLOR FH 247514 04-03, 248276 04-03, 252221 
04-03 

TAYLOR KM 226850 01-03, 250333 04-03 

TAYLOR M 225572 01-03, 250939 04-02 

TAYLOR MA 253617 04-09 

TAYLOR RJ 245016 04-09 

TEALEJD 241256 03-03 

TEAS DC 234682 02-03 

TECCEJJ 230863 01-14 

TEIGEN JR 228224 01-08 

TEIGER DG 248646 04-02 

TEITELBAUM H 249484 04-03 

TEITELMAN G 249666 04-03 

TEMKOV I 236363 02-10, 236732 02-09 

TEMPLER Dl 252131 04-11 

TEN HAMM 241359 03-02 

TEPLAN I 248349 04-03 

TEPPEMA L 238321 02-03 

TERNAUX JP 247213 04-03, 249512 04-03 

TERRELL CL 238727 03-03 

TERRIS BZ 248647 0402, 248651 04-02 

TESSEL RE 230874 01 04, 238688 03-03 

TETSCHE K 241221 03-04 

TEUTSCH H 242503 03-08 

TEYCHENNE PF 245647 04-13, 246699 04-15 

THADDEU R 227138 01-04 

THAETE LG 238723 03-03 

THATCHER JW 230830 01-14 

THATCHER KM 241681 03-04 

THEISS P 226726 01-03, 237736 02 03, 237737 
02-03, 241224 03-04 

THEL S 244681 04-03 

THIELEMANN H 243340 04-01 

THIERRY AM 237103 02-04, 248964 04-04 

THIESSEN I 235676 02-n 

THOA NB 226870 01-03, 227777 01-03, 237862 
02-03, 238673 03-03, 247028 04-03 

THOENEN H 251393 04-03, 251434 04-03 

THOMAS BH 231007 01-03 

THOMAS J R 23551) 02-04 

THOMAS RC 235589 02-06 

THOMNSE K 244651 04-03 

THOMPSON DM 250073 04-06 

THOMPSON H 237725 02-08 

THOMPSON J 251158 04-10 

THOMPSON K 251996 04-08 

THOMPSON LW 246440 04-14 

THOMPSON MK 251163 04-11 

THOMPSON RD 231700 01-03 

THOMPSON RM 238488 02-01 

THOMSEN J 251129 0417 

THOMSEN K 237110 02-04 

THOR DH 233418 02-03 

THORNTON EW 226871 01-03, 230829 01-04, 

237713 02-04, 252522 04-03 
THORNTON WE 227745 01-15, 253391 04-15 
THURMOND A 244686 04-1 1 
THUT PD 238737 03-03, 238847 03-04 
TIKAL K 251991 04-04 
TILSON HA 234810 02-04, 237717 02-04, 237718 

02-04 
TINKLENBERG JR 230871 01-14, 241474 03-14 
TISSOT R 226915 01-09, 239819 03-14 
TITTON JA 228241 01-11 
TIZABI Y 237862 02-03, 238673 03-03 
TJIOE SA 236521 02-03, 238777 03-03 
TOBIAS LL 252848 04-08 
TODA N 252757 04-03 
TOGLIA JU 251961 04 1 1 
TOGNONI G 241234 03-13 
TOLMACHEVA NS 236370 02 03 
TOLMAN KG 245806 04-15 
TOLOSA ES 237253 02-11,251958 04-13 
TOMIZAWA S 241394 03-03, 241395 03-03 
TOMOSKY TK 242749 04-04 
TOMOV T 236363 02-10 
TONDO L 232779 02-09 
TONG TO 247089 04-15 
TONGE SR 237976 02-03 
TONKOPIY VD 231072 01-06 



TONON GC 226406 01-03, 250356 04-03 

TOOMEY TC 232838 02-17 

TOPIARA 234653 02-17 

TORDOFF AFC 241979 03-04, 245600 04-04 

TORRADOA 246273 04-15 

TORRELIO M 227702 01-04, 232615 02-04, 
237108 02-04, 245601 04-04, 249001 04-04 

TORRES A 235364 02-08, 253056 04-1 1 

TORRIELLI MV 232530 01-07 

TOSCANO L 237834 02-02 

TOTARO JA 24491 1 04-04 

TOTH F 252450 04-11 

TOTH K 252446 04- 1 4, 252450 04- 1 1 

TOUCHARD FM 2491 44 04-1 1 

TOWEYJP 251428 04-05 

TRABERT N 233296 02-13 

TRABKA J 243234 04-04 

TRABUCCHI M 226406 01-03, 233815 02-08, 
241252 03-03, 247146 04-03, 248700 04-03, 
250356 04-03 

TRAFTON CL 251989 04-04 

TRANIER Y 238781 03-04 

TRENCHARD A 2271 39 01 -03 

TRESNAK NJ 238837 03-03 

TRETHOWAN WH 253374 04-17 

TREUL S 237926 02-11 

TREVOR AJ 250107 04-03, 250108 04-03 

TRI TB 247148 04-15 

TRICK KLK 239818 03-10,252144 04-17 

TRIMBACH C 226734 01-04 

TROFIMENKO SP 236234 02-03 

TROSKOJE 243814 04-03 

TROUPIN AS 239658 03-13, 251937 04 13 

TRUDINGER BJ 243085 04-15 

TRUHAUT R 244874 04-03, 2451 14 04-06 

TRUIJENS CL 253381 04-14 

TRUITT EB 238849 03-03 

TRULSON M 226734 01-04 

TRULSON ME 239978 03-04, 249078 04-03, 
250083 04-04 

TRUMBO DA 253381 04-14 

TRZEBIATOWSKA-TRZECIAK 243979 04 09 

TSAI CC 252847 04-08 

TSANG B 253135 04-03 

TSCHABITSCHER H 233718 02-15 

TSENG L 249315 04-03, 253107 04-03, 253108 

04-04 
TSILLI Yl 228548 01-03 
TSO TOT 239857 03-04, 239979 03 04 
TSUANG MT 244498 04-09 
TSUCHIE H 244779 04-15 
TSUJIMURA R 249123 04-13 
TSUKADA Y 226932 01-04, 253695 04-03 
TSURUMI K 241397 03 04 
TSUTSUMI E 250423 04 13 
TSVETANOVA Y 236732 02-09 
TUBERGEN DG 252825 04-13 
TUCHINDA P 239646 03-14 
TUCKER A 242742 03-04 
TUMAAH 229452 01-17 
TUNNICLIFF G 253695 04 03 
TUOMIKOSKI S 246623 04-09 
TUOMISTOJ 251700 04-03 
TUOMISTO L 251700 04-03 
TURIN J 247877 04 07, 252006 04-08 
TURANO P 229439 0116 
TURKANIS SA 231010 01-03, 238767 03-03 
TURKER RK 226762 01-03 
TURNBULL KW 251703 04-03 
TURNBULL WU 250077 04-04 
TURNER DM 247731 04-03 
TURNER EG 238787 03-04, 239523 03-04 
TURNER P 226187 01-10, 227139 01-03, 227210 
01-07, 240086 03 17, 240802 03-13, 251162 
04-13, 251986 04-14 
TURNER WJ 229439 0116 
TUTTLE JB 232917 02-03 
TUTTLE WW 238735 03 03 
TWYCROSS RG 252143 04 11 
TYBER MA 245523 04-15 
TYCHSEN RL 250073 04-06 
TYE NC 230828 01-04 
TYRER P 251157 04-10 
TYRER S 250725 04-13 
TZENG SF 238791 03 03, 249292 04-03 



A-19 



Author Index 



Psychopharmacology Abstracts 



U 

UEKI S 241363 03-04. 241367 0304, 241389 
03-03, 241390 03-03, 241398 03-04 

UHLENHUTH EH 232781 02-08, 246303 04-14 

UHLIR F 230997 0111 

ULUS IH 246820 04-04 

UMEDA T 250423 04-13 

UNGAR F 250081 04 03 

UNGERLEIDER LG 250278 04-03 

UNGERSTEDT U 238471 02-03, 243348 04-04, 
248288 04-03, 250086 04-04 

URETSKY NJ 237873 02-03 

URSCHEL CW 238743 03-03 

URSIN R 252216 04-03 

USDIN E 233941 02-03, 237829 02-17 

UTZINGER R 253536 04-03 

UYENO ET 238788 0304 

UZUNOV P 236674 02-03 



VACCHINI F 229557 01-14 

VADDADI K 226897 01-15 

VALARINO F 236658 02-10 

VALATX J 249676 04-04, 252171 04-04 

VALDMAN AV 2361 74 02-04 

VALENTINE M 251005 04-10 

VALLE-JONES JC 247030 04-11 

VALLIANT PM 252149 04-04 

VALZELLI L 245873 04-17 

VAMOS MJ 247743 04-11 

VAN BRUGGEN JAA 225571 01-04 

VAN BUREN J 238724 03-03 

VAN DEN BOGAARO JH 252033 04-03 

VAN DEN BURG W 235630 02-09 

VAN DEN DRIESSCHE J 247151 04-04 

VAN DER HELM HJ 252760 04-09 

VAN DER HEYDEN JAM 248285 04-02 

VAN DER KOLK BA 236300 02-17 

VAN DURME R 237025 02-10 

VAN GELDER GA 227385 01-04 

VAN GELDER NM 226737 01-13 

VAN HART DA 230835 01-03 

VAN HEMERT JCJ 238982 03-1 1 

VAN KAMMEN DP 231019 01-17, 231277 01-08, 

237716 02-14, 238489 02-08, 238491 02-13, 

238493 02-17, 248160 04-10 
VAN LAERE E 240033 03 11 
VAN MAANEN EF 238672 03-03 
VAN PRAAG HM 235630 02-09, 238997 03-13, 

241912 03-08, 245510 04-09 
VAN PUTTEN T 230562 01-11 
VAN RIPER DA 238762 03-01 
VAN ROSSUM JM 237104 02-03, 237270 02-06, 

237704 02-04, 238321 02-03, 248285 04-02, 

252033 04-03 
VAN SPANNING HW 230819 01-03 
VAN WOERT MH 251960 04-13 
VAN 2ANTEN AK 235630 02 09 
VAN ZOEREN JG 243815 04-03 
VAN ZWIETEN PA 230819 01-03 
VANDERHEEREN FAJ 244131 04-13 
VANINI M 230990 01-09, 230992 01-09 
VANOV SK 241274 03-14 
VARADYA 240916 03-04 
VARADY G 252448 04-07 
VARGA E 244501 04-08 
VASSAR HB 226826 01-03 
VAUGHEN CM 238849 03-03 
VAUPEL DB 237752 02-03 
VAZQUEZ AJ 240474 03-03, 249309 04-03 
VEALE WL 242736 03-03 
VELKOV V 236364 02-10 
VENCOVSK Y E 234420 02- 1 4, 234438 02- 1 7 
VENDSBORG PB 240054 03-13, 240055 03-09, 

249927 04-15, 25112904-17 
VERBURG D 236318 02-15 
VERDEAUX G 247554 04-09 
VEREVKINA IV 236369 02-03 
VERGARA L 235366 02 08, 253054 04- 1 1 
VERGNES M 239829 03-04 
VERHAEGEN JJ 225936 01-08 
VERNIER VG 249459 04-03 
VERSIANI CALDEIRA MV 247968 04-08 
VERTUA R 226827 01-03 
VESELl ES 244060 04-03 
VETULANI J 245 1 1 5 04-03, 249255 04-03 
VI ALA A 229906 0116 



VIANNA FILHO U 247968 04-08 

VICENTINI L 240643 03-03, 252030 04-04, 252201 

0403 
VIGELAND K 242868 04-11 
VIGOURET JM 241927 03-04, 249419 04-04, 

251405 04-03 
VIGRAN R 241222 03-03 
VIKHLYAYEV Yl 244456 04-04 
VILC M 234653 02-17 
VILLABLANCA J 249307 04-03 
VILLENEUVE A 251829 04-08 
VILLENEUVE R 244497 04-15, 250991 04-15 
VINCI M 229561 01-17 
VISHNUVAJJALA BR 238475 02-01 
VITOROVIC M 244620 04-08 
VIUKARI M 247967 04-11 
VIUKARI NMA 237162 02-17 
VIVIAN S 246586 04-03 
VIZI ES 252223 04-03 
VLAHOV V 248552 04-03 
VLAYEV S 236364 02-10 
VOGEL B 251649 04-07 
VOGEL GW 244686 04-11 
VOGEL JR 242882 04-04 
VOGEL WH 249036 04-03 
VOICULESCU V 226351 01-13 
VOISIN C 237118 02-03,237119 02-03 
VOITH K 245295 04-04 
VOLICER L 238845 03-04 
VOLLE RL 226855 01-03 
VOLPEJJ 251654 04-15 
VON CRAMON D 244896 04-14 
VON KNORRING L 226410 01-10, 244189 04-07 
VON PETRYKOWSKI W 243193 04-10 
VON SCHENCK H 226877 01-17 
VON SCHOULTZ B 226414 01-11 
VON SHNARTZENFELD I 228550 01-03 
VONVOIGTLANDER PF 238478 02-01, 248834 

04-03, 249930 04-03, 25! 184 04-03 
VORNE M 226927 01-03, 227696 01-03 
VOSPALEK DM 239856 03-04 
VOSSMER A 243865 04-03 
VRANCKX CH 227767 01-08 
VREEBURG JTM 244343 04-04 
VUKOVICH RA 253323 04-07 



W 



WACHTEL H 252028 04-04 

WADA JA 230475 01-03, 230478 01-03 

WADE ON 226829 01-13 

WAGENAAR WA 253381 04-14 

WAGERS PW 240843 03-15 

WAGNER BM 247208 04-03 

WAGNER JG 247846 04-06 

WAJDA I 237746 02-03, 240065 03-03 

WAKE A 230478 01-03 

WALDMANN K 234289 02-11 

WALDMEIER PC 251225 04-03, 251395 04-03, 

251398 04-03 
WALINDERJ 251374 04-08 
WALKER CA 238751 03-03 
WALKER J 251964 04-03 
WALKER J R 234682 02-03 
WALKER P 248222 04-10 
WALL FJ 250516 04-10 
WALL M 240064 03-03 
WALLACE JE 238789 03-03 
WALLACH MB 230878 01-04, 233963 02-03 
WALLER MB 239087 03-03 
WALLIN BG 251071 04-12 
WALTER GF 231629 01-14 
WALTERS J 251239 04-11 
WALTERS JR 233971 02-03, 241295 03-03, 

241296 03-03, 24721 1 04-03, 250085 04-03 
WALTON KG 246150 04-04, 251699 04-04 
WANG PEL 248600 04-03 
WANG PL 228390 01-04 
WANG RIH 237115 02-14, 237926 02-11, 243780 

04-03 
WANG SC 238702 03-03 
WARNERS 237734 02-14 
WARBURTON DM 242265 03-17 
WARD J W 251949 04-11 
WARNECKA-PRZYBYLSKA M 232545 01-17, 

234045 02-15 
WARNER AM 245789 04-15 
WARNER W 238808 03-03 
WARNES H 246296 0415 



WARSH JJ 238774 03-01 

WASER PG 246388 04-04, 251979 04-04 

WATANABE H 241391 03-03 

WATANABE K 241391 03-03. 243094 04-17, 

249253 04-04, 250682 04-05 
WATANABE M 228226 01 09, 245986 04-1 1 
WATANABE S 241367 03-04, 241389 03-03, 

241390 03-03 
WATANABE Y 241394 03-03, 241395 03-03 
WATERS IW 226849 01-03, 227389 01 -03, 

227390 01-03 
WATKINS JW 250077 04-04 
WATSON E 233291 02-03, 245300 04-03 
WATSON J 237696 02-14 
WATSON Y 247711 04-09 
WATTS DT 238808 03-03 
WATTS G 231749 01-17 
WAUD BE 233289 02-03 
WAUD DR 233289 02-03 
WAUQUIER A 230452 01-04, 232529 01-04, 

241229 03-04, 249289 04-04, 250656 04-03 
WAX/WAN S 248543 04-16 
WAY EL 237870 02-03, 241338 03-03, 249288 

04-04, 250079 04-04, 250087 04-02, 2531 12 

04-04 
WAY WL 250107 04-03,250108 04-03 
WAYNER MJ 242744 03-1 7, 248358 04-03 
WDOWI AK M 232545 01-17, 234045 02- 1 5 
WEAVER LC 231006 01-03 
WEAVER S 249004 04-06 
WEBER A 253587 04-12 
WEBER RO 251407 04-17 
WEBSTER CD 235322 02-11, 245786 04-14, 

252798 04-11 
WEI E 250087 04-02 
WEICHSEL M 243814 04-03 
WEIDLER DJ 247846 04-06 
WEINBERG WA 233499 02-15 
WEINBERGER J 237140 02-03 
WEINBERGER SB 249268 04-03, 249270 04-04, 

249290 04-03 
WEINER BE 248947 04-03 
WEINER N 238690 03-03, 246844 04-03 
WEINER WJ 251959 04-05 
WEINGARTNER H 243013 04-04 
WEINMAN J 230580 0115 
WEINRYB I 245949 04-06 
WEINTRAUB ST 230451 01-03, 253106 04-03 
WEISER G 237124 02-08 
WEISS AN 231318 01-13 
WEISS B 249287 04-03 
WEISS G 247384 04-14 
WEISS GB 238714 03-03 
WEISS GK 23881103 04 
WEISS J 244692 04-03 
WEISSMAN A 248406 04-02 
WEISSMAN L 251824 04-16 
WEISSMAN MM 229450 01-09, 238981 03-10 
WEITHORN CJ 240599 03-17 
WELBEL L 231983 0110, 243986 04-08, 244049 

04-08 
WELBURN PJ 239859 03-03 
WELCH J 249304 04-03 
WELIKY I 229036 01-07 
WELTMAN AS 251215 04-04 
WEMMER D 239932 03-11 
WENDLANDT S 239841 03-04 
WENDLER H 233717 02-11 
WENGER GR 237757 02-04, 2501 12 04-04 
WEPIERREJ 230450 01-03 
WERNECKE 243180 04-11 
WERNER G 244681 04-03 
WERNER SS 236667 02-15 
WERNER TE 250021 04-04 
WERRY JS 247378 04-15, 247743 04-11, 243593 

04-11 
WESELUCHA P 229515 01-10 
WESLEY VH 241225 03-04 
WESTJW 244136 04-11 
WEST NR 249036 04-03 
WEST SK 227923 01-11 
WEST WL 225766 01-11, 249253 04-04 
WESTERINK BHC 226727 01-03. 241207 03-03, 

249984 04-03, 252523 04-03 
WESTERMANN KH 250058 04-03 
WESTFALL OP 248413 04-03 
WESTFALL FC 241247 03-03, 252217 04-03 
WESTON PF 247206 04-04 
WHALEY K 228208 01-15 



A-20 



VOLUME 14, AUTHOR INDEX 




Author Index 


WHEATLEY D 229471 01-13, 248977 04-09 


WOODWARD DJ 240242 03-03 


ZATZ M 234919 02-03, 2371 70 02-03, 237921 


WHEATLEY DP 227224 01-09 


WOODWARD WA 252520 04-05 


02-03, 243795 04-03 


WHEATLEY J 237713 02-04 


WOODY GE 229852 01-17 


ZAWADZKI Z 229684 01-14 


WHEELDEN JA 252793 04 11 


WOOLLEY DE 227384 01-03 


ZEBROWSKA-LUPINA 1 227636 01-04, 237032 


WHEELER TJ 225572 01-03. 252522 04-03 


WORRALL EP 247711 04-09 


02-04 


WHELAN JE 241978 0303. 243848 04-03 


WORSHAM E 241546 03-04 


ZEMLAN FP 243878 04-04 


WHELIHAN W 237141 02-14 


WORZ R 238866 03-11 


ZEMLYANKIN AS 23671102-04 


WHELPTON R 237750 02-06 


WRAAE 253411 04-03 


ZEMPJW 226528 01-04 


WHISHAW IQ 242736 03-03 


WRIGHT DG 233295 02-14 


ZENTALL SS 251154 04-14 


WHITE A 238816 03-03 


WRIGHT J 238682 03-03 


ZENTALL TR 251154 04-14 


WHITE HL 249273 04-03, 249308 04-03 


WRIGHT JM 248724 04-03 


ZETLER G 237705 02-04 


WHITE JH 240522 03-17 


WRIGHT MW 229650 01-14 


ZETTLER G 249624 04-04 


WHITE PR 250107 04-03, 250108 04-03 


WURSTER RM 240014 03-04 


ZHARKOVSKIY AM 242544 03-03, 244455 04-04 


WHITE TG 246671 04-03 


WURTMAN RJ 233290 02-03, 238719 03-03, 


ZHURAVLEVA GV 236369 02-03 


WHITEHOUSE LW 231007 01-03 


238726 03-03 


ZIANCE RJ 238689 0303 


WHITESIDES GH 242749 04-04 


WURZBURGER RJ 236527 02-03 


ZIEGLER DK 237138 02-11 


WHITFIELD LR 251777 04-06, 251778 04-16 


WUTTKE W 233681 02-06, 239828 03-03, 240020 


ZIEGLER MG 239305 03-13 


WHITMAN RM 235534 02-17 


03-04, 246855 04-04, 251414 04-03 


ZIEGLGANSBERGER W 251433 04-03 


WHYTE MP 238796 03-13 


WYATT HJ 236863 02-03 


ZIEHER LM 249666 04-03 


WIDELITZ H 237871 02-03 


WYATT RJ 227802 01-04, 232324 01-11, 233817 


ZIELEMAN M 249984 04-03 


WIDELITZ MM 237871 02-03 


02-08, 234798 02-08, 235801 02-15, 236672 


ZIGMOND AAJ 227125 01-04, 229499 0104 


WIDLOCHER D 239607 03-17 


02-04, 236750 02-08, 238761 03-03, 241474 


ZILM DH 250779 04-11 


WIOMAN M 238316 02-03 


03-14, 243822 04-14, 244195 04-12, 251128 


ZIMMER U 228493 01-03 


WIECHERT V 244298 04-11 


04-09, 252519 04-03 


ZIMMERBERG B 240750 03-04 


WIECHMANN M 244681 04-03 


WYLLIE MG 243801 04-03 


ZIMMERMAN AW 233832 02-13 


WIECK HH 239768 03-17 


WYMAN SM 245789 04-15 


ZIMMERMANN RL 253048 04-08 


WIEDEKING C 248222 04-10 


WYNDOWEJ 237896 02-10 


ZINGERMAN AM 242702 03-14 


WIESEL F 251131 04-03 




ZINKIN S 241330 03-04 


WIESEN RL 237926 02-n 


Y 


ZIRNISA 237174 02-01 


WIESLER B 243194 04-10 




ZIS AP 227134 01-03 


WILBERT DE 225932 01-08. 236318 02-15 


YAGER RD 251951 04-04 


ZITRIN CM 22945101-10 


WILDMAN RW 229169 01-15. 229169 01-15 


YAGI G 228323 01-17, 252181 04-17 


ZIVKOVIC B 226185 01-04, 232921 02-03, 


WILEY RA 238476 02-01 


YAGI K 237923 02-03 


248698 04-05 


WILK S 233291 02-03. 245300 0403. 247216 


YAKSH TL 239576 03-04 


ZOL FAGH ARI M 2339 74 02- 1 1 . 25 1 649 040 7 


04-09 


YAMADA K 241372 03-04 


ZOUBOK B 247481 04-07 


WILKENING D 238739 03-03 


YAMAGUCHI E 229026 01-07 


ZSILLAG 250362 04-03 


WILKINSON GR 241730 03 13 


YAMAGUCHI T 249123 04-13 


ZUNG WWK 243862 04-17, 25306) 04-1 1 


WILKUS RJ 251937 04-13 


YAMAMOTO 1 241338 03-03 


ZWEIG JS 236520 02 03 


WILLARD DH 238806 03-03 


YAMAMOTO K 238971 03-03, 241388 03-03 


ZWERLING 1 227330 01-11 


WILLARD SP 228503 01-04 


YAMAMOTO T 24 1 297 03-03, 24 1 363 03-04, 


ZWIRNER PP 249668 04-04 


WILLEMSJL 237160 02-03 


241390 03-03 




WILLERJ 240657 03-11 


YAMAMURA H 229025 0110 




WILLIAMS CH 247020 04-03 


YAMAMURA HI 227400 01-03, 238715 03-03, 




WILLIAMS CL 250984 04-04 


238773 03-03, 249074 04-03, 249301 04-03, 




WILLIAMS EJ 232623 02 13. 237872 02-13 


252515 04-05 




WILLIAMS FM 243085 04-15 


YAMAMURA S 238563 02-03 




WILLIAMS JM 227099 01-04 


YAMANE H 249121 04-08 




WILLIAMS R 238845 03-04. 241754 03-17 


YAMAUCHI 1 249120 04-08 




WILLIAMS RT 250723 04-03 


YAMAUE S 228324 01-08 




WILSON JT 243086 04-13 


YAMAZAK 1 T 229026 1 -07, 229504 01-11 




WILSON MC 242747 04-04 


YANAGIDA T 228309 01-17 




WILSON RM 228221 01 08 


YANG HT 233947 02-03 




WINDORFERA 240723 03-17 


YANG RK 250175 04-15 




WINGER G 237874 02-04 


YARYURA-TOBIAS JA 233870 02-1 1 




WINN M 248648 04-02. 248652 04-02 


YEHUDA S 237097 02-03 




WINSON J 251061 04-03 


YELLIN AM 244932 04-15, 247380 04-14 




WINSTEAD DK 240278 03-17 


YERSHOVAVP 228554 01-05 




WINTER JC 230837 01-04, 245299 04-04, 249262 


YOKEL RA 250010 04-04 




04-04 


YONEDA R 241374 03-04 




WINTER M 243794 04-03 


YORK DH 238819 03-04 




WINTERS WO 238795 03-03, 249240 04-03 


YORK JL 245299 04 04, 249262 04-04 




WISE CD 232508 01-03 


YORKSTON N 251164 04-08 




WISE RA 249749 04-03 


YOSHIDA K 241383 03-03,241393 03-03 




WITIAK DT 238475 02-01 


YOSHIDA T 228325 01-08 




WITTEK F 239823 03-08 


YOSHIMURAM 249124 04-14 




WITTENBORN JR 25364104-11 


YOSHIZAKI T 241388 03-03 




WITTER A 246853 04-04 


YOUDIM MBH 239960 03-03, 241931 03-03 




WITZELL-OSTLUND G 226408 01-08 


YOUNG DN 238716 03-03 




WNEK D 230838 0104 


YOUNG GA 251533 04-04 




WOGGON B 238864 03-08. 24 1 76 1 03-08. 25 1 1 1 8 


YOUNG LD 229717 01-11 




04-09 


YOUNG RC 245612 04-02 




WOJCIAK Z 240237 03-04 


YU RK 237826 02-03 




WOLF AP 248537 04-01 


YUNGER LM 241251 03-04 




WOLF G 238719 03-03 


YUWILER A 237105 02-04, 248956 04-04 




WOLF HH 248880 04-03 






WOLF R 226612 01-09 


z 




WOLFARTH S 242745 04-04 






WOLFSON SK 238792 03-03 


ZABIKJE 226992 01-04 




WOLLERT U 251176 04-01.251177 04-01 


ZACCHEI AG 238684 03-03 




WOLTERS RJ 233361 02-01 


ZAIMOV K 236732 02-09 




WONG DT 238840 03-03. 246848 04-03, 250380 


ZAJACZKOWSKA A 244050 04-08 




04-03 


ZAJACZKOWSKA M 227635 01-03 




WOOD PL 253407 0403 


ZAKOWSKA DABROWSKA T 234044 02-09 




WOOD WG 239863 03-04 


ZAKUSOV VV 236232 02-03 




WOODBURY DM 237243 02-03 


ZALICK DH 237624 02-11 




WOODRUFF ML 231701 01-03 


ZALIPSKY JJ 239659 03-01 




WOODS JH 227127 01-04, 230874 01-04, 237874 


ZAMBOTTI F 240643 03-03, 252030 04-04, 




0204, 240015 03 04, 240018 03-04, 241250 


252201 04-03 




03 04, 249246 0404 


A-21 





SUBJECT INDEX 



ITht' Subiect Index is niachino generated. Keywords in the titles of abstrocts appear olphaheticolly in the left hand margin,- under each keyword is o list of titles in which the 
keyword appears The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the some word may appear in this index for example, 
BEHAVIOR ond BEHAVIOUR I 



COMPARISON OF THE EFFECTS OF LESION IN THE 0B9 CELL BODY GROUP 
AND P CHLOROAMPHETAMINE ON TRYPTOPHAN-HYDROXYLASE AND 
5-HYDR0XYTRYPTA/\AINE IN RAT BRAIN NUCLEI. 

237863 02-03 
iT4 

THE INFLUENCE OF DIETARY IODINE ON LITHIUM BLOOD LEVEL, SERUM 
0T4 AND THYROID GLAND WEIGHT. 

236528 02-03 
iBDOMINAL 

EVALUATION OF COMBINED PHARMACOLOGICAL AND 

PSYCHOTHERAPEUTIC TREATMENT IN PATIENTS WITH FUNCTIONAL 
ABDOMINAL DISORDERS. 

235782 02-11 
EFFECT OF CANNABINOIDS ON THE ABDOMINAL CONSTRICTION 
RESPONSE IN MICE: WITHIN CANNABINOID INTERACTIONS. 

239859 03-03 
ABILITIES 

EFFECTS OF SULTHIAME UPON INTELLECTUAL, NEUROPSYCHOLOGICAL, 
AND SOCIAL FUNCTIONING ABILITIES AMONG ADULT EPILEPTICS: 
COMPARISON WITH DIPHENYLHYDANTOIN. 

240475 03-14 
kBIUTY 

THE EFFECTS OF LOW-LEVEL DIELDRIN EXPOSURE ON THE EEG AND 
LEARNING ABILITY OF THE SQUIRREL-MONKEY. 

227385 01-04 
ON THE ABILITY OF NARCOTIC ANTAGONISTS TO PRODUCE THE 
NARCOTIC CUE. 

251429 04-03 
kBLATION 

EFFECTS OF FRONTAL POLAR CORTICAL ABLATION AND CYCLOHEXIMIDE 
ON ETHANOL TOLERANCE IN RATS. 

242741 03-03 
ABNORMAL 

EFFECTS OF CHOLINERGIC DRUGS ON ABNORMAL SOCIAL BEHAVIOR IN 
THE RHESUS MONKEY. (PH.D. DISSERTATION). 

241109 03-04 
kBNORMALITIES 

CHLORPROMAZINE-INDUCED ELECTROCARDIOGRAM ABNORMALITIES. 

231037 01-08 
OPHTHALMOLOGICAL FINDINGS ON NEUROPSYCHIATRIC PATIENTS 
DURING PSYCHOPHARMACOTHERAPY. I. OUTLINE OF THE INCIDENCE 
OF OPHTHALMOLOGICAL ABNORMALITIES. 

244779 04-15 
IMIPRAMINE DOSAGE IN CHILDREN: A COMMENT ON IMIPRAMINE AND 
ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE 
CHILDREN. 

245001 04-14 
DEVELOPMENT AND ADULT BEHAVIORAL ABNORMALITIES IN MICE 
TREATED NEONATALLY WITH CYCLOPHOSPHAMIDE. 

249296 04-02 
ABNORMALITY 

SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES: 

1) 
ABNORMALITY IN CENTRAL NORADRENERGIC NEURONS IN 
SPONTANEOUSLY HYPERTENSIVE RATS. 

241360 03-03 
VBOIISHES 

SELF-STIMULATION AND NORADRENALINE: EVIDENCE THAT INHIBITION 
OF SYNTHESIS ABOLISHES RESPONDING ONLY IF THE RESERVE POOL IS 
DISPERSED FIRST. 

246774 04-03 
kBRUPT 

MEDICAL EFFECTS OF ABRUPT NEUROLEPTIC WITHDRAWAL. 

251996 04-08 
kBSENCE 

PARADOXICAL ABSENCE OF AGGRESSION DURING NALOXONE 
PRECIPITATED MORPHINE WITHDRAWAL. 

227132 01-04 
LEARNING IN THE ABSENCE OF FOREBRAIN NORADRENALINE. 

234917 02-04 
EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE INJECTIONS ON 
SERUM PROLACTIN AND LH LEVELS: ABSENCE OF STRESS-INDUCED 
PITUITARY PROLACTIN RELEASE. 

239828 03-03 
VERBAL RETRIEVAL OF RIGHT HEMISPHERE MEMORIES ESTABLISHED IN 
THE ABSENCE OF LANGUAGE. 

251939 04 14 
kBSINTHE 

MARUUANA, ABSINTHE AND THE CENTRAL-NERVOUS-SYSTEM. 

249783 04 01 



ABSORBING 

THE NATURE OF THE 455-NM ABSORBING COMPLEX FORMED DURING 
THE CYT0CHROME-P450 DEPENDENT OXIDATIVE METABOLISM OF 
AMPHETAMINE. 

241350 03-01 
ABSORPTION 

IMIPRAMINE MEDIATED INTERFERENCE WITH LEVODOPA ABSORPTION 
FROM THE GASTROINTESTINAL TRACT IN MAN. 

233296 02-13 
INFLUENCE OF MAGNESIUM AND ALUMINUM HYDROXIDE MIXTURE ON 
CHLORDIAZEPOXIDE ABSORPTION. 

237116 02-13 
PHARMACOKINETIC STUDIES IN ABSORPTION AND EXCRETION OF 
OXAZEPAM IN COMBINATION WITH ALCOHOL. 

237123 02-13 
THE INFLUENCE OF NITROGEN, CHAIN AND RING SUBSTITUTION ON 

SOME PHYSIO-ORGANIC PROPERTIES AND ON BUCCAL ABSORPTION OF 
AMPHETAMINES. 

237981 02-02 
THE INFLUENCE OF FOOD ON SIDE-EFFECTS AND ABSORPTION OF 
LITHIUM. 

238998 03-15 
IMPAIRED ABSORPTION OF CHLORPROMAZINE IN RATS GIVEN 
TRIHEXYPHENIDYL. 

241920 03-03 
ABSORPTION, DISTRIBUTION AND EXCRETION OF TRIFLUOPERAZINE IN 
RATS. 

249036 04-03 
CORRELATION BETWEEN DISSOLUTION CHARACTERISTICS AND 
ABSORPTION OF METHAQUALONE FROM SOLID DOSAGE FORMS. 

250332 04-06 
ABSORPTION OF LITHIUM FOLLOWING ADMINISTRATION OF SLOW- 
RELEASE AND CONVENTIONAL PREPARATIONS. 

250725 04-13 
INTESTINAL ABSORPTION, DEMETHYLATION, AND ENTEROHEPATIC 
CIRCULATION OF IMIPRAMINE. 

252231 04-13 
ABSORPTION AND EXCRETION OF A NEW ANTIDEPRESSIVE (SQ-10996) IN 
HUMANS. 

253323 04-07 
ABSORPTIVE 

DISTRIBUTION OF CHLORPROMAZINE IN THE GASTROINTESTINAL TRACT 
OF THE RAT AND ITS EFFECT ON ABSORPTIVE FUNCTION. 

230918 01-03 
ABSTINENCE 

CHANGES IN THE ELECTROENCEPHALOGRAM AND REM SLEEP TIME 
DURING MORPHINE ABSTINENCE IN PELLET IMPLANTED RATS. 

227701 01-03 
DIFFERENTIAL EFFECT OF CANNABINOL AND CANNABIDIOL ON THC 

INDUCED RESPONSES DURING ABSTINENCE IN MORPHINE-DEPENDENT 
RATS. 

227702 01-04 
ATTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE 

DEPENDENT RATS BY DELTA9-THC. 

232615 02-04 
CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

237106 02-04 
TETRAHYDROCANNABINOL ATTENUATED ABSTINENCE AND INDUCED 
ROTATION IN MORPHINE-DEPENDENT RATS: POSSIBLE INVOLVEMENT 
OF DOPAMINE. 

245601 04-04 
CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

248959 04-04 
INTERACTIONS BETWEEN CANNABIDIOL AND DELTA9 THC DURING 
ABSTINENCE IN MORPHINE-DEPENDENT RATS 

249001 04-04 
WEIGHT LOSS AND SHOCK-ELICITED AGGRESSION AS INDICES OF 
MORPHINE ABSTINENCE IN RATS. 

249671 04-04 
ABUSE 

THE USE OF TRANQUILIZERS IN THE TREATMENT OF MIXED DRUG 
ABUSE 

229044 01 11 
MISUSE AND ABUSE OF DIAZEPAM: AN INCREASINGLY COMMON 
MEDICAL PROBLEM 

229852 01-17 
ABUSE OF PSYCHOPHARMACEUTICAL AGENTS IN DRUG DEPENDENCE 
(ANALYSIS OF CASES HOSPITALIZED IN A PSYCHIATRIC DEPARTMENT 
IN THE YEARS 1970 TO 1973). 

234653 02 17 



e 
% 

I 
s 

I 

t 



S-l 



Silbject Index 



Psychopharmacoiogy Abstra< 



EXPERIMENTAL HUMAN DRUG SELF-ADMINISTRATION: METHODOLOGY 
AND APPLICATION TO THE STUDY OF SEDATIVE ABUSE 

240831 03-14 
PENTAZOCINE ABUSE AND PROBLEMS OF WITHDRAWAL 

246617 04-17 
MAO INHIBITORS HAVE POTENTIAL FOR ABUSE. 

248339 04-15 
URGENT PHARMACOTHERAPY FOR DRUG ABUSE. 

251755 04- 17 
BENZODIAZEPINE-INDUCED STATE DEPENDENT LEARNING: A 
CORRELATIVE OF ABUSE POTENTIAL? 

252674 04-04 
ACCELERATION 

NEONATAL HYPERTHYROIDISM: MATURATIONAL ACCELERATION AND 
LEARNING DEFICIT IN TRIIODOTHYRONINE STIMULATED RATS. 

228143 01-04 
ACCESS 

ETHANOL AS A REINFORCER FOR RATS: EFFECTS OF CONCURRENT 
ACCESS TO WATER AND ALTERNATE POSITIONS OF WATER AND 
ETHANOL. 

227128 0104 
SELF-ADMINISTRATION OF PSYCHOMOTOR STIMULANT DRUGS: THE 
EFFECTS OF UNLIMITED ACCESS. 

250066 04-04 
ACCESSIBILITY 

STATE DEPENDENT ACCESSIBILITY OF RETRIEVAL CUES IN THE 
RETENTION OF A CATEGORIZED LIST. 

243013 04-04 
A^CH 

EFFECT OF LABELLED ACETYLCHOLINE (ACCH) UPTAKE BY RAT BRAIN 
SLICES ON ENDOGENOUS LEVELS OF ACCH AND CHOLINE (CH). 

249298 04-03 
ACCIDENT 

NARCOSIS INTRODUCTION WITH FLUNITRAZEPAM IN ACCIDENT 
SURGERY. 

244045 04-1 1 
ACCIDENTAL 

ENCEPHALOPATHY SUBSEQUENT TO ACCIDENTAL POISONING WITH 
CHLORPROMAZINE. 

239089 03-05 
ACCIDENTAL POISONING WITH PSYCHOTROPIC DRUGS IN CHILDREN. 

252656 04- 15 
ACCUMATISED 

AMPHETAMINE TOXICITY IN TEMPERATURE ACCLIMATISED MICE. 

23909) 03-05 
ACCUMULATE 

THE CAPACITY OF ADRENERGIC NERVES TO ACCUMULATE EXOGENOUS 
NOREPINEPHRINE UNDER THE INFLUENCE OF SOME 
PHARMACOLOGICAL AGENTS 

228551 01-03 
ACCUMULATION 

SUBSENSITIVITY OF NORADRENALINE STIMULATED CYCLIC-AMP 
ACCUMULATION IN BRAIN SLICES OF D-AMPHETAMINE TREATED 
MICE. 

226651 01-02 
ACCUMULATION OF LABELED EPHEDRINE, NOREPHEDRINE. 

AMPHETAMINE AND TYRAMINE IN PIGMENTED AND NONPIGMENTED 
EYES OF BLACK AND WHITE RATS. 

230450 01-03 
LITHIUM ACCUMULATION BY SNAIL NEURONES MEASURED BY A NEW 
Ll-f SENSITIVE MICROELECTRODE 

235589 02-06 
THE ACTION OF CHLORPROMAZINE, TRIFLUOPERAZINE AND DROPERIDOL 
ON THE CAPTURE AND ACCUMULATION OF EXOGENOUS 
NOREPINEPHRINE. 

236713 02-03 
ELECTROCONVULSIVE SHOCK INCREASES THE BEHAVIOURAL RESPONSES 
OF RATS TO BRAIN 5-HYDROXYTRYPTAMINE ACCUMULATION AND 
CENTRAL NERVOUS SYSTEM STIMULANT DRUGS 

24 1 979 03-04 
INHIBITION OF SYNAPTOSOMAL ACCUMULATION OF L-NOREPINEPHRINE 
I: N-ARYLALKYL AND N-ARYLOXYALKYL DL-AMPHETAMINES AND 
RELATED COMPOUNDS 

2463 1 6 04-03 
STUDIES ON ACCUMULATION OF (I4C) MESCALINE IN BRAIN 

HOMOGENATES: EFFECTS OF PSYCHOTROPIC AND OTHER AGENTS. 

246817 04-03 
ACCUMULATION OF NOREPINEPHRINE (NE) BY RAT ORGANS IN VIVO. 

246822 04-03 
INHIBITION OF SYNAPTOSOMAL ACCUMULATION OF L-NOREPINEPHRINE 
II: N ARYLOXYALKYLPHENTERMINES, QUATERNARY D-AMPHETAMINES, 
AND 3ARYL0XYPR0PYLAMINES 

248637 04-01 
CENTRAL DOPAMINERGIC NEURONS: EFFECTS OF ALTERATIONS IN 
IMPULSE FLOW ON THE ACCUMULATION OF 
DIHYDROXYPHENYLACETIC ACID. 

250085 04-03 



ACCUMULATION OF CGMP IN STRIATUM OF RATS INJECTED WITH 
NARCOTIC ANALGESICS: ANTAGONISM BY NALTREXONE. 

250362 04 
THE EFFECT OF VARIOUS PHENOTHIAZINES AND TRICYCLIC 
ANTIDEPRESSANTS ON THE ACCUMULATION AND RELEASE OF 3H- 
NOREPINEPHRINE AND 3H-5-HYDROXYTRYPTAMINE IN SLICES OF RA 
OCCIPITAL CORTEX. 

253691 04 
ACETAZOLAMIDE 

TREATMENT WITH ACETAZOLAMIDE OF BRAINSTEM AND SPINAL 
PAROXYSAAAL DISTURBANCES IN MULTIPLE SCLEROSIS. 

226351 01 
ACETYLATED 

EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251130 0^ 
ACETYLATOR 

THE RELATIONSHIP BETWEEN ACETYLATOR STATUS AND INHIBITION C 
MONOAMINE-OXIDASE, EXCRETION OF FREE DRUG AND 
ANTIDEPRESSANT RESPONSE IN DEPRESSED PATIENTS ON PHENELZII 

251985 O-i 
ACETYLBUFOTENINE 

BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE: 
COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N,N 
DIMETHYLTRYPTAMINE AND 5-METH0XY-N,N DIMETHYLTRYPTAMir 

249317 0': 
ACETYLCHOLINE 

THE EFFECTS OF ADRENALINE, RESERPINE, AND ATROPINE ON 

ACETYLCHOLINE CONTENT OF THE BRAIN AND PERIPHERAL GANGLI, 
IN STRESS. 

227635 01 
SYNTHESIS, RELEASE AND DISTRIBUTION OF ACETYLCHOLINE IN THE 
BRAIN OF RATS UNDER THE INFLUENCE OF CHOLINERGIC AGENTS. 

228550 01 
DICHLORVOS AND THE CHOLINERGIC SYSTEM: EFFECTS ON 

CHOLINESTERASE AND ACETYLCHOLINE AND CHOLINE CONTENTS 01 
RAT TISSUES. 

230451 01 
THE EFFECTS OF ACETYLCHOLINE AND DOPAMINE ON THE CAUDATE- 
NUCLEUS DEPLETED OF BIOGENIC AMINES. 

230457 01 
PHARMACOLOGIC STUDIES OF NARCOLEPSY INVOLVING SEROTONIN, 
ACETYLCHOLINE, AND MONOAMINE-OXIDASE. {UNPUBLISHED PAPEf 

232324 01 
THE EFFECTS OF BETA-CARBOLINES ON RESPONSES TO ACETYLCHOLINi 
NORADRENALINE, 5-HYDROXYTRYPTAMINE AND AMINO-ACIDS IN T 
RAT SPINAL CORD. 

235863 02 
EFFECTS OF (-)DELTA9-TETRAHYDR0CANNABIN0L ON REGIONAL BRAIN 
ACETYLCHOLINE IN THE RAT. 

238709 03 
THE EFFECT OF DELTA9-THC ON HIGH AND LOW AFFINITY UPTAKE OF 
CHOLINE AND ITS RELATIONSHIP TO TURNOVER OF ACETYLCHOLINE 
MOUSE BRAIN 

238765 03 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN 
FOLLOWING HEAD FOCUSED MICROWAVE SACRIFICE: EFFECT OF ( * 
AMPHETAMINE AND ( t OR-) P-CHLOROAMPHETAMINE. 

239976 03 
IN VIVO ACTIONS OF CLOZAPINE AND HALOPERIDOL ON THE TURNOV 
RATE OF ACETYLCHOLINE IN RAT STRIATUM. 

241252 03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: IV. THE EFFECTS OF ACETYLCHOLINE, GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY. 

241318 03 
MANIPULATION OF ACETYLCHOLINE LEVELS IN DEVELOPING RAT BRAI 
BIOCHEMICAL AND BEHAVIORAL CONSIDERATIONS. (PH.D. 
DISSERTATION). 

241680 03 
EFFECTS OF MORPHINE ON ACETYLCHOLINE RELEASE FROM THE FROG 
SPINAL CORD. 

241922 03 
ALPHA-BUNGAROTOXIN, COBRA NEUROTOXIN AND EXCITATION OF 
RENSHAW CELLS BY ACETYLCHOLINE. 

244203 04 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN Vl 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE. 

244514 04 
THE RELATIVE ROLE OF BRAIN ACETYLCHOLINE AND HISTAMINE IN 
PERPHENAZINE CATATONIA AND INFLUENCE OF ANTIDEPRESSANTS 
AND DIPHENHYDRAMINE ALONE AND IN COMBINATION. 

245.593 04 
DRUG-INDUCED CHANGES IN BEHAVIOUR AND GANGLIONIC 
ACETYLCHOLINE CONCENTRATION OF THE LEECH. 

245595 04 



S-2 



/OLUME 14, SUBJECT INDEX 



Subject Index 



DETERMINATION AND CHARACTERIZATION OF THE ANTINOCICEPTIVE 
ACTIVITY OF INTRAVENTRICULARLY ADMINISTERED ACETYLCHOLINE 
IN MICE. 

246852 04-04 
STEADY-STATE CONCENTRATIONS OF CHOLINE AND ACETYLCHOLINE IN 
RAT BRAIN PARTS DURING A CONSTANT RATE INFUSION OF 
DEUTERATED CHOLINE. 

247146 04-03 
EFFECT OF NOMIFENSINE ON ACETYLCHOLINE AND CHOLINE IN THE RAT 
STRIATUM AND BRAINSTEM. 

248291 04-03 
ACETYLCHOLINE, AN INHIBITORY TRANSMITTER IN THE RAT LATERAL 
HYPOTHALAMUS. 

248358 04-03 
FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCLE. 

248409 04-03 
DECREASE IN RAT STRIATAL ACETYLCHOLINE LEVELS BY SOME DIRECT 

AND INDIRECT ACTING DOPAMINERGIC ANTAGONISTS. 

248410 04-03 
ACETYLCHOLINE SYNTHESIS IN RAT BRAIN: DISSIMILAR EFFECTS OF 

CLOZAPINE AND CHLORPROMAZINE. 

248600 04-03 
APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE 

ESTIMATION OF BRAIN ACETYLCHOLINE TURNOVER RATE: EFFECTS OF 
OXOTREMORINE AND PHYSOSTIGMINE. 
, 248700 04-03 

THE EFFECT OF ATROPINE UPON ACETYLCHOLINE RELEASE FROM CAT 
SUPERIOR CERVICAL GANGLIA AND RAT CORTICAL SLICES: 
MEASUREMENT BY A RADIOENZYMIC METHOD. 

248724 04-03 
CHOLINESTERASE (CHE) INHIBITION AND SYNAPTOSOMAL 

ACETYLCHOLINE (ACH) SYNTHESIS AND RELEASE FOLLOWING IN VIVO 
PARAOXON (PX) ADMINISTRATION. 

249295 04-03 
EFFECT OF LABELLED ACETYLCHOLINE (ACCH) UPTAKE BY RAT BRAIN 
SLICES ON ENDOGENOUS LEVELS OF ACCH AND CHOLINE (CH). 

249298 04-03 
ACETYLCHOLINE LEVELS AND TURNOVER IN BRAINS OF LITHIUM 

TREATED AND STRESSED MICE. 

249299 04-03 
EFFECT OF D-AMPHETAMINE AND D,L P-CHLOROAMPHETAMINE ON 

REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN. 

249300 04-03 
SODIUM DEPENDENT HIGH AFFINITY CHOLINE UPTAKE AS A 

REGULATORY STEP IN ACETYLCHOLINE SYNTHESIS. 

249303 04-03 
STIMULATION BY MORPHINE OF ACETYLCHOLINE OUTPUT FROM THE 
CEREBRAL CORTEX OF SEPTAL RATS. 

249664 04-03 
EFFECT OF OXOTREMORINE ON ENDOGENOUS ACETYLCHOLINE AND ON 
UPTAKE AND BIOTRANSFORMATION OF RADIOACTIVE CHOLINE IN 
DISCRETE REGIONS OF MOUSE BRAIN IN VIVO 

251175 0403 
EFFECTS OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 3-CHL0R0-4- 
STILBAZOLE ON BRAIN ACETYLCHOLINE METABOLISM. 

251181 04-03 
SUPERSENSITIVITY OF CORTICAL NEURONES OF THE RAT TO 
ACETYLCHOLINE AND L-GLUTAMATE FOLLOWING CHRONIC MORPHINE 
TREATMENT. 

251433 04-03 
NICOTINIC EFFECT OF ACETYLCHOLINE ON THE RELEASE OF NEWLY 
SYNTHESIZED 3H-D0PAMINE IN RAT STRIATAL SLICES AND CAT 
CAUDATE-NUCLEUS. 

25221 7 04-03 
USE OF 300-MSEC MICROWAVE IRRADIATION FOR ENZYME 

INACTIVATION: A STUDY OF EFFECTS OF SODIUM PENTOBARBITAL ON 
ACETYLCHOLINE CONCENTRATION IN MOUSE BRAIN REGIONS. 

253106 04-03 
kCETYLCHOllNESTERASE 

THE EFFECT OF SYMPATHOLYTIC AND SYMPATHOMIMETIC AGENTS ON 
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITY, IN VITRO. 

243794 04-03 
IVCETYLTRANSFERASE 

6-HYDROXYDOPAMINE (6-OHDA) ADMINISTRATION TO NEONATAL RATS 
FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC ACID- 
DECARBOXYLASE (GAD) IN THE CNS 

238826 03-03 
ELEVATION OF AMPHETAMINE LEVELS IN RAT BRAIN AFTER 
ADMINISTRATION OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 4 
1-NAPHTHYLVINYLPYRIDINE (NVP). 

249027 04-03 
CHOLINE ACETYLTRANSFERASE ACTIVITY INCREASES IN THE BRAINSTEM 
OF RATS TREATED AT BIRTH WITH 6-HYDROXYDOPA. 

249666 04-03 



EFFECTS OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 3-CHL0R0-4- 
STILBAZOLE ON BRAIN ACETYLCHOLINE METABOLISM 

251181 04-03 
ACH 

CHOLINESTERASE (CHE) INHIBITION AND SYNAPTOSOMAL 

ACETYLCHOLINE (ACH) SYNTHESIS AND RELEASE FOLLOWING IN VIVO 
PARAOXON (PX) ADMINISTRATION. 

249295 04-03 
ACHETA-DOMESTICUS 

PSYCHOPHARMACOLOGICAL CHARACTERIZATION OF A DRUG INDUCED 
GROOMING BEHAVIOR IN THE CRICKET, ACHETA-DOMESTICUS 
(INSECTA, ORTHOPTERA). (PH D. DISSERTATION). 

241994 03 04 
ACHIEVEMENT 

INFLUENCE OF PSYCHOPHARMACEUTICALS ON ACHIEVEMENT 
MOTIVATION: III. DIFFERENTIAL INFLUENCE ON CONTENT CATEGORIES. 

240644 03-14 
ACID 

ISOLATION OF LYSERGIDE (LSD) WITH AGAROSE BOUND ANTIBODIES TO 
LYSERGIC-ACID. ACID. 

233278 02-01 
NEUROTOXICITY OF A NON-METABOLIZABLE AMINO ACID, L- 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (ACPC): ACPC TRANSPORT 
MECHANISMS IN TISSUES. 

241298 03-03 
INTERACTIONS OF LEVODOPA WITH INHIBITORS OF MONOAMINE- 
OXIDASE AND L-AROMATIC AMINO ACID DECARBOXYLASE. 

245647 04-13 
NEUROTOXICITY OF DIELDRIN IN RELATION TO THE SEROTONIN 
METABOLISM AND ACID TRANSPORT IN MOUSE BRAIN. 

249265 04-05 
ACID-DIETHYLAMIDE 

ANTAGONISM OF D-LYSERGIC ACID-DIETHYLAMIDE AND MESCALINE BY 
1 METHYL 1,2,5,6 TETRAHYDROPYRIDINE N,N DIETHYLCARBOXAMIDE 
(THPC). 

230453 01-03 
ACIDOSIS 

SUIDICAL INGESTION OF ISONIAZID: AN UNCOMMON CAUSE OF 
METABOLIC ACIDOSIS AND SEIZURES. 

237813 02-15 
ACOUSTIC 

EFFECTS OF D- AND L-AMPHETAMINE ON HABITUATION AND 
SENSITIZATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS. 

227126 01-04 
INVOLVEMENT OF CORTICOSTEROIDS IN ACOUSTIC INDUCTION OF 
AUDIOGENIC SEIZURE SUSCEPTIBILITY IN MICE. 

237706 02-03 
STUDIES ON ACOUSTIC PRIMING. (PH.D. DISSERTATION). 

238201 02-03 
P-CHLOROAMPHETAMINE (PCA): ACUTE AND CHRONIC EFFECTS ON 
HABITUATION AND SENSITIZATION OF THE ACOUSTIC STARTLE 
RESPONSE IN RATS. 

240062 03-04 
ACPC 

NEUROTOXICITY OF A NON-METABOLIZABLE AMINO ACID, L 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (ACPC): ACPC TRANSPORT 
MECHANISMS IN TISSUES. 

241298 03-03 
ACQUISITION 

EFFECT OF P-CHLOROPHENYLALANINE ON THE ACQUISITION OF 
TOLERANCE TO ETHANOL AND PENTOBARBITAL 

237720 02-04 
THE EFFECTS OF N DIPROPYLACETATE ON THE ACQUISITION OF 

CONDITIONED BEHAVIOUR WITH NEGATIVE REINFORCEMENT IN MICE 

237723 0204 
ANALYTICAL STUDY OF ACQUISITION ON FREE-OPERANT AVOIDANCE 
RESPONSE FOR EVALUATION OF PSYCHOTROPIC DRUGS IN RATS. 

238564 02-04 
IMPAIRED ACQUISITION OF A PASSIVE AVOIDANCE RESPONSE AFTER 
LESIONS INDUCED IN THE LOCUS-COERULEUS BY 6-OH DOPAMINE 

239841 03 04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON ACTIVE AVOIDANCE 
ACQUISITION AND PASSIVE AVOIDANCE RETENTION IN RATS WITH 
AMYGDALOID LESIONS 

246819 04-04 
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL AND LSD ON THE 
ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN THE RAT 

251979 04-04 
ACUTE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE 

ACQUISITION OF SHUTTLEBOX CONDITIONED AVOIDANCE RESPONSE, 

251989 0404 
ACTH 

STUDY OF SEROTONIN AND ACTH BRAIN LEVELS AND BEHAVIOR, 

229498 01-03 
EXCITABILITY OF THE HYPOTHALAMUS AND LIMBIC BRAIN STRUCTURES 
OF RABBITS UNDER THE EFFECT OF GLUCOCORTICOIDS AND ACTH 

236716 02 03 



S-3 



Subject Index 



Psychopharmacology Abstrac 



ACTH4-9 

CORRELATION BETWEEN STRUCTURE, BEHAVIORAL ACTIVITY AND RATE 
OF BIOTRANSFORMATION OF SOME ACTH4-9 ANALOGS. 

246853 04-04 
ACTING 

STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 
EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT. 

230860 01-03 
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC 
AGONISTS. 

233973 02-03 
IS METOCLOPRAMIDE A DIRECTLY ACTING DOPAMINE RECEPTOR 
ANTAGONIST?, 

241929 03-03 
EFFECTS OF DRUGS ACTING ON CEREBRAL 5-HYDROXYTRYPTAMINE 
MECHANISMS ON DOPAMINE-DEPENDENT TURNING BEHAVIOUR IN 
MICE. 

243803 04-04 
AN ANALYSIS OF THE DRUGS ACTING ON CEREBRAL ENERGY 
METABOLISM. 

247012 04-03 
DECREASE IN RAT STRIATAL ACETYLCHOLINE LEVELS BY SOME DIRECT 
AND INDIRECT ACTING DOPAMINERGIC ANTAGONISTS. 

248410 04-03 
CHANGES IN THE ARTERIAL BLOOD-PRESSURE RESPONSES OF 

HYPERTENSIVE RATS TO SOME DRUGS ACTING ON THE CENTRAL 
SYMPATHETIC MECHANISMS. 

248551 04-03 
EFFECTS OF CENTRALLY ACTING DRUGS ON STRESS-INDUCED INCREASE 
OF CGMP IN MOUSE BRAIN. 

251416 04-03 
THE TOXICITY OF DIRECT ACTING DOPAMINE AGONISTS: IMPLICATIONS 
FOR THE THERAPY OF PARKINSONISM. 

251959 04-05 
ACTION 

DRUG ACTION IN MANAGEMENT OF HYPERTENSION. 

225766 01-11 
MOLECULAR MECHANISMS IN THE ACTION OF MORPHINE AND VIMINOL 
(R2) ON RAT STRIATUM. 

226851 01-03 
EVIDENCE FOR AN INVOLVEMENT OF GABA IN THE MEDIATION OF THE 
CEREBELLAR CGMP DECREASE AND THE ANTICONVULSANT ACTION OF 
DIAZEPAM. 

226857 01-03 
HYPNOTICS AND SLEEP: CLASSIFICATION. METABOLISM, MECHANISM OF 
ACTION OF HYPNOTICS AND ALTERATIONS OF PHASES OF SLEEP BY 
HYPNOTICS, 

228094 01-14 
THE ACTION OF CHLORPROMAZINE ON THE PERMEABILITY OF THE BRAIN 
AND LIVER LYSOSOMES OF RATS IN A STATE OF HYPOXIA. 

228548 01-03 
ON THE MECHANISMS OF ACTION OF AMINOPYRINE. 

228552 01-03 
BEHAVIOR ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION OF 
BENZODIAZEPINES. 

229461 01-04 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 

BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

229462 01-03 
INVOLVEMENT OF GABA IN THE ACTION OF BENZODIAZEPINE - STUDIES 

ON RAT CEREBELLUM. 

229466 01-03 
PSYCHOTROPIC ACTION OF SEX HORMONES. 

229470 01-14 
THE MECHANISM OF ACTION OF AMPHETAMINE IN BRAIN. 

229491 01-03 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN MAMMALIAN BRAIN: A 
POSSIBLE SITE OF ACTION OF ANTIPSYCHOTIC DRUGS. 

230602 01-13 
THE EFFECTS OF THREE BENZODIAZEPINES AND OF MEPROBAMATE ON 
THE ACTION OF SMOOTH MUSCLE STIMULANTS ON THE GUINEA-PIG 
ILEUM. 

230859 01-03 
STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 

EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT. 

230860 01-03 
INHIBITION OF CENTRALLY EVOKED PRESSOR RESPONSES BY DIAZEPAM: 

EVIDENCE FOR AN EXCLUSIVELY SUPRAMEDULLARY ACTION. 

231039 01-03 
PHARMACOLOGICAL STUDIES OF DRUG ACTION ON CNS, WITH SPECIAL 
REFERENCE TO EFFECTS OF MAPROTILINE. 

231316 01-04 
STUDIES ON THE MECHANISM OF ACTION OF TRICYCLIC 
ANTIDEPRESSANT DRUGS, USING IPRINDOLE AS A TOOL. (PHD 
DISSERTATION). 

231438 01-03 



THE ACTION OF FENFLURAMINE AND P-CHLOROAMPHETAMINE ON 
SEROTONERGIC MECHANISMS: A COMPARATIVE STUDY IN RAT BRA 
NUCLEI. (UNPUBLISHED PAPER). 

232325 01 
STUDIES ON THE ACTION OF AN ANTICHOLINERGIC IN COMBINATION 
WITH A TRANQUILIZER ON GASTRIC JUICE SECRETION IN MAN. 

232503 01 
MECHANISM OF ACTION OF BENZODIAZEPINES. 

232506 01 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION 

BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

232507 01 
BEHAVIORAL ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTIO 

OF BENZODIAZEPINES. 

232509 01 
ACTION OF THE BENZODIAZEPINES ON THE CHOLINERGIC SYSTEM. 

232510 01 
PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF 

ACTION OF BENZODIAZEPINES. 

232512 01 
EVIDENCE FOR GABA INVOLVEMENT IN THE ACTION OF DIAZEPAM ON 

PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC 
GANGLIA. 

232513 01 
EVIDENCE FOR INVOLVEMENT OF GABA IN THE ACTION OF 

BENZODIAZEPINES: STUDIES ON RAT CEREBELLUM. 

232514 01 
A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF 

PSYCHOTOMIMETICS (LSD-25, DOM AND KETAMINE). 

232703 02 
CORTICAL AND SUBCORTICAL PROJECTED FOCI IN CATS: INHIBITORY 
ACTION OF TAURINE. 

233299 02 
BIOCHEMICAL MECHANISMS OF ACTION AND PHARAAACOKINETICS OF 
PSYCHOTROPIC DRUGS. 

233682 02 
GOOD TRIP OR BAD TRIP: THE ROLES OF TOLERANCE AND STRESS IN 
HALLUCINOGENIC DRUG ACTION. 

23481 1 02 
ON THE INTRACELLULAR MECHANISM OF ACTION OF IMIPRAMINE ANI 
DIAZEPAM. 

236232 02 
THE NATURE OF BACKGROUND SPIKE ACTIVITY OF CORTICAL NEURON 
UNDER THE ACTION OF PSYCHOTROPIC DRUGS. 

236265 02 
INVESTIGATION OF THE MECHANISM OF ACTION OF THE NEW 
ANTIDEPRESSANT PYRAZIDOL. 

236369 02 
CLINICAL EVALUATION OF THE ANTIDEPRESSIVE ACTION OF THE 
PREPARATION AZAFEN. 

236429 02 
RESERPINE ACTION ON THE ARREST REACTION FOLLOWING 
STIMULATION OF THE CAUDATE-NUCLEUS IN CATS. 

236712 02 
THE ACTION OF CHLORPROAAAZINE, TRIFLUOPERAZINE AND DROPERID' 

ON THE CAPTURE AND ACCUMULATION OF EXOGENOUS 
NOREPINEPHRINE. 

236713 02 
VESTIBULAR TEST IN INVESTIGATING THE SPECTRUM OF ACTION OF 

PSYCHOTROPIC AGENTS. 

236714 02- 
MECHANISM OF ACTION OF ANTICONVULSANTS: ROLE OF THE 

DIFFERENTIAL EFFECTS ON THE ACTIVE UPTAKE OF PUTATIVE 
NEUROTRANSMITTERS. 

237140 02- 
DOES INCREASING STRESS CHANGE THE BEHAVIORAL ACTION OF 
MESCALINE FROM DISRUPTION TO FACILITATION?. 

237732 02- 
SELECTIVE BLOCKING ACTION OF LSD ON INHIBITORY DOPAMINE 
RECEPTORS. 

237782 02- 
BARBITURATE REINFORCED RESPONDING IN RHESUS MONKEYS: 

COMPARISONS OF DRUGS WITH DIFFERENT DURATIONS OF ACTION. 

237874 02- 
INFLUENCE OF THE ROUTE OF ADMINISTRATION OF THE CLINICAL 
ACTION OF DIAZEPAM. 

238531 02- 
STUDIES ON MODE OF ANTAGONISM BETWEEN ADRENERGIC BETA- 
MIMETICS AND BETA-BLOCKING AGENTS (I). BETA-BLOCKING ACTIOI 
OF MESCALINE AND ITS DERIVATIVES. 

238563 02- 
INHIBITION OF NEURONAL SEROTONIN (5-HT) UPTAKE AND THE 
ANTICONVULSANT ACTION OF TRIMETHADIONE (TMD). 

23875'' 03- 
DOPAMINE AND PSYCHOACTIVE DRUG ACTION: A FURTHER 
EVALUATION. 

238768 03-1 
CENTRAL ACTION OF AMPHETAMINE-INDUCED MYDRIASIS IN THE DOG 

238772 03-1 



S-4 



>LUME 14, SUBJECT INDEX 



Subject Index 



MECHANISM OF VASOCONSTRICTOR ACTION OF DELTA9- 

TETRAHYDROCANNABINOL IN PITHED AND ANESTHETIZED RATS. 

238809 03-03 
THE EFFECTS OF DEITA9-TETRAHYDR0CANNABIN0L ON ACTION 
POTENTIALS IN THE MOLLUSC APLYSIA. 

239261 03-03 
ANTAGONISM BY METHYSERGID AND CINANSERIN OF THE 

ANTINOCICEPTIVE ACTION OF MORPHINE ADMINISTERED INTO THE 
PERIAQUEDUCTAL GRAY. 

239576 03-04 
ACTION OF NEUROLEPTIC AGENTS ON HISTAMINE SENSITIVE ADENYLATE- 
CYCLASE IN RABBIT CEREBRAL CORTEX. 

239582 03-03 
ALTERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS AFTER CHRONIC HALOPERIDOL: INDIRECT EVIDENCE FOR 
CHOLINERGIC HYPOSENSITIVITY. 

239826 03-04 
DESTRUCTIVE ACTION OF SYSTEMICALLY ADMINISTERED 6- 
HYDROXYDOPAMINE ON THE RAT AREA POSTREMA. 

239832 03-03 
INHIBITORY ACTION OF NORADRENALINE AND CYCLIC-AMP IN EXPLANTS 
OF RAT CEREBELLUM. 

239836 03-03 
DUAL ACTION OF MORPHINE AND REL>^TED DRUGS ON COMPULSIVE 
GNAWING OF RATS. 

239860 03-04 
THE ACTION OF CHLORPROMAZINE ON THE ELECTRODERMAL RESPONSE 
IN THE CAT. 

239963 03-03 
HALLUCINOGENIC INDOLEAMINES: PREFERENTIAL ACTION UPON 
PRESYNAPTIC SEROTONIN RECEPTORS. 

240073 03-03 
CENTRAL ACTION OF NORMETANEPHRINE. EFFECT ON THE BEHAVIOR OF 
RATS. 

240240 03-03 
ON THE MECHANISMS OF ACTION AND KINETICS OF LITHIUM. 

240740 03-03 
THE EFFECT OF ETHANOL STRESS IN COMBINATION ON THE 

PHARMACOLOGIC ACTION OF HEXOBARBITAL. (PH.D. DISSERTATION). 

240933 03-03 
SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF 
PHYSICAL DEPENDENCE IN RATS: I. COMPARISON OF PRECIPITATED 
MORPHINE WITHDRAWAL AFTER INTRAPERITONEAL AND 
INTRAVENTRICULAR INJECTION OF MORPHINE ANTAGONISTS. 

241223 03-04 
ANTINOCICEPTIVE ACTION OF QUIPAZINE: RELATION TO CENTRAL 
SEROTONERGIC RECEPTOR STIMULATION. 

241235 03-03 
ON THE MECHANISM OF ACTION OF CLOZAPINE ON THE ADRENERGIC 
NEURONE, 

241919 03-03 
INCREASE IN HYPOTHALAMIC SENSITIVITY TO THE INHIBITORY ACTION 
OF ESTROGENS CAUSED BY THE USE OF L-DOPA, DILANTIN 
EPITHALAMIN, AND PHENOFORMIN IN OLD RATS. 

241983 03-05 
THE MODIFICATION OF INOTROPIC ACTION OF OUABAIN BY 6- 
HYDROXYDOPAMINE AND ALPHA-METHYL-P-TYROSINE IN DOGS. 

242200 03-03 
ON THE MECHANISM OF ACTION OF CLOZAPINE ON THE ADRENERGIC 
NEURONE. 

243760 04-03 
PSYCHOTOGENIC DRUG ACTION ON CHEMICALLY DEFINED NEURONS. 

244072 04-03 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VIVO 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE. 

244514 04-03 
FENFLURAMINE-INDUCED ENHANCEMENT OF CONFINEMENT MOTOR 
ACTIVITY: AN INDIRECT 5-HYDROXYTRYPTAMINE LIKE ACTION?. 

24491 1 04-04 
ACTION OF VARIOUS ANTIDEPRESSANT TREATMENTS REDUCES 

REACTIVITY OF NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM 
IN LIMBIC FOREBRAIN. 

245115 04-03 
THE EFFECTS OF HARMALINE ON SODIUM TRANSPORT IN HUMAN 
ERYTHROCYTES: EVIDENCE IN FAVOR OF ACTION AT INTERIOR 
SODIUM SENSITIVE SITES. 

246856 04-13 
STUDIES ON THE MECHANISM OF LITHIUM ACTION: PRELIMINARY 
REPORT. 

247208 04-03 
FENFLURAMINE: EVIDENCE FOR A NEUROTOXIC ACTION ON MIDBRAIN 
AND A LONG-TERM DEPLETION OF SEROTONIN. 

247214 04-05 
PENTOBARBITAL: ACTION ON FROG MOTONEURONS. 

247513 04-03 



ENHANCEMENT BY CHLORPROMAZINE OF HYPERGYLCEMIC ACTION OF 
DIAZOXIDE. 

247715 04-15 
DIFFERENTIAL EFFECTS OF ALPHA MT ON ANORECTIC AND 
STIMULATORY ACTION OF AMPHETAMINES. 

247729 0402 
APORPHINES 15: ACTION OF APORPHINE ALKALOIDS ON DOPAMINERGIC 
MECHANISMS IN RAT BRAIN. 

248286 04-03 
APORPHINES 16: ACTION OF APORPHINE ALKALOIDS ON LOCOMOTOR 

ACTIVITY IN RATS WITH 6-HYDROXYDOPAMINE LESIONS OF THE 
NUCLEUS-ACCUMBENS. 

248287 04-02 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEEN CLINICAL 

POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS. 

248466 04-03 
STUDIES ON THE ROLE OF PHENETHYLAMINE IN METHYLAMPHETAMINE 
ACTION MECHANISM. 

248515 04-03 
MORPHINES PROCONVULSANT ACTION: IMPORTANCE OF ENDOGENOUS 
NOREPINEPHRINE. 

248880 04-03 
SELF-INHIBITING ACTION OF NORTRIPTYLINE ANTIDEPRESSIVE EFFECT AT 
HIGH PLASMA LEVELS: A RANDOMIZED, DOUBLE-BLIND STUDY 
CONTROLLED BY PLTVSMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION. 

248955 04-10 
DIURNAL ACTION OF KETAMINE IN THE YOUNG CHICK: INFLUENCE BY 
PINEAL METABOLITES. 

249240 04-03 
THE CONTRIBUTION OF NEURONAL UPTAKE BLOCKADE TO THE 
ANTIEPILEPTIC ACTION OF CARBAMAZEPINE (TEGRETOL). 

249242 04-03 
STUDIES ON THE ANALEPTIC ACTION OF THYROTROPIN-RELEASING 
HORMONE (TRH) IN RABBITS. 

249280 04-04 
ACTION OF PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE 
CEREBRAL CORTEX AND LUNG FOLLOWING MICROWAVE 
IRRADIATION. 

249286 04-03 
ACTION OF ALPHA-METHYL-DOPA ON WAKING-SLEEP CYCLES IN TWO 
INBRED STRAINS OF MICE, C57BR AND C57BL/6. 

249676 04-04 
MORPHINE HYPERTHERMIA IN THE RAT: AN ACTION ON THE CENTRAL 
THERMOSTATS. 

250078 04-03 
THE MECHANISM OF ACTION OF FENFLURAMINE. 

250936 04-03 
COMPARISON OF DEPOT FLUPHENAZINES: DURATION OF ACTION AND 
INCIDENCE OF SIDE-EFFECTS. 

252006 04-08 
THE ACTION OF NOREPINEPHRINE IN THE RAT HIPPOCAMPUS. III. 
HIPPOCAMPAL CELLULAR RESPONSES TO LOCUS COERULEUS 
STIMULATION IN THE AWAKE RAT. 

252012 04-03 
DIRECT DOPAMINERGIC ACTION OF LISURIDE HYDROGEN AAALEATE, AN 
ERGOT DERIVATIVE, IN MICE. 

252028 04-04 
COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYL- 
CYCLIC-AMP AND ANALEPTIC DRUGS ON AMOBARBITAL-INDUCED 
NARCOSIS IN THE RAT. 

252221 04-03 
ACTIONS 

EVIDENCE FOR DRUG ACTIONS ON BOTH PRE- AND POSTSYNAPTIC 
CATECHOLAMINE RECEPTORS IN THE CNS. 

229431 01-03 
POSSIBLE INVOLVEMENT OF GABA IN THE CENTRAL ACTIONS OF 
BENZODIAZEPINES. 

229465 01-03 
FENFLURAMINE AND N-ETHYLAMPHETAMINE: COMPARISON OF THE 
REINFORCING AND RATE DECREASING ACTIONS IN THE RHESUS 
MONKEY. 

230874 01-04 
THE ROLE OF CENTRAL GLYCINE RECEPTORS IN THE PHARMACOLOGIC 
ACTIONS OF BENZODIAZEPINES. 

232511 01-03 
POSSIBLE INVOLVEMENT OF GABA IN THE CENTRAL ACTIONS OF 
BENZODIAZEPINES. 

232515 01-03 
THE DYSTONIC HYPERKINETIC SYNDROME: A CASUISTICAL 
CONTRIBUTION TO THE UNDERSTANDING OF THE ACTIONS OF DRUGS 
IN CHILDREN. 

233717 02-11 
ACTIONS OF PHENOTHIAZINE ANALOGS ON DOPAMINE SENSITIVE 

ADENYLATE-CYCLASE IN NEURONAL AND GLIAL ENRICHED FRACTIONS 
FROM RAT BRAIN. 

237241 02-03 



S-5 



Subject Index 



Psychopharmacology Abstract! 



ACTIONS OF METHOXAMINE AND TRYPTAMINE AND THEIR 

INTERACTIONS WITH CYPROHEPTADINE AND PHENOXYBENZAMINE ON 
CAT SPINAL CORD SEGMENTAL REFLEXES. 

237752 0203 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE: BIOCHEMICAL AND 

PHARMACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE AS 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINE 
AND OTHER PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION). 

238077 02-03 
SYNTHESIS AND BIOLOGICAL ACTIONS OF 2-SUBSTITUTED 
QUINOLIZIDINES. 

238477 02-02 
IN VIVO ACTIONS OF CLOZAPINE AND HALOPERIDOL ON THE TURNOVER 
RATE OF ACETYLCHOLINE IN RAT STRIATUM. 

241252 03-03 
ACTIONS OF 6 HYDROXYDOPAMINE INJECTED INTRAVENTRICULARLY 
INTO DEVELOPING RATS (2). INFLUENCE ON MOTOR ACTIVITIES AND 
AGGRESSIVE BEHAVIOR. 

241372 03-04 
CENTRAL NERVOUS DEPRESSIVE ACTIONS OF NEUROTROPIN ON MICE 
AND RATS. 

241374 03-04 
CENTRAL ACTIONS OF HALLUCINOGENIC DRUGS. 

244071 04-12 
THE ACTIONS OF SPERMIDINE AND SPERMINE ON THE CENTRAL- 
NERVOUS-SYSTEM. 

245596 04-05 
BRAIN 2-PHENYLETHYLAMINE AS A MAJOR MEDIATOR FOR THE 
CENTRAL ACTIONS OF AMPHETAMINE AND METHYLPHENIDATE. 

248162 04-01 
EVIDENCE FOR 2-PHENYLETHYLAMINE (PEA) AS A MEDIATOR FOR THE 
CENTRAL STIMULANT AND ANTITREMORGENIC ACTIONS OF DELTA9- 
TETRAHYDROCANNABINOL (THC). 

249309 04-03 
CATECHOLAMINES AND 2-PHENYLETHYLAMINE (PEA) IN THE CENTRAL 
AND PERIPHERAL ACTIONS OF AMPHETAMINES. 

24931 1 04-03 
ON THE IN VIVO AND IN VITRO ACTIONS OF FENFLURAMINE AND ITS 
DERIVATIVES ON CENTRAL MONOAMINE NEURONS, ESPECIALLY 5- 
HYDROXYTRYPTAMINE NEURONS, AND THEIR RELATION TO THE 
ANORECTIC ACTIVITY OF FENFLURAMINE. 

250937 04-03 
ON THE ACTIONS OF COMPOUNDS RELATED TO DOPAMINE AT A 
NEUROSECRETORY SYNAPSE 

251703 0403 
COMPARATIVE ACTIONS OF MONOMETHOXYAMPHETAMINES ON THE 
RELEASE AND UPTAKE OF BIOGENIC AMINES IN BRAIN TISSUE. 

253107 04-03 
ACTIVATE 

CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 
ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
A COMPARISON BETWEEN A MELANOCYTE STIMULATING HORMONE 
INHIBITORY FACTOR (MIF I) AND SUBSTANCES KNOWN TO ACTIVATE 
CENTRAL DOPAMINE RECEPTORS. 

250082 04-03 
ACTIVATING 

ATTENUATION OF THE EUPHORIANT AND ACTIVATING EFFECTS OF D- 
AMPHETAMINE AND AND L-AMPHETAMINE BY LITHIUM CARBONATE 
TREATMENT 

237716 02 14 
COURSE AND RESULTS OF TREATMENT WITH THREE ACTIVATING 
NEUROLEPTIC DRUGS. 

244049 04-08 
ACTIVATION 

TYROSINE-HYDROXYLASE: ALLOSTERIC ACTIVATION INDUCED BY 
STIMULATION OF CENTRAL NORADRENERGIC NEURONS. 

226856 01-03 
IN VIVO ACTIVATION OF RAT PINEAL CAMP PHOSPHODIESTERASE BY 
ISOPROTERENOL (UNPUBLISHED PAPER). 

228032 01-03 
AN ELECTROENCEPHALOGRAPHIC STUDY OF THE VALUE OF ACTIVATION 
BY MEGIMID IN PSYCHIATRIC DISEASES. 

229115 01-13 
ACTIVATION AND NUCLEAR TRANSLOCATION OF HISTONE KINASE 
DURING THE TRANSSYNAPTIC INDUCTION OF TYROSINE-3- 
MONOOXYGENASE. (UNPUBLISHED PAPER). 

237172 02-03 
ENDOGENOUS DOPAMINE RELEASE DEPENDENT AND INDEPENDENT 
ACTIVATION OF DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL 
SYNAPTOSOMES 

238729 03 03 
IN VIVO AND IN VITRO ACTIVATION OF SOIUBLE TRYPTOPHAN- 
HYDROXYLASE FROM RAT BRAINSTEM 

249512 0403 



ACTIVATOR 

RELEASE OF PHOSPHODIESTERASE ACTIVATOR FROM PARTICULATE 
FRACTIONS OF CEREBELLUM AND STRIATUM BY PUTATIVE 
NEUROTRANSMITTERS. (UNPUBLISHED PAPER). 

236674 02-0 
ACTIVE 

REDUCTION IN T-LYMPHOCYTES FORMING ACTIVE ROSETTES IN CHRONh 
MARIJUANA SMOKERS. 

229039 OM 
DIAZEPAM AND ACTIVE METABOLITE IN BREAST MILK AND THEIR 
TRANSFER TO THE NEONATE. 

230424 01-1 
TREATMENT OF ENDOGENOUS PSYCHOSES WITH DOMINAL AND 
DOMINAL FORTE IN COMBINATION WITH HIGHLY ACTIVE 
NEUROLEPTICS. 

235305 02-1 
MECHANISM OF ACTION OF ANTICONVULSANTS: ROLE OF THE 
DIFFERENTIAL EFFECTS ON THE ACTIVE UPTAKE OF PUTATIVE 
NEUROTRANSMITTERS. 

237140 02-C 
EFFECTS OF PROTEIN SYNTHESIS INHIBITION ON MEMORY FOR ACTIVE 
AVOIDANCE TRAINING. 

237264 02-C 
MONOAMINE OXIDASE ACTIVE SITE; THE BINDING TO AND TITRATION 
OF MONOAMINE-OXIDASE WITH (14C) SELECTIVE INHIBITORS. 

241931 03-C 
SKELETAL MUSCLE NECROSIS FOLLOWING MEMBRANE ACTIVE DRUGS 
PLUS SEROTONIN. 

243813 04-C 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON ACTIVE AVOIDANCE 
ACQUISITION AND PASSIVE AVOIDANCE RETENTION IN RATS WITH 
AMYGDALOID LESIONS. 

246819 04-C 
CENTRAL-NERVOUS-SYSTEM ACTIVE 5-OXOHEXAHYDROCINNOLINES. 

248649 04-C 
BACLOFEN (BF): AN UNUSUAL CNS ACTIVE AGENT. 

249304 04-C 
INTER-GROUP AGGRESSION IN MICE: A NEW METHOD FOR TESTING THE 
EFFECTS OF CENTRALLY ACTIVE DRUGS. 

249668 04-( 
ROLE OF STIMULUS LOCALE ON STRAIN DIFFERENCES IN ACTIVE 
AVOIDANCE AFTER SCOPOLAMINE OR D-AMPHETAMINE TREATMENT. 

250074 04-C 
INFLUENCE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES ON A 
CONDITIONED BLOOD-PRESSURE INCREASE IN SQUIRREL-MONKEYS. 

251414 04-( 
SOME EFFECTS OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A 
PURPORTED HASHISH AND LSD ANTAGONIST, ON BRAIN 
NORADRENERGIC AND SEROTONERGIC SYSTEAAS. 

251534 04-( 
THE EFFECT OF DEI TA9 TETRAHYDROCANNABINOL AND LSD ON THE 
ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN THE RAT. 

251979 04-( 
ACTIVITIES 

DEPRESSIVE EFFECTS OF MORPHINE UPON LAMINA V CELLS ACTIVITIES 
IN THE DORSAL HORN OF THE SPINAL CAT. 

232328 01 -( 
EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO ACTIVITIES (PGO 
ACTIVITY IN THE REM SLEEP AND RESERPINE-INDUCED PGO ACTIVITY 

233077 02-( 
DISTRIBUTION OF TYPE A AND B MONOAMINE-OXIDASE ACTIVITIES IN 
THE CENTRAL-NERVOUS-SYSTEM OF RAT AND CHICK. 

237923 02-( 
ANATOMICAL ORGANIZATION OF THE PHASIC ACTIVITIES PRODUCED B 
RESERPINE AT THE LEVEL OF THE OCULOMOTOR SYSTEM. 

238503 02-( 
THE EFFECT OF DL-254 ON THE PHARMACOLOGICAL ACTIVITIES OF D- 
AMPHETAMINE AND APOMORPHINE: A COMPARISON WITH 
ANTIANXIETY AND NEUROLEPTIC AGENTS 

238846 03-( 
SYNTHESIS OF SUBSTITUTED THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION OF CELLULAR RESPIRATORY AND MONOAMINE-OXIDASE 
ACTIVITIES AND ANTICONVULSANT PROPERTY. 

239661 03-( 
ACTIONS OF 6-HYDROXYDOPAMINE INJECTED INTRAVENTRICULARLY 
INTO DEVELOPING RATS (2) INFLUENCE ON MOTOR ACTIVITIES AND 
AGGRESSIVE BEHAVIOR 

241372 03-1 
EFFECTS OF PASSIVE IMMUNIZATION WITH RABBIT 

ANTIPHENOBARBITAL IGG ON CYCLOBARBITAL-INDUCED SLEEPING 
TIME AND HEPATIC ENZYME ACTIVITIES OF C3H MICE. 

242201 03-1 
CORRELATION BETWEEN THE 5-HYDROXYTRYPTAMINE CONTENTS IN TH 
BRAIN AND DEGREES OF SENSORY, AND LOCOMOTOR ACTIVITIES IN 
THE RAT. 

242205 03-( 
EFFECTS OF ANTICONVULSANT AND CONVULSANT DRUGS ON THE 
ATPASE ACTIVITIES OF SYNAPTOSOMES AND THEIR COMPONENTS. 

243801 04-( 



S-6 



LUME 14, SUBJECT INDEX 



Subject Index 



THE EFFECTS OF TANDAMINE, A NEW POTENTIAL ANTIDEPRESSANT 
AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED 
ACTIVITIES, 

244316 04-02 
EFFECTS OF TANDAMINE AND PIRANDAMINE. NEW POTENTIAL 
ANTIDEPRESSANTS, ON THE BRAIN UPTAKE OF NOREPINEPHRINE AND 
5-HYDROXYTRYPTAMINE AND RELATED ACTIVITIES. 

244678 04-03 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAIN 
MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS. 

246318 04-04 
EFFECTS OF RESERPINE ON ACTIVITIES AND AMOUNTS OF TYROSINE- 
HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN 
CATECHOLAMINE NEURONAL SYSTEMS IN RAT BRAIN. 

246845 04-03 
EFFECTS OF PIRANDAMINE (PA) AND TANDAMINE (TA), POTENTIAL 
ANTIDEPRESSANTS, ON THE UPTAKE OF NOREPINEPHRINE (NE) AND 5- 
HYDROXYTRYPTAMINE (5-HT) AND RELATED ACTIVITIES. 

249313 04-03 
ANTIACETYLCHOLINE ACTIVITIES OF PSYCHOACTIVE DRUGS: A 

COMPARISON OF THE (3H)QUINUCLIDINYL BENZILATE BINDING ASSAY 
WITH CONVENTIONAL METHODS 

250360 04-02 
VITY 

BIOGENIC AMINES AND THE EFFECT OF SHORT-TERM LITHIUM 
ADMINISTRATION ON OPEN-FIELD ACTIVITY IN RATS. 

225573 01-04 
THE EFFECT OF SUCCINIC SEMIALDEHYDE AND SODIUM SUCCINATE ON 
THE HIGHER NERVOUS ACTIVITY IN NORMAL SUBJECTS. 

226900 01-13 
INCREASED TYROSINE-HYDROXYLASE ACTIVITY IN FRONTAL CORTEX 
AND CEREBELLUM AFTER RESERPINE. 

226935 01-03 
OLFACTORY BULB REMOVAL IN MICE: ACTIVITY LEVELS AND 

RESPONSIVENESS TO THE LOCOMOTOR STIMULANT AND ANOREXIC 
PROPERTIES OF D-AMPHETAMINE SULFATE. (PH.D. DISSERTATION). 

227074 01-04 
TOLERANCE TO THE EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L IN 
MICE ON INTESTINAL MOTILITY, TEMPERATURE AND LOCOMOTOR 
ACTIVITY 

227130 01-04 
THE EFFECT OF DIAZEPAM AND TRIFLUOPERAZINE ON BLOOD SUPPLY 
AND CARDIAC ACTIVITY. 

228553 01 03 
EVALUATION OF NEW COMPOUNDS FOR PSYCHOTROPIC ACTIVITY, 

229477 01-04 
CHANGES IN IMIPRAMINE-INDUCED NORADRENALINE POTENTIATION BY 
VARYING ACTIVITY OF GASTRIC JUICE UNDER ORAL MEDICATION. 

229826 01-13 
THE EFFECTS OF METIAMIDE ON THE ACTIVITY STRESS ULCER IN RATS. 

230835 01-03 
DIFFERENTIAL EFFECTS OF METHYLPHENIDATE ON RETICULAR 
FORMATION AND THALAMIC NEURONAL ACTIVITY. 

230840 01-03 
TYROSINE-HYDROXYLASE ACTIVITY IN RAT BRAIN REGIONS AFTER 
CHRONIC TREATMENT WITH PLUS/MINUS PROPRANOLOL. 

230853 01-03 
CHLORPROMAZINE EFFECTS ON BRAIN ACTIVITY (CONTINGENT NEGATIVE 
VARIATION) AND REACTION TIME IN NORMAL WOMEN. 

230863 01-14 
OPPOSING RESPONSES IN SYMPATHETIC NERVE ACTIVITY INDUCED BY 
CENTRAL INJECTIONS OF OUABAIN. 

231006 01-03 
SUBSTITUTED CYCLOALKANOL ETHERS OF PSYCHOSTIMULANT ACTIVITY: 
STUDIES ON QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS. 

231008 01-03 
LATERAL GENICULATE MULTIPLE-UNIT ACTIVITY RELATED TO METRAZOL 
POTENTIATED AFTER-DISCHARGES 

231719 0103 
BARBITURATE SPINDLE ACTIVITY IN FUNCTIONALLY CORRESPONDING 
THALAMIC AND CORTICAL SOMATOSENSORY AREAS IN THE CAT 

232606 02-03 
BARBITURATE SPINDLE ACTIVITY IN THE THALAMIC LATERAL 

VENTROPOSTERIOR NUCLEUS AND THE SECOND SOMATOSENSORY 
AREA OF THE CORTEX. 

232607 02-03 
EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON TYROSINE-HYDROXYLASE 

ACTIVITY IN CENTRAL CATECHOLAMINERGIC NEURONS OF THE RAT. 

232624 02 03 
THE EFFECTS OF GABA, PICROTOXIN AND BICUCULLINE ON THE 
SPONTANEOUS BIOELECTRIC ACTIVITY OF CULTURED CEREBELLAR 
PURKINJE CELLS. 

232906 02-03 
EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO ACTIVITIES (PGO 
ACTIVITY IN THE REM SLEEP AND RESERPINE-INDUCED PGO ACTIVITY). 

233077 02 04 



IDENTIFICATION OF TWO RELATED PENTAPEPTIDES FROM THE BRAIN 
WITH POTENT OPIATE AGONIST ACTIVITY. 

233300 02-01 
EPILEPTIFORM ACTIVITY IN THE ELECTROENCEPHALOGRAM INDUCED BY 
LITHIUM CARBONATE. 

233499 02-15 
CHICK PHASIC BIOELECTRIC ACTIVITY AT THE TIME OF HATCHING AND 
THE EFFECTS OF PREVIOUS NIALAMIDE INJECTION. 

235317 02-04 
EFFECTS OF SCOPOLAMINE ON HABITUATION OF EXPLORATORY 
ACTIVITY IN RATS. 

235509 02-04 
DRUG-INDUCED RHYTHMICAL ACTIVITY IN THE INFERIOR OLIVARY 
COMPLEX OF THE RAT. 

235866 02-03 
AN EXPERIMENTAL STUDY OF THE SPECTRUM OF INDIVIDUAL 
PSYCHOTROPIC ACTIVITY OF CLOZAPINE (LEPONEX). 

236174 02-04 
THE NATURE OF BACKGROUND SPIKE ACTIVITY OF CORTICAL NEURONS 
UNDER THE ACTION OF PSYCHOTROPIC DRUGS. 

236265 02-03 
CHOLINESTERASE ACTIVITY AND CONTENT OF ADENOSINE 

TRIPHOSPHATE IN DEPRESSED PATIENTS AND THEIR CHANGES UNDER 
THE INFLUENCE OF MONOCHLORIMIPRAMINE. 

236364 02-10 
EFFECTS OF MOLINDONE ON CENTRAL DOPAMINERGIC NEURONAL 
ACTIVITY AND METABOLISM: SIMILARITY TO OTHER NEUROLEPTICS. 

236519 02-03 
THE EFFECT OF CHRONIC SELF ADMINISTRATION OF D AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

237109 02-04 
FENFLURAMINE AND 5-HYDROXYTRYPTAMINE. PART 2, INVOLVEMENT 
OF BRAIN AND 5 HYDROXYTRYPTAMINE IN THE ANORECTIC ACTIVITY 
OF FENFLURAMINE. 

237119 0203 
EFFECT OF NOMIFENSINE ON MOTOR ACTIVITY, DOPAMINE TURNOVER 
RATE AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE 
CONCENTRATIONS OF RAT STRIATUM. 

237156 02-04 
MECHANISMS OF QUINIDINE AND CHLORPROMAZINE INHIBITION OF 
SARCOTUBULAR ATPASE ACTIVITY. 

237245 02-03 
EFFECTS OF SCOPOLAMINE, D AMPHETAMINE AND OTHER DRUGS 
AFFECTING CATECHOLAMINES ON SPONTANEOUS ALTERNATION AND 
LOCOMOTOR ACTIVITY IN MICE 

237703 02-04 
DOSE-RESPONSE EFFECTS OF SCOPOLAMINE ON ACTIVITY IN AN OPEN- 
FIELD. 

237728 0204 
MOUSE BRAIN CATECHOLAMINES, 5-HYDROXYTRYPTAMINE AND THE 
ANTINOCICEPTIVE ACTIVITY OF PETHIDINE. 

237741 02-03 
THE EFFECT OF SELECTIVE LESIONING OF BRAIN CATECHOLAMINE 

CONTAINING NEURONS ON THE ACTIVITY OF VARIOUS ANORECTICS IN 
THE RAT. 

237742 02-03 
CENTRAL EFFECTS OF SCOPOLAMINE AND ( t ) AMPHETAMINE ON 

LOCOMOTOR ACTIVITY: INTERACTION WITH STRAIN AND STRESS 
VARIABLES. 

237778 02-04 
THE EFFECT OF LSD UPON SPONTANEOUS PGO WAVE ACTIVITY AND 
REM SLEEP IN THE CAT. 

237780 02-04 
INCREASE OF TYROSINE-HYDROXYLASE ACTIVITY AFTER RESERPINE: 
EVIDENCE FOR THE SELECTIVE RESPONSE OF NORADRENERGIC 
NEURONS. 

237881 02 03 
EFFECTS OF METHAMPHE FAMINE AND CHLORPROMAZINE ON NIGRAL 
AND STRIATAL TYROSINE HYDROXYLASE ACTIVITY AND ON STRIATAL 
DOPAMINE LEVELS (PH D DISSERTATION) 

238079 02-03 
EFFECTS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTOPHAN 
TREATMENT ON SPONTANEOUS MOTOR ACTIVITY AND BRAIN 
MONOAMINES IN MICE. 

238565 02-03 
MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE (TPH) ACTIVITY BY 
BRAIN TRYPTOPHAN (TP) CONTENT, 

238677 03-03 
TRYPTOPHAN-HYDROXYLASE IN DISCRETE NUCLEI: COMPARISON OF 

ACTIVITY IN VITRO AND IN VIVO. 

238678 03-03 
REDUCED SPONTANEOUS LOCOMOTOR ACTIVITY EVOKED BY L- 

TRYPTOPHAN & PREVENTED BY D TRYPTOPHAN 

238698 0304 
ANTICONVULSANT ACTIVITY OF NEWER SUBSTITUTED TRIAZOLES. 

238712 0303 



S-7 



Subject Index 



Psychopharmacology Abstract 



COMPARISON OF THYROID RELEASING HORMONE (TRH) AND 

AMPHETAMINE (AMP) ON CHANGES IN ACTIVITY LEVELS OF RATS 
FOLLOWING INJECTIONS INTO THE CAUDATE-NUCLEUS, SEPTUM, AND 
HYPOTHALAMUS 

238744 03-04 
THE REVERSAL OF APOMORPHINE-ELICITED INHIBITION OF 
SYNAPTOSOMAL TYROSINE-HYDROXYLASE ACTIVITY BY 
NEUROLEPTICS, 

238758 03-03 
PURIFICATION OF (3H)TAURINE OF HIGH SPECIFIC ACTIVITY. 

238773 03-03 
GAMMA-ACETYLENIC-GABA (AMIN0-4-HEX-5-YN0IC ACID); A GABA- 
TRANSAMINASE INHIBITOR WITH SELECTIVE ANTISEIZURE ACTIVITY. 

238781 03-04 
DOSE-RESPONSE STUDIES ON EFFECTS OF AMPHETAMINE ON ACTIVITY 
AND OXYGEN CONSUMPTION IN DOG AND CAT MODELS OF 
HYPERKINESIS (HYPOINHIBITORY SYNDROME). 

238825 03-03 
INHIBITION OF SPONTANEOUS AND METHAMPHETAMINE-INDUCED 
LOCOMOTOR ACTIVITY IN MICE. 

238842 03-04 
AGE-RELATED CHANGES OF LOCOMOTOR ACTIVITY AFTER 
AMPHETAMINE ADMINISTRATION. 

238845 03-04 
EFFECT OF LILLY-1 10140 AND METHYSERGID ON L-DOPA-INDUCED 
CHANGES IN LOCOMOTOR ACTIVITY (MA) IN MICE. 

238847 03-04 
ANXIETY AND EEG ALPHA ACTIVITY IN NEUROTIC PATIENTS. 

239022 03-10 
CHOLINERGIC MEDIATION OF THE INHIBITORY EFFECT OF 

METHYLPHENIDATE ON NEURONAL ACTIVITY IN THE RETICULAR 
FORMATION. 

239086 03-03 
OLFACTORY BULB REMOVAL RESULTS IN ELEVATED SPONTANEOUS 
LOCOMOTOR ACTIVITY IN MICE. 

239284 03-04 
ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF 

NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL PHENOTHIAZINES. 

239662 03-03 
INFLUENCE OF SECOBARBITAL AND CHLORPROMAZINE ON PRECENTRAL 
NEURON ACTIVITY DURING ATTENTIVE BEHAVIOR IN MONKEYS. 

239848 03-04 
PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER- 
DISCHARGES IN RATS; INCREMENTAL DOSE, HIPPOCAMPAL EEG AND 
BEHAVIORAL ACTIVITY CORRELATES 

239858 03-03 
EFFECTS OF P-CHLOROAMPHETAMINE ON LOCOMOTOR ACTIVITY AND 
BRAIN 5-HYDROXYINDOLES. 

239958 03-04 
QUIPAZINE; ITS EFFECTS ON RAT BRAIN 5-HYDROXYTRYPTAMINE 
METABOLISM, MONOAMINE OXIDASE ACTIVITY AND BEHAVIOUR. 

239960 03-03 
CHANGES IN THE PHARMACODYNAMICS AND PHARMACOKINETICS OF 
PSYCHOLEPTIC DRUGS IN RADIATION SICKNESS. EFFECT OF X-RAY 
RADIATION ON PHARMACODYNAMIC ACTIVITY OF NITRAZEPAM IN 
ANIMALS. 

240237 03-04 
PROLACTIN AND GONADOTROPHIN ACTIVITY IN FEMALES TREATED FOR 
ANOREXIA NERVOSA. 

240423 03-11 
INDIVIDUAL DIFFERENCES AMONG MICE IN NORMAL AND 

AMPHETAMINE-ENHANCED LOCOMOTOR ACTIVITY; RELATIONSHIP TO 
BEHAVIORAL INDICES OF STRIATAL ASYMMETRY. 

240750 03-04 
EVIDENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
MOTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS. 

241203 03-03 
5-HYDROXY L-TRYPTOPHAN-DECARBOXYLASE ACTIVITY; MICROASSAY 
AND DISTRIBUTION IN DISCRETE RAT BRAIN NUCLEI 

241208 03-03 
RELATIONSHIP BETWEEN THE SUBCELLULAR DISTRIBUTION OF DELTA9- 
TETRAHYDROCANNABINOL AND ITS METABOLITES IN RAT BRAIN AND 
THE DURATION OF THE EFFECT ON MOTOR ACTIVITY. 

241242 03-03 
REDUCTION OF TRYPTOPHAN-HYDROXYLASE ACTIVITY AND 5- 
HYDROXYTRYPTAMINE CONCENTRATION IN CERTAIN RAT BRAIN 
NUCLEI AFTER P-CHLOROAMPHETAMINE. 

241253 03-03 
SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDICATOR OF 
SYMPATHETIC ACTIVITY AND PRIMARY HYPERTENSION. 

241294 03-13 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT; I. PGO WAVE ACTIVITY INDUCED BY RO-4-1284 AND 
BY P-CHLOROPHENYLALANINE (PCPA) AS A BASIS FOR 
NEUROPHARMACOLOGICAL STUDIES. 

241315 03-03 



DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT; II. PGO WAVE ACTIVITY AND BRAIN 5- 
HYDROXYTRYPTAMINE. 

241316 03-( 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: III. PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES. 

241317 03-( 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT; IV. THE EFFECTS OF ACETYLCHOLINE, GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY. 

241318 03-( 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: V. MISCELLANEOUS COMPOUNDS. SYNOPSIS OF TH 
ROLE OF CENTRAL NEUROTRANSMITTERS ON PGO WAVE ACTIVITY. 

241319 03-1 
EFFECT OF CANNABIS EXTRACT ON THE UTERINE MONOAMINE-OXIDASE 

ACTIVITY OF NORMAL AND ESTRADIOL TREATED RATS. 

241343 03-1 
PHARMACOLOGICAL STUDIES ON THE MIDBRAIN RAPHE SYSTEM (III). 
EFFECTS OF MIDBRAIN RAPHE STIMULATION AND LESION ON EEG 
ACTIVITY IN RATS. 

241390 03-1 
TOLERANCE TO THE ACTIVITY ENHANCING EFFECT OF D-AMPHETAMINE 
(PH.D. DISSERTATION). 

241575 03-1 
HISTOTOPOGRAPHY OF THE CHANGES IN ENZYME ACTIVITY IN THE RA 
BRAIN UNDER THE EFFECT OF FLUOROPHENAZINE. 

241989 03 J 
BEHAVIOR AND INTELLECTUAL ACTIVITY OF THE ELDERLY: DOUBLE- 
BLIND STUDY OF HYDROSARPAN-711 IN A HOSPICE ENVIRONMENT. 

242900 04- 
CYCLIC-AMP IN CEREBROSPINAL FLUID IN PATIENTS WITH AFFECTIVE 
ILLNESS; EFFECTS OF PROBENECID, ACTIVITY, AND PSYCHOTROPIC 
MEDICATIONS. (UNPUBLISHED PAPER 

243023 04-1 
THE CHEMICAL CONTROL OF NEURONAL ACTIVITY. (UNPUBLISHED 
PAPER). 

243183 04- 
NEONATAL HYPERTHYROIDISM; ALTERATIONS IN BEHAVIOURAL 
ACTIVITY AND THE METABOLISM OF BRAIN NOREPINEPHRINE AND 
DOPAMINE 

243792 04-' 
EFFECT OF BENZOPYRENE AND CHLORPROMAZINE ON ARYL 

HYDROCARBON HYDROXYLASE ACTIVITY FROM RAT TISSUES. 

243793 04- 
THE EFFECT OF SYMPATHOLYTIC AND SYMPATHOMIMETIC AGENTS ON 

ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITY, IN VITRO. 

243794 04- 
EFFECTS OF AXOTOMY ON THE TRANS-SYNAPTIC REGULATION OF 

ENZYME ACTIVITY IN ADULT RAT SUPERIOR CERVICAL GANGLIA. 

244200 04- 
REGULATION OF ADRENAL TYROSINE-HYDROXYLASE ACTIVITY; 

NEURONAL VERSUS LOCAL CONTROL STUDIED WITH APOMORPHINE. 

244314 04- 
THE EFFECT OF LITHIUM ON RED BLOOD CELL CHOLINESTERASE ACTIVE 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

244495 04-1 
MOUSE-KILLING AND MOTOR ACTIVITY: EFFECTS OF CHRONIC DELTA9- 
TETRAHYDROCANNABINOL AND PILOCARPINE. 

244682 04- 
FENFLURAMINE-INDUCED ENHANCEMENT OF CONFINEMENT MOTOR 
ACTIVITY; AN INDIRECT 5-HYDROXYTRYPTAMINE LIKE ACTION?. 

24491 1 04- 
IS THERE AN INCREASE IN MONOAMINE-OXIDASE ACTIVITY IN 
DEPRESSIVE ILLNESS?. 

245233 04- 
LONG-TERM EFFECTS OF BARBITAL ON SPONTANEOUS ACTIVITY OF RA 
TRAINED TO USE THE DRUG AS A DISCRIMINATIVE STIMULUS. 

245299 04- 
TIME-DEPENDENT VARIATIONS IN AVERSIVELY MOTIVATED BEHAVIORS 
NONASSOCIATIVE EFFECTS OF CHOLINERGIC AND 
CATECHOLAMINERGIC ACTIVITY. 

245486 04- 
PERSISTENCE OF CHRONIC MORPHINE EFFECTS UPON ACTIVITY IN RAT! 
8 MONTHS AFTER CEASING THE TREATMENT. 

245602 04-' 
THE EFFECT OF ADRENALINE ON HUMAN PLATELET MAO ACTIVITY. 

246312 04- 
CAFFEINE AND CHLORDIAZEPOXIDE; EFFECTS ON MOTOR ACTIVITY IN 
THE CHRONIC THALAMIC RAT. 

246388 04-1 
RENAL LITHIUM, SODIUM, POTASSIUM, AND WATER EXCRETION AND 
PLASMA RENIN ACTIVITY IN RATS IN THE COLD 

246673 04-1 
DETERMINATION AND CHARACTERIZATION OF THE ANTINOCICEPTIVE 
ACTIVITY OF INTRAVENTRICULARLY ADMINISTERED ACETYLCHOLINE 
IN MICE. 

246852 04-1 



S-8 



VOLUME 14, SUBJECT INDEX 



Subject Index 



CORRELATION BETWEEN STRUCTURE, BEHAVIORAL ACTIVITY AND RATE 
OF BIOTRANSFORMATION OF SOME ACTH4-9 ANALOGS. 

246853 04-04 
MEASUREMENT OF THE EFFECTS OF DRUGS ON ACTIVITY OF PERMANENT 
GROUPS OF RATS. 

247207 04-04 
THE EFFECT OF VARIOUS CHLORPROMAZINE DERIVATIVES ON THE 
APOMORPHINE-ELICITED INHIBITION OF SYNAPTOSOMAL TYROSINE- 
HYDROXYLASE ACTIVITY. 

247212 04-03 
AROUSAL AND ACTIVITY LEVEL OF RATS WITH LESIONS IN THE DORSAL 
HIPPOCAMPUS. 

247420 04-04 
ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED WITH THREE OTHER DRUGS. 

248283 04-02 
EFFECTS OF CHEMICAL STIMULATION OF THE MESOLIMBIC DOPAMINE 
SYSTEM UPON LOCOMOTOR ACTIVITY. 

248285 04-02 
APORPHINES 16: ACTION OF APORPHINE ALKALOIDS ON LOCOMOTOR 
ACTIVITY IN RATS WITH 6-HYDROXYDOPAMINE LESIONS OF THE 
NUCLEUS-ACCUMBENS. 

248287 04-02 
THE EFFECT OF MEPIPRAZOLE ON CENTRAL MONOAMINE NEURONS. 

EVIDENCE FOR INCREASED 5-HYDROXYTRYPTAMINE AND DOPAMINE 
RECEPTOR ACTIVITY. 

248288 04-03 
LITHIUM EFFECTS UPON COMPONENTS OF ACTIVITY IN RATS. 

248516 04-03 
SYNTHESIS AND BIOLOGICAL ACTIVITY OF NEW 2-SUBSTITUTED 
ANALOGS OF FLUPHENAZINE. 

248538 04-02 
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM DEPRESSANT ACTIVITY OF 

SOME BICYCLIC AMIDES. 

248539 04-02 
SYNTHESIS AND DOPAMINERGIC ACTIVITY OF ( -I- OR-)- (-t^)- AND (-) 2- 

DIPROPYLAMINO-5-HYDROXYTETRAHYDRONAPHTHALENE. 

248650 04-02 
POSTNATAL ELEVATION OF BRAIN TYROSINE-HYDROXYLASE ACTIVITY 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 
CATECHOLAMINE LEVELS, RESULTING FROM DL-ALPHA-METHYL-P- 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 04-03 
RECEPTOR BINDING AND PHARMACOLOGICAL ACTIVITY OF OPIATES IN 
THE GUINEA-PIG INTESTINE. 

248703 04-03 
SYNTHESIS AND NEUROLEPTIC ACTIVITY OF ISOMERIC 
THIENOBENZOTHIAZINES. 

248949 04-01 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

248961 04-03 
RAPHE NEURONS: DEPRESSION OF ACTIVITY BY L-5- 
HYDROXYTRYPTOPHAN. 

249078 04-03 
REDUCTION OF BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN 
SCHIZOPHRENIC PATIENTS ON PHENOTHIAZINES. 

249121 04-08 
A COMPARISON OF NARCOTIC ANALGESICS WITH NEUROLEPTICS ON 
BEHAVIORAL MEASURES OF DOPAMINERGIC ACTIVITY. 

249)39 04-04 
EFFECTS OF MORPHINE ON SINGLE UNIT ACTIVITY OF NEURONS IN THE 
NUCLEUS RAPHE DORSALIS. 

249249 04-03 
EFFECTS OF MONOAMINE-OXIDASE INHIBITORS (MAOIS) ON 

SPONTANEOUS AND D-AMPHETAMINE STIMULATED LOCOMOTOR 
ACTIVITY. 

249273 04-03 
THE EFFECT OF AMPHETAMINE PRETREATMENT ON THE AMPHETAMINE- 
INDUCED CHANGES IN MOTOR ACTIVITY AND BRAIN 
CATECHOLAMINES IN MICE. 

249274 04-04 
EFFECT OF RESTRICTION OF MOVEMENT AND BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE HYDROCHLORIDE ON 

SODIUM BARBITAL ACTIVITY IN THE RAT. 

249278 04-04 
TYROSINE-HYDROXYLASE ACTIVITY IS LOWER IN FOREBRAIN DURING 

NALOXONE PRECIPITATED WITHDRAWAL IN MORPHINE PELLETED 

RATS. 

249291 04-03 
BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE- 

COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N N 

DIMETHYLTRYPTAMINE AND 5-METH0XY-N,N DIMETHYLTRYPTAMINE. 

249317 04-05 
CORRELATIONS BETWEEN THE ACTIVITY OF DIMETHYLTRYPTAMINES AS 

5-HYDROXYTRYPTAMINE ANTAGONISTS AND THEIR QUANTUM 
CHEMICAL PARAMETERS. 

249318 04-03 



CHOLINE ACETYLTRANSFERASE ACTIVITY INCREASES IN THE BRAINSTEM 
OF RATS TREATED AT BIRTH WITH 6-HYDROXYDOPA. 

249666 04-03 
PLASAAA RENIN ACTIVITY IN DEPRESSED PATIENTS TREATED WITH 
INCREASING DOSES OF LITHIUM CARBONATE. 

249673 04- 13 
EFFECTS OF NEONATAL THYROXINE STIMULATION ON ADULT OPEN-FIELD 
BEHAVIOR AND THYROID ACTIVITY IN RATS. 

250013 04-04 
EFFECTS OF HARMINE AND BRAIN LESIONS ON APOMORPHINE INDUCED 
MOTOR ACTIVITY. 

250058 04-03 
COMBINATIONS OF SELECTED CNS DEPRESSANTS WITH D-AMPHETAMINE 
OR /WAZINDOL ON FOOD INTAKE AND MOTOR ACTIVITY OF RATS. 

250080 04-03 
THE NARCOTIC DISCRIMINATIVE STIMULUS COMPLEX: RELATION TO 
ANALGESIC ACTIVITY. 

250355 04-03 
COMPARISON OF THE APPARENT ANTIDEPRESSANT ACTIVITY OF (-) AND 
( -I- ) TRANYLCYPROMINE IN AN ANIMAL MODEL. 

250376 04-03 
CLONAZEPAM IN THE TREATMENT OF CHOREIFORM ACTIVITY. 

250932 04-07 
ON THE IN VIVO AND IN VITRO ACTIONS OF FENFLURAMINE AND ITS 
DERIVATIVES ON CENTRAL MONOAMINE NEURONS, ESPECIALLY 5- 
HYDROXYTRYPTAMINE NEURONS, AND THEIR RELATION TO THE 
ANORECTIC ACTIVITY OF FENFLURAMINE. 

250937 04-03 
CHANGES OF SKIN NERVE SYMPATHETIC ACTIVITY DURING INDUCTION 
OF GENERAL ANESTHESIA WITH THIOPENTONE IN AAAN. 

25107! 04)2 
EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251130 04-02 
MESOLIMBIC AREA AND C. STRIATUM: RELATIVE INCREASES IN 

DOPAMINE TURNOVER BY NEUROLEPTIC AND RELATED COMPOUNDS 
DEVOID OF ANTIPSYCHOTIC ACTIVITY. 

251395 04-03 
ANTIDEPRESSANT AND ANTICONVULSANT ACTIVITY OF PHENYL-4-0X0 2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED PIPERAZINES. 

251701 04-01 
EVIDENCE CONCERNING THE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE 
IN THE LOCOMOTOR ACTIVITY PRODUCED BY AMPHETAMINE OR 
TRANYLCYPROMINE PLUS L-DOPA. 

251704 04-04 
INFLUENCE OF METHAMPHETAMINE ON NIGRAL AND STRIATAL 
TYROSINE-HYDROXYLASE ACTIVITY AND ON STRIATAL DOPAMINE 
LEVELS. 

252027 04-03 
ACTIVITY, AVOIDANCE LEARNING AND REGIONAL 5- 

HYDROXYTRYPTAMINE FOLLOWING INTRABRAIN STEM 5,7 
DIHYDROXYTRYPTAMINE AND ELECTROLYTIC MIDBRAIN RAPHE 
LESIONS IN THE RAT. 

252173 04-03 
ANTICHOLINERGIC ACTIVITY OF ANTIPSYCHOTIC DRUGS IN RELATION TO 
THEIR EXTRAPYRAMIDAL EFFECTS. 

252520 04-05 
THE INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES. 

2527)1 04-03 
INCREASED ERYTHROCYTE NA -t^ PUMP AND NAK-ATPASE ACTIVITY 
DURING LITHIUM THERAPY. 

253137 04-13 
NORMAL GLUTAMIC-DECARBOXYLASE ACTIVITY IN RAT STRIATUM AND 
RETAIN FOLLOWING ADMINISTRATION OF L-DOPA. 

253695 04-03 
ACTS 

FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCLE, 

248409 04-03 
ACUITY 

EFFECTS OF ALCOHOL AND MARUUANA ON DYNAMIC VISUAL ACUITY- I 
THRESHOLD MEASUREMENTS. 

235759 02-14 
ACUTE 

ACUTE SEDATIVE PROPERTIES OF SKF-525-A IN RATS: IMPLICATIONS FOR 
ITS USE AS A METABOLISM INHIBITOR IN THE STUDY OF 
PSYCHOACTIVE DRUGS. 

225572 01-03 
A CONTROLLED TRIAL OF CLOTHIAPINE AND CHLORPROMAZINE IN 
ACUTE SCHIZOPHRENIC SYNDROMES. 

226412 01-08 
ACUTE AND SUBACUTE EFFECTS OF NEUROLEPTICS ON DOPAMINE 
SYNTHESIS AND RELEASE IN THE RAT STRIATUM. 

226858 0) -03 



I 

I 

r 

I 



S-9 



Subject Index 



Psychopharmacology Abstracts 



ACUTt EFFECTS OF HEROIN AND MORPHINE ON NEWLY SYNTHESIZED 
SEROTONIN IN RAT BRAIN 

226870 01-03 
ACUTE BEHAVIORAL CHANGES INDUCED IN THE RAT BY THE 

INTRACEREBROVENTRICULAR ADMINISTRATION OF THYROTROPIN- 
RELEASING FACTOR (TRF) AND SOMATOSTATIN. 

227386 01-04 
HALOPERIDOL AND PROPRANOLOL IN THE TREATMENT OF ACUTE 
AMPHETAMINE INTOXICATION IN THE DOG, 

227389 01-03 
DEPRESSION AND THE ACUTE SCHIZOPHRENIC PROCESS. 

228240 01-08 
PIRACETAM IN A CASE OF ACUTE CEREBRAL HYPOXEMIA: CASUISTIC 
REPORT 

229128 01-14 
CHLORPROMAZINE METABOLISM AND CLINICAL RESPONSE IN ACUTE 
SCHIZOPHRENIA: A PRELIMINARY REPORT 

229445 01 08 
PLASMA LEVELS OF MESORIDAZINE AND ITS METABOLITES AND 

CLINICAL RESPONSES IN ACUTE SCHIZOPHRENIA AFTER A SINGLE 
INTRAMUSCULAR DRUG DOSE. 

229446 01-08 
LONG-ACTING PHENOTHIAZINE AND SOCIAL THERAPY IN THE 

COMMUNITY TREATMENT OF ACUTE SCHIZOPHRENICS. 

229448 01 08 
THE MEDICAL PHARMACOLOGICAL MANAGEMENT OF ACUTE 
PSYCHOSES 

229717 01-11 
A CONTROLLED TRIAL OF CHLORMETHIAZOLE AND CHLORDIAZEPOXIDE 
IN THE TREATMENT OF THE ACUTE WITHDRAWAL PHASE OF 
ALCOHOLISM. 

230104 01 11 
SCHEDULE-INDUCED ORAL NARCOTIC SELF-ADMINISTRATION: ACUTE 
AND CHRONIC EFFECTS. 

233293 02-04 
INDIVIDUAL DIFFERENCES AND SETTING AS DETERMINANTS OF ACUTE 
ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS. 

233377 02-12 
ON THE DIFFERENTIAL DIAGNOSIS OF ACUTE EXTRAPYRAMIDAL MOTOR 
DISTURBANCES IN CHILDHOOD: CASUISTIC ACCOUNT. 

234291 02-11 
PLASMA CORTICOIDS AND BRAIN TRYPTOPHAN AFTER ACUTE AND 
TOLERANCE DOSAGE OF LSD 

234311 02-03 
ADVANTAGES OF THE INITIAL THERAPY OF ACUTE SCHIZOPHRENIA WITH 
LARGE DOSES OF DROPERIDOL: A COMPARATIVE STUDY. 

237124 02-08 
RESPONSE OF NIGRAL DOPAMINE NEURONS TO ACUTE AND PROLONGED 
MORPHINE TREATMENT: EFFECT OF EXPOSURE TO COLD, 
PHYSOSTIGMINE AND NICOTINE 

237158 02-03 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY. 

237458 02-10 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 
AND SEROTONIN IN RATS - ACUTE MORPHINE ADMINISTRATION. 

237736 02-03 
EFFECT OF ACUTE AND CHRONIC IPRINDOLE ON SEROTONIN TURNOVER 
IN MOUSE BRAIN. 

237922 02-03 
TREATMENT OF ACUTE PSYCHOTIC PATIENTS WITH LOXAPINE 
PARENTERALLY 

238551 02-09 
RESPONSES OF FLEXOR REFLEX TO LSD. TRYPTAMINE (T), 5 HTP, 
METHOXAMINE (M) AND D AMPHETAMINE (A) IN ACUTE AND 
CHRONIC SPINAL RATS. 

238704 03-04 
EFFECTS OF ACUTE ETHANOL ADMINISTRATION ON BRAIN BIOGENIC 
AMINES 

238751 03-03 
EFFECTS OF ACUTE AND CHRONIC PENTOBARBITAL ADMINISTRATION ON 
BRAIN GAMMA-AMINOBUTYRATE (GABA) AND GLUTAMATE (GLU) 
LEVELS IN THE MOUSE. 

238791 03-03 
THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE- 
CONTROLLED BEHAVIOR IN THE RHESUS MONKEY. 

238794 03 04 
ENVIRONMENTAL INFLUENCES ON THE BEHAVIORAL RESPONSE TO ACUTE 
AND CHRONIC AMPHETAMINE ADMINISTRATION. 

238843 03-04 
A DOUBLE BLIND COMPARISON OF FLUPHENAZINE-DECANOATE AND 
FLUPENTHIXOL-DECANOATE IN THE TREATMENT OF ACUTE 
SCHIZOPHRENIA . 

238996 03 08 
ACUTE EFFECTS OF OXAZEPAM, DIAZEPAM AND ME FHYLPERONE, ALONE 
AND IN COMBINATION WITH ALCOHOL ON SEDATION, COORDINATION 
AND MOOD 

239042 03-14 



ACUTE AND CHRONIC EFFECTS OF VASOPRESSIN IN RATS WITH LITHIUM 
POLYURIA. 

239046 03-05 
ACUTE CONFUSIONAL STATES. 

239607 03-17 
ACUTE AND CHRONIC EFFECTS OF 4-CHLOROAMPHETAMINE ON 
MONOAMINE METABOLISM IN THE RAT BRAIN. 

239849 03-03 
PCHLOROAMPHETAMINE (PCA): ACUTE AND CHRONIC EFFECTS ON 
HABITUATION AND SENSITIZATION OF THE ACOUSTIC STARTLE 
RESPONSE IN RATS. 

240062 03-04 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIAAALS AND MAN. (UNPUBLISHED PAPER). 

240241 03-04 
TREATMENT OF ACUTE SCHIZOPHRENIA WITH SULPHORIDAZINE. 

240850 03-08 
INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE-HCL IN 
ACUTE/SCHIZOPHRENIA: A RETROSPECTIVE STUDY. 

241277 03-08 
THE EFFECT OF ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION 
ON SEIZURE SUSCEPTIBILITY AND BRAIN CATECHOLAMINES IN MICE. 
(PH.D. DISSERTATION). 

241576 03-03 
NORMAL DISPOSITION OF OXAZEPAM IN ACUTE VIRAL HEPATITIS AND 
CIRRHOSIS. 

241730 03-13 
A PRIAAATE MODEL OF ACUTE DYSTONIC REACTION TO NEUROLEPTICS. 

241934 03-05 
PRESYNAPTIC AND POSTSYNAPTIC ORIGIN OF LITHIUM-INDUCED ACUTE 
BLOCKADE ON ADRENERGIC TRANSMISSION IN RABBIT HEART. 

242204 03-03 
INTRAVENOUS LORAZEPAM IN THE ACUTE ANXIETY CRISIS: A 
PRELIMINARY REPORT ON 60 CASES. 

242250 03- 10 
PSYCHIATRIC EMERGENCY CAUSED BY ACUTE INTOXICATION AND 
DETOXIFICATION SYNDROMES. 

242751 04-17 
THE LEVEL OF THE GROWTH HORMONE PROLACTIN AND INSULIN IN THE 
COURSE OF THE ACUTE ADMINISTRATION OF CHLORPROMAZINE 
(PLEGOMAZIN) IN MENTAL PATIENTS. 

242863 04-15 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER 

243024 04-17 
INTRACAUDATE NEUROTRANSMITTER PROCESSES IN RELATION TO 
RAPHE NEUROTRANSMITTER PROCESSES: A BEHAVIOURAL ANALYSIS 
OF INTRACEREBRALLY APPLIED DRUGS IN ACUTE AND LONG-TERM 
MORPHINE TREATED CATS. 

244215 04-04 
IDENTIFICATION AND QUANTIFICATION OF CHLORPROMAZINE AND ITS 
METABOLITES IN ACUTE EXPERIMENTAL INTOXICATION. 

244462 04-06 
ACUTE POISONING BY MEANS OF A VETERINARY USED SULFONE: A CASE 
STUDY. 

245116 04 05 
TECHNIQUE OF FLUPHENAZINE-DECANOATE THERAPY IN ACUTE 
SCHIZOPHRENIC ILLNESSES 

246186 04-08 
ACUTE MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 
HORMONE AND CORTICOSTERONE 

246661 04-03 
HOMOVANILLIC-ACID AND 5HY0R0XYIND0LEACETIC-ACID IN THE CSF 
OF PATIENTS AFTER A SEVERE HEAD INJURY. II. VENTRICULAR CSF 
CONCENTRATIONS IN ACUTE BRAIN POSTTRAUMATIC SYNDROMES. 

246994 04-13 
PHENCYCLIDINE - STATES OF ACUTE INTOXICATION AND FATALITIES. 

247147 04-15 
A DOUBLE-BLIND EVALUATION OF METIAPINE IN HOSPITALIZED ACUTE 
SCHIZOPHRENICS. 

248976 04 08 
DIFFERENCES BETWEEN THE EFFECTS OF ACUTE AND LONG-TERM 
TREATMENT WITH DESMETHYLIMIPRAMINE ON RESERPINE-INDUCED 
RELEASE OF AMINES FROM RAT BRAIN, 

249233 04-03 
EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN 
GLUTAMATE (GLU) AND GAMAAA-AMINOBUTYRATE (GABA) LEVELS IN 
THE MOUSE. 

249292 0403 
ACUTE TOLERANCE TO BARBITURATE IN THE RAT. 

250077 04-04 
EFFECTS OF THIORIDAZINE AND DIAZEPAM ON THE PHARMACOKINETICS 
OF (I4C)IMIPRAMINE IN RAT: ACUTE STUDY 

250655 04-03 
EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251130 04-02 



S-10 



k^OLUME 14, SUBJECT INDEX 



Subject Index 



ACUTE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE 

ACQUISITION OF SHUTTLEBOX CONDITIONED AVOIDANCE RESPONSE. 

251989 04-04 
EFFECTS OF ACUTE AND CHRONIC METHADONE TREATMENT ON THE 
UPTAKE OF 3H 5-HYDROXYTRYPTAMINE IN RAT HYPOTHALAMUS 
SLICES. 

252023 04-03 
POTENTIATION OF AMPHETAMINE-INDUCED HYPERACTIVITY BY ACUTE 
BUT NOT BY CHRONIC P-CHLOROPHENYLALANINE TREATMENT IN THE 
RAT 

252519 04-03 
CLINICAL APPLICATIONS OF A NEW RATIONALE IN THE TREATMENT OF 
ACUTE ALCOHOL WITHDRAWAL. 

252694 04-11 
A CONTROLLED DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND 
HALOPERIDOL IN ACUTE NEWLY HOSPITALIZED SCHIZOPHRENIC 
PATIENTS. 

253051 04-08 
ACUTE MANIA: CLINICAL AND GENETIC STUDY OF RESPONDERS AND 
NONRESPONDERS TO TREATMENTS 

253617 0409 
ANTIDEPRESSANT TREATMENT WITH MAPROTILINE IN THE 

MANAGEMENT OF EMOTIONAL DISTURBANCES IN PATIENTS WITH 
ACUTE MYOCARDIAL INFARCTION; A CONTROLLED STUDY. 

253684 04-11 
\DAPTATION 

CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
PSYCHOTROPIC DRUGS. 

234797 02-09 
CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
PSYCHOTROPIC DRUGS. 

243819 04-13 
ADAPTIVE 

ADAPTIVE CHANGES IN BEHAVIOR AFTER REPEATED ADMINISTRATION 
OF VARIOUS PSYCHOACTIVE DRUGS. 

234810 02-04 
EFFECT OF AMPHETAMINE AND GUTIMIN ON ADAPTIVE CHANGES IN 
ARTERIAL PRESSURE ARISING IN RESPONSE TO CONTRACTION OF THE 
SKELETAL MUSCLES. 

241988 03-03 
THE ROLE OF THE AMYGDALOID NUCLEI IN THE REGULATION OF 
ADAPTIVE BEHAVIOR. 

243234 04-04 
\DAPTIVENESS 

ADAPTIVENESS AND BEHAVIOR OF THE ELDERLY SUBJECT. 

242898 04-11 
\ODICT 

CONTINGENT NALOXONE (N-ALLYLNOROXYMORPHONE) TREATMENT OF 
THE PAROLED NARCOTIC ADDICT. 

226901 01 14 
A CONTROLLED COMPARISON OF CYCLAZOCINE AND NALOXONE 
TREATMENT OF THE PAROLED NARCOTIC ADDICT. 

239824 03-11 
VDDICTION 

METHYLPHENIDATE ADDICTION - EFFECT REVERSAL IN WITHDRAWAL. 

238862 03-15 
HEROIN ADDICTION: SEQUENTIAL TREATMENT EMPLOYING 
PHARMACOLOGIC SUPPORTS. 

239939 03-11 
\DOICTIVE 

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY 
MORPHINE AND LATERAL HYPOTHALAMIC SELF-STIMULATION. 

250019 04-04 
VDDICTS 

ASSISTING MULTIPLE DRUG ADDICTS. PSYCHOTHERAPY AND 
PSYCHOPHARMACOLOGY 

237095 02- II 
THERAPEUTIC ATTEMPTS WITH LITHIUM IN YOUNG DRUG ADDICTS. 

238988 03-11 
THE MEDICAL SAFETY OF THE COMBINED USAGE OF DISULFIRAM AND 
METHADONE: PHARMACOLOGICAL TREATMENT FOR ALCOHOLIC 
HEROIN ADDICTS. 

239943 03 15 
^ODITIVE 

THE FOOD ADDITIVE HYPOTHESIS, LEAD, AND HYPERACTIVITY. 

251572 04 II 
VDDITIVES 

AN INVESTIGATION ON THE DOSE RESPONSE RELATIONSHIP BETWEEN 
CONVENTIONAL ANTIOXIDANT FOOD ADDITIVES AND 
NEUROTRANSMITTER METABOLISM. 

238745 03-03 
RELAY TOXICITY: A NEW APPROACH TO A METHODOLOGY OF 

EVALUATING THE TOXICITY OF ADDITIVES TO FARM ANIMAL FEED. 

245114 04-06 
VOENINE 

ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF 

NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS BY 
10 2 ARYLIMINO-3 ACETYLAMINO-4 THIAZOLIDONYL PHENOTHIAZINES. 

239662 03-03 



ADENOSINE 

REGULATION OF PROTEIN PHOSPHORYLATION AND MEMBRANE 

PERMEABILITY BY BETA-ADRENERGIC AGENTS AND CYCLIC ADENOSINE 
3:5-MONOPHOSPHATE IN THE AVIAN ERYTHROCYTE. 

231014 01-03 
CHOLINESTERASE ACTIVITY AND CONTENT OF ADENOSINE 

TRIPHOSPHATE IN DEPRESSED PATIENTS AND THEIR CHANGES UNDER 
THE INFLUENCE OF MONOCHLORIMIPRAMINE. 

236364 02-10 
EFFECT OF NOMIFENSINE ON MOTOR ACTIVITY, DOPAMINE TURNOVER 
RATE AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE 
CONCENTRATIONS OF RAT STRIATUM. 

237156 02-04 
EFFECTS OF ALDEHYDES ON SODIUM PLUS POTASSIUM ION-STIMULATED 
ADENOSINE TRIPHOSPHATASE OF MOUSE BRAIN. 

237920 02-03 
EVIDENCE THAT DIPHENYLHYDANTOIN DOES NOT AFFECT ADENOSINE 
TRIPHOSPHATASES FROM BRAIN, 

239962 03-03 
CYCLIC ADENOSINE MONOPHOSPHATE IN CEREBROSPINAL FLUID: 
EFFECTS OF THEOPHYLLINE, L-OOPA AND A DOPAMINE RECEPTOR 
STIMULANT IN RATS. 

240447 03-03 
EFFECTS OF STIMULATORY AND DEPRESSANT DRUGS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE LEVELS IN MOUSE BRAIN. 

241246 03-03 
CENTRAL GAMAAA-AMINOBUTYRIC-ACID RECEPTORS AND THE 

REGULATION OF 35 CYCLIC ADENOSINE MONOPHOSPHATE CONTENT 
IN RAT PITUITARY. (UNPUBLISHED PAPER). 

243041 04-03 
NEUROTRANSMITTER REGULATION OF ADENOSINE 3,5 MONOPHOSPHATE 
IN CLONAL NERVE, GLIA, AND MUSCLE CELL LINES. 

243482 04-03 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAIN 
MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS. 

246318 04-04 
EFFECTS OF ARECOLINE AND CHOLINESTERASE INHIBITORS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE IN MOUSE BRAIN. 

246389 04-03 
INTERRELATIONSHIP BETWEEN CATECHOLAMINE STIMULATED 

FORMATION OF ADENOSINE 3,5 MONOPHOSPHATE IN CEREBELLAR 
SLICES AND INHIBITORY EFFECTS ON CEREBELLAR PURKINJE CELLS: 
ANTAGONISM BY NEUROLEPTIC COMPOUNDS. 

253109 04-03 
ADENYLATE-CYCLASE 

LSD AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN VARIOUS RAT 
BRAIN AREAS. 

226406 01-03 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN AAAMMALIAN BRAIN: A 
POSSIBLE SITE OF ACTION OF ANTIPSYCHOTIC DRUGS. 

230602 01-13 
A DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN ANTERIOR LIMBIC 
CORTEX AND MESOLIMBIC REGION OF PRIMATE BRAIN. 

231304 01-03 
INTERACTIONS OF OPIATE RECEPTORS WITH ADENYLATE-CYCLASE. 
(UNPUBLISHED PAPER). 

232960 02-03 
RAPID CHANGES IN RAT PINEAL BETA-ADRENERGIC RECEPTOR 

ALTERATIONS IN 3H ALPRENOLOL BINDING AND ADENYLATE-CYCLASE. 
(UNPUBLISHED PAPER). 

237170 02-03 
OPIATE RECEPTORS AS REGULATORS OF ADENYLATE-CYCLASE. 
(UNPUBLISHED PAPER), 

237175 02-03 
ACTIONS OF PHENOTHIAZINE ANALOGS ON DOPAMINE SENSITIVE 

ADENYLATE CYCLASE IN NEURONAL AND GLIAL ENRICHED FRACTIONS 
FROM RAT BRAIN, 

237241 02-03 
OPIATE RECEPTORS AND ADENYLATE-CYCLASE IN NEUROBLASTOMA X 
GLIOMA CELL LINES, (UNPUBLISHED PAPER) 

238571 02-03 
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE- 
CYCLASE AND ON CYCLIC-GMP FORMATION IN MONKEY BRAIN 
AMYGDALA, 

238739 03-03 
INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS ON THE ADENYLATE- 
CYCLASE PHOSPHODIESTERASE SYSTEM IN THE RAT CORTEX. 

239085 03-03 
ACTION OF NEUROLEPTIC AGENTS ON HISTAMINE SENSITIVE ADENYLATE- 
CYCLASE IN RABBIT CEREBRAL CORTEX. 

239582 03-03 
LITHIUM INHIBITION OF ADRENALINE STIMULATED ADENYLATE-CYCLASE 
IN HUMANS 

239728 03-09 



I 

% 

\ 

•0 

2 
t 



S-ll 



Subject Index 



Psychopharmacology Abstracts 



COMPARISON OF THE INHIBITORY EFFECTS OF NEUROLEPTIC DRUGS ON 
ADENYLATE-CYCLASE IN RAT TISSUES STIMULATED BY DOPAMINE, 
NORADRENALINE AND GLUCAGON. 

241347 03-03 
LIMITING FACTORS IN THE ANTAGONISM OF NEUROLEPTICS ON 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE. 

250359 04-03 
EFFECT OF NARCOTIC DEPENDENCE AND WITHDRAWAL ON STRIATAL 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND SYNAPTOSOMAL 
CYCLIC-AMP METABOLISM. 

253135 04-03 
ADENYICYCLASE 

CHRONIC ETHANOL FEEDING AND BRAIN ADENYLCYCLASE AND 
PHOSPHODIESTERASE LEVELS IN MICE. 

249294 0403 
ADH 

DOSE-RESPONSE RELATIONS IN DRUG-INDUCED INAPPROPRIATE 

SECRETION OF ADH: EFFECTS OF CLOFIBRATE AND CARBAMAZEPINE. 

232638 02-13 
ADJUNCT 

USE OF BETA-BLOCKERS AS AN ADJUNCT IN BEHAVIOURAL TECHNIQUES. 

251158 04-10 
ADJUSTMENT 

SIMPLIFIED LITHIUM DOSE ADJUSTMENT BY LOAD TEST. 

230866 01-16 
ADMINISTERED 

AN EVALUATION OF THE USE OF INTRAVENTRICULARLY ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE AS A MARKER FOR ENDOGENOUS BRAIN 
5-HYDROXYTRYPTAMINE. 

226400 01-03 
BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5,7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 
ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02-04 
BEHAVIORAL EFFECTS OF INTRACEREBRALLY ADMINISTERED 
CATECHOLAMINES IN MICE AND THEIR MODIFICATIONS BY SOME 
ADRENERGIC BLOCKING AGENTS. 

237707 02-04 
PASSIVE BARBITURATE IMMUNITY IN MICE: EFFECT ON SERUM LEVELS 
AND PHARMACOLOGIC RESPONSE TO ADMINISTERED BARBITURATES. 

238763 03-03 
EFFECT OF SOME INTRACEREBRALLY ADMINISTERED DRUGS ON A 
CONDITIONED REFLEX IN THE CAT. 

239275 03-04 
ANTAGONISM BY METHYSERGID AND CINANSERIN OF THE 

ANTINOCICEPTIVE ACTION OF MORPHINE ADMINISTERED INTO THE 
PERIAQUEDUCTAL GRAY. 

239576 03-04 
DESTRUCTIVE ACTION OF SYSTEMICALLY ADMINISTERED 6- 
HYDROXYDOPAMINE ON THE RAT AREA POSTREMA. 

239832 03-03 
INTRAMUSCULARLY ADMINISTERED FLUPHENAZINE-HCL IN 
ACUTE/SCHIZOPHRENIA: A RETROSPECTIVE STUDY. 

241277 03-08 
TOLERANCE TO CENTRALLY ADMINISTERED PHENOBARBITAL. 

241346 03-03 
STUDY ON HEAD-TWITCHES INDUCED BY INTRACEREBRALLY 

ADMINISTERED TYRAMINE IN ISOCARBOXAZIDE PRETREATED MICE. 

241380 03-04 
DETERMINATION AND CHARACTERIZATION OF THE ANTINOCICEPTIVE 
ACTIVITY OF INTRAVENTRICULARLY ADMINISTERED ACETYLCHOLINE 
IN MICE. 

246852 04-04 
BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE- 
COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N,N 
DIMETHYLTRYPTAMINE AND 5-METH0XY-N,N DIMETHYLTRYPTAMINE. 

249317 04-05 
ADMINISTERING 

PROBLEMS INVOLVED IN ADMINISTERING L-DOPA. 

239695 03-15 
ADMINISTRATION 

BIOGENIC AMINES AND THE EFFECT OF SHORT-TERM LITHIUM 
ADMINISTRATION ON OPEN-FIELD ACTIVITY IN RATS. 

225573 01-04 
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL CHANGES ASSOCIATED 
WITH PAPAVERINE ADMINISTRATION IN HEALTHY GERIATRIC 
SUBJECTS. 

226478 01-11 
NEONATAL THYROXINE ADMINISTRATION, BEHAVIORAL MATURATION 
AND BRAIN GROWTH IN MICE OF DIFFERENT BRAIN WEIGHT. 

226532 01-04 
BIOCHEMICAL OBSERVATIONS FOLLOWING ADMINISTRATION OF 
TAURINE TO PATIENTS WITH EPILEPSY. 

226737 01-13 
INHIBITION OF 4,ALPHA DIMETHYL-M-TYRAMINE H77-77 INDUCED 

HYPERMOBILITY IN RATS BY SINGLE AND REPEATED ADMINISTRATION 
OF CHLORPROMAZINE HALOPERIDOL, CLOZAPINE AND THIORIDAZINE. 

227129 01-04 



PARATHION ADMINISTRATION IN THE MONKEY: TIME COURSE OF 

INHIBITION AND RECOVERY OF BLOOD CHOLINESTERASES AND VISUAL 
DISCRIMINATION PERFORMANCES. 

227384 01-03 
ACUTE BEHAVIORAL CHANGES INDUCED IN THE RAT BY THE 

INTRACEREBROVENTRICULAR ADMINISTRATION OF THYROTROPIN- 
RELEASING FACTOR (TRF) AND SOAAATOSTATIN. 

227386 01-04 
BEHAVIORAL EFFECTS OF REDUCING THE DAILY FREQUENCY OF 
PHENOTHIAZINE ADMINISTRATION. 

228224 01-08 
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TRANS- 
TETRAHYDROCANNABINOL (DELTA9THC) IN GUINEA-PIGS. 

229033 01-03 
A SURVEY OF PSYCHOACTIVE DRUG USE IN THE AGED IN VETERANS 
ADMINISTRATION HOSPITALS. 

229458 01-11 
BARBITAL-INDUCED CROSS-TOLERANCE TO BARBITURATES BY THE 
INTRACISTERNAL ROUTE OF ADMINISTRATION. 

231011 01-03 
THE EFFECT OF TRIFLUOPERAZINE ON THE TRANSMISSION OF 
EXCITATION IN THE RABBIT BRAIN DURING PROLONGED 
ADMINISTRATION OF THE PREPARATION. 

231070 01-03 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING. (UNPUBLISHED 
PAPER). 

231771 01-04 
THE INFLUENCE OF ALCOHOL AND OTHER DRUGS ON MENTAL TASK 
PERFORAMNCES UNDER THEIR COMBINED ADMINISTRATION. 

233281 02-14 
RELATIONSHIP OF DOPAMINE NEURAL SYSTEMS TO THE BEHAVIORAL 
ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION 
INTO BRAIN. 

233970 02-03 
NOREPINEPHRINE METABOLISM AFTER SHORT-TERM AND LONG-TERM 
ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANT DRUGS AND 
ELECTROCONVULSIVE SHOCK. 

234804 02-03 
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF REPEATED D- 
AMPHETAMINE ADMINISTRATION. 

234809 02-04 
ADAPTIVE CHANGES IN BEHAVIOR AFTER REPEATED ADMINISTRATION 

OF VARIOUS PSYCHOACTIVE DRUGS. 

234810 02-04 
METHODS OF ASSESSMENT OF DRUG ADMINISTRATION IN A 

PSYCHIATRIC HOSPITAL. 

235545 02-17 
CEREBELLAR ATAXIA DUE TO DIPHENYLHYDANTOIN ADMINISTRATION - 
CLINICAL AND PATHOLOGICAL STUDIES ON TWO CASES OF CHRONIC 
DIPHENYLHYDANTOIN INTOXICATION. 

236696 02-15 
PROGRESSIVE CHANGES IN BEHAVIOR AND SEIZURES FOLLOWING 
CHRONIC COCAINE ADMINISTRATION: RELATIONSHIP TO KINDLING 
AND PSYCHOSIS. (UNPUBLISHED PAPER). 

237169 02-04 
A DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR BY INTRAVENOUS 
ADMINISTRATION OF DRUGS IN RATS. 

237701 02-04 
PLASMA CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES AFTER 
PERORAL, INTRAMUSCULAR, AND RECTAL ADMINISTRATION: 
CORRELATION BETWEEN PLASAAA CONCENTRATION AND SEDATORY 
EFFECT OF DIAZEPAM. 

237735 02-13 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 

AND SEROTONIN IN RATS - ACUTE MORPHINE ADMINISTRATION. 

237736 02-03 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 

AND SEROTONIN IN RATS - CHRONIC MORPHINE ADMINISTRATION. 

237737 02-03 
INFLUENCE OF THE ROUTE OF ADMINISTRATION OF THE CLINICAL 

ACTION OF DIAZEPAM. 

238531 02-13 
THE TRANSCALLOSALLY EVOKED POTENTIAL (TEP) FOLLOWING 
ADMINISTRATION OF LSD, MESCALINE, DMT, APOMORPHINE AND 
METHOXAMINE IN THE DOG. 

238703 03-03 
EFFECTS OF ACUTE ETHANOL ADMINISTRATION ON BRAIN BIOGENIC 
AMINES. 

238751 03-03 
THE EFFECTS OF INTRACRANIAL ADMINISTRATION OF NOREPINEPHRINE 
AND INTRAPERITONEAL CHLORPROMAZINE ON ATTENTION IN THE 
RAT. 

238755 03-04 
DISCRIMINATIVE PENTOBARBITAL STIMULUS AFTER INTRAVENOUS 

ADMINISTRATION: A COMPARISON WITH THE INTRAPERITONEAL 
ROUTE. 

238756 03-04 



S-12 



OLUME 14, SUBJECT INDEX 



Subject Index 



EFFECT OF CHRONIC BARBITAL ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL ON CATECHOLAMINE CONTENT AND TURNOVER IN RAT 
BRAIN 

238790 03-03 
EFFECTS OF ACUTE AND CHRONIC PENTOBARBITAL ADMINISTRATION ON 

BRAIN GAMMA-AMINOBUTYRATE (GABA) AND GLUTAAAATE (GLU) 
LEVELS IN THE MOUSE. 

238791 03-03 
6HYDR0XYD0PAMINE (60HDA) ADMINISTRATION TO NEONATAL RATS 

FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) IN THE CNS. 

238826 03-03 
ENVIRONMENTAL INFLUENCES ON THE BEHAVIORAL RESPONSE TO ACUTE 
AND CHRONIC AMPHETAMINE ADMINISTRATION. 

238843 03-04 
AGE-RELATED CHANGES OF LOCOMOTOR ACTIVITY AFTER 
AMPHETAMINE ADMINISTRATION. 

238845 03-04 
PERORAL AND PARENTERAL ADMINISTRATION OF LONG-ACTING 

NEUROLEPTICS: A DOUBLE-BLIND STUDY OF PENFLURIDOL COMPARED 
TO FLUPENTHIXOL-DECANOATE IN THE TREATMENT OF 
SCHIZOPHRENIA. 

239023 03-08 
EFFECT OF LONG-LASTING TRIOXAZIN ADMINISTRATION ON THE 
REACTION TIME IN NORMAL INDIVIDUALS. 

239992 03-14 
GLUCOSE TOLERANCE AND SERUM LIPIDS IN MAN AFTER LONG-TERM 
LITHIUM ADMINISTRATION. 

240054 03-13 
INFLUENCE OF PRENATAL D-AMPHETAMINE ADMINISTRATION ON 
DEVELOPMENT AND BEHAVIOR OF RATS. 

241245 03-04 
LONG-TERM DEFICITS IN STIMULATION-INDUCED BEHAVIORS AND SELF- 
STIMULATION AFTER 6-HYDROXYDOPAMINE ADMINISTRATION IN 
RATS. 

241300 03-04 
EFFECTS OF CHRONIC ADMINISTRATION OF MORPHINE ON 
PENTOBARBITAL RESPONSES IN THE MOUSE. 

241338 03-03 
EFFECTS OF LONG-TERM ADMINISTRATION OF LEVOMETHIOMEPRAZINE 
TO RATS. 

241381 03-03 
MODIFICATIONS OF EFFECTS OF CHLORPROMAZINE ON ADRENERGIC 
DRUGS AND BARBITURATES BY REPEATED ADMINISTRATION TO RATS. 

241406 03-03 
EFFECTS OF A SINGLE ADMINISTRATION OF CLOZAPINE ON MOUSE 
BRAIN CATECHOLAMINES. 

241416 03-03 
THE EFFECT OF ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION 
ON SEIZURE SUSCEPTIBILITY AND BRAIN CATECHOLAMINES IN MICE 
(PH.D. DISSERTATION). 

241576 03-03 
TICS FOLLOWING METHYLPHENIDATE ADMINISTRATION: A REPORT OF 
20 CASES. 

241990 03-15 
BIOAVAILABILITY OF TWO CARBAMAZEPINE PREPARATIONS DURING 
CHRONIC ADMINISTRATION TO EPILEPTIC PATIENTS. 

242212 03-11 
EFFECT OF 10 DAYS RESERPINE OR APOMORPHINE ADMINISTRATION ON 
SLEEP CYCLES IN RATS. 

242732 03-04 
THE LEVEL OF THE GROWTH HORMONE PROLACTIN AND INSULIN IN THE 
COURSE OF THE ACUTE ADMINISTRATION OF CHLORPROMAZINE 
(PLEGOMAZIN) IN MENTAL PATIENTS. 

242863 04-15 
CHANGE OF THE HEARTRATE AND SLEEP-WAKEFULNESS CYCLE AFTER 
ISOPROTERENOL ADMINISTRATION IN WHITE RATS. 

244449 04-04 
THE EFFECT OF PROLONGED ADMINISTRATION OF NITRAZEPAM ON 
SLEEP CYCLES IN RATS. 

244456 04-04 
INFLUENCE OF THE ADMINISTRATION OF PSYCHOPHARAAACOLOGICAL 
COMPOUNDS ON THE TAKE UP TIME OF AN ALIMENTARY MATERIAL 
IN THE HAMSTER AND A STUDY OF RELATED BEHAVIOR. 

244899 04-04 
DELAYED SEVERE EXTRAPYRAMIDAL DISTURBANCE FOLLOWING 
FREQUENT DEPOT PHENOTHIAZINE ADMINISTRATION, 

245789 04-15 
PLASMA LEVELS OF IMIPRAMINE AND DESIPRAMINE IN MAN AFTER 
DIFFERENT ROUTES OF ADMINISTRATION 

246387 04-13 
PLASMA LEVELS OF DIAZEPAM AFTER PARENTERAL AND RECTAL 
ADMINISTRATION IN CHILDREN. 

246891 04-11 
GIC DETERMINATION OF PLASMA DRUG LEVELS AFTER ORAL 
ADMINISTRATION OF CLORAZEPATE POTASSIUM SALTS. 

246968 04-03 



SUPERSENSITIVITY TO D-AMPHETAMINE AND APOMORPHINE-INDUCED 
STEREOTYPED BEHAVIOR INDUCED BY CHRONIC D-AMPHETAMINE 
ADMINISTRATION. 

247683 04-04 
NOREPINEPHRINE CONTENT OF VARIOUS RAT ORGANS AFTER CHRONIC 
ADMINISTRATION OF DESMETHYLIMIPRAMINE. 

247777 04-03 
ENDOCRINE EFFECTS OF CHRONIC INTRAVENTRICULAR ADMINISTRATION 
OF DELTA9-TETRAHYDR0CANNABIN0L TO PREPUBERAL AND ADULT 
MALE RATS. 

248275 04-05 
POSTNATAL ELEVATION OF BRAIN TYROSINE-HYDROXYLASE ACTIVITY, 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 
CATECHOLAMINE LEVELS, RESULTING FROM DL-ALPHA-METHYL-P- 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 04-03 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING. 

249005 04-04 
ELEVATION OF AMPHETAMINE LEVELS IN RAT BRAIN AFTER 

ADMINISTRATION OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 4- 
1-NAPHTHYLVINYLPYRIDINE (NVP). 

249027 04-03 
EFFECTS OF HYDROXYLAMINE ON THE CONSEQUENCES OF LONG-LASTING 
ADMINISTRATION OF MORPHINE IN MICE. I. EFFECT ON THE 
MORPHINE TOLERANCE. 

249030 04-03 
EFFECTS OF HYDROXYLAMINE ON THE CONSEQUENCES OF LONG-LASTING 

ADMINISTRATION OF MORPHINE IN MICE. II, TIME COURSE OF THE 
HYDROXYLAMINE EFFECT ON MORPHINE TOLERANCE. 

249031 04-03 
EFFECT OF HYDROXYLAMINE ON THE CONSEQUENCES OF LONG-LASTING 

ADMINISTRATION OF MORPHINE IN MICE: III. EFFECT ON PREFERRED 
DRINKING OF MORPHINE SOLUTION, 

249032 04-04 
THYROID FUNCTION LEVELS AND THYROTROPIN RESPONSES TO TRH 

ADMINISTRATION IN MANIC PATIENTS RECEIVING LITHIUM 
CARBONATE. 

249124 04-14 
DISTRIBUTION STUDIES OF (14C)DELTA9-TETRAHYDR0CANNABIN0L IN 
MICE: EFFECT OF VEHICLE, ROUTE OF ADMINISTRATION. AND 
DURATION OF TREATMENT, 

249223 04-03 
CONJUGATION OF L-DOPA AND ITS METABOLITES AFTER ORAL AND 
INTRAVENOUS ADMINISTRATION TO PARKINSONIAN PATIENTS 

249232 04-15 
REVERSAL OF RESIDUAL TOLERANCE TO MORPHINE AND BLOCKADE OF 
EFFECTS OF MORPHINE WITH CHRONIC NALTREXONE 
ADMINISTRATION. 

249268 04 03 
EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN 
GLUTAMATE (GLU) AND GAMMA-AMINOBUTYRATE (GABA) LEVELS IN 
THE MOUSE. 

249292 04-03 
CHOLINESTERASE (CHE) INHIBITION AND SYNAPTOSOMAL 

ACETYLCHOLINE (ACH) SYNTHESIS AND RELEASE FOLLOWING IN VIVO 
PARAOXON (PX) ADMINISTRATION. 

249295 04-03 
OPIATE RECEPTOR BINDING - ENHANCEMENT BY OPIATE 
ADMINISTRATION IN VIVO. 

250378 04-03 
ABSORPTION OF LITHIUM FOLLOWING ADMINISTRATION OF SLOW- 
RELEASE AND CONVENTIONAL PREPARATIONS. 

250725 04-13 
ANATOMICAL AND BEHAVIORAL EFFECTS OF COLCHICINE 
ADMINISTRATION TO RATS LATE IN UTERO. 

252148 04-05 
DEPRESSION OF GROWTH HORMONE AND CORTISOL RESPONSE TO 
INSULIN-INDUCED HYPOGLYCEMIA AFTER PROLONGED ORAL DELTA9- 
TETRAHYDROCANNABINOL ADMINISTRATION IN MAN. 

252327 04-13 
EFFECTS OF PRENATAL RESERPINE ADMINISTRATION ON DEVELOPMENT 
OF THE RAT ADRENAL MEDULLA AND CENTRAL-NERVOUS-SYSTEM. 

253110 04-03 
EFFECTS OF INTERMITTENT AND REPEATED ADMINISTRATION OF D- 

AMPHETAMINE ON RESTRICTED WATER INTAKE IN RATS. 

253111 04-04 
GAMMA-AMINOBUTYRIC-ACID: SELECTIVE INHIBITION OF ELECTRICALLY- 
INDUCED HEAD TURNING FOLLOWING INTRACAUDATE 
ADMINISTRATION. 

253392 04-04 
THE ROLE OF NORADRENALINE, DOPAMINE AND 5 HYDROXYTRYPTAMINE 
IN THE HYPERACTIVITY RESPONSE RESULTING FROM THE 
ADMINISTRATION OF TRANYLCYPROMINE TO RATS PRETREATED WITH 
LITHIUM OR RUBIDIUM. 

253593 04-04 
NORMAL GLUTAMIC-DECARBOXYLASE ACTIVITY IN RAT STRIATUM AND 
RETAIN FOLLOWING ADMINISTRATION OF L-DOPA. 

253695 04 03 



S 

i 

> 

t 

I 

■c 

2 
ffj 
t 



S-13 



Subject index 



Psychopharmacology Abstracts 



ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE 
DRUGS TO PREPUBERTAL MALE RATS. IF LSD 

253700 04-03 
ADMINISTRATIVE 

ADMINISTRATIVE AND JUDICIAL PROBLEMS IN PSYCHOPHARMACOLOGY. 

237121 02-17 
ADMIHED 

THE IMMEDIATE EFFECTS OF CHLORPROMAZINE IN NEWLY ADMITTED 
SCHIZOPHRENIC PATIENTS 

234700 02-08 
A DOUBLE-BLIND COMPARISON OF LOXAPINE SUCCINATE AND 

TRIFLUOPERAZINE IN NEWLY ADMITTED SCHIZOPHRENIC PATIENTS 

237828 02-08 
CLOZAPINE IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC 
PATIENTS: A PILOT STUDY 

251828 04-08 
ADOLESCENCE 

PRESENT ASPECTS OF PSYCHOPHARAAACOTHERAPY IN CHILDHOOD AND 
ADOLESCENCE. 

236150 02-17 
ADOLESCENT 

AN INVESTIGATION OF THE SELECTION PROCESS AND DRUG TREATMENT 
OF EXPLOSIVELY AGGRESSIVE ADOLESCENT FEMALES. {PH.D 
DISSERTATION). 

228726 01-11 
A CONTROLLED EVALUATION OF LOXITANE IN SEVENTY-FIVE 
ADOLESCENT SCHIZOPHRENIC PATIENTS. 

247483 04-08 
ADOLESCENTS 

STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAMAZEPINE 
IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 2- 
18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 
WITH BEHAVIOR AND CHARACTER. 

244958 04- 11 
ADRENAL 

REGULATION OF 5-HYDROXYTRYPTAMINE METABOLISM IN MOUSE 
BRAIN BY ADRENAL GLUCOCORTICOIDS 

226401 01-03 
INTERACTIONS OF DELTA9-TETRAHYDR0CANNABIN0L, ADRENAL 
STEROIDS, AND ETHANOL. 

226763 01-03 
PITUITARY ADRENAL FUNCTION IN DEPRESSED PATIENTS: RESISTANCE 
TO DEXAMETHASONE SUPPRESSION. 

236801 02-13 
THE ROLE OF NEURAL INPUT IN THE EFFECTS OF MORPHINE ON THE RAT 
ADRENAL MEDULLA. 

243779 04-03 
EFFECTS OF RESERPINE ON MATURING ADRENAL MEDULLA. 

243796 04-03 
REGULATION OF ADRENAL TYROSINE-HYDROXYLASE ACTIVITY: 

NEURONAL VERSUS LOCAL CONTROL STUDIED WITH APOMORPHINE. 

244314 04-03 
THE ROLE OF ADRENAL CATECHOLAMINES IN THE RELEASE OF 
CORTICOSTERONE AND FATTY-ACIDS BY NICOTINE IN THE RAT. 

247731 04-03 
LACK OF CORRELATION BETWEEN CHANGES IN CYCLIC NUCLEOTIDES 
AND SUBSEQUENT INDUCTION OF TYROSINE-HYDROXYLASE IN RAT 
ADRENAL MEDULLA. 

251434 04-03 
EFFECTS OF PRENATAL RESERPINE ADMINISTRATION ON DEVELOPMENT 
OF THE RAT ADRENAL MEDULLA AND CENTRAL-NERVOUS-SYSTEM. 

253110 04-03 
ADRENALECTOMIZED 

EFFECT OF CORTISONE, ALDOSTERONE AND NIALAMIDE ON 

AMPHETAMINE STEREOTYPES AND BRAIN METHAMPHETAMINE LEVELS 
OF ADRENALECTOMIZED RATS. 

251990 04-04 
ADRENALINE 

THE EFFECT OF ADRENALINE, TYRAMINE AND GUANETHIDINE ON TWO- 
WAY AVOIDANCE CONDITIONING AND ON PSEUDOCONDITIONING. 

227138 01-04 
THE EFFECTS OF ADRENALINE, RESERPINE, AND ATROPINE ON 
ACETYLCHOLINE CONTENT OF THE BRAIN AND PERIPHERAL GANGLIA 
IN STRESS. 

227635 01-03 
LITHIUM INHIBITION OF ADRENALINE STIMULATED ADENYLATE-CYCLASE 
IN HUMANS. 

239728 03-09 
THE EFFECT OF ADRENALINE ON HUMAN PLATELET MAO ACTIVITY. 

246312 04 13 
ADRENERGIC 

INTERACTIONS OF ADRENERGIC STIMULANTS AND BLOCKERS ON SELF 
STIMULATION BEHAVIOR IN RATS. 

226943 01-04 
THE CAPACITY OF ADRENERGIC NERVES TO ACCUMULATE EXOGENOUS 
NOREPINEPHRINE UNDER THE INFLUENCE OF SOME 
PHARMACOLOGICAL AGENTS. 

228551 01-03 



THE INFLUENCE OF CARBIDINE ON THE ADRENERGIC 

NEUROTRANSMITTER CONTENT AND STORAGE IN SYNAPTIC VESICLES. 

236233 02-03 
BEHAVIORAL EFFECTS OF INTRACEREBRALLY ADMINISTERED 

CATECHOLAMINES IN MICE AND THEIR MODIFICATIONS BY SOME 
ADRENERGIC BLOCKING AGENTS. 

237707 02-04 
THE EFFECT OF CHRONIC CENTRAL ADRENERGIC DENERVATION ON 
LEARNING AND MEMORY OF AN AVERSIVE DISCRIMINATION TASK IN 
MICE: STUDIES WITH 6-HYDROXYDOPAMINE. (PH.D. DISSERTATION). 

238157 02-03 
STUDIES ON MODE OF ANTAGONISM BETWEEN ADRENERGIC BETA- 
MIMETICS AND BETA-BLOCKING AGENTS (I). BETA-BLOCKING ACTION 
OF MESCALINE AND ITS DERIVATIVES. 

238563 02-03 
EFFECTS OF SOME DOPAMINE ANALOGS AND HALOPERIDOL ON 
RESPONSE TO STIMULATION OF ADRENERGIC NERVES USING CAT 
ATRIA IN VITRO. 

241313 03-03 
THE POTENTIATING EFFECT OF LICL ON ADRENERGIC DRUG-INDUCED 
AGGRESSIVE BEHAVIOR IN MICE. 

241364 03-04 
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS. 4TH 
REPORT. COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
MODIFICATIONS OF EFFECTS OF CHLORPROMAZINE ON ADRENERGIC 
DRUGS AND BARBITURATES BY REPEATED ADMINISTRATION TO RATS. 

241406 03-03 
ON THE MECHANISM OF ACTION OF CLOZAPINE ON THE ADRENERGIC 
NEURONE. 

241919 03-03 
PRESYNAPTIC AND POSTSYNAPTIC ORIGIN OF LITHIUM-INDUCED ACUTE 
BLOCKADE ON ADRENERGIC TRANSMISSION IN RABBIT HEART. 

242204 03-03 
ON THE MECHANISM OF ACTION OF CLOZAPINE ON THE ADRENERGIC 
NEURONE. 

243760 04-03 
INGESTION IN THE SATIATED RAT; ROLE OF ALPHA AND BETA 

RECEPTORS IN MEDIATING EFFECTS OF HYPOTHALAMIC ADRENERGIC 
STIMULATION. 

245930 04-02 
THE EFFECTS OF CHRONIC GANGLION BLOCKADE AND CHRONIC 
CHOLINESTERASE INHIBITION ON THE SENSITIVITY OF RABBIT 
STOMACH MUSCULARIS TO CHOLINERGIC AND ADRENERGIC 
AGONISTS. 

246842 04 03 
A COMPARISON OF 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE. 
SALSOLINOL AND TETRAHYDROPAPAVEROLINE AN INHIBITORS OF 
MONOAMINE-OXIDASE WITHIN THE ADRENERGIC NERVE PLEXUS OF 
THE ISOLATED MOUSE ATRIUM. 

248603 04-03 
EVIDENCE FOR ALPHA, BETA AND PHENYLETHYLAMINIC ADRENERGIC 
RECEPTORS IN ISOLATED FROG SCIATIC NERVE. 

249257 04-03 
CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 
ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
ADRENERGIC RECEPTORS AND VASCULAR RESISTANCE IN CEREBRAL 
CIRCULATION OF THE CAT. 

251820 04-03 
ADRENO 

PARTICIPATION OF ADRENO, DOPAMINE, AND SEROTONERGIC 
MECHANISMS OF THE SEPTUM IN CONDITIONED REFLEX REACTIONS 
TO VARIOUS BIOLOGICAL MODALITIES IN RATS 

236828 02-04 
ADRENOMIMETIC 

PHARMACOLOGICAL ANALYSIS OF SOME ADRENOMIMETIC EFFECTS OF 
SEROTONIN. 

241982 03-05 
ADULT 

BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5,7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 
ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02-04 
EFFECTS OF CATECHOLAMINE RECEPTOR BLOCKING AGENTS ON 
TOXICITY AND THERMAL RESPONSES INDUCED BY AMPHETAMINE 
ISOMERS IN ADULT AND DEVELOPING MICE. 

239043 03-05 
EFFECTS OF SULTHIAME UPON INTELLECTUAL, NEUROPSYCHOLOGICAL, 
AND SOCIAL FUNCTIONING ABILITIES AMONG ADULT EPILEPTICS: 
COMPARISON WITH DIPHENYLHYDANTOIN. 

240475 03-14 
CONCENTRATION OF AMPHETAMINE ISOMERS IN BRAIN AND HEART OF 
ADULT AND DEVELOPING MICE. 

241414 03-03 



S-14 



VOLUME 14, SUBJECT INDEX 



Subject Index 



EFFECTS OF AXOTOMY ON THE TRANS-SYNAPTIC REGULATION OF 
ENZYME ACTIVITY IN ADULT RAT SUPERIOR CERVICAL GANGLIA, 

244200 04-03 
PLASMA PROTEIN BINDING OF DRUGS AS A FUNCTION OF AGE IN ADULT 
HUMAN SUBJECTS 

246970 04-13 
ENDOCRINE EFFECTS OF CHRONIC INTRAVENTRICULAR ADMINISTRATION 
OF DELTA9-TETRAHY0R0CANNABIN0L TO PREPUBERAL AND ADULT 
MALE RATS. 

248275 04-05 
DEVELOPMENT AND ADULT BEHAVIORAL ABNORMALITIES IN MICE 
TREATED NEONATALLY WITH CYCLOPHOSPHAMIDE. 

249296 04-02 
EFFECT OF AMPHETAMINE AND APOMORPHINE ON BRAIN MONOAMINES 
AND BEHAVIOUR IN THE IMMATURE AND YOUNG ADULT RAT 

249785 04-04 
EFFECTS OF NEONATAL THYROXINE STIMULATION ON ADULT OPEN-FIELD 
BEHAVIOR AND THYROID ACTIVITY IN RATS. 

250013 04-04 
TESTOSTERONE MANIPULATIONS: EFFECTS ON RANACIDE AGGRESSION 
AND BRAIN MONOAMINES IN THE ADULT FEMALE RAT. 

250068 04-02 
DIFFERENTIAL BEHAVIORAL RESPONSES OF MALE AND FEMALE ADULT 
RATS TREATED W/ITH FIVE PSYCHOTROPIC DRUGS IN THE NEONATAL 
STAGE. 

251981 04-04 
DUITS 

COMPARISON OF SERUM LEVELS AND URINARY EXCRETION OF THREE 
MAJOR ANTICONVULSANTS BETWEEN CHILDREN AND ADULTS. 

233832 02-13 
CHANGES IN PSYCHOACTIVE DRUG USE AMONG ADULTS IN 
METROPOLITAN TORONTO - 1971-1974. 

236046 02- 1 7 
CYPROHEPTADINE: WEIGHT GAIN AND APPETITE STIMULATION IN 
ESSENTIAL ANOREXIC ADULTS. 

237900 02-10 
DVANTAGES 

ADVANTAGES OF THE INITIAL THERAPY OF ACUTE SCHIZOPHRENIA WITH 
LARGE DOSES OF DROPERIDOL: A COMPARATIVE STUDY. 

237124 02-08 
VALUE AND ADVANTAGES OF ORAP IN OUTPATIENT TREATMENT OF 
SCHIZOPHRENIC PSYCHOSES. 

244188 04-08 
DVERSE 

ADVERSE REACTIONS ASSOCIATED WITH MOOD-ALTERING DRUGS. 

231995 01 15 
INDIVIDUAL DIFFERENCES AND SETTING AS DETERMINANTS OF ACUTE 
ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS. 

233377 02-12 
METHAQUALONE WITH PSYCHOTROPIC DRUGS: ADVERSE INTERACTION. 

253531 04 15 
DViCE 

DEPARTMENT SEEKS ADVICE ON SAFETY OF PSYCHOTROPICS. 

251232 04- 17 
EROSOl 

AN INHALATION AEROSOL OF DELTA9-TETRAHYDR0CANNABIN0L. 

237787 02-16 
ETHIOPS 

BEHAVIOURAL EFFECTS OF THYMOLEPTICS IN VERVET MONKEYS 
(CERCOPITHECUS-AETHIOPS). AETHIOPS). 

230869 01-04 
FFECT 

THE EFFECTS OF LSD ON THE EXPRESSION OF AFFECT IN 
PSYCHOTHERAPY (PH.D. DISSERTATION). 

231480 01-12 
6-HYDROXYDOPAMINE (6-OHDA) ADMINISTRATION TO NEONATAL RATS 
FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) IN THE CNS. 

238826 03-03 
EVIDENCE THAT DIPHENYLHYDANTOIN DOES NOT AFFECT ADENOSINE 
TRIPHOSPHATASES FROM BRAIN. 

239962 03-03 
ANTIDEPRESSANT DRUGS AFFECT DOPAMINE UPTAKE. 

247021 04 03 
FFECTIVE 

THE LONG-TERM LITHIUM TREATMENT OF AFFECTIVE DISORDERS LONG 
TERM EFFECTS AND SIDE-EFFECTS. 

226612 01-09 
PRECLINICAL STUDIES OF RUBIDIUM IN AFFECTIVE ILLNESS. 

229495 01-02 
EFFECT OF LITHIUM ON HYPOTHALAMIC PITUITARY THYROID FUNCTION 
IN PATIENTS WITH AFFECTIVE DISORDERS 

230763 01-13 
CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM 
PRECURSORS, ENZYME INHIBITORS, AND STUDIES OF CENTRAL 
DOPAMINE TURNOVER. 

233964 02 14 



ELECTROENCEPHALOGRAPHIC STUDIES IN PATIENTS WITH AFFECTIVE 
DISORDERS DURING PROPHYLACTIC TREATMENT WITH LITHIUM 
CARBONATE. 

234044 02-09 
LITHIUM CARBONATE IN AFFECTIVE DISORDERS: IV. A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS IN UNIPOLAR RECURRENT DEPRESSION. 

234203 02-09 
OVERVIEW: MAINTENANCE THERAPY IN PSYCHIATRY: II. AFFECTIVE 
DISORDERS. 

236303 02-17 
THE COURSE OF TREATMENT IN SCHIZOPHRENIA AS RELATED TO THE 
APPEARANCE OF AFFECTIVE DISORDERS. 

236421 02-08 
PLASMA AND ERYTHROCYTE MAGNESIUM LEVELS IN PATIENTS WITH 
PRIAAARY AFFECTIVE DISORDER DURING CHRONIC LITHIUM 
TREATMENT. 

238977 03-15 
PROPHYLAXIS OF AFFECTIVE DISORDERS: CURRENT STATUS OF 
KNOWLEDGE. 

239937 03-09 
BIOGENIC AMINES AND AFFECTIVE DISORDERS. 

241937 03-09 
CYCLIC-AMP IN CEREBROSPINAL FLUID IN PATIENTS WITH AFFECTIVE 
ILLNESS: EFFECTS OF PROBENECID, ACTIVITY, AND PSYCHOTROPIC 
MEDICATIONS. (UNPUBLISHED PAPER 

243023 04-09 
PROPHYLACTIC EFFECTIVENESS OF LITHIUM IN PATIENTS WITH 
AFFECTIVE DISTURBANCES. 

243985 04-09 
THE EFFECT OF LITHIUM ON RED BLOOD CELL CHOLINESTERASE ACTIVITY 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

244495 04-09 
LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS. 

245416 04-09 
LITHIUM CARBONATE AND AFFECTIVE DISORDERS. V: A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS OF DEPRESSION IN BIPOLAR ILLNESS. 

247582 04-09 
AFFERENT 

EXCITATORY EFFECTS OF 5-HYDROXYTRYPTAMINE, HISTAMINE AND 
POTASSIUM IONS ON MUSCULAR GROUP IV AFFERENT UNITS; A 
COMPARISON WITH BRADYKININ. 

241798 03-03 
AFFINITY 

HIGH AFFINITY CHOLINE UPTAKE: AN EARLY INDEX OF CHOLINERGIC 
INNERVATION IN RAT BRAIN. 

226739 01-03 
BLOCKAGE OF LSD BINDING AT ITS HIGH AFFINITY SITE ON 
SYNAPTOSOMAL MEMBRANES BY 1 METHYL 1,2,5,6 
TETRAHYDROPYRIDINE N,N DIETHYLCARBOXAMIDE. 

227692 01-03 
TAURINE: A SODIUM DEPENDENT HIGH AFFINITY UPTAKE SYSTEM INTO 
SYNAPTOSOMES OF RAT BRAIN. 

238715 03-03 
THE EFFECT OF DELTA9-THC ON HIGH AND LOW AFFINITY UPTAKE OF 
CHOLINE AND ITS RELATIONSHIP TO TURNOVER OF ACETYLCHOLINE IN 
MOUSE BRAIN. 

238765 03-03 
SODIUM DEPENDENT HIGH AFFINITY CHOLINE UPTAKE AS A 
REGULATORY STEP IN ACETYLCHOLINE SYNTHESIS. 

249303 04-03 
AFTER-DISCHARGE 

INTRACELLUIAR RECORDING OF AFTER-DISCHARGE INDUCED BY 
VERATRUM ALKALOIDS IN THE GUINEA PIG NODOSE GANGLION. 

232333 01-03 
EFFECTS OF ANTIDEPRESSANT DRUGS ON AMYGDALOID AFTER- 
DISCHARGE IN RATS, 

24/039 04-03 
AFTER-DISCHARGES 

LATERAL GENICULATE MULTIPLE-UNIT ACTIVITY RELATED TO METRAZOL 
POTENTIATED AFTER-DISCHARGES. . 

231719 01-03 
PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER 
DISCHARGES IN RATS: INCREMENTAL DOSE, HIPPOCAMPAL EEG AND 
BEHAVIORAL ACTIVITY CORRELATES. 

239858 03-03 
AGAROSE 

ISOLATION OF LYSERGIDE (LSD) WITH AGAROSE BOUND ANTIBODIES TO 
LYSERGIC-ACID. ACID. 

233278 02-01 



e 

9 
I 

% 

\ 

•fl 

t 



AGE 



227750 01-11 



MEDICINES AND MENTAL-ILLNESS IN OLD AGE. 

DRUGS FOR MENTAL DISORDERS OF OLD AGE, 

229315 01-11 
EFFECTS OF TESTING AGE AND FOSTERING EXPERIENCE ON SEIZURE 
SUSCEPTIBILITY OF RATS TREATED PRENATALLY WITH 
CHLORPROMAZINE. 

234739 02-04 



S-15 



Subject Index 

EFFECT OF AGE OF HABIT ON SUSCEPTIBILITY TO CYCLOHEXIMIDE- 
INDUCED AMNESIA IN MICE. 

245614 04-02 
PLASMA PROTEIN BINDING OF DRUGS AS A FUNCTION OF AGE IN ADULT 
HUMAN SUBJECTS. 

246970 04-13 
DEPENDENCE ON AGE OF METHAMPHETAMINE PRODUCED CHANGES IN 
THERMOREGULATION AND METABOLISM. 

248951 04-03 
INFLUENCE OF AGE AND DRUGS ON BEHAVIORAL THERMOREGULATION 
IN RATS. 

251409 04-04 
AN OVERVIEW OF PSYCHOPHARMACOLOGY OF OLD AGE. 

253062 04-17 
AGE-RELATED 

AGE-RELATED CHANGES OF LOCOMOTOR ACTIVITY AFTER 
AMPHETAMINE ADMINISTRATION. 

238845 03-04 
AGED 

A SURVEY OF PSYCHOACTIVE DRUG USE IN THE AGED IN VETERANS 
ADMINISTRATION HOSPITALS. 

229458 01 11 
CYCLANDELATE CHECKS MENTAL DECAY: AGED PATIENTS IQ AND 
MEMORY PRESERVED WITH USE OF VASODILATOR. 

247022 04-11 
TREATMENT OF DEPRESSION IN THE AGED WITH GER0VITAL-H3- 
CLINICAL EFFICACY AND NEUROPHYSIOLOGICAL EFFECTS. 

253061 04-11 
AGES 

CHANGES IN EXCITABILITY OF THE HIPPOCAMPUS AFTER STIMULATION 
OF SEROTONERGIC SYSTEMS IN RABBITS OF DIFFERENT AGES. 

231119 01-04 

KINETICS AND METABOLISM OF AMPHETAMINE IN THE BRAIN OF RATS 
OF DIFFERENT AGES, 

234316 02-03 
THE NATURAL HISTORY OF HYPERACTIVITY IN CHILDHOOD AND 

TREATMENT WITH STIMULANT MEDICATION AT DIFFERENT AGES- A 
SUMMARY OF RESEARCH FINDINGS. 

247384 04-14 
AGGRESSION 

PARADOXICAL ABSENCE OF AGGRESSION DURING NALOXONE 
PRECIPITATED MORPHINE WITHDRAWAL. 

227132 01-04 
METHADONE INDUCED BEHAVIORAL CHANGES: CIRCULAR MOVEMENTS 
AGGRESSION, AND ELECTROPHYSIOLOGICAL ASPECTS. 

229286 01-04 
DRUGS, AGGRESSION, AND NEUROCHEMISTRY 

229488 01-04 
TOTAL SUPPRESSION OF IRRITABLE AGGRESSION IN RATS BY SENSORY 
DEPRIVATION. 

233418 02-03 
EFFECTS OF HASHISH ON ISOLATION INDUCED AGGRESSION IN WILD 
MICE 

237714 02-04 
INTRASPECIES AGGRESSION INDUCED BY ELECTRICAL SHOCK AND 
REACTIVITY AFTER RAPHE LESIONS IN THE RAT EFFECTS OF 
PHYSOSTIGMINE. 

239829 03-04 
APOMORPHINE-INDUCED AGGRESSION: AN EVALUATION OF POSSIBLE 
SENSITIZING FACTORS IN THE RAT. 

248008 04-04 
INTER-GROUP AGGRESSION IN MICE: A NEW METHOD FOR TESTING THE 
EFFECTS OF CENTRALLY ACTIVE DRUGS. 

249668 04-04 
WEIGHT LOSS AND SHOCK-ELICITED AGGRESSION AS INDICES OF 
MORPHINE ABSTINENCE IN RATS. 

249671 04-04 
TESTOSTERONE MANIPULATIONS: EFFECTS ON RANACIDE AGGRESSION 
AND BRAIN MONOAMINES IN THE ADULT FEMALE RAT. 

250068 04-02 
EXTINCTION-INDUCED MIRROR RESPONDING AS A BASELINE FOR 
STUDYING DRUG EFFECTS ON AGGRESSION. 

250073 04-06 
EFFECT OF AROUSAL BY SOCIAL ISOLATION, GROUPING, AND D- 
AMPHETAMINE ON INTER-MALE AGGRESSION IN MICE (MUS- 
MUSCULUS), 

253485 04-04 
AGGRESSIVE 

AN INVESTIGATION OF THE SELECTION PROCESS AND DRUG TREATMENT 
OF EXPLOSIVELY AGGRESSIVE ADOLESCENT FEMALES. (PH D 
DISSERTATION). 

228726 01-11 
DIFFERENTIATION BY MORPHINE OF TWO TYPES OF AGGRESSIVE 
BEHAVIOR IN THE CONVICT CICHLID (CICHLASOMA- 
NIGROFASCIATUM), 

230865 01 04 
INVOLVEMENT OF BIOGENIC AMINES IN DRUG-INDUCED AGGRESSIVE 
PECKING IN CHICKS 

230878 01-04 



Psychopharmacology Abstracts 



EFFECT OF CAFFEINE AND AMPHETAMINE ON CAUDATE INHIBITION OF 
AGGRESSIVE REACTIONS OF CATS. 

236371 02-04 
EFFECTS OF SOME PSYCHOTROPIC DRUGS ON AGGRESSIVE BEHAVIOR IN 
RATS. 

238754 03-04 
DEPRESSED 5-HYDROXYINDOLE LEVELS ASSOCIATED WITH HYPERACTIVE 
AND AGGRESSIVE BEHAVIOR: RELATIONSHIP TO DRUG RESPONSE. 

239936 03-13 
AMANTADINE: AGGRESSIVE EFFECT; EFFECT ON APOMORPHINE-INDUCED 
AGGRESSIVITY IN THE RAT. 

241227 03-04 
THE POTENTIATING EFFECT OF LICL ON ADRENERGIC DRUG-INDUCED 
AGGRESSIVE BEHAVIOR IN MICE. 

241364 03-04 
ACTIONS OF 6-HYDROXYDOPAMINE INJECTED INTRAVENTRICULARLY 
INTO DEVELOPING RATS (2). INFLUENCE ON MOTOR ACTIVITIES AND 
AGGRESSIVE BEHAVIOR. 

241372 03-04 
RESISTANCE OF ANDROGEN MEDIATED AGGRESSIVE BEHAVIOR IN MICE 
TO FLUTAMIDE, AN ANTIANDROGEN. 

244685 04-04 
AGGRESSIVE BEHAVIOR OF JUVENILE MICE: INFLUENCE OF ANDROGEN 
AND OLFACTORY STIMULI. 

245406 04-04 
POTENTIATING EFFECT OF LITHIUM CHLORIDE ON AGGRESSIVE 

BEHAVIOUR INDUCED IN MICE BY NIALAMIDE PLUS L-DOPA AND BY 
CLONIDINE. 

246664 04-04 
AGGRESSIVITY 

CATECHOLAMINE CONCENTRATION IN DISCRETE AREAS OF BRAIN OF 
SEVERAL STRAINS OF MICE: CORRELATION WITH AGGRESSIVITY. 

238673 03-03 
AMANTADINE: AGGRESSIVE EFFECT, EFFECT ON APOMORPHINE-INDUCED 
AGGRESSIVITY IN THE RAT. 

241227 03-04 
AGING 

EFFECTS OF AGING ON LH AND PROLACTIN AFTER LHRH LDOPA, 
METHYL-DOPA, AND STRESS IN MALE RAT. 

240642 03-03 
CHLORPROAAAZINE, CATECHOLAMINES AND AGING IN MICE. 

247587 04-02 
EFFECT OF ESTROGEN TREATMENT ON ESTRADIOL BINDING CAPACITY IN 

UTERI OF AGING RATS, 

247588 04-03 
AGITATION 

ALLEVIATING AGITATION, APPREHENSION, AND RELATED SYMPTOMS IN 
GERIATRIC PATIENTS: A DOUBLE-BLIND COMPARISON OF A 
PHENOTHIAZINE AND A BENZODIAZEPINE. 

234114 02-11 
AGONIST 

STRUCTURE-ACTIVITY RELATIONSHIPS FOR AGONIST AND ANTAGONIST 
DRUGS AT PRESYNAPTIC AND POSTSYNAPTIC RECEPTOR SITES IN RAT 
BRAIN. 

229435 01-03 
IDENTIFICATION OF TWO RELATED PENTAPEPTIDES FROM THE BRAIN 
WITH POTENT OPIATE AGONIST ACTIVITY. 

233300 0201 
3,4 DIHYDROXYPHENYLAMINO 2 IMIDAZOLINE (DPI), A NEW POTENT 
AGONIST AT DOPAMINE RECEPTORS MEDIATING NEURONAL 
INHIBITION. 

238321 02-03 
DOPAMINE AGONIST INDUCED ASYMMETRY AFTER LESIONS OF 
SUPERIOR COLLICULUS IN RATS. 

238699 03-03 
METHYLPHENIDATE AS A CHOLINERGIC AGONIST: FURTHER 
OBSERVATIONS. 

238708 03-03 
CF-25-397, DIDEHYDR0-METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINE, A 
NEW CENTRAL DOPAMINE RECEPTOR AGONIST. 

241927 03-04 
THE DOPAMINE RECEPTOR: DIFFERENTIAL BINDING OF D-LSD AND 
RELATED AGENTS TO AGONIST AND ANTAGONIST STATES. 

247862 04-03 
LSD AS AN AGONIST AT MESOLIMBIC DOPAMINE RECEPTORS. 

249680 04-04 
AGONISTS 

EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS ON SCHEDULE- 
INDUCED WATER AND MORPHINE INGESTION. 

233292 02-04 
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC 
AGONISTS. 

233973 02-03 
EFFECTS OF DOPAMINERGIC AGONISTS AND ELECTRICAL STIMULATION 
OF THE MIDBRAIN RAPHE ON THE RELEASE OF 5- 
HYDROXYTRYPTAMINE FROM THE CAT BRAIN IN VIVO. 

237154 02-03 



S-16 



UME 14, SUBJECT INDEX 



Subject Index 



OMPARISON OF WITHDRAWAL PRECIPTATING PROPERTIES OF VARIOUS 
MORPHINE ANTAGONISTS AND PARTIAL AGONISTS IN RELATION TO 
THEIR STEREOSPECIFIC BINDING TO BRAIN HOMOGENATES. 

239854 0303 
IDUCTION OF TYROSINE-HYDROXYLASE IN THE SUPERIOR CERVICAL 
GANGLIA OF RATS: OPPOSITE INFLUENCE OF MUSCARINIC AND 
NICOTINIC RECEPTOR AGONISTS. 

239977 03-03 
EINSTATEMENT OF EATING BY DOPAMINE AGONISTS IN APHAGIC 
DOPAMINE DENERVATED RATS. 

243348 04-04 
iTERS OF APOMORPHINE AND N,N DIMETHYLDOPAMINE AS AGONISTS 
OF DOPAMINE RECEPTORS IN THE RAT BRAIN IN VIVO. 

246150 04-04 
HE EFFECTS OF CHRONIC GANGLION BLOCKADE AND CHRONIC 
CHOLINESTERASE INHIBITION ON THE SENSITIVITY OF RABBIT 
STOMACH MUSCULARIS TO CHOLINERGIC AND ADRENERGIC 
AGONISTS. 

246842 04-03 
lORPHINE TOLERANCE AND PHYSICAL DEPENDENCE: INFLUENCE OF 
CHOLINERGIC AGONISTS AND ANTAGONISTS. 

250079 04-04 
HE EFFECT OF CARBON DISULFIDE ON THE STEREOTYPIC EFFECT OF 
DOPAMINE AGONISTS. 

250090 04-04 
^FECT OF DOPAMINE AGONISTS AND ANTAGONISTS ON ASYMMETRIC 
BEHAVIOUR OCCURRING DURING PRECIPITATED MORPHINE 
WITHDRAWAL AFTER UNILATERAL INACTIVATION OF THE STRIATUM 
IN RATS. 

251402 04-04 
HE TOXICITY OF DIRECT ACTING DOPAMINE AGONISTS: IMPLICATIONS 
FOR THE THERAPY OF PARKINSONISM. 

251959 04-05 
■FECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS OF 
PRE- AND POSTSYNAPTICALLY LOCATED ALPHA-ADRENOCEPTORS. 

252025 04-03 
APHOBICS 

(POSURE IN VIVO OF AGORAPHOBICS: CONTRIBUTIONS OF DIAZEPAM 
GROUP EXPOSURE, AND ANXIETY EVOCATION. 

250727 04-10 
277 

LOT OPEN-LABEL STUDY OF LENPERONE (AHR-2277), A 
BUTYROPHENONE, IN ANXIETY. 

241278 03-10 

ILECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS AS AIDS IN 
EVALUATING THE ROLE OF TYPE A AND B ENZYMES. 

237776 02-03 
SIA 

ODIFICATION OF THE L-DOPA REVERSAL OF RESERPINE AKINESIA BY 
INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE. 

248289 04-04 

roN 

;UROPSYCHOLOGICAL INVESTIGATIONS ON THE SHORT-TERM EFFECTS 
OF BIPERIDEN (AKINETON) IN PARKINSONS DISEASE. 

238516 02-11 
>5 
'JTIPSYCHOTIC EFFECTS OF AL-1965. 



251720 04-08 



IE EFFECT OF CHRONIC INJECTIONS OF CHLORPROMAZINE ON 
OOGENESIS AND PROGENY DEVELOPMENT IN ALBINO MICE. 

228554 01-05 
lANGE IN ETHANOL CONSUMPTION BY ALBINO RATS UNDER THE 
EFFECT OF NEUROLEPTICS AND TRANQUILIZERS. 

241987 03-03 
UN 

lANGES IN SERUM TRYPTOPHAN AND ALBUMIN BINDING OF 
TRYPTOPHAN IN CHLORPROMAZINE TREATED CHRONIC 
SCHIZOPHRENICS ON WITHDRAWAL AND RESTORATION OF DRUG 
THERAPY, 

235629 02-08 
.CTORS AFFECTING THE BINDING OF TRICYCLIC TRANQUILLIZERS AND 
ANTIDEPRESSANTS TO HUMAN SERUM ALBUMIN. 

239684 03-13 
NDING OF THIORIDAZINE AND SOME IT OF ITS METABOLITES TO 
HUMAN SERUM PROTEIN AND HUMAN ALBUMIN 

244131 04-13 
NDING OF CHLORPROMAZINE AND IMIPRAMINE TO RED CELLS, 
ALBUMIN, LIPOPROTEINS AND OTHER BLOOD COMPONENTS. 

247129 04-03 
TERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 
ALBUMIN ■ I. GEL FILTRATION STUDIES. 

251176 04-01 
TERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 
ALBUMIN II. CIRCULAR DICHROISM STUDIES. 

251177 04-01 



AlCOHOL 

INTERACTIONS OF ALCOHOL, BARBITURATES, AND NARCOTICS WITH 

BLOOD VESSELS. 

229474 01-03 
EFFECT OF TWO WEEKS TREATMENT WITH CHLORDIAZEPOXIDE OR 

FLUPENTHIXOL, ALONE OR IN COMBINATION WITH ALCOHOL, ON 

PSYCHOMOTOR SKILLS RELATED TO DRIVING. 

229907 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. I. THEORETICAL 

CONSIDERATIONS AND LITERATURE REVIEW. 

232517 01 17 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. II. FIVE 
EXPERIMENTS. 

232518 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. Ill, THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAAAATE IN THE BLOOD 
AND THEIR EFFECTS ON PERFORAAANCE; APPLICATION OF 
MATHEAAATICAL MODELS, 

232519 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. IV. THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAAAATE IN THE BLOOD. 

232520 01-13 
DRUG INTERACTIONS: THE EFFECT OF ALCOHOL AND MEPROBAAAATE 

APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. V. SUMMARY 
AND CONCLUSIONS 

232521 01 14 
THE INFLUENCE OF ALCOHOL AND OTHER DRUGS ON MENTAL TASK 

PERFORMANCES UNDER THEIR COMBINED ADMINISTRATION. 

233281 02-14 
EFFECTS OF ALCOHOL AND AAARIJUANA ON DYNAMIC VISUAL ACUITY: I. 
THRESHOLD MEASUREMENTS, 

235759 02-14 
PHARMACOKINETIC STUDIES IN ABSORPTION AND EXCRETION OF 
OXAZEPAM IN COMBINATION WITH ALCOHOL. 

237123 02-13 
ACUTE EFFECTS OF OXAZEPAM, DIAZEPAM AND METHYLPERONE, ALONE 
AND IN COMBINATION WITH ALCOHOL ON SEDATION, COORDINATION 
AND MOOD. 

239042 03 14 
REDUCTION OF ALCOHOL SELECTION BY PARGYLINE IN MICE 

241225 03 04 
EFFECT OF SUBACUTE TREATMENT WITH HYPNOTICS, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON PSYCHOMOTOR SKILLS RELATED 
TO DRIVING. 

241417 03-15 
INTERACTION OF ALCOHOL AND BENZODIAZEPINE HYPNOTICS. 

242947 04 15 
THE INTERACTION BETWEEN DRUGS, ALCOHOL AND DRIVING AN 
AUTOMOBILE. 

244453 04-15 
SALSOLINOL DIFFERENTIALLY AFFECTS MICE SELECTED FOR SENSITIVITY 
TO ALCOHOL. 

244680 04-04 
THE MORNING AFTER: RESIDUAL EEC EFFECTS OF TRIAZOLAM AND 
FLURAZEPAM, ALONE AND IN COMBINATION WITH ALCOHOL. 

244960 04-13 
EFFECTS OF ALCOHOL AND LITHIUM HABITUATION ON THE 

DEVELOPMENT OF ALCOHOL AVERSIONS THROUGH CONTINGENT 
LITHIUM INJECTION. 

246093 04-04 
DIVIDED ATTENTION PERFORMANCE OF CANNABIS USERS AND 
NONUSERS FOLLOWING CANNABIS AND ALCOHOL. 

246305 04 13 
EFFECT OF TWO WEEKS TREATMENT WITH THIORIDAZINE, 

CHLORPROMAZINE, SULPIRIDE AND BROMAZEPAM, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY IN MAN. 

246315 04-14 
COMPARISON BETWEEN INTRAVENOUS AND INTRAGASTRIC ALCOHOL 
SELF-ADMINISTRATION. 

250021 04-04 
EFFECTS OF ALCOHOL, CHLORDIAZEPOXIDE, COCAINE, AND 
PENTOBARBITAL ON RESPONDING MAINTAINED UNDER FIXED- 
INTERVAL SCHEDULES OF FOOD OR SHOCK PRESENTATION. 

250111 04-04 
CLINICAL APPLICATIONS OF A NEW RATIONALE IN THE TREATMENT OF 
ACUTE ALCOliOL WITHDRAWAL 

252694 04-11 
ALCOHOLIC 

TREATMENT OF ALCOHOLIC METHADONE MAINTENANCE PATIENTS WITH 
DISULFIRAM 

237624 02 11 
THE MEDICAL SAFETY OF THE COMBINED USAGE OF DISULFIRAM AND 
METHADONE. PHARMACOLOGICAL TREATMENT FOR ALCOHOLIC 
HEROIN ADDICTS. 

239943 03 15 



C9 



£ 



I 

2 



S-17 



Subject Index 



Psychopharmacology Abstract) 



PROPRANOLOL EFFECT ON TREMOR IN ALCOHOLIC WITHDRAWAL. 

250779 04-1) 
CLORAZEPATE DIPOTASSIUM (TRANXENE): A CONTROLLED EVALUATION 
IN ALCOHOIIC PATIENTS AFTER WITHDRAWAL 

251718 04-11 
RAT DATA WHICH SUGGEST ALCOHOLIC BEVERAGES SHOULD BE 
SWALLOWED DURING CHEMICAL AVERSION THERAPY. NOT JUST 
TASTED 

252859 04 17 
ALCOHOLICS 

PLASMA LEVELS OF CHLORPROTHIXENE IN ALCOHOLICS. 

226413 01-11 
AN EXPERIMENTAL THERAPY AND RE-EDUCATION PROGRAM FOR 
ALCOHOLICS INCLUDING CHEMOTHERAPY WITH PROPRANOLOL 
HYDROCHLORIDE. (PH D. DISSERTATION). 

228750 01-11 
DRUG TREATMENT IN A REHABILITATION CENTER FOR CHRONIC 
ALCOHOLICS. 

228908 01 11 
EFFECTS OF DISCONTINUITY OF MEDICATION ON THE RESULTS OF A 
DOUBLE BLIND DRUG STUDY IN OUTPATIENT ALCOHOLICS. 

229091 01-11 
TREATMENT OF DEPRESSION IN ALCOHOLICS. 

245521 04-09 
ALCOHOLISM 

A CONTROLLED TRIAL OF CHLORMETHIAZOLE AND CHLORDIAZEPOXIDE 
IN THE TREATMENT OF THE ACUTE WITHDRAWAL PHASE OF 
ALCOHOLISM. 

230104 01-11 
EVALUATION OF DISULFIRAM TREATMENT OF CHRONIC ALCOHOLISM. 

237026 02-11 
ALCOHOLISM: A GENERAL HOSPITAL MFK<; thf THALLENGE. 

244136 04-11 
ALCOHOLS 

SOLUBILITY OF STRAIGHT-CHAIN AND BRANCHED ALKYL BARBITURATES 
IN STRAIGHT-CHAIN ALCOHOLS. 

238487 02-01 
ALDEHYDES 

EFFECTS OF ALDEHYDES ON SODIUM PLUS POTASSIUM ION-STIMULATED 
ADENOSINE TRIPHOSPHATASE OF MOUSE BRAIN. 

237920 02-03 
ALDOSTERONE 

EFFECT OF CORTISONE, ALDOSTERONE AND NIALAMIDE ON 
AMPHETAMINE STEREOTYPES AND BRAIN METHAMPHETAMINE LEVELS 
OF ADRENALECTQMIZED RATS. 

251990 04-04 
ALIMEMAZIN 

STUDIES ON SLEEP EFFECTS OF ALIMEMAZIN (THERALENE) 

240710 03-11 
ALIMENTARY 

INFLUENCE OF THE ADMINISTRATION OF PSYCHOPHARMACOLOGICAL 
COMPOUNDS ON THE TAKE UP TIME OF AN ALIMENTARY MATERIAL 
IN THE HAMSTER AND A STUDY OF RELATED BEHAVIOR, 

244899 04-04 
ALKALI 

EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR; I. GLUTAMIC-ACID AND GABA IN BRAIN REGIONS 

237098 02-03 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: II INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

237105 02-04 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: II. INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

248956 04-04 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 

AND BEHAVIOR: I. GLUTAMIC-ACID AND GABA IN BRAIN REGIONS 

248957 04-03 
ALKALOIDS 

INTRACELLULAR RECORDING OF AFTER DISCHARGE INDUCED BY 
VERATRUM ALKALOIDS IN THE GUINEA-PIG NODOSE GANGLION. 

232333 01-03 
NEUROAMINE DERIVED ALKALOIDS: SUBSTRATE PREFERRED INHIBITORS 
OF RAT BRAIN MONOAMINE-OXIDASE IN VITRO. 

243778 04-03 
APORPHINES 15: ACTION OF APORPHINE ALKALOIDS ON DOPAMINERGIC 
MECHANISMS IN RAT BRAIN 

248286 04-03 
APORPHINES 16 ACTION OF APORPHINE ALKALOIDS ON LOCOMOTOR 

ACTIVITY IN RATS WITH 6-HYDROXYDOPAMINE LESIONS OF THE 
NUCLEUS ACCUMBENS. 

248287 04-02 

ALKYL 

SOLUBILITY OF STRAIGHT CHAIN AND BRANCHED ALKYL BARBITURATES 
IN STRAIGHT-CHAIN ALCOHOLS. 

238487 02-01 
DRUGS DERIVED FROM CANNABINOIDS. 4. EFFECT OF ALKYL 
SUBSTITUTION IN SULFUR AND CAR80CYCLIC ANALOGS 

248652 04-02 



ALKYLATING 

IRREVERSIBLE INACTIVATION OF THE OPIATE RECEPTOR BY THE 
ALKYLATING LOCAL ANESTHETIC Wt2099. 

238686 03-0 
ALLEVIATING 

ALLEVIATING AGITATION, APPREHENSION, AND RELATED SYMPTOMS IN 
GERIATRIC PATIENTS; A DOUBLE-BUND COMPARISON OF A 
PHENOTHIAZINE AND A BENZODIAZEPINE. 

234114 02-1 
ALLOSTERIC 

TYROSINE-HYDROXYLASE: ALLOSTERIC ACTIVATION INDUCED BY 
STIMULATION OF CENTRAL NORADRENERGIC NEURONS. 

226856 OK 
ALPHA-AORENERGIC 

POSSIBLE ROLE OF THE ALPHA-ADRENERGIC SYSTEM IN NARCOTIC 
WITHDRAWAL: TOXIC INTERACTION BETWEEN METHADONE AND 
PHENOXYBENZAMINE. (UNPUBLISHED PAPER). 

226848 01 -C 
DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC RECEPTORS BY 
CHLORPROMAZINE. 

238672 03-C 

ALPHA-ADRENOCEPTOR 

EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS OF 
PRE- AND POSTSYNAPTICALLY LOCATED ALPHA-ADRENOCEPTORS. 

252025 04-( 
ALPHA-ADRENOCEPTORS 

EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS OF 
PRE- AND POSTSYNAPTICALLY LOCATED ALPHA-ADRENOCEPTORS. 

252025 04-( 
ALPHA-ADRENORECEPTOR 

NORADRENALINE SYNTHESIS AND UTILIZATION: CONTROL BY NERVE 
IMPULSE FLOW UNDER NORMAL CONDITIONS AND AFTER TREATMEN 
WITH ALPHA-ADRENORECEPTOR BLOCKING AGENTS. 

251227 04-( 

ALPHA-ADRENORECEPTORS 

DIFFERENT Al PHA-ADRENORECEPTORS IN THE CENTRAL-NERVOUS- 
SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF 
CLONIDINE AND RECEPTOR BLOCKING AGENTS. 

251226 04-1 

ALPHA-BUNGAROTOXIN 

ALPHA-BUNGAROTOXIN, COBRA NEUROTOXIN AND EXCITATION OF 
RENSHAW CELLS BY ACETYLCHOLINE. 

244203 04-1 
ALPHA-DIMETHYL-M-TRYAMINE 

EVALUATION OF THE ANTINOCICEPTIVE EFFECTS OF 4,ALPHA-DIMETHYt 
M-TRYAMINE {H77-77) IN THE RAT. 

252026 04-1 
ALPHA-METHYL 

THE SELECTIVE EFFECTS OF ALPHA-METHYL AROMATIC AMINOACIOS C 
BRAIN MONOAMINE METABOLITES AND BEHAVIOR IN CATS. 

231009 01-1 
ALPHA-METHYL-DOPA 

THE INTERACTION BETWEEN ALPHA-METHYL-DOPA AND TRICYCLIC 
ANTIDEPRESSANTS. 

230819 01-1 
EFFECTS OF EARLY POSTNATAL ALPHA-METHYL-DOPA TREATMENT ON 
BEHAVIOR IN THE RAT. 

245304 04J 
ACTION OF ALPHA-METHYL-DOPA ON WAKING-SLEEP CYCLES IN TWO 
INBRED STRAINS OF MICE, C57BR AND C57BL/6. 

249676 04-1 
AlPHA-METHYL-M-TYROSINE 

REGIONAL ROLE OF CATECHOLAMINES IN ALPHA-METHYL-M-TYROSINE 
INDUCED ELECTROENCEPHALOGRAPHIC AROUSAL. 

234067 02j 
STUDIES ON THE MECHANISM OF DEPLETION OF STRIATAL DOPAMINE 
BY ALPHA METHYL-M-TYROSINE. 

237873 02-1 
AlPHA-METHYL-P-TYROSINE 

MODULATION BY RESPONSE REQUIREMENTS OF THE EFFECTS AND 
INTERACTIONS OF D-AMPHETAMINE AND ALPHA-METHYL-P-TYROSIN 
ON SCHEDULE-CONTROLLED PERFORMANCE IN RATS. 

238844 03- 
CATECHOLAMINES IN BRAIN ISCHEMIA - EFFECTS OF ALPHA-METHYL-F 
TYROSINE AND PARGYLINE. 

239577 03- 
THE MODIFICATION OF INOTROPIC ACTION OF OUABAIN BY 6- 
HYDROXYDOPAMINE AND ALPHA-METHYL-P-TYROSINE IN DOGS. 

242200 03- 
ENHANCEMENT OF RESERPINEELICITED DOPAMINERGIC 

SUPERSENSITIVITY BY REPEATED TREATMENT WITH APOMORPHINE 
AND ALPHA-METHYL-P-TYROSINE. 

249002 04- 
EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVEAU ISOLE AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT. 

249307 04- 



S-18 



OLUME 14, SUBJECT INDEX 



Subject Index 



INTRACRANIAL SELF-STIMULATION FROM THE DORSAL RAPHE NUCLEUS 
OF THE RAT; EFFECTS OF THE INJECTION OF P CHLOROPHENYLALANINE 
AND OF ALPHA-METHYLP TYROSINE. 

250982 04-04 
LPHA-METHYITYROSINE 

MORPHINE ENHANCEMENT OF SHUTTLE AVOIDANCE PREVENTED BY 
ALPHA-METHYLTYROSINE. 

230825 01-04 
ATTENUATION BY ALPHA-METHYLTYROSINE OF AMPHETAMINE-INDUCED 
CONDITIONED TASTE AVERSION IN RATS 

237713 02-04 
LPHA-RECEPTOR 

EFFECTS OF ALPHA-RECEPTOR BLOCKERS AND ANTIDEPRESSANT DRUGS 
ON THE PRESYNAPTIC ALPHA-RECEPTOR OF RAT CEREBRAL CORTEX. 

251394 04-03 
LPRENOLOL 

TRANQUILIZATION EFFECT OF BETA-BLOCKADE ALPRENOLOL; A CLINICAL 
STUDY. 

228311 01-11 
ITERATION 

ALTERATION OF MEMBRANE INTEGRITY OF DELTAl- 
TETRAHYDROCANNABINOL. 

229035 01-03 
ALTERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS AFTER CHRONIC HALOPERIDOL: INDIRECT EVIDENCE FOR 
CHOLINERGIC HYPOSENSITIVITY. 

239826 03-04 
DOPAMINERGIC NEURONS - ALTERATION IN THE SENSITIVITY OF 

TYROSINE-HYDROXYLASE TO INHIBITION BY ENDOGENOUS DOPAMINE 
AFTER CESSATION OF IMPULSE FLOW. 

241295 03-03 
DOPAMINERGIC NEURONS - ALTERATION IN THE KINETIC PROPERTIES OF 

TYROSINE-HYDROXYLASE AFTER CESSATION OF IMPULSE FLOW. 

241296 03-03 
BARBITAL ALTERATION OF CENTRAL-NERVOUS-SYSTEM SENSITIVITY TO 

HEXOBARBITAL IN THE RAT. 

244688 04-03 
EFFECTS OF A CHOLINE-DEFICIENT DIET ON THE INDUCTION OF DRUG 
AND ETHANOL METABOLIZING ENZYMES AND ON THE ALTERATION Of 
RATES OF ETHANOL DEGRADATION BY ETHANOL AND 
PHENOBARBITAL. 

247032 04-03 
PROTEST DESPAIR RESPONSE TO PEER SEPARATION IN RHESUS MONKEYS 
AND ITS POTENTIATION BY ALTERATION OF CATECHOLAMINE 
METABOLISM. 

248437 04-04 
ALTERATION OF DOPAMINE METABOLISM IN RAT BRAIN BY BACLOFEN 
(LIORESAL (R)). 

251398 04-03 
ITERATIONS 

5-HYDROXYTRYPTAMINE 14C AND DEXAMPHETAMINE-14C UPTAKE BY 
FUNDAL SARCOLEMMA PREPARATIONS: EFFECT OF THERMAL AND 
CHEMICAL ALTERATIONS AS INDIRECT APPROACH TO THE PROBLEM 
OF THE COMMON RECEPTOR. 

226827 01-03 
HYPNOTICS AND SLEEP: CLASSIFICATION, METABOLISM, MECHANISM OF 
ACTION OF HYPNOTICS AND ALTERATIONS OF PHASES OF SLEEP BY 
HYPNOTICS. 

228094 01-14 
RELATIONSHIP OF DOPAMINE NEURAL SYSTEMS TO THE BEHAVIORAL 
ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION 
INTO BRAIN. 

233970 02-03 
EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER 

METABOLISM IN CENTRAL DOPAMINERGIC NEURONES. 

233971 02-03 
LIPIOOSIS-LIKE ULTRASTRUCTURAL ALTERATIONS IN RAT LYMPH NODES 

AFTER TREATMENT WITH TRICYCLIC ANTIDEPRESSANTS OR 
NEUROLEPTICS. 

237153 02-05 
RAPID CHANGES IN RAT PINEAL BETA-ADRENERGIC RECEPTOR: 
ALTERATIONS IN 3H-ALPREN0L0L BINDING AND ADENYLATE-CYCLASE. 
(UNPUBLISHED PAPER) 

237170 02-03 
ALTERATIONS IN CA45 UPTAKE AND EFFLUX IN RAT CORTEX, STRIATUM 
AND HYPOTHALAMUS SLICES. 

238714 03 03 
MARUUANA-INDUCED ALTERATIONS IN FEEDING BEHAVIOR AND 
HYPOTHALAMIC CONCENTRATIONS OF NOREPINEPHRINE AND 
SEROTONIN IN THE RAT. 

238720 03-04 
ALTERATIONS OF THE EEG OF EXTRAPYRAMIDAL NUCLEI FOLLOWING 6- 
HYDROXYDOPAMINE LESIONS. 

238735 03-03 
ALTERATIONS IN DOPAMINE UPTAKE IN RAT CORPUS-STRIATUM 
INDUCED BY COMBINATIONS OF STRESS AND DELTAS 
TETRAHYDROCANNABINOL (DELTA8-THC). 

241926 03-03 



NEONATAL HYPERTHYROIDISM: ALTERATIONS IN BEHAVIOURAL 
ACTIVITY AND THE METABOLISM OF BRAIN NOREPINEPHRINE AND 
DOPAMINE. 

243792 04-03 
INFLUENCE OF DESMETHYLIMIPRAMINE ON SOME NEUROCHEMICAL 
ALTERATIONS DURING EXPERIMENTAL HYPOTHYROIDISM. 

246152 04-03 
DRUG-INDUCED ALTERATIONS OF SLOW POTENTIAL RESPONSES IN THE 
RAT. 

249250 04-03 
CENTRAL DOPAMINERGIC NEURONS: EFFECTS OF ALTERATIONS IN 
IMPULSE FLOW ON THE ACCUMULATION OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085 04-03 
ALTERED 

ALTERED 5-HT METABOLISM WITH CLONAZEPAM, DIAZEPAM AND 
DIPHENYLHYDANTOIN. 

230855 01-03 
ALTERED HYPOTHERMIC RESPONSIVENESS TO ( t ) AMPHETAMINE. 

239685 03-03 
COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY 
SHORT SENSORY DEPRIVATION AND BY DELTA9-TRANS- 
TETRAHYOROCANNABINOL 

240645 03-14 
OPIATE RECEPTOR IN NORMAL AND DRUG ALTERED BRAIN FUNCTION. 

246996 04-03 
ALTERED PATTERN OF DOPA METABOLISM. 

251185 04-03 
ALTERING 

VARIATIONS IN EFFECT OF MEMORY ALTERING DRUGS AS A FUNCTION 
OF THE STRENGTH OF THE LEARNED RESPONSE. (PH.D. DISSERTATION). 

241689 03-04 
ALTERNATE 

ETHANOL AS A REINFORCER FOR RATS: EFFECTS OF CONCURRENT 
ACCESS TO WATER AND ALTERNATE POSITIONS OF WATER AND 
ETHANOL. 

227128 01 04 
ALTERNATION 

EFFECTS OF SCOPOLAMINE, D AMPHETAMINE AND OTHER DRUGS 
AFFECTING CATECHOLAMINES ON SPONTANEOUS ALTERNATION AND 
LOCOMOTOR ACTIVITY IN MICE. 

237703 02-04 
ALTERS 

DELTA9-TETRAHYDR0CANNABIN0L ALTERS FLOW OF BLOOD TO 
SUBCORTICAL AREAS OF THE CONSCIOUS RAT BRAIN. 

226874 01-04 
LONG-TERM CONSUMPTION OF A TRYPTOPHAN POOR DIET ALTERS THE 
BEHAVIORAL RESPONSE TO DRUGS. 

238741 03 03 
ALUMINUM 

INFLUENCE OF MAGNESIUM AND ALUMINUM HYDROXIDE MIXTURE ON 
CHLORDIAZEPOXIDE ABSORPTION. 

237116 02-13 
AAAANTADINE 

PLASMA CONCENTRATIONS OF L-DOPA AND 3-METHOXYDOPA AND 
IMPROVEMENT IN CLINICAL RATINGS AND MOTOR PERFORMANCE IN 
PATIENTS WITH PARKINSONISM TREATED WITH L-DOPA ALONE OR IN 
COMBINATION WITH AMANTADINE. 

226349 01 14 
AMANTADINE: AGGRESSIVE EFFECT; EFFECT ON APOMORPHINE-INDUCED 
AGGRESSIVITY IN THE RAT. 

241227 03-04 
RESPONSES OF NEURONES IN THE CEREBRAL CORTEX AND CAUDATE- 
NUCLEUS TO AAAANTADINE, AMPHETAMINE AND DOPAMINE. 

243805 04-03 
A CONTROLLED TRIAL OF AMANTADINE IN DRUG-INDUCED 
EXTRAPYRAMIDAL DISORDERS. 

244701 04 15 
AMANTADINE DECREASES D-AMPHETAMINE STIMULATION AND 
INCREASES D-AMPHETAMINE ANOREXIA IN MICE. 

249459 04 03 
AAABIENT 

INTERACTION EFFECTS OF D-AMPHETAMINE TREATMENT AND AMBIENT 
TEMPERATURE ON RATS FOOD INTAKE. 

237097 02-03 
BODY TEMPERATURE RESPONSES AT DIFFERENT AMBIENT 

TEMPERATURES FOLLOWING INJECTIONS OF PROSTAGLANDIN-El AND 
NORADRENALINE INTO THE BRAIN. 

242736 03 03 
AMBLYOPIA 

BICUCULLINE REVERSAL OF DEPRIVATION AMBLYOPIA IN THE CAT 

249983 04 03 
AMBULATORY 

AMITRIPTYLINE PERPHENAZINE INTERACTION IN AMBULATORY 
SCHIZOPHRENIC PATIENTS. 

228225 01-08 
ON THE EFFECTIVENESS OF PSYCHIATRIC AMBULATORY STATIONS 

234289 02-11 



5 



a 
2 

03 
I 

i 



S-19 



Subject Index 



Psychopharmacology Abstract! 



AMFONEIIC-ACIO 

AMFONELICACID FACILITATION OF IMPULSE-INDUCED STRIATAL 
DOPAMINE RELEASE. 

238730 03-03 
AMIDES 

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM DEPRESSANT ACTIVITY OF 
SOME BICYCLIC AMIDES. 

248539 04-02 
AMINE 

INABILITY OF AN INHIBITOR OF AMINE UPTAKE {LILLY-1 10140) TO 
BLOCK DEPLETION OF BRAIN 5-HYDROXYTRYPTAMINE BY L-DOPA. 

226765 01-03 
CHEMISTRY AND PHARMACOLOGY OF BIOGENIC AMINE UPTAKE. 

229478 01-03 
BIOGENIC AMINE EFFECTS ON CNS PHOSPHOLIPID METABOLISM. 

229482 01-03 
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL ON BRAIN AMINE 
CONCENTRATION AND TURNOVER IN WHOLE RAT BRAIN AND IN 
VARIOUS REGIONS OF THE BRAIN. 

230856 01-03 
THE USE OF SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS TO 
MODIFY AMINE METABOLISM IN BRAIN. 

233947 02-03 
METABOLIC 0-DEMETHYLATION OF THE PSYCHOTOMIMETIC AMINE 1 2,5 
DIMETHOXY-4-METHYLPHENYL 2 AMINOPROPANE. 

236520 02-03 
COMPARATIVE PHARMACOLOGY OF AMPHETAMINE AND PEMOLINE ON 
BIOGENIC AMINE SYSTEMS. 

238728 03-03 
THE EFFECTS OF TANDAMINE, A NEW POTENTIAL ANTIDEPRESSANT 
AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED 
ACTIVITIES. 

244316 04-02 
EFFECTS OF TRAZODONE ON BEHAVIOR AND BRAIN AMINE CONTENT OF 
MICE. 

247485 04-04 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASURE 
THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

248834 04-03 
EFFECT OF MORPHINE ON INTRACRANIAL SELF-STIMULATION BEHAVIOR 
FOLLOWING BRAIN AMINE DEPLETION. 

249138 04-04 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASURE 
THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

249930 04-03 
EXTRAPINEAL AMINE N-ACETYLATION IN RAT BRAIN: REGIONAL AND 
SUBCELLULAR DISTRIBUTION AND ENZYME KINETICS. 

250377 04-01 
EFFECTS OF MAZINDOL, A NONPHENYLETHYLAMINE ANOREXIGENIC 
AGENT, ON BIOGENIC AMINE LEVELS AND TURNOVER RATE. 

252201 04-03 
AMINERGIC 

THE SEROTONERGIC SYSTEM IN THE BRAIN AND ITS POSSIBLE 
FUNCTIONAL CONNECTIONS WITH OTHER AMINERGIC SYSTEMS. 

248159 04-03 
AMINES 

BIOGENIC AMINES AND THE EFFECT OF SHORT-TERM LITHIUM 
ADMINISTRATION ON OPEN-FIELD ACTIVITY IN RATS. 

225573 01-04 
ANALYSIS OF DRUGS AND PSYCHOACTIVE PHENOLIC AMINES. 

229486 01-03 
THE EFFECTS OF ACETYLCHOLINE AND DOPAMINE ON THE CAUDATE- 
NUCLEUS DEPLETED OF BIOGENIC AMINES. 

230457 01-03 
INVOLVEMENT OF BIOGENIC AMINES IN DRUG-INDUCED AGGRESSIVE 
PECKING IN CHICKS. 

230878 01-04 
BEHAVIORAL EFFECTS OF DIBUTYRYL-CYCLIC-AMP AND BIOGENIC 
AMINES IN RATS. 

232484 01-04 
ROLE OF BIOGENIC AMINES IN THE EFFECTS OF MARIJUANA ON EEG 
PATTERNS IN CATS. 

235564 02-03 
BIOGENIC AMINES AND THE PHOTOMYOCLONIC SYNDROME IN THE 
BABOON, PAPIO-PAPIO, 

237755 02-04 
EFFECTS OF ACUTE ETHANOL ADMINISTRATION ON BRAIN BIOGENIC 
AMINES, 

238751 03-03 
EVIDENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
MOTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS. 

241203 03-03 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (I). RELATIONSHIP 
BETWEEN BRAIN MONOAMINES AND DEFECATION IN RATS. 

241370 03-04 



STUDIES ON BIOGENIC AMINES AND BEHAVIOR (II). RELATIONSHIP 
BETWEEN EMOTIONALITY AND DEFECATION. 

241371 03-0. 
STUDIES ON THE CORRELATION BETWEEN BEHAVIOR AND BRAIN AMINE: 
WITH PSYCHOTROPIC DRUGS. 

241378 03-0 
BRAIN FUNCTION AND BIOGENIC AMINES (4). ROLE OF MONOAMINERGK 
MECHANISM ON SELECTIVE INHIBITION OF PARADOXICAL SLEEP. 

241388 03-0 
BIOGENIC AMINES AND AFFECTIVE DISORDERS. 

241937 03-0 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAII 
MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS. 

246318 04-0 
ACUTE MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 
HORMONE AND CORTICOSTERONE. 

246661 04-C 
CHRONIC MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 

HORMONE AND CORTICOSTERONE. 

246662 04-0 
D-AMPHETAMINE AS A RELEASER OR REUPTAKE INHIBITOR OF BIOGENK 

AMINES IN SYNAPTOSOMES. 

246665 04-C 
USE OF SYNTHESIS INHIBITORS IN DEFINING A ROLE FOR BIOGENIC 
AMINES DURING IMIPRAMINE TREATMENT IN DEPRESSED PATIENTS. 

247216 04-C 
DIFFERENCES BETWEEN THE EFFECTS OF ACUTE AND LONG-TERM 
TREATMENT WITH DESMETHYLIMIPRAMINE ON RESERPINE-INDUCED 
RELEASE OF AMINES FROM RAT BRAIN. 

249233 04-C 
COMPARISON OF THE MONOMETHOXYAMPHETAMINES ON THE UPTAKE 
AND RELEASE OF BIOGENIC AMINES IN BRAIN TISSUE. 

249315 04-C 
EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251 130 04-C 
UPTAKE OF BIOGENIC AMINES INTO SYNAPTIC VESICLES OF THE 
CAUDATE-NUCLEUS. 

251392 04-C 
COMPARATIVE ACTIONS OF MONOMETHOXYAMPHETAMINES ON THE 
RELEASE AND UPTAKE OF BIOGENIC AMINES IN BRAIN TISSUE. 

253107 04-C 
AMINO 

NEUROTOXICITY OF A NON-METABOLIZABLE AMINO ACID, L- 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (ACPC): ACPC TRANSPOR 
MECHANISMS IN TISSUES. 

241298 03-C 
INTERACTIONS OF LEVODOPA WITH INHIBITORS OF MONOAMINE- 
OXIDASE AND L AROMATIC AMINO ACID DECARBOXYLASE, 

245647 04-1 
AMINO-ACIO 

COMPARISON OF BICUCULLINE METHOCHLORIDE WITH BICUCULLINE 
AND PICROTOXIN AS ANTAGONISTS OF AMINO-ACID AND 
A1.0N0AMINE DEPRESSION OF NEURONES IN THE RAT BRAINSTEM. 

237783 02-( 
THE EFFECT OF NUTRITIONAL FACTORS ON BRAIN AMINO-ACID LEVELS 
AND MONOAMINE SYNTHESIS. 

241472 03-1 
AMINO-ACIDS 

SERUM AMINO-ACIDS AND BRAIN TRYPTOPHAN UPTAKE. 

227712 01-( 
THE SELECTIVE EFFECTS OF ALPHA-METHYL AROMATIC AMINO-ACIDS 
BRAIN MONOAMINE METABOLITES AND BEHAVIOR IN CATS 

231009 01-( 
THE EFFECTS OF BETA-CARBOLINES ON RESPONSES TO ACETYLCHOLINE, 
NORADRENALINE, 5-HYDROXYTRYPTAMINE AND AMINO-ACIDS IN TH 
RAT SPINAL CORD. 

235863 02-( 
EFFECTS OF ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE ON THE 
INCORPORATION OF AMINO-ACIDS INTO PROTEINS OF MOUSE BRAIN 
SUBCELLULAR FRACTIONS. 

237155 02-( 
ANTAGONISMS BY NEUTRAL AMINO-ACIDS (NAA) OF THE HYPOTHERMI 
EFFECT OF D-AMPHETAMINE (AMP). 

238726 03-( 
INJECTIONS OF AMINO-ACIDS THAT ALTER BRAIN SEROTONIN INCREASI 
THE SENSITIVITY TO ELECTROSHOCK IN RATS. 

238783 03-( 
A STUDY OF THE METABOLISM AND RELEASE OF DOPAMINE AND 
AMINO-ACIDS FROM NERVE ENDINGS ISOLATED FROM SHEEP CORPU: 
STRIATUM, 

241206 03-( 
DRUG-INDUCED PARKINSONISM IN THE RAT - A MODEL FOR 

BIOCHEMICAL INVESTIGATION OF THE PARKINSON SYNDROME. Ill: 
THE INCORPORATION OF D-GLUC0SE-14C(U) IN AMINO-ACIDS OF 



S-20 



OLUME 14, SUBJECT INDEX 



Subject Index 



BRAIN AND LIVER FROM RATS PRETREATED WITH RESERPINE OR 
WITH PHENOTHIAZINES- 

244692 04-03 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACIDS 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG-INDUCED 
BEHAVIORAL EXCITATION. 

250067 04-04 
V1INO-4-HEX-5-ENOIC-ACID 

A COMPARISON OF THE BIOCHEMICAL EFFECT OF TWO CATALYTIC 
INHIBITORS OF MAMMALIAN BRAIN GABA-TRANSAMINASE: GAMMA- 
VINYL-GABA (AMINO-4-HEX-5-ENOIC-ACID) AND GAMAAA-ACETYLENIC- 
GABA (AMIN0-4-HEX-5-YN0IC-ACID). 

238782 03-03 
MINO-4-HEX-S-YNOIC-ACID 

GAMMA-ACETYLENIC-GABA (AMIN0-4-HEX-5-YN0IC-ACID): A GABA- 
TRANSAMINASE INHIBITOR WITH SELECTIVE ANTISEIZURE ACTIVITY. 

238781 03-04 
A COMPARISON OF THE BIOCHEMICAL EFFECT OF TWO CATALYTIC 

INHIBITORS OF MAMMALIAN BRAIN GABA-TRANSAMINASE: GAMMA- 
VINYL-GABA (AMIN0-4-HEX-5-EN0IC-ACID) AND GAMAAA-ACETYLENIC- 
GABA (AMIN0-4-HEX-5-YN0IC-ACID). 

238782 03-03 
MINOPHYLLINE 

L-DOPA, AMINOPHYLLINE, EPHEDRINE: ANTAGONISTIC INTERACTION 
WITH ETHANOL IN HUMANS. 

238748 03-13 
MINOPROPANE 

METABOLIC 0-DEMETHYLATION OF THE PSYCHOTOMIMETIC AMINE 1 2,5 
DIMETHOXY-4-METHYLPHENYL 2 AMINOPROPANE. 

236520 02-03 
MINOPYRINE 

ON THE MECHANISMS OF ACTION OF AMINOPYRINE. 

228552 01-03 
VtlNOTRANSFERASE 

THE INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES. 

25271 1 04-03 
VHTRIPTYUNE 

AMITRIPTYLINE PERPHENAZINE OVERDOSE PRODUCING DELAYED 
HYPOMANIA IN MANIC-DEPRESSIVE ILLNESS. 

227572 01-09 
AMITRIPTYLINE PERPHENAZINE INTERACTION IN AMBULATORY 
SCHIZOPHRENIC PATIENTS. 

228225 01-08 
AMITRIPTYLINE IN THE PROPHYLAXIS OF MIGRAINE: EFFECTIVENESS AND 
RELATIONSHIP ON ANTIMIGRAINE AND ANTIDEPRESSANT EFFECTS. 

237138 02-11 
APPARENT PHARMACOKINETIC INTERACTION OF DIAZEPAM AND 
AMITRIPTYLINE IN PSYCHIATRIC PATIENTS: A PILOT STUDY. 

237901 02-13 
BIOTRANSFORMATION OF AMITRIPTYLINE IN THE DOG. 

238684 03-03 
A DOUBLE-BLIND TRIAL OF MAPROTILINE (LUDIOMIL) AND 
AMITRIPTYLINE IN DEPRESSED OUTPATIENTS. 

238981 03-10 
DOUBLE-BLIND COMPARISON OF MAPROTILINE WITH AMITRIPTYLINE IN 
THE TREATMENT OF DEPRESSIVE ILLNESS. 

239818 03-10 
DOUBLE-BLIND TRIAL OF DIFFUCAPS AMITRIPTYLINE AND ORDINARY 
AMITRIPTYLINE IN SLEEP DISORDERS OF DEPRESSIVE ORIGIN. 

240032 03-09 
AMITRIPTYLINE POISONING CAUSING LEFT BUNDLE BRANCH BLOCK. 

241357 03-15 
DECOMPOSITION OF AMITRIPTYLINE HYDROCHLORIDE IN AQUEOUS 
SOLUTION: IDENTIFICATION OF DECOMPOSITION PRODUCTS. 

246317 04-01 
EFFECT OF FENFLURAMINE ON STEADY-STATE PLASMA LEVELS OF 
AMITRIPTYLINE (ABSTRACT). 

250943 04-07 
MNESIA 

CYCLOHEXIMIDE-INDUCED AMNESIA FOR TASTE AVERSION MEMORY IN 
RATS. 

242742 03-04 
EFFECT OF AGE OF HABIT ON SUSCEPTIBILITY TO CYCLOHEXIMIDE- 
INDUCED AMNESIA IN MICE. 

245614 04-02 
VtNESIC 

AN AMNESIC EFFECT OF BENZODIAZEPINES IN RATS'. 

251216 04-04 
MOBARBITAl 

THYROTROPIN-RELEASING HORMONE (TRH) AN ANTIDOTE TO 
AMOBARBITAL OVERDOSAGE IN THE RHESUS MONKEY. 

238792 03-03 
MATERNAL AND NEONATAL ELIMINATION OF AMOBARBITAL AFTER 
TREATMENT OF THE MOTHER WITH BARBITURATES DURING LATE 
PREGNANCY. 

243085 04-15 



MEASUREMENTS OF BRAIN AMOBARBITAL CONCENTRATIONS IN RATS 
ANESTHETIZED AND OVERDOSED WITH AMOBARBITAL AND TREATED 
CENTRALLY WITH DIBUTYRYL-CYCLIC-AMP. 

248276 04-03 
AMOBARBITAL-INDUCED 

COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYL- 
CYCLIC-AMP AND ANALEPTIC DRUGS ON AMOBARBITAL-INDUCED 
NARCOSIS IN THE RAT. 

252221 04-03 
AMOXAPINE 

THE EFFECTS OF AMOXAPINE ON ELECTROENCEPHALOGRAPHIC STAGES 
OF SLEEP IN NORMAL HUMAN SUBJECTS. 

237696 02-14 
AMP 

ANTAGONISMS BY NEUTRAL AMINO-ACIDS (NAA) OF THE HYPOTHERMIC 
EFFECT OF D-AMPHETAMINE (AMP). 

238726 03-03 
COMPARISON OF THYROID-RELEASING HORMONE (TRH) AND 

AMPHETAMINE (AMP) ON CHANGES IN ACTIVITY LEVELS OF RATS 
FOLLOWING INJECTIONS INTO THE CAUDATE-NUCLEUS. SEPTUM, AND 
HYPOTHALAMUS. 

238744 03-04 
THE EFFECT OF LITHIUM ON UNSTIMULATED AND GLUCAGON 

STIMULATED URINARY CYCLIC AMP EXCRETION IN RAT AND MAN. 

251129 04-17 
AMPHETAMINE 

SEPARATING THE EFFECTS OF RESPONSE RATE AND REINFORCEMENT 
FREQUENCY IN THE RATE-DEPENDENT EFFECTS OF AMPHETAMINE AND 
SCOPOLAMINE ON THE SCHEDULE-CONTROLLED PERFORAMNCE OF 
RATS AND PIGEONS. 

226853 01-04 
AMPHETAMINE AND APOMORPHINE RESPONSES IN THE RAT FOLLOWING 
6-OHDA LESIONS OF THE NUCLEUS-ACCUMBENS SEPTI AND CORPUS- 
STRIATUM. 

226937 01-04 
SCOPOLAMINE AND AMPHETAMINE EFFECTS ON DISCRIMINATION: 
INTERACTION WITH STIMULUS CONTROL. 

227131 01-04 
HALOPERIDOL AND PROPRANOLOL IN THE TREATMENT OF ACUTE 
AMPHETAMINE INTOXICATION IN THE DOG. 

227389 01-03 
STUDIES ON THE CNS AVAILABILITY OF AMPHETAMINE FROM 
AMPHETAMINIL. 

229041 01-03 
THE MECHANISM OF ACTION OF AMPHETAMINE IN BRAIN. 

229491 01-03 
ACCUMULATION OF LABELED EPHEDRINE, NOREPHEDRINE, 

AMPHETAMINE AND TYRAMINE IN PIGMENTED AND NONPIGMENTED 
EYES OF BLACK AND WHITE RATS. 

230450 01-03 
EFFECTS OF DRUG EXPERIENCE ON DRUG-INDUCED CONDITIONED TASTE 
AVERSIONS: STUDIES WITH AMPHETAMINE AND FENFLURAMINE. 

230829 01-04 
COCAINE AND AMPHETAMINE MODIFICATION OF CEREBRAL ENERGY 
METABOLISM IN VIVO. 

230834 01-03 
EFFECTS OF PRIOR EXPERIENCE ON DIFFERENTIAL LEARNING UNDER 
AMPHETAMINE. 

230868 01-04 
A COMPARISON OF FENFLURAMINE AND AMPHETAMINE IN MAN. 

23131901-13 
CATECHOLAMINERGIC MECHANISMS OF THE LATERAL HYPOTHALAMUS: 
THEIR ROLE IN THE MEDIATION OF AMPHETAMINE ANOREXIA. 

232610 02-03 
BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AND AMPHETAMINE 
AFTER CHRONIC HIGH DOSE HALOPERIDOL TREATMEN 

232616 02-04 
HYPERTHERMIA INDUCED BY AMPHETAMINE, P-CHLOROAMPHETAMINE 
AND FENFLURAMINE IN THE RAT. 

233301 02-03 
BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF 
PSYCHOSIS. 

233965 02-03 
DOPAMINE, PSYCHOMOTOR STIMULANTS, AND SCHIZOPHRENIA: 
EFFECTS OF METHYLPHENIDATE AND THE STEREOISOMERS OF 
AMPHETAMINE IN SCHIZOPHRENICS. 

233967 02-08 
KINETICS AND METABOLISM OF AMPHETAMINE IN THE BRAIN OF RATS 
OF DIFFERENT AGES. 

234316 02-03 
EFFECT OF CAFFEINE AND AMPHETAMINE ON CAUDATE INHIBITION OF 
AGGRESSIVE REACTIONS OF CATS. 

236371 02-04 
EFFECT OF SODIUM OXYBUTYRATE, AMPHETAMINE, TRANSAMINE, L- 

DOPA ON THE PROCESSES OF RESTORATION OF WORKING CAPACITY 
UNDER CONDITIONS OF MINIMAL REST. 

236372 02-04 



i 






S-21 



Subject Index 



Psychopharmacoiogy Abstract 



BEHAVIORAL AND BIOCHEMICAL INTERACTION BETWEEN A/WT AND ( t ) 
AMPHETAMINE: RELEVANCE TO THE IDENTIFICATION OF THE 
FUNCTIONAL POOL OF BRAIN CATECHOLAMINES. 

237698 02-03 
BEHAVIORAL AND NEUROPHARMACOLOGICAL ANALYSIS OF 

AMPHETAMINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN 
RATS, 

237718 02-04 
EFFECT OF AMPHETAMINE AND FENFLURAMINE ON BRAIN 
NORADRENALINE AND M0PEG-S04, 

237740 02-03 
ATTENUATION OF AMPHETAMINE ANOREXIA BY UNILATERAL NIGRAL 
STRIATAL LESIONS. 

237777 02-03 
CENTRAL EFFECTS OF SCOPOLAMINE AND ( t ) AMPHETAMINE ON 

LOCOMOTOR ACTIVITY: INTERACTION WITH STRAIN AND STRESS 
VARIABLES 

237778 02-04 
IN VITRO METABOLIC STUDIES USING THE METABONATES OF 

AMPHETAMINE, 2 NITROSO-I-PHENYLPROPANE AND 
BENZYLMETHYLKETOXIME 

237980 02-01 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE: BIOCHEMICAL AND 

PHARMACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE AS 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINE 
AND OTHER PSYCHOTROPIC DRUGS (PH.D. DISSERTATION). 

238077 02-03 
AMPHETAMINE TACHYPHYLAXIS IN THE PITHED GUINEA-PIG. 

23831 5 02-03 
FURTHER STUDIES ON BRAIN CONCENTRATIONS OF AMPHETAMINE AND 
ITS METABOLITES IN STRAINS OF MICE SHOWING DIFFERENT 
SENSITIVITY TO PHARMACOLOGICAL EFFECTS OF AMPHETAMINE. 

238322 02-03 
N-HYDROXYAMPHETAMINE: A MAJOR METABOLITE OF AMPHETAMINE IN 
RABBIT LIVER EXTRACT. 

238682 03-03 
THE AROMATIC HYDROXYLATION OF AMPHETAMINE WITH RAT LIVER 

MICROSOMES, PERFUSED LIVER AND ISOLATED HEPATOCYTES. 

238683 03-06 
COMPARATIVE PHARMACOLOGY OF AMPHETAMINE AND PEMOLINE ON 

BIOGENIC AMINE SYSTEMS. 

238728 03 03 
COMPARISON OF THYROID-RELEASING HORMONE (TRH) AND 

AMPHETAMINE (AMP) ON CHANGES IN ACTIVITY LEVELS OF RATS 
FOLLOWING INJECTIONS INTO THE CAUDATE-NUCLEUS, SEPTUM, AND 
HYPOTHALAMUS. 

238744 03 04 
THE EFFECTS OF ASCORBIC-ACID (AA) PRETREATMENT ON 
AMPHETAMINE (A) EXCRETION IN MAN. 

238797 03-13 
DOSE RESPONSE STUDIES ON EFFECTS OF AMPHETAMINE ON ACTIVITY 
AND OXYGEN CONSUMPTION IN DOG AND CAT MODELS OF 
HYPERKINESIS (HYPOINHIBITORY SYNDROME) 

238825 03-03 
ENVIRONMENTAL INFLUENCES ON THE BEHAVIORAL RESPONSE TO ACUTE 
AND CHRONIC AMPHETAMINE ADMINISTRATION 

238843 03-04 
AGE RELATED CHANGES OF LOCOMOTOR ACTIVITY AFTER 
AMPHETAMINE ADMINISTRATION. 

238845 03-04 
EFFECTS OF CATECHOLAMINE RECEPTOR BLOCKING AGENTS ON 
TOXICITY AND THERMAL RESPONSES INDUCED BY AMPHETAMINE 
ISOMERS IN ADULT AND DEVELOPING MICE. 

239043 03-05 
AMPHETAMINE TOXICITY IN TEMPERATURE ACCLIMATISED MICE 

239091 03-05 
ALTERED HYPOTHERMIC RESPONSIVENESS TO ( i ) AMPHETAMINE. 

239685 03-03 
AMPHETAMINE AND THE REWARD SYSTEM: EVIDENCE FOR TOLERANCE 
AND POST-DRUG DEPRESSION 

239850 03 04 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN 
FOLLOWING HEAD FOCUSED MICROWAVE SACRIFICE: EFFECT OF ( i ) 
AMPHETAMINE AND ( i OR ) P-CHLOROAMPHETAMINE 

239976 03-03 
AN INTEGRATED APPROACH FOR THE VALUATION OF PSYCHOTROPIC 
DRUG IN MAN- I STUDIES ON AMPHETAMINE RELATIONSHIP 
BtTWEEN DRUG LEVELS AND PSYCHOPHYSIOLOGICAL 
MEASUREMENTS 

241234 03-13 
Df lERMINAllONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESIS IN 
A SINGLE MOUSE BRAIN: BIPHASIC EFFECTS OF ( i ) AMPHETAMINE. 

241257 03-03 
EFFECTS OF THE D ISOMERS AND L ISOMERS OF AMPHETAMINE ON 
UPIAKE RELEASE AND CATABOLISM OF NOREPINEPHRINE, DOPAMINE 
AND 5 HYDROXYTRYPTAMINE IN SEVERAL REGIONS OF RAT BRAIN 

241345 03-03 



THE NATURE OF THE 455-NM ABSORBING COMPLEX FORMED DURING 
THE CYTOCHROME-P450 DEPENDENT OXIDATIVE METABOLISM OF 
AMPHETAMINE. 

241350 03-1 
CONCENTRATION OF AMPHETAMINE ISOMERS IN BRAIN AND HEART 01 
ADULT AND DEVELOPING MICE. 

241414 03-1 
THE EFFECT OF ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION 
ON SEIZURE SUSCEPTIBILITY AND BRAIN CATECHOLAMINES IN MICE 
(PH.D. DISSERTATION). 

241576 03- 
BLOCKADE OF THE ELECTROCORTICAL CHANGES INDUCED BY PERFUSIC 
OF AMPHETAMINE IN THE BRAINSTEM RETICULAR FORAMTION. 

241930 03- 
EFFECT OF AMPHETAMINE AND GUTIMIN ON ADAPTIVE CHANGES IN 
ARTERIAL PRESSURE ARISING IN RESPONSE TO CONTRACTION OF TH 
SKELETAL MUSCLES. 

241988 03- 
RESPONSES OF NEURONES IN THE CEREBRAL CORTEX AND CAUDATE- 
NUCLEUS TO AMANTADINE, AMPHETAMINE AND DOPAMINE. 

243805 04- 
COMPARATIVE PSYCHOPHARAAACOLOGY OF COCAINE AND 
AMPHETAMINE. 

243820 04- 
THE EFFECT OF AMPHETAMINE STEREOISOMERS ON THE FUNCTION OF 
DOPAMINE SYNAPSES IN VITRO. 

244043 04 
EFFECTS OF AMPHETAMINE, FOOD DEPRIVATION AND CURRENT 
INTENSITY ON SELF-STIMULATION IN THE RAT. 

244214 04 
EFFECT OF METHADONE AND DEXTROMORAMIDE ON DOPAMINE 
METABOLISM: COMPARISON WITH HALOPERIDOL AND 
AMPHETAMINE. 

244513 04 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VI' 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE 

244514 04 

BEHAVIORAL EFFECTS OF AMPHETAMINE IN A GROUP OF RHESUS 
MONKEYS WITH LESIONS OF DORSOLATERAL FRONTAL CORTEX. 

244684 04 
AMPHETAMINE PSYCHOSIS: OVERVIEW AND A HYPOTHESIS. 

245019 04 
THE DURATION OF TOLERANCE TO THE ANOREXIGENIC EFFECT OF 
AMPHETAMINE IN RATS. 

245298 04 
THE ROLES OF MONOAMINE NEURAL SYSTEMS IN THE ANOREXIA 
INDUCED BY ( I ) AMPHETAMINE AND RELATED COMPOUNDS. 

246149 04 
BENZODIAZEPINES AND AMPHETAMINE ON AVOIDANCE BEHAVIOUR It 
MICE 

247778 04 
A COMPARISON OF DEXTROAMPHETAMINE AND RACEMIC 

AMPHETAMINE IN THE TREATMENT OF THE HYPERKINETIC SYNDRO/ 
OR MINIMAL-BRAIN DYSFUNCTION. 

247878 04 
BRAIN 2-PHENYLETHYLAMINE AS A MAJOR MEDIATOR FOR THE 
CENTRAL ACTIONS OF AMPHETAMINE AND METHYLPHENIDATE. 

248162 04 
AMPHETAMINE EVALUATION OF D-ISOMERS AND L-ISOMERS AS 
RELEASING AGENTS AND UPTAKE INHIBITORS FOR 3H-D0PAMINE Al 
3H-N0RFPINEPHRINE IN SLICES OF RAT NEOSTRIATUM AND CEREBR> 
CORTEX 

248699 04 
ELEVATION OF AMPHETAMINE LEVELS IN RAT BRAIN AFTER 

ADMINISTRATION OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 
1 NAPHTHYLVINYLPYRIDINE (NVP). 

249027 04 
COMPARISON OF THE EFFECTS OF COCAINE AND AMPHETAMINE IN 
MONKEYS MAINTAINED ON NALTREXONE. 

249270 04 
ELICITATION OF MOUSE JUMPING BY COMBINED TREATMENT WITH 
AMPHETAMINE AND L-DOPA: BLOCKADE BY KNOWN NEUROLEPTICS 

249272 04 
THE EFFECT OF AMPHETAMINE PRETREATMENT ON THE AMPHFTAMIN 
INDUCED CHANGES IN MOTOR ACTIVITY AND BRAIN 
CATECHOLAMINES IN MICE 

249274 04 
STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE 
RECEPTORS IN COMPARISON TO APOMORPHINE, ( ( ) AMPHETAMIN 
AND L-DOPA. 

249419 04 
LITHIUM DIFFERENTIALLY ANTAGONISES SELF-STIMULATION 
FACILITATED BY MORPHINE AND ( ■ ) AMPHETAMINE 

249486 04 
EFFECT OF AMPHETAMINE AND APOMORPHINE ON BRAIN MONOAMIN 
AND BEHAVIOUR IN THE IMMATURE AND YOUNG ADULT RAT. 

249785 04 



S-22 



>LUME 14, SUBJECT INDEX 



Subject Index 



EXTINCTION RESPONDING FOLLOWING AMPHETAMINE SELF- 
ADMINISTRATION: DETERMINATION OF REINFORCEMENT MAGNITUD 

250010 04-04 
THOUGHT DISORDER IN AMPHETAMINE PSYCHOSIS: A CASE REPORT. 

250196 04-13 
NORADRENERGIC INFLUENCE ON THE STEREOTYPED BEHAVIOUR INDUCED 
BY AMPHETAMINE, PHENETHYLAMINE AND APOMORPHINE. 

250361 04-04 
REVERSAL BY A CENTRAL ANTIACETYLCHOLINE DRUG OF PIMOZIDE- 
INDUCED INHIBITION OF MOUSE JUMPING IN AMPHETAMINE DOPA 
TREATED MICE. 

250656 04-03 
EFFECT OF HALOPERIDOL ON ( O AMPHETAMINE SELF-ADMINISTRATION 

250658 04-04 
TOLERANCE TO AMPHETAMINE IN TWO SPECIES (RAT AND GUINEA-PIG) 
THAT METABOLIZE IT DIFFERENTLY 

250723 04-03 
ASSESSMENT OF REINFORCING PROPERTIES OF AMPHETAMINE 
ANALOGUES IN SELF-ADMINISTERING RATS. 

250941 04-04 
CONFORMATIONALLY RIGID AMPHETAMINE ANALOGS AS INHIBITORS OF 
MONOAMINE UPTAKE BY BRAIN SYNAPTOSOMES. 

251700 04-03 
EVIDENCE CONCERNING THE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE 
IN THE LOCOMOTOR ACTIVITY PRODUCED BY AMPHETAMINE OR 
TRANYLCYPROMINE PLUS L-DOPA. 

251704 04-04 
A PARADOXICAL RESPONSE TO AMPHETAMINE IN DEVELOPING RATS 
TREATED WITH 6-HYDROXYDOPAMINE. 

251951 04-04 
COMPARISON OF THE EFFECTS OF MORPHINE, PENTAZOCINE, 
CYCLAZOCINE AND AMPHETAMINE ON INTRACRANIAL SELF- 
STIMULATION IN THE RAT. 

251975 04-04 
0ELTA9-TETRAHYDR0CANNABIN0L, ETHANOL, AND AMPHETAMINE AS 
DISCRIMINATIVE STIMULI GENERALIZATION TESTS WITH OTHER 
DRUGS. 

251977 04-04 
RATE-DEPENDENT EFFECT OF AMPHETAMINE IN RATS: EXTENSION TO 
BETWEEN SUBJECTS EFFECT. 

251988 04-04 
EFFECT OF CORTISONE, ALDOSTERONE AND NIALAMIDE ON 
AMPHETAMINE STEREOTYPES AND BRAIN METHAMPHETAMINE LEVELS 
OF ADRENALECTOMIZED RATS. 

251990 04 04 
AMPHETAMINE AND BARBITURATE EFFECTS ON TWO TASKS PERFORMED 
SINGLY AND IN COMBINATION. 

253381 04 14 
PHETAMINE-ENHANCED 

INDIVIDUAL DIFFERENCES AMONG MICE IN NORMAL AND 
AMPHETAMINE-ENHANCED LOCOMOTOR ACTIVITY: RELATIONSHIP TO 
BEHAVIORAL INDICES OF STRIATAL ASYMMETRY. 

240750 03 04 
PHETAMINE-INOUCED 

EFFECTS OF A DOPAMINE-BETA-HYDROXYLASE INHIBITOR ON 
AMPHETAMINE-INDUCED HYPERACTIVITY IN RATS. 

226766 01-03 
METHADONE INTERACTION WITH APOMORPHINE AND AMPHETAMINE- 
INDUCED TURNING. 

226945 01 04 
THE EFFECTS OF TEST ENVIRONMENT AND REARING CONDITION ON 
AMPHETAMINE-INDUCED STEREOTYPY IN THE GUINEA-PIG. 

237712 02-04 
ATTENUATION BY ALPHA-METHYLTYROSINE OF AMPHETAMINE-INDUCED 

CONDITIONED TASTE AVERSION IN RATS. 

237713 02-04 
CENTRAL ACTION OF AMPHETAMINE-INDUCED MYDRIASIS IN THE DOG. 

238772 03 03 
AMPHETAMINE-INDUCED POLYPHASIC MORBIDITY: STUDIES ON STRAIN 
DIFFERENCES, POLYDRUG EFFECTS AND MECHANISM. 

238789 03-03 
THE AMPHETAMINE-INDUCED INHIBITION OF DOPAMINE BIOSYNTHESIS 
IN RAT STRIATUM 

240065 03 03 
FAILURE OF INCREASED BRAIN GAMMA-AMINOBUTYRIC ACID LEVELS TO 
INFLUENCE AMPHETAMINE INDUCED STEREOTYPED BEHAVIOR 

247730 0403 
DOPAMINERGIC NATURE OF AMPHETAMINE-INDUCED PECKING IN 
PIGEONS 

248408 04-03 
THE EFFECT OF AMPHETAMINE PRETREATMENT ON THE AMPHETAMINE- 
INDUCED CHANGES IN MOTOR ACTIVITY AND BRAIN 
CATECHOLAMINES IN MICE 

249274 04 04 
POTENTIATION OF AMPHETAMINE-INDUCED HYPERACTIVITY BY ACUTE 
BUT NOT BY CHRONIC P-CHLOROPHENYLALANINE TREATMENT IN THE 
RAT. 

252519 04 03 



AMPHETAMINE-IIKE 

THE INCREASE IN BRAIN TRYPTOPHAN CAUSED BY AMPHETAMINE-LIKE 
DRUGS: CORRELATION WITH AN INCREASE IN BODY TEMPERATURE. 

237891 02-03 
CORRELATION OF THE INCREASE IN BRAIN TRYPTOPHAN PRODUCED BY 
AMPHETAMINE-LIKE DRUGS WITH AN INCREASE IN BODY 
TEMPERATURE. 

249316 04-03 
AMPHETAMINE-TYPE 

TREATMENT OF REACTIONS TO AMPHETAMINE-TYPE STIMULANTS. 

251754 04-15 
AMPHETAMINES 

DISSOCIATION OF RAT BRAIN POLYRIBOSOMES IN VIVO BY 
AMPHETAMINES. 

237871 02-03 
THE INFLUENCE OF NITROGEN, CHAIN AND RING SUBSTITUTION ON 
SOME PHYSIO-ORGANIC PROPERTIES AND ON BUCCAL ABSORPTION OF 
AMPHETAMINES. 

237981 02-02 
EFFECTS OF METHOXYLATED AMPHETAMINES ON THE MAZE 
PERFORAAANCE BY THE RAT. 

238788 03-04 
NMR SIUDY OF AMPHETAMINES USING EUROPIUM SHIFT REAGENTS. 

239660 03 01 
DIFFERENTIAL EFFECTS OF ALPHA MT ON ANORECTIC AND 
STIMULATORY ACTION OF AMPHETAMINES. 

247729 04-02 
CATECHOLAMINES AND 2-PHENYLETHYLAMINE (PEA) IN THE CENTRAL 
AND PERIPHERAL ACTIONS OF AMPHETAMINES. 

249311 04-03 
AMPHETAMINES PARADOXICAL EFFECTS MAY BE PREDICTABLE. 

251154 04-14 
AMPHETAMINIL 

STUDIES ON THE CNS AVAILABILI I Y 01 AMPHE TAMINt I ROM 
AMPHETAMINIL. 

229041 01-03 
THE STABILITY OF AMPHETAMINIL: SYNTHESES WITH AMPHETAMINIL. 

232527 01-01 
AMPT 

EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVFAII ISOl t AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT. 

249307 04-03 
AMI 

BEHAVIORAL AND BIOCHEMICAL INTERACTION BETWEEN AMT AND ( i ) 
AMPHETAMINE: RELEVANCE TO THE IDENTIFICATION OF THE 
FUNCTIONAL POOL OF BRAIN CATECHOLAMINES. 

237698 02-03 
AMT CATALEPSY AND HYPOKINESIA: INTERACTION WITH MORPHINE 
AND COCAINE 

241224 03-04 
AMYGDALA 

EFFECTS or INSULIN INJECTION ON RESPONSES OF OLFACTORY BULB 
AND AMYGDALA SINGLE UNITS TO ODORS. 

232905 02-03 
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE- 
CYCLASE AND ON CYCLIC-GMP FORMATION IN MONKEY BRAIN 
AMYGDAIA. 

238739 03-03 
ON MONOAMINERGIC MECHANISMS OF THE AMYGDALA COMPLEX 
IMPLEMENTING fONDIllONIO RfrirxE<; or VARIOUS BIOLOGICAL 
MODALITIES. 

241980 03-03 
INTERACTING EFFECTh UL AMYtvLvu.'X liMUNS WIIH 

CHLORDIAZEPOXIDE AND PILOCARPINE ON MOUSE-KILLING BY RATS 

248394 04-04 
AMYGDALOID 

EFFECTS OF TETRAHYDROCANNABINOLS ON KINDLED AMYGDALOID 
SEIZURES AND PHOTOGENIC SEIZURES IN SENEGALESE BABOONS. 
PAPIO PAPIO. 

230475 01 03 
ANTIEPILEPTIC AND PROPHYLACTIC EFFECTS OF 

TETRAHYDROCANNABINOLS IN AMYGDALOID KINDLED CATS. 

230478 01-03 
CHANGES IN EXCITABILITY OF AMYGDAIOID AND SEPTAL NUCLEI 
INDUCED BY MEDAZEPAM HYDROCHLORIDE 

241232 03 03 
THE ROLE OF THE AMYGDALOID NUCLEI IN THE REGULATION OF 
ADAPTIVE BEHAVIOR. 

243234 04-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN01 ON ACTIVE AVOIDANCE 
ACQUISITION AND PASSIVE AVOIDANCE RETENTION IN RATS WITH 
AMYGDALOID LESIONS. 

246819 04-04 
EFFECTS OF ANTIDEPRESSANT DRUGS ON AMYGDALOID AFTER 
DISCHARGE IN RATS. 

247039 0403 



I 



^ 



00 

I 

tti 



S-23 



Subject Index 



AMYLOBARBITONE 

SODIUM AMYLOBARBITONE AND THE PATThKNINf^. FFFECT^ 

24421 7 04-04 

ANABOLIC 

CNS STIMULANTS AND ANABOLIC SUBSTANCES IN GEROPSYCHIATRIC 
THERAPY. 

229459 01-11 

ANAESTHESIA 

THE EFFECT OF DELTA9TETRAHYDR0CANNABIN0L, CANNABIDIOL AND 
CANNABINOL ON ETHER ANAESTHESIA IN MICE. 

226764 01-04 

ANAFRANIL 

A DOUBLE-BLIND CONTROLLED COMPARISON OF CLOMIPRAMINE 
(ANAFRANIL) AND IMIPRAMINE ON DEPRESSION 

228327 01-09 
TREATMENT OF DEPRESSION IN GERIATRICS WITH ANAFRANIL. 

229370 01-11 
ANAFRANIL IN OBSESSIVE-COMPULSIVE NEUROSIS. 

237896 02-10 
ANAFRANIL IN THE MANAGEMENT OF LONG-TERM PAIN: A PRELIMINARY 
REPORT. 

252141 04-07 
ANALEPTIC 

STUDIES ON THE ANALEPTIC ACTION OF THYROTROPIN-RELEASING 
HORMONE (TRH) IN RABBITS. 

249280 04-04 
COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYL- 
CYCLIC-AMP AND ANALEPTIC DRUGS ON AMOBARBITAL-INDUCED 
NARCOSIS IN THE RAT. 

252221 04-03 
ANALGESIA 

MORPHINE ANALGESIA: BLOCKADE BY RAPHE MAGNUS LESIONS. 

23261 1 02-03 
ASCENDING CATECHOLAMINE SYSTEMS AND MORPHINE ANALGESIA. 

232915 02-03 
AN ATTEMPT TO CORRELATE ANALGESIA TO CHANGES IN BRAIN 
NEUROMEDIATORS IN RATS. 

233336 02-03 
STRUCTURE-ACTIVITY RELATIONSHIPS IN ANALOGS OF DELTA9- 
TETRAHYDROCANNABINOL: TACHYCARDIA VS. ANALGESIA. 

238805 03-02 
IMPAIRED DEVELOPMENT OF TOLERANCE TO MORPHINE ANALGESIA IN 
RATS WITH HEREDITARY DIABETES-INSIPIDUS. 

239851 03-03 
THE PERIAQUEDUCTAL GRAY AND ANALGESIA: FURTHER STUDIES OF 
DRUG AND TEST SPECIFICITY. 

249248 04-03 
NALOXONE BLOCKADE OF MORPHINE ANALGESIA - A DOSE EFFECT 
STUDY OF DURATION AND MAGNITUDE. 

249271 04-02 
ANALGESIA AND HYPERREACTIVITY FOLLOWING MORPHINE 
MICROINJECTION INTO MOUSE BRAIN. 

250062 04-04 
SOME ASPECTS OF THE PHARMACOLOGY OF ANALGESIA. 

252134 04-17 
ANALGESIC 

A STUDY OF THE EFFECT OF D-AMPHETAMINE ON THE TOXICITY, 
ANALGESIC POTENCY AND SWIMMING IMPAIRMENT CAUSED BY 
POTENT ANALGESICS IN MICE. 

226926 01-04 
THE EFFECT OF DIAZEPAM, FLUNITRAZEPAM AND DROPERIDOL WITH AN 
ANALGESIC ON BLOOD-PRESSURE AND HEARTRATE IN MAN. 

232531 01-13 
ANALGESIC EFFECT OF VAGINAL STIMULATION IN RATS: MODULATION 
BY CATECHOLAMINES AND STEROIDS. 

238822 03-03 
THE NARCOTIC DISCRIMINATIVE STIMULUS COMPLEX: RELATION TO 
ANALGESIC ACTIVITY. 

250355 04-03 
DISCRIMINATIVE STIMULUS PROPERTIES OF ANALGESIC DRUGS: 
NARCOTIC VERSUS NONNARCOTIC ANALGESICS. 

253394 04-04 

ANALGESICS 

A STUDY OF THE EFFECT OF DAMPHETAMINE ON THE TOXICITY, 
ANALGESIC POTENCY AND SWIMMING IMPAIRMENT CAUSED BY 
POTENT ANALGESICS IN MICE. 

226926 01-04 
GENERALIZATION OF MORPHINE AND LYSERGIC-ACID-DIETHYLAMIDE 
(LSD) STIMULUS PROPERTIES TO NARCOTIC ANALGESICS. 

244683 04-04 
FURTHER STUDIES ON SELF-ADMINISTRATION OF ANTIPYRETIC 

ANALGESICS AND COMBINATIONS OF ANTIPYRETIC ANALGESICS WITH 
CODEINE IN RHESUS MONKEYS 

246855 04-04 
A COMPARISON OF NARCOTIC ANALGESICS WITH NEUROLEPTICS ON 
BEHAVIORAL MEASURES OF DOPAMINERGIC ACTIVITY. 

249139 04-04 



Psychopharmacology Abstra< 

ACCUMULATION OF CGMP IN STRIATUM OF RATS INJECTED WITH 
NARCOTIC ANALGESICS: ANTAGONISM BY NALTREXONE. 

250362 04 
CROSS-TOLERANCE BETWEEN MORPHINE AND OTHER ANALGESICS. 

251408 0/ 
DISCRIMINATIVE STIMULUS PROPERTIES OF ANALGESIC DRUGS: 
NARCOTIC VERSUS NONNARCOTIC ANALGESICS. 

253394 0^ 

ANALGETIC 

ANALGETIC EFFECTS OF LANTHANUM: CROSS-TOLERANCE WITH 
MORPHINE. 

237870 O: 
ANALOG 

THYROTROPIN-RELEASING HORMONE (TRH) AND ITS BETA-ALANINE 
ANALOG: POTENTIATION OF THE ANTICONVULSANT POTENCY OF 
PHENOBARBITAL IN MICE. 

232618 0: 
PHARMACOLOGICAL IMPLICATIONS OF THE X-RAY STRUCTURE OF A 
RIGID ANALOG OF THE TRICYCLIC ANTIDEPRESSANTS. 

238317 0: 
SOME PHARAAACOLOGICAL PROPERTIES OF CYCLOCHOLINE, A REACT! 
ANALOG OF CHOLINE. 

238828 
POTENCY OF THE N3IM-METHYL ANALOG OF TRH IN THE INDUCTION 
SHAKING MOVEMENTS IN THE RAT. 

250087 

ANALOGS 

CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE II. 

233361 
ACTIONS OF PHENOTHIAZINE ANALOGS ON DOPAMINE SENSITIVE 
ADENYLATE-CYCLjASE in NEURONAL AND GLIAL ENRICHED FRACTIC 
FROM RAT BRAIN. 

237241 
EFFECT OF ANGIOTENSIN-II AND ITS ANALOGS ON UPTAKE AND RELE 
OF C14-5-HYDR0XYTRYPTAMINE BY RAT BRAIN. 

237739 
NOVEL ANALOGS OF TRICYCLIC PSYCHOPHARMACOLOGICAL AGENTS 

238476 
INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY SOME ANALOGS C 
METHIMAZOLE. 

238691 C 
STRUCTURE-ACTIVITY RELATIONSHIPS IN ANALOGS OF DELTA9- 
TETRAHYDROCANNABINOL: TACHYCARDIA VS. ANALGESIA. 

238805 C 
EFFECTS OF SOME DOPAMINE ANALOGS AND HALOPERIDOL ON 
RESPONSE TO STIMULATION OF ADRENERGIC NERVES USING CAT 
ATRIA IN VITRO. 

241313 C 
CORRELATION BETWEEN STRUCTURE, BEHAVIORAL ACTIVITY AND RJ 
OF BIOTRANSFORMATION OF SOME ACTH4-9 ANALOGS. 

246853 C 
RADIOPHARMACEUTICALS. 16. HALOGENATED DOPAMINE ANALOGS. 
SYNTHESIS AND RADIOLABELING OF 6-IODODOPAMINE AND TISSU 
DISTRIBUTION STUDIES IN ANIMALS. 

248537 C 
SYNTHESIS AND BIOLOGICAL ACTIVITY OF NEW 2-SUBSTITUTED 

ANALOGS OF FLUPHENAZINE. 

248538 C 
DRUGS DERIVED FROM CANNABINOIDS. 1. NITROGEN ANALOGS, 

BENZOPYRANOPYRIDINES AND BENZOPYRANOPYRROLES. 

248646 ( 
DRUGS DERIVED FROM CANNABINOIDS. 2. BASIC ESTERS OF NITROG 
AND CARBOCYCLIC ANALOGS. 

248647 ( 
DRUGS DERIVED FROM CANNABINOIDS. 5. DELTA 

TETRAHYDROCANNABINOL AND HETEROCYCLIC ANALOGS 
CONTAINING AROMATIC SIDE-CHAINS. 

248648 ( 
DRUGS DERIVED FROM CANNABINOIDS. 3. SULFUR ANALOGS, 
THIOPYRANOBENZOPYRANS AND THIENOBENZOPYRANS. 

248651 ( 
DRUGS DERIVED FROM CANNABINOIDS. 4. EFFECT OF ALKYL 

SUBSTITUTION IN SULFUR AND CARBOCYCLIC ANALOGS. 

248652 ( 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASl 

THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMIN: 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

248834 ( 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASl 
THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMIN 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

249930 ( 
CONFORMATIONALLY RIGID AMPHETAMINE ANALOGS AS INHIBITOR 
MONOAMINE UPTAKE BY BRAIN SYNAPTOSOMES. 

251700 1 

ANALOGUE 

EFFECTS OF N-HYDROXYETHYL-PYRROLIDINIUM METHIODIDE, A CHO 
ANALOGUE, ON PASSIVE AVOIDANCE BEHAVIOUR IN MICE. 

245594 I 



S-24 



VOLUME 14, SUBJECT INDEX 



Subject Index 



ANALOGUES 

CEREBRAL ARTERIAL SPASM. PART 4-. IN VITRO EFFECTS OF 

TEMPERATURE. SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY, 

243797 04-03 
PRESSOR EFFECTS OF TRYPTAMINE ANALOGUES. 

243798 04-03 
EFFECTS OF INTRAVENTRICULAR P-CHLOROAMPHETAMINE AND ITS 

ANALOGUES ON CEREBRAL 5-HT. 

246151 04-03 
ASSESSMENT OF REINFORCING PROPERTIES OF AMPHETAMINE 
ANALOGUES IN SELF-ADMINISTERING RATS. 

250941 04-04 
ANALOGUES OF S-ADENOSYLHOMOCYSTEINE AS POTENTIAL INHIBITORS 
OF BIOLOGICAL TRANSMETHYLATION. SYNTHESIS OF ANALOGUES 
WITH MODIFICATIONS AT THE 5-THIOETHER LINKAGE. 

251698 04-01 
ANALYSES 

PSYCHOLOGICAL ANALYSES OF PATIENTS SUFFERING FROM 
HYPOTHYROIDISM. 

232364 01-14 
ANALYSIS 

OPERANT ANALYSIS OF BEHAVIOR ASSOCIATED WITH ORAL SELF- 
ADMINISTRATION OF DRUG SOLUTIONS IN RATS. (PH.D. 
DISSERTATION). 

226992 01-04 
ANGIOTENSIN-INDUCED DRINKING IN THE CAT: A DOSE-RESPONSE AND 
BIOCHEMICAL ANALYSIS. (PH.D. DISSERTATION). 

227106 01-04 
ANALYSIS AND DISPLAY OF PSYCHOPHARMACOLOGICAL DATA. 

228978 01-17 
DRUGS AND PSYCHOTHERAPY IN DEPRESSION REVISITED: ISSUES IN THE 
ANALYSIS OF LONG-TERM TRIALS. 

229450 01-09 
BEHAVIOR ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION OF 
BENZODIAZEPINES. 

229461 01-04 
ANALYSIS OF DRUGS AND PSYCHOACTIVE PHENOLIC AMINES. 

229486 01-03 
RELATIONS BETWEEN ORIENTING, PSEUDOCONDITIONED AND 
CONDITIONED RESPONSES IN THE SHUTTLEBOX - A 
PHARMACOLOGICAL ANALYSIS BY MEANS OF LSD AND DIBENAMINE. 

230570 01-04 
BEHAVIORAL ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION 
OF BENZODIAZEPINES. 

232509 01-04 
PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF 
ACTION OF BENZODIAZEPINES. 

232512 01-03 
CHARACTERIZATION OF HYDROGEN BONDING BETWEEN SELECTED 
BARBITURATES AND POLYETHYLENE-GLYCOL-4000 BY IR SPECTRAL 
ANALYSIS. 

233276 02-01 
ANALYSIS OF VARIANCE STUDY OF A SLEEP INDUCING DRUG. 

233698 02-07 
ABUSE OF PSYCHOPHARMACEUTICAL AGENTS IN DRUG DEPENDENCE 
(ANALYSIS OF CASES HOSPITALIZED IN A PSYCHIATRIC DEPARTMENT 
IN THE YEARS 1970 TO 1973). 

234653 02- 17 
BEHAVIORAL AND NEUROPHARMACOLOGICAL ANALYSIS OF 
AMPHETAMINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN 
RATS. 

237718 02-04 
BIOAVAILABILITY ANALYSIS OF CHLORPROMAZINE IN HUMANS FROM 
PUPILOMETRIC DATA. 

237872 02-13 
ELECTRON BEAM IONIZATION MASS FRAGMENTOGRAPHIC ANALYSIS OF 
TRICYCLIC ANTIDEPRESSANTS IN HUMAN PLASMA 

238486 02-16 
GAS CHROMATOGRAPHY MASS FRAGMENTOGRAPHIC (GC-MF) ANALYSIS 
OF TRYPTAMINE IN BIOLOGICAL SAMPLES. 

238774 03-01 
TRIAL OF A NEW THERAPEUTIC AGENT, PERVINCAMINE IN THE 

POSTCONCUSSION SYNDROME OF CRANIAL TRAUMAS: APPLICATION 
OF A DOUBLE-BLIND CONTROL AND SEQUENTIAL ANALYSIS. 

240033 03-11 
ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 
BROMAZEPAM IN CONSCIOUS TRAINED DOGS 

240064 03-03 
AN ANALYSIS OF THE DOUBLE-PULSE TECHNIQUES USE IN MEASURING 
HYPOTHALAMIC REFRACTORY PERIODS IN REWARD NEURONS (PH D 
DISSERTATION). 

241129 03-03 
PHARMACOLOGICAL ANALYSIS OF SOME ADRENOMIMETIC EFFECTS OF 
SEROTONIN. 

241982 03-05 



ANALYSIS OF THE DISCREPANCY IN MAN-AAACHINE TRACKING SYSTEMS 

UNDER CONDITIONS OF DELAYED FEEDBACK. 

242702 03-14 
INTRACAUDATE NEUROTRANSMITTER PROCESSES IN RELATION TO 

RAPHE NEUROTRANSMITTER PROCESSES: A BEHAVIOURAL ANALYSIS 

OF INTRACEREBRALLY APPLIED DRUGS IN ACUTE AND LONG-TERM 

MORPHINE TREATED CATS. 

244215 04-04 
ANALYSIS OF HORMONAL MEDIATION OF DRINKING BEHAVIOR. 

244469 04-04 
LOGICAL ANALYSIS OF THE RESPECTIVE INFLUENCE OF THREE 

EXPERIMENTAL VARIABLES BY MEANS OF A DIAGRAM OF L. CARROLL. 
APPLICATION OF THIS METHOD TO A CLINICAL TRIAL OF TWO FORMS 
OF NOVERIL. 

245971 04-06 
AN ANALYSIS OF THE DRUGS ACTING ON CEREBRAL ENERGY 
METABOLISM. 

247012 04-03 
CHARACTERIZATION OF EEG EFFECTS PRODUCED BY THE INTERACTION 
OF SECOBARBITAL WITH PSYCHOMOTOR STIMULANTS USING 
SPECTRAL ANALYSIS TECHNIQUES. 

249251 04-03 
GLC ANALYSIS OF THIORIDAZINE, MESORIDAZINE AND THEIR 
METABOLITES. 

251776 04-16 
COMPARATIVE ANALYSIS OF PERSISTENT DYSKINESIAS OF LONG TERM 
USAGE WITH NEUROLEPTICS IN FRANCE AND IN JAPAN. 

252181 04-17 
AN EXAMPLE OF EUROPEAN MULTICENTER TRIALS: MULTISPECTRAL 
ANALYSIS OF CLOZAPINE. 

253052 04-08 
ANALYTICAL 

SIMILARITY IN CNS SENSITIVITY TO HEXOBARBITAL IN THE RAT AND 
MOUSE AS DETERMINED BY AN ANALYTICAL, A PHARMACOKINETIC, 
AND AN ELECTROENCEPHALOGRAPHIC MEASURE. 

226865 01 03 
ANALYTICAL STUDY OF ACQUISITION ON FREE-OPERANT AVOIDANCE 
RESPONSE FOR EVALUATION OF PSYCHOTROPIC DRUGS IN RATS. 

238564 02-04 
ANALYZED 

THE EFFECT OF PROBENECID ON CATECHOLAMINE METABOLITES IN 
HUAAAN CEREBROSPINAL FLUID ANALYZED BY MASS 
FRAGMENTOGRAPHY. 

248464 04 13 
ANATOMICAL 

ANATOMICAL ORGANIZATION OF THE PHASIC ACTIVITIES PRODUCED BY 
RESERPINE AT THE LEVEL OF THE OCULOMOTOR SYSTEM. 

238503 02-03 
BEHAVIOURAL AND ANATOMICAL EFFECTS OF 6-OHDA INJECTIONS IN 
THE VENTRAL MESENCEPHALIC TEGMENTUM IN THE RAT. 

244216 04-04 
ANATOMICAL AND BEHAVIORAL EFFECTS OF COLCHICINE 

ADMINISTRATION TO RATS LATE IN UTERO. 

252148 04-05 
ANDROGEN 

RESISTANCE OF ANDROGEN MEDIATED AGGRESSIVE BEHAVIOR IN MICE 
TO FLUTAMIDE, AN ANTIANDROGEN. 

244685 04-04 
AGGRESSIVE BEHAVIOR OF JUVENILE MICE: INFLUENCE OF ANDROGEN 
AND OLFACTORY STIMULI. 

245406 04-04 
EFFECTS OF ESTROGEN AND ANDROGEN ON THE SEXUAL BEHAVIOUR OF 
THE OVARIECTOMIZED EWE, 

248223 04-04 
ANDROGENS 

DIFFERENTIAL EFFECTS OF THE ANTIESTROGEN MER-25 AND OF THREE 
5ALPHA-REDUCED ANDROGENS ON MOUNTING AND LORDOSIS 
BEHAVIOR IN THE RAT. 

244343 04-04 
ANEMIA 

COOMBS-POSITIVE HEMOLYTIC ANEMIA PROVOKED BY 
CHLORPROMAZINE. 

237161 02-15 
ANESTHESIA 

RETROACTIVE AND PROACTIVE EFFECTS OF ANESTHESIA ON FOLLOWING 
IN CHICKS, 

241330 03-04 
ANTIDEPRESSANT DRUGS AND ANESTHESIA. 

247544 04-15 
EFFECTS OF HALOTHANE ANESTHESIA ON THE BIODISPOSITION OF 
KETAMINE IN RATS. 

250108 04-03 
CHANGES OF SKIN NERVE SYMPATHETIC ACTIVITY DURING INDUCTION 
OF GENERAL ANESTHESIA WITH THIOPENTONE IN MAN. 

251071 04-12 
EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251130 04-02 



i33 



"fii 



?© 



h 






S-25 



Subject Index 



Psychopharmacology Abstracts 



ANESTHESIOIOGIC 

ANESTHESIOLOGIC CONSIDERATIONS IN PSYCHIATRIC CONVULSIVE 
THERAPY. 

249765 04-17 

ANESTHETIC ^ ^ 

RELATIONSHIPS BETWEEN ANESTHETIC SUBSTANCES, CONVULSIONS, 
AND PSYCHIC DISTURBANCES 

229118 01-15 

IRREVERSIBLE INACTIVATION OF THE OPIATE RECEPTOR BY THE 
ALKYLATING LOCAL ANESTHETIC W12099. 

238686 03-03 

ANESTHETICS 

LOCAL ANESTHETICS AND BARBITURATES: EFFECTS ON EVOKED 
POTENTIALS IN ISOLATED MAMMALIAN CORTEX. 

237875 02-03 
EFFECTS OF INTRAVENOUS ANESTHETICS ON CONTINUOUS AVOIDANCE 
BEHAVIOR IN THE RAT. 

241314 03-04 

ANESTHETIZED 

RELATIONSHIP BETWEEN SEROTONIN IN THE INTACT BRAIN AND 
RELEASE OF PROTEIN INTO THE PERFUSED CEREBROSPINAL FLUID 
COMPARTMENT OF CONSCIOUS AND ANESTHETIZED RABBITS. 

238681 03-03 
MECHANISM OF VASOCONSTRICTOR ACTION OF DELTA9- 

TETRAHYDROCANNABINOL IN PITHED AND ANESTHETIZED RATS. 

238809 03-03 
MEASUREMENTS OF BRAIN AMOBARBITAL CONCENTRATIONS IN RATS 
ANESTHETIZED AND OVERDOSED WITH AMOBARBITAL AND TREATED 
CENTRALLY WITH DIBUTYRYL-CYCLIC-AMP. 

248276 04-03 
ANGIOTENSIN 

SOME ASPECTS OF THE ROLES OF ISOPROTERENOL, ANGIOTENSIN AND 
THE PERIPHERAL NERVOUS SYSTEM IN THIRST. (PH.D. DISSERTATION). 

228493 01-03 
•ANGIOTENSIN-II 

EFFECT OF ANGIOTENSIN-II AND ITS ANALOGS ON UPTAKE AND RELEASE 
OF C14-5HYDR0XYTRYPTAMINE BY RAT BRAIN. 

237739 02-03 
THE EFFECT OF SUBFORNICAL ORGAN LESIONS AND VENTRICULAR 
BLOCKADE ON DRINKING INDUCED BY ANGIOTENSIN-II 

252170 04-03 
ANGIOTENSIN-INDUCED 

ANGIOTENSIN-INDUCED DRINKING IN THE CAT: A DOSE-RESPONSE AND 
BIOCHEMICAL ANALYSIS. (PH.D. DISSERTATION). 

227106 01-04 

ANIMAL 

ANIMAL PHARMACOLOGY OF VILOXAZINE (VIVALAN). 

227208 01-02 
THE CLINICAL APPLICATION OF LABORATORY ANIMAL EXPERIMENTAL 
FINDINGS: TREATMENT OF HYPERSEXUALIZED BEHAVIOR IN A MALE. 

229037 01-11 
CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
RELAY TOXICITY: A NEW APPROACH TO A METHODOLOGY OF 

EVALUATING THE TOXICITY OF ADDITIVES TO FARM ANIMAL FEED. 

245114 04-06 
FLUPHENAZINE: DIFFICULTIES AND LIMITATIONS IN ANIMAL 
EXPERIMENTATION WITH NEUROLEPTIC SUBSTANCES. 

247151 04-04 
USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) IN 
NEUROPHARMACOLOGICAL STUDIES 

250071 04-06 
COMPARISON OF THE APPARENT ANTIDEPRESSANT ACTIVITY OF (-) AND 
( I ) TRANYLCYPROMINE IN AN ANIMAL MODEL. 

250376 04-03 

ANIMALS 

EVALUATING POTENTIAL ANTIDEPRESSANTS IN ANIMALS. 

227207 01-06 
CHEMISTOR: A REUSABLE TELESTIMULATION DEVICE FOR DIRECT 
CHEMICAL STIMULATION OF THE NONHUMAN PRIMATE BRAIN IN 
FREELY MOVING ANIMALS 

237270 02-06 
CLONAZEPAM-INDUCED CHANGES IN 5-HYDROXYTRYPTAMINE (5-HT) 
METABOLISM IN ANIMALS AND MAN, 

237977 02 13 
NEUROHUMORAL MECHANISMS RELATING TO CIRCADIAN SLEEP- 
WAKEFULNESS CYCLES OF HUMORAL EXPERIMENTAL ANIMALS. 

238971 03-03 
CHANGES IN THE PHARMACODYNAMICS AND PHARMACOKINETICS OF 
PSYCHOLEPnC DRUGS IN RADIATION SICKNESS. EFFECT OF X-RAY 
RADIATION ON PHARMACODYNAMIC ACTIVITY OF NITRAZEPAM IN 

ANIMALS. 

240237 03-04 

CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER). 

240241 03-04 



EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS. 4TH 
REPORT COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIAAALS AND MAN. (UNPUBLISHED PAPER 

243024 04-17 
RADIOPHARMACEUTICALS. 16. HALOGENATED DOPAMINE ANALOGS. 
SYNTHESIS AND RADIOLABELING OF 6-IODODOPAMINE AND TISSUE 
DISTRIBUTION STUDIES IN ANIMALS. 

248537 0401 

A REVIEW OF THE CNS EFFECTS OF FENFLURAMINE, 780SE AND 
NORFENFLURAMINE ON ANIMALS AND MAN. 

250935 04-17 

ANORECTIC 

FENFLURAMINE AND 5-HYDROXYTRYPTAMlNE. PART 2: INVOLVEMENT 
OF BRAIN AND 5-HYDROXYTRYPTAMINE IN THE ANORECTIC ACTIVITY 
OF FENFLURAMINE. 

237119 02-03 

DO ANORECTIC DRUGS PRODUCE WEIGHT LOSS BY APPETITE 
SUPPRESSION?. 

240802 03-13 

ANORECTIC DRUrS. 

243869 04-11 

DIFFERENTIAL EFFECTS OF ALPHA MT ON ANORECTIC AND 
STIMULATORY ACTION OF AMPHETAMINES. 

247729 04-02 
ON THE IN VIVO AND IN VITRO ACTIONS OF FENFLURAMINE AND ITS 
DERIVATIVES ON CENTRAL MONOAMINE NEURONS, ESPECIALLY 5- 
HYDROXYTRYPTAMINE NEURONS, AND THEIR RELATION TO THE 
ANORECTIC ACTIVITY OF FENFLURAMINE. 

250937 04-03 

ANORECTICS 

THE EFFECT OF SELECTIVE LESIONING OF BRAIN CATECHOLAMINE 

CONTAINING NEURONS ON THE ACTIVITY OF VARIOUS ANORECTICS IN 

^^^^^ 237742 02-03 

ANOREXIA 

CATECHOLAMINERGIC MECHANISMS OF THE LATERAL HYPOTHALAMUS: 
THEIR ROLE IN THE MEDIATION OF AMPHETAMINE ANOREXIA. 

232610 02-03 
INHIBITION OF DRUG-INDUCED ANOREXIA IN RATS BY METHYSERGIDE. 

237745 02-04 
FAILURE OF DEPLETION OF RAT BRAIN 5-HYDROXYTRYPTAMINE TO 
ALTER FENFLURAMINE-INDUCED ANOREXIA. 

237748 02-03 
ATTENUATION OF AMPHETAMINE ANOREXIA BY UNILATERAL NIGRAL 

STRIATAL LESIONS. 

237777 02-03 

PROLACTIN AND GONADOTROPHIN ACTIVITY IN FEMALES TREATED FOR 

ANOREXIA NERVOSA. 

240423 03-11 
ON GROWTH HORMONE REGULATION IN ANOREXIA NERVOSA BEFORE 

AND AFTER PHENOTHIAZINE TREATMENT. 

243193 04-10 
SOMATIC ORIENTED TREATMENT OF ANOREXIA NERVOSA, 

243194 04-10 
THE ROLES OF MONOAMINE NEURAL SYSTEMS IN THE ANOREXIA 

INDUCED BY ( n AMPHETAMINE AND RELATED COMPOUNDS. 

246149 04-03 
AMANTADINE DECREASES D-AMPHETAMINE STIMULATION AND 
INCREASES D-AMPHETAMINE ANOREXIA IN MICE. 

249459 0403 
HYPOTHALAMIC LESIONS AND DRUG-INDUCED ANOREXIA. 

250938 04-03 
ANOREXIA AND CONDITIONED TASTE AVERSIONS IN THE RAT. 

251629 04-05 
EFFECTS OF LILLY-1 10140, A SPECIFIC INHIBITOR OF 5- 

HYDROXYTRYPTAMINE UPTAKE, ON FOOD INTAKE AND ON 5- 
HYDROXYTRYPTOPHAN-INDUCED ANOREXIA. EVIDENCE FOR 
SEROTONINERGIC INHIBITION OF FEEDING. 

252522 04-03 

ANOREXIC 

OLFACTORY BULB REMOVAL IN MICE: ACTIVITY LEVELS AND 

RESPONSIVENESS TO THE LOCOMOTOR STIMULANT AND ANOREXIC 
PROPERTIES OF D-AMPHETAMINE SULFATE. (PH.D. DISSERTATION) 

227074 01-04 
CYPROHEPTADINE: WEIGHT GAIN AND APPETITE STIMULATION IN 
ESSENTIAL ANOREXIC ADULTS. 

237900 02- 10 

COMP/^RISONS BETWEEN THE BEHAVIOURAL AND ANOREXIC EFFECTS OF 
780SE AND OTHER PHENYLETHYLAMINES IN THE RAT. 

250939 04-02 

ANOREXIGENIC 

THE DURATION OF TOLERANCE TO THE ANOREXIGENIC EFFECT OF 

AMPHETAMINE IN RATS. 245298 04-03 



S-26 



VOLUME 14, SUBJECT INDEX 



Subject Index 



SUBJECTIVE EFFECTS OF TWO ANOREXIGENIC AGENTS - FENFLURAMINE 
AND AN 448 IN NORMAL SUBJECTS. 

250945 04-07 
BEHAVIOURAL EFFECTS OF A NEW NONPHENYLETHYLAMINE 
ANOREXIGENIC AGENT; MAZINDOL. 

252030 04-04 
EFFECTS OF MAZINDOL, A NONPHENYLETHYLAMINE ANOREXIGENIC 
AGENT, ON BIOGENIC AMINE LEVELS AND TURNOVER RATE. 

252201 04-03 
KNOXrC 

CYCLIC EEG CHANGES IN SUBACUTE SPONGIFORM AND ANOXIC 
ENCEPHALOPATHY. 

235563 02-13 
\NTAGONISES 

LITHIUM DIFFERENTIALLY ANTAGONISES SELF-STIMULATION 
FACILITATED BY MORPHINE AND ( t ) AMPHETAMINE. 

249486 04-03 
ANTAGONISM 

A STUDY OF INHIBITORY ANTAGONISM IN CAT VISUAL CORTEX. 

226397 01-03 
ANTAGONISM OF D-LYSERGIC ACID DIETHYLAMIDE AND MESCALINE BY 
1 METHYL 1,2,5,6 TETRAHYDROPYRIDINE N,N DIETHYLCARBOXAMIDE 
(THPC). 

230453 01-03 
ANTAGONISM OF APOMORPHINE AND D-AMPHETAMINE-INOUCED 
STEREOTYPED BEHAVIOUR BY INJECTION OF LOW DOSES OF 
HALOPERIOOL INTO THE CAUDATE-NUCLEUS AND THE NUCLEUS- 
ACCUMBENS. 

237704 02-04 
METHAMPHETAMINE WITHDRAWAL AS A MODEL FOR THE DEPRESSIVE 
STATE: ANTAGONISM OF POST-AMPHETAMINE DEPRESSION BY 
IMIPRAMINE. 

237976 02-03 
CESIUM ION: ANTAGONISM TO CHLORPROMAZINE AND L-DOPA 
PRODUCED BEHAVIOURAL DEPRESSION IN MICE. 

238318 02-04 
STUDIES ON MODE OF ANTAGONISM BETWEEN ADRENERGIC BETA- 
MIMETICS AND BETA-BLOCKING AGENTS (I). BETA-BLOCKING ACTION 
OF MESCALINE AND ITS DERIVATIVES. 

238563 02-03 
NALOXONE ANTAGONISM OF CONDITIONAL REVERSAL OF NARCOTIC 
WITHDRAWAL SIGNS AND CONDITIONAL MORPHINE HYPERTHERMIA: 
AN INDIRECT EVIDENCE FOR RELEASE OF ENDOGENOUS OPIOID-LIKE 
SUBSTANCE IN THE RAT. 

238713 03-04 
ANTAGONISM BY METHYSERGID AND CINANSERIN OF THE 
ANTINOCICEPTIVE ACTION OF MORPHINE ADMINISTERED INTO THE 
PERIAQUEDUCTAL GRAY. 

239576 03-04 
THE SUPPRESSION OF BEHAVIOUR IN RATS BY PREVIOUS EXPERIENCE 
AND ELECTRIC SHOCK AND ITS ANTAGONISM BY ATROPINE. 

245305 04-04 
ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE APPLIED 
INTRACEREBRALLY TO THE NUCLEUS-ACCUMBENS SEPTI BY TYPICAL 
NEUROLEPTICS AND BY CLOZAPINE, SULPIRIDE AND THIORIDAZINE. 

248290 04-06 
NEUROLEPTIC ANTAGONISM OF DYSKINETIC PHENOMENA. 

248407 04-04 
DRUG ANTAGONISM AND REVERSIBILITY OF THE BINDING OF 
INDOLEAMINES IN BRAIN. 

250081 04-03 
LIMITING FACTORS IN THE ANTAGONISM OF NEUROLEPTICS ON 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE. 

250359 04-03 
ACCUMULATION OF CGMP IN STRIATUM OF RATS INJECTED WITH 
NARCOTIC ANALGESICS: ANTAGONISM BY NALTREXONE. 

250362 04-03 
ANTAGONISM BY SULPIRIDE OF THREE APOMORPHINE-INDUCED EFFECTS 
IN RODENTS. 

252032 04-04 
COCAINE AND LITHIUM: NEUROBIOLOGICAL ANTAGONISM IN THE 
SEROTONIN BIOSYNTHETIC SYSTEM IN RAT BRAIN. 

252514 04-03 
SEROTONIN ANTAGONISM IN ISOLATED CANINE CEREBRAL ARTERIES 

252757 04-03 
INTERRELATIONSHIP BETWEEN CATECHOLAMINE STIMULATED 

FORMATION OF ADENOSINE 3,5 MONOPHOSPHATE IN CEREBELLAR 
SLICES AND INHIBITORY EFFECTS ON CEREBELLAR PURKINJE CELLS: 
ANTAGONISM BY NEUROLEPTIC COMPOUNDS. 

253109 04-03 
ANTAGONISMS 

ANTAGONISMS BY NEUTRAL AMINO-ACIDS (NAA) OF THE HYPOTHERMIC 
EFFECT OF D-AMPHETAMINE (AMP). 

238726 03-03 
ANTAGONIST 

STRUCTURE-ACTIVITY RELATIONSHIPS FOR AGONIST AND ANTAGONIST 
DRUGS AT PRESYNAPTIC AND POSTSYNAPTIC RECEPTOR SITES IN RAT 
BRAIN 

229435 01-03 



THE MECHANISMS BY WHICH METHIOTHEPIN, A PUTATIVE SEROTONIN 
RECEPTOR ANTAGONIST, INCREASES BRAIN 5-HYDROXYINDOLE 
LEVELS. 

233290 02-03 
IS METOCLOPRAMIDE A DIRECTLY ACTING DOPAMINE RECEPTOR 
ANTAGONIST?. 

241929 03-03 
THE DOPAMINE RECEPTOR: DIFFERENTIAL BINDING OF D-LSD AND 
RELATED AGENTS TO AGONIST AND ANTAGONIST STATES. 

247862 04-03 
SOME EFFECTS OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A 
PURPORTED HASHISH AND LSD ANTAGONIST, ON BRAIN 
NORADRENERGIC AND SEROTONERGIC SYSTEMS. 

251534 04-03 
ANTAGONISTIC 

L-DOPA, AMINOPHYLLINE, EPHEDRINE: ANTAGONISTIC INTERACTION 
WITH ETHANOL IN HUMANS. 

238748 03-13 
ANTAGONISTIC EFFECTS OF GABA AND BENZODIAZEPINES ON 
VESTIBULAR AND CEREBELLAR NEURONES. 

240523 03-03 
USE OF THE MOUSE JUMPING TEST FOR ESTIMATING ANTAGONISTIC 
POTENCIES OF MORPHINE ANTAGONISTS. 

250354 04-04 
ANTAGONISTS 

EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS ON SCHEDULE- 
INDUCED WATER AND MORPHINE INGESTION, 

233292 02-04 
SPECIFIC EFFECTS OF NEUROTRANSMITTER ANTAGONISTS ON GANGLION 
CELLS IN RABBIT RETINA, 

236863 02-03 
EFFECT OF MORPHINE ANTAGONISTS ON DRUG INDUCED HYPOTHERMIA 
IN MICE AND RATS, 

237100 02-03 
EFFECTS OF MORPHINE AND NARCOTIC ANTAGONISTS ON AVOIDANCE 
BEHAVIOR OF THE SQUIRREL-MONKEY. 

237754 02-04 
COMPARISON OF BICUCULLINE METHOCHLORIDE WITH BICUCULLINE 
AND PICROTOXIN AS ANTAGONISTS OF AMINO-ACID AND 
MONOAMINE DEPRESSION OF NEURONES IN THE RAT BRAINSTEM. 

237783 02-03 
lONTOPHORETIC APPLICATION OF ANTAGONISTS TO PUTATIVE 
TRANSMITTERS ON VESTIBULAR UNITS INVOLVED IN A SPECIFIC 
INHIBITORY INTERACTION. 

238823 03-03 
COMPARISON OF WITHDRAWAL PRECIPTATING PROPERTIES OF VARIOUS 
MORPHINE ANTAGONISTS AND PARTIAL AGONISTS IN RELATION TO 
THEIR STEREOSPECIFIC BINDING TO BRAIN HOMOGENATES. 

239854 03-03 
A BEHAVIORAL PARADIGM FOR THE EVALUATION OF NARCOTIC 
ANTAGONISTS. 

239941 03-11 
SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF 
PHYSICAL DEPENDENCE IN RATS: I, COMPARISON OF PRECIPITATED 
MORPHINE WITHDRAWAL AFTER INTRAPERITONEAL AND 
INTRAVENTRICULAR INJECTION OF MORPHINE ANTAGONISTS, 

241223 03-04 
DIAZEPAM AND CHLORDIAZEPOXIDE: POWERFUL GABA ANTAGONISTS IN 
EXPLANTS OF RAT CEREBELLUM, 

244205 04-03 
DECREASE IN RAT STRIATAL ACETYLCHOLINE LEVELS BY SOME DIRECT 
AND INDIRECT ACTING DOPAMINERGIC ANTAGONISTS. 

248410 04-03 
ON THE SPECIFICITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS IN THE 
RAT CEREBRAL CORTEX 

248725 04-03 
EEG AND BEHAVIORAL EFFECTS OF NARCOTIC ANTAGONISTS ALONE AND 
IN COMBINATION WITH OTHER PSYCHOACTIVE DRUGS IN MORPHINE- 
DEPENDENT MACACA-MULATTA 

249267 04-04 
CORRELATIONS BETWEEN THE ACTIVITY OF DIMETHYLTRYPTAMINES AS 
5 HYDROXYTRYPTAMINE ANTAGONISTS AND THEIR QUANTUM 
CHEMICAL PARAMETERS. 

249318 04-03 
MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE: INFLUENCE OF 
CHOLINERGIC AGONISTS AND ANTAGONISTS 

250079 04-04 
USE OF THE MOUSE JUMPING TEST FOR ESTIMATING ANTAGONISTIC 
POTENCIES OF MORPHINE ANTAGONISTS, 

250354 04 04 
5-HT ANTAGONISTS IN RAT HIPPOCAMPUS, 

251072 04-03 
EFFECT OF DOPAMINE AGONISTS AND ANTAGONISTS ON ASYMMETRIC 
BEHAVIOUR OCCURRING DURING PRECIPITATED MORPHINE 
WITHDRAWAL AFTER UNILATERAL INACTIVATION OF THE STRIATUM 
IN RATS, 

251402 04-04 



00 

331 

« 



i 

h 

i 

3K 



S-27 



Subject Index 



Psychopharmacology Abstracts 



ON THE ABILITY Of NARCOTIC ANTAGONISTS TO PRODUCE THE 
NARCOTIC CUE 

251429 04-03 
EFFECTS OF ALPHA ADRENOCEPTOR AGONISTS AND ANTAGONISTS OF 
PRE AND POSTSYNAPTICALLY LOCATED ALPHA-ADRENOCEPTORS. 

252025 04-03 
ANTI-HLA 

INTERFERENCE BETWEEN ANTLHLA ANTIBODIES AND CHLORPROMAZINE. 

250476 04-07 
ANTIACETYLCHOIINE 

ANTIACETYLCHOLINE ACTIVITIES OF PSYCHOACTIVE DRUGS: A 

COMPARISON OF THE (3H)QUINUCLIDINYL BENZILATE BINDING ASSAY 
WITH CONVENTIONAL METHODS. 

250360 04-02 
REVERSAL BY A CENTRAL ANTIACETYLCHOLINE DRUG OF PIMOZIDE- 
INDUCED INHIBITION OF MOUSE JUMPING IN AMPHETAMINE DOPA 
TREATED MICE. 

250656 04-03 
ANTIANDROGEN 

RESISTANCE OF ANDROGEN MEDIATED AGGRESSIVE BEHAVIOR IN MICE 
TO FLUTAMIDE, AN ANTIANDROGEN. 

244685 04-04 
47-XYY AND 46-XY MALES WITH ANTISOCIAL AND/OR SEX OFFENDING 
BEHAVIOR: ANTIANDROGEN THERAPY PLUS COUNSELING. 

248222 04-10 
ANTIANESTHETIC 

COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYL- 
CYCLIC-AMP AND ANALEPTIC DRUGS ON AMOBARBITAL-INDUCED 
NARCOSIS IN THE RAT. 

252221 04-03 
ANTIANXIETY 

A SINGLE DOSE ANTIANXIETY DRUG: A REPORT FROM THE GENERAL 
PRACTITIONER RESEARCH GROUP. 

227914 01-10 
A COMBINATION OF ANTIANXIETY DRUGS: REPORT FROM THE GENERAL 
PRACTITIONER RESEARCH GROUP 

228207 01-10 
CLINICAL USE OF ANTIANXIETY DRUGS. 

237165 02-10 
EFFECTS OF BENZODIAZEPINE ANTIANXIETY AGENTS ON PUNISHED 
(CONFLICT) AND UNPUNISHED BEHAVIOR IN DRUG-NAIVE RATS. 

238697 03-04 
THE EFFECT OF DL 254 ON THE PHARMACOLOGICAL ACTIVITIES OF D- 
AMPHETAMINE AND APOMORPHINE: A COMPARISON WITH 
ANTIANXIETY AND NEUROLEPTIC AGENTS. 

238846 03-03 
EFFECTS OF ANTIANXIETY DRUGS ON CEREBRAL MONOAMINE 
TURNOVER. 

241392 03-03 
MEDICAL PRACTICE WITHOUT ANTIANXIETY DRUGS. 

245524 04-17 
THE ANTINICOTINIC EFFECTS OF DRUGS WITH CLINICALLY USEFUL 
SEDATIVE ANTIANXIETY PROPERTIES. 

248009 04-03 
EFFECTS OF ANTIANXIETY DRUGS ON FOOD INTAKE IN TRAINED AND 
UNTRAINED RATS AND MICE. 

249678 04-04 

ANTIAUTISTIC 

ANTIAUTISTIC EFFECT OF FLUPENTHIXOL. 

227771 01-08 
ANTIBIOTICS 

ANTIBIOTICS AND MEMORY. 

239673 03-04 
ANTIBODIES 

BEHAVIORAL CHANGES IN 2-MONTH-OLD RATS FOLLOWING PRENATAL 
EXPOSURE TO ANTIBODIES AGAINST SYNAPTIC MEMBRANES. 

226186 01-04 
ANTINUCLEAR ANTIBODIES IN PSYCHIATRIC ILLNESS: THEIR 
RELATIONSHIP TO DIAGNOSIS AND DRUG TREATMENT. 

228208 01-15 
ANTINUCLEAR ANTIBODIES IN CHRONIC PSYCHOTIC PATIENTS TREATED 

WITH CHLORPROMAZINE. 

232865 02-15 
ISOLATION OF LYSERGIDE (LSD) WITH AGAROSE BOUND ANTIBODIES TO 
LYSERGIC-ACID ACID. 

233278 02-01 
EFFECT OF ANTIPHENOBARBITAL ANTIBODIES ON SLEEPING TIME 
INDUCED BY CYCLOBARBITAL TO MICE. 

241403 03-03 
INTERFERENCE BETWEEN ANTI-HLA ANTIBODIES AND CHLORPROMAZINE. 

250476 04-07 
ANTIBODY 

EVIDENCE FOR A DOPAMINE RECEPTOR ANTIBODY. 



ANTICARCINOGENIC 

ARE NEUROLEPTIC DRUGS ANTICARCINOGENIC?. 



238736 03-03 
241736 03-15 



ANTICHOLINERGIC 

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF 
TRICYCLIC ANTIDEPRESSANTS. 

226411 01-09 
STUDIES ON THE ACTION OF AN ANTICHOLINERGIC IN COMBINATION 
WITH A TRANQUILIZER ON GASTRIC JUICE SECRETION IN MAN. 

232503 01-13 
ALTERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS AFTER CHRONIC HALOPERIDOL: INDIRECT EVIDENCE FOR 
CHOLINERGIC HYPOSENSITIVITY. 

239826 03-04 
ANTICHOLINERGIC ACTIVITY OF ANTIPSYCHOTIC DRUGS IN RELATION TO 
THEIR EXTRAPYRAMIDAL EFFECTS. 

252520 04-05 
ANTICOAGULANT 

CHANGES IN ANTICOAGULANT TOLERANCE: I. INFLUENCE OF SEDATIVES 
AND PSYCHOPHARMACEUTICALS. 

235336 02- 15 
ANTICONVULSANT 

EVIDENCE FOR AN INVOLVEMENT OF GABA IN THE MEDIATION OF THE 
CEREBELLAR CGMP DECREASE AND THE ANTICONVULSANT ACTION OF 
DIAZEPAM. 

226857 01-03 
THYROTROPIN-RELEASING HORMONE (TRH) AND ITS BETA-ALANINE 
ANALOG: POTENTIATION OF THE ANTICONVULSANT POTENCY OF 
PHENOBARBITAL IN MICE. 

232618 02-03 
THE INFLUENCE OF PSYCHOTROPIC AND ANTICONVULSANT AGENTS ON 
CONFORMANT TRANSITIONS IN THE TRANSPORT ATPASE. 

236715 02-03 
METABOLISM, DISTRIBUTION AND ANTICONVULSANT PROPERTIES OF 
N N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT. 

237758 02-03 
ANTICONVULSANT ACTIVITY OF NEWER SUBSTITUTED TRIAZOLES. 

238712 03-03 
INHIBITION OF NEURONAL SEROTONIN (5-HT) UPTAKE AND THE 
ANTICONVULSANT ACTION OF TRIMETHADIONE (TMD). 

238753 03-03 
SYNTHESIS OF SUBSTITUTED THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION OF CELLULAR RESPIRATORY AND MONOAMINE-OXIDASE 
ACTIVITIES AND ANTICONVULSANT PROPERTY. 

239661 03-03 
ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF 

NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS BY 
10-2-ARYLIMIN0-3-ACETYLAMIN0-4-THIAZ0LID0NYL PHENOTHIAZINES. 

239662 03-03 
EFFECTS OF ANTICONVULSANT AND CONVULSANT DRUGS ON THE 

ATPASE ACTIVITIES OF SYNAPTOSOMES AND THEIR COMPONENTS. 

243801 04-03 
OSTEOMALACIA ASSOCIATED WITH ANTICONVULSANT DRUG THERAPY 
IN MENTALLY RETARDED CHILDREN. 

245806 04-15 
ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED WITH THREE OTHER DRUGS. 

248283 04-02 
ANTIDEPRESSANT AND ANTICONVULSANT ACTIVITY OF PHENYL-4-0X0-2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED PIPERAZINES. 

251701 04-01 
THE INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES. 

252711 04-03 

ANTICONVULSANTS 

COMPARISON OF SERUM LEVELS AND URINARY EXCRETION OF THREE 
MAJOR ANTICONVULSANTS BETWEEN CHILDREN AND ADULTS. 

233832 02-13 
MECHANISM OF ACTION OF ANTICONVULSANTS: ROLE OF THE 
DIFFERENTIAL EFFECTS ON THE ACTIVE UPTAKE OF PUTATIVE 
NEUROTRANSMITTERS. 

237140 0203 

ANTICONVULSIVE 

EFFECT OF CONVULSIONS AND ANTICONVULSIVE DRUGS ON 
CEREBROSPINAL FLUID CYCLIC-AMP IN RABBITS. 

239090 03-03 
ANTIDEPRESSANT 

SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH PARTICULAR 
REFERENCE TO DOTHIEPIN. 

226897 01-15 
VILOXAZINE (VIVALAN) - A NEW ANTIDEPRESSANT. 

227224 01-09 
A CENTRAL-NERVOUS-SYSTEM DEPRESSANT ANTIDEPRESSANT. 

227695 01-0: 
DOXEPIN, A NEW ANTIDEPRESSANT DRUG FOR PATIENTS IN THE 
INTERNAL MEDICINE CLINIC. 

229515 Otic 
THE PHARMACOLOGIC MEANING OF SUCCESSFUL ANTIPSYCHOTIC 
ANTIDEPRESSANT COMBINATIONS. 

230010 01-11 



S-28 



VOLUME 14, SUBJECT INDEX 



Subject Index 



CLINICAL EXPERIENCES WITH ANTIDEPRESSANT DRUGS IN THE 
TREATMENT OF ANXIOUS PHOBIC PATIENTS. 

230015 0110 
POISONING BY TRICYCLIC ANTIDEPRESSANT DRUGS: GENERAL AND 
PHARMACOKINETIC CONSIDERATIONS 

230820 01-15 
A CLINICAL TRIAL WITH NOMIFENSIN, A NEW ANTIDEPRESSANT DRUG. 

231035 01-09 
THE USE OF ANTIDEPRESSANT DRUGS IN SCHIZOPHRENIA. 

231277 01-08 
TRICYCLIC ANTIDEPRESSANT OVERDOSE: CLINICAL PRESENTATION AND 
PLASMA LEVELS. 

231318 0113 
STUDIES ON THE MECHANISM OF ACTION OF TRICYCLIC 
ANTIDEPRESSANT DRUGS, USING IPRINDOLE AS A TOOL (PH D 
DISSERTATION). 

231438 01-03 
NOREPINEPHRINE METABOLISM AFTER SHORT-TERM AND LONG-TERM 
ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANT DRUGS AND 
ELECTROCONVULSIVE SHOCK. 

234804 02-03 
THYROTROPIN-RELEASING HORMONE (TRH) AS A POSSIBLE QUICK- 
ACTING BUT SHORT-LASTING ANTIDEPRESSANT. 

235630 02-09 
INVESTIGATION OF THE MECHANISM OF ACTION OF THE NEW 
ANTIDEPRESSANT PYRAZIDOL. 

236369 02-03 
AMITRIPTYLINE IN THE PROPHYLAXIS OF MIGRAINE: EFFECTIVENESS AND 
RELATIONSHIP ON ANTIMIGRAINE AND ANTIDEPRESSANT EFFECTS. 

237138 02-11 
BASIC DERIVATIVES OF 6,7 DIHYDROINDOLOBENZAZEPINE AND 6H 
INDOLOBENZOXAZEPINE AS POTENTIAL ANTIDEPRESSANT AGENTS. 

237834 02-02 
EVALUATION OF CESIUM CHLORIDE AS ANTIDEPRESSANT. 

238836 03-03 
PHARMACOLOGY OF R-806, A TETRACYCLIC ANTIDEPRESSANT. 

238837 03-03 
PHARMACOLOGICAL STUDIES WITH HP-505, A POTENTIAL 

ANTIDEPRESSANT COMPOUND. 

238839 03-03 
RELATIONSHIP BETWEEN ANTIDEPRESSANT EFFECT AND PLASMA LEVEL 
OF NORTRIPTYLINE. CLINICAL STUDIES. 

240217 03-09 
EXPLORATION OF THE ANTIDEPRESSANT POTENTIAL OF IPRINDOLE. 

241241 03-04 
ANTIDEPRESSANT PREDICTABILITY: CARTAZOLATE. 

242251 03-09 
CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, ICI-58834. 

244189 04-07 
THE EFFECTS OF TANDAMINE, A NEW POTENTIAL ANTIDEPRESSANT 
AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED 
ACTIVITIES. 

244316 04-02 
THE DRUG TREATMENT OF MOOD DISORDERS. PART IF ANTIMANIC AND 
ANTIDEPRESSANT AGENTS, MAINTENANCE TREATMENT, AND RECENT 
ADVANCES. (UNPUBLISHED PAPER). 

244574 04-09 
ACTION OF VARIOUS ANTIDEPRESSANT TREATMENTS REDUCES 

REACTIVITY OF NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM 
IN LIMBIC FOREBRAIN. 

245115 04-03 
NEUROCHEMICAL AND PHARMACOLOGICAL STUDIES ON A NEW 5-HT 
UPTAKE INHIBITOR, FG4963, WITH POTENTIAL ANTIDEPRESSANT 
PROPERTIES. 

245296 04-03 
DEPRESSION AND ANTIDEPRESSANT DRUGS, 

245646 04-09 
ANTIDEPRESSANT DRUGS AFFECT DOPAMINE UPTAKE. 

247021 04-03 
EFFECTS OF ANTIDEPRESSANT DRUGS ON AMYGDALOID AFTER- 
DISCHARGE IN RATS 

247039 04-03 
EFFICACY AND TOLERANCE LIMITS IN THE USE OF ANTIDEPRESSANT 
DRUGS. 

247543 04-09 
ANTIDEPRESSANT DRUGS AND ANESTHESIA. 

247544 04-15 
A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF A NEW 

ANTIDEPRESSANT AGENT, MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE CHLORHYDRATE (CIBA 34276BA). 

247554 04-09 
3ARYLQUIN0LIZIDINES, POTENTIAL ANTIDEPRESSANT AGENTS. 

247586 04-01 
CLINICAL EVALUATION OF CDP-CHOLINE (NICHOLIN): EFFICACY AS 
ANTIDEPRESSANT TREATMENT, 

247969 04-09 
MEMORY FUNCTIONS IN DEPRESSION: IMPROVEMENT WITH 
ANTIDEPRESSANT MEDICATION, 

248583 04-09 



CONTROLLED CLINICAL TRIAL OF A NEW ANTIDEPRESSANT (ORG-GB-94) 
OF NOVEL CHEMICAL FORMULATION. 

248977 04-09 
DEVELOPMENT OF THE INFLUENCES OF SODIUM, CATECHOLAMINE AND 
TRICYCLIC ANTIDEPRESSANT DRUG ON THE UPTAKE OF 3H-5 
HYDROXYTRYPTAMINE BY RAT BRAIN SYNAPTOSOMES. 

249667 04-03 
COMPARISON OF THE APPARENT ANTIDEPRESSANT ACTIVITY OF (-) AND 
( -H ) TRANYLCYPROMINE IN AN ANI/WAL MODEL. 

250376 04-03 
THE ENDOGENOUS NEUROTIC DISTINCTION AS A PREDICTOR OF 
RESPONSE TO ANTIDEPRESSANT DRUGS. 

250726 04-11 
PSYCHOMETRIC ASSESSMENT OF THE THERAPEUTIC EFFICIENCY OF 
ANTIDEPRESSANT AGENTS. 

251004 04-10 
EFFECTS OF ALPHA-RECEPTOR BLOCKERS AND ANTIDEPRESSANT DRUGS 
ON THE PRESYNAPTIC ALPHA-RECEPTOR OF RAT CEREBRAL CORTEX. 

251394 04-03 
CHEMISTRY AND PHARMACOLOGY OF DIV-154, A NEW POTENTIAL 
NONTRICYCLIC ANTIDEPRESSANT COMPOUND. 

251407 04-17 
ANTIDEPRESSANT AND ANTICONVULSANT ACTIVITY OF PHENYL-4-0X0-2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED PIPERAZINES. 

251701 04-01 
THE EFFECT OF TRICYCLIC ANTIDEPRESSANT COMPOUNDS ON PATIENTS 
WITH PASSIVE-DEPENDENT PERSONALITY TRAITS, 

251717 04-11 
THE RELATIONSHIP BETWEEN ACETYLATOR STATUS AND INHIBITION OF 
MONOAMINE-OXIDASE, EXCRETION OF FREE DRUG AND 
ANTIDEPRESSANT RESPONSE IN DEPRESSED PATIENTS ON PHENELZINE. 

251985 04-10 
A COMPARISON OF ANTIDEPRESSANT MEDICATIONS IN NEUROTIC AND 
PSYCHOTIC PATIENTS 

253641 04-11 
ANTIDEPRESSANT TREATMENT WITH MAPROTILINE IN THE 

MANAGEMENT OF EMOTIONAL DISTURBANCES IN PATIENTS WITH 
ACUTE MYOCARDIAL INFARCTION: A CONTROLLED STUDY, 

253684 04 11 
ANTIDEPRESSANTS 

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF 
TRICYCLIC ANTIDEPRESSANTS. 

226411 01-09 
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON DRUG METABOLISM, 

226829 01-13 
INTERACTIONS OF TRICYCLIC ANTIDEPRESSANTS AND BARBITURATES IN 
BARBITURATE-TOLERANT AND NONTOLERANT RATS 

226849 01-03 
HOSTILITY, SOMATIC SYMPTOMS AND RECOVERY WITH 
ANTIDEPRESSANTS, 

226898 01-09 
EVALUATING POTENTIAL ANTIDEPRESSANTS IN ANIMALS. 

227207 01-06 
THE METHODOLOGY OF TRIALS OF ANTIDEPRESSANTS FOR DEPRESSED 
INPATIENTS. 

227213 01 16 
INTERACTIONS OF TRICYCLIC ANTIDEPRESSANTS AND PENTOBARBITAL 
IN PENTOBARBITAL TOLERANT AND NONTOLERANT RATS. 

227390 01-03 
NEUROLEPTICS AND ANTIDEPRESSANTS ON CENTRAL MONOAMINE 
NEURONS. 

229483 01-03 
THE INTERACTION BETWEEN ALPHA METHYL-DOPA AND TRICYCLIC 
ANTIDEPRESSANTS. 

230819 01 03 
CARDIOVASCULAR SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS - A 
RISK IN THE USE OF THESE DRUGS. 

23131701 15 
PRACTICAL CLINICAL PSYCHOPHARMACOLOGY: THE ANTIDEPRESSANTS 
AND LITHIUM. 

232762 02-17 
THE USE OF BETHANECHOL CHLORIDE WITH TRICYCLIC 
ANTIDEPRESSANTS. 

232864 02-15 
EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON THE 

ELECTROCARDIOGRAMS OF PATIENTS WITH ENDOGENOUS DEPRESSION 
(INTRODUCTORY REPORT). 

234046 02-09 
LIPIDOSIS-LIKE ULTRASTRUCTURAL ALTERATIONS IN RAT LYMPH NODES 
AFTER TREATMENT WITH TRICYCLIC ANTIDEPRESSANTS OR 
NEUROLEPTICS. 

237153 02-05 
DO TRICYCLIC ANTIDEPRESSANTS WORK^. 

237162 02-17 
A REVIEW OF THE CARDIOVASCULAR EFFECTS AND TOXICITY OF 
TRICYCLIC ANTIDEPRESSANTS. 

237909 02 15 






s 

i 



S-29 



Subject Index 



Psychopharmacology Abstracts 



PHARMACOLOGICAL IMPLICATIONS OF THE X-RAY STRUCTURE OF A 
RIGID ANALOG OF THE TRICYCLIC ANTIDEPRESSANTS 

238317 02-01 
ELECTRON BEAM IONIZATION MASS FRAGMENTOGRAPHIC ANALYSIS OF 
TRICYCLIC ANTIDEPRESSANTS IN HUMAN PLASMA. 

238486 02-16 
RADIOIMMUNOASSAY OF TRICYCLIC ANTIDEPRESSANTS. 

238775 03-01 
INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS ON THE ADENYLATE- 
CYCLASE PHOSPHODIESTERASE SYSTEM IN THE RAT CORTEX. 

239085 03-03 
TREATMENT WITH RESERPINE OF PATIENTS RESISTANT TO TRICYCLIC 
ANTIDEPRESSANTS: A DOUBLE-BLIND TRIAL. 

239348 03-09 
FACTORS AFFECTING THE BINDING OF TRICYCLIC TRANQUILLIZERS AND 
ANTIDEPRESSANTS TO HUMAN SERUM ALBUMIN. 

239684 03- 13 
COMBINATION OF TRICYCLIC ANTIDEPRESSANTS AND MAOI IN 
DEPRESSION. 

240839 0309 
OVERDOSAGE - THE RISE AND FALL OF TRICYCLIC ANTIDEPRESSANTS. 

243064 04-15 
PSYCHOTHERAPY AND TRICYCLIC ANTIDEPRESSANTS. 

243860 04-09 
CLINICAL USE OF TRICYCLIC ANTIDEPRESSANTS. 

243861 04-09 
THE ROLE OF RATING SCALES IN THE USE OF ANTIDEPRESSANTS. 

243862 04- 17 
EFFECTS OF TANDAMINE AND PIRANDAMINE, NEW POTENTIAL 

ANTIDEPRESSANTS, ON THE BRAIN UPTAKE OF NOREPINEPHRINE AND 
5-HYDROXYTRYPTAMINE AND RELATED ACTIVITIES. 

244678 04-03 
THE RELATIONSHIP BETWEEN HIATUS HERNIA AND TRICYCLIC 
ANTIDEPRESSANTS: A REPORT OF FIVE CASES. 

245523 04-15 
THE RELATIVE ROLE OF BRAIN ACETYLCHOLINE AND HISTAMINE IN 
PERPHENAZINE CATATONIA AND INFLUENCE OF ANTIDEPRESSANTS 
AND DIPHENHYDRAMINE ALONE AND IN COMBINATION. 

245593 04-05 
TOXICOLOGY UPDATE OF THE ARKANSAS POISON CONTROL DRUG- 
INFORMATION-CENTER: THE TRICYCLIC ANTIDEPRESSANTS. 

245822 04-13 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASURE 
THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

248834 04-03 
TRICYCLIC ANTIDEPRESSANTS AND THE CENTRAL CHOLINERGIC 
MUSCARINIC RECEPTOR 

249301 04-03 
EFFECTS OF PIRANDAMINE (PA) AND TANDAMINE (TA), POTENTIAL 
ANTIDEPRESSANTS, ON THE UPTAKE OF NOREPINEPHRINE (NE) AND 5- 
HYDROXYTRYPTAMINE (5-HT) AND RELATED ACTIVITIES. 

249313 04-03 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASURE 
THE BLOCKADE OF NOREPINEPHRINE AND 5HYDR0XYTRYPTAMINE 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

249930 04-03 
INHIBITION OF PHENYLETHYLAMINE METABOLISM IN VIVO - EFFECT OF 
ANTIDEPRESSANTS. 

251184 04-03 
DO TRICYCLIC ANTIDEPRESSANTS WORK?. 

253314 04-09 
THE EFFECT OF VARIOUS PHENOTHIAZINES AND TRICYCLIC 

ANTIDEPRESSANTS ON THE ACCUMULATION AND RELEASE OF 3H- 
NOREPINEPHRINE AND 3H-5-HYDROXYTRYPTAMINE IN SLICES OF RAT 
OCCIPITAL CORTEX 

253691 04-03 
ANTIDEPRESSED 

PSYCHOTROPIC DRUGS AND THE ANTIDEPRESSED PERSONALITY. 

240251 03-15 
ANTIDEPRESSIVE 

DEPLETION OF S-ADENOSYL-L METHIONINE IN MOUSE BRAIN BY 
ANTIDEPRESSIVE DRUGS 

226850 01-03 
CLINICAL PHARMACOLOGY OF SO 10996, A POTENTIAL ANTIDEPRESSIVE 
AGENT. 

229036 01-07 
CLINICAL EXPERIENCE IN USING MAPROTILINE, A NEW ANTIDEPRESSIVE 
MEDICINE. 

229760 01-09 
CLINICAL EVALUATION OF THE ANTIDEPRESSIVE ACTION OF THE 
PREPARATION AZAFEN 

236429 02-10 
PLASMA LEVELS AND ANTIDEPRESSIVE EFFECT OF IMIPRAMINE. 

243089 04-13 
SULPIRIDE AS A CURRENT ANTIDEPRESSIVE TECHNIQUE: WHAT CAN BE 
SAID AND THOUGHT ABOUT IT TODAY?. 

244433 04-17 



SELF-INHIBITING ACTION OF NORTRIPTYLINE ANTIDEPRESSIVE EFFECT AT 
HIGH PLASMA LEVELS: A RANDOMIZED, DOUBLE-BLIND STUDY 
CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION. 

248955 04-10 
COMPARISON OF A NEW ANTIDEPRESSIVE, LOFEPRAMINE WITH 
IMIPRAMINE IN A DOUBLE-BLIND MULTICENTRE TRIAL. 

251118 04-09 
ABSORPTION AND EXCRETION OF A NEW ANTIDEPRESSIVE (SQ-10996) IN 
HUAMNS. 

253323 04-07 

ANTIDEPRESSIVES 

THE CLINICAL PHARMACOLOGY OF ANTIDEPRESSIVES. 

227209 01 17 
ANTIDIURETIC 

EFFECT OF ANTIDIURETIC DRUGS IN RATS WITH LITHIUM-INDUCED 
POLYURIA. 

239041 03-05 

ANTIDOPAMINERGIC 

ANTIDOPAMINERGIC AND ANTIMUSCARINIC EFFECTS OF 
DIBENZODIAZEPINES: RELATIONSHIP TO DRUG-INDUCED 
PARKINSONISM. 

241248 03-03 
ANTIDOPAMINERGIC EFFECTS OF APOMORPHINE IN PATIENTS WITH 
DYSKINESIAS. 

251958 04-13 

ANTIDOTE 

THYROTROPIN-RELEASING HORMONE (TRH) AN ANTIDOTE TO 
AMOBARBITAL OVERDOSAGE IN THE RHESUS MONKEY. 

238792 03-03 
ANTIEPILEPTIC 

BEHAVIORAL EFFECTS OF ANTIEPILEPTIC DRUGS. 

230368 01-11 
ANTIEPILEPTIC AND PROPHYLACTIC EFFECTS OF 

TETRAHYDROCANNABINOLS IN AMYGDALOID KINDLED CATS. 

230478 01-03 
THE CONTRIBUTION OF NEURONAL UPTAKE BLOCKADE TO THE 
ANTIEPILEPTIC ACTION OF CARBAAAAZEPINE (TEGRETOL). 

249242 04-03 
ANTIESTROGEN 

DIFFERENTIAL EFFECTS OF THE ANTIESTROGEN MER-25 AND OF THREE 
5ALPHA-REDUCED ANDROGENS ON MOUNTING AND LORDOSIS 
BEHAVIOR IN THE RAT. 

244343 04-04 

ANTIHISTAMINIC 

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE 
METABOLISM. 

238838 03-03 
ANTIHYPERTENSIVE 

THE INFLUENCE OF THE DECARBOXYLASE INHIBITOR BENSERAZIDE ON 
ANTIHYPERTENSIVE EFFECT AND METABOLISM OF METHYLDOPA IN 
HYPERTENSIVE PATIENTS. 

2514)8 04-11 

ANTIAAANIC 

BIOCHEMICAL VS CLINICAL PHYSIOGNOMY OF NEUROLEPTICS, WITH 
SPECIAL REFERENCE TO THEIR ANTIMANIC EFFECT 

227/63 01-04 
ATARAXIC AND ANTIMANIC EFFECTS OF THIOXANTHENES. 

227768 01 09 
THE DRUG TREATMENT OF MOOD DISORDERS. PART II: ANTIMANIC AND 
ANTIDEPRESSANT AGENTS, MAINTENANCE TREATMENT, AND RECENT 
ADVANCES. (UNPUBLISHED PAPER). 

244574 04-09 

ANTIMIGRAINE 

DISCOVERY OF SPECIFIC CNS EFFECTS OF LISURIDE HYDROGEN MALEATE 
- AN ANTIMIGRAINE COMPOUND. 

229473 01-13 
AMITRIPTYLINE IN THE PROPHYLAXIS OF MIGRAINE: EFFECTIVENESS AND 
RELATIONSHIP ON ANTIMIGRAINE AND ANTIDEPRESSANT EFFECTS. 

237138 0211 
ANTIMUSCARINIC 

ANTIDOPAMINERGIC AND ANTIMUSCARINIC EFFECTS OF 
DIBENZODIAZEPINES: RELATIONSHIP TO DRUG-INDUCED 
PARKINSONISM. 

241248 03-03 

ANTINICOTINIC 

THE ANTINICOTINIC EFFECTS OF DRUGS WITH CLINICALLY USEFUL 
SEDATIVE ANTIANXIETY PROPERTIES. 

248009 04-03 

ANTINOCICEPTIVE 

MOUSE BRAIN CATECHOLAMINES, 5-HYDROXYTRYPTAMINE AND THE 
ANTINOCICEPTIVE ACTIVITY OF PETHIDINE. 

237741 0203 
ANTAGONISM BY METHYSERGID AND CINANSERIN OF THE 

ANTINOCICEPTIVE ACTION OF MORPHINE ADMINISTERED INTO THE 
PERIAQUEDUCTAL GRAY. 

239576 03 04 



S-30 



S^OLUME 14, SUBJECT INDEX 



Subject Index 



ANTINOCICEPTIVE ACTION OF QUIPAZINE: RELATION TO CENTRAL 
SEROTONERGIC RECEPTOR STIMULATION. 

241235 03-03 
DETERMINATION AND CHARACTERIZATION OF THE ANTINOCICEPTIVE 
ACTIVITY OF INTRAVENTRICULARLY ADMINISTERED ACETYLCHOLINE 
IN MICE. 

246852 04-04 
EVALUATION OF THE ANTINOCICEPTIVE EFFECTS OF 4.ALPHA-DIMETHYL- 
MTRYAMINE (H77-77) IN THE RAT. 

252026 04-03 
IVNTINUCLEAR 

ANTINUCLEAR ANTIBODIES IN PSYCHIATRIC ILLNESS: THEIR 
RELATIONSHIP TO DIAGNOSIS AND DRUG TREATMENT. 

228208 01-15 
ANTINUCLEAR ANTIBODIES IN CHRONIC PSYCHOTIC PATIENTS TREATED 
WITH CHLORPROMAZINE. 

232865 02-15 
IVNTIOBESITY 

STRATEGIES AND TACTICS IN THE USE OF ANTIOBESITY DRUGS. 

253315 04 11 
IVNTIOXIDANT 

AN INVESTIGATION ON THE DOSE-RESPONSE RELATIONSHIP BETWEEN 
CONVENTIONAL ANTIOXIDANT FOOD ADDITIVES AND 
NEUROTRANSMITTER METABOLISM. 

238745 03-03 
ANTIPARKINSON 

OPEN WITHDRAWAL OF ANTIPARKINSON DRUGS IN THE NEUROLEPTIC- 
INDUCEO PARKINSON SYNDROME. 

239822 03-15 
SHOULD PATIENTS RECEIVING MAJOR TRANQUILIZER THERAPY RECEIVE 
ANTIPARKINSON DRUGS PROPHYLACTICALLY?. 

247359 04-15 
ANTIPARKINSONIAN 

A CLINICAL CONTRIBUTION ON THE EFFECTS OF SUSPENDING 
ANTIPARKINSONIAN DRUGS IN PROLONGED TREATMENT WITH 
NEUROLEPTIC DRUGS. 

235992 02-11 
ANTIPARKINSONIAN AGENTS AND FLUPHENAZINE-DECANOATE. 
DECANOATE. 

236317 02-15 
IMPLICATIONS OF PHENOTHIAZINE SIDE-EFFECTS: A STUDY OF 
ANTIPARKINSONIAN AGENTS IN AN OLDER POPULATION. 

238978 03-15 
THE ANTIPARKINSONIAN EFFICACY OF BROMOCRIPTINE. 

251649 04-07 
ANTIPHENOBARBITAl 

EFFECT OF ANTIPHENOBARBITAL ANTIBODIES ON SLEEPING TIME 
INDUCED BY CYCLOBARBITAL TO MICE. 

241403 03 03 
EFFECTS OF PASSIVE IMMUNIZATION WITH RABBIT 
ANTIPHENOBARBITAL IGG ON CYCLOBARBITAL INDUCED SLEEPING 
TIME AND HEPATIC ENZYME ACTIVITIES OF C3H MICE 

242201 03-03 
ANTIPSYCHOTIC 

GUIDELINES FOR ANTIPSYCHOTIC DRUG USE. 

227731 01-17 
PHARMACOLOGICAL VS. CLINICAL PHYSIOGNOMY OF NEUROLEPTICS. 
WITH SPECIAL REFERENCE TO THEIR SEDATIVE AND ANTIPSYCHOTIC 
EFFECTS. 

227762 01-04 
FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE, WITH SPECIAL 
REFERENCE TO THEIR ANTIPSYCHOTIC EFFECT. 

227770 01-08 
OPHTHALMOLOGICAL FINDINGS ON NEUROPSYCHIATRIC PATIENTS 
DURING PSYCHOPHARMACOTHERAPY: II. SEVEN CASES DUE TO 
ANTIPSYCHOTIC DRUGS 

227808 01-15 
THE PHARMACOLOGIC MEANING OF SUCCESSFUL ANTIPSYCHOTIC 
ANTIDEPRESSANT COMBINATIONS. 

230010 01-11 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN MAMMALIAN BRAIN: A 
POSSIBLE SITE OF ACTION OF ANTIPSYCHOTIC DRUGS. 

230602 01-13 
ARE BENZODIAZEPINES ANTIPSYCHOTIC AGENTS'. 

23381 5 02-08 
ARE BENZODIAZEPINES ANTIPSYCHOTIC AGENTS?. 

235327 02-08 
MAINTENANCE ANTIPSYCHOTIC THERAPY: IS THE CURE WORSE THAN 
THE DISEASE?. 

236307 02-08 
PRACTICAL CONSIDERATIONS ON TREATMENT WITH ANTIPSYCHOTIC 
DRUGS. 

236359 02-08 
PRETREATMENT CPK AND CLINICAL RESPONSE TO ANTIPSYCHOTIC 
MEDICATION. {UNPUBLISHED PAPER). 

238489 02-08 
LACK OF A RELATION BETWEEN THE ANTIPSYCHOTIC AND THE 
EXCITABILITY DEPRESSANT PROPERTIES OF MAJOR TRANQUILIZERS. 

238710 0303 



CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: II. ANTIPSYCHOTIC EFFECT OF HALOPERIDOL IN PATIENTS 
WITH CHRONIC ORGANIC BRAIN DAMAGE. 

240219 03-11 
NEUROPHARMACOLOGICAL EFFECTS OF PENFLURIDOL, A NEW 
ANTIPSYCHOTIC AGENT. 

241384 03-03 
COMPARISON TRIAL OF TWO ANTIPSYCHOTIC DRUGS: 
CHLORPROMAZINE AND CLOZAPINE. 

241760 03-08 
DOSAGE OF ANTIPSYCHOTIC DRUGS. 

242269 03-17 
DRUG THERAPY: NEUROLOGIC SYNDROMES ASSOCIATED WITH 
ANTIPSYCHOTIC DRUG USE. 

246061 04-15 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEEN CLINICAL 
POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS. 

248466 04-03 
ANTIPSYCHOTIC PHENOTHIAZINE DRUGS AND THE SIGNIFICANCE OF THE 
X-RAY STRUCTURE OF PROMAZINE HCL 

250357 04-01 
MESOLIMBIC AREA AND C. STRIATUM: RELATIVE INCREASES IN 

DOPAMINE TURNOVER BY NEUROLEPTIC AND RELATED COMPOUNDS 
DEVOID OF ANTIPSYCHOTIC ACTIVITY. 

251395 04-03 
ANTIPSYCHOTIC EFFECTS OF AL-1965. 

251720 04-08 
BASIC PRINCIPLES IN THE USE OF ANTIPSYCHOTIC AGENTS 

251751 04-17 
ANTICHOLINERGIC ACTIVITY OF ANTIPSYCHOTIC DRUGS IN RELATION TO 
THEIR EXTRAPYRAMIDAL EFFECTS. 

252520 04-05 
MAINTENANCE ANTIPSYCHOTIC DRUGS DO PREVENT RELAPSE: A REPLY 
TO TOBIAS AND MACDONALD. 

252847 04-08 
DOSAGE OF ANTIPSYCHOTIC DRUGS. 

253018 04-08 
ANTIPSYCHOTICS 

ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VIVO 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE. 

244514 04-03 
EFFECT OF THIORIDAZINE, CLOZAPINE AND OTHER ANTIPSYCHOTICS ON 
THE KINETIC STATE OF TYROSINE-HYDROXYLASE AND ON THE 
TURNOVER RATE OF DOPAMINE IN STRIATUM AND NUCLEUS- 
ACCUMBENS. 

248698 04-05 
ANTIPYRETIC 

FURTHER STUDIES ON SELF ADMINISTRATION OF ANTIPYRETIC 
ANALGESICS AND COMBINATIONS OF ANTIPYRETIC ANALGESICS WITH 
CODEINE IN RHESUS MONKEYS 

246855 04-04 
ANTISCHIZOPHRENIC 

DOPAMINE RECEPTOR BINDING PREDICTS CLINICAL AND 

PHARMACOLOGICAL POTENCIES OF ANTISCHIZOPHRENIC DRUGS. 

243483 04-03 
ANTISEIZURE 

GAMMA-ACETYLENIC-GABA (AMINO-4-HEX-5-YNOIC-ACID); A GABA 
TRANSAMINASE INHIBITOR WITH SELECTIVE ANTISEIZURE ACTIVITY. 

238781 03-04 
ANTISOCIAL 

PSYCHOPHARMACOLOGY IN THE PREVENTION OF ANTISOCIAL AND 
DELINQUENT BEHAVIOR. 

247385 04-17 
47-XYY AND 46-XY MALES WITH ANTISOCIAL AND/OR SEX OFFENDING 
BEHAVIOR: ANTIANDROGEN THERAPY PLUS COUNSELING 

248222 04-10 
ANTITREMORGENIC 

EVIDENCE FOR 2-PHENYLETHYLAMINE (PEA) AS A MEDIATOR FOR THE 
CENTRAL STIMULANT AND ANTITREMORGENIC ACTIONS OF DELTA9- 
TETRAHYDROCANNABINOL (THC). 

249309 04-03 
ANXIETY 

A DOUBLE-BLIND COMPARISON BETWEEN DOXEPIN AND DIAZEPAM IN 
THE TREATMENT OF STATES OF ANXIETY. 

226410 0110 
ANXIETY IN SCHIZOPHRENIA: THE RESPONSES TO CHLORDIAZEPOXIDE IN 
AN INTENSIVE DESIGN STUDY. 

228221 01-08 
THERAPY OF ANXIETY IN PATIENTS WITH RHEUMATIC DISEASE: 
CROSSOVER DOUBLE-BLIND STUDY COMPARING LORAZEPAM WITH 
PLACEBO. 

228241 01-11 
THE TREATMENT OF PSYCHOTIC ANXIETY. 

229559 01-10 
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN 
ANXIETY NEUROSIS. 

230907 01-08 



?0 

s 

P 



S 

s 

i 
S 



S-31 



Subject Index 



Psychopharmacoiogy Abstracts 



LORAZEPAM AND DIAZEPAM IN THE TREATMENT OF NEUROTIC 
ANXIETY: DOUBLE-BLIND TRIAL 

236658 02- 10 
THE USE OF DOTHIEPIN IN THE TREATMENT OF PSYCHONEUROTIC 
ANXIETY WITH DEPRESSIVE FEATURES. 

237774 02-10 
A BRIEF ANXIETY RATING SCALE IN EVALUATING ANXIOLYTICS. 

237926 02-11 
ANXIETY AND EEG ALPHA ACTIVITY IN NEUROTIC PATIENTS. 

239022 03-10 
SUBJECTIVE RATINGS OF SLEEP QUALITY AND ANXIETY AFTER PLACEBO, 
DRUG AND A FOOD DRINK. 

239059 03-14 
THE ANXIOLYTIC EFFECT OF SMALL CUMULATIVE DOSES OF OXYPERTIN 
IN RATS IN AN ANXIETY TEST AND THE POSSIBLE NEUROCHEMICAL 
CORRELATES IN THE HYPOTHALAMUS AND STRIATUM. 

239834 03-04 
A MULTIPLE DOSE, CONTROLLED STUDY OF PHENELZINE IN DEPRESSION 
ANXIETY STATES. 

239938 03-10 
BETA-BLOCKERS IN ANXIETY AND STRESS. 

240694 03-10 
LORAZEPAM IN THE MANAGEMENT OF ANXIETY ASSOCIATED WITH 
CHRONIC GASTROINTESTINAL DISEASE: A DOUBLE-BLIND STUDY. 

241274 03-14 
CONTROLLED CLINICAL AND QUANTITATIVE EEG STUDIES OF 

TRIFLUBAZAM (ORF-8063) IN PATIENTS WITH ANXIETY SYNDROME. 

241275 03-10 
PILOT OPEN-LABEL STUDY OF LENPERONE (AHR-2277), A 

BUTYROPHENONE, IN ANXIETY. 

241278 03-10 
ORAL DIAZEPAM IN HOSPITALIZED ANXIETY PATIENTS (WITH 
OBSERVATIONS ON CONCENTRATION EFFECT RELATIONSHIPS). 

241427 03- 10 
INTRAVENOUS LORAZEPAM IN THE ACUTE ANXIETY CRISIS: A 
PRELIMINARY REPORT ON 60 CASES. 

242250 03-10 
A CASE OF PHOBIC ANXIETY DEPERSONALIZATION SYNDROME (ROTH). 

243094 04-17 
ANXIETY/DEPRESSION IN ELDERLY PATIENTS: A DOUBLE-BLIND 
COMPARATIVE STUDY OF FLUPHENAZINE/NORTRIPTYLINE AND 
PROMAZINE. 

247030 04-11 
LORAZEPAM IN GASTROINTESTINAL DISORDERS WITH ANXIETY OVERLAY 
(A DOUBLE-BLIND CROSSOVER STUDY). 

250193 04-14 
COMPARISON OF LOW DOSES OF HALOPERIDOL AND DIAZEPAM IN 
ANXIETY STATES. 

250491 04-10 
EXPOSURE IN VIVO OF AGORAPHOBICS: CONTRIBUTIONS OF DIAZEPAM, 
GROUP EXPOSURE, AND ANXIETY EVOCATION. 

250727 04-10 
BETA-ADRENERGIC BLOCKING DRUGS FOR ANXIETY. 

251155 04-14 
REPORT OF A SYMPOSIUM ON BETA-ADRENERGIC RECEPTOR BLOCKADE 

IN PSYCHIATRY, HELD IN FERNDOWN, DORSET, ON JUNE 21ST 1975. 
BETA-ADRENERGIC BLOCKING DRUGS IN ANXIETY. 

251156 04-10 
A PRACTICAL CLASSIFICATION OF MORBID ANXIETY 

251157 04-10 
CLINICAL TRIALS OF OXPRENOLOL IN ANXIETY. 

251159 04-10 
WORRYING ABOUT ANXIETY. 

251161 04-10 
MEASUREMENT OF ANXIETY IN OUTPATIENT TRIALS: DETECTION OF BIAS 
IN PATIENT AND DOCTOR RATINGS. 

253043 04-16 

ANXIOLYTIC 

ANXIOLYTIC DRUGS. 

232704 02-10 
THE ANXIOLYTIC EFFECT OF SMALL CUMULATIVE DOSES OF OXYPERTIN 
IN RATS IN AN ANXIETY TEST AND THE POSSIBLE NEUROCHEMICAL 
CORRELATES IN THE HYPOTHALAMUS AND STRIATUM. 

239834 03-04 
ANXIOLYTIC MEDICATIONS. 

241758 03-10 
ANXIOLYTIC PHARMACOTHERAPY IN GENERAL PRACTICE. 

241759 03-10 
CLINICAL RESPONSE TO A POTENTIAL NONSEDATIVE ANXIOLYTIC. 

251719 04-07 

ANXIOLYTICS 

A BRIEF ANXIETY RATING SCALE IN EVALUATING ANXIOLYTICS. 

237926 02-11 
ANXIOUS 

( 1 INICAL EXPERIENCES WITH ANTIDEPRESSANT DRUGS IN THE 
TREATMENT OF ANXIOUS PHOBIC PATIENTS. 

230015 01-10 



CLINICAL AND PHYSIOLOGICAL ASSESSMENT OF CHLORAZEPATE, 
DIAZEPAM AND PLACEBO IN ANXIOUS NEUROTICS. 

231036 01-10 
OXAZEPAM PROTRIPTYLINE: A DOUBLE-BLIND PHASE II EVALUATION OF 
THE EFFICACY AND SAFETY OF THE COMBINATION VERSUS PLACEBO 
IN NEUROTIC, DEPRESSED AND ANXIOUS PSYCHIATRIC OUTPATIENTS. 

248975 04-10 
APHAGIC 

REINSTATEMENT OF EATING BY DOPAMINE AGONISTS IN APHAGIC 
DOPAMINE DENERVATED RATS. 

243348 04-04 

APLYSIA 

ORGANIZATION OF RECEPTORS FOR NEUROTRANSMITTERS ON APLYSIA 
NEURONES. 

235588 02-03 
THE EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON ACTION 
POTENTIALS IN THE MOLLUSC APLYSIA. 

239261 03-03 

APOMORPHINE 

DIFFERENTIAL EFFECTS OF SEROTONIN ON TURNING AND STEREOTYPY 
INDUCED BY APOMORPHINE. 

226405 01-04 

AMPHETAMINE AND APOMORPHINE RESPONSES IN THE RAT FOLLOWING 
6-OHDA LESIONS OF THE NUCLEUS-ACCUMBENS SEPTI AND CORPUS- 
STRIATUM. 

226937 01-04 

METHADONE INTERACTION WITH APOMORPHINE AND AMPHETAMINE- 
INDUCED TURNING, 

226945 01-04 

APOMORPHINE AND PSYCHOPATHOLOGY. 

230743 01-11 
BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AND AMPHETAMINE 
AFTER CHRONIC HIGH DOSE HALOPERIDOL TREATMEN 

232616 02-04 
ANTAGONISM OF APOMORPHINE AND D-AMPHETAMINE-INDUCED 
STEREOTYPED BEHAVIOUR BY INJECTION OF LOW DOSES OF 
HALOPERIDOL INTO THE CAUDATE NUCLEUS AND THE NUCLEUS- 
ACCUMBENS. 

237704 02-04 
EFFECT OF CATECHOL-0-METHYLTRANSFERASE INHIBITORS ON BRAIN 
APOMORPHINE CONCENTRATIONS AND STEREOTYPED BEHAVIOUR IN 
THE RAT. 

237747 02-03 
ON THE DIRECT OR INDIRECT INFLUENCE OF APOMORPHINE ON CENTRAL 
SEROTONIN NEURONS. 

237785 02 03 
GAMMA-AMINOBUTYRIC-ACID: THE ESSENTIAL MEDIATOR OF 

BEHAVIOUR TRIGGERED BY NEOSTRIATALLY APPLIED APOMORPHINE 
AND HALOPERIDOL. 

237786 02-03 
DISSOCIATION BY THE APOMORPHINE DERIVATIVES OF THE 

STEREOTYPIC AND HYPERACTIVITY RESPONSES RESULTING FROM 
INJECTIONS INTO THE NUCLEUS-ACCUMBENS SEPTI. 

238319 02-04 
THE TRANSCALLOSALLY EVOKED POTENTIAL (TEP) FOLLOWING 
ADMINISTRATION OF LSD, MESCALINE, DMT, APOMORPHINE AND 
METHOXAMINE IN THE DOG. 

238703 03-03 
THE EFFECT OF DL-254 ON THE PHARMACOLOGICAL ACTIVITIES OF D 
AMPHETAMINE AND APOMORPHINE: A COMPARISON WITH 
ANTIANXIETY AND NEUROLEPTIC AGENTS. 

238846 03-03 
EFFECT OF 10 DAYS RESERPINE OR APOMORPHINE ADMINISTRATION ON 
SLEEP CYCLES IN RATS. 

242732 03-04 
REGULATION OF ADRENAL TYROSINE-HYDROXYLASE ACTIVITY: 

NEURONAL VERSUS LOCAL CONTROL STUDIED WITH APOMORPHINE. 

244314 04-03 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VIVO 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE 

244514 04-03 
ESTERS OF APOMORPHINE AND N,N DIMETHYLDOPAMINE AS AGONISTS 
OF DOPAMINE RECEPTORS IN THE RAT BRAIN IN VIVO. 

246150 04-04 
PENFLURIDOL BLOCKADE OF APOMORPHINE: DEPENDENCE OF DURATION 
ON SPECIES AND ENDPOINT 

248406 04-02 
ENHANCEMENT OF RESERPINE-ELICITED DOPAMINERGIC 

SUPERSENSITIVITY BY REPEATED TREATMENT WITH APOMORPHINE 
AND ALPHA-METHYL-P TYROSINE 

249002 04 03 
CARDIOVASCULAR EFFECTS OF CENTRAL MICROINJECTIONS OF 
APOMORPHINE IN CATS. 

249033 04-03 



S-32 



•LUME 14, SUBJECT INDEX 



Subject Index 



STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE 
RECEPTORS IN COMPARISON TO APOMORPHINE, ( ( ) AMPHETAMINE 
AND L-DOPA. 

249419 04-04 
EFFECT OF AMPHETAMINE AND APOMORPHINE ON BRAIN MONOAMINES 
AND BEHAVIOUR IN THE IMMATURE AND YOUNG ADULT RAT. 

249785 04-04 
EFFECTS OF HARMINE AND BRAIN LESIONS ON APOMORPHINE INDUCED 
MOTOR ACTIVITY. 

250058 04-03 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE AND CLONIDINE 
FOLLOWING FRONTAL CORTICAL DAMAGE IN RATS. 

250089 04-04 
CHANGES IN SENSITIVITY TO APOMORPHINE DURING MORPHINE- 
DEPENDENCE AND WITHDRAWAL IN RATS 

250114 04-03 
NORADRENERGIC INFLUENCE ON THE STEREOTYPED BEHAVIOUR INDUCED 
BY AMPHETAMINE, PHENETHYLAMINE AND APOMORPHINE. 

250361 04-04 
DIESTER DERIVATIVES AS APOMORPHINE PRODRUGS. 

251699 04-04 
ANTIDOPAMINERGIC EFFECTS OF APOMORPHINE IN PATIENTS WITH 
DYSKINESIAS. 

251958 04-13 
IMORPHINE-EUCITED 

THE REVERSAL OF APOMORPHINE-ELICITED INHIBITION OF 
SYNAPTOSOMAL TYROSINE-HYDROXYLASE ACTIVITY BY 
NEUROLEPTICS. 

238758 03-03 
THE EFFECT OF VARIOUS CHLORPROMAZINE DERIVATIVES ON THE 
APOMORPHINE-ELICITED INHIBITION OF SYNAPTOSOMAL TYROSINE 
HYDROXYLASE ACTIVITY. 

247212 04-03 
)MORPHINE-INDUCED 

THE EFFECTS OF HALOPERIDOL AND THIORIDAZINE ON APOMORPHINE- 
INOUCED AND LSD-INDUCED HYPERTHERMIA IN THE RABBIT. 

228977 01 05 
APOMORPHINE-INDUCED HYPERTHERMIA IN THE RABBIT: A 

PHARMACOLOGICAL STUDY OF THE NEUROAMINERGIC MECHANISMS 
UNDERLYING THE RESPONSE. (PH.D. DISSERTATION). 

240936 03-03 
AMANTADINE: AGGRESSIVE EFFECT, EFFECT ON APOMORPHINE INDUCED 
AGGRESSIVITY IN THE RAT. 

241227 03-04 
SUPERSENSITIVITY TO D-AMPHETAMINE AND APOMORPHINE-INDUCED 
STEREOTYPED BEHAVIOR INDUCED BY CHRONIC D AMPHETAMINE 
ADMINISTRATION. 

247683 04-04 
APOMORPHINE-INDUCED STEREOTYPED BITING IN THE TORTOISE IN 
RELATION TO DOPAMINERGIC MECHANISMS. 

247875 04 04 
APOMORPHINE INDUCED AGGRESSION: AN EVALUATION OF POSSIBLE 
SENSITIZING FACTORS IN THE RAT. 

248008 04-04 
INHIBITION AND POTENTIATION OF APOMORPHINE-INDUCED 
HYPERMOTILITY IN RATS BY NEUROLEPTICS. 

252029 04 04 
ANTAGONISM BY SULPIRIDE OF THREE APOMORPHINE-INDUCED EFFECTS 
IN RODENTS 

252032 04-04 
>RPHINE 
APORPHINES 15: ACTION OF APORPHINE ALKALOIDS ON DOPAMINERGIC 
MECHANISMS IN RAT BRAIN, 

248286 04-03 
APORPHINES 16: ACTION OF APORPHINE ALKALOIDS ON LOCOMOTOR 

ACTIVITY IN RATS WITH 6-HYDROXYDOPAMINE LESIONS OF THE 
NUCLEUSACCUMBENS. 

248287 04-02 
>RPHINES 

TREATMENT OF PARKINSONS DISEASE WITH APORPHINES: POSSIBLE 

ROLE OF GROWTH HORMONE 

237253 02-11 
APORPHINES 15: ACTION OF APORPHINE ALKALOIDS ON DOPAMINERGIC 

MECHANISMS IN RAT BRAIN 

248286 04 03 
APORPHINES 16: ACTION OF APORPHINE ALKALOIDS ON LOCOMOTOR 

ACTIVITY IN RATS WITH 6-HYDROXYDOPAMINE LESIONS OF THE 
NUCLEUSACCUMBENS. 

248287 04-02 
'EARANCE 

APPEARANCE OF WET DOG SHAKE BEHAVIOR DURING COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT AND ITS SUPPRESSION BY 
RE5ERPINE 

230836 01 04 
THE COURSE OF TREATMENT IN SCHIZOPHRENIA AS RELATED TO THE 
APPEARANCE OF AFFECTIVE DISORDERS. 

236421 02-08 



APPETITE 

CYPROHEPTADINE: WEIGHT GAIN AND APPETITE STIMULATION IN 
ESSENTIAL ANOREXIC ADULTS. 

237900 02 10 
DO ANORECTIC DRUGS PRODUCE WEIGHT LOSS BY APPETITE 
SUPPRESSION^. 

240802 03 13 
APPLICATIONS 

PHARMACOLOGICAL APPROACHES TO THE FUNCTION OF CERTAIN 
NONSPECIFIC SUBCORTICAL STRUCTURES PARTICIPATING IN THE 
GENESIS OF THE VISUAL EVOKED POTENTIAL. APPLICATIONS TO THE 
STUDY OF SEVERAL PSYCHOTROPICS. 

244874 04-03 
CLINICAL APPLICATIONS OF A NEW RATIONALE IN THE TREATMENT OF 
ACUTE ALCOHOL WITHDRAWAL. 

252694 04-11 
APPRAISAL 

CLOZAPINE AND THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA, A 
CRITICAL APPRAISAL 

246671 04-03 
APPREHENSION 

ALLEVIATING AGITATION, APPREHENSION, AND RELATED SYMPTOMS IN 
GERIATRIC PATIENTS: A DOUBLE BLIND COMPARISON OF A 
PHENOTHIAZINE AND A BENZODIAZEPINE. 

234114 02-11 
APPROACH 

5-HYDROXYTRYPTAMINE 14C AND DEXAMPHETAMINE 14C UPTAKE BY 
FUNDAL SARCOLEMMA PREPARATIONS: EFFECT OF THERMAL AND 
CHEMICAL ALTERATIONS AS INDIRECT APPROACH TO THE PROBLEM 
OF THE COMMON RECEPTOR. 

226827 01-03 
RECENT VIEWS IN PSYCHOPHARMACOLOGY: APPROACH TO 
SCHIZOPHRENIA. 

228308 CI 08 
A NOVEL APPROACH TO QUANTITATIVE DETERMINAIION OF 
SUBNANOMOLES OF PSYCHOACTIVE DRUGS IN BLOOD. 

229441 01-16 
PSYCHOPHARMACOLOGY A BIOLOGICAL APPROACH. 

232938 02-17 
AN INTEGRATED APPROACH FOR THE VALUATION OF PSYCHOTROPIC 
DRUG IN MAN: I. STUDIES ON AMPHETAMINE RELATIONSHIP 
BETWEEN DRUG LEVELS AND PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241234 03-13 
RELAY TOXICITY: A NEW APPROACH TO A METHODOLOGY OF 

EVALUATING THE TOXICITY OF ADDITIVES TO FARM ANIMAL FEED. 

245114 04-06 
APPROACH TO A COMBINED PHARMACOLOGIC THERAPY OF CHILDHOOD 
HYPERKINESIS 

249772 04-11 
APPROACHES 

PHARMACOLOGICAL APPROACHES TO THE FUNCTION OF CERTAIN 
NONSPECIFIC SUBCORTICAL STRUCTURES PARTICIPATING IN THE 
GENESIS OF THE VISUAL EVOKED POTENTIAL. APPLICATIONS TO THE 
STUDY OF SEVERAL PSYCHOTROPICS. 

244874 04-03 
ARECOLINE 

EFFECTS OF ARECOLINE AND CHOLINESTERASE INHIBITORS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE IN MOUSE BRAIN. 

246389 04 03 
ARKANSAS 

TOXICOLOGY UPDATE OF THE ARKANSAS POISON CONTROL DRUG 
INFORMATION CENTER: THE TRICYCLIC ANTIDEPRESSANTS 

245822 04 13 
AROMATIC 

THE SELECTIVE EFFECTS OF ALPHA-METHYL AROMATIC AMINO-ACIDS ON 
BRAIN MONOAMINE METABOLITES AND BEHAVIOR IN CATS. 

231009 01 03 
THE AROMATIC HYDROXYLATION OF AMPHETAMINE WITH RAT LIVER 
MICROSOMES, PERFUSED LIVER AND ISOLATED HEPATOCYTES 

238683 03-06 
DRUGS DERIVED FROM CANNABINOIDS 5 DELTA 

TETRAHYDROCANNABINOL AND HETEROCYCLIC ANALOGS 
CONTAINING AROMATIC SIDE CHAINS. 

248648 04 02 
AROUSAL 

THE EFFECT OF IMIPRAMINE ON AROUSAL FROM HIBERNATION 

228549 01 04 
REGIONAL ROLE OF CATECHOLAMINES IN ALPHA-METHYL M TYROSINE 
INDUCED ELECTROENCEPHALOGRAPHIC AROU,SAL 

234067 02 03 
DRUGS, AROUSAL. AND BRAIN STEADY POTENTIAL RESPONSES. 

243953 04-14 
EFFECT OF CHLORPROMAZINE ON THE INTERACTION BETWEEN PHASIC 
AND TONIC ELECTROCORTICAL AROUSAL MECHANISMS 

246311 0403 



I 

es 





s 

2 
as 

h 

I 

I 



S-33 



Subject Index 

DOSE-RELATFD EffECTS OF CENTRAL NORADRENALINE STIMULATION ON 
BEHAVIOURAL AROUSAL IN RATS^ 

247206 04-04 
AROUSAL AND ACTIVITY LEVEL OF RATS WITH LESIONS IN THE DORSAL 
HIPPOCAMPUS. 

247420 04-04 
EFFECT OF AROUSAL BY SOCIAL ISOLATION, GROUPING, AND D- 
AMPHFTAMINE ON INTER-MALE AGGRESSION IN MICE (MUS- 
MUSCULUS) 

253485 04-04 

ARREST 

RESERPINE ACTION ON THE ARREST REACTION FOLLOWING 
STIMULATION OF THE CAUDATE-NUCLEUS IN CATS. 

236712 02-04 

ARTERIAL 

ASTONINH IN THE TREATMENT OF ARTERIAL HYPERTENSION DUE TO 
PSYCHOTROPIC DRUGS 

240261 03-15 
EFFECT OF AMPHETAMINE AND GUTIMIN ON ADAPTIVE CHANGES IN 
ARTERIAL PRESSURE ARISING IN RESPONSE TO CONTRACTION OF THE 
SKELETAL MUSCLES. 

241988 03-03 
CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04-03 
CHANGES IN THE ARTERIAL BLOOD-PRESSURE RESPONSES OF 
HYPERTENSIVE RATS TO SOME DRUGS ACTING ON THE CENTRAL 
SYMPATHETIC MECHANISMS. 

248551 04-03 
DIFFERENTIAL EFFECTS OF ETHYLALCOHOL ON CONTRACTION OF 
ARTERIAL SMOOTH MUSCLE. 

251905 04-03 
DIFFERENTIAL EFFECTS OF ETHANOL AND MANNITOL ON CONTRACTION 
OF ARTERIAl SMOOTH MUSCLE 

253113 04-03 

ARTERIES 

RESPONSES OF ISOLATED HUMAN BASILAR ARTERIES TO 5- 

HYROXYTRYPAMINE, NORADRENALINE, SERUM, PLATELETS, AND 
ERYTHROCYTES. 

230739 01-13 
SEROTONIN ANTAGONISM IN ISOLATED CANINE CEREBRAL ARTERIES. 

252757 04-03 
ARTERY 

CEREBRAL ARTERIAL SPASM. PART 4. IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN INDUCED CONTRACTIONS OF THE 
CANINE BASH AR ARTERY 

243797 04-03 

ARYl 

EFFECT OF BENZOPYRENE AND CHLORPROMAZINE ON ARYL 
HYDROCARBON HYDROXYLASE ACTIVITY FROM RAT TISSUES. 

243793 04-03 
ASCENDING 

ASCENDING CATECHOLAMINE SYSTEMS AND MORPHINE ANALGESIA. 

232915 02-03 
BEHAVIORAL EFFECTS OF L 5 HYDROXYTRYPTOPHAN AFTER 

DESTRUCTION OF ASCENDING SEROTONERGIC PATHWAYS IN THE RAT: 
THE ROLE OF CATECHOLAMINERGIC NEURONS. 

241251 03-04 

ASCORBIC-ACID 

THE EFFECTS OF ASCORBIC-ACID (AA) PRETREATMENT ON 
AMPHETAMINE (A) EXCRETION IN MAN 

238797 03-13 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAIN 
MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS. 

246318 04-04 

ASIAIIA 

XEROSTOMIA AND ASIAIIA CAUSED BY PSYCHOTROPIC DRUGS AND 
THEIR TRFATMENl WITH TPMP (TRITHIO-P-METHOXYPHENYLPROPENE). 

233718 02-15 
ASPARTATE 

THF INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES 

252711 0403 

ASSAY 

CHLORPROMAZINE EXCRETION: ISOTOPE VERSUS CHEMICAL ASSAY 

229481 01-03 
ANTIACfTYLCHOLINt ACTIVITIES OF PSYCHOACTIVE DRUGS: A 

COMPARISON OF THE (3H)0UINUCLIDINYL BENZILATE BINDING ASSAY 
WIIH CONVENTIONAL METHODS. 

250360 04 02 



Psychopharmacology Abstract 



ASSAYS 

INEXPENSIVE EQUIPMENT FOR HIGH PRESSURE LIQUID 

CHROMATOGRAPHY: APPLICATION TO ASSAYS FOR TAURINE, 
GAMMA-AMINOBUTYRIC-ACID AND 5-HYDROXYTRYPTOPHAN 
(UNPUBLISHED PAPER). 

231278 01-1 
IMPROVED ASSAYS OF CHLORPROMAZINE AND ITS METABOLITES. 

238818 03-1 
ASSEMBLY 

THE TOKYO ASSEMBLY OF THE WORLD MEDICAL ASSOCIATION. 

248166 04- 

ASSESSING 

ASSESSING THE SAFETY AND EFFICACY OF INTERNATIONAL TRIALS IN 
PSYCHOPHARMACOLOGY. (UNPUBLISHED PAPER). 

232902 02- 
METHODOLOGY USED IN ASSESSING METHYLPHENIDATE AND CAFFEINI 
TREATMENT OF MINIMAL BRAIN-DYSFUNCTIONING CHILDREN. 

252798 04- 

ASSESSMENT 

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF 
TRICYCLIC ANTIDEPRESSANTS. 

226411 01- 

THE HAMILTON RATING SCALE. AN ASSESSMENT BASED ON A 

DOTHIEPIN (PROTHIADEN) VERSUS IMIPRAMINE (TOFRANIL) CLINICA 

TRIAL. 

226899 01 

CLOMACRAN IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS: A 
COMPARISON OF TWO ASSESSMENT METHODS. 

231034 01 
CLINICAL AND PHYSIOLOGICAL ASSESSMENT OF CHLORAZEPATE, 
DIAZEPAM AND PLACEBO IN ANXIOUS NEUROTICS. 

231036 01 
THE ASSESSMENT OF THIOTHIXENE IN CHRONIC SCHIZOPHRENIA: A 
DOUBLE-BLIND CONTROLLED TRIAL. 

231609 01 

INTRODUCTION TO THE SYMPOSIUM ON SYSTEMATIC STUDIES WITH 
PSYCHOACTIVE DRUGS - NEW METHODS IN THE ASSESSMENT OF 
CHANGE. 

235355 02 
CLOMACRAN IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS - A 
COMPARISON OF TWO ASSESSMENT METHODS. 

235364 02 
METHODS OF ASSESSMENT OF DRUG ADMINISTRATION IN A 
PSYCHIATRIC HOSPITAL. 

235545 02 
THE AUTOMATED ASSESSMENT OF THE EFFECT OF FLURAZEPAM AND 
NITRAZEPAM ON MOOD STATE. 

239010 03 
A RETROSPECTIVE ASSESSMENT OF THE LONG-TERM EFFECTS OF 

DOTHIEPIN. 

239820 03 

CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRON 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER). 

240241 03 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRON 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER 

243024 0^ 

ASSESSMENT OF CEREBPOSPINAL FLUID LEVELS OF DOPAMINE 
METABOLITES BY GAS CHRO/WATOGRAPHY. 

245300 0' 
ASSESSMENT OF DIAZEPAM AFTER THREE YEARS USE IN CHILD 

PSYCHIATRY. 

249144 0^ 

ASSESSMENT OF REINFORCING PROPERTIES OF AMPHETAMINE 
ANALOGUES IN SELF-ADMINISTERING RATS. 

250941 0' 
PSYCHOMETRIC ASSESSMENT OF THE THERAPEUTIC EFFICIENCY OF 
ANTIDEPRESSANT AGENTS. 

251004 0- 

NATURALISTIC ASSESSMENT OF NEUROLOGICAL DIAGNOSES AND 
PHARMACOLOGICAL INTERVENTION. 

251149 a 
RELATIONSHIP BETWEEN OBJECTIVE AND SUBJECTIVE ASSESSMENT 
EXPERIMENTALLY-INDUCED FATIGUE. 

253587 0. 

ASSISTANCE 

REFLECTIONS ON PSYCHIATRIC ASSISTANCE IN AN OUTPATIENT 
GERIATRIC CENTER: THE USE OF PSYCHOTROPIC DRUGS. 

239641 O: 

ASSISTING 

ASSISTING MULTIPLE DRUG ADDICTS. PSYCHOTHERAPY AND 
PSYCHOPHARMACOLOGY. 

237095 O: 

ASSOCIATION 

ASSOCIATION BETWEEN CLEFT LIP WITH OR WITHOUT CLEFT PALATE 
AND PRENATAL EXPOSURE TO DIAZEPAM. 

229349 



S-34 



ILUME 14, SUBJECT INDEX 



Subject Index 



ASSOCIATION BETWEEN MATERNAL INTAKE OF DIAZEPAM AND ORAL 
CLEFTS 

229350 CM 5 
FLUPHENAZINE-DECANOATE IN ASSOCIATION WITH OTHER 
PSYCHOTROPIC DRUGS (PRELIMINARY NOTE). 

22956T0M7 
THE TOKYO ASSEMBLY OF THE WORLD MEDICAL ASSOCIATION. 

248166 04-17 
THE INFLUENCE OF PYRITHIOXINE HYPERVENTILATION ASSOCIATION ON 
CSF LACTATE IN CEREBRAL INFARCTION PATIENTS. 

252713 04 11 
OCIATIVE 

THE EFFECT OF NEUROTROPIC AGENTS ON EVOKED POTENTIALS OF THE 
ASSOCIATIVE AND PROJECTION AREAS OF THE CAT NEOCORTEX. 

236261 02-03 
ONIN-H 

ASTONIN-H IN THE TREATMENT OF ARTERIAL HYPERTENSION DUE TO 
PSYCHOTROPIC DRUGS. 

240261 03 15 
MMETRIC 

CIRCLING BEHAVIOUR PRODUCED BY ASYMMETRIC MEDIAL RAPHE 
NUCLEI LESIONS IN RATS. 

250358 04 04 
EFFECT OF DOPAMINE AGONISTS AND ANTAGONISTS ON ASYMMETRIC 
BEHAVIOUR OCCURRING DURING PRECIPITATED MORPHINE 
WITHDRAWAL AFTER UNILATERAL INACTIVATION OF THE STRIATUM 
IN RATS. 

251402 04-04 
MMETRY 

DOPAMINE AGONIST INDUCED ASYMMETRY AFTER LESIONS OF 
SUPERIOR COLLICULUS IN RATS. 

238699 03-03 
INDIVIDUAL DIFFERENCES AMONG MICE IN NORMAL AND 
AMPHETAMINE-ENHANCED LOCOMOTOR ACTIVITY: RELATIONSHIP TO 
BEHAVIORAL INDICES OF STRIATAL ASYMMETRY. 

240750 03-04 
.RACTICS 

ON THE THIN LAYER CHROMATOGRAPHY OF SOME NONBARBITURETE 
HYPNOTICS AND ATARACTICS. 

243340 04-01 
.RAXIC 
ATARAXIC AND ANTIMANIC EFFECTS OF THIOXANTHENES. 

227768 01 09 
XIA 

CEREBELLAR ATAXIA DUE TO DIPHENYLHYDANTOIN ADMINISTRATION - 
CLINICAL AND PATHOLOGICAL STUDIES ON TWO CASES OF CHRONIC 
DIPHENYLHYDANTOIN INTOXICATION 

236696 02-15 
IMS 

EFFECTS OF D AMPHETAMINE ON THE INCORPORATION OF CARBON 
ATOMS OF D-GLUCOSE INTO THE BRAINS OF DIFFERENTIALLY HOUSED 
MICE. 

249672 04-04 
ASE 

THE INFLUENCE OF PSYCHOTROPIC AND ANTICONVULSANT AGENTS ON 
CONFORMANT TRANSITIONS IN THE TRANSPORT ATPASE. 

236715 02 03 
MECHANISMS OF QUINIDINE AND CHLORPROMAZINE INHIBITION OF 
SARCOTUBULAR ATPASE ACTIVITY. 

237245 02-03 
EFFECTS OF ANTICONVULSANT AND CONVULSANT DRUGS ON THE 
ATPASE ACTIVITIES OF SYNAPTOSOMES AND THEIR COMPONENTS. 

243801 0403 
lA 

EFFECTS OF SOME DOPAMINE ANALOGS AND HALOPERIDOL ON 
RESPONSE TO STIMULATION OF ADRENERGIC NERVES USING CAT 
ATRIA IN VITRO. 

241313 03-03 
lUM 

A COMPARISON OF 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL AND TETRAHYDROPAPAVEROLINE AN INHIBITORS OF 
MONOAMINE-OXIDASE WITHIN THE ADRENERGIC NERVE PLEXUS OF 
THE ISOLATED MOUSE ATRIUM 

248603 04-03 
OPINE 

THE EFFECTS OF ADRENALINE, RESERPINE, AND ATROPINE ON 
ACETYLCHOLINE CONTENT OF THE BRAIN AND PERIPHERAL GANGLIA 
IN STRESS. 

227635 01 03 
ATROPINE COMA THERAPY IN PSYCHIATRY: CLINICAL OBSERVATIONS 
OVER A 20- YEAR PERIOD AND A REVIEW OF THE LITERATURE. 

234826 02-17 
THE SUPPRESSION OF BEHAVIOUR IN RATS BY PREVIOUS EXPERIENCE 
AND ELECTRIC SHOCK AND ITS ANTAGONISM BY ATROPINE 

245305 04-04 
THE EFFECT OF ATROPINE UPON ACETYLCHOLINE RELEASE FROM CAT 
SUPERIOR CERVICAL GANGLIA AND RAT CORTICAL SLICES 
MEASUREMENT BY A RADIOENZYMIC METHOD 

248724 04-03 



INTERACTION OF ATROPINE OR METHYLATROPINIUM WITH FOUR 
EFFECTS OF TWO CHOLINERGIC DRUGS. 

251217 04-03 
ATROPINE-INDUCED 

OXOTREMORINE AND ATROPINE-INDUCED CHANGES OF DOPAMINE 
METABOLISM IN THE RAT STRIATUM. 

230854 01-03 
ATROPINESTERASE 

RESOLUTION, PURIFICATION AND CHARACTERIZATION OF RABBIT 
SERUM ATROPINESTERASE AND COCAINESTERASE. 

251180 04-01 
ATTACK 

A CRITICISM OF WILLIAM SARGANTS ATTACK ON THE MEDICAL 
RESEARCH COUNCILS STUDY OF MODITEN. 

235429 02-08 
ATTACKS 

SLEEP ATTACKS. 

240260 03-1 1 
ATTENTION 

THE INFLUENCES OF METHYLPHENIDATE ON HEARTRATE AND 

BEHAVIORAL MEASURES OF ATTENTION IN HYPERACTIVE CHILDREN 

231629 01-14 
THE EFFECTS OF INTRACRANIAL ADMINISTRATION OF NOREPINEPHRINE 
AND INTRAPERITONEAL CHLORPROMAZINE ON ATTENTION IN THE 
RAT. 

238755 0304 
MEASUREMENT OF ATTENTION DEFICIT IN THE COURSE OF 
INTOXICATIONS. 

244896 04 14 
DIVIDED ATTENTION PERFORMANCE OF CANNABIS USERS AND 
NONUSERS FOLLOWING CANNABIS AND ALCOHOL 

246305 04-13 
ATTENTIONAL 

EFFECT OF CARBAMAZEPINE (TEGRETOL) ON ATTENTIONAL AND 
PERCEPTUAL FUNCTIONS OF CHILDREN WITH EPILEPSY. 

251949 04-11 
ATTENTIVE 

INFLUENCE OF SECOBARBITAL AND CHLORPROMAZINE ON PRECENTRAL 
NEURON ACTIVITY DURING ATTENTIVE BEHAVIOR IN MONKEYS. 

239848 03 04 
ATTENUATED 

TWENTY-FOUR-HOUR RETENTION OF CHLORDIAZEPOXIDE (LIBRIUM) 
ATTENUATED THREAT BEHAVIOR IN MALE SIAMESE FIGHTING FISH 
(BETTASPLENDENS). 

242892 04-04 
TETRAHYDROCANNABINOL ATTENUATED ABSTINENCE AND INDUCED 
ROTATION IN MORPHINE-DEPENDENT RATS: POSSIBLE INVOLVEMENT 
OF DOPAMINE. 

245601 04-04 
ATTENUATION 

ATTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE 
DEPENDENT RATS BY DELTA9-THC. 

232615 02-04 
ATTENUATION BY ALPHA-METHYLTYROSINE OF AMPHETAMINE INDUCED 
CONDITIONED TASTE AVERSION IN RATS 

237713 02-04 
ATTENUATION OF THE EUPHORIANT AND ACTIVATING EFFECTS OF D- 
AMPHETAMINE AND AND L AMPHETAMINE BY LITHIUM CARBONATE 
TREATMENT. 

237716 02-14 
ATTENUATION OF AMPHETAMINE ANOREXIA BY UNILATERAL NIGRAL 
STRIATAL LESIONS. 

237777 02 03 
LYSERGIC-ACID-DIETHYLAMIDE AND MESCALINE INDUCED ATTENUATION 
OF THE EFFECT OF PUNISHMENT IN THE RAT. 

252824 04-04 
ATTITUDES 

PROVIDERS AS PRESCRIBERS: ATTITUDES TOWARD ASPECTS OF 
PRESCRIBING AND THEIR RELATIONSHIP TO MANAGEMENT OF 
HYPERTENSION IN THE ELDERLY. 

227923 OMl 
ATTRIBUTED 

PROLONGED PSYCHOSIS ATTRIBUTED TO PHENCYCLIDINE. REPORT OF 
THREE CASES. 

234713 02 15 
ATYPICAL 

ATYPICAL AND SEVERE FORMS OF DEPRESSION 

234597 02-09 
AUDIOGENIC 

INVOLVEMENT OF CORTICOSTEROIDS IN ACOUSTIC INDUCTION OF 
AUDIOGENIC SEIZURE SUSCEPTIBILITY IN MICE 

237706 02-03 
THE INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES 

25271 1 04 03 



c 
I 



dS 

§1 
I 

s- 



S-35 



Subject Index 



Psychopharmacology Abstract 



AUDIOVISUAL 

DIFFERENTIAL POTENCY OF TASTE AND AUDIOVISUAL STIMULI IN THE 
CONDITIONING OF MORPHINE WITHDRAWAL IN RATS. 

251978 04-04 
AUDITORY 

EFFECTS OF METHYLPHENIDATE ON AUDITORY INTENSITY 

DISCRIMINATION AND GENERALIZATION IN THE IMMATURE RAT. 
(PH.D. DISSERTATION). 

231533 01 04 
THE EFFECT OF SMALL CONCENTRATIONS OF SODIUM PENTOBARBITAL 
ON AUDITORY EVOKED RESPONSES. 

234682 02-03 
EFFECTS OF SELECTED DRUGS ON AN AUDITORY OR THALAMIC 
CONDITIONED STIMULUS ELICITING RECRUITMENT IN THE CAT. 

246967 04-04 
AUTISM 

PHARMACOTHERAPY IN EARLY INFANTILE AUTISM. 

229921 01-11 
AUTOAAATED 

THE AUTOMATED ASSESSMENT OF THE EFFECT OF FLURAZEPAM AND 
NITRAZEPAM ON MOOD STATE. 

239010 03-15 
AUTOMATIC 

AUTOMATIC REGISTRATION OF BEHAVIOUR RELATED TO DOPAMINE AND 
NORADRENALINE TRANSMISSION. 

250086 04-04 
AUTOMOBILE 

THE INTERACTION BETWEEN DRUGS, ALCOHOL AND DRIVING AN 
AUTOMOBILE 

244453 04-15 
AUTOMUTILATION 

AUTOMUTILATION INDUCED BY CLONIDINE IN MICE. 

241398 03-04 
AUTONOMIC 

THE THERAPY OF AUTONOMIC REGULATORY DISTURBANCES THROUGH 
DRUGS 

232260 01-15 
HYPOTHALAMIC CHEMOSTIMULATION AND AUTONOMIC CHANGES IN 
CURARIZED RATS. 

244691 04-03 
AUTOOXIDATION 

EFFECTS OF SUPEROXIDE DISMUTASE ON THE AUTOOXIDATION OF 7,8 
DIHYDROXYCHLORPROMAZINE IN THE PRESENCE OF RAT BRAIN 
MITOCHONDRIA. 

236521 02-03 
AUTORADIOGRAPHIC 

THE AUTORADIOGRAPHIC LOCALIZATION OF (3H)DEXAMETHAS0NE IN 
THE BRAIN AND PITUITARY OF THE RAT. 

237864 02-03 
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF H3- 
TRIMETHOXY-BETA-PHENYLETHYLAMINE IN THE MOUSE. 

239855 03-03 
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF H3-MESCALINE 
IN THE BRAIN OF THE MARMOSET, CALLITHRIX-JACCHUS. 

239864 03-03 
COMPARATIVE AUTORADIOGRAPHIC AND METABOLIC STUDY OF 
DELTAS AND DELTA9TETRAHYDR0CANNABIN0L IN THE BRAIN OF 
THE MARMOSET CALLITHRIX JACCHUS 

244681 04-03 
AUTORADIOGRAPHIC DISTRIBUTION STUDY OF 14C DOPA IN CAT BRAIN. 

253393 04-03 
AVAILABILITY 

STUDIES ON THE CNS AVAILABILITY OF AMPHETAMINE FROM 
AMPHETAMINIL 

229041 01 03 
AVERAGE 

INTRAVENOUS L DOPA PLUS CARBIDOPA IN DEPRESSED PATIENTS: 

AVERAGE EVOKED RESPONSE, LEARNING, AND BEHAVIORAL CHANGES. 

244664 04 09 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
METHYLTRANSFERASE, AND FAMILY HISTORY. 

246629 04-09 
AVERSION 

C0NDI1I0NED AVERSION BY PSYCHOACTIVE DRUGS: DOES IT HAVE 
SIGNIFICANCE FOR AN UNDERSTANDING OF DRUG DEPENDENCE 

233488 02-14 
ATTENUATION BY ALPHA METHYLTYROSINE OF AMPHETAMINE-INDUCED 
CONDITIONED TASTE AVERSION IN RATS 

237713 02-04 
CYCLOHEXIMIDE INDUCED AMNESIA FOR TASTE AVERSION MEMORY IN 
RATS 

242742 03 04 
HORMONAI INFLUENCES ON IHE EXTINCTION OF CONDITIONED TASTE 
AVERSION 

251980 04-04 



RAT DATA WHICH SUGGEST ALCOHOLIC BEVERAGES SHOULD BE 
SWALLOWED DURING CHEMICAL AVERSION THERAPY, NOT JUST 
TASTED. 

252859 04-1 
AVERSIONS 

EFFECTS OF DRUG EXPERIENCE ON DRUG-INDUCED CONDITIONED TASTE 
AVERSIONS: STUDIES WITH AMPHETAMINE AND FENFLURAMINE. 

230829 01 -( 
FORMATION AND RETENTION OF CONDITIONED TASTE AVERSIONS AND 
UCS HABITUATION. 

241521 03-( 
TASTE AVERSIONS INDUCED BY D-AMPHETAMINE: DOSE-RESPONSE 
RELATIONSHIP. 

242882 04-( 
EFFECTS OF ALCOHOL AND LITHIUM HABITUATION ON THE 

DEVELOPMENT OF ALCOHOL AVERSIONS THROUGH CONTINGENT 
LITHIUM INJECTION. 

246093 04-1 
ANOREXIA AND CONDITIONED TASTE AVERSIONS IN THE RAT. 

251629 04-( 
AVERSIVE 

THE EFFECT OF CHRONIC CENTRAL ADRENERGIC DENERVATION ON 
LEARNING AND MEMORY OF AN AVERSIVE DISCRIMINATION TASK II 
MICE: STUDIES WITH 6-HYDROXYDOPAMINE. (PH.D. DISSERTATION). 

238157 02-1 
EFFECTS OF HALOPERIDOL ON AVERSIVE THRESHOLD OF RATS. 

240886 03-1 
THE EFFECTS OF MEPROBAAAATE UPON THE AVERSIVE THRESHOLD OF 
RATS. 

242894 04-1 
AVERSIVE EFFECTS OF REPEATED INJECTIONS OF THC IN RATS. 

249158 04-1 
AVERSIVELY 

TIME-DEPENDENT VARIATIONS IN AVERSIVELY MOTIVATED BEHAVIORS 
NONASSOCIATIVE EFFECTS OF CHOLINERGIC AND 
CATECHOLAMINERGIC ACTIVITY. 

245486 04- 
AVIAN 

REGULATION OF PROTEIN PHOSPHORYLATION AND MEMBRANE 

PERMEABILITY BY BETA-ADRENERGIC AGENTS AND CYCLIC ADENOSI 
3:5-MONOPHOSPHATE IN THE AVIAN ERYTHROCYTE. 

231014 01- 
AVOIDANCE 

FACILITATION AND DISRUPTION BY MESCALINE OF SHUTTLEBOX 
AVOIDANCE IN RATS. (PH.D. DISSERTATION). 

226991 01- 
THE EFFECT OF ADRENALINE, TYRAMINE AND GUANETHIDINE ON TWO- 
WAY AVOIDANCE CONDITIONING AND ON PSEUDOCONDITIONING. 

227138 01- 
5 METHOXY N,N:DIMETHYLTRYPTAMINE (5-MEO-DMT) SHARES 

INHIBITORY EFFECTS WITH MESCALINE BUT NOT EXCITATORY EFFEC 
ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS. (UNPUBLISHED PAPEI 

227802 01- 
EFFECTS OF PHYSOSTIGMINE ON AVOIDANCE CONDITIONING AND 
RETENTION IN THE ISOLATED COCKROACH GANGLION. (PH.D. 
DISSERTATION). 

228503 01- 
MORPHINE ENHANCEMENT OF SHUTTLE AVOIDANCE PREVENTED BY 
ALPHA-METHYLTYROSINE. 

230825 01- 
STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 
EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT. 

230860 01- 
THE INFLUENCE OF D,L-AMPHETAMINE AND CAFFEINE ON CAUDATE 
INHIBITION OF CONDITIONED AVOIDANCE REACTIONS IN CATS. 

231248 01- 
AVOIDANCE BEHAVIOR IN VITAMIN-B6 DEFICIENT RATS. 

232639 02- 
INERT GAS NARCOSIS: AVOIDANCE BEHAVIOR IN RATS BREATHING 
ELEVATED PRESSURES OF NITROGEN AND HELIUM. 

235511 02- 
EFFECTS OF PROTEIN SYNTHESIS INHIBITION ON MEMORY FOR ACTIVE 
AVOIDANCE TRAINING. 

237264 02- 
EFFECTS OF MORPHINE AND NARCOTIC ANTAGONISTS ON AVOIDANCE 
BEHAVIOR OF THE SQUIRREL-MONKEY. 

237754 02- 
ANALYTICAL STUDY OF ACQUISITION ON FREE-OPERANT AVOIDANCE 
RESPONSE FOR EVALUATION OF PSYCHOTROPIC DRUGS IN RATS 

238564 02- 
IMPAIRED ACQUISITION OF A PASSIVE AVOIDANCE RESPONSE AFTER 
LESIONS INDUCED IN THE LOCUS-COERULEUS BY 6-OH-DOPAMINE 

239841 03- 
EFFECTS OF INTRAVENOUS ANESTHETICS ON CONTINUOUS AVOIDANCE 
BEHAVIOR IN THE RAT ^ 

241314 03- 
COMPARISON OF THE EFFECTS OF NEUROLEPTICS ON SELF-STIMULATIO 
AND CONDITIONED AVOIDANCE RESPONSE IN RATS 

241375 03- 



S-36 



>LUME 14, SUBJECT INDEX 



Subject Index 



THE EFFECTS OF INTRA AMYGDALOID INJECTIONS OF 6- 

HYDROXYDOPAMINE ON AVOIDANCE RESPONDING IN RATS. 

241918 03-04 
THE EFFECTS OF INTRA-AMYGDALOID INJECTIONS OF 6- 

HYDROXYDOPAMINE ON AVOIDANCE RESPONDING IN RATS. 

243758 04-04 
THE EFFECT OF LITHIUM CHLORIDE ON ONE-TRIAL PASSIVE AVOIDANCE 
LEARNING IN RATS. 

243804 04-04 
EFFECTS OF N-HYDROXYETHYL-PYRROLIDINIUM METHIODIDE, A CHOLINE 
ANALOGUE, ON PASSIVE AVOIDANCE BEHAVIOUR IN MICE. 

245594 04-04 
DOSE-RESPONSE EFFECTS OF D-AMPHETAMINE ON PASSIVE AVOIDANCE 
LEARNING IN THE RAT. 

246313 04-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON ACTIVE AVOIDANCE 
ACQUISITION AND PASSIVE AVOIDANCE RETENTION IN RATS WITH 
AMYGDALOID LESIONS. 

246819 04-04 
BENZODIAZEPINES AND AMPHETAMINE ON AVOIDANCE BEHAVIOUR IN 
MICE. 

247778 04-02 
EFFECTS OF CHLORDIAZEPOXIDE, CNS STIMULANTS AND THEIR 
COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE. 

249026 04-04 
THE EFFECT OF LITHIUM CHLORIDE ON ONE-TRIAL PASSIVE AVOIDANCE 
LEARNING IN RATS. 

249381 04-04 
INHIBITION OF CEREBRAL PROTEIN SYNTHESIS: PERFORMANCE AT 
DIFFERENT TIMES AFTER PASSIVE AVOIDANCE TRAINING. 

250060 04-14 
CHRONIC DELTA9-TETRAHYDR0CANNABIN0L. TRANSIENT AND LASTING 

EFFECTS ON AVOIDANCE BEHAVIOR. 

250061 04-04 
ROLE OF STIMULUS LOCALE ON STRAIN DIFFERENCES IN ACTIVE 

AVOIDANCE AFTER SCOPOLAMINE OR D-AMPHETAMINE TREATMENT. 

250074 04-04 
EFFECTS OF CHLORPROMAZINE ON AVOIDANCE AND ESCAPE 
RESPONDING IN HUMANS. 

250076 04-14 
MODIFICATION OF CONDITIONED AVOIDANCE AND TURNING BEHAVIOUR 
BY BACLOFEN AND ITS INFLUENCE ON CHOLINERGIC DOPAMINERGIC 
NERVOUS SYSTEM. 

251397 04-03 
THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L AND LSD ON THE 
ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN THE RAT. 

251979 04-04 
ACUTE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE 
ACQUISITION OF SHUTTLEBOX CONDITIONED AVOIDANCE RESPONSE. 

251989 04-04 
ACTIVITY, AVOIDANCE LEARNING AND REGIONAL 5- 

HYDROXYTRYPTAMINE FOLLOWING INTRABRAIN STEM 5,7 
DIHYDROXYTRYPTAMINE AND ELECTROLYTIC MIDBRAIN RAPHE 
LESIONS IN THE RAT. 

252173 04-03 
BEHAVIORAL DEPRESSION IN SIDMAN AVOIDANCE LEARNING INDUCED 
BY DOPAMINE-BETA-HYDROXYLASE INHIBITORS. 

253450 04-04 

^KE 

THE ACTION OF NOREPINEPHRINE IN THE RAT HIPPOCAMPUS III 
HIPPOCAMPAL CELLULAR RESPONSES TO LOCUS-COERULEUS 
STIMULATION IN THE AWAKE RAT. 

252012 04-03 

)NAL 

SPECIFIC AXONAL EFFECTS OF A CONVULSANT BARBITURATE. 

249258 04-03 
INS 

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE 
DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING 
NEURONS AND AXONS BY GLYOXYLIC-ACID INDUCED FLUORESCENCE: 
II. A DETAILED DESCRIPTION OF METHODOLOGY. (UNPUBLISHED 
PAPER). 

236875 02-06 
IPLASMIC 
AXOPLASMIC TRANSPORT OF NOREPINEPHRINE IN THE RAT BRAIN. 

243791 04-03 
MONOAMINES AS POSSIBLE MEDIATORS IN THE REGULATION OF FAST 
AXOPLASMIC FLOW. 

253407 04-03 
ITOMY 

EFFECTS OF AXOTOMY ON THE TRANS-SYNAPTIC REGULATION OF 
ENZYME ACTIVITY IN ADULT RAT SUPERIOR CERVICAL GANGLIA. 

244200 04-03 
13028 

THE BEHAVIORAL PHARMACOLOGY OF BUTACLAMOL HYDROCHLORIDE 
(AY-23028), A NEW POTENT NEUROLEPTIC DRUG. 

245295 04-04 



AZAFEN 

EFFECT OF AZAFEN ON THE ELECTROENCEPHALOGRAM. 

234430 02- 1 3 
CLINICAL EVALUATION OF THE ANTIDEPRESSIVE ACTION OF THE 
PREPARATION AZAFEN. 

236429 02-10 
AZAPEROL 

AZAPEROL, A NEW METABOLITE OF THE VETERINARY BUTYROPHENONE 
TRANQUILIZER AZAPERONE. 

241359 03-02 
AZAPERONE 

THE EFFECTS OF AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE 

BUTYROPHENONE SERIES, ON DOMINANT SUBORDINATE BEHAVIOUR 
IN WISTAR RATS COMPETING FOR FOOD. 

225571 01-04 
AZAPEROL, A NEW METABOLITE OF THE VETERINARY BUTYROPHENONE 
TRANQUILIZER AZAPERONE 

241359 03-02 
EFFECTS OF AZAPERONE ON CARDIOVASCULAR AND RESPIRATORY 
FUNCTIONS IN THE HORSE. 

243759 04-03 
A23I87 

lONOPHORES X573A AND A23187: EFFECTS ON THE PERMEABILITY OF 
LIPID BIMOLECULAR MEMBRANES TO DOPAMINE AND CALCIUM. 
(UNPUBLISHED PAPER). 

236873 02-03 
B-9 

SYNAPTOSOMAL UPTAKE AND LEVELS OF SEROTONIN IN RAT BRAIN 
AREAS AFTER P-CHLOROAMPHETAMINE OR B 9 LESIONS. 

248414 04-05 
BABOON 

BIOGENIC AMINES AND THE PHOTOMYOCLONIC SYNDROME IN THE 
BABOON, PAPIO-PAPIO. 

237755 02-04 
CONTRASTING EFFECTS OF MORPHINE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN THE CHIMPANZEE AND BABOON. 

246854 04-02 
BABOONS 

EFFECTS OF TETRAHYDROCANNABINOLS ON KINDLED AMYGDALOID 
SEIZURES AND PHOTOGENIC SEIZURES IN SENEGALESE BABOONS, 
PAPIO-PAPIO. 

230475 01-03 
BACKGROUND 

THE NATURE OF BACKGROUND SPIKE ACTIVITY OF CORTICAL NEURONS 
UNDER THE ACTION OF PSYCHOTROPIC DRUGS. 

236265 02-03 
BACLOFEN 

BACLOFEN (BE): AN UNUSUAL CNS ACTIVE AGENT. 

249304 04-03 
MODIFICATION OF CONDITIONED AVOIDANCE AND TURNING BEHAVIOUR 
BY BACLOFEN AND ITS INFLUENCE ON CHOLINERGIC DOPAMINERGIC 
NERVOUS SYSTEM. 

251397 04-03 
ALTERATION OF DOPAMINE METABOLISM IN RAT BRAIN BY BACLOFEN 

(LIORESAL (R)). 

251398 04 03 
BARBITAL 

EFFECT OF CHRONIC BARBITAL ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL ON CATECHOLAMINE CONTENT AND TURNOVER IN RAT 
BRAIN. 

238790 03 03 
BARBITAL ALTERATION OF CENTRAL-NERVOUSSYSTEM SENSITIVITY TO 
HEXOBARBITAL IN THE RAT. 

244688 04-03 
LONG-TERM EFFECTS OF BARBITAL ON SPONTANEOUS ACTIVITY OF RATS 
TRAINED TO USE THE DRUG AS A DISCRIMINATIVE STIMULUS. 

245299 04-04 
DISCRIMINATIVE STIMULUS PROPERTIES OF ETHANOL AND BARBITAL. 

249262 04-04 
EFFECT OF RESTRICTION OF MOVEMENT AND BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE HYDROCHLORIDE ON 
SODIUM BARBITAL ACTIVITY IN THE RAT. 

249278 04-04 
BARBITAL-INDUCED 

BARBITAL-INDUCED CROSS TOLERANCE TO BARBITURATES BY THE 
INTRACISTERNAL ROUTE OF ADMINISTRATION. 

231011 01-03 
BARBITURATE 

IMMUNOLOGIC INVESTIGATION OF BARBITURATE PHARMACOLOGY. 

229480 01-03 
BARBITURATE SPINDLE ACTIVITY IN FUNCTIONALLY CORRESPONDING 
THALAMIC AND CORTICAL SOAAATOSENSORY AREAS IN THE CAT. 

232606 02-03 
BARBITURATE SPINDLE ACTIVITY IN THE THALAMIC LATERAL 

VENTROPOSTERIOR NUCLEUS AND THE SECOND SOMATOSENSORY 
AREA OF THE CORTEX. 

232607 02-03 



i 



s 



s 



S-37 






Subject Index 



Psychopharmacology Abstrac 



BARBITURATE REINFORCED RESPONDING IN RHESUS MONKEYS: 

COMPARISONS OF DRUGS WITH DIFFERENT DURATIONS OF ACTION. 

237874 02-04 
PASSIVE BARBITURATE IMMUNITY IN MICE: EFFECT ON SERUM LEVELS 
AND PHARMACOLOGIC RESPONSE TO ADMINISTERED BARBITURATES. 

238763 03-03 
LOSS OF INHIBITION IN SPINAL CORD DURING BARBITURATE 
WITHDRAWAL 

238770 03-03 
BARBITURATE INTOXICATION: MORBIDITY AND MORTALITY. 

240843 03-15 
SUSCEPTIBILITY TO ELECTROSHOCK CONVULSION AFTER BARBITURATE 
PELLET IMPLANTATION IN THE MOUSE. 

249254 0405 
SPECIFIC AXONAL EFFECTS OF A CONVULSANT BARBITURATE. 

249258 04-03 
BARBITURATE RESPONSE IN IMMUNIZED MICE. 

249297 04-03 
ACUTE TOLERANCE TO BARBITURATE IN THE RAT. 

250077 04-04 
EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251130 04-02 
AMPHETAMINE AND BARBITURATE EFFECTS ON TWO TASKS PERFORMED 
SINGLY AND IN COMBINATION. 

253381 04-14 
BARBITURATE-INDUCED 

THE POTENTIATION OF BARBITURATE-INDUCED NARCOSIS BY 
PROCARBAZINE. 

250109 04-03 
BARBITURATE-LIKE 

STUDY OF DEVELOPMENT OF TOLERANCE TO AND BARBITURATE-LIKE 
PHYSICAL DEPENDENCE ON THE TRANQUILLIZER TEMPIDON. 

240205 03-05 
BARBITURATE-TOLERANCE 

BRAIN LIVER INTERRELATIONSHIP IN BARBITURATE-TOLERANCE. 

229490 01-03 
A NOVEL METHOD FOR RAPID DEVELOPMENT OF BARBITURATE- 
TOLERANCE AND PHYSICAL DEPENDENCE IN MICE. 

238701 03-03 
A STUDY ON THE DEVELOPMENT OF BARBITURATE-TOLERANCE AND 
DEPENDENCE IN HAMSTER GLIAL CELLS IN CULTURE. 

241348 03-03 
BARBITURATE-TOLERANT 

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANTS AND BARBITURATES IN 
BARBITURATE TOLERANT AND NONTOLERANT RATS. 

226849 01-03 
BARBITURATES 

INTERACTIONS OF TRICYCLIC ANTIDEPRESSANTS AND BARBITURATES IN 
BARBITURATE-TOLERANT AND NONTOLERANT RATS. 

226849 01-03 
INTERACTIONS OF ALCOHOL, BARBITURATES, AND NARCOTICS WITH 
BLOOD VESSELS. 

229474 01-03 
CONTRACTOR EFFECT OF BARBITURATES ON SMOOTH MUSCLE 

230454 01-03 
BARBITAL INDUCED CROSS TOLERANCE TO BARBITURATES BY THE 
INTRACISTERNAL ROUTE OF ADMINISTRATION. 

231011 01-03 
CURB ON BARBITURATES. 

231749 01-17 
CHARACTERIZATION OF HYDROGEN BONDING BETWEEN SELECTED 
BARBITURATES AND POLYETHYLENE-GLYCOL-4000 BY IR SPECTRAL 
ANALYSIS. 

233276 02-01 
A COMPARISON OF THE POTENCIES OF A SERIES OF BARBITURATES AT 
THE NEUROMUSCULAR JUNCTION AND ON THE CENTRAL-NERVOUS- 
SYSTEM 

233289 02-03 
IHE DISTRIBUTION AND METABOLISM OF ETHANOL AND BARBITURATES 
IN THE ORGANISM DURING THEIR COMBINED USE (LITERATURE 
SURVEY). 

236717 02-03 
BARBITURATES BLOCK CALCIUM UPTAKE BY STIMULATED AND 
POTASSIUM DEPOLARIZED RAT SYMPATHETIC GANGLIA. 

237751 02-03 
LOCAL ANESTHETICS AND BARBITURATES: EFFECTS ON EVOKED 
POTENTIALS IN ISOLATED MAMMALIAN CORTEX 

237875 02-03 
SOLUBILIIY OF STRAIGHT CHAIN AND BRANCHED ALKYL BARBITURATES 
IN STRAIGHT-CHAIN ALCOHOLS. 

238487 02-01 
PTRMETHYLATION OF BARBITURATES: VARIATION IN PRODUCT RATIOS 

WITH VARYING METHYLSULFINYLMETHIDE CARBANION. 

238488 02-01 
PASSIVI BARBITURATE IMMUNITY IN MICE: EFFECT ON SERUM LEVELS 

AND PHARMACOLOGIC RESPONSE TO ADMINISTERED BARBITURATES 

238763 03-03 



RESPONSE TO DELTA9-TETRAHYDR0CANNABIN0L, BARBITURATES AND 
ETHANOL IN LACTATING, VIRGIN FEMALE. AND MALE MICE. 

238766 03 

INFLUENCE OF DRUGS AND CHEMICALS UPON HEPATIC ENZYMES AND 
PROTEINS - I. STRUCTURE ACTIVITY RELATIONSHIP BETWEEN 
VARIOUS BARBITURATES AND MICROSOMAL ENZYME INDUCTION ir 
RAT LIVER. 

241297 03 

EFFECTS OF BARBITURATES ON BLOOD-PRESSURE IN LIDOCAINE 
INJECTED SHR. 

241405 03 
MODIFICATIONS OF EFFECTS OF CHLORPROMAZINE ON ADRENERGIC 

DRUGS AND BARBITURATES BY REPEATED ADMINISTRATION TO RA 

241406 03 
MATERNAL AND NEONATAL ELIMINATION OF AMOBARBITAL AFTER 

TREATMENT OF THE MOTHER WITH BARBITURATES DURING LATE 
PREGNANCY. 

243085 04 
BARBITURATES. 

250715 04 
BARRIER 

EFFECTS OF CAFFEINE AND ETHANOL ON THE BLOOD-BRAIN BARRIER I 
RATS. 

252222 04 
BASAL 

INTERACTION BETWEEN POSSIBLE TRANSMITTERS AND 

BUTYROPHENONES APPLIED MICROELECTROPHORETICALLY IN THE 
CEREBELLUM AND BASAL GANGLIA OF THE CAT. 2ND REPORT: 
EFFECTS OF SOME PHENOTHIAZINES ON THE PURKINJE CELLS OF TH 
CEREBELLUM. 

241386 03 
BASELINE 

EXTINCTION-INDUCED MIRROR RESPONDING AS A BASELINE FOR 
STUDYING DRUG EFFECTS ON AGGRESSION. 

250073 04 
BASILAR 

RESPONSES OF ISOLATED HUMAN BASILAR ARTERIES TO 5- 

HYROXYTRYPAMINE, NORADRENALINE, SERUM, PLATELETS, AND 
ERYTHROCYTES. 

230739 01 
CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGIC/l 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04 
BATTERY 

THE EFFECTS OF DRUGS ON PSYCHIATRIC PATIENTS PERFORMANCE 01 
THE HALSTEAD-REITAN NEUROPSYCHOLOGICAL TEST BATTERY. 

229650 01 
A COMPARATIVE STUDY OF THIOTHIXENE AND CHLORPROMAZINE IN 
CHRONIC SCHIZOPHRENIC PATIENTS: APPLICATION OF SPECIAL 
PSYCHOMETRIC TEST BATTERY. 

235366 02 
BC-51 

THERAPY OF PSYCHOPHARMACEUTICAL SIDE-EFFECTS WITH 
DISTIGMINBROMIDE (UBRETID, BC-5!). 

239782 03 
BEAGLE 

TOXICITY OF MARIJUANA AND TOBACCO SMOKING IN THE BEAGLE. 

229034 01 
THE EFFECT OF CHRONIC MARIHUANA SMOKING ON THE BEAGLE DOG 

238806 03 
EFFECT OF DELTA9-THC ON PHYSICAL SYMPTOMS AND EEC IN THE 
NATURALLY EPILEPTIC BEAGLE. 

238811 03 
BEAM 

ELECTRON BEAM IONIZATION MASS FRAGMENTOGRAPHIC ANALYSIS i 
TRICYCLIC ANTIDEPRESSANTS IN HUMAN PLASMA. 

238486 02 
BEHAVIOR 

DRUGS IN THE MANAGEMENT OF LEARNING AND BEHAVIOR DISORDEI 
IN SCHOOL CHILDREN. 

225783 01 
EFFECTS OF PHENOBARBITAL GIVEN TO PREGNANT MICE ON BEHAVIO 
OF MATURE OFFSPRING 

226528 01 
RELATIONSHIP OF RATS SPATIAL PREFERENCES TO EFFECTS OF D- 
AMPHETAMINE ON TIMING BEHAVIOR 

226729 01 
EFFECTS OF D-AMPHETAMINE ON THE BEHAVIOR OF PIGEONS 

MAINTAINED BY A SECOND-ORDER SCHEDULE OF REINFORCEMENT. 

226852 01 
RATE-DEPENDENT EFFECTS OF DRUGS ON THE VARIABLE-INTERVAL 
BEHAVIOR OF RATS 

226854 01 
INTERACTIONS OF ADRENERGIC STIMULANTS AND BLOCKERS ON SELF 
STIMULATION BEHAVIOR IN RATS. 

226943 01 



S-38 



LUME 14, SUBJECT INDEX 



Subject Index 



OPERANT ANALYSIS OF BEHAVIOR ASSOCIATED WITH ORAL SELf- 
ADMINISTRATION OF DRUG SOLUTIONS IN RATS. (PH.D. 
DISSERTATION). 

226992 01-04 
RECENT VIEWS IN PSYCHOPHARMACOLOGY: BEHAVIOR 
PHARMACOLOGICAL ASPECTS. 

228309 01 17 
NEUROTRANSMITTER INFLUENCES ON AMTING BEHAVIOR IN MALE 
RATS. (PH.D. DISSERTATION). 

228390 01-04 
FHE CLINICAL APPLICATION OF LABORATORY ANIMAL EXPERIMENTAL 
FINDINGS: TREATMENT OF HYPERSEXUALIZED BEHAVIOR IN A MALE. 

229037 01-11 
ATTEMPTS AT A NEUROCHEMICAL INTERPRETATION OF NATURAL 
BEHAVIOR AND BEHAVIOR MODIFIED BY NEUROLEPTIC DRUGS. 

229113 01-14 
INTERACTION OF MESCALINE WITH PHENOTHIAZINES: EFFECT ON 
BEHAVIOR, BODY TEMPERATURE, AND TISSUE LEVELS OF 
HALLUCINOGEN IN MICE. 

229264 01-04 
(MIPRAMINE, BEHAVIOR THERAPY, AND PHOBIA 

229451 01-10 
3EHAVI0R ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION OF 
BENZODIAZEPINES. 

229461 01-04 
=OLICACID AND BEHAVIOR. 

229476 01-03 
DRUG SCHEDULE INTERACTIONS AND INTERCURRENT BEHAVIOR. 

229479 01-04 
DRUGS, BEHAVIOR, AND THE CHOLINERGIC NERVOUS SYSTEM. 

229485 01-04 
STUDY OF SEROTONIN AND ACTH BRAIN LEVELS AND BEHAVIOR. 

229498 01-03 
NEUROPHARMACOLOGY OF BRAIN MONOAMINES AND BEHAVIOR. 

229499 01-04 
EFFECTS OF D-AMPHETAMINE, CHLORPROMAZINE, AND 

CHLORDIAZEPOXIDE ON INTERCURRENT BEHAVIOR DURING SPACED 
RESPONDING SCHEDULES. 

229639 01-04 
APPEARANCE OF WET DOG SHAKE BEHAVIOR DURING COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT AND ITS SUPPRESSION BY 
RESERPINE. 

230836 01-04 
DIFFERENTIATION BY MORPHINE OF TWO TYPES OF AGGRESSIVE 
BEHAVIOR IN THE CONVICT CICHLID (CICHLASOMA- 
NIGROFASCIATUM). 

230865 01-04 
THE SELECTIVE EFFECTS OF ALPHA-METHYL AROMATIC AMINO-ACIDS ON 
BRAIN MONOAMINE METABOLITES AND BEHAVIOR IN CATS. 

231009 01-03 
DRUGS AND BEHAVIOR: A PRIMER IN NEUROPSYCHOPHARMACOLOGY 

231227 01-17 
EFFECT OF VENTROMEDIAL HYPOTHALAMIC PROCAINE INJECTIONS ON 
FEEDING, LEVER PRESSING, AND OTHER BEHAVIOR IN RATS. 

231707 01-04 
COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 

232483 01-04 
iVVOIDANCE BEHAVIOR IN VITAMIN-B6 DEFICIENT RATS. 

232639 02-04 
EFFECTS OF COMBINING METHYLPHENIDATE AND CLASSROOM TOKEN 
SYSTEM IN MODIFYING HYPERACTIVE BEHAVIOR. 

232807 02-11 
i/IOLENT BEHAVIOR, BRAIN DYSRHYTHMIA, AND GLUCOSE 
DYSFUNCTION: A NEW SYNDROME. 

233870 02- 11 
DRUG-INDUCED STEREOTYPED BEHAVIOR: SIMILARITIES AND 
DIFFERENCES. 

233963 02-03 
EATECHOLAMINES, DRUGS, AND BEHAVIOR: MUTUAL INTERACTIONS. 

233968 02-04 
rHE EFFECT OF CATECHOL-0-METHYLTRANSFERASE INHIBITORS ON 

BEHAVIOR AND DOPAMINE METABOLISM. 

233969 02-03 
\DAPTIVE CHANGES IN BEHAVIOR AFTER REPEATED ADMINISTRATION 

OF VARIOUS PSYCHOACTIVE DRUGS. 

234810 02-04 
NERT GAS NARCOSIS: AVOIDANCE BEHAVIOR IN RATS BREATHING 
ELEVATED PRESSURES OF NITROGEN AND HELIUM 

235511 02-04 
MODIFICATION OF BETA-PHENYLETHYLAMINE-INDUCED STEREOTYPED 
BEHAVIOR BY NEUROLEPTIC AGENTS 

236672 0204 
:FFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: I GLUTAMIC ACID AND GABA IN BRAIN REGIONS 

237098 02-03 
:FFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR II. INTRACRANIAL SELF-STIMULATION BEHAVIOR 

237105 0204 



CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

237106 02-04 
PROGRESSIVE CHANGES IN BEHAVIOR AND SEIZURES FOLLOWING 
CHRONIC COCAINE ADMINISTRATION: RELATIONSHIP TO KINDLING 
AND PSYCHOSIS. (UNPUBLISHED PAPER) 

237169 02-04 
A DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR BY INTRAVENOUS 
ADMINISTRATION OF DRUGS IN RATS 

237701 02 04 
EFFECTS OF MORPHINE AND NARCOTIC ANTAGONISTS ON AVOIDANCE 
BEHAVIOR OF THE SQUIRREL-MONKEY. 

237754 02-04 
THE EFFECT OF PHENCYCLIDINE AND KFTAMINE ON SCHEDULE- 
CONTROLLED BEHAVIOR IN THE PICLON 

237757 02-04 
EFFECTS OF CARBON DISULFIDE ON OPERANT BEHAVIOR IN PIGEONS, 
(PH.D. DISSERTATION). 

238081 02-04 
ROTATORY BEHAVIOR INDUCED BY GLYCINE INJECTED INTO THE 
SUBSTANTIA-NIGRA OF THE RAT. 

238347 02-04 
CHANGES IN THE SELF STIMULATION BEHAVIOR BY INTRAVENTRICULAR 
INJECTION OF EPINEPHRINE, NOREPINEPHPINF ISOPROTERENOL AND 
DOPAMINE. 

238566 02-04 
EFFECTS OF BENZODIAZEPINE ANTIANXIETY AGENTS ON PUNISHED 
(CONFLICT) AND UNPUNISHED BEHAVIOR IN DRUG NAIVE RATS, 

238697 03-04 
MARIJUANA-INDUCED ALTERATIONS IN FEEDING BEHAVIOR AND 
HYPOTHALAMIC CONCENTRATIONS OF NORFPINEPHRINE AND 
SEROTONIN IN THE RAT. 

238720 03-04 
EFFECTS OF SOME PSYCHOTROPIC DRUGS ON AGGRESSIVE BEHAVIOR IN 
RATS. 

238754 03-04 
CORRELATION BETWEEN THE EFFECTS OF SEVERAL CANNABINOIDS ON 
CATECHOLAMINE SYNTHESIS, BODY TEMPERATURE, AND BEHAVIOR. 

238769 03-03 
THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE- 
CONTROLLED BEHAVIOR IN THE RHESUS MONKEY. 

238794 03-04 
A QUANTITATIVE COMPARISON OF RELATIONSHIPS BETWEEN PLASMA 
TESTOSTERONE (T) AND TWO CENTRAL FUNCTIONS: LH FEEDBACK 
AND SEX BEHAVIOR, 

238800 03-04 
EFFECTS OF HALLUCINOGENS ON OPERANT BEHAVIOR 

238814 03-04 
NEURAL DISCHARGE ASSOCIATED WITH TAIL PINCH INDUCED 
STEREOTYPED BEHAVIOR 

2388 1 9 03 04 
EFFECTS OF LITHIUM ON CHRONIC ETHANOL CONSUMPTION AND 
BEHAVIOR. 

238849 03-03 
INFLUENCE OF SECOBARBITAl AND CHLORPROMAZINE ON PRECENTRAL 
NEURON ACTIVITY DURING ATTENTIVE BEHAVIOR IN MONKEYS. 

239848 03-04 
DEPRESSED 5-HYDROXYINDOLE LEVELS ASSOCIATED WITH HYPERACTIVE 
AND AGGRESSIVE BEHAVIOR: RELATIONSHIP TO DRUG RESPONSE. 

239936 03-13 
INTRODUCTION: THE CONTROL OF BEHAVIOR BY CONSEQUENT DRUG 
INJECTIONS 

240009 03-04 
CHARACTERISTICS OF BEHAVIOR CONTROLLED BY SCHEDULED 

INJECTIONS OF DRUGS. 

240010 03-04 
STIMULI ASSOCIATED WITH DRUG INJECTIONS AS EVENTS THAT 

CONTROL BEHAVIOR 

24001 1 03-04 
DRUG EFFECTS AND THE ENVIRONMENTAL CONTROL OF BEHAVIOR. 

240021 03-04 
CENTRAL ACTION OF NORMETANEPHRINE EFFECT ON THE BEHAVIOR OF 
RATS 

240240 03-03 
BEHAVIOR DISORDERS IN CHILDHOOD AND THEIR TREATMENT. 

240711 03 11 
EFFECTS OF CHLORPROMAZINE ON FEAR MOTIVATED BEHAVIOR, 
URINARY CORTISOL, URINARY VOLUME, AND HEARTRATE IN THE 
DOG 

240916 03-04 
REDUCTION IN MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE AND 
OPIOID SEEKING BEHAVIOR BY INTRACEREBRAL 6 
HYDROXYDOPAMINE, (PHD DISSERTATION) 

241100 0303 
EFFECTS OF CHOLINERGIC DRUGS ON ABNORMAL SOCIAL BEHAVIOR IN 
THE RHESUS MONKEY. (PH.D. DISSERTATION). 

241109 03-04 



00 

JO 



■ft 



% 

r-' 
I 

2K 



S-39 



Subject Index 

EUFLAVINE EFFEf T ON BRAIN HEAVY (VilTAL CONTENT AND STAINING 
PATTERN, AND ON SHUTTLEBOX BEHAVluR IN GOLDRSH. 

241221 03-04 
WET DOG SHAKE BEHAVIOR IN NORMAL RATS, ELICITED BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID DERIVATIVES. 

241231 03-04 
INFLUENCE OF PRENATAL D-AMPHETAMINE ADMINISTRATION ON 
DEVELOPMENT AND BEHAVIOR OF RATS. 

241245 03-04 
SPONTANEOUS AND DRUG-INDUCED ROTATION (CIRCLING BEHAVIOR) IN 
THE MONGOLIAN GERBIL (MERIONES UNGUICULATUS). 

241311 03-04 
EFFECTS OF INTRAVENOUS ANESTHETICS ON CONTINUOUS AVOIDANCE 
BEHAVIOR IN THE RAT. 

241314 03-04 
INFLUENCE OF PSYCHOTROPIC DRUGS AND BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE (SKF-525-A) ON MESCALINE-INDUCED 
BEHAVIOR AND ON TISSUE LEVELS OF MESCALINE IN MICE. 

241349 03-04 
SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES: 

4) 
THE ROLE OF BRAIN SEROTONIN IN EMOTIONAL BEHAVIOR OF THE RAT. 

241363 03-04 
THE POTENTIATING EFFECT OF LICL ON ADRENERGIC DRUG-INDUCED 

AGGRESSIVE BEHAVIOR IN MICE. 

241364 03-04 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (I). RELATIONSHIP 

BETWEEN BRAIN MONOAMINES AND DEFECATION IN RATS. 

241370 03-04 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (II). RELATIONSHIP 

BETWEEN EMOTIONALITY AND DEFECATION. 

241371 03-04 
ACTIONS OF 6HYDR0XYD0PAMINE INJECTED INTRAVENTRICULARLY 

INTO DEVELOPING RATS (2). INFLUENCE ON MOTOR ACTIVITIES AND 
AGGRESSIVE BEHAVIOR. 

241372 03-04 
EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON THE METABOLISM OF 

BRAIN MONOAMINES WITH SPECIAL REFERENCE TO THE 
RELATIONSHIP BETWEEN NORADRENALINE CONTENTS OF THE 
OLFACTORY BULB AND MURICIDE BEHAVIOR. 

241373 03-04 
DIFFERENTIAL SENSITIVITY OF THE RESPONSE DURATION AND RESPONSE 

RATE TO IMIPRAMINE DURING OPERANT BEHAVIOR IN RATS. 

241377 03-04 
STUDIES ON THE CORRELATION BETWEEN BEHAVIOR AND BRAIN AMINES 

WITH PSYCHOTROPIC DRUGS. 

241378 03-04 
CYCLIC-AMP AS A POSSIBLE MEDIATOR IN DOPAMINERGIC 

STIMULATION-INDUCED ROTATIONAL BEHAVIOR OF RATS LESIONED 
UNILATERAL! Y IN SUBSTANTIA NIGRA. 

241382 03-04 
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS. 4TH 
REPORT COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON SQUIRREL-MONKEY 
INCENTIVE COMPETITION BEHAVIOR. (PHD DISSERTATION). 

241668 03-04 
PSYCHOPHARMACOLOGICAL CHARACTERIZATION OF A DRUG-INDUCED 
GROOMING BEHAVIOR IN THE CRICKET, ACHETA-DOMESTICUS 
(INSECTA, ORTHOPTERA) (PH.D. DISSERTATION). 

241994 03-04 
INTRACRANIAL CYCLOHEXIMIDE: EFFECT ON MALE MOUSE SEXUAL 
BEHAVIOR AND PLASMA TESTOSTERONE. 

242743 03-04 
EFFECTS OF P-CHLOROPHENYLALANINE ON THE PREDATORY BEHAVIOR 
OF ONYCHOMYS TORRIDUS. 

242749 04-04 
TWENTY-FOUR HOUR RETENTION OF CHLORDIAZEPOXIDE (LIBRIUM) 
ATTENUATED THREAT BEHAVIOR IN MALE SIAMESE FIGHTING FISH 
(BETTASPLENDENS). 

242892 04-04 
ADAPTIVENESS AND BEHAVIOR OF THE ELDERLY SUBJECT. 

242898 04-11 
BEHAVIOR AND INTELLECTUAL ACTIVITY OF THE ELDERLY: DOUBLE- 
BLIND STUDY OF HYDR0SARPAN-7n IN A HOSPICE ENVIRONMENT. 

242900 04-11 
THE ROLE OF THE AMYGDALOID NUCLEI IN THE REGULATION OF 
ADAPTIVE BEHAVIOR 

243234 04-04 
TOLERANCE PHYSICAL DEPENDENCE AND OPIOID-SEEKING BEHAVIOR: 
DEPENDENCE ON DIENCEPHALIC NOREPINEPHRINE. 

244202 04-04 
DIFFERENTIAL EFFECTS OF THE ANTIESTROGEN MER-25 AND OF THREE 
5ALPHA REDUCED ANDROGENS ON MOUNTING AND LORDOSIS 
BEHAVIOR IN THE RAT. 

244343 04-04 
ANALYSIS OF HORMONAL MEDIATION OF DRINKING BEHAVIOR. 

244469 04-04 



Psychopharmacology Abstra< 



RESISTANCE OF ANDROGEN MEDIATED AGGRESSIVE BEHAVIOR IN Ml( 
TO FLUTAMIDE, AN ANTIANDROGEN. 

244685 0^ 
INFLUENCE OF THE ADMINISTRATION OF PSYCHOPHARMACOLOGICAL 
COMPOUNDS ON THE TAKE UP TIME OF AN ALIMENTARY MATERIA 
IN THE HAMSTER AND A STUDY OF RELATED BEHAVIOR. 

244899 0' 

STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAMAZEPIN 

IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 

18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 

WITH BEHAVIOR AND CHARACTER. 

244958 0. 
THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION IN 
VARYING DEGREES OF HYPERKINETIC BEHAVIOR. 

245012 0. 
EFFECTS OF EARLY POSTNATAL ALPHA-METHYL-DOPA TREATMENT Oh 
BEHAVIOR IN THE RAT. 

245304 0. 
AGGRESSIVE BEHAVIOR OF JUVENILE MICE: INFLUENCE OF ANDROGEI 
AND OLFACTORY STIMULI. 

245406 
CONTRASTING EFFECTS OF MORPHINE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN THE CHIMPANZEE AND BABOON. 

246854 
PSYCHOPHARMACOLOGY IN THE PREVENTION OF ANTISOCIAL AND 
DELINQUENT BEHAVIOR. 

247385 
EFFECTS OF TRAZODONE ON BEHAVIOR AND BRAIN AMINE CONTENT 
MICE. 

247485 
SUPERSENSITIVITY TO D-AMPHETAMINE AND APOMORPHINE-INDUCE 
STEREOTYPED BEHAVIOR INDUCED BY CHRONIC D-AMPHETAMINE 
ADMINISTRATION. 

247683 
FAILURE OF INCREASED BRAIN GAMMA-AMINOBUTYRIC-ACID LEVELS 
INFLUENCE AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR. 

247730 Q 
47-XYy AND 46-XY MALES WITH ANTISOCIAL AND/OR SEX OFFENDIN 
BEHAVIOR: ANTIANDROGEN THERAPY PLUS COUNSELING. 

248222 Q 

EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISl 

AND BEHAVIOR: II. INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

248956 C 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISl 

AND BEHAVIOR: I. GLUTAMIC-ACID AND GABA IN BRAIN REGIONS 

248957 C 
CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHIN 

TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

248959 C 
EFFECT OF MORPHINE ON INTRACRANIAL SELF-STIMULATION BEHAVI 
FOLLOWING BRAIN AMINE DEPLETION. 

249138 C 
ELECTRICALLY-INDUCED HIPPOCAMPAL AND CORTICAL SEIZURES AN 
THEIR EFFECTS ON OPERANT BEHAVIOR. 

249241 C 
FURTHER STUDIES ON THE SENSITIVITY OF OPERANT BEHAVIOR TO 
DETECT OPIATE WITHDRAWAL IN RATS. 

249247 C 
SOME EFFECTS OF PARATHION ON THE SCHEDULE-CONTROLLED 
BEHAVIOR OF THE PIGEON. 

249266 C 

INHIBITION OF CIRCLING BEHAVIOR BY NEUROLEPTIC DRUGS IN MIC 

WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF THE STRIAT 

249679 C 
ESTRADIOL BENZOATE, NOREPINEPHRINE, AND WEIGHT REGULATOR> 
BEHAVIOR IN FEMALE RATS. 

250012 C 
EFFECTS OF NEONATAL THYROXINE STIMULATION ON ADULT OPEN-F 
BEHAVIOR AND THYROID ACTIVITY IN RATS. 

250013 C 
CHRONIC DELTA9-TETRAHYDR0CANNABIN0L. TRANSIENT AND LASTI 
EFFECTS ON AVOIDANCE BEHAVIOR. 

250061 ( 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACI 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG-INDUCE 
BEHAVIORAL EXCITATION. 

250067 C 
THE EFFECTS OF PHENCYCLIDINE, KETAMINE, D-AMPHETAMINE AND 
PENTOBARBITAL ON SCHEDULE-CONTROLLED BEHAVIOR IN THE 
MOUSE. 

2501 12 ( 
A CRITIQUE OF OBSTETRICAL PAIN RELIEVING DRUGS AS PREDICTOR 
INFANT BEHAVIOR VARIABILITY. 

2501 75 C 
MONOAMINE NEUROTOXINS: SELECTIVE AND DELAYED EFFECTS ON 
BEHAVIOR IN COLONIES OF LABORATORY RATS. 

251063 C 



S-40 



/OLUME 14, SUBJECT INDEX 



BEHAVIOR AND ENDOCRINE EFFECTS OF 3,4,5 
TRIMETHOXYAMPHETAMINE IN MALE MICE. 

25t2I5 04-04 
SCHEDULE DEPENDENT EFFECTS OF CHLORDIAZEPOXIDE ON OPERANT 
BEHAVIOR IN RATS. 

251670 04-04 
THE EFFECT OF PYRITHIOXINE AND PYRIDOXINE ON INDIVIDUAL 
BEHAVIOR, SOCIAL INTERACTIONS, AND LEARNING IN RATS 
MALNOURISHED IN EARLY POSTNATAL LIFE. 

25199) 04-04 
DRUGGING TO SUPPRESS BEHAVIOR. 

252315 04-17 
EHAVIORAl 

BEHAVIORAL CHANGES IN 2-MONTH-OLD RATS FOLLOW/ING PRENATAL 
EXPOSURE TO ANTIBODIES AGAINST SYNAPTIC MEMBRANES. 

226186 01-04 
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL CHANGES ASSOCIATED 
WITH PAPAVERINE ADMINISTRATION IN HEALTHY GERIATRIC 
SUBJECTS. 

226478 01 11 
NEONATAL THYROXINE ADMINISTRATION, BEHAVIORAL MATURATION 
AND BRAIN GROWTH IN MICE OF DIFFERENT BRAIN WEIGHT. 

226532 01-04 
UTILIZATION OF CELLULAR STUDIES OF NEUROTRANSMITTER RELATED 
ENZYMES AND TRANSPORT PROCESSES IN MAN FOR THE 
INVESTIGATION OF BIOLOGICAL FACTORS IN BEHAVIORAL DISORDERS 
(UNPUBLISHED PAPER). 

226731 01-13 
BEHAVIORAL EFFECTS IN RATS FOLLOWING INTRASTRIATAL 
MICROINJECTION OF MANGANESE. 

226932 01-04 
HANDBOOK OF DRUG AND CHEMICAL STIMULATION OF THE BRAIN. 
BEHAVIORAL, PHARMACOLOGICAL AND PHYSIOLOGICAL ASPECTS. 

227382 01-06 
ACUTE BEHAVIORAL CHANGES INDUCED IN THE RAT BY THE 

INTRACEREBROVENTRICULAR ADMINISTRATION OF THYROTROPIN- 
RELEASING FACTOR (TRF) AND SOMATOSTATIN. 

227386 01-04 
BEHAVIORAL EFFECTS OF REDUCING THE DAILY FREQUENCY OF 
PHENOTHIAZINE ADMINISTRATION. 

228224 0108 
ONTOGENY OF BEHAVIORAL SENSITIVITY TO STRYCHNINE IN THE CHICK 
EMBRYO: EVIDENCE FOR THE EARLY ONSET OF CNS INHIBITION. 

228630 01-04 
METHADONE-INDUCED BEHAVIORAL CHANGES. CIRCULAR MOVEMENTS 
AGGRESSION, AND ELECTROPHYSIOLOGICAL ASPECTS. 

229286 01-04 
BEHAVIORAL EFFECTS OF ANTIEPILEPTIC DRUGS, 

230368 01-11 
MODIFICATION OF THE BEHAVIORAL RESPONSE TO DRUGS IN RATS 
EXPOSED PRENATALLY TO CHLORPROMAZINE. 

230864 01-04 
THE INFLUENCES OF METHYLPHENIDATE ON HEARTRATE AND 

BEHAVIORAL MEASURES OF ATTENTION IN HYPERACTIVE CHILDREN. 

231629 01-14 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING, (UNPUBLISHED 
PAPER). 

231771 01-04 
BEHAVIORAL EFFECTS OF DIBUTYRYL-CYCLIC-AMP AND BIOGENIC 
AMINES IN RATS. 

232484 01-04 
BEHAVIORAL ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION 
OF BENZODIAZEPINES. 

232509 01-04 
BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5 7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 
ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02-04 
BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AND AMPHETAMINE 
AFTER CHRONIC HIGH DOSE HALOPERIDOL TREATMEN 

232616 02-04 
CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN 
MONOAMINES AND SOME BEHAVIORAL AND PHYSIOLOGICAL 
FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS. 

233962 02-03 
BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF 
PSYCHOSIS. 

233965 02-03 
RELATIONSHIP OF DOPAMINE NEURAL SYSTEMS TO THE BEHAVIORAL 
ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION 
INTO BRAIN. 

233970 02-03 



Subject Index 

BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC 
AGONISTS. 

233973 02-03 
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF REPEATED D- 
AMPHETAMINE ADMINISTRATION. 

234809 02-04 
DIFFERENTIAL BEHAVIORAL AND BIOCHEMICAL EFFECTS OF REGIONAL 
INJECTION OF CYCLOHEXIMIDE INTO MOUSE BRAIN. 

235320 02-04 
THYROTROPIN-RELEASING HORMONE TRHINDUCED HYPERTHERMIA AND 
BEHAVIORAL EXCITATION IN RABBITS. 

236524 02-04 
MODIFICATION OF THE BEHAVIORAL EFFECTS OF CHOLINOMIMETICS BY 
PHENTOLAMINE. 

237032 02-04 
BEHAVIORAL AND BIOCHEMICAL INTERACTION BETWEEN AMT AND ( + ) 
AMPHETAMINE: RELEVANCE TO THE IDENTIFICATION OF THE 
FUNCTIONAL POOL OF BRAIN CATECHOLAMINES. 

237698 02-03 
BEHAVIORAL EFFECTS OF INTRACEREBRALLY ADMINISTERED 

CATECHOLAMINES IN MICE AND THEIR MODIFICATIONS BY SOME 
ADRENERGIC BLOCKING AGENTS. 

237707 02-04 
BEHAVIORAL AND NEUROPHARAAACOLOGICAL ANALYSIS OF 

AMPHETAMINE AND 2,5 OIMETHOXY-4-METHYLAMPHETAMINE IN 
RATS. 

237718 02-04 
BEHAVIORAL SUPERSENSITIVITY TO 5-HYDROXYTRYPTOPHAN-INDUCED 
BY CHRONIC METHYSERGIDE PRETREATMENT. 

237729 02-04 
DOES INCREASING STRESS CHANGE THE BEHAVIORAL ACTION OF 
MESCALINE FROM DISRUPTION TO FACILITATION?. 

237732 02-04 
GAMMA-HYDROXYBUTYRATE: CORRELATION OF SERUM AND 

CEREBROSPINAL FLUID LEVELS WITH ELECTROENCEPHALOGRAPHIC 
AND BEHAVIORAL EFFECTS. 

237826 02-03 
DRUG DISSOCIATION OF NEUROELECTRICAL AND BEHAVIORAL 
RESPONSES IN MICE. (PH.D. DISSERTATION). 

238159 02-03 
PREVENTION OF REVERSAL OF OPERANT BEHAVIORAL DISRUPTION 
DURING PRECIPITATED WITHDRAWAL BY TREATMENT WITH 
MORPHINE BEFORE OR AFTER NALOXONE. 

238687 03-04 
BEHAVIORAL EVIDENCE OF THE INTERACTION OF PHENCYCLIDINE WITH 
CATECHOLAMINES IN PRIMATE SOCIAL COLONIES. 

238696 03-04 
EFFECTS OF CHRONIC PRENATAL HYPOXIA ON PHYSIOLOGICAL 
NEUROCHEMICAL AND BEHAVIORAL DEVELOPMENT, 

238722 03-04 
LONG-TERM CONSUMPTION OF A TRYPTOPHAN POOR DIET ALTERS THE 
BEHAVIORAL RESPONSE TO DRUGS, 

238741 03-03 
DELTA9-TETRAHYDR0CANNABIN0L (DELTA9-THC) AND 1 1-0H-DELTA9- 
THC: ONSET, PATTERN AND DURATION OF BEHAVIORAL EFFECTS AND 
TOLERANCE IN RATS. 

238813 03-04 
ENVIRONMENTAL INFLUENCES ON THE BEHAVIORAL RESPONSE TO ACUTE 
AND CHRONIC AMPHETAMINE ADMINISTRATION. 

238843 03-04 
PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER- 
DISCHARGES IN RATS: INCREMENTAL DOSE, HIPPOCAMPAL EEG AND 
BEHAVIORAL ACTIVITY CORRELATES, 

239858 03-03 
NICOTINE-LIKE BEHAVIORAL EFFECT AFTER SMALL DOSE OF 
MECAMYLAMINE IN ROMAN HIGH-AVOIDANCE RATS. 

239865 03-04 
A BEHAVIORAL PARADIGM FOR THE EVALUATION OF NARCOTIC 
ANTAGONISTS, 

239941 03-11 
INDIVIDUAL DIFFERENCES AMONG MICE IN NORMAL AND 

AMPHETAMINE-ENHANCED LOCOMOTOR ACTIVITY: RELATIONSHIP TO 
BEHAVIORAL INDICES OF STRIATAL ASYMMETRY. 

240750 03-04 
BEHAVIORAL DISINHIBITION BY MESCALINE. 

241243 03-04 
BEHAVIORAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN AFTER 

DESTRUCTION OF ASCENDING SEROTONERGIC PATHWAYS IN THE RAT- 
THE ROLE OF CATECHOLAMINERGIC NEURONS, 

241251 03-04 
BEHAVIORAL EFFECTS OF PENFLURIDOL IN RATS 

241376 03-04 
BEHAVIORAL EFFECT OF PHTHALAZINOPHTHALAZINEDIONE (L-5418), 

241397 03-04 
THE BEHAVIORAL AND NEUROPHARMACOLOGICAL EFFECTS OF TAURINE 
(PH,D, DISSERTATION). 

241574 03-03 



00 

ye 

i 



■Hi 



I 



"[:. 

5 
jB 

3K 



S-41 






Subject Index 



Psychopharmacology Abstracts 



MANIPULATION OF ACETYLCHOLINE LEVELS IN DEVELOPING RAT BRAIN: 
BIOCHEMICAL AND BEHAVIORAL CONSIDERATIONS' (PHD. 
DISSERTATION). 

241680 03-04 
BEHAVIORAL TERATOGENESIS: A CRITICAL EVALUATION 

242744 03- 17 
CEREBRAL AND CEREBELLAR NEUROCHEMICAL CHANGES AND 

BEHAVIORAL MANIFESTATIONS IN RATS CHRONICALLY EXPOSED TO 
MARIJUANA SMOKE 

243181 04-04 
INTRAVENOUS L-DOPA PLUS CARBIDOPA IN DEPRESSED PATIENTS: 
AVERAGE EVOKED RESPONSE, LEARNING, AND BEHAVIORAL CHANGES. 

244664 04-09 
BEHAVIORAL EFFECTS OF AMPHETAMINE IN A GROUP OF RHESUS 
MONKEYS WITH LESIONS OF DORSOLATERAL FRONTAL CORTEX. 

244684 04-04 
THE BEHAVIORAL PHARMACOLOGY OF BUTACLAMOL HYDROCHLORIDE 
{AY-23028), A NEW POTENT NEUROLEPTIC DRUG 

245295 04-04 
CHOLECYSTOKININ ELICITS THE COMPLETE BEHAVIORAL SEQUENCE OF 
SATIETY IN RATS. 

245612 04-02 
CORRELATION BETWEEN STRUCTURE, BEHAVIORAL ACTIVITY AND RATE 
OF BIOTRANSFORMATION OF SOME ACTH4-9 ANALOGS. 

246853 04-04 
ARE BEHAVIORAL AND PSYCHOMETRIC CHANGES RELATED IN 
METHYLPHENIDATE TREATED, HYPERACTIVE CHILDREN?. 

247382 04-14 
MYELOID HYPERPLASIA IN GROWING RATS AFTER CHRONIC TREATMENT 
WITH DELTA9-THC AT BEHAVIORAL DOSES. 

248915 04 05 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING. 

249005 04-04 
BEHAVIORAL EFFECTS OF L-DOPA AND THYROTROPIN-RELEASING 
HORMONE IN SCHIZOPHRENIC PATIENTS. A PRELIMINARY REPORT. 

249120 04-08 
A COMPARISON OF NARCOTIC ANALGESICS WITH NEUROLEPTICS ON 
BEHAVIORAL MEASURES OF DOPAMINERGIC ACTIVITY. 

249139 04-04 
KETOCYCLAZOCINE: BEHAVIORAL EFFECTS IN PIGEONS AND MONKEYS. 

249246 04-04 
EEG AND BEHAVIORAL EFFECTS OF NARCOTIC ANTAGONISTS ALONE AND 
IN COMBINATION WITH OTHER PSYCHOACTIVE DRUGS IN MORPHINE- 
DEPENDENT MACACA-MULATTA 

249267 04-04 
DEVELOPMENT AND ADULT BEHAVIORAL ABNORMALITIES IN MICE 
TREATED NEONATALLY WITH CYCLOPHOSPHAMIDE. 

249296 04-02 
RELATIONSHIP BETWEEN THE BEHAVIORAL AND 

ELECTROENCEPHALOGRAPHIC EFFECTS OF CHLORPROMAZINE AND 
FLUPHENAZINE IN RATS. 

249623 0402 
DOGMATIL AND BEHAVIORAL PROBLEMS IN MIGRANT WORKERS. 

249693 04- 11 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACIDS 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG INDUCED 
BEHAVIORAL EXCITATION 

250067 04-04 
BEHAVIORAL EVIDENCE FOR THE RAPID RELEASE OF CNS SEROTONIN BY 
PCA AND FENFLURAMINE. 

250083 04-04 
SOME BEHAVIORAL EFFECTS OF MORPHINE, NALOXONE AND 
NALORPHINE IN THE SOUIRREL-MONKEY AND THE PIGEON. 

250113 04-04 
FRONTAL-STRIATAL CONTROL OF BEHAVIORAL INHIBITION IN THE RAT 

251138 04-04 
IMPORTANCE OF O-METHYLATION IN DOPAMINE-INDUCED MOTOR AND 
BEHAVIORAL PHENOMENA. 

251143 04-04 
INFLUENCE OF AGE AND DRUGS ON BEHAVIORAL THERMOREGULATION 
IN RATS. 

251409 04-04 
DIFFERENTIAL BEHAVIORAL RESPONSES OF MALE AND FEMALE ADULT 
RATS TREATED WITH FIVE PSYCHOTROPIC DRUGS IN THE NEONATAL 
STAGE. 

251981 04-04 
ANATOMICAL AND BEHAVIORAL EFFECTS OF COLCHICINE 
ADMINISTRATION TO RATS LATE IN UTERO. 

2.52148 04-05 
WEAK INHIBITORY BEHAVIORAL EFFECTS OF POSTNATAL/PREWEANING 
TAURINE INJECTIONS IN RATS. 

252149 04-04 
BEHAVIORAL STUDIES FOLLOWING LESIONS OF THE MESOLIMBIC AND 
MESOSTRIATAL SEROTONERGIC PATHWAYS. 

253255 04-04 
BEHAVIORAL DEPRESSION IN SIDMAN AVOIDANCE LEARNING INDUCED 
BY DOPAMINE-BETAHYDROXYLASE INHIBITORS. 

253450 0404 



BEHAVIORAUY 

BEHAVIORALLY INDUCED SENSITIVITY TO THE DISCRIMINABLE 
PROPERTIES OF LSD. 

230876 01-04 
USES OF DOUBLE-PULSE STIMULATION BEHAVIORALLY TO INFER 
REFRACTORINESS, SUMMATION, CONVERGENCE, AND TRANSMITTER 
CHARACTERISTICS OF HYPOTHALAMIC REWARD SYSTEMS. 

250278 04-03 
SOME EFFECTS OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A 
PURPORTED HASHISH AND LSD ANTAGONIST, ON BRAIN 
NORADRENERGIC AND SEROTONERGIC SYSTEMS. 

251534 04-03 
BEHAVIORS 

THE CHEMISTRY OF REWARD AND RELATED BEHAVIORS. 

229475 01-04 
CHOLINERGIC MEDIATION OF INSTRUMENTAL AND CONSUMMATORY 
BEHAVIORS. 

233448 02-04 
LONG-TERM DEFICITS IN STIMULATION-INDUCED BEHAVIORS AND SELF- 
STIMULATION AFTER 6-HYDROXYDOPAMINE ADMINISTRATION IN 
RATS. 

241300 03-04 
TIME-DEPENDENT VARIATIONS IN AVERSIVELY MOTIVATED BEHAVIORS: 
NONASSOCIATIVE EFFECTS OF CHOLINERGIC AND 
CATECHOLAMINERGIC ACTIVITY. 

245486 04-04 
BEHAVIOUR 

EFFECTS OF CANNABIS RESIN ON SOCIAL BEHAVIOUR IN THE 
LABORATORY MOUSE. 

225569 01-04 
THE EFFECTS OF AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE 

BUTYROPHENONE SERIES, ON DOMINANT SUBORDINATE BEHAVIOUR 
IN WISTAR RATS COMPETING FOR FOOD. 

225571 01-04 
TRANSPLACENTAL EFFECTS OF DRUGS ON HEARING, VISION, AND 
BEHAVIOUR. 

227391 01-05 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

237107 02-04 
A 1,4 BENZODIAZEPINE, TEMAZEPAM (K-3917), ITS EFFECT ON SOME 
PSYCHOLOGICAL PARAMETERS OF SLEEP AND BEHAVIOUR. 

237122 02-14 
ANTAGONISM OF APOMORPHINE AND D-AMPHETAMINE-INDUCED 
STEREOTYPED BEHAVIOUR BY INJECTION OF LOW DOSES OF 
HALOPERIDOL INTO THE CAUDATE-NUCLEUS AND THE NUCLEUS- 
ACCUMBENS. 

237704 02-04 
CANNABIS RESIN AND SEXUAL BEHAVIOUR IN THE LABORATORY 
MOUSE. 

237715 02-04 
THE INTERACTIVE EFFECTS OF PRENATAL IMIPRAMINE EXPOSURE AND 
POSTNATAL REARING CONDITIONS ON BEHAVIOUR AND HISTOLOGY. 

237721 02-05 
THE EFFECTS OF N DIPROPYLACETATE ON THE ACQUISITION OF 

CONDITIONED BEHAVIOUR WITH NEGATIVE REINFORCEMENT IN MICE. 

237723 02-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON SOCIAL BEHAVIOUR 
IN THE LABORATORY MOUSE AND RAT. 

237727 02-04 
BRAIN DOPAMINE AND JUMPING BEHAVIOUR IN MICE. 

237746 02-03 
EFFECT OF CATECHOL-0-METHYLTRANSFERASE INHIBITORS ON BRAIN 

APOMORPHINE CONCENTRATIONS AND STEREOTYPED BEHAVIOUR IN 
THE RAT 

237747 02-03 
GAMMA-AMINOBUTYRIC-ACID: THE ESSENTIAL MEDIATOR OF 

BEHAVIOUR TRIGGERED BY NEOSTRIATALLY APPLIED APOMORPHINE 
AND HALOPERIDOL. 

237786 02-03 
QUIPAZINE: ITS EFFECTS ON RAT BRAIN 5 HYDROXYTRYPTAMINE 
METABOLISM. MONOAMINE-OXIDASE ACTIVITY AND BEHAVIOUR. 

239960 03-03 
ROLE OF SUPERIOR COLLICULUS SEROTONIN IN THE GROOMING 
BEHAVIOUR OF CATS. 

239978 03-04 
EFFECTIVENESS OF MORPHINE AND INEFFECTIVENESS OF DIAZEPAM AND 
PHENOBARBITAL ON THE MOTIVATIONAL PROPERTIES OF 
HYPOTHALAMIC SELF-STIMULATION BEHAVIOUR. 

239981 0304 
NEUROCHEMICAL CORRELATES OF BEHAVIOUR - CONTENT OF 
TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, SEROTONIN, 5- 
HYDROXYINDOLEACETIC-ACID, TYROSINE, DOPAMINE AND 
NOREPINEPHRINE IN FOUR BRAIN PARTS OF THE PIGEON DURING 
BEHAVIOURAL DEPRESSION FOLLOWING AN INJECTION. 

241205 03-04 

BRAIN, BEHAVIOUR AND DRUGS. 

242265 03-17 



S-42 



VOLUME 14, SUBJECT INDEX 



Subject Index 



EFFECTS OF DRUGS ACTING ON CEREBRAL 5-HYDROXYTRYPTAMINE 
MECHANISMS ON DOPAMINE-DEPENDENT TURNING BEHAVIOUR IN 
MICE, 

243803 0404 
EFFECTS OF 0ELTA9-TETRAHYDR0CANNABIN0L ON SOCIAL BEHAVIOUR 
IN MICE; COMPARISON BETWEEN TWO VEHICLES. 

244687 04-04 
THE SUPPRESSION OF BEHAVIOUR IN RATS BY PREVIOUS EXPERIENCE 
AND ELECTRIC SHOCK AND ITS ANTAGONISM BY ATROPINE. 

245305 04-04 
EFFECTS OF N-HYDROXYETHYL-PYRROLIDINIUM METHIODIDE, A CHOLINE 
ANALOGUE, ON PASSIVE AVOIDANCE BEHAVIOUR IN MICE. 

245594 04-04 
DRUG-INDUCED CHANGES IN BEHAVIOUR AND GANGLIONIC 

ACETYLCHOLINE CONCENTRATION OF THE LEECH 

245595 04-03 
THE CONCENTRATION OF 5-METHOXYTRYPTAMINE IN RAT BRAIN AND 

ITS EFFECTS ON BEHAVIOUR FOLLOWING ITS PERIPHERAL INJECTION. 

245600 04-04 
EFFECTS OF TESTOSTERONE ON THE BEHAVIOUR OF THE DOMESTIC 
CHICK. I. EFFECTS PRESENT IN MALES BUT NOT IN FEMALES. 

245712 04-04 
EFFECTS OF TESTOSTERONE ON THE BEHAVIOUR OF THE DOMESTIC 

CHICK. II. EFFECTS PRESENT IN BOTH SEXES. 

245713 04-04 
THE EFFECTS OF TRANQUILLIZING DRUGS ON TIMING BEHAVIOUR IN 

RATS. 

246306 04-04 
POTENTIATING EFFECT OF LITHIUM CHLORIDE ON AGGRESSIVE 

BEHAVIOUR INDUCED IN MICE BY NIALAMIDE PLUS L-DOPA AND BY 
CLONIDINE. 

246664 04-04 
STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOUR) BY P- 
CHLOROPHENYLALANINE (PCPA) IN THE RAT. 

246674 04-04 
BENZODIAZEPINES AND AMPHETAMINE ON AVOIDANCE BEHAVIOUR IN 
MICE. 

247778 04-02 
EFFECTS OF ESTROGEN AND ANDROGEN ON THE SEXUAL BEHAVIOUR OF 
THE OVARIECTOMIZED EWE. 

248223 04-04 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 
CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA INDUCED 
GNAWING OF MICE. 

248960 04-02 
EFFECTS OF CHLORDIAZEPOXIDE, CNS STIMULANTS AND THEIR 
COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE. 

249026 04-04 
CIRCLING BEHAVIOUR PRODUCED BY UNILATERAL LESIONS IN THE 
REGION OF THE LOCUS-COERULEUS IN RATS. 

249076 04-04 
CHANGES IN SENSITIVITY OF MORPHINE-INDUCED CIRCLING BEHAVIOUR 
AFTER CHRONIC TREATMENT AND PERSISTENCE AFTER WITHDRAWAL 
IN RATS, 

249485 04-04 
INHIBITION OF TURNING BEHAVIOUR BY CLOZAPINE IN MICE WITH 
UNILATERAL DESTRUCTION OF DOPAMINERGIC NERVE TERMINALS. 

249629 04-04 
EFFECT OF AMPHETAMINE AND APOMORPHINE ON BRAIN MONOAMINES 
AND BEHAVIOUR IN THE IMMATURE AND YOUNG ADULT RAT. 

249785 04-04 
AUTOMATIC REGISTRATION OF BEHAVIOUR RELATED TO DOPAMINE AND 
NORADRENALINE TRANSMISSION. 

250086 04-04 
CIRCLING BEHAVIOUR PRODUCED BY ASYMMETRIC MEDIAL RAPHE 
NUCLEI LESIONS IN RATS, 

250358 04-04 
NORADRENERGIC INFLUENCE ON THE STEREOTYPED BEHAVIOUR INDUCED 
BY AMPHETAMINE, PHENETHYLAMINE AND APOMORPHINE. 

250361 04-04 
MODIFICATION OF CONDITIONED AVOIDANCE AND TURNING BEHAVIOUR 
BY BACLOFEN AND ITS INFLUENCE ON CHOLINERGIC DOPAMINERGIC 
NERVOUS SYSTEM. 

251397 04-03 
EFFECT OF DOPAMINE AGONISTS AND ANTAGONISTS ON ASYMMETRIC 
BEHAVIOUR OCCURRING DURING PRECIPITATED MORPHINE 
WITHDRAWAL AFTER UNILATERAL INACTIVATION OF THE STRIATUM 
IN RATS. 

251402 04-04 
SEPARATION OF INHIBITING AND STIMULATING EFFECTS OF MORPHINE 
ON SELF-STIMULATION BEHAVIOUR BY INTRACEREBRAL 
MICROINJECTIONS. 

252033 0403 
CORRELATION BETWEEN NEUROLEPTIC-INDUCED SUPPRESSION OF 

STEREOTYPED BEHAVIOUR AND HVA CONCENTRATIONS IN RAT BRAIN 

252523 04-03 



THE MONOAMINE-OXIDASE B INHIBITOR DEPRENYL POTENTIATES 
PHENYLETHYLAMINE BEHAVIOUR IN RATS WITHOUT INHIBITION OF 
CATECHOLAMINE METABOLITE FORMATION. 

253643 04-04 
BEHAVIOURAL 

BEHAVIOURAL SEQUELAE OF DOPAMINERGIC DEGENERATION: 
POSTSYNAPTIC SUPERSENSITIVITY? 

229434 01-03 
BEHAVIOURAL EFFECTS OF THYMOLEPTICS IN VERVET MONKEYS 
(CERCOPITHECUS-AETHIOFS). AETHIOPS). 

230869 01-04 
CESIUM ION: ANTAGONISM TO CHLORPROMAZINE AND L-DOPA 
PRODUCED BEHAVIOURAL DEPRESSION IN MICE. 

2383)8 02-04 
STUDIES ON THE BEHAVIOURAL EFFECTS OF TRYPTOPHAN AND P- 
CHLOROPHENYLALANINE. 

239959 03-03 
NEUROCHEMICAL CORRELATES OF BEHAVIOUR - CONTENT OF 
TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, SEROTONIN, 5- 
HYDROXYINDOLEACETIC-ACID, TYROSINE, DOPAMINE AND 
NOREPINEPHRINE IN FOUR BRAIN PARTS OF THE PIGEON DURING 
BEHAVIOURAL DEPRESSION FOLLOWING AN INJECTION. 

241205 0304 
ELECTROCONVULSIVE SHOCK INCREASES THE BEHAVIOURAL RESPONSES 
OF RATS TO BRAIN 5-HYDROXYTRYPTAMINE ACCUMULATION AND 
CENTRAL NERVOUS SYSTEM STIMULANT DRUGS. 

241979 03-04 
NEONATAL HYPERTHYROIDISM: ALTERATIONS IN BEHAVIOURAL 
ACTIVITY AND THE METABOLISM OF BRAIN NOREPINEPHRINE AND 
DOPAMINE, 

243792 04-03 
INTRACAUDATE NEUROTRANSMITTER PROCESSES IN RELATION TO 
RAPHE NEUROTRANSMITTER PROCESSES: A BEHAVIOURAL ANALYSIS 
OF INTRACEREBRALLY APPLIED DRUGS IN ACUTE AND LONG-TERM 
MORPHINE TREATED CATS 

244215 04-04 
BEHAVIOURAL AND ANATOMICAL EFFECTS OF 6-OHDA INJECTIONS IN 

THE VENTRAL MESENCEPHALIC TEGMENTUM IN THE RAT, 

244216 04-04 
A STUDY OF THE CENTRAL EFFECTS OF SYMPATHOMIMETIC DRUGS: EEG 

AND BEHAVIOURAL INVESTIGATIONS ON CLONIDINE AND 
NAPHAZOLINE, 

246148 04-04 
BEHAVIOURAL CHANGES IN LABORATORY MICE DURING CANNABIS 
FEEDING AND WITHDRAWAL, 

246310 04-04 
DOSE-RELATED EFFECTS OF CENTRAL NORADRENALINE STIMULATION ON 
BEHAVIOURAL AROUSAL IN RATS, 

247206 04-04 
COMPARISONS BETWEEN THE BEHAVIOURAL AND ANOREXIC EFFECTS OF 
780SE AND OTHER PHENYLETHYLAMINES IN THE RAT. 

250939 04-02 
BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF FENFLURAMINE IN 
PATIENTS WITH NEUROLOGIC DISEASE. 

250942 04-11 
BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF THIOTHIXENE: RELATION 
TO TISSUE LEVELS OF THE DRUG 

251131 04-03 
USE OF BETA-BLOCKERS AS AN ADJUNCT IN BEHAVIOURAL TECHNIQUES. 

251158 04-10 
BEHAVIOURAL EFFECTS OF A NEW NONPHENYLETHYLAMINE 
ANOREXIGENIC AGENT; MAZINDOL 

252030 04-04 
BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS OF 
CHOLERA TOXIN. 

252034 04-03 
BENSERAZID 

TWO YEAR COMBINED THERAPY OF PARKINSONS DISEASE WITH L-DOPA 
AND THE DECARBOXYLASE INHIBITOR BENSERAZID (RO 4-4602). 

233917 02-11 
BENSERAZIDE 

THE INFLUENCE OF THE DECARBOXYLASE INHIBITOR BENSERAZIDE ON 
ANTIHYPERTENSIVE EFFECT AND METABOLISM OF METHYLDOPA IN 
HYPERTENSIVE PATIENTS, 

251418 04-11 
SIX-YEAR RESULTS OF TREATMENT WITH LEVODOPA PLUS BENSERAZIDE 
IN PARKINSONS DISEASE, 

251648 04-11 
BENZAMIOES 

THE SUBSTITUTED BENZAMIDES. 

247546 04- 17 
BENZILATE 

ANTIACETYLCHOLINE ACTIVITIES OF PSYCHOACTIVE DRUGS; A 

COMPARISON OF THE (3H)QUINUCLIDINYL BENZILATE BINDING ASSAY 
WITH CONVENTIONAL METHODS. 

250360 04-02 






I 



A' 

is 



S-43 



Subject Index 



Psychopharmacology Abstracts 



BENZOATE 

ESTRADIOL BENZOATE, NOREPINEPHRINE, AND WEIGHT REGULATORY 
BEHAVIOR IN EEMALE RATS. 

250012 04-04 
BENZOCr AMINE 

BENZOCTAMINE IN THE TREATMENT OF NEUROSIS - AN UNCONTROLLED 
CLINICAL STUDY. 

235356 02-07 
BENZODIAZEPINE 

INVOLVEMENT OF GABA IN THE ACTION OF BENZODIAZEPINE - STUDIES 
ON RAT CEREBELLUM. 

229466 01-03 
SEDATIVE HYPNOTIC PROPERTIES OF A NEW BENZODIAZEPINE IN 

COMPARISON WITH FLURAZEPAM: PHARMACOLOGICAL AND CLINICAL 
FINDINGS. 

232530 01-07 
ALLEVIATING AGITATION, APPREHENSION, AND RELATED SYMPTOMS IN 
GERIATRIC PATIENTS: A DOUBLE-BLIND COMPARISON OF A 
PHENOTHIAZINE AND A BENZODIAZEPINE. 

234114 02-11 
A 1,4 BENZODIAZEPINE, TEMAZEPAM {K-3917), ITS EFFECT ON SOME 
PSYCHOLOGICAL PARAMETERS OF SLEEP AND BEHAVIOUR. 

237122 02-14 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY. 

237458 02-10 
EFFECTS OF BENZODIAZEPINE ANTIANXIETY AGENTS ON PUNISHED 
(CONFLICT) AND UNPUNISHED BEHAVIOR IN DRUG-NAIVE RATS. 

238697 03-04 
INTERACTION OF ALCOHOL AND BENZODIAZEPINE HYPNOTICS. 

242947 04-15 
DIFFERENTIAL PHARMACOTHERAPY FOR NEUROTIC STATES 
(COMPARATIVE EFFECTIVENESS OF BENZODIAZEPINE DERIVATIVES). 

244349 04-10 
EFFECTS OF THIENODIAZEPINE DERIVATIVES ON HUMAN SLEEP AS 
COMPARED TO THOSE OF BENZODIAZEPINE DERIVATIVES. 

246309 04-07 
FLURAZEPAM HYDROCHLORIDE, A BENZODIAZEPINE HYPNOTIC. 

250780 04-17 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 
ALBUMIN - I. GEL FILTRATION STUDIES. 

251176 04-01 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 

ALBUMIN - II. CIRCULAR DICHROISM STUDIES. 

251177 04-01 
BENZODIAZEPINE-INDUCED 

BENZODIAZEPINE-INDUCEO STATE-DEPENDENT LEARNING: A 
CORRELATIVE OF ABUSE POTENTIAL?. 

252674 04-04 
BENZODIAZEPINES 

BENZODIAZEPINES: A COMPARISON OF THEIR EFFECTS IN MICE ON THE 
MAGNITUDE OF THE PALMAR SKIN CONDUCTIVITY RESPONSE AND ON 
PENTYLENETETRAZOL-INDUCED SEIZURES. 

227694 01-03 
BEHAVIOR ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION OF 
BENZODIAZEPINES. 

229461 01-04 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 

BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

229462 01-03 
POSSIBLE INVOLVEMENT OF GABA IN THE CENTRAL ACTIONS OF 

BENZODIAZEPINES. 

229465 01-03 
THE EFFECTS OF THREE BENZODIAZEPINES AND OF MEPROBAMATE ON 
THE ACTION OF SMOOTH MUSCLE STIMULANTS ON THE GUINEA-PIG 
ILEUM. 

230859 01-03 
MECHANISM OF ACTION OF BENZODIAZEPINES. 

232506 01-03 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 

BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

232507 01-03 
EFFECTS OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC 

MECHANISMS. 

232508 01-03 
BEHAVIORAL ANALYSIS OF THE EFFECTS AND MECHANISMS OF ACTION 

OF BENZODIAZEPINES. 

232509 01-04 
ACTION OF THE BENZODIAZEPINES ON THE CHOLINERGIC SYSTEM. 

232510 01-03 
THE ROLE OF CENTRAL GLYCINE RECEPTORS IN THE PHARMACOLOGIC 

ACTIONS OF BENZODIAZEPINES. 

232511 01-03 
PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF 

ACTION OF BENZODIAZEPINES. 

232512 01-03 



EVIDENCE FOR INVOLVEMENT OF GABA IN THE ACTION OF 
BENZODIAZEPINES: STUDIES ON RAT CEREBELLUM. 

232514 01-03 
POSSIBLE INVOLVEMENT OF GABA IN THE CENTRAL ACTIONS OF 

BENZODIAZEPINES. 

232515 01-03 
ARE BENZODIAZEPINES ANTIPSYCHOTIC AGENTS?. 

233815 02-08 
ARE BENZODIAZEPINES ANTIPSYCHOTIC AGENTS?. 

235327 02-08 
EFFECTS OF MORPHINE AND BENZODIAZEPINES ON LIMBIC SYSTEM. 

238702 03-03 
ANTAGONISTIC EFFECTS OF GABA AND BENZODIAZEPINES ON 
VESTIBULAR AND CEREBELLAR NEURONES. 

240523 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: IV. THE EFFECTS OF ACETYLCHOLINE, GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY. 

241318 03-03 
BENZODIAZEPINES AND CENTRAL GLYCINE RECEPTORS. 

241921 03-03 
BENZODIAZEPINES AND CENTRAL GLYCINE RECEPTORS. 

243762 04-03 
BENZODIAZEPINES AND REPRODUCTION OF SWISS-WEBSTER MICE. 

243788 04-04 
VORACIOUSNESS INDUCED IN CATS BY BENZODIAZEPINES. 

244690 04-04 
EFFECTS OF BENZODIAZEPINES ON THE BINDING OF TRYPTOPHAN IN 
SERUM. CONSEQUENCES ON 5-HYDROXYINDOLES CONCENTRATIONS IN 
THE RAT BRAIN. 

247213 04-03 
BENZODIAZEPINES AND AMPHETAMINE ON AVOIDANCE BEHAVIOUR IN 
MICE. 

247778 04-02 
AN AMNESIC EFFECT OF BENZODIAZEPINES IN RATS?. 

251216 04-04 
INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL 
DOPAMINERGIC SYSTEMS: INVOLVEMENT OF GABA. 

251399 04-03 
BENZODIAZEPINES: GABA AND GLYCINE RECEPTORS ON SINGLE 
NEURONS IN THE RAT MEDULLA. 

252521 04-03 
BENZOPYRANOPYRIDINES 

DRUGS DERIVED FROM CANNABINOIDS. 1. NITROGEN ANALOGS, 
BENZOPYRANOPYRIDINES AND BENZOPYRANOPYRROLES. 

248646 04-02 
BENZOPYRANOPYRROLES 

DRUGS DERIVED FROM CANNABINOIDS. 1. NITROGEN ANALOGS, 
BENZOPYRANOPYRIDINES AND BENZOPYRANOPYRROLES. 

248646 04-02 
BENZOPYRENE 

EFFECT OF BENZOPYRENE AND CHLORPROMAZINE ON ARYL 
HYDROCARBON HYDROXYLASE ACTIVITY FROM RAT TISSUES. 

243793 04-03 
BENZOQUINOUZINE 

RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY 
NERVE STIMULATION. V. ENHANCED RELEASE ASSOCIATED WITH A 
GRANULAR EFFECT OF A BENZOQUINOLIZINE DERIVATIVE WITH 
RESERPINE-LIKE PROPERTIES. 

246844 04-03 
BENZOTHIAZOLES 

SYNTHESIS OF SUBSTITUTED THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION OF CELLULAR RESPIRATORY AND MONOAMINE-OXIDASE 
ACTIVITIES AND ANTICONVULSANT PROPERTY. 

239661 03-03 
BENZTROPINE-INDUCED 

BENZTROPINE-INDUCED RELEASE OF DOPAMINE FROM BRAIN IN VIVO. 

245598 04-03 
BENZYLAMINE 

IDENTIFICATION AND DISTRIBUTION OF BENZYLAMINE IN TISSUE 
EXTRACTS ISOLATED FROM RATS PRETREATED WITH PARGYLINE. 

250379 04-03 
BENZYUDENEAMINOOXYCARBONIC-ACID 

WET DOG SHAKE BEHAVIOR IN NORMAL RATS, ELICITED BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID DERIVATIVES. 

241231 03-04 
BENZYIMETHYLKETOXIME 

IN VITRO METABOLIC STUDIES USING THE METABONATES OF 
AMPHETAMINE, 2-NITROSO-l-PHENYLPROPANE AND 
BENZYLMETHYLKETOXIME. 

237980 0201 
BETA-ADRENERGIC 

REGULATION OF PROTEIN PHOSPHORYLATION AND MEMBRANE 

PERMEABILITY BY BETA-ADRENERGIC AGENTS AND CYCLIC ADENOSINE 
3:5-MONOPHOSPHATE IN THE AVIAN ERYTHROCYTE. 

231014 01-03 
CIRCADIAN CYCLES IN BINDING OF 3H-ALPREN0L0L TO BETA- 
ADRENERGIC RECEPTOR SITES IN RAT PINEAL. 

234919 02-03 



S-44 



'OLUME 14, SUBJECT INDEX 



RAPID CHANGES IN RAT PINEAL BETA-ADRENERGIC RECEPTOR 
ALTERATIONS IN 3H-ALPREN0L0L BINDING AND ADENYLATE-CYCLASE 
(UNPUBLISHED PAPER). 

237170 02-03 
DIFFERENTIAL INTERACTIONS OF PENTOBARBITAL AND PHENOBARBITAL 
WITH BETA-ADRENERGIC MECHANISMS. 

238725 03-03 
EVIDENCE FOR A BETA-ADRENERGIC RECEPTOR MEDIATED POSITIVE 
FEEDBACK MECHANISM REGULATING RELEASE OF NOREPINEPHRINE. 

238727 03-03 
THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS AND BETA- 
ADRENERGIC BLOCKERS. 

239783 03-15 
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN 
CEREBELLUM: PHARAAACOLOGICAL HETEROGENEITY CONFIRMED BY 
DESTRUCTION OF INTERNEURONS. (UNPUBLISHED PAPER). 

240242 03-03 
BETA-ADRENERGIC BLOCKING DRUGS FOR ANXIETY. 

251155 04-14 
REPORT OF A SYMPOSIUM ON BETA-ADRENERGIC RECEPTOR BLOCKADE 

IN PSYCHIATRY, HELD IN FERNDOWN, DORSET, ON JUNE 21ST 1975 
BETA-ADRENERGIC BLOCKING DRUGS IN ANXIETY. 

251156 04-10 
BETA-ADRENERGIC BLOCKADE IN THE CONTROL OF SCHIZOPHRENIC 

SYMPTOMS - A CASE FOR CONTROLLED STUDIES. 

251164 04-08 
ITA-ALANINE 

THYROTROPIN-RELEASING HORMONE (TRH) AND ITS BETA-ALANINE 
ANALOG: POTENTIATION OF THE ANTICONVULSANT POTENCY OF 
PHENOBARBITAL IN MICE. 

232618 02-03 
:TA-AMINOPROPIONITRILE 

EFFECT OF BETA-AMINOPROPIONITRILE OR PREDNISOLONE ON SURVIVAL 
OF MALE LAF-J MICE. 

246586 04-03 

;ta-blockade 

TRANQUILIZATION EFFECT OF BETA-BLOCKADE ALPRENOLOL- A CLINICAL 
STUDY. 

228311 01-11 
BETA-BLOCKADE IN LITHIUM TREMOR. 

230742 01-15 
TA-BLOCKERS 

BETA-BLOCKERS IN ANXIETY AND STRESS. 

240694 03-10 
USE OF BETA-BLOCKERS AS AN ADJUNCT IN BEHAVIOURAL TECHNIQUES. 

251158 04-10 
CLINICAL EXPERIENCE WITH BETA-BLOCKERS IN CONSULTANT 
PSYCHIATRIC PRACTICE. 

251165 04-10 
BETA-BLOCKERS AND THE CENTRAL-NERVOUS-SYSTEM. 

253529 04-17 
TA-BIOCKING 

STUDIES ON MODE OF ANTAGONISM BETWEEN ADRENERGIC BETA- 
MIMETICS AND BETA-BLOCKING AGENTS (I). BETA-BLOCKING ACTION 
OF MESCALINE AND ITS DERIVATIVES. 

238563 02-03 
TA-CARBOUNES 
THE EFFECTS OF BETA-CARBOLINES ON RESPONSES TO ACETYLCHOLINE 
NORADRENALINE, 5-HYDROXYTRYPTAMINE AND AMINO-ACIDS IN THE 
RAT SPINAL CORD, 

235863 02-03 
rA-OIETHYlAMINOETHYL-DIPHENYLPROPYLACETATE 
INFLUENCE OF PSYCHOTROPIC DRUGS AND BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE (SKF-525-A) ON MESCALINE-INDUCED 
BEHAVIOR AND ON TISSUE LEVELS OF MESCALINE IN MICE. 

241349 03-04 
rA-01ETHYLAMINOETHYLDIPHENy|.PROPYLACETATE 
EFFECT OF RESTRICTION OF MOVEMENT AND BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE HYDROCHLORIDE ON 
SODIUM BARBITAL ACTIVITY IN THE RAT. 

249278 04-04 
FA-HYDROXYIATED 

EFFECTS OF BETA HYDROXYLATED PHENOTHIAZINE DERIVATIVES ON 
ISOLATED BRAIN MITOCHONDRIA. 

238777 03-03 
rA-MIMETICS 

STUDIES ON MODE OF ANTAGONISM BETWEEN ADRENERGIC BETA- 
MIMETICS AND BETA BLOCKING AGENTS (I). BETA-BLOCKING ACTION 
OF MESCALINE AND ITS DERIVATIVES. 

238563 02-03 
A-PHENYIETHYLAMINE 
BETA PHENYLETHYLAMINE (PEA) AND THE NEUROPSYCHIATRIC 
DISTURBANCES. (UNPUBLISHED PAPER). 

241474 03-14 
A-PHENYIETHYLAMINE-INOUCED 
MODIFICATION OF 8ETA-PHENYLETHYLAMINEINDUCED STEREOTYPED 
BEHAVIOR BY NEUROLEPTIC AGENTS. 

236672 0204 



Subject Index 

BETA-PHENYLISOPROPYLAMINES 

SYNTHESIS OF 0-TRANSMETHYLATED CATECHOLAMINES AND 
PSYCHODYSLEPTIC BETA-PHENYLISOPROPYLAMINES (PH D 
DISSERTATION). 

242003 03-01 
BETA-RECEPTOR 

LITHIUM TREMOR - COMBINATION TREATMENT WITH BETA-RECEPTOR 
BLOCKERS?. 

240741 03-14 
SOME STUDIES OF BETA-RECEPTOR BLOCKING DRUGS ON THE CENTRAL- 
NERVOUS-SYSTEM IN MAN. 

251162 04-13 
BETHANECHOL 

THE USE OF BETHANECHOL CHLORIDE WITH TRICYCLIC 
ANTIDEPRESSANTS. 

232864 02-15 
BETTA-SPLENDENS 

TWENTY-FOUR-HOUR RETENTION OF CHLORDIAZEPOXIDE (LIBRIUM) 
ATTENUATED THREAT BEHAVIOR IN MALE SIAMESE FIGHTING FISH 
(BETTA-SPLENDENS). 

242892 04-04 
BEVERAGES 

RAT DATA WHICH SUGGEST ALCOHOLIC BEVERAGES SHOULD BE 
SWALLOWED DURING CHEMICAL AVERSION THERAPY, NOT JUST 
TASTED. 

252859 04-17 
BIAS 

STRONG MEANING-RESPONSE BIAS IN SCHIZOPHRENIA. 

245559 04-08 
MEASUREMENT OF ANXIETY IN OUTPATIENT TRIALS: DETECTION OF BIAS 
IN PATIENT AND DOCTOR RATINGS. 

253043 04-16 
BrBLIOGRAPHY 

SELECTED BIBLIOGRAPHY ON DETECTION OF DEPENDENCE PRODUCING 
DRUGS IN BODY FLUIDS. 

229112 01-17 
A BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM - 
APPENDIX II. 

253064 04-17 
BICUCULLINE 

THE EFFECTS OF GABA, PICROTOXIN AND BICUCULLINE ON THE 
SPONTANEOUS BIOELECTRIC ACTIVITY OF CULTURED CEREBELLAR 
PURKINJE CELLS. 

232906 02-03 
COMPARISON OF BICUCULLINE METHOCHLORIDE WITH BICUCULLINE 
AND PICROTOXIN AS ANTAGONISTS OF AMINO-ACID AND 
MONOAMINE DEPRESSION OF NEURONES IN THE RAT BRAINSTEM. 

237783 02-03 
BICUCULLINE REVERSAL OF DEPRIVATION AMBLYOPIA IN THE CAT. 

249983 04-03 
BICYCUC 

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM DEPRESSANT ACTIVITY OF 
SOME BICYCLIC AMIDES. 

248539 04-02 
BILATERAL 

BILATERAL ELECTROENCEPHALOGRAPHIC RESPONSE AND UNILATERAL 
TOLERANCE TO UNILATERAL INTRACEREBRAL MORPHINE INJECTIONS. 

249484 04-03 
BILAYER 

THE INTERACTION OF HASHISH COMPOUNDS WITH PLANAR LIPID 
BILAYER MEMBRANES (BLM). 

244725 04-03 
BILIARY 

BIOTRANSFORMATION AND BILIARY EXCRETION OF IMIPRAMINE IN 
RATS UNDER VARIOUS EXPERIMENTAL CONDITIONS. 

226928 01 03 
BILIARY ELIMINATION OF DIAZEPAM IN MAN, 

250423 04-13 
BIMOLECULAR 

lONOPHORES X573A AND A23187: EFFECTS ON THE PERMEABILITY OF 
LIPID BIMOLECULAR MEMBRANES TO DOPAMINE AND CALCIUM 
(UNPUBLISHED PAPER). 

236873 02-03 
BINDING 

REGIONAL DISTRIBUTION OF POSTSYNAPTIC RECEPTOR BINDING FOR 
GAMMA-AMINOBUTYRIC-ACID (GABA) IN MONKEY BRAIN. 

226407 01-03 
STEREOSPECIFIC BINDING OF D-LYSERGIC-ACID DIETHYLAMIDE (LSD) TO 
BRAIN MEMBRANES: RELATIONSHIP TO SEROTONIN RECEPTORS, 

226936 01-12 
BLOCKAGE OF LSD BINDING AT ITS HIGH AFFINITY SITE ON 
SYNAPTOSOMAL MEMBRANES BY 1 METHYL 1,2 5 6 
TETRAHYDROPYRIDINE N,N DIETHYLCARBOXAMIDE. 

227692 01-03 
SATURABLE BINDING OF DIHYDROMORPHINE AND NALOXONE TO RAT 
BRAIN TISSUE IN VITRO. 

230919 01-0.'^ 
DIPHENYLHYDANTOIN POTENCY AND PLASMA PROTEIN BINDING. 

231003 01-03 



3 
I 









32 



S-45 



Subject Index 



Psychopharmacology Abstrac 



CIRCADIAN CYCLES IN BINDING OF 3H-ALPREN0L0L TO BETA- 
ADRENERGIC RECEPTOR SITES IN RAT PINEAL. 

234919 02-03 

CHANGES IN SERUM TRYPTOPHAN AND ALBUMIN BINDING OF 
TRYPTOPHAN IN CHLORPROMAZINE TREATED CHRONIC 
SCHIZOPHRENICS ON WITHDRAWAL AND RESTORATION OF DRUG 
THERAPY. 

235629 02-08 
RAPID CHANGES IN RAT PINEAL BETA-ADRENERGIC RECEPTOR 
ALTERATIONS IN 3H-ALPREN0L0L BINDING AND ADENYLATE-CYCLASE 
(UNPUBLISHED PAPER) 

S-HVDROXYTRYPTAMINE BINDING TO SYNAPTIC MEMBRANES FROM RAT 
BRAIN. 

237890 02-03 
BINDING OF GLYCINE AND GAMMA-AMIN08UTYRIC-ACID TO 
SYNAPTOSOAAAL FRACTIONS OF THE BRAINS OF DIFFERENTIALLY 
HOUSED MICE. 

238349 02-03 

LSD BINDING IN SUBCELLULAR FRACTIONS OF RAT BRAIN AND 

INHIBITORY EFFECTS OF RING SUBSTITUTED TRYPTAMINES. 
r.^T^^^ 238674 03-03 

FACTORS AFFECTING THE BINDING OF TRICYCLIC TRANQUILLIZERS AND 
ANTIDEPRESSANTS TO HUMAN SERUM ALBUMIN. 

COMPARISON OF WITHDRAWAL PRECIPTATING PROPERTIES OF VARIOUS 
MORPHINE ANTAGONISTS AND PARTIAL AGONISTS IN RELATION TO 
THEIR STEREOSPECIFIC BINDING TO BRAIN HOMOGENATES. 

239854 03-03 
MONOAMINE OXIDASE ACTIVE SITE, THE BINDING TO AND TITRATION 
OF MONOAMINE-OXIDASE WITH (I4C) SELECTIVE INHIBITORS. 

241931 03-03 
DOPAMINE RECEPTOR BINDING PREDICTS CLINICAL AND 

PHARMACOLOGICAL POTENCIES OF ANTISCHIZOPHRENIC DRUGS. 

243483 04-03 
BINDING OF THIORIDAZINE AND SOME IT OF ITS METABOLITES TO 
HUMAN SERUM PROTEIN AND HUMAN ALBUMIN. 

244131 04-13 
PLASMA PROTEIN BINDING OF DRUGS AS A FUNCTION OF AGE IN ADULT 
HUMAN SUBJECTS. 

246970 04- 1 3 
BINDING OF CHLORPROMAZINE AND IMIPRAMINE TO RED CELLS 
ALBUMIN, LIPOPROTEINS AND OTHER BLOOD COMPONENTS. 

247129 04-03 
EFFECTS OF BENZODIAZEPINES ON THE BINDING OF TRYPTOPHAN IN 
SERUM. CONSEQUENCES ON 5-HYDROXYINDOLES CONCENTRATIONS IN 
THE RAT BRAIN. 

rrrn^^ ^ 247213 0403 

EFFECT OF ESTROGEN TREATMENT ON ESTRADIOL BINDING CAPACITY IN 
UTERI OF AGING RATS. , 

247588 04-03 
THE DOPAMINE RECEPTOR: DIFFERENTIAL BINDING OF D-LSD AND 
RELATED AGENTS TO AGONIST AND ANTAGONIST STATES. 

247862 04-03 
IS THE SEROTONIN BINDING PROTEIN (SBP) A SOLUBLE STORAGE FORM 
FOR SEROTONIN? 

248604 04-03 
RECEPTOR BINDING AND PHARMACOLOGICAL ACTIVITY OF OPIATES IN 
THE GUINEA-PIG INTESTINE. 

^„ ^ 248703 04-03 

DRUG ANTAGONISM AND REVERSIBILITY OF THE BINDING OF 
INDOLEAMINES IN BRAIN. 

250081 04-03 
ANTIACETYLCHOLINE ACTIVITIES OF PSYCHOACTIVE DRUGS A 

COMPARISON OF THE (3H)QUINUCLIDINYL BENZILATE BINDING ASSAY 
WITH CONVENTIONAL METHODS. 

250360 04-02 
OPIATE RECEPTOR BINDING - ENHANCEMENT BY OPIATE 
ADMINISTRATION IN VIVO. 

250378 04-03 
STEREOSPECIFIC BINDING OF ETORPHINE IN ISOLATED NEURAL CELLS 
AND IN RETINA, DETERMINED BY A SENSITIVE MICROASSAY. 

252178 04-03 
MUSCARINIC CHOLINERGIC RECEPTOR BINDING: INFLUENCE OF PIMOZIDE 
AND CHLORPROMAZINE METABOLITES. 

252515 04-05 
BIOASSAY 

A METHOD FOR BIOASSAY OF PHYSICAL DEPENDENCE ON SEDATIVE 
DRUGS IN DOG. 

244674 04-06 
BIOAVAILABtllTY 

PHARMACOLOGICAL RESPONSE DATA FOR COMPARATIVE 

BIOAVAILABILITY STUDIES OF CHLORPROMAZINE ORAL DOSAGE 
FORMS IN HUMANS: I. PUPILOMETRY 

232623 02-13 
BIOAVAILABILITY ANALYSIS OF CHLORPROMAZINE IN HUMANS FROM 
PUPILOMETRIC DATA 

237872 02-13 



BIOAVAILABILITY OF TWO CARBAAAAZEPINE PREPARATIONS CURING 
CHRONIC ADMINISTRATION TO EPILEPTIC PATIENTS. 

242212 03 
BIOBEHAVIORAl 

THE BIOCHEMICAL AND BIOBEHAVIORAL PROFILE OF 5- 
METHOXYTRYPTAMINE. (UNPUBLISHED PAPER). 

239307 03 
BIOCHEMICAL 

BIOCHEMICAL OBSERVATIONS FOLLOWING ADMINISTRATION OF 
TAURINE TO PATIENTS WITH EPILEPSY. 

226737 01 
ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY. 

226961 01 
ANGIOTENSIN-INDUCED DRINKING IN THE CAT: A DOSE-RESPONSE ANC 
BIOCHEMICAL ANALYSIS. (PH.D. DISSERTATION). 

227106 01- 
BIOCHEMICAL IDENTIFICATION OF THE /WAMMALIAN MUSCARINIC 
CHOLINERGIC RECEPTOR. 

227400 01- 
BIOCHEMICAL VS CLINICAL PHYSIOGNOMY OF NEUROLEPTICS WITH 
SPECIAL REFERENCE TO THEIR ANTIMANIC EFFECT. 

227763 01- 
RECENT VIEWS IN PSYCHOPHARAAACOLOGY, ITS BIOCHEMICAL ASPECT 

228310 01- 
BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5 7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 
ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02- 
BIOCHEMICAL MECHANISMS OF ACTION AND PHARMACOKINETICS OF 
PSYCHOTROPIC DRUGS. 

233682 02- 
DIFFERENTIAL BEHAVIORAL AND BIOCHEMICAL EFFECTS OF REGIONAL 
INJECTION OF CYCLOHEXIMIDE INTO MOUSE BRAIN. 

235320 02-1 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES. II BLOOD LEVELS 
AND THERAPEUTIC RESPONSIVENESS. 

235367 02-1 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES: III. 

DEXAMETHASONE SUPPRESSION TEST RESULTS AND THERAPEUTIC 
RESPONSIVENESS. 

235368 02-( 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES: I AN 

UNCONTROLLED CLINICAL TRIAL IN DEPRESSION. 

235369 02-( 
EXCITATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 

RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL 
FUNCTIONAL AND CLINICAL DATA. 

237104 02-( 
BEHAVIORAL AND BIOCHEMICAL INTERACTION BETWEEN AMT AND ( f 
AMPHETAMINE: RELEVANCE TO THE IDENTIFICATION OF THE 
FUNCTIONAL POOL OF BRAIN CATECHOLAMINES. 

237698 02-C 
DIFFERENTIAL EFFECTS OF AN INHIBITOR OF DECARBOXYLASE ON L- 
DOPA AND L-5-HTP: POLYGRAPHIC AND BIOCHEMICAL DATA. 

237709 02-C 
PERFUSION WITH L-5-HTP, ALONG WITH A DECARBOXYLASE INHIBITOR 

IN THE RABBIT. POLYGRAPHIC AND BIOCHEMICAL DATA. 

237710 02-0 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE: BIOCHEMICAL AND 

PHARMACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE AS 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINE 
AND OTHER PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION). 

238077 02-0 
A COMPARISON OF THE BIOCHEMICAL EFFECT OF TWO CATALYTIC 
INHIBITORS OF MAMMALIAN BRAIN GABA-TRANSAMINASE GAMMA- 
VINYL-GA8A (AMIN0-4-HEX-5-EN0IC-ACID) AND GAMMA-ACETYLENIC- 
GABA (AMIN0-4-HEX-5-YN0IC-ACID). 

238782 03-0: 
BIOCHEMICAL RESEARCH INTO PSYCHOSIS: RESULTS OF A NEW 
RESEARCH STRATEGY. 

238997 03- 1: 
THE BIOCHEMICAL AND BIOBEHAVIORAL PROFILE OF 5- 
METHOXYTRYPTAMINE. (UNPUBLISHED PAPER). 

239307 03-0; 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 
TREATMENT: I. INVESTIGATIONS WITH HALOPERIDOL. 

240218 03-OJ 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: II. ANTIPSYCHOTIC EFFECT OF HALOPERIDOL IN PATIENTS 
WITH CHRONIC ORGANIC BRAIN DAAAAGE. 

240219 03-11 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: III PRIMITIVE REFLEXES DURING NEUROLEPTIC 
TREATMENT. 

240220 03- 14 



S-46 



VOLUME 14, SUBJECT INDEX 



Subject Index 



SOME RECENT ADVANCES IN THE BIOCHEMICAL PHARMACOLOGY OF 
GAMMA-AMINOBUTYRICACID (GABA). (UNPUBLISHED PAPER). 

240699 03-03 
INFLUENCE OF DIURNAL CYCLES ON BIOCHEMICAL PARAMETERS OF 
DRUG SENSITIVITY: THE PINEAL GLAND AS A MODEL. 

241471 03-17 
MANIPULATION OF ACETYLCHOLINE LEVELS IN DEVELOPING RAT BRAIN: 
BIOCHEMICAL AND BEHAVIORAL CONSIDERATIONS. (PH.D. 
DISSERTATION). 

241680 03-04 
THE GENETIC. BIOCHEMICAL AND PHARMACOLOGICAL CORRELATES OF 
RESPONSES TO PRIMING IN MICE. (PH.D. DISSERTATION). 

241687 03-04 
BIOCHEMICAL RESEARCH IN SCHIZOPHRENIA: RESULTING IN A NEW 
RESEARCH STRATEGY. 

241912 03-08 
DOPAMINERGIC CHOLINERGIC INTERACTIONS IN THE CENTRAL-NERVOUS- 
SYSTEM: BIOCHEMICAL PHARMACOLOGICAL ASPECTS. 

244038 04-17 
BIOCHEMICAL PHARMACOLOGICAL BASES FOR THE CLINICAL USE OF L- 

DIHYDROXYPHENYLALANINE IN PARKINSONS SYNDROME. 

244039 04- 17 
DRUG-INDUCED PARKINSONISM IN THE RAT - A MODEL FOR 

BIOCHEMICAL INVESTIGATION OF THE PARKINSON SYNDROME: Ml- 
THE INCORPORATION OF 0-GLUC0SE14C(U) IN AMINO-ACIDS OF 
BRAIN AND LIVER FROM RATS PRETREATED WITH RESERPINE OR 
WITH PHENOTHIAZINES. 

244692 04-03 
CORRELATION BETWEEN BRAIN LEVELS AND BIOCHEMICAL EFFECTS ON 
THE OPTICAL ISOMERS OF P-CHLOROAMPHETAMINE. 

246851 04-03 
A RELATIONSHIP BETWEEN CLINICAL EFFICACY AND VARIOUS 

BIOCHEMICAL PARAMETERS OF MONOAMINE-OXIDASE INHIBITORS 
(MAOIS). 

249308 04-03 
BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF FENFLURAMINE IN 
PATIENTS WITH NEUROLOGIC DISEASE. 

250942 04-11 
BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF THIOTHIXENE RELATION 
TO TISSUE LEVELS OF THE DRUG. 

251131 04-03 
DIFFERENT ALPHA-ADRENORECEPTORS IN THE CENTRAL-NERVOUS- 
SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF 
CLONIDINE AND RECEPTOR BLOCKING AGENTS. 

251226 04-02 
lOCHEMISTRY 

BIOCHEMISTRY AND THE SEARCH FOR THERAPEUTIC AGENTS. 

245949 04-06 
lODISPOSmON 

BIODISPOSITION OF KETAMINE IN THE RAT: SELF-INDUCTION OF 
METABOLISM. 

250107 04-03 
EFFECTS OF HALOTHANE ANESTHESIA ON THE BIODISPOSITION OF 

KETAMINE IN RATS. 

250108 04-03 
lOElECTRIC 

THE EFFECTS OF GABA, PICROTOXIN AND BICUCULLINE ON THE 
SPONTANEOUS BIOELECTRIC ACTIVITY OF CULTURED CEREBELLAR 
PURKINJE CELLS. 

232906 02-03 
CHICK PHASIC BIOELECTRIC ACTIVITY AT THE TIME OF HATCHING AND 
THE EFFECTS OF PREVIOUS NIALAMIDE INJECTION. 

235317 02-04 
BIOELECTRIC EFFECTS OF ISOPROTERENOL AND PROPRANOLOL ON NERVE 
CELLS IN EXPLANTS OF RAT CEREBELLUM. 

237880 02-03 
lOGENIC 

BIOGENIC AMINES AND THE EFFECT OF SHORT-TERM LITHIUM 
ADMINISTRATION ON OPEN-FIELD ACTIVITY IN RATS. 

225573 01-04 
CHEMISTRY AND PHARMACOLOGY OF BIOGENIC AMINE UPTAKE. 

229478 01-03 
BIOGENIC AMINE EFFECTS ON CNS PHOSPHOLIPID METABOLISM. 

229482 01-03 
THE EFFECTS OF ACETYLCHOLINE AND DOPAMINE ON THE CAUDATE- 
NUCLEUS DEPLETED OF BIOGENIC AMINES. 

230457 01 03 
INVOLVEMENT OF BIOGENIC AMINES IN DRUG-INDUCED AGGRESSIVE 
PECKING IN CHICKS. 

230878 01 04 
BEHAVIORAL EFFECTS OF DIBUTYRYL-CYCLICAMP AND BIOGENIC 
AMINES IN RATS 

232484 01-04 
ROLE OF BIOGENIC AMINES IN THE EFFECTS OF MARUUANA ON EEG 
PATTERNS IN CATS 

235564 02-03 
BIOGENIC AMINES AND THE PHOTOMYOCLONIC SYNDROME IN THE 
BABOON, PAPIO-PAPIO. 

237755 02-04 



COMPARATIVE PHARAAACOLOGY OF AMPHETAMINE AND PEMOLINE ON 
BIOGENIC AMINE SYSTEMS. 

238728 03-03 
EFFECTS OF ACUTE ETHANOL ADMINISTRATION ON BRAIN BIOGENIC 
AMINES. 

238751 03-03 
EVIDENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
MOTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS. 

241203 03-03 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (I). RELATIONSHIP 
BETWEEN BRAIN MONOAMINES AND DEFECATION IN RATS. 

241370 03-04 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (II). RELATIONSHIP 

BETWEEN EMOTIONALITY AND DEFECATION. 

241371 03-04 
BRAIN FUNCTION AND BIOGENIC AMINES (4) ROLE OF MONOAMINERGIC 

MECHANISM ON SELECTIVE INHIBITION OF PARADOXICAL SLEEP. 

241388 03-03 
BIOGENIC AMINES AND AFFECTIVE DISORDERS. 

241937 03-09 
THE EFFECTS OF TANDAMINE, A NEW POTENTIAL ANTIDEPRESSANT 
AGENT, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED 
ACTIVITIES. 

244316 04-02 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAIN 
MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS. 

246318 04-04 
D AMPHETAMINE AS A RELEASER OR REUPTAKE INHIBITOR OF BIOGENIC 
AMINES IN SYNAPTOSOMES. 

246665 04-03 
USE OF SYNTHESIS INHIBITORS IN DEFINING A ROLE FOR BIOGENIC 
AMINES DURING IMIPRAMINE TREATMENT IN DEPRESSED PATIENTS. 

247216 04-09 
COMPARISON OF THE MONOMETHOXYAMPHETAMINES ON THE UPTAKE 
AND RELEASE OF BIOGENIC AMINES IN BRAIN TISSUE. 

249315 04-03 
UPTAKE OF BIOGENIC AMINES INTO SYNAPTIC VESICLES OF THE 
CAUDATE-NUCLEUS. 

251392 04-03 
EFFECTS OF MAZINOOL, A NONPHENYLETHYLAMINE ANOREXIGENIC 
AGENT, ON BIOGENIC AMINE LEVELS AND TURNOVER RATE 

252201 04-03 
COMPARATIVE ACTIONS OF MONOMETHOXYAMPHETAMINES ON THE 
RELEASE AND UPTAKE OF BIOGENIC AMINES IN BRAIN TISSUE. 

253107 04-03 
BIOLOGICAL 

UTILIZATION OF CELLULAR STUDIES OF NEUROTRANSMITTER RELATED 
ENZYMES AND TRANSPORT PROCESSES IN MAN FOR THE 
INVESTIGATION OF BIOLOGICAL FACTORS IN BEHAVIORAL DISORDERS. 
(UNPUBLISHED PAPER). 

226731 01-13 
PSYCHOPHARMACOLOGY: A BIOLOGICAL APPROACH. 

232938 02-17 
QUANTITATIVE GLC DETERMINATION OF PENTYLENETETRAZOL IN 
BIOLOGICAL FLUIDS 

233277 02-06 
PARTICIPATION OF ADRENO, DOPAMINE, AND SEROTONERGIC 
MECHANISMS OF THE SEPTUM IN CONDITIONED REFLEX REACTIONS 
TO VARIOUS BIOLOGICAL MODALITIES IN RATS. 

236828 0204 
SYNTHESIS AND BIOLOGICAL ACTIONS OF 2-SUBSTITUTED 
QUINOLIZIDINES. 

238477 02-02 
GAS CHROMATOGRAPHY MASS FRAGMENTOGRAPHIC (GC-MF) ANALYSIS 
OF TRYPTAMINE IN BIOLOGICAL SAMPLES. 

238774 03-01 
ON MONOAMINERGIC MECHANISMS OF THE AMYGDALA COMPLEX 
IMPLEMENTING CONDITIONED REFLEXES OF VARIOUS BIOLOGICAL 
MODALITIES. 

241980 03-03 
ISOLATION AND RADIOENZYMIC ESTIMATION OF PICOGRAM QUANTITIES 
OF DOPAMINE AND NOREPINEPHRINE IN BIOLOGICAL SAMPLES. 

244636 04-06 
SYNTHESIS AND BIOLOGICAL ACTIVITY OF NEW 2-SUBSTITUTED 
ANALOGS OF FLUPHENAZINE. 

248538 04-02 
ANALOGUES OF S-ADENOSYLHOMOCYSTEINE AS POTENTIAL INHIBITORS 
OF BIOLOGICAL TRANSMETHYLATION. SYNTHESIS OF ANALOGUES 
WITH MODIFICATIONS AT THE 5-THIOETHER LINKAGE. 

251698 04-01 
BIOLOGY 

A BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM - 
APPENDIX II. 

253064 04-17 



s 
i 



s 

I 

I 

IS- 



S-47 



Subject Index 



Psychopharmacology Abstracts 



BIOSYNTHESIS 

EFFECTS OF PSYCHOTROPIC DRUGS ON PROSTAGLANDIN BIOSYNTHESIS 
IN VITRO. 

238320 0203 
RATE OF BIOSYNTHESIS OF DOPAMINE BETA-HYDROXYLASE IN LOCUS- 
COERULEUS OF RAT BRAIN AFTER RESERPINE. 

238759 03-03 
THE AMPHETAMINE-INDUCED INHIBITION OF DOPAMINE BIOSYNTHESIS 
IN RAT STRIATUM. 

240065 03-03 
EFFECT OF TETRAHYDROCANNABINOLS ON H3-ACETYLCH0LINE 
BIOSYNTHESIS IN VARIOUS RAT BRAIN SLICES. 

241254 03-03 
THE EFFECTS OF NOREPINEPHRINE BIOSYNTHESIS INHIBITION ON THE 
CONSOLIDATION OF TWO DISCRIMINATED ESCAPE RESPONSES. 

241301 03-04 
BIOSYNTHETIC 

EFFECTS OF LITHIUM CHLORIDE ON PARAMETERS OF BIOSYNTHETIC 
CAPACITY FOR 5-HYDROXYTRYPTAMINE IN RAT BRAIN. 

246849 04-03 
COCAINE AND LITHIUM: NEUROBIOLOGICAL ANTAGONISM IN THE 
SEROTONIN BIOSYNTHETIC SYSTEM IN RAT BRAIN. 

252514 04-03 
BIOTRANSFORMATION 

BIOTRANSFORMATION AND BILIARY EXCRETION OF IMIPRAMINE IN 
RATS UNDER VARIOUS EXPERIMENTAL CONDITIONS. 

226928 01-03 
BIOTRANSFORMATION OF AMITRIPTYLINE IN THE DOG. 

238684 03-03 
CORRELATION BETWEEN STRUCTURE, BEHAVIORAL ACTIVITY AND RATE 
OF BIOTRANSFORMATION OF SOME ACTH4-9 ANALOGS. 

246853 04-04 
EFFECT OF OXOTREMORINE ON ENDOGENOUS ACETYLCHOLINE AND ON 
UPTAKE AND BIOTRANSFORMATION OF RADIOACTIVE CHOLINE IN 
DISCRETE REGIONS OF MOUSE BRAIN IN VIVO. 

251175 04-03 
BIPERIDEN 

NEUROPSYCHOLOGICAL INVESTIGATIONS ON THE SHORT-TERM EFFECTS 
OF BIPERIDEN (AKINETON) IN PARKINSONS DISEASE. 

238516 02-11 
BIPHASIC 

DETERMINATIONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESIS IN 
A SINGLE MOUSE BRAIN: BIPHASIC EFFECTS OF ( -l- ) AMPHETAMINE. 

241257 03-03 
BIPOLAR 

THE FORGOTTEN TREATMENT MODALITY IN BIPOLAR ILLNESS: 
PSYCHOTHERAPY. 

231611 01-09 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
0-METHYLTRANSFERASE, AND FAMILY HISTORY. 

246629 04-09 
LITHIUM CARBONATE AND AFFECTIVE DISORDERS. V: A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS OF DEPRESSION IN BIPOLAR ILLNESS. 

247582 04-09 
BIRTH 

CHOLINE ACETYLTRANSFERASE ACTIVITY INCREASES IN THE BRAINSTEM 
OF RATS TREATED AT BIRTH WITH 6-HYDROXYDOPA. 

249666 04-03 
BITING 

PHARMACOLOGICAL DISSOCIATION BETWEEN VOCALIZATION AND 
BITING PRODUCED IN RATS BY THE COMBINATION OF IMIPRAMINE 
AND ISOCARBOXAZID, 

237705 02-04 
APOMORPHINE-INDUCEO STEREOTYPED BITING IN THE TORTOISE IN 
RELATION TO DOPAMINERGIC MECHANISMS. 

247875 04-04 
DISSOCIATION OF STEREOTYPED BITING RESPONSES AND ORO-BUCCO- 
LINGUAL DYSKINESIAS. 

252031 04-03 
BIVENTER 

FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCLE 

248409 04-03 
BLACK 

ACCUMULATION OF LABELED EPHEDRINE, NOREPHEDRINE, 

AMPHETAMINE AND TYRAMINE IN PIGMENTED AND NONPIGMENTED 
EYES OF BLACK AND WHITE RATS. 

230450 01-03 
BLAST 

EFFECT OF CHLORPROMAZINE ON THE REACTION OF BLAST 
TRANSFORMATION OF LYMPHOCYTES. 

236373 02-03 



BLM 



THE INTERACTION OF HASHISH COMPOUNDS WITH PLANAR LIPID 
BILAYER MEMBRANES (BLM). 

244725 04-03 



BLOCK 

INABILITY OF AN INHIBITOR OF AMINE UPTAKE (LILLY-1 10140) TO 
BLOCK DEPLETION OF BRAIN 5-HYDROXYTRYPTAMINE BY L-DOPA. 

226765 01-03 
BARBITURATES BLOCK CALCIUM UPTAKE BY STIMULATED AND 
POTASSIUM DEPOLARIZED RAT SYMPATHETIC GANGLIA. 

237751 02-03 
DIFFERENTIATION OF SENSORY-MOTOR MECHANISMS IN PERIPHERAL 
NERVE BLOCK BY MODIFIED RAT SCIATIC BLOCK METHOD. 

238724 03-03 
AMITRIPTYLINE POISONING CAUSING LEFT BUNDLE BRANCH BLOCK. 

241357 03-15 
BLOCKADE 

CHOLINERGIC BLOCKADE, SEPTAL LESIONS, AND DRL PERFORAAANCE IN 
THE RAT. 

226305 01-04 
DOPAMINE RECEPTOR BLOCKADE AND THE NEUROLEPTICS, A 
CRYSTALLOGRAPHIC STUDY. 

226761 01-03 
MORPHINE ANALGESIA: BLOCKADE BY RAPHE MAGNUS LESIONS. 

23261 1 02-03 
DISRUPTION OF BRAIN STIMULATION-INDUCED FEEDING BY DOPAMINE 
RECEPTOR BLOCKADE. 

235587 02-04 
PITUITARY HORMONE LEVELS IN SCHIZOPHRENIA BEFORE AND AFTER 
DOPAMINE BLOCKADE. (UNPUBLISHED PAPER). 

238491 02-13 
DIFFERENTIAL BLOCKADE OF ALPHA ADRENERGIC RECEPTORS BY 
CHLORPROMAZINE. 

238672 03-03 
INHIBITION OF FIRING OF RAPHE NEURONES BY TRYPTOPHAN AND 5- 
HYDROXYTRYPTOPHAN: BLOCKADE BY INHIBITING SEROTONIN 
SYNTHESIS WITH RO-4-4602. 

239957 03-03 
BLOCKADE OF THE ELECTROCORTICAL CHANGES INDUCED BY PERFUSION 
OF AMPHETAMINE IN THE BRAINSTEM RETICULAR FORMATION. 

241930 03-03 
PRESYNAPTIC AND POSTSYNAPTIC ORIGIN OF LITHIUM-INDUCED ACUTE 
BLOCKADE ON ADRENERGIC TRANSMISSION IN RABBIT HEART, 

242204 03-03 
EFFECTS OF DOPAMINE RECEPTOR BLOCKADE ON SELF-STIMULATION IN 
THE MONKEY. 

242748 04-04 
THE EFFECTS OF CHRONIC GANGLION BLOCKADE AND CHRONIC 
CHOLINESTERASE INHIBITION ON THE SENSITIVITY OF RABBIT 
STOMACH MUSCULARIS TO CHOLINERGIC AND ADRENERGIC 
AGONISTS. 

246842 04-03 
THE EFFECTS OF GANGLIONIC BLOCKADE, RESERPINE AND VINBLASTINE 

ON PLASMA CATECHOLAMINES AND DOPAMINE-BETA-HYDROXYLASE 
IN THE RAT, 

246843 04-03 
BLOCKADE OF MORPHINE WITHDRAWAL BODY SHAKES BY 

HALOPERIDOL. 

248274 04-03 
PENFLURIDOL BLOCKADE OF APOMORPHINE: DEPENDENCE OF DURATION 
ON SPECIES AND ENDPOINT. 

248406 04-02 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASURE 
THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS. 

248834 04-03 
THE CONTRIBUTION OF NEURONAL UPTAKE BLOCKADE TO THE 
ANTIEPILEPTIC ACTION OF CARBAMAZEPINE (TEGRETOL). 

249242 04-03 
REVERSAL OF RESIDUAL TOLERANCE TO MORPHINE AND BLOCKADE OF 
EFFECTS OF MORPHINE WITH CHRONIC NALTREXONE 
ADMINISTRATION. 

249268 04-03 
NALOXONE BLOCKADE OF MORPHINE ANALGESIA - A DOSE EFFECT 
STUDY OF DURATION AND MAGNITUDE, 

249271 04-02 
ELICITATION OF MOUSE JUMPING BY COMBINED TREATMENT WITH 

AMPHETAMINE AND L-DOPA: BLOCKADE BY KNOWN NEUROLEPTICS, 

249272 04-04 
ON THE USE OF SELECTIVE NEUROTOXIC AMINE ANALOGS TO MEASURE 

THE BLOCKADE OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE 
UPTAKE SYSTEMS BY ANTIDEPRESSANTS, 

249930 04-03 
REPORT OF A SYMPOSIUM ON BETA-ADRENERGIC RECEPTOR BLOCKADE 
IN PSYCHIATRY. HELD IN FERNDOWN, DORSET, ON JUNE 21 ST 1975. 
BETA-ADRENERGIC BLOCKING DRUGS IN ANXIETY 

251156 04 10 
BETA ADRENERGIC BLOCKADE IN THE CONTROL OF SCHIZOPHRENIC 
SYMPTOMS - A CASE FOR CONTROLLED STUDIES. 

251164 04-08 
EFFECTS OF GABA BLOCKADE ON LATERAL HYPOTHALAMIC SELF- 
STIMULATION 

252017 04-04 



S-48 



>LUME 14, SUBJECT INDEX 



Subject Index 



THE EFFECT OF SUBFORNICAL ORGAN LESIONS AND VENTRICULAR 
BLOCKADE ON DRINKING INDUCED BY ANGIOTENSIN-II. 

252170 04-03 
ICKAGE 
BLOCKAGE OF LSD BINDING AT ITS HIGH AFFINITY SITE ON 
SYNAPTOSOMAL MEMBRANES BY 1 METHYL 1,2,5,6 
TETRAHYDROPYRIDINE N,N DIETHYLCARBOXAMIDE. 

227692 01-03 
CKERS 

INTERACTIONS OF ADRENERGIC STIMULANTS AND BLOCKERS ON SELF- 
STIMULATION BEHAVIOR IN RATS 

226943 01-04 
THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS AND BETA- 
ADRENERGIC BLOCKERS. 

239783 03-15 
LITHIUM TREMOR - COMBINATION TREATMENT WITH BETA-RECEPTOR 
BLOCKERS?. 

240741 03-14 
EFFECTS OF ALPHA-RECEPTOR BLOCKERS AND ANTIDEPRESSANT DRUGS 
ON THE PRESYNAPTIC ALPHA-RECEPTOR OF RAT CEREBRAL CORTEX. 

251394 04-03 
CKING 
BEHAVIORAL EFFECTS OF INTRACEREBRALLY ADMINISTERED 

CATECHOLAMINES IN MICE AND THEIR MODIFICATIONS BY SOME 
ADRENERGIC BLOCKING AGENTS. 

237707 02-04 
SELECTIVE BLOCKING ACTION OF LSD ON INHIBITORY DOPAMINE 
RECEPTORS. 

237782 02-03 
CONFORMATIONAL REQUIREMENTS FOR BLOCKING UPTAKE OF 
CATECHOLAMINES AND SEROTONIN INTO CRUDE RAT BRAIN 
SYNAPTOSOMES. 

238738 03-01 
EFFECTS OF CATECHOLAMINE RECEPTOR BLOCKING AGENTS ON 
TOXICITY AND THERMAL RESPONSES INDUCED BY AMPHETAMINE 
ISOMERS IN ADULT AND DEVELOPING MICE. 

239043 03-05 
BETA-ADRENERGIC BLOCKING DRUGS FOR ANXIETY. 

251155 04-14 
REPORT OF A SYMPOSIUM ON BETA ADRENERGIC RECEPTOR BLOCKADE 

IN PSYCHIATRY, HELD IN FERNDOWN, DORSET, ON JUNE 21 ST 1975. 
BETA-ADRENERGIC BLOCKING DRUGS IN ANXIETY. 

251156 04-10 
SOME STUDIES OF BETA-RECEPTOR BLOCKING DRUGS ON THE CENTRAL- 
NERVOUS-SYSTEM IN MAN. 

251162 04-13 
DIFFERENT ALPHA-ADRENORECEPTORS IN THE CENTRAL-NERVOUS- 
SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF 
CLONIDINE AND RECEPTOR BLOCKING AGENTS. 

251226 04-02 
NORADRENALINE SYNTHESIS AND UTILIZATION: CONTROL BY NERVE 

IMPULSE FLOW UNDER NORMAL CONDITIONS AND AFTER TREATMENT 
WITH ALPHA-ADRENORECEPTOR BLOCKING AGENTS. 

251227 04-02 
CKS 

NISOXETINE (LILLY-94939) SELECTIVELY BLOCKS THE UPTAKE OF 
NOREPINEPHRINE IN VITRO AND IN VIVO IN RAT BRAIN. 

238840 03-03 
OD 

DELTA9-TETRAHYDR0CANNABIN0L ALTERS FLOW OF BLOOD TO 
SUBCORTICAL AREAS OF THE CONSCIOUS RAT BRAIN. 

226874 01-04 
PARATHION ADMINISTRATION IN THE MONKEY: TIME COURSE OF 

INHIBITION AND RECOVERY OF BLOOD CHOLINESTERASES AND VISUAL 
DISCRIMINATION PERFORMANCES. 

227384 01-03 
THE EFFECT OF DIAZEPAM AND TRIFLUOPERAZINE ON BLOOD SUPPLY 
AND CARDIAC ACTIVITY. 

228553 01-03 
SERUM GROWTH HORMONE, SERUM IMMUNOREACTIVE INSULIN AND 
BLOOD GLUCOSE RESPONSE TO ORAL AND INTRAVENOUS DIAZEPAM 
IN MAN. 

229042 01-13 
PLASMA/BLOOD LEVEL MONITORING TECHNIQUES IN PSYCHIATRY. 

229438 01-16 
BLOOD LEVEL, MOOD, AND MHPG RESPONSES TO DIAZEPAM IN MAN. 

229440 01-14 
A NOVEL APPROACH TO QUANTITATIVE DETERMINATION OF 

SUBNANOMOLES OF PSYCHOACTIVE DRUGS IN BLOOD. 

229441 01-16 
A PRELIMINARY REPORT ON CLINICAL RESPONSE AND BLOOD LEVELS OF 

CHLORPROMAZINE AND ITS SULFOXIDE DURING CHLORPROMAZINE 
THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS. 

229444 01-08 
INTERACTIONS OF ALCOHOL, BARBITURATES, AND NARCOTICS WITH 
BLOOD VESSELS. 

229474 01-03 



DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 
APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. III. THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAMATE IN THE BLOOD 
AND THEIR EFFECTS ON PERFORMANCE,- APPLICATION OF 
MATHEAAATICAL MODELS. 

232519 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. IV. THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAMATE IN THE BLOOD. 

232520 0'-13 
CHANGES IN PERIPHERAL BLOOD DURING TREATMENT WITH SOME 

NEUROLEPTICS AND THYMOLEPTICS. 

234045 02-15 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES. II. BLOOD LEVELS 
AND THERAPEUTIC RESPONSIVENESS. 

235367 02-09 
THE INFLUENCE OF DIETARY IODINE ON LITHIUM BLOOD LEVEL, SERUM 
0T4 AND THYROID GLAND WEIGHT 

236528 02-03 
THE EFFECT OF LITHIUM ON RED BLOOD CELL CHOLINESTERASE ACTIVITY 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

244495 04-09 
TRAZODONE: THERAPEUTIC EFFECTIVENESS IN ENDOGENOUS 
DEPRESSION, COMPARED WITH BLOOD LEVELS. 

244588 04-09 
BUTAPERAZINE PHARMACOKINETICS: EFFECT OF DOSAGE REGIMEN ON 
STEADY-STATE BLOOD LEVELS. 

245842 04-08 
BINDING OF CHLORPROMAZINE AND IMIPRAMINE TO RED CELLS, 
ALBUMIN, LIPOPROTEINS AND OTHER BLOOD COMPONENTS. 

247129 04 03 
ROLE OF THE PROSTAGLANDINS IN THE REGULATION OF THE CEREBRAL 
BLOOD CIRCULATION. 

248552 04-03 
REDUCTION OF BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN 
SCHIZOPHRENIC PATIENTS ON PHENOTHIAZINES. 

249121 04-08 
EFFECTS OF SEROTONIN UPTAKE INHIBITOR, LILLY! 10140, ON 

TRANSPORT OF SEROTONIN IN RAT AND HUMAN BLOOD PLATELETS. 

250380 04-03 
CHLORPROMAZINE METABOLISM Vllh BLOOD LEVELS OF 

CHLORPROMAZINE AND ITS SULFOXIDE IN SCHIZOPHRENIC PATIENTS 

251778 04-16 
BLOOD-BRAIN 

EFFECTS OF CAFFEINE AND ETHANOL ON THE BLOOD BRAIN BARRIER IN 
RATS. 

252222 04-03 
BIOOO-PRESSURE 

THE EFFECT OF DIAZEPAM, FLUNITRAZEPAM AND DROPERIDOL WITH AN 
ANALGESIC ON BLOOD-PRESSURE AND HEARTRATE IN MAN 

232531 01-13 
EFFECTS OF BARBITURATES ON BLOOD-PRESSURE IN LIDOCAINE 
INJECTED SHR. 

241405 03-03 
BLOOD-PRESSURE AND PULSE CHANGES IN HYPERACTIVE CHILDREN 
TREATED WITH IMIPRAMINE AND METHYLPHENIDATE. 

244932 04-15 
CHANGES IN THE ARTERIAL BLOOD-PRESSURE RESPONSES OF 

HYPERTENSIVE RATS TO SOME DRUGS ACTING ON THE CENTRAL 
SYMPATHETIC MECHANISMS 

248551 04-03 
INFLUENCE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES ON A 
CONDITIONED BLOOD-PRESSURE INCREASE IN SQUIRREL-MONKEYS. 

251414 04 03 
BODY 

SELECTED BIBLIOGRAPHY ON DETECTION OF DEPENDENCE PRODUCING 
DRUGS IN BODY FLUIDS. 

229112 0117 
INTERACTION OF MESCALINE WITH PHENOTHIAZINES: EFFECT ON 
BEHAVIOR, BODY TEMPERATURE, AND TISSUE LEVELS OF 
HALLUCINOGEN IN MICE. 

229264 01-04 
REDUCTION OF MORPHINE WITHDRAWAL BODY SHAKES BY A 
CONDITIONAL STIMULUS IN THE RAT. 

232617 02-03 
COMPARISON OF THE EFFECTS OF LESION IN THE 0B9 CELL BODY GROUP 
AND P-CHLOROAMPHETAMINE ON TRYPTOPHAN-HYDROXYLASE AND 
5-HYDROXYTRYPTAMINE IN RAT BRAIN NUCLEI. 

237863 02-03 
THE INCREASE IN BRAIN TRYPTOPHAN CAUSED BY AMPHETAMINE LIKE 
DRUGS: CORRELATION WITH AN INCREASE IN BODY TEMPERATURE 

237891 02-03 
CORRELATION BETWEEN THE EFFECTS OF SEVERAL CANNABINOIDS ON 
CATECHOLAMINE SYNTHESIS, BODY TEMPERATURE, AND BEHAVIOR. 

238769 03 03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZEO CAT: I. PGO WAVE ACTIVITY INDUCED BY RO 4 1284 AND 



09 
99 

I 



3 



i 

I 

I 



S-49 



Subject Index 



Psychopharmacology Abstract 



BY P-CHLOROPHENYLALANINE (PCPA) AS A BASIS FOR 
NEUROPHARMACOLOGICAL STUDIES. 

241315 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARI2ED CAT: II. PGO WAVE ACTIVITY AND BRAIN 5- 
HYDROXYTRYPTAMINE 

241316 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: III. PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES. 

241317 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: IV. THE EFFECTS OF ACETYLCHOLINE, GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY. 

241318 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: V. MISCELLANEOUS COMPOUNDS. SYNOPSIS OF THE 
ROLE OF CENTRAL NEUROTRANSMITTERS ON PGO WAVE ACTIVITY. 

241319 03-03 
DRUG-INDUCED CHANGES IN BODY TEMPERATURE AND 5- 

HYDROXYTRYPTAMINE (5-HT) TURNOVER RATE IN THE RAT BRAIN. 

241395 03-03 
BODY TEMPERATURE RESPONSES AT DIFFERENT AMBIENT 

TEMPERATURES FOLLOWING INJECTIONS OF PROSTAGLANDIN-El AND 
NORADRENALINE INTO THE BRAIN. 

242736 03-03 
DRUGS AND PUNISHED RESPONDING VI: BODY WEIGHT AS A 
DETERMINANT OF DRUG EFFECTS. 

247845 04-04 
BLOCKADE OF MORPHINE WITHDRAWAL BODY SHAKES BY 
HALOPERIDOL. 

248274 04-03 
CORRELATION OF THE INCREASE IN BRAIN TRYPTOPHAN PRODUCED BY 
AMPHETAMINE-LIKE DRUGS WITH AN INCREASE IN BODY 
TEMPERATURE. 

249316 04-03 
BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS OF 
CHOLERA TOXIN. 

252034 04-03 
THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON GROWTH AND 
BODY COMPOSITION OF HYPERACTIVE CHILDREN 

253041 04-15 
BONDING 

CHARACTERIZATION OF HYDROGEN BONDING BETWEEN SELECTED 
BARBITURATES AND POLYETHYLENE-GLYCOL-4000 BY IR SPECTRAL 
ANALYSIS. 

233276 02-01 
BONE 

UNWANTED CORTICOSTEROID EFFECTS IN CHILDHOOD BONE MARROW 
FAILURE, RENAL FAILURE AND BRAIN DAMAGE: CASE REPORT. 

245856 04-13 
OUTPATIENT PHENOTHIAZINE USE AND BONE MARROW DEPRESSION: A 
REPORT FROM THE DRUG EPIDEMIOLOGY UNIT AND THE BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM. 

253661 04- 15 
BOSTON 

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE 
SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG 
SURVEILLANCE PROGRAM. 

225722 01-15 
OUTPATIENT PHENOTHIAZINE USE AND BONE MARROW DEPRESSION: A 
REPORT FROM THE DRUG EPIDEMIOLOGY UNIT AND THE BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM. 

253661 04-15 
BOUND 

ISOLATION OF LYSERGIDE (LSD) WITH AGAROSE BOUND ANTIBODIES TO 
LYSERGIC ACID. ACID. 

233278 02-01 
BOVINE 

INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 
ALBUMIN - I. GEL FILTRATION STUDIES. 

251176 04-01 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 

ALBUMIN ■ II. CIRCULAR DICHROISM STUDIES. 

251177 04-01 
BRADYKININ 

EXCITATORY EFFECTS OF 5-HYDROXYTRYPTAMINE, HISTAMINE AND 
POTASSIUM IONS ON MUSCULAR GROUP IV AFFERENT UNITS: A 
COMPARISON WITH BRADYKININ. 

241798 03-03 
BRAIN 

AN EVALUATION OF THE USE OF INTRAVENTRICULARLY ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE AS A MARKER FOR ENDOGENOUS BRAIN 
5HYDR0XYTRYPTAMINE 

226400 01-03 
REGULATION OF 5HYDR0XYTRYP1AMINE METABOLISM IN MOUSE 

BRAIN BY ADRENAL GLUCOCORTICOIDS. 

226401 01-03 



LSD AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN VARIOUS RAT 
BRAIN AREAS. 

226406 1-0 
REGIONAL DISTRIBUTION OF POSTSYNAPTIC RECEPTOR BINDING FOR 

GAMMA-AMINOBUTYRIC-ACID (GABA) IN MONKEY BRAIN. 

226407 01 -C 
NEONATAL THYROXINE ADMINISTRATION, BEHAVIORAL MATURATION, 

AND BRAIN GROWTH IN MICE OF DIFFERENT BRAIN WEIGHT. 

226532 01 -C 
SUBSENSITIVITY OF NORADRENALINE STIMULATED CYCLIC-AMP 
ACCUMULATION IN BRAIN SLICES OF D-AMPHETAMINE TREATED 
MICE. 

226651 01-C 
THE EFFECT OF YOHIMBINE ON THE TURNOVER OF BRAIN 
CATECHOLAMINES AND SEROTONIN. 

226726 01-C 
INFLUENCE OF DRUGS ON STRIATAL AND LIMBIC HOMOVANILLIC-ACID 

CONCENTRATION IN THE RAT BRAIN. 

226727 01-C 
HIGH AFFINITY CHOLINE UPTAKE: AN EARLY INDEX OF CHOLINERGIC 

INNERVATION IN RAT BRAIN. 

226739 01-C 
INABILITY OF AN INHIBITOR OF AMINE UPTAKE (LILLY-1 10140) TO 
BLOCK DEPLETION OF BRAIN 5-HYDROXYTRYPTAMINE BY L-DOPA. 

226765 01-C 
THE EFFECT OF ERGOTAMINE AND METHYSERGIDE ON SEROTONIN 
METABOLISM IN THE RAT BRAIN. 

226826 01-C 
DEPLETION OF S-ADENOSYL-L-METHIONINE IN MOUSE BRAIN BY 
ANTIDEPRESSIVE DRUGS. 

226850 01-C 
ACUTE EFFECTS OF HEROIN AND MORPHINE ON NEWLY SYNTHESIZED 
SEROTONIN IN RAT BRAIN. 

226870 01-C 
RAPID REPLETION OF BRAIN SEROTONIN IN MALNOURISHED CORN-FED 
RATS FOLLOWING L-TRYPTOPHAN INJECTION. 

226873 01-C 
DELTA9-TETRAHYDR0CANNABIN0L ALTERS FLOW OF BLOOD TO 

SUBCORTICAL AREAS OF THE CONSCIOUS RAT BRAIN. 

226874 01-C 
BRAIN DYSFUNCTION IN CHRONIC SEDATIVE USERS. 

226922 01-1 
STEREOSPECIFIC BINDING OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) TO 
BRAIN MEMBRANES: RELATIONSHIP TO SEROTONIN RECEPTORS. 

226936 01-1 
HANDBOOK OF DRUG AND CHEMICAL STIMULATION OF THE BRAIN: 
BEHAVIORAL, PHARMACOLOGICAL AND PHYSIOLOGICAL ASPECTS. 

227382 01-C 
DIFFERENTIAL REGIONAL EFFECTS OF THE CONVULSANT METHIONINE 
SULFOXIMINE ON SEROTONIN TURNOVER IN THE RAT BRAIN. 

227387 01-C 
THE EFFECTS OF ADRENALINE, RESERPINE, AND ATROPINE ON 

ACETYLCHOLINE CONTENT OF THE BRAIN AND PERIPHERAL GANGLIA 
IN STRESS. 

227635 01-C 
COMPARISON OF CENTRAL EFFECTS OF NORADRENALINE AND DOPAMIN 

INJECTED INTO THE LATERAL BRAIN VENTRICLE IN RATS. 

227636 01-C 
SERUM AMINO-ACIDS AND BRAIN TRYPTOPHAN UPTAKE. 

227712 01 -0 
ISOLATION OF AN ENDOGENOUS COMPOUND FROM THE BRAIN WITH 
PHARMACOLOGICAL PROPERTIES SIMILAR TO MORPHINE 

227774 01 -0 
RAPID AND DISSOCIATED CHANGES IN SENSITIVITIES OF DIFFERENT 
DOPAMINE RECEPTORS IN MOUSE BRAIN. 

227996 01-0 
THE ACTION OF CHLORPRO/WAZINE ON THE PERMEABILITY OF THE BRAI 
AND LIVER LYSOSOMES OF RATS IN A STATE OF HYPOXIA. 

228548 01-0 
SYNTHESIS, RELEASE AND DISTRIBUTION OF ACETYLCHOLINE IN THE 
BRAIN OF RATS UNDER THE INFLUENCE OF CHOLINERGIC AGENTS. 

228550 01-0 
STRUCTURE-ACTIVITY RELATIONSHIPS FOR AGONIST AND ANTAGONIST 
DRUGS AT PRESYNAPTIC AND POSTSYNAPTIC RECEPTOR SITES IN RAl 
BRAIN. 

229435 01-0 
BRAIN LIVER INTERRELATIONSHIP IN BARBITURATE-TOLERANCE. 

229490 01-0 
THE MECHANISM OF ACTION OF AMPHETAMINE IN BRAIN. 

229491 01 
EFFECTS OF PSYCHOTROPIC DRUGS ON BRAIN NUCLEAR RNA. 

229494 01-0 
STUDY OF SEROTONIN AND ACTH BRAIN LEVELS AND BEHAVIOR. 

229498 10 
NEUROPHARMACOLOGY OF BRAIN MONOAMINES AND BEHAVIOR 

229499 01-0 



S-50 



OLUME 14, SUBJECT INDEX 



Subject Index 



THE EFFECTS OF DEXETIMIDE ON PIMOZIDE, AND HALOPERIDOL AND 
PIPAMERONE-INDUCED INHIBITION OF BRAIN SELF-STIMULATION IN 
RATS 

230452 01-04 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN MAMMALIAN BRAIN: A 
POSSIBLE SITE OF ACTION OF ANTIPSYCHOTIC DRUGS. 

230602 01-13 
INVOLVEMENT OF BRAIN MONOAMINES IN THE STIMULANT AND 
PARADOXICAL INHIBITORY EFFECTS OF METHYLPHENIDATE. 

230841 01-03 
TYROSINE-HYDROXYLASE ACTIVITY IN RAT BRAIN REGIONS AFTER 
CHRONIC TREATMENT WITH PLUS/MINUS PROPRANOLOL. 

230853 01-03 
THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON BRAIN AMINE 
CONCENTRATION AND TURNOVER IN WHOLE RAT BRAIN AND IN 
VARIOUS REGIONS OF THE BRAIN. 

230856 01-03 
CHLORPROMAZINE EFFECTS ON BRAIN ACTIVITY (CONTINGENT NEGATIVE 
VARIATION) AND REACTION TIME IN NORMAL WOMEN. 

230863 01-14 
SATURABLE BINDING OF DIHYDROMORPHINE AND NALOXONE TO RAT 
BRAIN TISSUE IN VITRO. 

230919 01-03 
INTRATHECAL CHEMOTHERAPY: BRAIN TISSUE PROFILES AFTER 
VENTRICULOCISTERNAL PERFUSION. 

231002 01-03 
EFFECT OF METHAMPHETAMINE ON NOREPINEPHRINE METABOLISM IN 
VARIOUS REGIONS OF BRAIN. 

231004 01-03 
THE SELECTIVE EFFECTS OF ALPHA-METHYL AROMATIC AMINO-ACIDS ON 
BRAIN MONOAMINE METABOLITES AND BEHAVIOR IN CATS. 

231009 01-03 
THE EFFECT OF TRIFLUOPERAZINE ON THE TRANSMISSION OF 
EXCITATION IN THE RABBIT BRAIN DURING PROLONGED 
ADMINISTRATION OF THE PREPARATION. 

231070 01-03 
A DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN ANTERIOR LIMBIC 
CORTEX AND MESOLIMBIC REGION OF PRIMATE BRAIN. 

231304 01 03 
THE ACTION OF FENFLURAMINE AND P-CHLOROAMPHETAMINE ON 
SEROTONERGIC MECHANISMS: A COMPARATIVE STUDY IN RAT BRAIN 
NUCLEI. (UNPUBLISHED PAPER). 

232325 01-03 
COMPUTERIZED ELECTROENCEPHALOGRAM: A MODEL OF 

UNDERSTANDING THE BRAIN FUNCTION IN CHILDHOOD PSYCHOSIS 
AND ITS TREATMENT. 

232635 02-11 
THE MECHANISMS BY WHICH METHIOTHEPIN, A PUTATIVE SEROTONIN 
RECEPTOR ANTAGONIST, INCREASES BRAIN 5-HYDROXYINDOLE 
LEVELS. 

233290 02-03 
DIFFERENTIAL SENSITIVITY OF TWO DOPAMINERGIC STRUCTURES IN RAT 

BRAIN TO HALOPERIDOL AND TO CLOZAPINE. 

233291 02-03 
IDENTIFICATION OF TWO RELATED PENTAPEPTIDES FROM THE BRAIN 

WITH POTENT OPIATE AGONIST ACTIVITY 

233300 02-01 
AN ATTEMPT TO CORRELATE ANALGESIA TO CHANGES IN BRAIN 
NEUROMEDIATORS IN RATS. 

233336 0203 
VIOLENT BEHAVIOR, BRAIN DYSRHYTHMIA, AND GLUCOSE 
DYSFUNCTION: A NEW SYNDROME. 

233870 02 11 
THE USE OF SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS TO 
MODIFY AMINE METABOLISM IN BRAIN. 

233947 0203 
EFFECT OF CHRONIC TREATMENT W'TH CENTRAL STIMULANTS ON BRAIN 
MONOAMINES AND SOME BEHAVIOR/.L AND PHYSIOLOGICAL 
FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS. 

233962 02-03 
RELATIONSHIP OF DOPAMINE NEURAL SYSTEMS TO THE BEHAVIORAL 
ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION 
INTO BRAIN. 

233970 02-03 
SYMPATHETIC NERVOUS SYSTEM EFFECTS ON RAT BRAIN METABOLISM 

234309 02-03 
PLASMA CORTICOIDS AND BRAIN TRYPTOPHAN AFTER ACUTE AND 
TOLERANCE DOSAGE OF LSD 

23431 1 02-03 
KINETICS AND METABOLISM OF AMPHETAMINE IN THE BRAIN OF RATS 
OF DIFFERENT AGES 

234316 02-03 
EFFECT OF L-5-HYDROXYTRYPTOPHAN ON BRAIN MONOAMINE 
METABOLISM AND EVALUATION OF ITS CLINICAL EFFECT IN 
DEPRESSED PATIENTS. 

234673 02 09 
DIFFERENTIAL DRUG EFFECTS ON BRAIN SEROTONERGIC SYSTEMS. 

234805 02-03 



DIFFERENTIAL BEHAVIORAL AND BIOCHEMICAL EFFECTS OF REGIONAL 
INJECTION OF CYCLOHEXIMIDE INTO MOUSE BRAIN. 

235320 02-04 
DISRUPTION OF BRAIN STIMULATION-INDUCED FEEDING BY DOPAMINE 
RECEPTOR BLOCKADE. 

235587 02-04 
EFFECT OF PSYCHOTROPIC DRUGS ON (H3) GAMMA-AMI NOBUTYRIC- 
ACID UPTAKE BY SYNAPTOSOMES OF THE RAT BRAIN. 

236370 02-03 
EFFECTS OF SUPEROXIDE DISMUTASE ON THE AUTOOXIDATION OF 7,8 
DIHYDROXYCHLORPROMAZINE IN THE PRESENCE OF RAT BRAIN 
MITOCHONDRIA. 

236521 02-03 
THE RELEASE OF GLUTAMIC-ACID FROM ISOLATED BRAIN TISSUES 

236522 02-03 
CORRELATION OF CHLORPROAAAZINE LEVELS IN RAT BRAIN AND SERUM 

WITH ITS HYPOTHERMIC EFFECT. 

236527 02-03 
EXCITABILITY OF THE HYPOTHALAMUS AND LIMBIC BRAIN STRUCTURES 
OF RABBITS UNDER THE EFFECT OF GLUCOCORTICOIDS AND ACTH. 

236716 02-03 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: I. GLUTAMIC ACID AND GABA IN BRAIN REGIONS. 

237098 02-03 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: II. INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

237105 02-04 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

237107 02-04 
FENFLURAMINE AND 5-HYDROXYTRYPTAMINE PART 1: IS 

FENFLURAMINE OR NORFENFLURAMINE INVOLVED IN THE DECREASE 
OF BRAIN 5-HYDROXYTRYPTAMINE?. 

237118 02-03 
FENFLURAMINE AND 5-HYDROXYTRYPTAMINE PART 7. INVOLVEMENT 

OF BRAIN AND 5-HYDROXYTRYPTAMINE IN THE ANORECTIC ACTIVITY 
OF FENFLURAMINE. 

237119 02 03 
EFFECTS OF DOPAMINERGIC AGONISTS AND ELECTRICAL STIMULATION 

OF THE MIDBRAIN RAPHE ON THE RELEASE OF 5- 
HYDROXYTRYPTAMINE FROM THE CAT BRAIN IN VIVO. 

237154 02-03 
EFFECTS OF ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE ON THE 

INCORPORATION OF AMINO-ACIDS INTO PROTEINS OF MOUSE BRAIN 
SUBCELLULAR FRACTIONS 

237155 02-03 
EFFECTS OF TRAZODONE ON SEROTONIN IN THE BRAIN AND PLATELETS 

OF THE RAT. 

237240 02-03 
ACTIONS OF PHENOTHIAZINE ANALOGS ON DOPAMINE SENSITIVE 

ADENYLATE-CYCLASE IN NEURONAL AND GLIAL ENRICHED FRACTIONS 
FROM RAT BRAIN. 

237241 02-03 
INHIBITION OF RAT BRAIN TRYPTOPHAN HYDROXYLATION WITH P 

CHLOROAMPHETAMINE 

237242 02 03 
CHEMISTOR: A REUSABLE TELESTIMULATION DEVICE FOR DIRECT 

CHEMICAL STIMULATION OF THE NONHUMAN PRIMATE BRAIN IN 
FREELY MOVING ANIMALS. 

237270 02-06 
MORPHINE-INDUCED INHIBITION OF DIFFERENT PAIN RESPONSES IN 
RELATION TO THE REGIONAL TURNOVER OF RAT BRAIN 
NORADRENALINE AND DOPAMINE. 

237697 02-04 
BEHAVIORAL AND BIOCHEMICAL INTERACTION BETWEEN AMT AND ( i ) 

AMPHETAMINE: RELEVANCE TO THE IDENTIFICATION OF THE 
FUNCTIONAL POOL OF BRAIN CATECHOLAMINES. 

237698 02-03 
METABOLISM OF 5-HYDR0XYTRYPT0PHAN-14C AFTER INTRACISTERNAL 

INJECTION WITH AND WITHOUT THE INFLUENCE OF DRUGS IN THE 
RAT BRAIN. 

237700 02-03 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 
AND SEROTONIN IN RATS - ACUTE MORPHINE ADMINISTRATION 

237736 02-03 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 

AND SEROTONIN IN RATS - CHRONIC MORPHINE ADMINISTRATION. 

237737 02 03 
EFFECT OF ANGIOTENSIN-II AND ITS ANALOGS ON UPTAKE AND RELEASE 

OF C14-5-HYDR0XYTRYPTAMINE BY RAT BRAIN. 

237739 02-03 
EFFECT OF AMPHETAMINE AND FENFLURAMINE ON BRAIN 

NORADRENALINE AND M0PEG-S04. 

237740 02 03 
MOUSE BRAIN CATECHOLAMINES, 5-HYDROXYTRYPTAMINE AND THE 

ANTINOCICEPTIVE ACTIVITY OF PETHIDINE. 

237741 02 03 



C0 



eo 
> 



S-51 



Subject index 



Psychopharmacology Abstract 



THE EFFECT OF SELECTIVE LESIONING OF BRAIN CATECHOLAMINE 

CONTAINING NEURONS ON THE ACTIVITY OF VARIOUS ANORECTICS IN 
THE RAT. 

237742 02-03 
THE EFFECT OF NOMIFENSINE ON THE DEPLETION OF BRAIN SEROTONIN 

AND CATECHOLAMINES INDUCED RESPECTIVELY BY FENFLURAMINE 
AND 6-HYDROXYDOPAMINE IN RATS. 

237743 02-03 
BRAIN DOPAMINE AND JUMPING BEHAVIOUR IN MICE. 

237746 02-03 
EFFECT OF CATECHOLO METHYLTRANSFERASE INHIBITORS ON BRAIN 

APOMORPHINE CONCENTRATIONS AND STEREOTYPED BEHAVIOUR IN 
THE RAT. 

237747 02-03 
FAILURE OF DEPLETION OF RAT BRAIN 5-HYDROXYTRYPTAMINE TO 

ALTER FENFLURAMINEINDUCED ANOREXIA. 

237748 02-03 
CATECHOLAMINE CONCENTRATION OF DISCRETE BRAIN AREAS 

FOLLOWING SELF-STIMULATION IN THE VENTROMEDIAL TEGMENTUM 
OF THE RAT. 

237862 02-03 
COMPARISON OF THE EFFECTS OF LESION IN THE 0B9 CELL BODY GROUP 

AND P-CHLOROAMPHETAMINE ON TRYPTOPHAN-HYDROXYLASE AND 
5-HYDROXYTRYPTAMINE IN RAT BRAIN NUCLEI. 

237863 02-03 
THE AUTORADIOGRAPHIC LOCALIZATION OF (3H)DEXAMETHAS0NE IN 

THE BRAIN AND PITUITARY OF THE RAT. 

237864 02-03 
DISSOCIATION OF RAT BRAIN POLYRIBOSOMES IN VIVO BY 

AMPHETAMINES. 

237871 02-03 
5-HYDROXYTRYPTAMINE BINDING TO SYNAPTIC MEMBRANES FROM RAT 
BRAIN. 

237890 02-03 
THE INCREASE IN BRAIN TRYPTOPHAN CAUSED BY AMPHETAMINE-LIKE 

DRUGS: CORRELATION WITH AN INCREASE IN BODY TEMPERATURE. 

237891 02-03 
EFFECTS OF ALDEHYDES ON SODIUM PLUS POTASSIUM ION-STIMULATED 

ADENOSINE TRIPHOSPHATASE OF MOUSE BRAIN. 

237920 02-03 
EFFECT OF ACUTE AND CHRONIC IPRINDOLE ON SEROTONIN TURNOVER 
IN MOUSE BRAIN. 

237922 02-03 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE: BIOCHEMICAL AND 

PHARMACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE AS 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINE 
AND OTHER PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION). 

238077 02-03 
FURTHER STUDIES ON BRAIN CONCENTRATIONS OF AMPHETAMINE AND 
ITS METABOLITES IN STRAINS OF MICE SHOWING DIFFERENT 
SENSITIVITY TO PHARMACOLOGICAL EFFECTS OF AMPHETAMINE. 

238322 02-03 
EFFECTS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTOPHAN 
TREATMENT ON SPONTANEOUS MOTOR ACTIVITY AND BRAIN 
MONOAMINES IN MICE. 

238565 02-03 
CATECHOLAMINE CONCENTRATION IN DISCRETE AREAS OF BRAIN OF 
SEVERAL STRAINS OF MICE: CORRELATION WITH AGGRESSIVITY. 

238673 03-03 
LSD BINDING IN SUBCELLULAR FRACTIONS OF RAT BRAIN AND 

INHIBITORY EFFECTS OF RING-SUBSTITUTED TRYPTAMINES. 

238674 03-03 
DIFFERENTIAL EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON 

INDOLEAMINE SYSTEMS IN BRAIN. 

238675 03-03 
STIMULATION OF BRAIN SEROTONIN (5-HT) SYNTHESIS BY L- 

TRYPTOPHAN (TRP) INJECTION IN MALNOURISHED, CORN-FED RATS. 

238676 03-03 
MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE (TPH) ACTIVITY BY 

BRAIN TRYPTOPHAN (TP) CONTENT. 

238677 03-03 
RELATIONSHIP BETWEEN SEROTONIN IN THE INTACT BRAIN AND 

RELEASE OF PROTEIN INTO THE PERFUSED CEREBROSPINAL FLUID 
COMPARTMENT OF CONSCIOUS AND ANESTHETIZED RABBITS. 

238681 03-03 
EFFECTS OF (-)DELTA9 TETRAHYDROCANNABINOL ON REGIONAL BRAIN 
ACETYLCHOLINE IN THE RAT 

238709 03-03 
TAURINE: A SODIUM DEPENDENT HIGH AFFINITY UPTAKE SYSTEM INTO 
SYNAPTOSOMES OF RAT BRAIN. 

238715 03-03 
PROTECTION AGAINST STRESS INDUCED DEPLETION OF BRAIN 
NOREPINEPHRINE AFTER PRIOR EXPOSURE TO CHRONIC STRESSES. 

238718 03-04 
NECESSITY OF HYPERTHERMIA FOR L DOPA OR D AMPHETAMINE TO 

DISAGGREGATE RAT BRAIN POLYSOMES. 

238719 03-03 



DEVELOPMENT OF BRAIN CEREBROSIDES AND CEREBROSIDE SULFATE 

(SULFATIDE) IN OFFSPRING OF CONTROL RATS AND RATS 

CHRONICALLY TREATED WITH METHADONE. 

238723 03-( 
ENDOGENOUS DOPAMINE RELEASE DEPENDENT AND INDEPENDENT 

ACTIVATION OF DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL 

SYNAPTOSOMES. 

238729 03-1 
MODIFICATION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS BY 

DRUGS WHICH ALTER BRAIN CATECHOLAMINE LEVELS OR STIMULAT 

CATECHOLAMINE RECEPTORS. 

238734 03-1 
CONFORMATIONAL REQUIREMENTS FOR BLOCKING UPTAKE OF 

CATECHOLAMINES AND SEROTONIN INTO CRUDE RAT BRAIN 

SYNAPTOSOMES. 

238738 03-1 
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE- 
CYCLASE AND ON CYCLIC-GMP FORMATION IN MONKEY BRAIN 
AMYGDALA. 

238739 03-i 
EFFECT OF DEXTROAMPHETAMINE ON IDENTIFIED CHOLINOCEPTIVE 

CELLS OF THE SNAIL BRAIN. 

238740 03-1 
EFFECTS OF ACUTE ETHANOL ADMINISTRATION ON BRAIN BIOGENIC 

AMINES. 

238751 03-' 
RATE OF BIOSYNTHESIS OF DOPAMINE-BETA-HYDROXYLASE IN LOCUS- 
COERULEUS OF RAT BRAIN AFTER RESERPINE. 

238759 03- 
THE DYNAMICS OF DOPAMINE METABOLISM IN VARIOUS REGIONS OF 
RAT BRAIN. 

238761 03- 
THE EFFECT OF DELTA9-THC ON HIGH AND LOW AFFINITY UPTAKE OF 
CHOLINE AND ITS RELATIONSHIP TO TURNOVER OF ACETYLCHOLINE 
MOUSE BRAIN. 

238765 03- 
EFFECTS OF BETA-HYDROXYLATED PHENOTHIAZINE DERIVATIVES ON 
ISOLATED BRAIN MITOCHONDRIA. 

238777 03- 
A COMPARISON OF THE BIOCHEMICAL EFFECT OF TWO CATALYTIC 
INHIBITORS OF MAMMALIAN BRAIN GABA-TRANSAMINASE: GAMAA/ 
VINYL-GABA (AMIN0-4-HEX-5-EN0IC-ACID) AND GAMAAA-ACETYLENK 
GABA (AMIN0-4-HEX-5-YN0IC-ACID). 

238782 03- 
INJECTIONS OF AMINO-ACIDS THAT ALTER BRAIN SEROTONIN INCREAS 

THE SENSITIVITY TO ELECTROSHOCK IN RATS. 

238783 03- 
EFFECT OF CHRONIC BARBITAL ADMINISTRATION AND SUBSEQUENT 

WITHDRAWAL ON CATECHOLAMINE CONTENT AND TURNOVER IN R/ 
BRAIN. 

238790 03- 
EFFECTS OF ACUTE AND CHRONIC PENTOBARBITAL ADMINISTRATION C 

BRAIN GAMMA-AMINOBUTYRATE (GABA) AND GLUTAMATE (GLU) 
LEVELS IN THE MOUSE. 

238791 03- 
BRAIN SYNAPTIC MEMBRANE NAK-ATPASE FOLLOWING CHRONIC 

INJECTION OF DELTA9-TETRAHYDR0CANNABIN0L (THC). 

238812 03- 
EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE 
METABOLISM. 

238838 03-' 
NISOXETINE (LILLY-94939) SELECTIVELY BLOCKS THE UPTAKE OF 
NOREPINEPHRINE IN VITRO AND IN VIVO IN RAT BRAIN. 

238840 03-' 
CATECHOLAMINES IN BRAIN ISCHEMIA - EFFECTS OF ALPHA-METHYL-F 
TYROSINE AND PARGYLINE. 

239577 03-1 
TRYPTOPHAN REGULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE. 

239581 03-1 
ACUTE AND CHRONIC EFFECTS OF 4-CHLOROAMPHETAMINE ON 
MONOAMINE METABOLISM IN THE RAT BRAIN 

239849 03-i 
COMPARISON OF WITHDRAWAL PRECIPTATING PROPERTIES OF VARIOL 
MORPHINE ANTAGONISTS AND PARTIAL AGONISTS IN RELATION TO 
THEIR STEREOSPECIFIC BINDING TO BRAIN HOMOGENATES. 

239854 03-1 
EFFECT OF CLOZAPINE ON THE METABOLISM OF SEROTONIN IN RAT 
BRAIN. 

239862 03-1 
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF H3-MESCALINI 
IN THE BRAIN OF THE MARMOSET, CALLITHRIX-JACCHUS. 

239864 03-1 
EFFECTS OF P-CHLOROAMPHETAMINE ON LOCOMOTOR ACTIVITY AND 
BRAIN 5-HYDROXYINDOLES. 

239958 03-1 
QUIPAZINE: ITS EFFECTS ON RAT BRAIN 5-HYDROXYTRYPTAMINE 
METABOLISM, MONOAMINE-OXIDASE ACTIVITY AND BEHAVIOUR. 

239960 03-1 



S-52 



OLUME 14, SUBJECT INDEX 



Subject Index 



EVIDENCE THAT DIPHENYLHYDANTOIN DOES NOT AFFECT ADENOSINE 
TRIPHOSPHATASES FROM BRAIN. 

239962 03-03 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN 
FOLLOWING HEAD FOCUSED MICROWAVE SACRIFICE: EFFECT OF ( f ) 
AMPHETAMINE AND ( t OR) P-CHLOROAMPHETAMINE. 

239976 03-03 
EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON SELF-STIMULATION IN 
POSTERIOR HYPOTHALAMIC AND PREOPTIC REGIONS AND ON THE 
THERMOREGULATORY RESPONSES TO REWARDING BRAIN 
STIMULATION. 

239980 03-04 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: II. ANTIPSYCHOTIC EFFECT OF HALOPERIDOL IN PATIENTS 
WITH CHRONIC ORGANIC BRAIN DAMAGE. 

240219 03-11 
STIMULATORY ROLE FOR BRAIN SEROTONINERGIC SYSTEM ON 
PROLACTIN SECRETION IN THE MALE RAT. 

240643 03-03 
EFFECT OF DIPHENYLHYDANTOIN ON THE ENDOGENOUS 
PHOSPHORYLATION OF BRAIN PROTEIN. 

240746 03-03 
EVIDENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
MOTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS. 

241203 03-03 
NEUROCHEMICAL CORRELATES OF BEHAVIOUR - CONTENT OF 
TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, SEROTONIN, 5- 
HYDROXYINDOLEACETIC-ACID, TYROSINE, DOPAMINE AND 
NOREPINEPHRINE IN FOUR BRAIN PARTS OF THE PIGEON DURING 
BEHAVIOURAL DEPRESSION FOLLOWING AN INJECTION. 

241205 03-04 
5-HYDROXY-L-TRYPTOPHAN-DECARBOXYLASE ACTIVITY: MICROASSAY 
AND DISTRIBUTION IN DISCRETE RAT BRAIN NUCLEI. 

241208 03-03 
EUFLAVINE: EFFECT ON BRAIN HEAVY METAL CONTENT AND STAINING 
PATTERN, AND ON SHUTTLEBOX BEHAVIOR IN GOLDFISH. 

241221 03-04 
RELATIONSHIP BETWEEN THE SUBCELLULAR DISTRIBUTION OF DELTA9- 
TETRAHYDROCANNABINOL AND ITS METABOLITES IN RAT BRAIN AND 
THE DURATION OF THE EFFECT ON MOTOR ACTIVITY. 

241242 03-03 
EFFECTS OF STIMULATORY AND DEPRESSANT DRUGS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3 5 
MONOPHOSPHATE LEVELS IN MOUSE BRAIN. 

241246 03-03 
EFFECTS OF DIETHYLDITHIOCARBAMATE ON THE CATABOLISM OF 
TYROSINE IN THE RAT BRAIN. 

241249 03-05 
REDUCTION OF TRYPTOPHAN-HYDROXYLASE ACTIVITY AND 5- 
HYDROXYTRYPTAMINE CONCENTRATION IN CERTAIN RAT BRAIN 
NUCLEI AFTER P-CHLOROAMPHETAMINE. 

241253 03-03 
EFFECT OF TETRAHYDROCANNABINOLS ON H3-ACETYLCH0LINE 

BIOSYNTHESIS IN VARIOUS RAT BRAIN SLICES. 

241254 03-03 
DETERMINATIONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESIS IN 
A SINGLE MOUSE BRAIN: BIPHASIC EFFECTS OF ( + ) AMPHETAMINE. 

241257 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: II. PGO WAVE ACTIVITY AND BRAIN 5- 
HYOROXYTRYPTAMINE. 

241316 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: III. PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES. 

241317 03-03 
INABILITY OF METHADONE TO PREVENT THE DEPLETION OF BRAIN 5- 

HYDROXYINDOLES BY P-CHLOROAMPHETAMINE. 

241339 03-03 
EFFECTS OF THE D-ISOMERS AND L-ISOMERS OF AMPHETAMINE ON 
UPTAKE, RELEASE AND CATABOLISM OF NOREPINEPHRINE, DOPAMINE 
AND 5-HYDROXYTRYPTAMINE IN SEVERAL REGIONS OF RAT BRAIN. 

241345 03-03 
SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES: 



ABNORMALITY IN CENTRAL NORADRENERGIC NEURONS IN 
SPONTANEOUSLY HYPERTENSIVE RATS. 

SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES: 

NEUROCHEMICAL STANDPOINT. 

SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES 



1) 



241360 03-03 



241361 03-03 



THE ROLE OF BRAIN SEROTONIN IN EMOTIONAL BEHAVIOR OF THE RAT. 

241363 03-04 



SPONTANEOUS AND GUANETHIDINE-INDUCED CHANGES OF REGIONAL 
MONOAMINE CONTENT AND MONOAMINE UPTAKE DURING 
POSTNATAL DEVELOPMENT OF THE RAT BRAIN. 

241366 03-03 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (1). RELATIONSHIP 
BETWEEN BRAIN MONOAMINES AND DEFECATION IN RATS. 

241370 03-04 
EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON THE METABOLISM OF 
BRAIN MONOAMINES WITH SPECIAL REFERENCE TO THE 
RELATIONSHIP BETWEEN NORADRENALINE CONTENTS OF THE 
OLFACTORY BULB AND MURICIDE BEHAVIOR. 

241373 03-04 
STUDIES ON THE CORRELATION BETWEEN BEHAVIOR AND BRAIN AMINES 
WITH PSYCHOTROPIC DRUGS. 

241378 03-04 
BRAIN FUNCTION AND BIOGENIC AMINES (4). ROLE OF MONOAMINERGIC 
MECHANISM ON SELECTIVE INHIBITION OF PARADOXICAL SLEEP. 

241388 03-03 
CHANGES IN CARDIOVASCULAR RESPONSES TO BRAIN STIMULATION 

FOLLOWING OLFACTORY BULBECTOMY AND THE EFFECTS OF 
PSYCHOTROPIC DRUGS IN RATS. 

241389 03-03 
EFFECTS OF LOWERING THE SEROTONIN CONTENT IN THE RAT BRAIN ON 

GASTRIC ULCER INDUCED BY WATER IMMERSION STRESS. 

241391 03-03 
EFFECTS OF ENVIRONMENTAL TEMPERATURE ON 5- 

HYDROXYTRYPTAMINE (5-HT) TURNOVER RATE IN THE RAT BRAIN (III). 

241394 03-03 
DRUG-INDUCED CHANGES IN BODY TEMPERATURE AND 5- 

HYDROXYTRYPTAMINE (5-HT) TURNOVER RATE IN THE RAT BRAIN. 

241395 03 03 
EFFECTS OF CHOLINERGIC DRUGS ON 5-HYDROXYTRYPTAMINE (5-HT) 

TURNOVER RATE IN THE RAT BRAIN. 

241396 03-03 
EFFECTS OF MORPHINE ON 5-HYDROXYTRYPTAMINE (5-HT) TURNOVER IN 

THE RAT BRAIN (III). 

241402 03-03 
CONCENTRATION OF AMPHETAMINE ISOMERS IN BRAIN AND HEART OF 
ADULT AND DEVELOPING MICE. 

241414 03-03 
EFFECTS OF A SINGLE ADMINISTRATION OF CLOZAPINE ON MOUSE 
BRAIN CATECHOLAMINES. 

241416 03-03 
THE EFFECT OF NUTRITIONAL FACTORS ON BRAIN AMINO-ACID LEVELS 
AND MONOAMINE SYNTHESIS. 

241472 03-17 
THE EFFECT OF ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION 
ON SEIZURE SUSCEPTIBILITY AND BRAIN CATECHOLAMINES IN MICE. 
(PH.D. DISSERTATION). 

241576 03-03 
MANIPULATION OF ACETYLCHOLINE LEVELS IN DEVELOPING RAT BRAIN: 
BIOCHEMICAL AND BEHAVIORAL CONSIDERATIONS. (PHD 
DISSERTATION). 

241680 03-04 
EFFECT OF LSD ON RAT BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AT 
ELEVATED ENVIRONMENTAL TEMPERATURE. 

241925 03-03 
ELECTROCONVULSIVE SHOCK INCREASES THE BEHAVIOURAL RESPONSES 
OF RATS TO BRAIN 5-HYDROXYTRYPTAMINE ACCUMULATION AND 
CENTRAL NERVOUS SYSTEM STIMULANT DRUGS. 

241979 03-04 
HISTOTOPOGRAPHY OF THE CHANGES IN ENZYME ACTIVITY IN THE RAT 
BRAIN UNDER THE EFFECT OF FLUOROPHENAZINE. 

241989 03-03 
CORRELATION BETWEEN THE 5-HYDROXYTRYPTAMINE CONTENTS IN THE 
BRAIN AND DEGREES OF SENSORY, AND LOCOMOTOR ACTIVITIES IN 
THE RAT. 

242205 03-04 
BRAIN, BEHAVIOUR AND DRUGS. 

242265 03-17 
PARTICIPATION OF THE SEROTONERGIC SYSTEM OF THE BRAIN IN THE 
REGULATION OF EMOTIONAL REACTIVITY 

242544 03-03 
BODY TEMPERATURE RESPONSES AT DIFFERENT AMBIENT 

TEMPERATURES FOLLOWING INJECTIONS OF PROSTAGLANDIN-El AND 
NORADRENALINE INTO THE BRAIN. 

242736 03-03 
EFFECT OF THE NOREPINEPHRINE RECEPTOR STIMULATING AGENT 
CLONIDINE ON THE TURNOVER OF 5-HYDROXYTRYPTAMINE IN SOME 
AREAS OF THE RAT BRAIN. 

243777 04-03 
NEUROAMINE DERIVED ALKALOIDS: SUBSTRATE PREFERRED INHIBITORS 

OF RAT BRAIN MONOAMINE-OXIDASE IN VITRO. 

243778 04-03 
EFFECTS OF DIMETHYLSULFOXIDE ON METABOLISM OF ISOLATED 

PERFUSED RAT BRAIN. 

243782 04-03 



iff 

•pa 

« 



I 



its 

3K 



S-53 



Subject Index 



Psychopharmacology Abstra( 



INFLUENCE OF THYROID HORMONE ON NOREPINEPHRINE METABOLISM 
IN RAT BRAIN DURING MATURATION. 

243790 04-03 
AXOPLASMIC TRANSPORT OF NOREPINEPHRINE IN THE RAT BRAIN. 

243791 04-03 
NEONATAL HYPERTHYROIDISM; ALTERATIONS IN BEHAVIOURAL 

ACTIVITY AND THE METABOLISM OF BRAIN NOREPINEPHRINE AND 
DOPAMINE 

243792 04-03 
DRUGS, AROUSAL, AND BRAIN STEADY POTENTIAL RESPONSES. 

243953 04-14 
THE EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON THE RESTING 
MEMBRANE POTENTIAL OF DISSOCIATED BRAIN NEURONS IN 
CULTURE. 

244199 04-03 
EFFECTS OF L-DOPA ON EMOTIONAL REACTIONS AND METABOLISM OF 
SEROTONIN IN THE RAT BRAIN. 

244455 04-04 
EFFECTS OF TANDAMINE AND PIRANDAMINE, NEW POTENTIAL 
ANTIDEPRESSANTS, ON THE BRAIN UPTAKE OF NOREPINEPHRINE AND 
5 HYOROXYTRYPTAMINE AND RELATED ACTIVITIES. 

244678 04-03 
COMPARATIVE AUTORADIOGRAPHIC AND METABOLIC STUDY OF 
DELTAS- AND DELTA9-TETRAHYDR0CANNABIN0L IN THE BRAIN OF 
THE MARMOSET CALLITHRIX-JACCHUS. 

244681 04-03 
DRUG-INDUCED PARKINSONISM IN THE RAT - A MODEL FOR 

BIOCHEMICAL INVESTIGATION OF THE PARKINSON SYNDROME: IIL 
THE INCORPORATION OF D-GLUC0SE-14C(U) IN AMINO-ACIDS OF 
BRAIN AND LIVER FROM RATS PRETREATED WITH RESERPINE OR 
WITH PHENOTHIAZINES. 

244692 04-03 
THE RELATIVE ROLE OF BRAIN ACETYLCHOLINE AND HISTAMINE IN 
PERPHENAZINE CATATONIA AND INFLUENCE OF ANTIDEPRESSANTS 
AND DIPHENHYDRAMINE ALONE AND IN COMBINATION. 

245593 04-05 
BENZTROPINE-INDUCED RELEASE OF DOPAMINE FROM BRAIN IN VIVO. 

245598 04-03 
EEG SYNCHRONIZING EFFECT OF GAMMA-HYDROXYBUTYRATE AND I- 

HYDROXY-3 AMINO-PYRROLIDONE-2 (HA-966) IN RELATION OF 
DOPAMINERGIC BRAIN FUNCTION. 

245599 04-03 
THE CONCENTRATION OF 5-METHOXYTRYPTAMINE IN RAT BRAIN AND 

ITS EFFECTS ON BEHAVIOUR FOLLOWING ITS PERIPHERAL INJECTION. 

245600 04-04 
UNWANTED CORTICOSTEROID EFFECTS IN CHILDHOOD BONE MARROW 

FAILURE, RENAL FAILURE AND BRAIN DAMAGE: CASE REPORT. 

245856 04-13 
ESTERS OF APOMORPHINE AND N,N DIMETHYLDOPAMINE AS AGONISTS 
OF DOPAMINE RECEPTORS IN THE RAT BRAIN IN VIVO 

246150 04-04 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAIN 
MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS, 

246318 04 04 
EFFECTS OF ARECOLINE AND CHOLINESTERASE INHIBITORS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE IN MOUSE BRAIN. 

246389 04-03 
ACUTE MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 
HORMONE AND CORTICOSTERONE 

246661 04-03 
CHRONIC MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 

HORMONE AND CORTICOSTERONE. 

246662 04-03 
STUDIES ON ACCUMULATION OF (14C) MESCALINE IN BRAIN 

HOMOGENATES: EFFECTS OF PSYCHOTROPIC AND OTHER AGENTS. 

246817 04-03 
FFFFCTS OF RESERPINE ON ACTIVITIES AND AMOUNTS OF TYROSINE- 
HYDROXYLASE AND DOPAMINE-BETA HYDROXYLASE IN 
CATECHOLAMINE NEURONAL SYSTEMS IN RAT BRAIN 

246845 04-03 
EFFECT OF 3P TRIFLUOROMETHYLPHENOXY N-METHYL 3 

PHENYLPROPYLAMINE ON THE DEPLETION OF BRAIN SEROTONIN BY 4- 
CHLOROAMPHETAMINE. 

246847 0403 
A NEW SELECTIVE INHIBITOR FOR UPTAKE OF SEROTONIN INTO 

SYNAPTOSOMES OF RAT BRAIN: 3 P TRIFLUOROMETHYLPHENOXY-N- 
METHYL-3-PHENYLPROPYLAMINE 

246848 04-03 
EFFECTS OF LITHIUM CHLORIDE ON PARAMETERS OF BIOSYNTHETIC 

CAPACITY FOR 5 HYOROXYTRYPTAMINE IN RAT BRAIN. 

246849 04-03 
EFFECTS OF ETHANOL ON NEUROTRANSMITTER RELEASE BY RAT BRAIN 

CORTICAL SLICES. 

246850 04 03 



CORRELATION BETWEEN BRAIN LEVELS AND BIOCHEMICAL EFFECTS 
THE OPTICAL ISOMERS OF P-CHLOROAMPHETAMINE 

246851 0/ 

HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CSl 
OF PATIENTS AFTER A SEVERE HEAD INJURY. I. LUMBAR CSF 
CONCENTRATION IN CHRONIC BRAIN POSTTRAUMATIC SYNDROME: 

246993 0' 
HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CS 

OF PATIENTS AFTER A SEVERE HEAD INJURY. II. VENTRICULAR CSF 
CONCENTRATIONS IN ACUTE BRAIN POSTTRAUMATIC SYNDROMES 

246994 0. 
OPIATE RECEPTOR IN NORMAL AND DRUG ALTERED BRAIN FUNCTION 

246996 0. 
EFFECTS OF VARIOUS DRUGS ON SERUM FREE AND TOTAL TRYPTOPH 
LEVELS AND BRAIN TRYPTOPHAN METABOLISM IN RATS. 

247013 0. 
MEASUREMENT OF DESIPRAMINE IN BRAIN TISSUE BY A RADIOISOTO 
DERIVATIVE TECHNIQUE. 

247131 a 
STEADY-STATE CONCENTRATIONS OF CHOLINE AND ACETYLCHOLINE I 
RAT BRAIN PARTS DURING A CONSTANT RATE INFUSION OF 
DEUTERATED CHOLINE. 

247146 
EFFECTS OF BENZODIAZEPINES ON THE BINDING OF TRYPTOPHAN IN 
SERUM. CONSEQUENCES ON 5-HYDROXYINDOLES CONCENTRATION! 
THE RAT BRAIN. 

247213 
EFFECTS OF TRAZODONE ON BEHAVIOR AND BRAIN AMINE CONTENT 
MICE. 

247485 
FAILURE OF INCREASED BRAIN GAMMA-AMI NOBUTYRIC-ACID LEVELS 
INFLUENCE AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR. 

247730 
THE SEROTONERGIC SYSTEM IN THE BRAIN AND ITS POSSIBLE 
FUNCTIONAL CONNECTIONS WITH OTHER AMINERGIC SYSTEMS. 

248159 
BRAIN 2-PHENYLETHYLAMINE AS A MAJOR MEDIATOR FOR THE 
CENTRAL ACTIONS OF AMPHETAMINE AND METHYLPHENIDATE. 

248162 
MEASUREMENTS OF BRAIN AMOBARBITAL CONCENTRATIONS IN RAT 
ANESTHETIZED AND OVERDOSED WITH AMOBARBITAL AND TREAT 
CENTRALLY WITH DIBUTYRYL-CYCLIC-AMP. 

248276 
APORPHINES 15: ACTION OF APORPHINE ALKALOIDS ON DOPAMINER 
MECHANISMS IN RAT BRAIN. 

248286 
DISTRIBUTION OF 3H-ALPHA-MSH IN RAT BRAIN. 

248349 
SYNAPTOSOAML UPTAKE AND LEVELS OF SEROTONIN IN RAT BRAIN 
AREAS AFTER P-CHLOROAMPHETAMINE OR B-9 LESIONS. 

248414 
ACETYLCHOLINE SYNTHESIS IN RAT BRAIN: DISSIMILAR EFFECTS OF 
CLOZAPINE AND CHLORPROMAZINE. 

248600 
POSTNATAL ELEVATION OF BRAIN TYROSINE-HYDROXYLASE ACTIVIT> 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 
CATECHOLAMINE LEVELS. RESULTING FROM DL-ALPHA-METHYL-P- 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 
APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE 
ESTIMATION OF BRAIN ACETYLCHOLINE TURNOVER RATE: EFFECTS 
OXOTREMORINE AND PHYSOSTIGMINE. 

248700 
CANNABINOIDS: INFLUENCE ON NEUROTRANSMITTER UPTAKE IN RAT 

BRAIN SYNAPTOSOMES. 

248701 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMIST 

AND BEHAVIOR: II. INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

248956 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMIST 

AND BEHAVIOR: I. GLUTAMIC-ACID AND GABA IN BRAIN REGIONS 

248957 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCE 
GNAWING OF MICE. 

248960 
ELEVATION OF AMPHETAMINE LEVELS IN RAT BRAIN AFTER 

ADMINISTRATION OF THE CHOLINE ACETYLTRANSFERASE INHIBITO 
I-NAPHTHYLVINYLPYRIDINE (NVP). 

249027 
EFFECT OF MORPHINE ON INTRACRANIAL SELF-STIMULATION BEHAVI' 
FOLLOWING BRAIN AMINE DEPLETION. 

249138 
DIFFERENCES BETWEEN THE EFFECTS OF ACUTE AND LONG-TERM 
TREATMENT WITH DESMETHYLIMIPRAMINE ON RESERPINE-INDUCEI 
RELEASE OF AMINES FROM RAT BRAIN 

249233 
STUDIES OF METHYLPHENIDATE 14C IN RAT BRAIN. 

249243 



S-54 



3LUME 14, SUBJECT INDEX 



Subject Index 



STUDIES ON SULFATE CONJUGATION OF ESTROGENS IN BRAIN AND 
LIVER. 

249245 04-03 
NEUROTOXICITY OF DIELDRIN IN RELATION TO THE SEROTONIN 
METABOLISM AND ACID TRANSPORT IN MOUSE BRAIN. 

249265 04-05 
THE EFFECT OF AMPHETAMINE PRETREATMENT ON THE AMPHETAMINE- 
INDUCED CHANGES IN MOTOR ACTIVITY AND BRAIN 
CATECHOLAMINES IN MICE. 

249274 04-04 
ON THE MECHANISM OF THE INHIBITION OF BRAIN CYCLIC-AMP 
PHOSPHODIESTERASE BY PSYCHOTROPIC AGENTS. 

249287 04-03 
EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN 
GLUTAMATE (GLU) AND GAMMA-AMINOBUTYRATE (GABA) LEVELS IN 
THE MOUSE. 

249292 04-03 
CHRONIC ETHANOL FEEDING AND BRAIN ADENYLCYCLASE AND 
PHOSPHODIESTERASE LEVELS IN MICE 

249294 04-03 
EFFECT OF LABELLED ACETYLCHOLINE (ACCH) UPTAKE BY RAT BRAIN 
SLICES ON ENDOGENOUS LEVELS OF ACCH AND CHOLINE (CH). 

249298 04-03 
EFFECT OF D-AMPHETAMINE AND D,L P-CHLOROAMPHETAMINE ON 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN. 

249300 04-03 
COMPARISON OF THE MONOMETHOXYAMPHETAMINES ON THE UPTAKE 
AND RELEASE OF BIOGENIC AMINES IN BRAIN TISSUE. 

249315 04-03 
CORRELATION OF THE INCREASE IN BRAIN TRYPTOPHAN PRODUCED BY 

AMPHETAMINE-LIKE DRUGS WITH AN INCREASE IN BODY 
TEMPERATURE. 

249316 04-03 
BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE: 

COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N N 
DIMETHYLTRYPTAMINE AND 5-METH0XY-N,N DIMETHYLTRYPTAMINE. 

249317 04-05 
EFFECT OF METOCLOPRAMIDE ON TURNOVER OF BRAIN DOPAMINE 

NORADRENALINE AND 5-HYDROXYTRYPTAMINE. 

249628 04-03 
DEVELOPMENT OF THE INFLUENCES OF SODIUM, CATECHOLAMINE AND 
TRICYCLIC ANTIDEPRESSANT DRUG ON THE UPTAKE OF 3H-5- 
HYDROXYTRYPTAMINE BY RAT BRAIN SYNAPTOSOMES. 

249667 04-03 
A FUNCTIONAL EFFECT OF DOPAMINE IN THE NUCLEUS-ACCUMBENS AND 
IN SOME OTHER DOPAMINE RICH PARTS OF THE RAT BRAIN. 

249669 04 04 
EFFECT OF AMPHETAMINE AND APOMORPHINE ON BRAIN MONOAMINES 
AND BEHAVIOUR IN THE IMMATURE AND YOUNG ADULT RAT. 

249785 04-04 
EFFECTS OF HARMINE AND BRAIN LESIONS ON APOMORPHINE INDUCED 
MOTOR ACTIVITY. 

250058 04-03 
ANALGESIA AND HYPERREACTIVITY FOLLOWING MORPHINE 
MICROINJECTION INTO MOUSE BRAIN. 

250062 04-04 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACIDS 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG-INDUCED 
BEHAVIORAL EXCITATION. 

250067 04-04 
TESTOSTERONE MANIPULATIONS: EFFECTS ON RANACIDE AGGRESSION 

AND BRAIN MONOAMINES IN THE ADULT FEMALE RAT. 

250068 04-02 
DRUG ANTAGONISM AND REVERSIBILITY OF THE BINDING OF 

INOOLEAMINES IN BRAIN. 

250081 04-03 
PROPRANOLOL INHIBITS RAT BRAIN MONOAMINE-OXIDASE 

250333 04-03 
EXTRAPINEAL AMINE N-ACETYLATION IN RAT BRAIN: REGIONAL AND 
SUBCELLULAR DISTRIBUTION AND ENZYME KINETICS. 

250377 04-01 
ORIGIN OF BRAIN GROWTH RETARDATION IN YOUNG RATS TREATED 
WITH PHENOBARBITAL. 

250682 04-05 
EFFECT OF OXOTREMORINE ON ENDOGENOUS ACETYLCHOLINE AND ON 
UPTAKE AND BIOTRANSFORMATION OF RADIOACTIVE CHOLINE IN 
DISCRETE REGIONS OF MOUSE BRAIN IN VIVO 

251175 04-03 
EFFECTS OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 3-CHL0R0-4- 
STILBAZOLE ON BRAIN ACETYLCHOLINE METABOLISM 

251181 04-03 
PREFERENTIAL DEAMINATION OF DOPAMINE BY AN A TYPE 
MONOAMINE-OXIDASE IN RAT BRAIN. 

251225 04-03 
ALTERATION OF DOPAMINE METABOLISM IN RAT BRAIN BY BACLOFEN 
(LIORESAL (R)). 

251398 04-03 



CHANGES IN BRAIN CATECHOLAMINE TURNOVER DURING PRECIPITATED 
MORPHINE WITHDRAWAL IN THE RAT, 

251400 04-03 
EFFECTS OF CENTRALLY ACTING DRUGS ON STRESS INDUCED INCREASE 
OF CGMP IN MOUSE BRAIN 

251416 04-03 
EFFECTS OF DOPAMINERGIC STIMULANTS ON CYCLIC NUCLEOTIDE 
LEVELS IN MOUSE BRAIN IN VIVO. 

251432 04-03 
SOME EFFECTS OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A 
PURPORTED HASHISH AND LSD ANTAGONIST, ON BRAIN 
NORADRENERGIC AND SEROTONERGIC SYSTEMS 

251534 04-03 
CONFORMATIONALLY RIGID AMPHETAMINE ANALOGS AS INHIBITORS OF 
MONOAMINE UPTAKE BY BRAIN SYNAPTOSOMES. 

251700 04-03 
EFFECT OF CORTISONE, ALDOSTERONE AND NIALAMIDE ON 

AMPHETAMINE STEREOTYPES AND BRAIN METHAMPHETAMINE LEVELS 
OF ADRENALECTOMIZED RATS. 

251990 04-04 
THE REGIONAL DISTRIBUTION OF A MORPHINE-LIKE FACTOR ENKEPHALIN 
IN MONKEY BRAIN. 

252219 04-03 
EFFECTS OF TETRAHYDROPAPAVEROLINE ON DOPAMINE AND 5 

HYDROXYTRYPTAMINE METABOLISM IN RAT BRAIN IN VIVO. 

252220 04-03 
COCAINE AND LITHIUM: NEUROBIOLOGICAL ANTAGONISM IN THE 

SEROTONIN BIOSYNTHETIC SYSTFM IN RAT BRAIN. 

2525 M 04-03 
INTERACTION OF DIET AND DRUGS IN THE REGULATION OF BRAIN 5- 
HYDROXYINDOLES AND THE RESPONSE TO PAINFUL ELECTRIC SHOCK. 

252516 04-03 
CORRELATION BETWEEN NEUROLEPTICINDUCED SUPPRESSION OF 

STEREOTYPED BEHAVIOUR AND HVA CONCENTRATIONS IN RAT BRAIN. 

252523 04-03 
USE OF 300-MSEC MICROWAVE IRRADIATION FOR ENZYME 

INACTIVATION: A STUDY OF EFFECTS OF SODIUM PENTOBARBITAL ON 
ACETYLCHOLINE CONCENTRATION IN MOUSE BRAIN REGIONS. 

253106 04-03 
COMPARATIVE ACTIONS OF MONOMETHOXYAMPHETAMINES ON THE 

RELEASE AND UPTAKE OF BIOGENIC AMINES IN BRAIN TISSUE. 

253107 04-03 
AUTORADIOGRAPHIC DISTRIBUTION STUDY OF 14C-D0PA IN CAT BRAIN. 

253393 04 03 
EFFECT OF DELTA9TETRAHYDR0CANNABIN0L ON GANGLIOSIDES AND 
SIALOGLYCOPROTEINS IN SUBCELLULAR FRACTIONS OF RAT BRAIN. 

253406 04-03 
BRAIN-DYSFUNCTIONING 

METHODOLOGY USED IN ASSESSING METHYLPHENIDATE AND CAFFEINE 
TREATMENT OF MINIMAL BRAIN-DYSFUNCTIONING CHIIDREN. 

252798 04-11 
BRAINS 

BINDING OF GLYCINE AND GAMMA AMINOBUTYRIC ACID TO 

SYNAPTO.SOMAL FRACTIONS OF THE BRAINS OF DIFFERENTIALLY 
HOUSED MICE. 

238349 02-03 
THE BRAINS DOPAMINE RECEPTOR: LABELING WITH 3H-D0PAMINE AND 
3H-HAL0PERID0L . 

240077 03-03 
ACETYLCHOLINE LEVELS AND TURNOVER IN BRAINS OF LITHIUM 
TREATED AND STRESSED MICE. 

249299 04-03 
EFFECTS OF D AMPHETAMINE ON THE INCORPORATION OF CARBON 
ATOMS OF D GLUCOSE INTO THE BRAINS OF DIFFERENTIALLY HOUSED 
MICE 

249672 04-04 
THE EFFECT OF TRYPTOPHAN AND A TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN COMBINATION ON INDOLES IN THE BRAINS OF 
RATS FED A TRYPTOPHAN DEFICIENT DIET, 

249675 04-03 
BRAINSTEM 

TREATMENT WITH ACETAZOLAMIDF OF BRAINSTEM AND SPINAL 
PAROXYSMAL DISTURBANCES IN MULTIPLE SCLEROSIS. 

226351 01-13 
COMPARISON OF BICUCULLINE METHOCHLORIDE WITH BICUCULLINE 
AND PICROTOXIN AS ANTAGONISTS OF AMINO-ACID AND 
MONOAMINE DEPRESSION OF NEURONES IN THE RAT BRAINSTEM 

237783 02-03 
THE EFFECT OF DIAZEPAM AND PICROTOXIN ON BRAINSTEM EVOKED 
DORSAL ROOT POTENTIALS 

239982 03-03 
CHANGES IN BRAINSTEM MONOAMINE NEURONS AFTER SURGICAL AND 
CHEMICAL DENERVATION OF THE OLFACTORY BULB (OB) IN RATS. 

24 1 369 03-03 
BLOCKADE OF THE ELECTROCORTICAL CHANGES INDUCED BY PERFUSION 
OF AMPHETAMINE IN THE BRAINSTEM RETICULAR FORMATION, 

241930 0303 



09 

i 



GO 



S-55 



Subject Index 



Psychopharmacology Abstrai 



EFFECT OF NOMIFENSINE ON ACETYLCIIOLINP AND CHOLINE IN THE RAT 
STRIATUM AND BRAINSTEM. 

248291 04-03 
EFFECT OF CLONIDINE ON THE NOREPINEPHRINE (NE) SENSITIVE CYCLIC- 
AMP GENERATING SYSTEM IN SLICES OF RAT SPINAL CORD (SO, 
BRAINSTEM (BS) AND LIMBIC FOREBRAIN (LFB) AND ON MEDIAL 
FOREBRAIN BUNDLE (MFB) STIMULATION. 

249255 04-03 
IN VIVO AND IN VITRO ACTIVATION OF SOLUBLE TRYPTOPHAN- 
HYDROXYLASE FROM RAT BRAINSTEM, 

249512 04-03 
CHOLINE ACETYLTRANSFERASE ACTIVITY INCREASES IN THE BRAINSTEM 
OF RATS TREATED AT BIRTH WITH 6-HYDROXYDOPA. 

249666 04-03 
BRANCH 

AMITRIPTYLINE POISONING CAUSING LEFT BUNDLE BRANCH BLOCK. 

241357 03-15 
BRANCHED 

SOLUBILITY OF STRAIGHT-CHAIN AND BRANCHED ALKYL BARBITURATES 
IN STRAIGHT CHAIN ALCOHOLS. 

238487 02-01 
BREAST 

DIAZEPAM AND ACTIVE METABOLITE IN BREAST MILK AND THEIR 
TRANSFER TO THE NEONATE. 

230424 01-15 
BREATHING 

INERT GAS NARCOSIS: AVOIDANCE BEHAVIOR IN RATS BREATHING 
ELEVATED PRESSURES OF NITROGEN AND HELIUM. 

23551 1 02-04 
BRED 

EFFECTS OF PENTOBARBITAL IN MICE SELECTIVELY BRED FOR DIFFERENT 
SENSITIVITIES TO ETHANOL. 

249261 04-04 
BROAAAZEPAM 

DETERMINATION OF BROMAZEPAM IN PLASMA WITH AN INTERNAL 
STANDARD BY GAS LIQUID CHROMATOGRAPHY. 

229906 Oil 6 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY. 

237458 02-10 
ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 
BROMAZEPAM IN CONSCIOUS TRAINED DOGS. 

240064 03-03 
CLINICAL EXPERIENCE WITH RO-5-3350 (BROMAZEPAM). 

245138 04-10 
EFFECT OF TWO WEEKS TREATMENT WITH THIORIDAZINE, 

CHLORPROMAZINE, SULPIRIDE AND BROMAZEPAM, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY IN MAN. 

246315 04-14 
BROMISM 

MANIA AND BROMISM: A CASE REPORT AND A LOOK TO THE FUTURE. 

236754 02-09 
BROMOCRIPTINE 

STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE 
RECEPTORS IN COMPARISON TO APOMORPHINE, ( t ) AMPHETAMINE 
AND L DOPA 

249419 04-04 
BROMOCRIPTINE TREATMENT IN PARKINSONS DISEASE. 

251239 04-11 
THE ANTIPARKINSONIAN EFFICACY OF BROMOCRIPTINE. 

251649 04-07 
BS-100-141 

EFFECTS OF CLONIDINE AND BS 100 141 ON THE EEG SLEEP PATTERN IN 
RATS 

226728 01-03 
BUCCAL 

THE INFLUENCE OF NITROGEN, CHAIN AND RING SUBSTITUTION ON 
SOME PHYSIO-ORGANIC PROPERTIES AND ON BUCCAL ABSORPTION OF 
AMPHETAMINES. 

237981 02-02 
BUFOTENINE 

BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE: 
COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N,N 
DIMETHYLTRYPTAMINE AND 5 METHOXY-N,N DIMETHYLTRYPTAMINE. 

249317 04-05 
BULB 

OLFACTORY BULB REMOVAL IN MICE: ACTIVITY LEVELS AND 

RESPONSIVENESS TO THE LOCOMOTOR STIMULANT AND ANOREXIC 
PROPERTIES OF D-AMPHETAMINE SULFATE. (PH.D. DISSERTATION). 

227074 01-04 
EFFECTS OF INSULIN INJECTION ON RESPONSES OF OLFACTORY BULB 
AND AMYGDALA SINGLE UNITS TO ODORS. 

232905 02-03 
OLFACTORY BULB REMOVAL RESULTS IN ELEVATED SPONTANEOUS 
LOCOMOTOR ACTIVITY IN MICE. 

239284 03-04 



CHANGES IN BRAINSTEM MONOAMINE NEURONS AFTER SURGICAL Af 
CHEMICAL DENERVATION OF THE OLFACTORY BULB (OB) IN RATS. 

241369 0; 
EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON THE METABOLISM ( 
BRAIN MONOAMINES WITH SPECIAL REFERENCE TO THE 
RELATIONSHIP BETWEEN NORADRENALINE CONTENTS OF THE 
OLFACTORY BULB AND MURICIDE BEHAVIOR. 

241373 0: 
BULBAR 

THE EFFECT OF SEROTONIN INJECTION INTO THE BULBAR STRUCTURE; 
ON HEMODYNAMICS. 

236831 O: 
BULBECTOMIZED 

EFFECTS OF DRUGS INJECTED INTO THE HYPOTHALAMUS ON MURICII 
AND EEG IN THE OLFACTORY BULBECTOMIZED RATS. 

241367 0: 
BULBECTOMY 

CHANGES IN CARDIOVASCULAR RESPONSES TO BRAIN STIMULATION 
FOLLOWING OLFACTORY BULBECTOMY AND THE EFFECTS OF 
PSYCHOTROPIC DRUGS IN RATS. 

241389 
BULLFROG 

DIAZEPAM DEPOLARIZATION OF PRESYNAPTIC TERMINALS IN BULLFf 
SYMPATHETIC GANGLIA: MEDIATION THROUGH GABA? 

229463 
EVIDENCE FOR GABA INVOLVEMENT IN THE ACTION OF DIAZEPAM Oi 
PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC 
GANGLIA. 

232513 
BUNDLE 

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF 
VARIOUS STIMULUS PARAMETERS: VI. INFLUENCE OF FENTANYL, 
PIRITRAMIDE, AND MORPHINE ON MEDICAL FOREBRAIN BUNDLE 
STIMULATION WITH MONOPOLAR ELECTRODES. 

241229 
AMITRIPTYLINE POISONING CAUSING LEFT BUNDLE BRANCH BLOCK. 

241357 
EFFECT OF CLONIDINE ON THE NOREPINEPHRINE (NE) SENSITIVE CYCL 
AMP GENERATING SYSTEM IN SLICES OF RAT SPINAL CORD (SO, 
BRAINSTEM (BS) AND LIMBIC FOREBRAIN (LFB) AND ON MEDIAL 
FOREBRAIN BUNDLE (MFB) STIMULATION. 

249255 
BURIMAMIDE 

THE INFLUENCE OF MEPYRAMINE AND BURIMAMIDE ON HISTAMINE- 
INDUCED CATALEPSY IN THE RAT. 

240238 
BURONIL 

EFFECTS OF A NEW BUTYROPHENONE DERIVATIVE (BURONIL) ON 
NOCTURNAL SLEEP IN NORMAL MAN. 

227140 
BUTACLAAAOL 

THE BEHAVIORAL PHARMACOLOGY OF BUTACLAMOL HYDROCHLORK 
(AY-23028) A NEW POTENT NEUROLEPTIC DRUG. 

245295 
BUTAPERAZINE 

BUTAPERAZINE PHARMACOKINETICS: EFFECT OF DOSAGE REGIMEN C 
STEADY-STATE BLOOD LEVELS. 

245842 
BUTYROPHENONE 

THE EFFECTS OF AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE 
BUTYROPHENONE SERIES, ON DOMINANT SUBORDINATE BEHAVIOL 
IN WISTAR RATS COMPETING FOR FOOD. 

225571 
EFFECTS OF A NEW BUTYROPHENONE DERIVATIVE (BURONIL) ON 
NOCTURNAL SLEEP IN NORMAL MAN. 

227140 
PILOT OPEN-LABEL STUDY OF LENPERONE (AHR-2277), A 
BUTYROPHENONE, IN ANXIETY. 

241278 
AZAPEROL, A NEW METABOLITE OF THE VETERINARY BUTYROPHENO 
TRANQUILIZER AZAPERONE, 

241359 
BUTYROPHENONE INFLUENCES ON THE OPIATE RECEPTOR. 

250088 
BUTYROPHENONES 

INTERACTION BETWEEN POSSIBLE TRANSMITTERS AND 

BUTYROPHENONES APPLIED MICROELECTROPHORETICALLY IN THE 
CEREBELLUM AND BASAL GANGLIA OF THE CAT. 2ND REPORT: 
EFFECTS OF SOME PHENOTHIAZINES ON THE PURKINJE CELLS OF Tl 
CEREBELLUM. 

241386 
B6D2F1 

INHIBITION OF THE EJACULATORY REFLEX IN B6D2F1 MICE BY 
TESTOSTERONE PROPIONATE. 

250984 
CAERULEIN 

VENTROMEDIAL HYPOTHALAMUS AND SHORT-TERM FEEDING 
SUPPRESSION BY CAERULEIN IN MALE RATS. 

244311 



S-56 



VOLUME 14, SUBJECT INDEX 



Subject Index 



CAFFEINE 

CAFFEINE VERSUS METHYLPHENIDATE AND D-AMPHETAMINE IN 
MINIMAL-BRAIN-DYSFUNCTION: A DOUBLE-BLIND COMPARISON. 

227571 01-11 
THE INFLUENCE OF D.L-AMPHETAMINE AND CAFFEINE ON CAUDATE 
INHIBITION OF CONDITIONED AVOIDANCE REACTIONS IN CATS 

231248 01 04 
INDIVIDUAL RESPONSES TO METHYLPHENIDATE AND CAFFEINE IN 
CHILDREN WITH MINIMAL-BRAIN-DYSFUNCTION. 

235322 02-11 
THE DEPENDENCE OF THE MAGNITUDE OF CONDITIONED SALIVATION IN 
DOGS ON DOSES OF CAFFEINE. 

236249 02-03 
EFFECT OF CAFFEINE AND AMPHETAMINE ON CAUDATE INHIBITION OF 
AGGRESSIVE REACTIONS OF CATS. 

236371 02-04 
COMBINED EFFECTS OF METHAMPHETAMINE, CAFFEINE, DIAZEPAM AND 
PENTOBARBITAL ON DRL PERFORAAANCE IN RATS. 

241400 03-04 
METHYLPHENIDATE AND CAFFEINE IN THE TREATMENT OF CHILDREN 
WITH MINIMAL-BRAIN-DYSFUNCTION. 

245786 04-14 
CAFFEINE AND CHLORDIAZEPOXIDE: EFFECTS ON MOTOR ACTIVITY IN 
THE CHRONIC THALAMIC RAT. 

246388 04-04 
A PLACEBO CROSSOVER STUDY OF CAFFEINE TREATMENT OF 
HYPERKINETIC CHILDREN. 

247379 04-14 
THE EFFECT OF CAFFEINE ON HUMAN PERFORMANCE, ALONE AND IN 
COMBINATION WITH ETHANOL. 

249674 04-14 
EFFECTS OF CAFFEINE AND ETHANOL ON THE BLOOD-BRAIN BARRIER IN 
RATS. 

252222 04-03 
METHODOLOGY USED IN ASSESSING METHYLPHENIDATE AND CAFFEINE 
TREATMENT OF MINIMAL BRAIN-DYSFUNCTIONING CHILDREN. 

252798 04-11 
CALCIUM 

lONOPHORES X573A AND A23187, EFFECTS ON THE PERMEABILITY OF 
LIPID BIMOLECULAR MEMBRANES TO DOPAMINE AND CALCIUM 
(UNPUBLISHED PAPER). 

236873 02-03 
BARBITURATES BLOCK CALCIUM UPTAKE BY STIMULATED AND 
POTASSIUM DEPOLARIZED RAT SYMPATHETIC GANGLIA. 

237751 02-03 
CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 
TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY, 

243797 04-03 

:all 

diazepam use in military sick call. 

240278 03-17 
:allithrix-jacchus 

AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF H3-MESCALINE 
IN THE BRAIN OF THE MARMOSET, CALLITHRIX-JACCHUS. 

239864 03-03 
COMPARATIVE AUTORADIOGRAPHIC AND METABOLIC STUDY OF 
DELTAS- AND DELTA9-TETRAHYDR0CANNABIN0L IN THE BRAIN OF 
THE MARMOSET CALLITHRIX-JACCHUS. 

244681 04-03 

:ajvmzepam 

camazepam (sb-5833) in preparation for endoscopy inspection: 
open and double-blind study versus diazepam. 

241276 03-14 

:amp 

in vivo activation of rat pineal camp phosphodiesterase by 
isoproterenol. (unpublished paper). 

228032 01-03 
CAMP CONTENT AND THE REGULATION OF TYROSINE-3- 

MONOOXYGENASE IN RAT STRIATUM. (UNPUBLISHED PAPER). 

232921 02-03 

:ancer 

counseling, peak experiences and the human encounter with 
death: an empirical study of the efficacy of dpt-assisted 
counseling in enhancing the quality of life of persons with 
terminal cancer and their closest family members. (ph.d. 
dissertation). 

228686 01-11 
SCHIZOPHRENIA, EPILEPSY, CANCER, METHIONINE, AND FOLATE 
METABOLISM: PATHOGENESIS OF SCHIZOPHRENIA. 

248543 04-16 
lANINE 

CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 
TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 



AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04-03 
EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEG -- DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE. 

246319 04-03 
SEROTONIN ANTAGONISM IN ISOLATED CANINE CEREBRAL ARTERIES. 

252757 04-03 
CANNABICHROMENE 

INHALATION TOXICITY OF TURKISH MARIHUANA, CANNABICHROMENE 
(CBCH) AND CANNABIDIOL (CBD) IN RATS. 

238807 03-05 
CANNABIDIOL 

THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABIDIOL AND 
CANNABINOL ON ETHER ANAESTHESIA IN MICE. 

226764 01-04 
DIFFERENTIAL EFFECT OF CANNABINOL AND CANNABIDIOL ON THC- 
INDUCED RESPONSES DURING ABSTINENCE IN MORPHINE-DEPENDENT 
RATS. 

227702 01-04 
THE INFLUENCE OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABINOL 
AND CANNABIDIOL ON TISSUE OXYGEN CONSUMPTION. 

231010 01-03 
CANNABIDIOL AND ITS PHARMACOKINETIC INTERACTION WITH DELTAl- 
TETRAHYDROCANNABINOL. 

233279 02-03 
INHALATION TOXICITY OF TURKISH MARIHUANA, CANNABICHROMENE 
(CBCH) AND CANNABIDIOL (CBD) IN RATS. 

238807 03-05 
PLASMA CANNABINOIDS MEASURED BY RADIOIMMUNOASSAY IN 

RABBITS AFTER INTRAVENOUS INJECTION OF 

TETRAHYDROCANNABINOL, 1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL, AND CANNABIDIOL. 

241256 03-03 
INFLUENCE OF CANNABIDIOL OF DELTA9-TETRAHYDR0CANNABIN0L 
EFFECTS. 

243087 04-14 
INTERACTION OF DELTA9-TETRAHYDR0CANNABIN0L AND CANNABIDIOL 
WITH PHENOBARBITONE IN PROTECTING MICE FROM ELECTRICALLY- 
INDUCED CONVULSIONS. 

244894 04-04 
INTERACTIONS BETWEEN CANNABIDIOL AND DELTA9-THC DURING 
ABSTINENCE IN MORPHINE DEPENDENT RATS. 

249001 04-04 
CANNABINOID 

CANNABINOID PATTERN IN CANNABIS-SATIVA L. SEEDLINGS AS AN 
INDICATION OF CHEMICAL RACE. 

237982 02-01 
EFFECT OF CANNABINOIDS ON THE ABDOMINAL CONSTRICTION 
RESPONSE IN MICE: WITHIN CANNABINOID INTERACTIONS. 

239859 03-03 
PRECLINICAL PHARAAACOLOGIC PROFILE OF A PSYCHOACTIVE 
CANNABINOID. 

249276 04-02 
CANNABINOIDS 

EFFECTS OF CANNABINOIDS ON THE IN VITRO PERFUSED RAT HEART. 

238767 03-03 
CORRELATION BETWEEN THE EFFECTS OF SEVERAL CANNABINOIDS ON 
CATECHOLAMINE SYNTHESIS, BODY TEMPERATURE, AND BEHAVIOR. 

238769 03-03 
INHIBITION OF CORTICOSTEROIDOGENESIS BY CANNABINOIDS. 

238808 03-03 
EFFECT OF CANNABINOIDS ON THE ABDOMINAL CONSTRICTION 

RESPONSE IN MICE: WITHIN CANNABINOID INTERACTIONS. 

239859 03-03 
PLASMA CANNABINOIDS MEASURED BY RADIOIMMUNOASSAY IN 
RABBITS AFTER INTRAVENOUS INJECTION OF 

TETRAHYDROCANNABINOL, 1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL, AND CANNABIDIOL. 

241256 03-03 
DRUGS DERIVED FROM CANNABINOIDS. 1. NITROGEN ANALOGS, 
BENZOPYRANOPYRIDINES AND BENZOPYRANOPYRROLES. 

248646 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 2. BASIC ESTERS OF NITROGEN 

AND CARBOCYCLIC ANALOGS. 

248647 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 5. DELTA 

TETRAHYDROCANNABINOL AND HETEROCYCLIC ANALOGS 
CONTAINING AROMATIC SIDE-CHAINS. 

248648 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 3. SULFUR ANALOGS, 

THIOPYRANOBENZOPYRANS AND THIENOBENZOPYRANS 

248651 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 4. EFFECT OF ALKYL 

SUBSTITUTION IN SULFUR AND CARBOCYCLIC ANALOGS. 

248652 04-02 



i 



tf 



CO 

•a 

IS* 
3S 



S-57 



Subject Index 



Psychopharmacology Abstracts 



CANNABINOIDS: INFLUENCE ON NEUROTRANSMITTER UPTAKE IN RAT 
BRAIN S/NAPTOSOMES. 

248701 04-03 
CANNABINOL 

PHARMACOLOGICAL INTERACTION BETWEEN CANNABINOL AND DELTA9- 
TETRAHYDROCANNABINOL. 

225570 01-03 
THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABIDIOL AND 
CANNABINOL ON ETHER ANAESTHESIA IN MICE. 

226764 01-04 
DIFFERENTIAL EFFECT OF CANNABINOL AND CANNABIDIOL ON THC- 
INDUCED RESPONSES DURING ABSTINENCE IN MORPHINE-DEPENDENT 
RATS 

227702 01-04 
THE INFLUENCE OF DELTA9-TETRAHYDR0CANNABIN0L. CANNABINOL 
AND CANNABIDIOL ON TISSUE OXYGEN CONSUMPTION. 

231010 01-03 
PLASMA CANNABINOIDS MEASURED BY RADIOIMMUNOASSAY IN 
RABBITS AFTER INTRAVENOUS INJECTION OF 

TETRAHYDROCANNABINOL, 1 1-HYDROXYTETRAHYDROCANNABINOL. 
CANNABINOL, AND CANNABIDIOL. 

241256 03-03 
CLINICAL PHARMACOLOGY OF NABILONE, A CANNABINOL DERIVATIVE. 

248628 04-12 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L AND CANNABINOL IN 
MAN, 

249622 04-07 
CANNABIS 

EFFECTS OF CANNABIS RESIN ON SOCIAL BEHAVIOUR IN THE 
LABORATORY MOUSE 

225569 01-04 
RECENT PROGRESS IN THE LONG-TERM PHARMACOLOGICAL RESEARCH 
ON CANNABIS. 

229043 01-17 
CANNABIS: EFFECTS ON HUNGER AND THIRST. 

234626 02-14 
CANNABIS RESIN AND SEXUAL BEHAVIOUR IN THE LABORATORY 
MOUSE. 

237715 02-04 
THE STABILITY OF CANNABIS AND ITS PREPARATIONS ON STORAGE 

237784 02-01 
EFFECT OF CANNABIS EXTRACT ON THE UTERINE MONOAMINE-OXIDASE 
ACTIVITY OF NORMAL AND ESTRADIOL TREATED RATS. 

241343 03 03 
DIVIDED ATTENTION PERFORMANCE OF CANNABIS USERS AND 
NONUSERS FOLLOWING CANNABIS AND ALCOHOL. 

246305 04-13 
BEHAVIOURAL CHANGES IN LABORATORY MICE DURING CANNABIS 
FEEDING AND WITHDRAWAL. 

246310 04-04 
CANNABIS-SATIVA 

CANNABINOID PATTERN IN CANNABIS-SATIVA L. SEEDLINGS AS AN 
INDICATION OF CHEMICAL RACE. 

237982 02-01 
CAPACITY 

THE CAPACITY OF ADRENERGIC NERVES TO ACCUMULATE EXOGENOUS 
NOREPINEPHRINE UNDER THE INFLUENCE OF SOME 
PHARMACOLOGICAL AGENTS. 

228551 01-03 
EFFECT OF SODIUM OXYBUTYRATE, AMPHETAMINE, TRANSAMINE, L 
DOPA ON THE PROCESSES OF RESTORATION OF WORKING CAPACITY 
UNDER CONDITIONS OF MINIMAL REST 

236372 02 04 
EFFECTS OF LITHIUM CHLORIDE ON PARAMETERS OF BIOSYNTHETIC 
CAPACITY FOR 5-HYDROXYTRYPTAMINE IN RAT BRAIN, 

246849 04-03 
EFFECT OF ESTROGEN TREATMENT ON ESTRADIOL BINDING CAPACITY IN 
UTERI OF AGING RATS 

247588 04-03 
CAPTAGON 

TREATMENT OF THE MINIMAL-BRAINDYSFUNCTION SYNDROME WITH 
PSYCHOPHARMACOTHERAPY (A CLINICAL STUDY WITH CAPTAGON). 

230002 01-11 
CAPTURE 

THE ACTION OF CHLORPROMAZINE, TRIFLUOPERAZINE AND DROPERIDOL 
ON THE CAPTURE AND ACCUMULATION OF EXOGENOUS 
NOREPINEPHRINE. 

236713 02-03 
CAR 

REVERSAL OF THE 6-HYDROXYDOPAMINE-INOUCED SUPPRESSION OF A 
CAR BY DRUGS FACILITATING CENTRAL CATECHOLAMINERGIC 
MECHANISMS. 

246818 04-04 
CARBACHOL 

CARBACHOL ELICITED MOUSE KILLING BY RATS CIRCADIAN RHYTHM 
AND DOSE-RESPONSE. 

238006 02-04 



A PRESSOR RESPONSE TO INTRAVENTRICULAR INJECTIONS OF 
CARBACHOL 

251142 04-03 
CARBAMAZEPINE 

PSYCHOLOGICAL TEST INVESTIGATIONS OF PATIENTS TREATED WITH 
CARBAAAAZEPINE FOR NOCTURNAL ENURESIS AND TICS. 

229684 01 -l-t 
DOSE-RESPONSE RELATIONS IN DRUG-INDUCED INAPPROPRIATE 

SECRETION OF ADH: EFFECTS OF CLOFIBRATE AND CARBAAAAZEPINE. 

232638 02-1; 
PLACENTAL TRANSFER OF CARBAMAZEPINE IN THE RAT. 

237749 02-0; 
PHARMACOKINETIC MODEL TO DESCRIBE SELF-INDUCED DECREASES IN 
STEADY-STATE CONCENTRATIONS OF CARBAMAZEPINE. 

239658 03-1; 
BIOAVAILABILITY OF TWO CARBAAAAZEPINE PREPARATIONS DURING 
CHRONIC ADMINISTRATION TO EPILEPTIC PATIENTS. 

242212 03- r 
KINETICS OF CARBAAAAZEPINE AND ITS 10,1 1 EPOXIDE METABOLITE IN 
CHILDREN. 

243086 04- 1 ; 
CHARACTERISTIC CHANGES IN CONDITIONED DEFENSIVE REFLEXES 
CAUSED BY TRIFLUOPERAZINE, CARBAAAAZEPINE AND 
CHLORPROMAZINE. 

244352 04-0' 
STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAAAAZEPINE 
IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 2- 
18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 
WITH BEHAVIOR AND CHARACTER. 

244958 04-1 
THE CONTRIBUTION OF NEURONAL UPTAKE BLOCKADE TO THE 
ANTIEPILEPTIC ACTION OF CARBAMAZEPINE (TEGRETOL). 

249242 04-01 
CARBAAAAZEPINE (TEGRETOL) - A DOUBLE-BLIND COMPARISON WITH 
PHENYTOIN (DILANTIN). 

251937 04-1: 
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON ATTENTIONAL AND 
PERCEPTUAL FUNCTIONS OF CHILDREN WITH EPILEPSY. 

251949 04-1 
SERUM CONCENTRATION OF CARBAAAAZEPINE: COMPARISON OF 
HERRMANNS SPECTROPHOTOMETRIC METHOD AND A NEW GLC 
METHOD FOR THE DETERMINATION OF CARBAMAZEPINE. 

253011 04-a 
CARBANION 

PERMETHYLATION OF BARBITURATES: VARIATION IN PRODUCT RATIOS 
WITH VARYING METHYLSULFINYLMETHIDE CARBANION. 

238488 02-0 
CARBIDINE 

THE INFLUENCE OF CARBIDINE ON THE ADRENERGIC 

NEUROTRANSMITTER CONTENT AND STORAGE IN SYNAPTIC VESICLES. 

236233 02-0i 
CARBIDOPA 

INTRAVENOUS L-DOPA PLUS CARBIDOPA IN DEPRESSED PATIENTS: 
AVERAGE EVOKED RESPONSE, LEARNING, AND BEHAVIORAL CHANGES 

244664 04-0 
COMPARISON OF DOPA DECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE IN PARKINSONS 
DISEASE. 

248612 04-1 
COMPARISON OF DOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 

COMBINED WITH LEVODOPA AND LEVODOPA ALONE ON THE 
CARDIOVASCULAR SYSTEM OF PATIENTS WITH PARKINSONS DISEASE 

248613 04-1 
CARBOCYCLIC 

DRUGS DERIVED FROM CANNABINOIDS. 2. BASIC ESTERS OF NITROGEN 
AND CARBOCYCLIC ANALOGS 

248647 04-0 
DRUGS DERIVED FROM CANNABINOIDS. 4. EFFECT OF ALKYL 
SUBSTITUTION IN SULFUR AND CARBOCYCLIC ANALOGS. 

248652 04-0 
CARBON 

EFFECTS OF CARBON DISULFIDE ON OPERANT BEHAVIOR IN PIGEONS. 
(PH.D. DISSERTATION). 

238081 02-0 
EFFECTS OF D-AMPHETAMINE ON THE INCORPORATION OF CARBON 
ATOMS OF D-GLUCOSE INTO THE BRAINS OF DIFFERENTIALLY HOUSED 
MICE. 

249672 04-0 
THE EFFECT OF CARBON DISULFIDE ON THE STEREOTYPIC EFFECT OF 
DOPAMINE AGONISTS. 

250090 04-0 
CARBONATE 

FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM 

CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIV 
STUDY GROUP 

225718 01-0 
A DOUBLE-BLIND TRIAL OF LITHIUM CARBONATE AND HALOPERIDOL IN 
HUNTINGTONS-CHOREA. 

227550 01-1 



S-58 



VOLUME 14, SUBJECT INDEX 



Subject Index 



COMPARISON OF EFFICACY OF LITHIUM CARBONATE AND 

CHLORPROMAZINE IN MANIA: REPORT OF COLLABORATIVE STUDY 
GROUP ON TREATMENT OF MANIA IN JAPAN^ 

228226 01-09 
EPILEPTIFORM ACTIVITY IN THE ELECTROENCEPHALOGRAM INDUCED BY 
LITHIUM CARBONATE. 

233499 02-15 
ELECTROENCEPHALOGRAPHIC STUDIES IN PATIENTS WITH AFFECTIVE 
DISORDERS DURING PROPHYLACTIC TREATMENT WITH LITHIUM 
CARBONATE. 

234044 02-09 
LITHIUM CARBONATE IN AFFECTIVE DISORDERS; IV. A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS IN UNIPOLAR RECURRENT DEPRESSION. 

234203 02-09 
LITHIUM CARBONATE IN JUVENILE AAANIC-DEPRESSIVE ILLNESS. 

236663 02-10 
ATTENUATION OF THE EUPHORIANT AND ACTIVATING EFFECTS OF D- 
AMPHETAMINE AND AND L-AMPHETAMINE BY LITHIUM CARBONATE 
TREATMENT. 

237716 02-14 
THE EFFECTS OF LITHIUM CARBONATE UPON SUBJECTIVE STATE 
CHANGES INDUCED BY SODIUM PENTOBARBITAL. 

240074 03-14 
LITHIUM CARBONATE AND HYPOTHYROIDISM. 

244113 04-15 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
0-METHYLTRANSFERASE, AND FAMILY HISTORY. 

246629 04-09 
LITHIUM CARBONATE AND AFFECTIVE DISORDERS. V: A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS OF DEPRESSION IN BIPOLAR ILLNESS. 

247582 04-09 
THYROID FUNCTION LEVELS AND THYROTROPIN RESPONSES TO TRH 
ADMINISTPATION IN MANIC PATIENTS RECEIVING LITHIUM 
CARBONATE. 

249124 04-14 
THE RELATIONSHIP OF PLASMA TO ERYTHROCYTE LITHIUM LEVELS IN 
PATIENTS TAKING LITHIUM CARBONATE. 

249535 04-09 
PLASMA RENIN ACTIVITY IN DEPRESSED PATIENTS TREATED WITH 
INCREASING DOSES OF LITHIUM CARBONATE. 

249673 04-13 
SUSTAINED-RELEASE LITHIUM CARBONATE IN A DOUBLE-BLIND STUDY: 
SERUM LITHIUM LEVELS, SIDE-EFFECTS, AND PLACEBO RESPONSE. 

251826 04-15 
LITHIUM OROTATE, CARBONATE AND CHLORIDE: PHARMACOKINETICS, 
POLYDIPSIA AND POLYURIA IN RATS. 

252198 04-03 
MMPI DELINEATION OF A SUBGROUP OF DEPRESSED PATIENTS 
REFRACTORY TO LITHIUM CARBONATE THERAPY. 

253595 04-09 
CARCINOMA 

THE MEASUREMENT OF PAIN IN TERMINAL CARCINOMA. 

252143 04-11 
CARDIAC 

THE EFFECT OF DIAZEPAM AND TRIFLUOPERAZINE ON BLOOD SUPPLY 
AND CARDIAC ACTIVITY. 

228553 01-03 
ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 
BROMAZEPAM IN CONSCIOUS TRAINED DOGS 

240064 03-03 
USE OF INJECTABLE LORAZEPAM IN PREPARATION FOR CARDIAC 
CATHETERIZATION. 

244450 04-11 
CARDIORESPIRATORY 

METHYLPHENIDATE IN CHILDREN: EFFECTS UPON CARDIORESPIRATORY 
FUNCTION ON EXERTION, 

247378 04-15 
CARDIOTOXIC 

CARDIOTOXIC EFFECTS OF PSYCHOTROPIC DRUGS, 

247784 04-15 
CARDIOVASCULAR 

MONOAMINE-OXIDASES OF THE RAT CARDIOVASCULAR SYSTEM. 
(UNPUBLISHED PAPER). 

227783 01-03 
CARDIOVASCULAR SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS - A 
RISK IN THE USE OF THESE DRUGS, 

23131701-15 
A REVIEW OF THE CARDIOVASCULAR EFFECTS AND TOXICITY OF 
TRICYCLIC ANTIDEPRESSANTS. 

237909 02-15 
CHRONIC CARDIOVASCULAR EFFECTS OF 0ELTA9 

TETRAHYDROCANNABINOL (DELTA9-THC) IN THE MONGREL DOGS 

238810 03-03 
CHANGES IN CARDIOVASCULAR RESPONSES TO BRAIN STIMULATION 
FOLLOWING OLFACTORY BULBECTOMY AND THE EFFECTS OF 
PSYCHOTROPIC DRUGS IN RATS. 

241389 03-03 



EFFECTS OF AZAPERONE ON CARDIOVASCULAR AND RESPIRATORY 
FUNCTIONS IN THE HORSE. 

243759 04-03 
TOLERANCE TO THE CARDIOVASCULAR EFFECTS OF DELTA9- 
TETRAHYDROCANNABINOL IN THE RAT. 

243800 04-03 
COMPARISON OF DOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE ON THE 
CARDIOVASCULAR SYSTEM OF PATIENTS WITH PARKINSONS DISEASE. 

248613 04-11 
CARDIOVASCULAR EFFECTS OF CENTRAL MICROINJECTIONS OF 
APOMORPHINE IN CATS. 

249033 04-03 
TOLERANCE TO THE CARDIOVASCULAR EFFECTS OF DELTA9- 
TETRAHYDROCANNABINOL IN THE RAT, 

249418 04-03 
CARDIOVASCULAR EFFECTS OF PROLONGED DELTA9- 
TETRAHYDROCANNABINOL INGESTION. 

253609 04-13 
CARDIOVERSION 

THE USE OF INJECTABLE LORAZEPAM IN PREPARATION FOR ELECTRIC 
CARDIOVERSION. 

244451 04-11 
CARE 

DRUG THERAPY IN CHILD CARE. 

243897 04-15 
CARROLL 

LOGICAL ANALYSIS OF THE RESPECTIVE INFLUENCE OF THREE 

EXPERIMENTAL VARIABLES BY MEANS OF A DIAGRAM OF L. CARROLL. 
APPLICATION OF THIS METHOD TO A CLINICAL TRIAL OF TWO FORMS 
OF NOVERIL, 

24.5971 04-06 
CARTAZOLATE 

ANTIDEPRESSANT PREDICTABILITY: CARTAZOLATE, 

242251 03-09 
CASUISTIC 

PIRACETAM IN A CASE OF ACUTE CEREBRAL HYPOXEMIA: CASUISTIC 
REPORT, 

229128 01-14 
ON THE DIFFERENTIAL DIAGNOSIS OF ACUTE EXTRAPYRAMIDAL MOTOR 
DISTURBANCES IN CHILDHOOD: CASUISTIC ACCOUNT, 

234291 02-11 
EXTRAPYRAMIDAL SYMPTOMS UNDER CLOZAPINE: A CASUISTIC 
CONTRIBUTION 

238855 03-15 
CASUISTICAL 

THE DYSTONIC HYPERKINETIC SYNDROME: A CASUISTICAL 

CONTRIBUTION TO THE UNDERSTANDING OF THE ACTIONS OF DRUGS 
IN CHILDREN, 

233717 02-11 



CAT 



A STUDY OF INHIBITORY ANTAGONISM IN CAT VISUAL CORTEX, 

226397 01-03 
ANGIOTENSIN-INDUCED DRINKING IN THE CAT: A DOSE-RESPONSE AND 
BIOCHEMICAL ANALYSIS, (PHD, DISSERTATION). 

227106 01-04 
DEPRESSIVE EFFECTS OF MORPHINE UPON LAMINA V CELLS ACTIVITIES 
IN THE DORSAL HORN OF THE SPINAL CAT, 

232328 01-03 
BARBITURATE SPINDLE ACTIVITY IN FUNCTIONALLY CORRESPONDING 
THALAMIC AND CORTICAL SOMATOSENSORY AREAS IN THE CAT. 

232606 0203 
THE EFFECT OF NEUROTROPIC AGENTS ON EVOKED POTENTIALS OF THE 
ASSOCIATIVE AND PROJECTION AREAS OF THE CAT NEOCORTEX. 

236261 02-03 
EFFECTS OF DOPAMINERGIC AGONISTS AND ELECTRICAL STIMULATION 
OF THE MIDBRAIN RAPHE ON THE RELEASE OF 5 
HYDROXYTRYPTAMINE FROM THE CAT BRAIN IN VIVO. 

237154 02-03 
ACTIONS OF METHOXAMINE AND TRYPTAMINE AND THEIR 

INTERACTIONS WITH CYPROHEPTADINE AND PHENOXYBENZAMINE ON 
CAT SPINAL CORD SEGMENTAL REFLEXES. 

237752 0203 
THE EFFECT OF LSD UPON SPONTANEOUS PGO WAVE ACTIVITY AND 
REM SLEEP IN THE CAT. 

237780 02-04 
DOSE-RESPONSE STUDIES ON EFFECTS OF AMPHETAMINE ON ACTIVITY 
AND OXYGEN CONSUMPTION IN DOG AND CAT MODELS OF 
HYPERKINESIS (HYPOINHIBITORY SYNDROME) 

238825 03-03 
6-HYDROXYDOPAMINE (6-OHDA) ADMINISTRATION TO NEONATAL RATS 

FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC ACID- 
DECARBOXYLASE (GAD) IN THE CNS 

238826 03-03 
EFFECT OF SOME INTRACEREBRALLY ADMINISTERED DRUGS ON A 

CONDITIONED REFLEX IN THE CAT. 

239275 03-04 



00 

s 



gpv 

SI 
IS 



S-59 



Subject Index 



Psychopharmacology Abstracts 



THE ACTION OF CHLORPROMAZINE ON THE ELECTRODERMAL RESPONSE 

IN THE CAT. 

239963 03-03 
THE INVOLVEMENT OF METHYSERGID SENSITIVE RECEPTORS AND 

PROSTAGLANDINS IN THE HYPERTHERMIA EVOKED BY 5-HT IN THE 

CAT. 

241255 03-03 
EFFECTS OF SOME DOPAMINE ANALOGS AND HALOPERIDOL ON 

RESPONSE TO STI/W,ULATION OF ADRENERGIC NERVES USING CAT 

ATRIA IN VITRO. 

241313 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARI2ED CAT: I. PGO WAVE ACTIVITY INDUCED BY RO-4-1284 AND 

BY P-CHLOROPHENYLALANINE (PCPA) AS A BASIS FOR 

NEUROPHARMACOLOGICAL STUDIES. 

241315 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: II. PGO WAVE ACTIVITY AND BRAIN 5- 
HYDROXYTRYPTAMINE. 

241316 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: III. PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES. 

241317 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: IV. THE EFFECTS OF ACETYLCHOLINE, GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY. 

241318 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: V. MISCELLANEOUS COMPOUNDS. SYNOPSIS OF THE 
ROLE OF CENTRAL NEUROTRANSMITTERS ON PGO WAVE ACTIVITY. 

241319 03-03 
INTERACTION BETWEEN POSSIBLE TRANSMITTERS AND 

BUTYROPHENONES APPLIED MICROELECTROPHORETICALLY IN THE 
CEREBELLUM AND BASAL GANGLIA OF THE CAT. 2ND REPORT: 
EFFECTS OF SOME PHENOTHIAZINES ON THE PURKINJE CELLS OF THE 
CEREBELLUM 

241386 03-03 
EFFECTS OF SELECTED DRUGS ON AN AUDITORY OR THALAMIC 
CONDITIONED STIMULUS ELICITING RECRUITMENT IN THE CAT. 

246967 04-04 
THE EFFECT OF ATROPINE UPON ACETYLCHOLINE RELEASE FROM CAT 
SUPERIOR CERVICAL GANGLIA AND RAT CORTICAL SLICES- 
MEASUREMENT BY A RADIOENZYMIC METHOD. 

248724 04-03 
EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVEAU ISOLE AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT. 

249307 04-03 
BICUCULLINE REVERSAL OF DEPRIVATION AMBLYOPIA IN THE CAT. 

249983 04-03 
ADRENERGIC RECEPTORS AND VASCULAR RESISTANCE IN CEREBRAL 
CIRCULATION OF THE CAT. 

251820 04-03 
METHAMPHETAMINE SELF-ADMINISTRATION IN THE CAT. 

251976 04-04 
THE EFFECTS OF 5HYDR0XYTRYPT0PHAN AND L-TRYPTOPHAN ON 
WAKEFULNESS AND SLEEP PATTERNS IN THE CAT. 

252216 04-03 
NICOTINIC EFFECT OF ACETYLCHOLINE ON THE RELEASE OF NEWLY 

SYNTHESIZED 3H-D0PAMINE IN RAT STRIATAL SLICES AND CAT 
CAUDATE-NUCLEUS. 

252217 04-03 
AUTORADIOGRAPHIC DISTRIBUTION STUDY OF 14C-D0PA IN CAT BRAIN. 

253393 04-03 
CATABOIISM 

EFFECTS OF DIETHYLDITHIOCARBAMATE ON THE CATABOLISM OF 
TYROSINE IN THE RAT BRAIN. 

241249 03-05 
EFFECTS OF THE D-ISOMERS AND L-ISOMERS OF AMPHETAMINE ON 
UPTAKE, RELEASE AND CATABOLISM OF NOREPINEPHRINE, DOPAMINE 
AND 5-HYDROXYTRYPTAMINE IN SEVERAL REGIONS OF RAT BRAIN. 

241345 03-03 
CATALEPSY 

SEROTONERGIC INVOLVEMENT WITH NEUROLEPTIC CATALEPSY. 

237781 02-03 
THE INFLUENCE OF MEPYRAMINE AND BURIMAMIDE ON HISTAMINE- 
INDUCED CATALEPSY IN THE RAT. 

240238 03-03 
AMT CATALEPSY AND HYPOKINESIA: INTERACTION WITH MORPHINE 
AND COCAINE. 

241224 03-04 
HALOPERIDOL CATALEPSY IN GROUPED AND ISOLATED MICE. 

249624 04-04 
POSTNATAL DEVELOPMENT OF DOPAMINERGIC AND CHOLINERGIC 
CATALEPSY IN THE RAT. 

250084 04-03 



CATALYTIC 

A COMPARISON OF THE BIOCHEMICAL EFFECT OF TWO CATALYTIC 
INHIBITORS OF MAMMALIAN BRAIN GABA-TRANSAMINASE: GAMMA- 
VINYL-GABA (AMIN0-4-HEX-5-EN0IC-ACID) AND GAMAM-ACETYLENIC- 
GABA (AMIN0-4-HEX-5-YN0IC-ACID). 

238782 03-03 
CATATONIA 

THE RELATIVE ROLE OF BRAIN ACETYLCHOLINE AND HISTAMINE IN 
PERPHENAZINE CATATONIA AND INFLUENCE OF ANTIDEPRESSANTS 
AND DIPHENHYDRAMINE ALONE AND IN COMBINATION. 

245593 04-05 
CATECHOL-O-METHYITRANSFERASE 

THE EFFECT OF CATECHOLO-METHYLTRANSFERASE INHIBITORS ON 
BEHAVIOR AND DOPAMINE METABOLISM. 

233969 02-03 
EFFECT OF CATECHOLO-METHYLTRANSFERASE INHIBITORS ON BRAIN 
APOMORPHINE CONCENTRATIONS AND STEREOTYPED BEHAVIOUR IN 
THE RAT 

237747 02-03 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
O-METHYLTRANSFERASE, AND FAMILY HISTORY. 

246629 04-m 
CATECHOL-O-METHYLTRANSFERASE FROM RAT LIVER: TWO FORMS 
HAVING DIFFERENT META:PARA METHYLATION RATIOS. 

249035 04-01 
CATECHOLAMINE 

EVIDENCE FOR DRUG ACTIONS ON BOTH PRE- AND POSTSYNAPTIC 
CATECHOLAMINE RECEPTORS IN THE CNS. 

229431 Ol-O; 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 
BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

229462 01-00 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 
BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

232507 01-0: 
ASCENDING CATECHOLAMINE SYSTEMS AND MORPHINE ANALGESIA. 

232915 02-00 
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE 
DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING 
NEURONS AND AXONS BY GLYOXYLIC-ACID INDUCED FLUORESCENCE: 
II. A DETAILED DESCRIPTION OF METHODOLOGY. {UNPUBLISHED 
PAPER). 

236875 02-Ot 
RESERPINE-INDUCED CATECHOLAMINE DEPLETION FROM SMALL CELLS IN 
RAT SYMPATHETIC GANGLIA. 

237738 02-0: 
THE EFFECT OF SELECTIVE LESIONING OF BRAIN CATECHOLAMINE 

CONTAINING NEURONS ON THE ACTIVITY OF VARIOUS ANORECTICS IN 
THE RAT. 

237742 02-0; 
CATECHOLAMINE CONCENTRATION OF DISCRETE BRAIN AREAS 

FOLLOWING SELF-STIMULATION IN THE VENTROMEDIAL TEGMENTUM 
OF THE RAT. 

237862 02-0; 
CATECHOLAMINE CONCENTRATION IN DISCRETE AREAS OF BRAIN OF 
SEVERAL STRAINS OF MICE: CORRELATION WITH AGGRESSIVITY. 

238673 03-0; 
MODIFICATION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS BY 
DRUGS WHICH ALTER BRAIN CATECHOLAMINE LEVELS OR STIMULATE 
CATECHOLAMINE RECEPTORS. 

238734 03-0: 
CORRELATION BETWEEN THE EFFECTS OF SEVERAL CANNABINOIDS ON 
CATECHOLAMINE SYNTHESIS, BODY TEMPERATURE, AND BEHAVIOR. 

238769 03-0: 
EFFECT OF CHRONIC BARBITAL ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL ON CATECHOLAMINE CONTENT AND TURNOVER IN RAT 
BRAIN. 

238790 03-0; 
EFFECTS OF CATECHOLAMINE RECEPTOR BLOCKING AGENTS ON 
TOXICITY AND THERAAAL RESPONSES INDUCED BY AMPHETAMINE 
ISOMERS IN ADULT AND DEVELOPING MICE. 

239043 03-0; 
EFFECTS OF RESERPINE ON ACTIVITIES AND AMOUNTS OF TYROSINE- 
HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN 
CATECHOLAMINE NEURONAL SYSTEMS IN RAT BRAIN. 

246845 04-00 
PROTEST DESPAIR RESPONSE TO PEER SEPARATION IN RHESUS MONKEYS 
AND ITS POTENTIATION BY ALTERATION OF CATECHOLAMINE 
METABOLISM. 

248437 04-0^ 
THE EFFECT OF PROBENECID ON CATECHOLAMINE METABOLITES IN 
HUMAN CEREBROSPINAL FLUID ANALYZED BY MASS 
FRAGMENTOGRAPHY. 

248464 04- 1; 
POSTNATAL ELEVATION OF BRAIN TYROSINE-HYDROXYLASE ACTIVITY, 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 



S-60 



OLUME 14, SUBJECT INDEX 

CATECHOLAMINE LEVELS, RESULTING FROM DL-ALPHA-METHYL-P- 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 04-03 
DEVELOPMENT OF THE INFLUENCES OF SODIUM, CATECHOLAMINE AND 
TRICYCLIC ANTIDEPRESSANT DRUG ON THE UPTAKE OF 3H-5- 
HYOROXYTRYPTAMINE BY RAT BRAIN SYNAPTOSOMES. 

249667 04-03 
CHANGES IN BRAIN CATECHOLAMINE TURNOVER DURING PRECIPITATED 
MORPHINE WITHDRAWAL IN THE RAT. 

251400 04-03 
CATECHOLAMINE RELEASE BY INTRACEREBRAL PERFUSION OF 6- 
HYDROXYDOPAMINE AND DESIPRAMINE. 

252024 04-03 
INTERRELATIONSHIP BETWEEN CATECHOLAMINE STIMULATED 
FORMATION OF ADENOSINE 3,5 MONOPHOSPHATE IN CEREBELLAR 
SLICES AND INHIBITORY EFFECTS ON CEREBELLAR PURKINJE CELLS- 
ANTAGONISM BY NEUROLEPTIC COMPOUNDS. 

253109 04-03 
THE MONOAMINE-OXIDASE B INHIBITOR DEPRENYL POTENTIATES 
PHENYLETHYLAMINE BEHAVIOUR IN RATS WITHOUT INHIBITION OF 
CATECHOLAMINE METABOLITE FORMATION. 

253643 04-04 
kTECHOLAMINERGIC 

THE EFFECT OF CATECHOLAMINERGIC SUBSTANCES ON PROCONVULSIVE 
PROPERTIES OF THE CAUDATE-NUCLEUS. 

231071 01-03 
CATECHOLAMINERGIC MECHANISMS OF THE LATERAL HYPOTHALAMUS- 
THEIR ROLE IN THE MEDIATION OF AMPHETAMINE ANOREXIA. 

232610 02-03 
EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON TYROSINE-HYDROXYLASE 
ACTIVITY IN CENTRAL CATECHOLAMINERGIC NEURONS OF THE RAT. 

232624 02-03 
BEHAVIORAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN AFTER 

DESTRUCTION OF ASCENDING SEROTONERGIC PATHWAYS IN THE RAT 
THE ROLE OF CATECHOLAMINERGIC NEURONS. 

241251 03-04 
TIME-DEPENDENT VARIATIONS IN AVERSIVELY MOTIVATED BEHAVIORS 
NONASSOCIATIVE EFFECTS OF CHOLINERGIC AND 
CATECHOLAMINERGIC ACTIVITY. 

245486 04-04 
REVERSAL OF THE 6-HYDROXYDOPAMINE-INDUCED SUPPRESSION OF A 
CAR BY DRUGS FACILITATING CENTRAL CATECHOLAMINERGIC 
MECHANISMS. 

246818 04-04 
SOME EFFECTS OF FENFLURAMINE AND ITS DERIVATIVES ON THE 
CENTRAL CATECHOLAMINERGIC SYSTEMS OF MICE, 

250940 04-03 
JECHOLAMINES 
THE EFFECT OF YOHIMBINE ON THE TURNOVER OF BRAIN 
CATECHOLAMINES AND SEROTONIN. 

226726 01-03 
EFFECT OF VILOXAZINE (VIVALAN) ON THE URINARY EXCRETION OF 
CATECHOLAMINES AND THEIR METABOLITES. 

227212 01-07 
CATECHOLAMINES, DRUGS, AND BEHAVIOR: MUTUAL INTERACTIONS. 

233968 02-04 
REGIONAL ROLE OF CATECHOLAAAINES IN ALPHA-METHYL-M-TYROSINE 
INDUCED ELECTROENCEPHALOGRAPHIC AROUSAL. 

234067 02-03 
BEHAVIORAL AND BIOCHEMICAL INTERACTION BETWEEN AMT AND ( * ) 
AMPHETAMINE: RELEVANCE TO THE IDENTIFICATION OF THE 
FUNCTIONAL POOL OF BRAIN CATECHOLAMINES. 

237698 02-03 
EFFECTS OF SCOPOLAMINE, D-AMPHETAMINE AND OTHER DRUGS 
AFFECTING CATECHOLAMINES ON SPONTANEOUS ALTERNATION AND 
LOCOMOTOR ACTIVITY IN MICE. 

237703 02-04 
BEHAVIORAL EFFECTS OF INTRACEREBRALLY ADMINISTERED 

CATECHOLAMINES IN MICE AND THEIR MODIFICATIONS BY SOME 
ADRENERGIC BLOCKING AGENTS. 

237707 02-04 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 
AND SEROTONIN IN RATS -■ ACUTE MORPHINE ADMINISTRATION. 

237736 02-03 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 

AND SEROTONIN IN RATS - CHRONIC MORPHINE ADMINISTRATION. 

237737 02-03 
MOUSE BRAIN CATECHOLAMINES, 5-HYDROXYTRYPTAMINE AND THE 

ANTINOCICEPTIVE ACTIVITY OF PETHIDINE. 

237741 02-03 
IHE EFFECT OF NOMIFENSINE ON THE DEPLETION OF BRAIN SEROTONIN 
AND CATECHOLAMINES INDUCED RESPECTIVELY BY FENFLURAMINE 
AND 6 HYDROXYDOPAMINE IN RATS 

237743 02-03 
BEHAVIORAL EVIDENCE OF THE INTERACTION OF PHENCYCLIDINE WITH 
CATECHOLAMINES IN PRIMATE SOCIAL COLONIES. 

238696 03-04 



Subject Index 

CONFORMATIONAL REQUIREMENTS FOR BLOCKING UPTAKE OF 
CATECHOLAMINES AND SEROTONIN INTO CRUDE RAT BRAIN 
SYNAPTOSOMES. 

238738 03-01 
ANALGESIC EFFECT OF VAGINAL STIMULATION IN RATS: MODULATION 
BY CATECHOLAMINES AND STEROIDS. 

238822 03-03 
CATECHOLAMINES IN BRAIN ISCHEMIA - EFFECTS OF ALPHA-METHYL-P- 
TYROSINE AND PARGYLINE. 

239577 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: III. PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES. 

241317 03-03 
EFFECTS OF A SINGLE ADMINISTRATION OF CLOZAPINE ON MOUSE 
BRAIN CATECHOLAMINES. 

241416 0303 
THE EFFECT OF ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION 
ON SEIZURE SUSCEPTIBILITY AND BRAIN CATECHOLAMINES IN MICE. 
(PH.D. DISSERTATION). 

241576 03-03 
SYNTHESIS OF O-TRANSMETHYLATED CATECHOLAMINES AND 
PSYCHODYSLEPTIC BETA-PHENYLISOPROPYLAMINES (PH D 
DISSERTATION). 

242003 03-01 
NEUROLEPTICS, CATECHOLAMINES, AND PSYCHOSES: A STUDY OF THEIR 
INTERRELATIONS, 

245510 04-09 
THE EFFECTS OF GANGLIONIC BLOCKADE, RESERPINE AND VINBLASTINE 
ON PLASMA CATECHOLAMINES AND DOPAMINE-BETA-HYDROXYLASE 
IN THE RAT. 

246843 04-03 
CHLORPROAAAZINE, CATECHOLAMINES AND AGING IN MICE. 

247587 04-02 
THE ROLE OF ADRENAL CATECHOLAMINES IN THE RELEASE OF 
CORTICOSTERONE AND FATTY-ACIDS BY NICOTINE IN THE RAT. 

247731 04-03 
THE EFFECT OF AMPHETAMINE PRETREATMENT ON THE AMPHETAMINE- 
INDUCED CHANGES IN MOTOR ACTIVITY AND BRAIN 
CATECHOLAMINES IN MICE. 

249274 04-04 
CATECHOLAMINES AND 2-PHENYLETHYLAMINE (PEA) IN THE CENTRAL 
AND PERIPHERAL ACTIONS OF AMPHETAMINES. 

249311 04 03 
CATEGORIES 

INFLUENCE OF PSYCHOPHARMACEUTICALS ON ACHIEVEMENT 

MOTIVATION: III. DIFFERENTIAL INFLUENCE ON CONTENT CATEGORIES. 

240644 03-14 
CATEGORIZED 

STATE-DEPENDENT ACCESSIBILITY OF RETRIEVAL CUES IN THE 
RETENTION OF A CATEGORIZED LIST, 

243013 04-04 
CATHETERIZATION 

USE OF INJECTABLE LORAZEPAM IN PREPARATION FOR CARDIAC 
CATHETERIZATION. 

244450 04 II 
CATIONS 

THE UPTAKE OF LOW CONCENTRATIONS OF LITHIUM IONS INTO RAT 
CEREBRAL CORTEX SLICES AND ITS DEPENDENCE ON CATIONS. 

253411 04-03 
CATS 

EFFECT OF 5,5 DIPHENYLHYDANTOIN (DPH) ON LEARNING AND MEMORY 
IN CATS. 

229680 01-04 
EFFECT OF 5,5 DIPHENYLHYDANTOIN ON FIXED CONDITIONED REFLEXES 

IN CATS. 

229681 01-04 
ANTIEPILEPTIC AND PROPHYLACTIC EFFECTS OF 

TETRAHYDROCANNABINOLS IN AMYGDALOID KINDLED CATS. 

230478 01-03 
THE SELECTIVE EFFECTS OF ALPHA METHYL AROMATIC AMINO-ACIDS ON 
BRAIN MONOAMINE METABOLITES AND BEHAVIOR IN CATS. 

231009 01-03 
THE EFFECT OF PSYCHOTROPIC DRUGS ON CONDITIONED REFLEXES 
AFTER AN EMOTIONAL STRESS IN CATS. 

231069 01-04 
THE INFLUENCE OF D,L-AMPHETAMINE AND CAFFEINE ON CAUDATE 
INHIBITION OF CONDITIONED AVOIDANCE REACTIONS IN CATS. 

231248 01-04 
COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 

232483 01-04 
CORTICAL AND SUBCORTICAL PROJECTED FOCI IN CATS: INHIBITORY 
ACTION OF TAURINE. 

233299 02-03 
ROLE OF BIOGENIC AMINES IN THE EFFECTS OF MARIJUANA ON LEG 
PATTERNS IN CATS. 

235564 02-03 








£2 

3E 



S-61 



Subject Index 



Psychopharmacology Abstracts 



EFFECT OF CAFFEINE AND AMPHETAMINE ON CAUDATE INHIBITION OF 
AGGRESSIVE REACTIONS OF CATS 

236371 02-04 
RESERPINE ACTION ON THE ARREST REACTION FOLLOWING 
STIMULATION OF THE CAUDATE-NUCLEUS IN CATS. 

236712 02-04 
ROLE OF SUPERIOR COLLICULUS SEROTONIN IN THE GROOMING 
BEHAVIOUR OF CATS. 

239978 03-04 
EFFECT OF l,2-BENZISOXAZOLE-3-ACETAMIDOXIME ON CAUDATO- 
THALAMO-CORTICAL SYSTEM IN CATS. 

241383 03-03 
INTRACAUDATE NEUROTRANSMITTER PROCESSES IN RELATION TO 
RAPHE NEUROTRANSMITTER PROCESSES: A BEHAVIOURAL ANALYSIS 
OF INTRACEREBRALLY APPLIED DRUGS IN ACUTE AND LONG-TERM 
MORPHINE TREATED CATS. 

244215 04-04 
VORACIOUSNESS INDUCED IN CATS BY BENZODIAZEPINES. 

244690 04-04 
CARDIOVASCULAR EFFECTS OF CENTRAL MICROINJECTIONS OF 
APOMORPHINE IN CATS. 

249033 04-03 
INHIBITION OF SLOW WAVE SLEEP AND RAPID EYE MOVEMENT SLEEP BY 
THYROTROPIN-RELEASING HORMONE IN CATS 

249281 04-02 
CAUDATE 

THE INFLUENCE OF D.L-AMPHETAMINE AND CAFFEINE ON CAUDATE 
INHIBITION OF CONDITIONED AVOIDANCE REACTIONS IN CATS. 

231248 01-04 
CORRELATIONS BETWEEN THE EFFECTS OF DL-AMPHETAMINE AND 
RESERPINE ON THE MODEL OF THE CAUDATE REACTION OF 
RETARDATION. 

236235 02-03 
EFFECT OF CAFFEINE AND AMPHETAMINE ON CAUDATE INHIBITION OF 
AGGRESSIVE REACTIONS OF CATS. 

236371 02-04 
EFFECTS OF INTRACEREBROVENTRICULAR L-DOPA ON CAUDATE UNIT 
FIRING- 

238716 03-03 
CAUDATE-NUCLEUS 

THE EFFECTS OF ACETYLCHOLINE AND DOPAMINE ON THE CAUDATE- 
NUCLEUS DEPLETED OF BIOGENIC AMINES. 

230457 01-03 
THE EFFECT OF CATECHOLAMINERGIC SUBSTANCES ON PROCONVULSIVE 
PROPERTIES OF THE CAUDATE-NUCLEUS. 

231071 01-03 
MONOAMINERGIC INFLUENCES OF THE CAUDATE-NUCLEUS ON 
CONDITIONED FOOD PROCURING REACTIONS IN RATS. 

231251 01 04 
RESERPINE ACTION ON THE ARREST REACTION FOLLOWING 
STIMULATION OF THE CAUDATE-NUCLEUS IN CATS. 

236712 02-04 
ANTAGONISM OF APOMORPHINE AND D-AMPHETAMINE-INDUCED 
STEREOTYPED BEHAVIOUR BY INJECTION OF LOW DOSES OF 
HALOPERIDOL INTO THE CAUDATE NUCLEUS AND THE NUCLEUS- 
ACCUMBENS. 

237704 02-04 
DOPAMINE-INDUCED INCREASES IN CYCLIC-AMP, AND CYCLIC-AMP 
DEPENDENT PROTEIN PHOSPHORYLATION, IN THE RAT CAUDATE- 
NUCLEUS. (PHD DISSERTATION). 

238080 02-13 
CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN 
THE CAUDATE-NUCLEUS. (UNPUBLISHED PAPER). 

238471 02-03 
COMPARISON OF THYROID-RELEASING HORMONE (TRH) AND 

AMPHETAMINE (AMP) ON CHANGES IN ACTIVITY LEVELS OF RATS 
FOLLOWING INJECTIONS INTO THE CAUDATE-NUCLEUS, SEPTUM, AND 
HYPOTHALAMUS. 

238744 03-04 
RESPONSES OF NEURONES IN THE CEREBRAL CORTEX AND CAUDATE- 
NUCLEUS TO AMANTADINE, AMPHETAMINE AND DOPAMINE. 

243805 04-03 
UPTAKE OF BIOGENIC AMINES INTO SYNAPTIC VESICLES OF THE 
CAUDATE-NUCLEUS 

251392 04-03 
NICOTINIC EFFECT OF ACETYLCHOLINE ON THE RELEASE OF NEWLY 
SYNTHESIZED 3H-D0PAMINE IN RAT STRIATAL SLICES AND CAT 
CAUDATE-NUCLEUS. 

252217 04-03 
CAUDATO-THALAMO-CORTICAl 

EFFECT OF I,2BENZISOXAZOLE-3-ACETAMIDOXIME ON CAUDATO- 
THALAMO-CORTICAL SYSTEM IN CATS. 

241383 03-03 
CAUSAL 

MODEL OF CAUSAL CONFRONTATION IN INTEGRATIVE PSYCHOTHERAPY. 

234503 02-14 



CAUSISTIC 

EXTRAPYRAMIDAL SYMPTOMS IN A COMBINATION OF LITHIUM LONG- 
TERM THERAPY WITH NORTRIPTYLINE: A CAUSISTIC REPORT ON 
PATHOGENESIS AND HYPOTHESIS FORMULATION. 

239835 03-15 
CAVAIN-MAGNESIUM-OROTATE 

THE CLINICAL EFFECTIVENESS OF A CAVAIN-MAGNESIUM-OROTATE 
COMBINATION IN NURSING HOME PATIENTS IN A DOUBLE-BLIND 
STUDY. 

243180 04-11 
CA45 

ALTERATIONS IN CA45 UPTAKE AND EFFLUX IN RAT CORTEX, STRIATUM 
AND HYPOTHALAMUS SLICES. 

238714 03-03 
CBCH 

INHALATION TOXICITY OF TURKISH AAARIHUANA, CANNABICHROMENE 
(CBCH) AND CANNABIDIOL (CBD) IN RATS. 

238807 0305 
CBD 

INHALATION TOXICITY OF TURKISH MARIHUANA, CANNABICHROMENE 
(CBCH) AND CANNABIDIOL (CBD) IN RATS. 

238807 03-05 
CDP-CHOLINE 

CLINICAL EVALUATION OF CDP-CHOLINE (NICHOLIN): EFFICACY AS 
ANTIDEPRESSANT TREATMENT. 

247969 04-09 
CEASING 

PERSISTENCE OF CHRONIC MORPHINE EFFECTS UPON ACTIVITY IN RATS 
8 MONTHS AFTER CEASING THE TREATMENT. 

245602 04-04 
CELL 

COMPARISON OF THE EFFECTS OF LESION IN THE 089 CELL BODY GROUP 
AND P-CHLOROAMPHETAMINE ON TRYPTOPHAN-HYDROXYLASE AND 
5-HYOROXYTRYPTAMINE IN RAT BRAIN NUCLEI. 

237863 02-03 
OPIATE RECEPTORS AND ADENYLATE-CYCLASE IN NEUROBLASTOMA X 
GLIOMA CELL LINES. (UNPUBLISHED PAPER). 

238571 02-03 
OPIATE RECEPTORS IN CELL CULTURES. (UNPUBLISHED PAPER) 

239787 03-03 
NEUROTRANSMITTER REGULATION OF ADENOSINE 3,5 MONOPHOSPHATE 
IN CLONAL NERVE, GLIA, AND MUSCLE CELL LINES. 

243482 04-03 
THE EFFECT OF LITHIUM ON RED BLOOD CELL CHOLINESTERASE ACTIVITY 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

244495 04-09 
CELLS 

DEPRESSIVE EFFECTS OF MORPHINE UPON LAMINA V CELLS ACTIVITIES 
IN THE DORSAL HORN OF THE SPINAL CAT. 

232328 01-03 
THE EFFECTS OF GABA, PICROTOXIN AND BICUCULLINE ON THE 
SPONTANEOUS BIOELECTRIC ACTIVITY OF CULTURED CEREBELLAR 
PURKINJE CELLS. 

232906 02-03 
DIPHENYLHYDANTOIN INHIBITS IONIC EXCITATION OF MOUSE 
NEUROBLASTOMA CELLS. 

232917 02-03 
SPECIFIC EFFECTS OF NEUROTRANSMITTER ANTAGONISTS ON GANGLION 
CELLS IN RABBIT RETINA. 

236863 02-03 
RESERPINE-INDUCED CATECHOLAMINE DEPLETION FROM SMALL CELLS IN 
RAT SYMPATHETIC GANGLIA. 

237738 02-03 
BIOELECTRIC EFFECTS OF ISOPROTERENOL AND PROPRANOLOL ON NERVE 
CELLS IN EXPLANTS OF RAT CEREBELLUM. 

237880 02-03 
PROPERTIES OF TYROSINE HYDROXYLATION IN LIVING MOUSE 
NEUROBLASTOMA CELLS. 

238692 03-03 
EFFECT OF DEXTROAMPHETAMINE ON IDENTIFIED CHOLINOCEPTIVE 
CELLS OF THE SNAIL BRAIN. 

238740 0303 
A STUDY ON THE DEVELOPMENT OF BARBITURATE-TOLERANCE AND 
DEPENDENCE IN HAMSTER GLIAL CELLS IN CULTURE. 

241348 03-03 
INTERACTION BETWEEN POSSIBLE TRANSMITTERS AND 

6UTYR0PHEN0NES APPLIED MICROELECTROPHORETICALLY IN THE 
CEREBELLUM AND BASAL GANGLIA OF THE CAT. 2ND REPORT: 
EFFECTS OF SOME PHENOTHIAZINES ON THE PURKINJE CELLS OF THE 
CEREBELLUM. 

241386 03-03 
ALPHA-BUNGAROTOXIN, COBRA NEUROTOXIN AND EXCITATION OF 
RENSHAW CELLS BY ACETYLCHOLINE 

244203 04-03 
BINDING OF CHLORPROMAZINE AND IMIPRAMINE TO RED CELLS, 
ALBUMIN, LIPOPROTEINS AND OTHER BLOOD COMPONENTS. 

247129 04-03 



S-62 



OLUME 14, SUBJECT INDEX 



Subject Index 



0ELTA9-TETRAHYDR0CANNABIN0Lt EFFECT ON MACROMOLECULAR 
SYNTHESIS IN HUMAN AND OTHER MAMMALIAN CELLS. 

251420 04-13 
STEREOSPECIFIC BINDING OF ETORPHINE IN ISOLATED NEURAL CELLS 
AND IN RETINA, DETERMINED BY A SENSITIVE MICROASSAY. 

252178 04-03 
INTERRELATIONSHIP BETWEEN CATECHOLAMINE STIMULATED 

FORMATION OF ADENOSINE 3,5 MONOPHOSPHATE IN CEREBELLAR 
SLICES AND INHIBITORY EFFECTS ON CEREBELLAR PURKINJE CELLS: 
ANTAGONISM BY NEUROLEPTIC COMPOUNDS. 

253109 04-03 
LLUIAR 
UTILIZATION OF CELLULAR STUDIES OF NEUROTRANSMITTER RELATED 
ENZYMES AND TRANSPORT PROCESSES IN MAN FOR THE 
INVESTIGATION OF BIOLOGICAL FACTORS IN BEHAVIORAL DISORDERS 
(UNPUBLISHED PAPER). 

226731 01-13 
CELLULAR LOCALIZATION AND KINESTIC PROPERTIES OF GAMMA- 
GLUTAMYL-TRANSPEPTIDASE IN RAT CEREBRAL CORTEX. 

238680 03-03 
CELLULAR MEDIATED DECREASES IN SENSITIVITY TO THE INHIBITORY 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L (DELTA9-THC). 

238816 03-03 
SYNTHESIS OF SUBSTITUTED THIOBENZOXAZOLES/BENZOTHIAZOLES 
INHIBITION OF CELLULAR RESPIRATORY AND MONOAMINE-OXIDASE 
ACTIVITIES AND ANTICONVULSANT PROPERTY. 

239661 03-03 
THE ACTION OF NOREPINEPHRINE IN THE RAT HIPPOCAMPUS III 
HIPPOCAMPAL CELLULAR RESPONSES TO LOCUS-COERULEUS 
STIMULATION IN THE AWAKE RAT 

252012 04-03 
NTRAl 
TYROSINE-HYDROXYLASE: ALLOSTERIC ACTIVATION INDUCED BY 
STIMULATION OF CENTRAL NORADRENERGIC NEURONS. 

226856 01-03 
COMPARISON OF CENTRAL EFFECTS OF NORADRENALINE AND DOPAMINE 
INJECTED INTO THE LATERAL BRAIN VENTRICLE IN RATS. 

227636 01 04 
EFFECTS OF HANDLING BEFORE CENTRAL 6-HYDROXYDOPAMINE 
TREATMENT ON SUBSEQUENT EMOTIONALITY AND NEUROCHEMICAL 
CHANGES IN RATS. 

228142 01-04 
A HISTOCHEMICAL STUDY ON THE CENTRAL EFFECT OF MONOAA/IINE 
PRECURSORS. 

229068 01-03 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 
BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

229462 01-03 
POSSIBLE INVOLVEMENT OF GABA IN THE CENTRAL ACTIONS OF 
BENZODIAZEPINES, 

229465 01-03 
NEUROLEPTICS AND ANTIDEPRESSANTS ON CENTRAL MONOAMINE 
NEURONS. 

229483 01-03 
OPPOSING RESPONSES IN SYMPATHETIC NERVE ACTIVITY INDUCED BY 
CENTRAL INJECTIONS OF OUABAIN. 

231006 01-03 
THE POSSIBLE INVOLVEMENT OF GABA MECHANISMS IN THE ACTION OF 
BENZODIAZEPINES ON CENTRAL CATECHOLAMINE NEURONS. 

232507 01 03 
EFFECTS OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC 

MECHANISMS. 

232508 01-03 
THE ROLE OF CENTRAL GLYCINE RECEPTORS IN THE PHARMACOLOGIC 

ACTIONS OF BENZODIAZEPINES. 

232511 01-03 
POSSIBLE INVOLVEMENT OF GABA IN THE CENTRAL ACTIONS OF 
BENZODIAZEPINES 

232515 01-03 
EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON TYROSINE-HYDROXYLASE 
ACTIVITY IN CENTRAL CATECHOLAMINERGIC NEURONS OF THE RAT. 

232624 02-03 
A NEUROPHYSIOLOGICAL STUDY ON THE CENTRAL ACTION OF 
PSYCHOTOMIMETICS {LSD-25, DOM AND KETAMINE). 

232703 02-04 
CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN 
MONOAMINES AND SOME BEHAVIORAL AND PHYSIOLOGICAL 
FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS. 

233962 02-03 
CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM 
PRECURSORS, ENZYME INHIBITORS, AND STUDIES OF CENTRAL 
DOPAMINE TURNOVER. 

233964 02-14 



EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER 
METABOLISM IN CENTRAL DOPAMINERGIC NEURONES. 

233971 02-03 
EFFECTS OF MOLINDONE ON CENTRAL DOPAMINERGIC NEURONAL 
ACTIVITY AND METABOLISM: SIMILARITY TO OTHER NEUROLEPTICS 

236519 02-03 
THE ROLE OF CENTRAL AND PERIPHERAL CHOLINORECEPTORS IN THE 
PROCESSES OF SHORT-TERM MEMORY. 

23671 1 02-04 
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE 
DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING 
NEURONS AND AXONS BY GLYOXYLIC-ACID INDUCED FLUORESCENCE: 
II. A DETAILED DESCRIPTION OF METHODOLOGY. (UNPUBLISHED 
PAPER). 

236875 02-06 
CENTRAL EFFECTS OF SCOPOLAMINE AND (-t- ) AMPHETAMINE ON 
LOCOMOTOR ACTIVITY: INTERACTION WITH STRAIN AND STRESS 
VARIABLES. 

237778 02-04 
ON THE DIRECT OR INDIRECT INFLUENCE OF APOMORPHINE ON CENTRAL 
SEROTONIN NEURONS. 

237785 02-03 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE: BIOCHEMICAL AND 

PHARAAACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE AS 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINE 
AND OTHER PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION). 

238077 02-03 
THE EFFECT OF CHRONIC CENTRAL ADRENERGIC DENERVATION ON 
LEARNING AND MEMORY OF AN AVERSIVE DISCRIMINATION TASK IN 
MICE: STUDIES WITH 6-HYDROXYDOPAMINE. (PH.D. DISSERTATION). 

238157 02-03 
EFFECTS OF DOPAMINE (DA) DERIVATIVES ON CENTRAL DOPAMINERGIC 
MECHANISMS. 

238700 03-03 
CENTRAL ACTION OF AMPHETAMINE-INDUCED MYDRIASIS IN THE DOG. 

238772 03-03 
CENTRAL DEPLETION OF NOREPINEPHRINE IN GUINEA-PIG; LACK OF 
EFFECT ON NOREPINEPHRINE SENSITIVE CYCLIC-AMP GENERATING 
SYSTEMS. 

238798 03-03 
A QUANTITATIVE COMPARISON OF RELATIONSHIPS BETWEEN PLASMA 
TESTOSTERONE (T) AND TWO CENTRAL FUNCTIONS: LH FEEDBACK 
AND SEX BEHAVIOR. 

238800 03-04 
CENTRAL ACTION OF NORMETANEPHRINE. EFFECT ON THE BEHAVIOR OF 
RATS. 

240240 03-03 
EFFECTS OF 6-HYDROXYDOPAMINE ON CENTRAL NORADRENALINE 
NEURONS DURING ONTOGENY, 

241196 03-03 
ANTINOCICEPTIVE ACTION OF QUIPAZINE: RELATION TO CENTRAL 
SEROTONERGIC RECEPTOR STIMULATION. 

241235 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: V. MISCELLANEOUS COMPOUNDS. SYNOPSIS OF THE 
ROLE OF CENTRAL NEUROTRANSMITTERS ON PGO WAVE ACTIVITY. 

241319 03-03 
SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES: 

1) 
ABNORMALITY IN CENTRAL NORADRENERGIC NEURONS IN 
SPONTANEOUSLY HYPERTENSIVE RATS. 

241360 03-03 
CENTRAL NERVOUS DEPRESSIVE ACTIONS OF NEUROTROPIN ON MICE 
AND RATS. 

241374 03-04 
BENZODIAZEPINES AND CENTRAL GLYCINE RECEPTORS. 

241921 03-03 
CF-25-397, DIDEHYDRO METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINE, A 
NEW CENTRAL DOPAMINE RECEPTOR AGONIST, 

241927 03-04 
ARE CENTRAL CHOLINERGIC PATHWAYS INVOLVED IN THE HABITUATION 
OF EXPLORATION AND DISTRACTION? 

241932 03-04 
ELECTROCONVULSIVE SHOCK INCREASES THE BEHAVIOURAL RESPONSES 
OF RATS TO BRAIN 5-HYDROXYTRYPTAMINE ACCUMULATION AND 
CENTRAL NERVOUS SYSTEM STIMULANT DRUGS, 

241979 03-04 
CENTRAL GAMMA-AMINOBUTYRIC-ACID RECEPTORS AND THE 

REGULATION OF 35 CYCLIC ADENOSINE MONOPHOSPHATE CONTENT 
IN RAT PITUITARY. (UNPUBLISHED PAPER). 

243041 04-03 
BENZODIAZEPINES AND CENTRAL GLYCINE RECEPTORS. 

243762 04-03 
D-AMPHETAMINE-INDUCED INHIBITION OF CENTRAL DOPAMINERGIC 
NEURONS: MEDIATION BY A STRIATO-NIGRAL FEEDBACK PATHWAY. 

243882 04-03 
CENTRAL ACTIONS OF HALLUCINOGENIC DRUGS. 

244071 04-12 



2 



s 

3I?» 

is 



S-63 



Subject Index 



Psychopharmacology Abstracts 



A STUDY OF THE CENTRAL EFFECTS OF SYMPATHOMIMETIC DRUGS: EEG 
AND BEHAVIOURAL INVESTIGATIONS ON CLONIDINE AND 
NAPHAZOLINE 

246148 04-04 
REVERSAL OF THE 6HYDR0XYD0PAMINE-INDUCED SUPPRESSION OF A 
CAR BY DRUGS FACILITATING CENTRAL CATECHOLAMINERGIC 
MECHANISMS. 

246818 04-04 
INVOLVEMENT OF CENTRAL DOPAMINE IN THE HYPERTHERMIA IN RATS 
PRODUCED BY D-AMPHETAMINE. 

246820 04-04 
DOSE-RELATED EFFECTS OF CENTRAL NORADRENALINE STIMULATION ON 
BEHAVIOURAL AROUSAL IN RATS. 

247206 04-04 
D-AMPHETAMINE AND L-AMPHETAMINE STEREOISOMERS-. COMPARATIVE 
POTENCIES IN AFFECTING THE FIRING OF CENTRAL DOPAMINERGIC 
AND NORADRENERGIC NEURONS, 

24721 1 04-03 
BRAIN 2-PHENYLETHYLAMINE AS A MAJOR MEDIATOR FOR THE 
CENTRAL ACTIONS OF AMPHETAMINE AND METHYLPHENIDATE. 

248162 04-01 
THE EFFECT OF MEPIPRAZOLE ON CENTRAL MONOAMINE NEURONS. 
EVIDENCE FOR INCREASED 5-HYDROXYTRYPTAMINE AND DOPAMINE 
RECEPTOR ACTIVITY. 

248288 04-03 
CHANGES IN THE ARTERIAL BLOOD-PRESSURE RESPONSES OF 
HYPERTENSIVE RATS TO SOME DRUGS ACTING ON THE CENTRAL 
SYMPATHETIC MECHANISMS. 

248551 04-03 
CARDIOVASCULAR EFFECTS OF CENTRAL MICROINJECTIONS OF 
APOMORPHINE IN CATS. 

249033 04-03 
TRICYCLIC ANTIDEPRESSANTS AND THE CENTRAL CHOLINERGIC 
MUSCARINIC RECEPTOR. 

249301 04-03 
EVIDENCE FOR 2-PHENYLETHYLAMINE (PEA) AS A MEDIATOR FOR THE 
CENTRAL STIMULANT AND ANTITREMORGENIC ACTIONS OF DELTA9- 
TETRAHYDROCANNABINOL (THC). 

249309 04-03 
CATECHOLAMINES AND 2-PHENYLETHYLAMINE (PEA) IN THE CENTRAL 
AND PERIPHERAL ACTIONS OF AMPHETAMINES. 

249311 04-03 
STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE 
RECEPTORS IN COMPARISON TO APOMORPHINE, ( + ) AMPHETAMINE 
AND L-DOPA. 

249419 04-04 
CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 
ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
MORPHINE HYPERTHERMIA IN THE RAT: AN ACTION ON THE CENTRAL 
THERMOSTATS. 

250078 04-03 
A COMPARISON BETWEEN A MELANOCYTE STIMULATING HORMONE 
INHIBITORY FACTOR (MIF-I) AND SUBSTANCES KNOWN TO ACTIVATE 
CENTRAL DOPAMINE RECEPTORS. 

250082 04-03 
CENTRAL DOPAMINERGIC NEURONS: EFFECTS OF ALTERATIONS IN 
IMPULSE FLOW ON THE ACCUMULATION OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085 04-03 
REVERSAL BY A CENTRAL ANTIACETYLCHOLINE DRUG OF PIMOZIDE- 
INDUCED INHIBITION OF MOUSE JUMPING IN AMPHETAMINE DOPA 
TREATED MICE 

250656 04-03 
ON THE IN VIVO AND IN VITRO ACTIONS OF FENFLURAMINE AND ITS 
DERIVATIVES ON CENTRAL MONOAMINE NEURONS, ESPECIALLY 5- 
HYDROXYTRYPTAMINE NEURONS, AND THEIR RELATION TO THE 
ANORECTIC ACTIVITY OF FENFLURAMINE. 

250937 04-03 
SOME EFFECTS OF FENFLURAMINE AND ITS DERIVATIVES ON THE 
CENTRAL CATECHOLAMINERGIC SYSTEMS OF MICE. 

250940 04-03 
INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL 
DOPAMINERGIC SYSTEMS: INVOLVEMENT OF GABA. 

251399 04-03 
PHARMACOLOGICAL EVIDENCE FOR THE CENTRAL SEROTONERGIC 
EFFECTS OF MONOMETHOXYAMPHETAMINES. 

253108 04-04 
CENTRAL-NERVOUS-SYSTEM 

A CENTRAL-NERVOUS-SYSTEM DEPRESSANT ANTIDEPRESSANT. 

227695 01-02 
AN INVESTIGATION INTO THE POSSIBILITY OF IRREVERSIBLE CENTRAL- 
NERVOUS-SYSTEM DAMAGE AS A RESULT OF LONG-TERM 
CHLORPROMAZINE MEDICATION, 

229169 01-15 
FUNCTIONAL SIGNIFICANCE OF CENTRAL-NERVOUS SYSTEM 

NOREPINEPHRINE AND DOPAMINE A PSYCHOPHARMACOLOGICAL 
STUDY. (PH.D. DISSERTATION). 

231437 01-04 



A COMPARISON OF THE POTENCIES OF A SERIES OF BARBITURATES AT 
THE NEUROMUSCULAR JUNCTION AND ON THE CENTRAL-NERVOUS- 
SYSTEM. 

233289 02-03 
INHIBITORY SYNAPSES IN THE CENTRAL-NERVOUS-SYSTEM AND THEIR 
PHARMACOLOGICAL RESPONSES. 

236368 02-07 
3H-DELTA9-TETRAHYDR0CANNABIN0L TISSUE AND SUBCELLULAR 
DISTRIBUTION IN THE CENTRAL-NERVOUS-SYSTEM AND TISSUE 
DISTRIBUTION IN PERIPHERAL ORGANS OF TOLERANT AND 
NONTOLERANT DOGS. 

237753 02-03 
DISTRIBUTION OF TYPE A AND B MONOAMINE-OXIDASE ACTIVITIES IN 
THE CENTRAL-NERVOUS-SYSTEM OF RAT AND CHICK. 

237923 02-03 
CENTRAL-NERVOUS-SYSTEM DEPRESSANTS. 13. S- 
TRIAZOLOBENZODIAZEPIN-5-ONES. 

238478 02-01 
EFFECTS OF POLYAMINES ON THE CENTRAL-NERVOUS-SYSTEM. 

242202 03-03 
EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON AN IDENTIFIED 5- 
HYDROXYTRYPTAMINE CONTAINING NEURONE IN THE CENTRAL- 
NERVOUS-SYSTEM OF THE SNAIL HELIX POMATIA. 

243799 04-03 
DOPAMINERGIC CHOLINERGIC INTERACTIONS IN THE CENTRAL-NERVOUS- 
SYSTEM: BIOCHEMICAL PHARMACOLOGICAL ASPECTS. 

244038 04-17 
BARBITAL ALTERATION OF CENTRAL-NERVOUS-SYSTEM SENSITIVITY TO 
HEXOBARBITAL IN THE RAT. 

244688 04-03 
THE ACTIONS OF SPERMIDINE AND SPERMINE ON THE CENTRAL- 
NERVOUS-SYSTEM. 

245596 04-05 
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM DEPRESSANT ACTIVITY OF 
SOME BICYCLIC AMIDES. 

248539 04-02 
CENTRAL-NERVOUS-SYSTEM ACTIVE 5-OXOHEXAHYDROCINNOLINES. 

248649 04-02 
INFLUENCE OF A PERIPHERAL MONOAMINE-OXIDASE INHIBITOR (MAOI) 
UPON THE CENTRAL-NERVOUS-SYSTEM LEVELS AND 
PHARMACOLOGICAL EFFECTS OF 2-PHENYLETHYLAMINE (PEA). 

249310 04-03 
MARIJUANA, ABSINTHE AND THE CENTRAL-NERVOUS-SYSTEM. 

249783 04-01 
SOME STUDIES OF BETA-RECEPTOR BLOCKING DRUGS ON THE CENTRAL- 
NERVOUS-SYSTEM IN MAN. 

251162 04-13 
DIFFERENT ALPHA-ADRENORECEPTORS IN THE CENTRAL-NERVOUS- 
SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF 
CLONIDINE AND RECEPTOR BLOCKING AGENTS. 

251226 04-02 
TOURETTES SYNDROME AND CENTRAL-NERVOUS-SYSTEM STIMULANTS. 

251962 04-11 
EFFECTS OF PRENATAL RESERPINE ADMINISTRATION ON DEVELOPMENT 
OF THE RAT ADRENAL MEDULLA AND CENTRAL-NERVOUS-SYSTEM. 

253110 04-03 
BETA-BLOCKERS AND THE CENTRAL-NERVOUS-SYSTEM. 

253529 04-17 
CENTRALLY 

STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 
EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT. 

230860 01-03 
INHIBITION OF CENTRALLY EVOKED PRESSOR RESPONSES BY DIAZEPAM: 
EVIDENCE FOR AN EXCLUSIVELY SUPRAMEDULLARY ACTION, 

231039 01-03 
TOLERANCE TO CENTRALLY ADMINISTERED PHENOBARBITAL, 

241346 03-03 
MEASUREMENTS OF BRAIN AMOBARBITAL CONCENTRATIONS IN RATS 
ANESTHETIZED AND OVERDOSED WITH AMOBARBITAL AND TREATED 
CENTRALLY WITH DIBUTYRYL-CYCLIC-AMP, 

248276 04-03 
INTER-GROUP AGGRESSION IN MICE: A NEW METHOD FOR TESTING THE 
EFFECTS OF CENTRALLY ACTIVE DRUGS. 

249668 04-04 
EFFECTS OF CENTRALLY ACTING DRUGS ON STRESS-INDUCED INCREASE 
OF CGMP IN MOUSE BRAIN. 

251416 04-03 

CENTURY 

THE TRANSMETHYLATION HYPOTHESIS: A QUARTER OF A CENTURY 
LATER 

235801 02- 15 
CERCOPITHECUS-AETHIOPS 

BEHAVIOURAL EFFECTS OF THYMOLEPTICS IN VERVET MONKEYS 
(CERCOPITHECUS-AETHIOPS). AETHIOPS) 

230869 01 04 



S-64 



LUME 14, SUBJECT INDEX 



Subject Index 



iBELLAR 

EVIDENCE FOR AN INVOLVEMENT OF GABA IN THE MEDIATION OF THE 
CEREBEUAR CGMP DECREASE AND THE ANTICONVULSANT ACTION OF 
DIAZEPAM. 

226857 01-03 
THE EFFECTS OF GABA, PICROTOXIN AND BICUCULLINE ON THE 
SPONTANEOUS BIOELECTRIC ACTIVITY OF CULTURED CEREBELLAR 
PURKINJE CELLS. 

232906 02-03 
CEREBELLAR ATAXIA DUE TO DIPHENYLHYDANTOIN ADMINISTRATION - 
CLINICAL AND PATHOLOGICAL STUDIES ON TWO CASES OF CHRONIC 
DIPHENYLHYDANTOIN INTOXICATION 

236696 02-15 
ANTAGONISTIC EFFECTS OF GABA AND BENZODIAZEPINES ON 
VESTIBULAR AND CEREBELLAR NEURONES. 

240523 03-03 
CEREBRAL AND CEREBELLAR NEUROCHEMICAL CHANGES AND 

BEHAVIORAL MANIFESTATIONS IN RATS CHRONICALLY EXPOSED TO 
MARIJUANA SMOKE. 

243181 04-04 
INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF 
NORADRENALINE FROM RAT CEREBELLAR CORTEX SLICES. 

248980 04-03 
INTERRELATIONSHIP BETWEEN CATECHOLAMINE STIMULATED 

FORMATION OF ADENOSINE 3,5 MONOPHOSPHATE IN CEREBELLAR 
SLICES AND INHIBITORY EFFECTS ON CEREBELLAR PURKINJE CELLS: 
ANTAGONISM BY NEUROLEPTIC COMPOUNDS. 

253109 04-03 
iBEUUM 

INCREASED TYROSINE-HYDROXYLASE ACTIVITY IN FRONTAL CORTEX 
AND CEREBELLUM AFTER RESERPINE. 

226935 01-03 
INVOLVEMENT OF GABA IN THE ACTION OF BENZODIAZEPINE - STUDIES 
ON RAT CEREBELLUM. 

229466 01-03 
EVIDENCE FOR INVOLVEMENT OF GABA IN THE ACTION OF 
BENZODIAZEPINES: STUDIES ON RAT CEREBELLUM. 

232514 01-03 
RELEASE OF PHOSPHODIESTERASE ACTIVATOR FROM PARTICULATE 
FRACTIONS OF CEREBELLUM AND STRIATUM BY PUTATIVE 
NEUROTRANSMITTERS. (UNPUBLISHED PAPER). 

236674 02-03 
BIOELECTRIC EFFECTS OF ISOPROTERENOL AND PROPRANOLOL ON NERVE 
CELLS IN EXPLANTS OF RAT CEREBELLUM. 

237880 02-03 
INHIBITORY ACTION OF NORADRENALINE AND CYCLIC-AMP IN EXPLANTS 
OF RAT CEREBELLUM. 

239836 03-03 
BETA-ADRENERGIC CONTROL OF CYCLIC AMP GENERATING SYSTEMS IN 
CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY 
DESTRUCTION OF INTERNEURONS. (UNPUBLISHED PAPER). 

240242 03-03 
INTERACTION BETWEEN POSSIBLE TRANSMITTERS AND 

BUTYROPHENONES APPLIED MICROELECTROPHORETICALLY IN THE 
CEREBELLUM AND BASAL GANGLIA OF THE CAT. 2ND REPORT: 
EFFECTS OF SOME PHENOTHIAZINES ON THE PURKINJE CELLS OF THE 
CEREBELLUM. 

241386 03-03 
IN VIVO REVERSAL OF THYROXINE INDUCTION OF DNA SYNTHESIS BY 
DIBUTYRYL-CYCLIC-AMP IN DEVELOPING RAT CEREBELLUM. 

243814 04-03 
DIAZEPAM AND CHLORDIAZEPOXIDE: POWERFUL GABA ANTAGONISTS IN 
EXPLANTS OF RAT CEREBELLUM 

244205 04-03 
EBRAl 

PIRACETAM IN A CASE OF ACUTE CEREBRAL HYPOXEMIA: CASUISTIC 
REPORT. 

229128 01-14 
FENMETRAZOLE (DH 524): EUPHORIANT CLASSIFIED BY CEREBRAL 
ELECTROMETRY. 

230781 01-14 
COCAINE AND AMPHETAMINE MODIFICATION OF CEREBRAL ENERGY 
METABOLISM IN VIVO, 

230834 01 03 
H3-P-CHL0R0AMPHETAMINE. CEREBRAL LEVELS AND DISTRIBUTION. 

232614 02-03 
THE EFFECTS OF DIMETHYLAMINOETHANOL (DEANOL) ON CEREBRAL 
CORTICAL NEURONS. 

232621 02 03 
THE EFFECT OF CHLORPROMAZINE ON CEREBRAL CIRCULATION. 

236234 02 03 
THE EFFECT OF CHRONIC SELF ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14 LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN 

237109 02-04 
EFFECTS OF DIPHENYLHYDANTOIN AND PHENOBARBITAL ON PROTEIN 
METABOLISM IN THE RAT CEREBRAL CORTEX. 

237243 02 03 



NORADRENERGIC SUBSENSITIVITY AND SUPERSENSITIVITY OF THE 
CEREBRAL CORTEX AFTER RESERPINE TREATMENT. 

237756 02-03 
ELECTROCONVULSIVE SHOCK RAISES PROSTAGLANDINS F IN RAT 
CEREBRAL CORTEX. 

237921 02-03 
DEPRESSION OF NEURONES IN THE RAT CEREBRAL CORTEX BY LEPTAZOL. 

237925 02-03 
CELLULAR LOCALIZATION AND KINESTIC PROPERTIES OF GAMMA- 
GLUTAMYL-TRANSPEPTIDASE IN RAT CEREBRAL CORTEX. 

238680 03-03 
EFFECT OF MONOAMINE-OXIDASE INHIBITORS ON RELEASE AND UPTAKE 
OF H3-N0REPINEPHRINE IN RAT CEREBRAL CORTEX IN VITRO. 

238689 03-03 
ACTION OF NEUROLEPTIC AGENTS ON HISTAMINE SENSITIVE ADENYLATE- 
CYCLASE IN RABBIT CEREBRAL CORTEX. 

239582 03-03 
EFFECTS OF ANTIANXIETY DRUGS ON CEREBRAL MONOAMINE 
TURNOVER. 

241392 03-03 
CEREBRAL AND CEREBELLAR NEUROCHEMICAL CHANGES AND 

BEHAVIORAL MANIFESTATIONS IN RATS CHRONICALLY EXPOSED TO 
MARIJUANA SMOKE. 

24318) 04-04 
CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04-03 
EFFECTS OF DRUGS ACTING ON CEREBRAL 5-HYDROXYTRYPTAMINE 
MECHANISMS ON DOPAMINE-DEPENDENT TURNING BEHAVIOUR IN 
MICE. 

243803 04-04 
RESPONSES OF NEURONES IN THE CEREBRAL CORTEX AND CAUDATE- 
NUCLEUS TO AMANTADINE, AMPHETAMINE AND DOPAMINE. 

243805 04-03 
DEMONSTRATION OF AN INVERSELY PROPORTIONAL RELATIONSHIP 
BETWEEN DOPAMINE AND SEROTONIN IN CERTAIN CEREBRAL 
STRUCTURES: NEUROCHEMICAL AND MORPHOLOGICAL ASPECTS. 

244638 04-03 
EFFECTS OF INTRAVENTRICULAR P CHLOROAMPHETAMINE AND ITS 
ANALOGUES ON CEREBRAL 5-HT. 

246151 04 03 
EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEG - DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE. 

246319 04 03 
AN ANALYSIS OF THE DRUGS ACTING ON CEREBRAL ENERGY 
METABOLISM. 

247012 04-03 
ROLE OF THE PROSTAGLANDINS IN THE REGULATION OF THE CEREBRAL 
BLOOD CIRCULATION. 

248552 04-03 
AMPHETAMINE: EVALUATION OF D-ISOMERS AND L-ISOMERS AS 

RELEASING AGENTS AND UPTAKE INHIBITORS FOR 3H-D0PAMINE AND 
3H-N0REPINEPHRINE IN SLICES OF RAT NEOSTRIATUM AND CEREBRAL 
CORTEX, 

248699 04-03 
ON THE SPECIFICITY OF HISTAMINE H2 RECEPTOR ANTAGONISTS IN THE 
RAT CEREBRAL CORTEX. 

248725 04-03 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14 LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

248961 04-03 
MORPHINE TOLERANCE AND DEPENDENCE IN NORADRENALINE 
NEURONES OF THE RAT CEREBRAL CORTEX. 

248979 04 03 
ACTION OF PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE 
CEREBRAL CORTEX AND LUNG FOLLOWING MICROWAVE 
IRRADIATION, 

249286 04-03 
STIMULATION BY MORPHINE OF ACETYLCHOLINE OUTPUT FROM THE 
CEREBRAL CORTEX OF SEPTAL RATS 

249664 04 03 
INHIBITION OF CEREBRAL PROTEIN SYNTHESIS PERFORMANCE AT 
DIFFERENT TIMES AFTER PASSIVE AVOIDANCE TRAINING 

250060 04 14 
LOCALIZATION OF DOPAMINE RECEPTORS IN THE RAT CEREBRAL 
CORTEX, 

250356 04-03 
EFFECTS OF ALPHA RECEPTOR BLOCKERS AND ANTIDEPRESSANT DRUGS 
ON THE PRESYNAPTIC ALPHA-RECEPTOR OF RAT CEREBRAL CORTEX 

251394 04 03 
ADRENERGIC RECEPTORS AND VASCULAR RESISTANCE IN CEREBRAL 
CIRCULATION OF THE CAT, 

251820 04 03 



09 

I 

es 

I 

o 



es 

w 

•pBi 



S-65 



Subject Index 



Psychopharmacology Abstract 



UPTAKE AND RELEASE OF NOREPINEPHRINE BY SLICES OF RAT CEREBRAL 
CORTEX: EFFECTS OF AGENTS WHICH INCREASE CYCLIC-AMP LEVELS^ 

251964 04-03 
THE INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES. 

25271 1 04-03 
THE INFLUENCE OF PYRITHIOXINE HYPERVENTILATION ASSOCIATION ON 
CSF LACTATE IN CEREBRAL INFARCTION PATIENTS. 

252713 04-11 
SEROTONIN ANTAGONISM IN ISOLATED CANINE CEREBRAL ARTERIES. 

252757 04-03 
THE UPTAKE OF LOW CONCENTRATIONS OF LITHIUM IONS INTO RAT 
CEREBRAL CORTEX SLICES AND ITS DEPENDENCE ON CATIONS. 

253411 04-03 
CEREBROSIDE 

DEVELOPMENT OF BRAIN CEREBROSIDES AND CEREBROSIDE SULFATE 
(SULFATIDE) IN OFFSPRING OF CONTROL RATS AND RATS 
CHRONICALLY TREATED WITH METHADONE. 

238723 0303 
CEREBROSIDES 

DEVELOPMENT OF BRAIN CEREBROSIDES AND CEREBROSIDE SULFATE 
(SULFATIDE) IN OFFSPRING OF CONTROL RATS AND RATS 
CHRONICALLY TREATED WITH METHADONE. 

238723 03-03 
CEREBROSPINAL 

EFFECT OF PERIPHERAL DECARBOXYLASE INHIBITION ON HVA AND 5- 
HIAA IN CEREBROSPINAL FLUID OF DEPRESSED PATIENTS, 

226915 01-09 
THE EFFECT OF LITHIUM TREATMENT ON MANIC SYMPTOMS AND 
LEVELS OF MONOAMINE METABOLITES IN CEREBROSPINAL FLUID OF 
MANIC DEPRESSIVE PATIENTS, 

230824 01-09 
EFFECT OF ECT AND IMIPRAMINE TREATMENT ON THE CONCENTRATION 
OF 5-HYDRGXYINDOLEACETIC-ACID (5-HIAA) AND HOMOVANILLIC- 
ACID (HVA) IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS. 

230827 01-09 
PROBENECID: DOSAGE, LEVELS IN PLASMA AND CEREBROSPINAL FLUID 
(CSF) AND INFLUENCE UPON CSF LEVELS OF HOMOVANILLIC-ACID 
(HVA) AND 5-HYDROXYINDOLEACETIC-ACID (5-HIAA) IN THE RABBIT. 

230877 01 06 
CYTOLOGIC STUDY OF CEREBROSPINAL FLUID IN CHRONIC PSYCHIATRIC 
PATIENTS TREATED WITH NEUROLEPTICS. 

230997 01-11 
GAMMA-HYDROXYBUTYRATE: CORRELATION OF SERUM AND 

CEREBROSPINAL FLUID LEVELS WITH ELECTROENCEPHALOGRAPHIC 
AND BEHAVIORAL EFFECTS. 

237826 02-03 
RELATIONSHIP BETWEEN SEROTONIN IN THE INTACT BRAIN AND 
RELEASE OF PROTEIN INTO THE PERFUSED CEREBROSPINAL FLUID 
COMPARTMENT OF CONSCIOUS AND ANESTHETIZED RABBITS. 

238681 03-03 
EFFECT OF CONVULSIONS AND ANTICONVULSIVE DRUGS ON 
CEREBROSPINAL FLUID CYCLIC-AMP IN RABBITS. 

239090 03-03 
CYCLIC ADENOSINE MONOPHOSPHATE IN CEREBROSPINAL FLUID: 
EFFECTS OF THEOPHYLLINE, L-DOPA AND A DOPAMINE RECEPTOR 
STIMULANT IN RATS. 

240447 03 03 
TRANSMITTER PRECURSORS AND METABOLITES IN HUAAAN 
VENTRICULAR CEREBROSPINAL FLUID. 

241210 03-13 
CYCLIC-AMP IN CEREBROSPINAL FLUID IN PATIENTS WITH AFFECTIVE 
ILLNESS: EFFECTS OF PROBENECID, ACTIVITY, AND PSYCHOTROPIC 
MEDICATIONS. (UNPUBLISHED PAPER 

243023 04-09 
ASSESSMENT OF CEREBROSPINAL FLUID LEVELS OF DOPAMINE 
METABOLITES BY GAS CHROMATOGRAPHY. 

245300 04-03 
THE EFFECT OF PROBENECID ON CATECHOLAMINE METABOLITES IN 
HUMAN CEREBROSPINAL FLUID ANALYZED BY MASS 
FRAGMENTOGRAPHY. 

248464 04-13 
METHAQUALONE IN HUMAN SERUM AND CEREBROSPINAL FLUID AFTER 
ORAL INTAKE 

250657 04-13 
CEREBROSPINAL FLUID LEVELS OF CHLORPROMAZINE AND ITS 
METABOLITES IN SCHIZOPHRENIA 

251119 04-08 
CEREBROVASCULAR 

THE OBJECTIVE MEASUREMENT OF MENTAL PERFORMANCE IN 
CEREBROVASCULAR DISEASE: A DOUBLE-BLIND CONTROLLED STUDY, 
USING A GRADED-RELEASE PREPARATION OF ISOXSUPRINE. 

250414 04- 11 
CERUIOPLASMIN 

THE INFLUENCE OF LITHIUM ON SERUM CERULOPLASMIN. 

237924 02-03 



CERVEAU 

EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVEAU ISOLE AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT. 

249307 04-1 
CERVICAL 

INDUCTION OF TYROSINE-HYDROXYLASE IN THE SUPERIOR CERVICAL 
GANGLIA OF RATS: OPPOSITE INFLUENCE OF MUSCARINIC AND 
NICOTINIC RECEPTOR AGONISTS. 

239977 03-1 
EFFECTS OF AXOTOMY ON THE TRANS-SYNAPTIC REGULATION OF 
ENZYME ACTIVITY IN ADULT RAT SUPERIOR CERVICAL GANGLIA. 

244200 04-1 
ELECTROPHORETIC APPLICATION OF LIGNOCAINE TO THE CERVICAL ARI 
FOR THE TREATMENT OF VEGETATIVE NEUROSES. 

244467 04- 
THE EFFECT OF ATROPINE UPON ACETYLCHOLINE RELEASE FROM CAT 
SUPERIOR CERVICAL GANGLIA AND RAT CORTICAL SLICES: 
MEASUREMENT BY A RADIOENZYMIC METHOD. 

248724 04-1 
CERVICIS 

FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCLE. 

248409 04-1 
CESIUM 

CESIUM ION: ANTAGONISM TO CHLORPROMAZINE AND L-DOPA 
PRODUCED BEHAVIOURAL DEPRESSION IN MICE. 

238318 02-1 
EVALUATION OF CESIUM CHLORIDE AS ANTIDEPRESSANT. 

238836 03-1 
CESSATION 

DOPAMINERGIC NEURONS - ALTERATION IN THE SENSITIVITY OF 
TYROSINE-HYDROXYLASE TO INHIBITION BY ENDOGENOUS DOPAMIN 
AFTER CESSATION OF IMPULSE FLOW. 

241295 03-1 
DOPAMINERGIC NEURONS - ALTERATION IN THE KINETIC PROPERTIES ( 

TYROSINE-HYDROXYLASE AFTER CESSATION OF IMPULSE FLOW. 

241296 03-1 
CF-25-397 

CF-25-397, DIDEHYDR0METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINE, 
NEW CENTRAL DOPAMINE RECEPTOR AGONIST. 

241927 03-1 
CGMP 

EVIDENCE FOR AN INVOLVEMENT OF GABA IN THE MEDIATION OF THE 
CEREBELLAR CGMP DECREASE AND THE ANTICONVULSANT ACTION C 
DIAZEPAM. 

226857 01-1 
ACCUMULATION OF CGMP IN STRIATUM OF RATS INJECTED WITH 
NARCOTIC ANALGESICS: ANTAGONISM BY NALTREXONE. 

250362 04-1 
EFFECTS OF CENTRALLY ACTING DRUGS ON STRESS-INDUCED INCREASE 
OF CGMP IN MOUSE BRAIN. 

251416 04-( 
CHAIN 

THE INFLUENCE OF NITROGEN, CHAIN AND RING SUBSTITUTION ON 
SOME PHYSIO-ORGANIC PROPERTIES AND ON BUCCAL ABSORPTION ( 
AMPHETAMINES. 

237981 02-( 
CHAMBER 

EFFECTS OF CHLORPROMAZINE ON THE VERTICAL CHAMBER SYNDROM 
IN RHESUS MONKEYS. 

247889 04-( 
CHANCES 

CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHAR/WACOLOGICAL METHODS. 

233681 02-( 
CHANGE 

INFLUENCE OF PSYCHOTROPIC DRUGS ON CHRONIC SCHIZOPHRENIC 
SYNDROMES - WITH SPECIAL EMPHASIS ON THE CHANGE IN CLINIC/ 
PROCESS WITH A RELATIVELY HIGH DOSAGE OF SPIROPERIDOL. 

229761 01-( 
INTRODUCTION TO THE SYMPOSIUM ON SYSTEMATIC STUDIES WITH 
PSYCHOACTIVE DRUGS - NEW METHODS IN THE ASSESSMENT OF 
CHANGE. 

235355 02-1 
DOES INCREASING STRESS CHANGE THE BEHAVIORAL ACTION OF 
MESCALINE FROM DISRUPTION TO FACILITATION?. 

237732 02-C 
CHANGE IN ETHANOL CONSUMPTION BY ALBINO RATS UNDER THE 
EFFECT OF NEUROLEPTICS AND TRANQUILIZERS. 

241987 03-C 
CHANGE OF THE HEARTRATE AND SLEEP-WAKEFULNESS CYCLE AFTER 
ISOPROTERENOL ADMINISTRATION IN WHITE RATS. 

244449 04-C 
EFFECTS OF DRUG STATE CHANGE ON DISCRIMINATION PERFORMANCE. 

244679 04-C 



S-66 



UME 14, SUBJECT INDEX 



Subject Index 



HE EFFECT OF SCOPOLAMINE ON THE STIMULUS CHANGE 
PHENOMENON. 

247863 04-04 
IGES 

(EHAVIORAL CHANGES IN 2-MONTH-OLD RATS FOLLOWING PRENATAL 
EXPOSURE TO ANTIBODIES AGAINST SYNAPTIC MEMBRANES. 

226)86 01-04 
lEUROCHEMICAL AND MORPHOLOGICAL CHANGES DURING THE 
DEVELOPMENT OF COBALT-INDUCED EPILEPSY IN THE RAT. 

226399 01-03 
LECTROENCEPHALOGRAPHIC AND BEHAVIORAL CHANGES ASSOCIATED 
WITH PAPAVERINE ADMINISTRATION IN HEALTHY GERIATRIC 
SUBJECTS. 

226478 01-11 
AARIJUANA PRODUCED CHANGES IN PAIN TOLERANCE. EXPERIENCED 
AND NONEXPERIENCED SUBJECTS 

226903 01-14 
kCUTE BEHAVIORAL CHANGES INDUCED IN THE RAT BY THE 
INTRACEREBROVENTRICULAR ADMINISTRATION OF THYROTROPIN- 
RELEASING FACTOR (TRF) AND SOMATOSTATIN 

227386 01-04 
:HANGES in the electroencephalogram and rem SLEEP TIME 
DURING MORPHINE ABSTINENCE IN PELLET IMPLANTED RATS. 

227701 01-03 
iAPID AND DISSOCIATED CHANGES IN SENSITIVITIES OF DIFFERENT 
DOPAMINE RECEPTORS IN MOUSE BRAIN. 

227996 01-03 
FFECTS OF HANDLING BEFORE CENTRAL 6-HYDROXYDOPAMINE 
TREATMENT ON SUBSEQUENT EMOTIONALITY AND NEUROCHEMICAL 
CHANGES IN RATS. 

228142 01-04 
AETHADONE-INDUCED BEHAVIORAL CHANGES: CIRCULAR MOVEMENTS, 
AGGRESSION, AND ELECTROPHYSIOLOGICAL ASPECTS. 

229286 01-04 
:HANGES IN IMIPRAMINE-INDUCED NORADRENALINE POTENTIATION BY 
VARYING ACTIVITY OF GASTRIC JUICE UNDER ORAL MEDICATION. 

229826 OM 3 
IXOTREMORINE AND ATROPINE-INDUCED CHANGES OF DOPAMINE 
METABOLISM IN THE RAT STRIATUM. 

230854 01-03 
:HANGES in EXCITABILITY OF THE HIPPOCAMPUS AFTER STIMULATION 
OF SEROTONERGIC SYSTEMS IN RABBITS OF DIFFERENT AGES. 

231119 01-04 
'ROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING. (UNPUBLISHED 
PAPER). 

231771 01-04 
\N ATTEMPT TO CORRELATE ANALGESIA TO CHANGES IN BRAIN 
NEUROMEDIATORS IN RATS. 

233336 02-03 
lEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF 
PSYCHOSIS. 

233965 02-03 
:HANGES in PERIPHERAL BLOOD DURING TREATMENT WITH SOME 
NEUROLEPTICS AND THYMOLEPTICS. 

234045 02-15 
ADAPTIVE CHANGES IN BEHAVIOR AFTER REPEATED ADMINISTRATION 
OF VARIOUS PSYCHOACTIVE DRUGS. 

234810 02-04 
:HANGES in ANTICOAGULANT TOLERANCE: I. INFLUENCE OF SEDATIVES 
AND PSYCHOPHARMACEUTICALS 

235336 02-15 
YCLIC EEG CHANGES IN SUBACUTE SPONGIFORM AND ANOXIC 
ENCEPHALOPATHY. 

235563 02-13 
HANGES IN SERUM TRYPTOPHAN AND ALBUMIN BINDING OF 
TRYPTOPHAN IN CHLORPROMAZINE TREATED CHRONIC 
SCHIZOPHRENICS ON WITHDRAWAL AND RESTORATION OF DRUG 
THERAPY. 

235629 02 08 
ILTRASTRUCTURAL CHANGES IN THE NEURAL LOBE OF THE RAT 
PITUITARY INDUCED BY RESERPINE TREATMENT. 

235649 02-03 
HANGES IN PSYCHOACTIVE DRUG USE AMONG ADULTS IN 
METROPOLITAN TORONTO - 1971-1974 

236046 02 1 7 
HOLINESTERASE ACTIVITY AND CONTENT OF ADENOSINE 
TRIPHOSPHATE IN DEPRESSED PATIENTS AND THEIR CHANGES UNDER 
THE INFLUENCE OF MONOCHLORIMIPRAMINE. 

236364 02-10 
HANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

237106 02-04 
FFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I, POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

237107 02 04 



PROGRESSIVE CHANGES IN BEHAVIOR AND SEIZURES FOLLOWING 
CHRONIC COCAINE ADMINISTRATION: RELATIONSHIP TO KINDLING 
AND PSYCHOSIS. (UNPUBLISHED PAPER) 

237169 02 04 
RAPID CHANGES IN RAT PINEAL BETA-ADRENERGIC RECEPTOR: 

ALTERATIONS IN 3H ALPRENOLOL BINDING AND ADENYLATE-CYCLASE. 
(UNPUBLISHED PAPER). 

237170 02-03 
CLONAZEPAM-INDUCED CHANGES IN 5 HYDROXYTRYPTAMINE (5-HT) 

METABOLISM IN ANIMALS AND MAN 

237977 02 13 
CHANGES IN THE SELF-STIMULATION BEHAVIOR BY INTRAVENTRICULAR 
INJECTION OF EPINEPHRINE, NOREPINEPHRINE, ISOPROTERENOL AND 
DOPAMINE. 

238566 02-04 
COMPARISON OF THYROID RELEASING HORMONE (TRH) AND 

AMPHETAMINE (AMP) ON CHANGES IN ACTIVITY LEVELS OF RATS 
FOLLOWING INJECTIONS INTO THE CAUDATE-NUCLEUS, SEPTUM, AND 
HYPOTHALAMUS. 

238744 03-04 
AGE-RELATED CHANGES OF LOCOMOTOR ACTIVITY AFTER 
AMPHETAMINE ADMINISTRATION. 

238845 03-04 
EFFECT OF LILLY-1 10140 AND METHYSERGID ON L-DOPA-INDUCED 
CHANGES IN LOCOMOTOR ACTIVITY (AAA) IN MICE. 

238847 03-04 
CHANGES IN SKIN POTENTIAL LEVEL DURING SLEEP IN PSYCHIATRIC 
PATIENTS. 

239058 03 1 4 
THE EFFECTS OF LITHIUM CARBONATE UPON SUBJECTIVE STATE 
CHANGES INDUCED BY SODIUM PENTOBARBITAL. 

240074 03 14 
CHANGES IN THE PHARMACODYNAMICS AND PHARMACOKINETICS OF 
PSYCHOLEPTIC DRUGS IN RADIATION SICKNESS. EFFECT OF X-RAY 
RADIATION ON PHARMACODYNAMIC ACTIVITY OF NITRAZEPAM IN 
ANIAAALS. 

240237 03-04 
CHANGES IN EXCITABILITY OF AMYGDALOID AND SEPTAL NUCLEI 
INDUCED BY MEDAZEPAM HYDROCHLORIDE. 

241232 03-03 
SPONTANEOUS AND GUANETHIDINE-INDUCED CHANGES OF REGIONAL 
MONOAMINE CONTENT AND MONOAMINE UPTAKE DURING 
POSTNATAL DEVELOPMENT OF THE RAT BRAIN 

241366 03-03 
CHANGES IN BRAINSTEM MONOAMINE NEURONS AFTER SURGICAL AND 
CHEMICAL DENERVATION OF THE OLFACTORY BULB (OB) IN RATS. 

241369 03-03 
CHANGES IN CARDIOVASCULAR RESPONSES TO BRAIN STIMULATION 
FOLLOWING OLFACTORY BULBECTOMY AND THE EFFECTS OF 
PSYCHOTROPIC DRUGS IN RATS. 

241389 03-03 
DRUG-INDUCED CHANGES IN BODY TEMPERATURE AND 5- 

HYDROXYTRYPTAMINE (5-HT) TURNOVER RATE IN THE RAT BRAIN. 

241395 03-03 
BLOCKADE OF THE ELECTROCORTICAL CHANGES INDUCED BY PERFUSION 
OF AMPHETAMINE IN THE BRAINSTEM RETICULAR FORMATION. 

241930 03-03 
EFFECT OF AMPHETAMINE AND GUTIMIN ON ADAPTIVE CHANGES IN 
ARTERIAL PRESSURE ARISING IN RESPONSE TO CONTRACTION OF THE 
SKELETAL MUSCLES. 

241988 03 03 
HISTOTOPOGRAPHY OF THE CHANGES IN ENZYME ACTIVITY IN THE RAT 

BRAIN UNDER THE EFFECT OF FLUOROPHENAZINE, 

241989 03-03 
CHANGES IN THE PERSONALITY FUNCTIONING OF PSYCHOTICS WITH 

NEUROLEPTIC TREATMENT 

242868 04 11 
CEREBRAL AND CEREBELLAR NEUROCHEMICAL CHANGES AND 

BEHAVIORAL MANIFESTATIONS IN RATS CHRONICALLY EXPOSED TO 
MARIJUANA SMOKE. 

243181 04 04 
CHARACTERISTIC CHANGES IN CONDITIONED DEFENSIVE REFLEXES 
CAUSED BY TRIFLUOPERAZINE, CARBAMAZEPINE AND 
CHLORPROMAZINE. 

244352 04-04 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VIVO 
CHANGES OF 3.5 CYCLIC AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE, 

244514 04-03 
INTRAVENOUS L-DOPA PLUS CARBIDOPA IN DEPRESSED PATIENTS, 

AVERAGE EVOKED RESPONSE, LEARNING, AND BEHAVIORAL CHANGES 

244664 04 09 
HYPOTHALAMIC CHEMOSTIMULATION AND AUTONOMIC CHANGES IN 
CURARIZED RATS 

244691 04 03 
BLOOD-PRESSURE AND PULSE CHANGES IN HYPERACTIVE CHILDREN 
TREATED WITH IMIPRAMINE AND METHYLPHENIDATE, 

244932 04 15 



s 

« 







S 



S-67 



Subject Index 



Psychopharmacology Abstra< 



DRUG INDUCED CHANGES IN BEHAVIOUR AND GANGLIONIC 
ACETYLCHOLINE CONCENTRATION OF THE LEECH. 

245595 04-03 
SELECTIVE FIELD POTENTIAL CHANGES INDUCED BY L-DOPA. 

246145 04-03 
BEHAVIOURAL CHANGES IN LABORATORY MICE DURING CANNABIS 
FEEDING AND WITHDRAWAL. 

246310 04-04 
ELECTROPHYSIOLOGICAL EVIDENCE FOR A NEUROHORMONAL 

DEPENDENCE IN THE CHANGES OF THE LATE GLABELLAR RESPONSE IN 
MAN. 

246992 04-13 
ARE BEHAVIORAL AND PSYCHOMETRIC CHANGES RELATED IN 
METHYLPHENIDATE TREATED, HYPERACTIVE CHILDREN?. 

247382 04-14 
ORGANIC MENTAL CHANGES WITH FLUOROURACIL THERAPY. 

247978 04-15 
CHANGES IN THE ARTERIAL BLOOD-PRESSURE RESPONSES OF 

HYPERTENSIVE RATS TO SOME DRUGS ACTING ON THE CENTRAL 
SYMPATHETIC MECHANISMS. 

248551 04-03 
DEPENDENCE ON AGE OF METHAMPHETAMINE PRODUCED CHANGES IN 
THERMOREGULATION AND METABOLISM. 

248951 04-03 
CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

248959 04-04 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE 

248960 04-02 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 

ADMINISTRATION: RELATIONSHIP TO KINDLING. 

249005 04-04 
THE EFFECT OF AMPHETAMINE PRETREATMENT ON THE AMPHETAMINE- 
INDUCED CHANGES IN MOTOR ACTIVITY AND BRAIN 
CATECHOLAMINES IN MICE. 

249274 04-04 
CHANGES IN SENSITIVITY OF MORPHINE-INDUCED CIRCLING BEHAVIOUR 
AFTER CHRONIC TREATMENT AND PERSISTENCE AFTER WITHDRAWAL 
IN RATS. 

249485 04-04 
CHANGES IN SENSITIVITY TO APOMORPHINE DURING MORPHINE- 
DEPENDENCE AND WITHDRAWAL IN RATS. 

250114 04-03 
CHANGES OF SKIN NERVE SYMPATHETIC ACTIVITY DURING INDUCTION 
OF GENERAL ANESTHESIA WITH THIOPENTONE IN MAN. 

251071 04-12 
CHANGES IN BRAIN CATECHOLAMINE TURNOVER DURING PRECIPITATED 
MORPHINE WITHDRAWAL IN THE RAT. 

251400 04-03 
LACK OF CORRELATION BETWEEN CHANGES IN CYvILIC NUCLEOTIDES 
AND SUBSEQUENT INDUCTION OF TYROSINE-HYDROXYLASE IN RAT 
ADRENAL MEDULLA. 

251434 04-03 
CHANGING 

CHANGING PATTERNS IN THE MANAGEMENT OF DEPRESSION. 

243863 04-09 
CHARACTER 

STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAMAZEPINE 
IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 2- 
18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 
WITH BEHAVIOR AND CHARACTER. 

244958 04-11 
CHARACTERISTIC 

CHARACTERISTIC CHANGES IN CONDITIONED DEFENSIVE REFLEXES 
CAUSED BY TRIFLUOPERAZINE, CARBAMAZEPINE AND 
CHLORPROMAZINE 

244352 04-04 
CHARACTERISTICS 

CHARACTERISTICS OF TYROSINE HYDROXYLATION IN ISOLATED NERVE 
ENDINGS 

237244 02-03 
CHARACTERISTICS OF BEHAVIOR CONTROLLED BY SCHEDULED 
INJECIIONS OF DRUGS 

240010 03-04 
FURTHER EVIDENCE FOR CHOLINERGIC HABENULOINTERPEDUNCULAR 
NEURONS: PHARMACOLOGIC AND FUNCTIONAL CHARACTERISTICS. 

249074 04-03 
CHARACTERISTICS OF NARCOTIC DEPENDENCE PRODUCED BY ORAL 
INGESTION OF FENTANYL SOLUTIONS IN RATS. 

249289 04-04 
USES OF DOUBLE-PULSE STIMULATION BEHAVIORALLY TO INFER 

REFRACTORINESS. SUMMATION, CONVERGENCE, AND TRANSMITTER 
CHARACTERISTICS OF HYPOTHALAMIC REWARD SYSTEMS 

250278 04-03 
( ORREl ATION BETWEEN DISSOLUTION CHARACTERISTICS AND 
ABSORPTION OF METHAQUALONE FROM SOLID DOSAGE FORMS. 

250332 04-06 



THE MAIN PHARMACOLOGICAL CHARACTERISTICS OF GRANDAXIN 
(TOFIZOPAM, EGYT-341). 

252445 04 
CHARACTERIZATION 

CHARACTERIZATION OF HYDROGEN BONDING BETWEEN SELECTED 
BARBITURATES AND POLYETHYLENE-GLYC0L-400O BY IR SPECTRAL 
ANALYSIS. 

233276 02 
PHARMACOLOGICAL CHARACTERIZATION OF LITHIUM REABSORPTION 
THE RAT. 

237759 Oi 
PSYCHOPHARMACOLOGICAL CHARACTERIZATION OF A DRUG-INDUCEI 
GROOMING BEHAVIOR IN THE CRICKET, ACHETA-DOMESTICUS 
(INSECTA, ORTHOPTERA). (PH.D. DISSERTATION). 

241994 O; 
CHARACTERIZATION OF THREE MONOHYDROXYACID AND TWO 

DIHYDROXYACID METABOLITES OF DELTAl-TETRAHYDROCANNABIN 
IN MOUSE LIVER. 

243787 0^ 
DETERMINATION AND CHARACTERIZATION OF THE ANTINOCICEPTIVE 
ACTIVITY OF INTRAVENTRICULARLY ADMINISTERED ACETYLCHOLIN 
IN MICE. 

246852 0' 
CHARACTERIZATION OF EEG EFFECTS PRODUCED BY THE INTERACTIOI 
OF SECOBARBITAL WITH PSYCHOMOTOR STIMULANTS USING 
SPECTRAL ANALYSIS TECHNIQUES. 

249251 0' 
RESOLUTION, PURIFICATION AND CHARACTERIZATION OF RABBIT 
SERUM ATROPINESTERASE AND COCAINESTERASE. 

251180 0- 

CHARTS 

COMPENDIUM OF PHARMACOLOGY DRUG CHARTS. 

249768 0. 
CHE 

CHOLINESTERASE (CHE) INHIBITION AND SYNAPTOSOMAL 

ACETYLCHOLINE (ACH) SYNTHESIS AND RELEASE FOLLOWING IN VI' 
PARAOXON (PX) ADMINISTRATION. 

249295 0. 

CHECKS 

CYCLANDELATE CHECKS MENTAL DECAY: AGED PATIENTS IQ AND 
MEMORY PRESERVED WITH USE OF VASODILATOR. 

247022 a 
CHEMICAL 

5-HYDR0XYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE B' 
FUNDAL SARCOLEMMA PREPARATIONS: EFFECT OF THERMAL AND 
CHEMICAL ALTERATIONS AS INDIRECT APPROACH TO THE PROBLEM 
OF THE COMMON RECEPTOR. 

226827 
HANDBOOK OF DRUG AND CHEMICAL STIMULATION OF THE BRAIN: 
BEHAVIORAL, PHARMACOLOGICAL AND PHYSIOLOGICAL ASPECTS. 

227382 
CHLORPROAAAZINE EXCRETION: ISOTOPE VERSUS CHEMICAL ASSAY. 

229481 
COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 

232483 
CHEMISTOR: A REUSABLE TELESTIMULATION DEVICE FOR DIRECT 
CHEMICAL STIMULATION OF THE NONHUMAN PRIMATE BRAIN IN 
FREELY MOVING ANIMALS. 

237270 
CANNABINOID PATTERN IN CANNABIS-SATIVA L. SEEDLINGS AS AN 
INDICATION OF CHEMICAL RACE 

237982 a 
PIGMENTATION AND THE CHEMICAL BASIS OF SCHIZOPHRENIA. 

239001 

CHANGES IN BRAINSTEM MONOAMINE NEURONS AFTER SURGICAL A 

CHEMICAL DENERVATION OF THE OLFACTORY BULB (OB) IN RATS. 

241369 
THERAPEUTIC USEFULNESS OF HALLUCINOGENIC DRUGS AS A FUNCTI 
OF THEIR CHEMICAL STRUCTURE. 

241428 
THE CHEMICAL CONTROL OF NEURONAL ACTIVITY. (UNPUBLISHED 
PAPER) 

243183 
EFFECTS OF CHEMICAL STIMULATION OF THE MESOLIMBIC DOPAMIN 
SYSTEM UPON LOCOMOTOR ACTIVITY. 

248285 
CONTROLLED CLINICAL TRIAL OF A NEW ANTIDEPRESSANT (ORG-GB-5 
OF NOVEL CHEMICAL FORMULATION. 

248977 a 
CORRELATIONS BETWEEN THE ACTIVITY OF DIMETHYLTRYPTAMINES 
5-HYDROXYTRYPTAMINE ANTAGONISTS AND THEIR QUANTUM 
CHEMICAL PARAMETERS. 

249318 
FOR SENILE DEMENTIA: CHEMICAL CORRECTION?. 

249351 



S-68 



)LUME 14, SUBJECT INDEX 



Subject Index 



RAT DATA WHICH SUGGEST ALCOHOLIC BEVERAGES SHOULD BE 
SWALLOWED DURING CHEMICAL AVERSION THERAPY, NOT JUST 
TASTED. 

252859 04-17 
MICALLY 

EVIDENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
MOTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS. 

241203 03-03 
PSYCHOTOGENIC DRUG ACTION ON CHEMICALLY DEFINED NEURONS. 

244072 04-03 
MICALS 

INFLUENCE OF DRUGS AND CHEMICALS UPON HEPATIC ENZYMES AND 
PROTEINS - I. STRUCTURE-ACTIVITY RELATIONSHIP BETWEEN 
VARIOUS BARBITURATES AND MICROSOMAL ENZYME INDUCTION IN 
RAT LIVER. 

241297 03-03 
MISTOR 

CHEMISTOR: A REUSABLE TELESTIMULATION DEVICE FOR DIRECT 
CHEMICAL STIMULATION OF THE NONHUAAAN PRIMATE BRAIN IN 
FREELY MOVING ANIMALS. 

237270 02-06 
MISTRY 
THE CHEMISTRY OF REWARD AND RELATED BEHAVIORS. 

229475 01-04 
CHEMISTRY AND PHARMACOLOGY OF BIOGENIC AMINE UPTAKE. 

229478 01-03 
CHEMISTRY OF DOPAMINE RECEPTORS. 

230600 01-03 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: I, GLUTAMIC-ACID AND GABA IN BRAIN REGIONS. 

237098 02-03 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: II. INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

237105 02-04 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 
AND BEHAVIOR: II. INTRACRANIAL SELF-STIMULATION BEHAVIOR. 

248956 04-04 
EFFECT OF LITHIUM AND OTHER ALKALI METALS ON BRAIN CHEMISTRY 

AND BEHAVIOR: I. GLUTAMIC-ACID AND GABA IN BRAIN REGIONS. 

248957 04-03 
CHEMISTRY AND PHARMACOLOGY OF DIV-I54, A NEW POTENTIAL 

NONTRICYCLIC ANTIDEPRESSANT COMPOUND. 

251407 04-17 
MOSENSORY 

ULTRASENSITIVE CHEMOSENSORY RESPONSES BY A PROTOZOAN TO 
EPINEPHRINE AND OTHER NEUROCHEMICALS. 

248163 04-02 
MOSTIMULATION 

HYPOTHALAMIC CHEMOSTIMULATION AND AUTONOMIC CHANGES IN 
CURARIZED RATS. 

244691 04-03 
MOTHERAPY 

AN EXPERIMENTAL THERAPY AND RE-EDUCATION PROGRAM FOR 
ALCOHOLICS INCLUDING CHEMOTHERAPY WITH PROPRANOLOL 
HYDROCHLORIDE. (PH.D. DISSERTATION). 

228750 01-11 
INTRATHECAL CHEMOTHERAPY: BRAIN TISSUE PROFILES AFTER 
VENTRICULOCISTERNAL PERFUSION. 

231002 01-03 

:k 

ontogeny of behavioral sensitivity to strychnine in the chick 
embryo: evidence for the early onset of cns inhibition. 

228630 01-04 
EFFECTS OF DIAZEPAM ON THE ISOLATED CHICK EMBRYO HEART. 

230862 01-03 
CHICK PHASIC BIOELECTRIC ACTIVITY AT THE TIME OF HATCHING AND 
THE EFFECTS OF PREVIOUS NIALAMIDE INJECTION. 

235317 02-04 
RETROGRADE ENHANCEMENT OF MEMORY BY MILD FLUROTHYL 
TREATMENT IN THE CHICK. 

237260 02-04 
DISTRIBUTION OF TYPE A AND B MONOAMINE-OXIDASE ACTIVITIES IN 
THE CENTRAL-NERVOUS-SYSTEM OF RAT AND CHICK. 

237923 02-03 
PHARMACOLOGICAL STIMULATION OF THE PINEAL: POTENTIATION OF 
KETAMINE RESPONSE IN THE CHICK. 

238795 03-03 
EFFECTS OF TESTOSTERONE ON THE BEHAVIOUR OF THE DOMESTIC 
CHICK. I. EFFECTS PRESENT IN MALES BUT NOT IN FEMALES. 

245712 04-04 
EFFECTS OF TESTOSTERONE ON THE BEHAVIOUR OF THE DOMESTIC 

CHICK. II. EFFECTS PRESENT IN BOTH SEXES. 

245713 04-04 
FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCLE. 

248409 04-03 



DIURNAL ACTION OF KETAMINE IN THE YOUNG CHICK: INFLUENCE BY 
PINEAL METABOLITES. 

249240 04-03 
CHICKS 

INVOLVEMENT OF BIOGENIC AMINES IN DRUG-INDUCED AGGRESSIVE 
PECKING IN CHICKS 

230878 01-04 
RETROACTIVE AND PROACTIVE EFFECTS OF ANESTHESIA ON FOLLOWING 
IN CHICKS. 

241330 03-04 
CHILD 

SLEEP AND ITS DISTURBANCES IN THE CHILD: CONTRIBUTIONS OF 
ELECTROPHYSIOLOGY. 

228091 01-11 
RECENT ADVANCES IN CHILD PSYCHOPHARMACOLOGY. 

229053 01-11 
IS LITHIUM USEFUL IN CHILD PSYCHIATRY?. 

229081 01-14 
THE LEARNING DISABLED OR HYPERACTIVE CHILD: DIAGNOSIS AND 
TREATMENT. 

2335)3 02-17 
SUCCESS WITH LITHIUM IN A DISTURBED CHILD. 

236118 02-11 
DRUG THERAPY IN CHILD CARE, 

243897 04-15 
ASSESSMENT OF DIAZEPAM AFTER THREE YEARS USE IN CHILD 
PSYCHIATRY. 

249144 04-11 
CHILDHOOD 

COMPUTERIZED ELECTROENCEPHALOGRAM: A MODEL OF 

UNDERSTANDING THE BRAIN FUNCTION IN CHILDHOOD PSYCHOSIS 
AND ITS TREATMENT. 

232635 02-11 
ON THE DIFFERENTIAL DIAGNOSIS OF ACUTE EXTRAPYRAMIDAL MOTOR 
DISTURBANCES IN CHILDHOOD: CASUISTIC ACCOUNT. 

234291 02-11 
PRESENT ASPECTS OF PSYCHOPHARMACOTHERAPY IN CHILDHOOD AND 
ADOLESCENCE. 

236150 02-17 
BEHAVIOR DISORDERS IN CHILDHOOD AND THEIR TREATMENT. 

24071 1 03 II 
SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE CHILDHOOD 
EPILEPSY. 

245344 04- 11 
UNWANTED CORTICOSTEROID EFFECTS IN CHILDHOOD BONE MARROW 
FAILURE, RENAL FAILURE AND BRAIN DAMAGE: CASE REPORT. 

245856 04 13 
THE NATURAL HISTORY OF HYPERACTIVITY IN CHILDHOOD AND 

TREATMENT WITH STIMULANT MEDICATION AT DIFFERENT AGES: A 
SUMMARY OF RESEARCH FINDINGS. 

247384 04-14 
PSYCHOPHARMACOLOGY IN CHILDHOOD PSYCHOSIS. 

247386 04 17 
APPROACH TO A COMBINED PHARMACOLOGIC THERAPY OF CHILDHOOD 
HYPERKINESIS, 

249772 04 11 
CHILDREN 

DRUGS IN THE MANAGEMENT OF LEARNING AND BEHAVIOR DISORDERS 
IN SCHOOL CHILDREN, 

225783 0M4 
HYPERACTIVITY IN CHILDREN. 

226069 01 14 
SULPIRIDE IN DEPRESSIVE SCHOOL PHOBIC CHILDREN. 

227141 01-10 
COGNITIVE EFFECTS OF METHYLPHENIDATE ON HYPERACTIVE CHILDREN 
(PH.D. DISSERTATION). 

228431 01-11 
THE USE OF CLONAZEPAM IN TREATING CONVULSIVE MANIFESTATIONS 
WITH ENCEPHALOPATHY IN CHILDREN: STUDY OF 28 CASES. 

229083 01-11 
THE INFLUENCES OF METHYLPHENIDATE ON HEARTRATE AND 

BEHAVIORAL MEASURES OF ATTENTION IN HYPERACTIVE CHILDREN. 

231629 01-14 
THE DYSTONIC HYPERKINETIC SYNDROME: A CASUISTICAL 

CONTRIBUTION TO THE UNDERSTANDING OF THE ACTIONS OF DRUGS 
IN CHILDREN. 

233717 02- II 
COMPARISON OF SERUM LEVELS AND URINARY EXCRETION OF THREE 
MAJOR ANTICONVULSANTS BETWEEN CHILDREN AND ADULTS. 

233832 02-13 
INDIVIDUAL RESPONSES TO METHYLPHENIDATE AND CAFFEINE IN 
CHILDREN WITH MINIMAL-BRAIN-DYSFUNCTION, 

235322 02-11 
THE USE OF MEGAVITAMIN TREATMENT IN CHILDREN WITH LEARNING 
DISABILITIES. 

235676 02-11 
DEPRESSIVE STATE AND DIMENSIONS OF THE MAN ON GOODENOUGHS 
DRAW-A-MAN TEST IN CHILDREN. 

235998 02-10 



00 
SO 

S 
S 

cs 





i 



SIS 



S-69 



Subject Index 

PSYCHOSIS FOLLOWING INGESTION OF HEMP IN CHILDREN. 

237730 02- 15 
THE USE AND MISUSE OF PSYCHOTROPIC DRUGS IN CHILDREN. 

240522 03-17 
EFFECTS OF METHYLPHFNIDATE ON UNDERACHIEVING CHILDREN. 

240538 03-11 
NON MEDICATION MANAGEMENT OF HYPERKINETIC CHILDREN IN THE 
CLASSROOM. (PHD DISSERTATION) 

240977 03-11 
A TEST OF THE STATE-DEPENDENT LEARNING EFFECTS OF 
METHYLPHENIDATE IN HYPERACTIVE CHILDREN. (PH.D. 
DISSERTATION). 

241133 03-14 
KINETICS OF CARBAMAZEPINE AND ITS 10.1 1 EPOXIDE METABOLITE IN 
CHILDREN. 

243086 04-13 
BLOOD PRESSURE AND PULSE CHANGES IN HYPERACTIVE CHILDREN 
TREATED WITH IMIPRAMINE AND METHYLPHENIDATE 

244932 04-15 
STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAMAZEPINE 
IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 2- 
18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 
V>/ITH BEHAVIOR AND CHARA.CTER. 

244958 04-11 
IMIPRAMINE DOSAGE IN CHILDREN: A COMMENT ON IMIPRAMINE AND 
ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE 
CHILDREN. 

245001 04-14 
METHYLPHENIDATE AND CAFFEINE IN THE TREATMENT OF CHILDREN 
WITH MINIMAL BRAIN-DYSFUNCTION. 

245786 04-14 
OSTEOMALACIA ASSOCIATED WITH ANTICONVULSANT DRUG THERAPY 
IN MENTALLY RETARDED CHILDREN. 

245806 04-15 
PLASMA LEVELS OF DIAZEPAM AFTER PARENTERAL AND RECTAL 
ADMINISTRATION IN CHILDREN 

246891 04 11 
DRUGS HELP. BUT WONT CURE. MOST HYPERACTIVE CHILDREN. 

247143 04 17 
CONTROLLED TRIAL OF METHYLPHENIDATE IN PRESCHOOL CHILDREN 
WITH MINIMAL BRAIN-DYSFUNCTION. 

247375 04 11 
WHAT IS THE PROPER DOSE OF STIMULANT DRUGS IN CHILDREN''. 

247376 04-17 
SIDE EFFECTS FROM lONG TERM USE OF STIMULANTS IN CHILDREN. 

247377 04-15 
METHYLPHENIDATE IN CHILDREN: EFFECTS UPON CARDIORESPIRATORY 

FUNCTION ON EXERTION 

247378 04 15 
A PLACEBO CROSSOVER STUDY OF CAFFEINE TREATMENT OF 

HYPERKINETIC CHILDREN 

247379 04-14 
CLINICAL EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE IN 

HYPERACTIVE CHILDREN 

247380 04-14 
CLINICAL PHARMACOLOGICAL MANAGE/ViENT OF HYPERKINETIC 

CHILDREN. 

247381 04 17 

ARE BEHAVIORAL AND PSYCHOMETRIC CHANGES RELATED IN 
METHYLPHENIDATE TREATED, HYPERACTIVE CHILDREN''. 

247382 04-14 
LEVODOPA AND LEVOAMPHETAMINE A CROSSOVER STUDY IN YOUNG 

SCHIZOPHRENIC CHILDREN. 

247480 04-08 
CONNERS TEACHER RATING SCALE FOR USE IN DRUG STUDIES WITH 
CHILDREN AN EMPIRICAL STUDY 

248593 04 11 
HYPFRACTIVITY IN CHIIDREN 

250931 04-14 
IHE FFFECTS OF METHYLPHENIDATE ON THE SOFT NEUROLOGICAL SIGNS 
OF HYPERACTIVE CHIIDREN 

251569 04 14 
PHENYTOIN INDUCED DYSTONIA AND CHOREOATHETOSIS IN TWO 
RETARDED EPILEPTIC CHILDREN 

251654 04 15 
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON ATTENTIONAL AND 
PERCEPTUAL FUNCTIONS OF CHILDREN WITH EPIIEPSY 

251949 04 II 
ACCIDENTAL POISONING WITH PSYCHOTROPIC DRUGS IN CHILDREN. 

252656 04 15 
METHODOLOGY USED IN ASSESSING METHYLPHENIDATE AND CAFFEINE 
TREATMENT OF MINIMAL BRAIN DYSFUNCTIONING CHILDREN 

252798 04-11 
HIE fFFFCTS OF LONG TERM STIMULANT MEDICATION ON GROWTH AND 
BODY COMPOSITION OF HYPERACTIVE CHILDREN 

253041 04 15 



Psychopharmacology Abstra 



CHIMPANZEE 

CONTRASTING EFFECTS OF MORPHINE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN THE CHIMPANZEE AND BABOON. 

246854 
CHIORAZEPATE 

CLINICAL AND PHYSIOLOGICAL ASSESSMENT OF CHLORAZEPATE, 
DIAZEPAM AND PLACEBO IN ANXIOUS NEUROTICS. 

231036 
CHLORDIAZEPOXIDE 

CHLOROIAZEPOXIDE METABOLISM IN MICE FOLLOWING HEPATIC 
IRRADIATION. 

226840 
THE DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND OXAZEPAM 
HOSTILITY IN A SWIALL GROUP SETTING. 

227569 C 
ANXIETY IN SCHIZOPHRENIA: THE RESPONSES TO CHLOROIAZEPOXID 
AN INTENSIVE DESIGN STUDY. 

228221 C 
EFFECTS OF D-AMPHETAMINE, CHLORPROMAZINE, AND 

CHLORDIAZEPOXIDE ON INTERCURRENT BEHAVIOR DURING SPACE 
RESPONDING SCHEDULES. 

229639 C 
EFFECT OF TWO WEEKS TREATMENT WITH CHLORDIAZEPOXIDE OR 
FLUPENTHIXOL, ALONE OR IN COMBINATION WITH ALCOHOL, ON 
PSYCHOMOTOR SKILLS RELATED TO DRIVING. 

229907 ( 
A CONTROLLED TRIAL OF CHLORMETHIAZOLE AND CHLORDIAZEPOXI 
IN THE TREATMENT OF THE ACUTE WITHDRAWAL PHASE OF 
ALCOHOLISM. 

230104 ( 

CHLORDIAZEPOXIDE AND ISOLATION INDUCED TIMIDITY IN RATS. 

230828 ( 
RESPONSE SUPPRESSION IN RATS: A COMPARISON OF RESPONSE 
CONTINGENT AND NONCONTINGENT PUNISHMENT AND THE EFFEC 
THE MINOR TRANQUILLIZER, CHLORDIAZEPOXIDE. 

230831 ( 
CHLORDIAZEPOXIDE AND DIAZEPAM-INDUCED MOUSE-KILLING BY R 

230838 I 
INFLUENCE OF MAGNESIUM AND ALUMINUM HYDROXIDE MIXTURE 
CHLORDIAZEPOXIDE ABSORPTION. 

237116 1 
SERUM CREATINE-PHOSPHOKINASE CONCENTRATIONS AFTER 
INTRAMUSCULAR CHLORDIAZEPOXIDE AND ITS SOLVENT. 

237928 I 
COMPARISON BETWEEN CHRONIC CHLORDIAZEPOXIDE TREATMENT , 
SHOCK REMOVAL IN A CONFLICT SITUATION IN RATS. 

239979 I 
TWENTY-FOUR-HOUR RETENTION OF CHLORDIAZEPOXIDE (LIBRIUM) 
ATTENUATED THREAT BEHAVIOR IN MALE SIAMESE FIGHTING FIS 
(BETTASPLENDENS). 

242892 I 
DIAZEPAM AND CHLORDIAZEPOXIDE: POWERFUL GABA ANTAGONIS 
EXPLANTS OF RAT CEREBELLUM. 

244205 
RETROACTIVE IMPAIRMENT OF COOPERATIVE LEARNING BY IMIPRAi 
AND CHLORDIAZEPOXIDE IN RATS. 

245301 
CAFFEINE AND CHLORDIAZEPOXIDE: EFFECTS ON MOTOR ACTIVITY I 
THE CHRONIC THALAMIC RAT. 

246388 
INTERACTING EFFECTS OF AMYGDALA LESIONS WITH 

CHLORDIAZEPOXIDE AND PILOCARPINE ON MOUSE-KILLING BY R/ 

248394 
EFFECTS OF CHLORDIAZEPOXIDE, CNS STIMULANTS AND THEIR 
COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE. 

249026 
EFFECTS OF ALCOHOL, CHLORDIAZEPOXIDE, COCAINE, AND 
PENTOBARBITAL ON RESPONDING MAINTAINED UNDER FIXED- 
INTERVAL SCHEDULES OF FOOD OR SHOCK PRESENTATION. 

2501 1 1 
SCHEDULE-DEPENDENT EFFECTS OF CHLORDIAZEPOXIDE ON OPERAN 

BEHAVIOR IN RATS. 

251670 

CHLORHYDRATE 

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF A NEW 
ANTIDEPRESSANT AGENT, MELYLAMINOPROPYLDIBENZOBICYCLOI 
ADIENE CHLORHYDRATE (CIBA-34276-BA). 

247554 

CHLORIDE 

THE USE OF BETHANECHOL CHLORIDE WITH TRICYCLIC 
ANTIDEPRESSANTS. 

EVALUATION OF CESIUM CHLORIDE AS ANTIDEPRESSANT. 

EFFECT OF LITHIUM CHLORIDE ON LIPID METABOLISM. 

241986 
THE EFFECT OF LITHIUM CHLORIDE ON ONE-TRIAL PASSIVE AVOIDA 
LEARNING IN RATS 

243804 



232864 
238836 



S-70 



>LUME 14, SUBJECT INDEX 



Subject Index 



POTENTIATING EFFECT OF LITHIUM CHLORIDE ON AGGRESSIVE 

BEHAVIOUR INDUCED IN MICE BY NIALAMIDE PLUS L-DOPA AND BY 
CLONIDINE 

246664 0404 
EFFECTS OF LITHIUM CHLORIDE ON PARAMETERS OF BIOSYNTHETIC 
CAPACITY FOR 5-HYDROXYTRYPTAMINE IN RAT BRAIN. 

246849 0403 
THE EFFECT OF LITHIUM CHLORIDE ON ONE-TRIAL PASSIVE AVOIDANCE 
LEARNING IN RATS. 

249381 04-04 
LITHIUM OROTATE, CARBONATE AND CHLORIDE: PHARMACOKINETICS, 
POLYDIPSIA AND POLYURIA IN RATS. 

252198 04-03 
ORIMIPRAMINE 

EFFECTS OF CHLORIMIPRAMINE AND LYSERGIC-ACID-DIETHYLAMIDE ON 
EFFLUX OF PRECURSOR FORMED 3H-SER0T0NIN: CORRELATIONS WITH 
SEROTONERGIC IMPULSE FLOW. 

246846 04-03 
ORMETHIAZOLE 

A CONTROLLED TRIAL OF CHLORMETHIAZOLE AND CHLORDIAZEPOXIDE 
IN THE TREATMENT OF THE ACUTE WITHDRAWAL PHASE OF 
ALCOHOLISM. 

230104 01-11 
ORPROMAZINE 

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE 
SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG 
SURVEILLANCE PROGRAM. 

225722 01-15 
A CONTROLLED TRIAL OF CLOTHIAPINE AND CHLORPROAAAZINE IN 
ACUTE SCHIZOPHRENIC SYNDROMES. 

226412 C1-08 
INHIBITION OF 4,ALPHA DIMETHYL-M TYRAMINE H77-77 INDUCED 

HYPERMOBILITY IN RATS BY SINGLE AND REPEATED ADMINISTRATION 
OF CHLORPROAAAZINE HALOPERIDOL, CLOZAPINE AND THIORIDAZINE. 

227129 01-04 
COMPARISON OF EFFICACY OF LITHIUM CARBONATE AND 

CHLORPROMAZINE IN MANIA: REPORT OF COLLABORATIVE STUDY 
GROUP ON TREATMENT OF MANIA IN JAPAN. 

228226 01-09 
THE ACTION OF CHLORPROMAZINE ON THE PERMEABILITY OF THE BRAIN 
AND LIVER LYSOSOMES OF RATS IN A STATE OF HYPOXIA. 

228548 01-03 
THE EFFECT OF CHRONIC INJECTIONS OF CHLORPROMAZINE ON 
OOGENESIS AND PROGENY DEVELOPMENT IN ALBINO MICE. 

228554 01-05 
AN INVESTIGATION INTO THE POSSIBILITY OF IRREVERSIBLE CENTRAL- 
NERVOUS-SYSTEM DAMAGE AS A RESULT OF LONG-TERM 
CHLORPROMAZINE MEDICATION. 

229169 01-15 
AN ATTEMPT TO ESTABLISH QUALITY CONTROL IN DETERMINATION OF 
PLASMA CHLORPROMAZINE BY A MULTILABORATORY 
COLLABORATION. 

229439 01-16 
A PRELIMINARY REPORT ON CLINICAL RESPONSE AND BLOOD LEVELS OF 
CHLORPROMAZINE AND ITS SULFOXIDE DURING CHLORPROMAZINE 
THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS. 

229444 01-08 
CHLORPROMAZINE METABOLISM AND CLINICAL RESPONSE IN ACUTE 

SCHIZOPHRENIA: A PRELIMINARY REPORT. 

229445 01-08 
CHLORPROMAZINE EXCRETION: ISOTOPE VERSUS CHEMICAL ASSAY. 

229481 01-03 
PLASMA CHLORPROMAZINE IN PSYCHIATRIC MANAGEMENT. 

229492 01-13 
EFFECTS OF D-AMPHETAMINE, CHLORPROMAZINE, AND 
CHLORDIAZEPOXIDE ON INTERCURRENT BEHAVIOR DURING SPACED 
RESPONDING SCHEDULES. 

229639 01 04 
CHLORPROMAZINE EFFECTS ON BRAIN ACTIVITY (CONTINGENT NEGATIVE 
VARIATION) AND REACTION TIME IN NORMAL WOMEN. 

230863 01-14 
MODIFICATION OF THE BEHAVIORAL RESPONSE TO DRUGS IN RATS 

EXPOSED PRENATALLY TO CHLORPROMAZINE. 

230864 01-04 
DISTRIBUTION OF CHLORPROMAZINE IN THE GASTROINTESTINAL TRACT 

OF THE RAT AND ITS EFFECT ON ABSORPTIVE FUNCTION. 

230918 01-03 
PHARMACOLOGICAL RESPONSE DATA FOR COMPARATIVE 
BIOAVAILABILITY STUDIES OF CHLORPROMAZINE ORAL DOSAGE 
FORMS IN HUMANS: I. PUPILOMETRY. 

232623 02-13 
ANTINUCLEAR ANTIBODIES IN CHRONIC PSYCHOTIC PATIENTS TREATED 
WITH CHLORPROMAZINE 

232865 02-15 
COMPARISON OF THE THERAPEUTIC EFFECT OF CLOZAPINE AND 
CHLORPROMAZINE. 

234420 02-14 



THE IMMEDIATE EFFECTS OF CHLORPROMAZINE IN NEWLY ADMITTED 
SCHIZOPHRENIC PATIENTS 

234700 02-08 
EFFECTS OF TESTING AGE AND FOSTERING EXPERIENCE ON SEIZURE 
SUSCEPTIBILITY OF RATS TREATED PRENATALLY WITH 
CHLORPROMAZINE. 

234739 02-04 
A COMPARATIVE STUDY OF THIOTHIXENE AND CHLORPROMAZINE IN 
CHRONIC SCHIZOPHRENIC PATIENTS: APPLICATION OF SPECIAL 
PSYCHOMETRIC TEST BATTERY. 

235366 02-08 
CHANGES IN SERUM TRYPTOPHAN AND ALBUMIN BINDING OF 
TRYPTOPHAN IN CHLORPROMAZINE TREATED CHRONIC 
SCHIZOPHRENICS ON WITHDRAWAL AND RESTORATION OF DRUG 
THERAPY. 

235629 02-08 
THE EFFECT OF CHLORPROMAZINE ON CEREBRAL CIRCULATION. 

236234 02-03 
EFFECT OF CHLORPROMAZINE ON THE REACTION OF BLAST 
TRANSFORMATION OF LYMPHOCYTES. 

236373 02-03 
CORRELATION OF CHLORPROAAAZINE LEVELS IN RAT BRAIN AND SERUM 
WITH ITS HYPOTHERMIC EFFECT. 

236527 02-03 
THE ACTION OF CHLORPROMAZINE, TRIFLUOPERAZINE AND DROPERIDOL 
ON THE CAPTURE AND ACCUMULATION OF EXOGENOUS 
NOREPINEPHRINE. 

236713 02-03 
COOMBS-POSITIVE HEMOLYTIC ANEMIA PROVOKED BY 
CHLORPROMAZINE 

237161 02-15 
MECHANISMS OF QUINIDINE AND CHLORPROMAZINE INHIBITION OF 
SARCOTUBULAR ATPASE ACTIVITY. 

237245 02-03 
GAS CHROMATOGRAPHIC SEPARATION OF CHLORPROMAZINE, 
DIAZEPAM AND N-DESMETHYLDIAZEPAM 

237750 02-06 
BIOAVAILABILITY ANALYSIS OF CHLORPROMAZINE IN HUMANS FROM 
PUPILOMETRIC DATA. 

237872 02-13 
EFFECTS OF METHAMPHETAMINE AND CHLORPROMAZINE ON NIGRAL 
AND STRIATAL TYROSINE HYDROXYLASE ACTIVITY AND ON STRIATAL 
DOPAMINE LEVELS. (PH.D. DISSERTATION). 

2380/9 02-03 
CESIUM ION: ANTAGONISM TO CHLORPROMAZINE AND L DOPA 
PRODUCED BEHAVIOURAL DEPRESSION IN MICE 

238318 02-04 
DIFFERENTIAL BLOCKADE OF ALPHA ADRENERGIC RECEPTORS BY 
CHLORPROMAZINE. 

238672 03-03 
RESPONSES OF NORMAL AND ISOLATE MONKEYS TO D AMPHETAMINE, 
COCAINE, CHLORPROMAZINE AND DIAZEPAM. 

238694 03-04 
INTERACTION OF TRIHEXYPHENIDYL AND CHLORPROMAZINE: PROBABLE 
MECHANISM 

238732 03-03 
THE EFFECTS OF INTRACRANIAL ADMINISTRATION OF NOREPINEPHRINE 
AND INTRAPERITONEAL CHLORPROMAZINE ON ATTENTION IN THE 
RAT. 

238755 03-04 
IMPROVED ASSAYS OF CHLORPROMAZINE AND ITS METABOLITES. 

238818 03-01 
CHLORPROMAZINE AND HORMONAL ELEVATION OF CYCLIC AMP 
CONTENTS IN TURKEY ERYTHROCYTES AND PERFUSED RAT HEART 
AND LIVER. 

239044 03-03 
ENCEPHALOPATHY SUBSEQUENT TO ACCIDENTAL POISONING WITH 
CHLORPROMAZINE, 

239089 03-05 
INFLUENCE OF SECOBARBITAL AND CHLORPROMAZINE ON PRECENTRAL 
NEURON ACTIVITY DURING ATTENTIVE BEHAVIOR IN MONKEYS 

239848 03 04 
THE ACTION OF CHLORPROMAZINE ON THE ELECTRODERMAL RESPONSE 
IN THE CAT. 

239963 03-03 
DEPOSITS IN THE LENS AND CORNEA OF THE EYE DURING LONG-TERM 
CHLORPROMAZINE MEDICATION 

240048 03-15 
EFFECTS OF CHLORPROMAZINE ON FEAR MOTIVATED BEHAVIOR 
URINARY CORTISOL, URINARY VOLUME. AND HEARTRATE IN THE 
DOG 

240916 03-04 
EFFECTS OF PERIMETAZINE AND CHLORPROMAZINE ON THE 
TRANSCALLOSAL RESPONSE IN RABBITS 

241385 03-03 
MODIFICATIONS OF EFFECTS OF CHLORPROMAZINE ON ADRENERGIC 
DRUGS AND BARBITURATES BY REPEATED ADMINISTRATION TO RATS. 

241406 03-03 






a''-' 
1 



as 



S-71 



Subject Index 



Psychopharmacology Abstr 



COMPARISON TRIAL OF TWO ANTirCVrHOTir DRUGS: 
CHLORPROMAZINE AND CLOZAPINE 

241760 03-08 
IMPAIRED ABSORPTION OF CHLORPROMAZINE IN RATS GIVEN 
TRIHEXYPHENIDYL. 

241920 0303 
THE LEVEL OF THE GROWTH HORMONE PROLACTIN AND INSULIN IN THE 
COURSE OF THE ACUTE ADMINISTRATION OF CHLORPROMAZINE 
(PLEGOMAZIN) IN MENTAL PATIENTS. 

242863 04-15 
EFFECT OF BENZOPYRENE AND CHLORPROMAZINE ON ARYL 
HYDROCARBON HYDROXYLASE ACTIVITY FROM RAT TISSUES. 

243793 04-03 
URINARY EXCRETION OF METABOLITES OF CHLORPROMAZINE: CLINICO- 
CHEMICAL CORRELATIONS. 

244050 04-08 
CHARACTERISTIC CHANGES IN CONDITIONED DEFENSIVE REFLEXES 
CAUSED BY TRIFLUOPERAZINE, CARBAMAZEPINE AND 
CHLORPROMAZINE 

244352 04-04 
IDENTIFICATION AND QUANTIFICATION OF CHLORPROMAZINE AND ITS 
METABOLITES IN ACUTE EXPERIMENTAL INTOXICATION. 

244462 04-06 
EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE ON OBSERVING 
RESPONSES DURING A FIXED-INTERVAL SCHEDULE. 

245303 04-04 
EFFECT OF CHLORPROMAZINE ON THE INTERACTION BETWEEN PHASIC 
AND TONIC ELECTROCORTICAL AROUSAL MECHANISMS. 

246311 04-03 
PREDICTION OF RESPONSE TO CHLORPROMAZINE TREATMENT IN 
SCHIZOPHRENICS 

246314 04-08 
EFFECT OF TWO WEEKS TREATMENT WITH THIORIDAZINE, 

CHLORPROMAZINE, SULPIRIDE AND BROMAZEPAM, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY IN MAN. 
« 246315 04-14 

EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEG - DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE. 

246319 04-03 
BINDING OF CHLORPROMAZINE AND IMIPRAMINE TO RED CELLS, 
ALBUMIN, LIPOPROTEINS AND OTHER BLOOD COMPONENTS. 

247129 04-03 
THE EFFECT OF VARIOUS CHLORPROAAAZINE DERIVATIVES ON THE 
APOMORPHINE-ELICITED INHIBITION OF SYNAPTOSOMAL TYROSINE- 
HYDROXYLASE ACTIVITY. 

247212 04-03 
CHLORPROMAZINE, CATECHOLAMINES AND AGING IN MICE. 

247587 04-02 
ENHANCEMENT BY CHLORPROMAZINE OF HYPERGYLCEMIC ACTION OF 
DIAZOXIDE. 

247715 04 15 
EFFECTS OF CHLORPROMAZINE ON THE VERTICAL CHAMBER SYNDROME 
IN RHESUS MONKEYS. 

247889 04-04 
INFLUENCE OF CHLORPROMAZINE ON THE POSITIVE AND NEGATIVE 
FEEDBACK MECHANISM OF ESTROGENS IN MAN. 

248224 04-13 
ACETYLCHOLINE SYNTHESIS IN RAT BRAIN: DISSIMILAR EFFECTS OF 
CLOZAPINE AND CHLORPROMAZINE 

248600 04-03 
NATURE OF NEW CLASS OF CHLORPROMAZINE (CPZ) METABOLITES IN 
PRIMATE URINES. 

249328 04-01 
RELATIONSHIP BETWEEN THE BEHAVIORAL AND 

ELECTROENCEPHALOGRAPHIC EFFECTS OF CHLORPROMAZINE AND 
FLUPHENAZINE IN RATS 

249623 04-02 
EFFECTS OF CHLORPROMAZINE ON AVOIDANCE AND ESCAPE 
RESPONDING IN HUMANS. 

250076 04 14 
INTERFERENCE BETWEEN ANTI-HLA ANTIBODIES AND CHLORPROMAZINE. 

250476 04-07 
CEREBROSPINAL FLUID LEVELS OF CHLORPROMAZINE AND ITS 
METABOLITES IN SCHIZOPHRENIA. 

251119 04-08 
CHLORPROMAZINE METABOLISM VII: NEW QUANTITATIVE 

FLUOROMETRIC DETERMINATION OF CHLORPROMAZINE AND ITS 
SULFOXIDE. 

251777 04-06 
CHLORPROMAZINE METABOLISM VIII: BLOOD LEVELS OF 

CHLORPROMAZINE AND ITS SULFOXIDE IN SCHIZOPHRENIC PATIENTS 

251778 04-16 
ACUTE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE 

ACQUISITION OF SHUTTLEBOX CONDITIONED AVOIDANCE RESPONSE. 

251989 04-04 
MUSCARINIC CHOLINERGIC RECEPTOR BINDING: INFLUENCE OF PIMOZIDE 
AND CHLORPROMAZINE METABOLITES. 

252515 04-05 



CHIORPROAAAZINE-INDUCED 

CHLORPROMAZINE-INDUCED ELECTROCARDIOGRAM ABNORMALITIE 

231037 
FURTHER STUDIES ON THE CHLORPROAAAZINE-INDUCED PROLONGA: 
OF THE DISAPPEARANCE OF MESCALINE FROM MOUSE TISSUES. 

235670 
EFFECTS OF HYPOTHYROIDISM AND HYPERTHYROIDISM ON 5- 
HYDROXYTRYPTOPHAN AND CHLORPROMAZINE-INDUCED PROLA( 
RELEASE IN THE RAT. 

243951 
CHLORPROTHIXENE 

PLASMA LEVELS OF CHLORPROTHIXENE IN ALCOHOLICS. 

226413 
CLINICAL PHYSIOGNOMY OF CHLORPROTHIXENE AND CLOPENTIXOL 

227766 
CHOICE 

DISCRETE TRIAL CHOICE PROCEDURE: EFFECTS OF NALOXONE AND 
METHADONE ON CHOICE BETWEEN FOOD AND HEROIN. 

240014 
CHOLECYSTOKININ 

CHOLECYSTOKININ ELICITS THE COMPLETE BEHAVIORAL SEQUENCE 
SATIETY IN RATS. 

245612 
CHOLERA 

BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFEC 
CHOLERA TOXIN. 

252034 
CHOLINE 

HIGH AFFINITY CHOLINE UPTAKE: AN EARLY INDEX OF CHOLINERGh 
INNERVATION IN RAT BRAIN. 

226739 
DICHLORVOS AND THE CHOLINERGIC SYSTEM: EFFECTS ON 

CHOLINESTERASE AND ACETYLCHOLINE AND CHOLINE CONTENTS 
RAT TISSUES. 

230451 
THE EFFECT OF DELTA9-THC ON HIGH AND LOW AFFINITY UPTAKE ( 
CHOLINE AND ITS RELATIONSHIP TO TURNOVER OF ACETYLCHOLI 
MOUSE BRAIN. 

238765 

6-HYDROXYDOPAMINE (6-OHDA) ADMINISTRATION TO NEONATAL fi 

FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASI 

(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC-ACID- 

DECARBOXYLASE (GAD) IN THE CNS. 

238826 
SOME PHARMACOLOGICAL PROPERTIES OF CYCLOCHOLINE, A REAC 
ANALOG OF CHOLINE. 

238828 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN 
FOLLOWING HEAD FOCUSED MICROWAVE SACRIFICE: EFFECT OF 
AMPHETAMINE AND ( i OR-) P CHLOROAMPHETAMINE. 

239976 
EFFECTS OF N-HYDROXYETHYL-PYRROLIDINIUM METHIODIDE, A CHC 
ANALOGUE, ON PASSIVE AVOIDANCE BEHAVIOUR IN MICE. 

245594 
STEADY-STATE CONCENTRATIONS OF CHOLINE AND ACETYLCHOLINf 
RAT BRAIN PARTS DURING A CONSTANT RATE INFUSION OF 
DEUTERATED CHOLINE. 

247146 
EFFECT OF NOMIFENSINE ON ACETYLCHOLINE AND CHOLINE IN THE 
STRIATUM AND BRAINSTEM 

248291 
ELEVATION OF AMPHETAMINE LEVELS IN RAT BRAIN AFTER 
ADMINISTRATION OF THE CHOLINE ACETYLTRANSFERASE INHIBIT 
1-NAPHTHYLVINYLPYRIDINE (NVP). 

249027 
EFFECT OF LABELLED ACETYLCHOLINE (ACCH) UPTAKE BY RAT BRAL 
SLICES ON ENDOGENOUS LEVELS OF ACCH AND CHOLINE (CH). 

249298 
EFFECT OF D-AMPHETAMINE AND D,L P-CHLOROAMPHETAMINE ON 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAI 

249300 
SODIUM DEPENDENT HIGH AFFINITY CHOLINE UPTAKE AS A 
REGULATORY STEP IN ACETYLCHOLINE SYNTHESIS. 

249303 
CHOLINE ACETYLTRANSFERASE ACTIVITY INCREASES IN THE BRAINS 
OF RATS TREATED AT BIRTH WITH 6-HYDROXYDOPA. 

249666 
CHOLINE FOR TARDIVE-DYSKINESIA. 

25041 7 i 
EFFECT OF OXOTREMORINE ON ENDOGENOUS ACETYLCHOLINE AND I 
UPTAKE AND BIOTRANSFORMATION OF RADIOACTIVE CHOLINE IN 
DISCRETE REGIONS OF MOUSE BRAIN IN VIVO. 

251175 1 
EFFECTS OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 3-CHL0R( 
STILBAZOLE ON BRAIN ACETYLCHOLINE METABOLISM. 

251181 ( 



S-72 



VOLUME 14, SUBJECT INDEX 



:houne-oeficient 

effects of a choline-deficient diet on the induction of drug 
and ethanol metabolizing enzymes and on the alteration of 
rates of ethanol degradation by ethanol and 
phenobarbital. 

247032 04-03 
HOLINERGIC 

CHOLINERGIC BLOCKADE, SEPTAL LESIONS, AND DRL PERFORMANCE IN 
THE RAT. 

226305 01-04 
HIGH AFFINITY CHOLINE UPTAKE: AN EARLY INDEX OF CHOLINERGIC 
INNERVATION IN RAT BRAIN. 

226739 01-03 
BIOCHEMICAL IDENTIFICATION OF THE MAMMALIAN MUSCARINIC 
CHOLINERGIC RECEPTOR. 

227400 01-03 
DOPAMINERGIC AND CHOLINERGIC INFLUENCES ON MORPHINE SELF- 
ADMINISTRATION IN RATS. 

227703 01-04 
SYNTHESIS, RELEASE AND DISTRIBUTION OF ACETYLCHOLINE IN THE 
BRAIN OF RATS UNDER THE INFLUENCE OF CHOLINERGIC AGENTS 

228550 01-03 
DRUGS, BEHAVIOR, AND THE CHOLINERGIC NERVOUS SYSTEM. 

229485 01-04 
DICHLORVOS AND THE CHOLINERGIC SYSTEM; EFFECTS ON 
CHOLINESTERASE AND ACETYLCHOLINE AND CHOLINE CONTENTS OF 
RAT TISSUES. 

230451 01-03 
CHOLINERGIC MODULATION OF TONIC IMMOBILITY IN THE RABBIT 
(ORYCTOLAGUS-CUNICULUS). 

231701 01-03 
ACTION OF THE BENZODIAZEPINES ON THE CHOLINERGIC SYSTEM. 

232510 01-03 
CHOLINERGIC MEDIATION OF INSTRUMENTAL AND CONSUMMATORY 
BEHAVIORS. 

233448 02-04 
METHYLPHENIDATE AS A CHOLINERGIC AGONIST: FURTHER 
OBSERVATIONS. 

238708 03-03 
CHOLINERGIC MEDIATION OF THE INHIBITORY EFFECT OF 

METHYLPHENIDATE ON NEURONAL ACTIVITY IN THE RETICULAR 
FORMATION. 

239086 0303 
ALTERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS AFTER CHRONIC HALOPERIDOL: INDIRECT EVIDENCE FOR 
CHOLINERGIC HYPOSENSITIVITY. 

239826 03-04 
EFFECTS OF CHOLINERGIC DRUGS ON ABNORMAL SOCIAL BEHAVIOR IN 
THE RHESUS MONKEY. (PH.D. DISSERTATION). 

241109 03-04 
EFFECTS OF CHOLINERGIC DRUGS ON 5-HYDROXYTRYPTAMINE (5-HT) 
TURNOVER RATE IN THE RAT BRAIN. 

241396 03-03 
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS 4TH 
REPORT. COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
CHOLINERGIC MODIFICATION OF DRL PERFORMANCE IN NORMAL RATS 
AND RATS WITH LESIONS OF THE SEPTUM. (PH.D. DISSERTATION). 

241681 03-04 
ARE CENTRAL CHOLINERGIC PATHWAYS INVOLVED IN THE HABITUATION 
OF EXPLORATION AND DISTRACTION?. 

241932 0304 
DOPAMINERGIC CHOLINERGIC INTERACTIONS IN THE CENTRAL-NERVOUS- 
SYSTEM: BIOCHEMICAL PHARMACOLOGICAL ASPECTS. 

244038 04-17 
TIME-DEPENDENT VARIATIONS IN AVERSIVELY MOTIVATED BEHAVIORS 
NONASSOCIATIVE EFFECTS OF CHOLINERGIC AND 
CATECHOLAMINERGIC ACTIVITY, 

245486 04-04 
THE EFFECTS OF CHRONIC GANGLION BLOCKADE AND CHRONIC 
CHOLINESTERASE INHIBITION ON THE SENSITIVITY OF RABBIT 
STOMACH MUSCULARIS TO CHOLINERGIC AND ADRENERGIC 
AGONISTS. 

246842 04-03 
FURTHER EVIDENCE FOR CHOLINERGIC HABENULO-INTERPEDUNCULAR 
NEURONS: PHARMACOLOGIC AND FUNCTIONAL CHARACTERISTICS. 

249074 04-03 
TRICYCLIC ANTIDEPRESSANTS AND THE CENTRAL CHOLINERGIC 
MUSCARINIC RECEPTOR. 

249301 04-03 

MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE INFLUENCE OF 
CHOLINERGIC AGONISTS AND ANTAGONISTS. 

250079 04-04 
POSTNATAL DEVELOPMENT OF DOPAMINERGIC AND CHOLINERGIC 
CATALEPSY IN THE RAT, 

250084 04-03 



Subject Index 

INTERACTION OF ATROPINE OR METHYLATROPINIUM WITH FOUR 
EFFECTS OF TWO CHOLINERGIC DRUGS. 

251217 04-03 
MODIFICATION OF CONDITIONED AVOIDANCE AND TURNING BEHAVIOUR 
BY BACLOFEN AND ITS INFLUENCE ON CHOLINERGIC DOPAMINERGIC 
NERVOUS SYSTEM. 

251397 04-03 
MUSCARINIC CHOLINERGIC RECEPTOR BINDING: INFLUENCE OF PIMOZIDE 
AND CHLORPROMAZINE METABOLITES. 

252515 04-05 
CHOLINESTERASE 

DICHLORVOS AND THE CHOLINERGIC SYSTEM: EFFECTS ON 
CHOLINESTERASE AND ACETYLCHOLINE AND CHOLINE CONTENTS OF 
RAT TISSUES. 

230451 01-03 
CHOLINESTERASE ACTIVITY AND CONTENT OF ADENOSINE 

TRIPHOSPHATE IN DEPRESSED PATIENTS AND THEIR CHANGES UNDER 
THE INFLUENCE OF MONOCHLORIMIPRAMINE. 

236364 02-10 
INHIBITION OF CHOLINESTERASE BY 5-HYDROXYTRYPTAMINE. 

237117 02-03 
DRUG DISCRIMINATION IN RATS: EFFECTS OF MIXTURES OF DITRAN AND 
CHOLINESTERASE INHIBITORS. 

242737 03-04 
THE EFFECT OF SYMPATHOLYTIC AND SYMPATHOMIMETIC AGENTS ON 
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITY, IN VITRO. 

243794 04-03 
THE EFFECT OF LITHIUM ON RED BLOOD CELL CHOLINESTERASE ACTIVITY 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

244495 04-09 
EFFECTS OF ARECOLINE AND CHOLINESTERASE INHIBITORS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE IN MOUSE BRAIN. 

246389 04-03 
THE EFFECTS OF CHRONIC GANGLION BLOCKADE AND CHRONIC 
CHOLINESTERASE INHIBITION ON THE SENSITIVITY OF RABBIT 
STOMACH MUSCULARIS TO CHOLINERGIC AND ADRENERGIC 
AGONISTS. 

246842 04-03 
CHOLINESTERASE (CHE) INHIBITION AND SYNAPTOSOMAL 

ACETYLCHOLINE (ACH) SYNTHESIS AND RELEASE FOLLOWING IN VIVO 
PARAOXON (PX) ADMINISTRATION. 

249295 04-03 
CHOLINESTERASES 

PARATHION ADMINISTRATION IN THE MONKEY: TIME COURSE OF 

INHIBITION AND RECOVERY OF BLOOD CHOLINESTERASES AND VISUAL 
DISCRIMINATION PERFORMANCES. 

227384 01-03 
A SIMPLE METHOD OF EVALUATING THE COMPETITIVE INTERACTION OF 
REVERSIBLE INHIBITORS WITH CHOLINESTERASES. 

231072 01-06 
CHOLINOCEPTIVE 

EFFECT OF DEXTROAMPHETAMINE ON IDENTIFIED CHOLINOCEPTIVE 
CELLS OF THE SNAIL BRAIN. 

238740 03-03 
CHOLINOMIMETICS 

MODIFICATION OF THE BEHAVIORAL EFFECTS OF CHOLINOMIMETICS BY 
PHENTOLAMINE. 

237032 02-04 
CHOIINORECEPTORS 

THE ROLE OF CENTRAL AND PERIPHERAL CHOLINORECEPTORS IN THE 
PROCESSES OF SHORT-TERM MEMORY. 

236711 02-04 
CHOREA 

TREATMENT OF SYDENHAMS CHOREA WITH A COMBINATION OF L-DOPA 
AND A PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, 

237733 02-11 
CHOREIFORM 

CLONAZEPAM IN THE TREATMENT OF CHOREIFORM ACTIVITY. 

250932 04-07 
CHOREOATHETOSIS 

PHENYTOIN-INDUCED DYSTONIA AND CHOREOATHETOSIS IN TWO 
RETARDED EPILEPTIC CHILDREN. 

251654 04-15 
CHROMATOGRAPHIC 

A GAS CHROAAATOGRAPHIC METHOD FOR DETERMINING HALOPERIDOL- 
A SENSITIVE PROCEDURE FOR STUDYING SERUM CONCENTRATION 
AND PHARMACOKINETICS OF HALOPERIDOL IN PATIENTS. 

237152 02-16 
GAS CHROMATOGRAPHIC SEPARATION OF CHLORPROAAAZINE 
DIAZEPAM AND N-DESMETHYLDIAZEPAM. 

237750 02-06 
CHROMATOGRAPHY 

DETERMINATION OF BROMAZEPAM IN PLASMA WITH AN INTERNAL 
STANDARD BY GAS-LIQUID CHROMATOGRAPHY. 

229906 01-16 
INEXPENSIVE EQUIPMENT FOR HIGH PRESSURE LIQUID 

CHROMATOGRAPHY: APPLICATION TO ASSAYS FOR TAURINE, 



so 



00 



3K 



S-73 



Subject Index 



Psychopharmacology Abstracts 



n 

mm 



y.-A' 



'•v.t.; 



GAMMA AMINOBUTYRICACID AND 5 HYDROXYTRYPTOPHAN 
(UNPUBLISHED PAPER), 

231278 01 06 
GAS CHROMATOGRAPHY MASS FRAGMENTOGRAPHIC (GC-MF) ANALYSIS 
OF TRYPTAMINF IN BIOLOGICAL SAMPLES. 

238774 03-01 
ON THE THIN LAYER CHROMATOGRAPHY OF SOME NONBARBITURETE 
HYPNOTICS AND ATARACTICS. 

243340 04-01 
ASSESSMENT OF CEREBROSPINAL FLUID LEVELS OF DOPAMINE 
METABOLITES BY GAS CHROMATOGRAPHY. 

245300 04-03 
CHRONIC 

LOXAPINE SUCCINATE: A CONTROLLED DOUBLE-BLIND STUDY IN 
CHRONIC SCHIZOPHRENIA. 

225867 01 08 
BRAIN DYSFUNCTION IN CHRONIC SEDATIVE USERS. 

226922 01 15 
AN OPEN STUDY OF MESORIDAZINE (SERFNTIl.) IN CHRONIC 
SCHIZOPHRENICS. 

227821 01 08 
DEUTEROPATHY AFTER STOPPING PSYCHIATRIC MEDICATION FOR 
CHRONIC SCHIZOPHRENIA 

228325 01 08 
THE EFFECT OF CHRONIC INJECTIONS OF CHLORPROMAZINE ON 
OOGENESIS AND PROGENY DEVELOPMENT IN ALBINO MICE, 

228554 01 05 
DRUG TREATMENT IN A REHABILITATION CENTER FOR CHRONIC 
ALCOHOLICS 

228908 0111 
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9 TRANS- 
TETRAHYDROCANNABINOL (DELTA9-THC) IN GUINEA-PIGS. 

229033 01-03 
REDUCTION IN T-LYMPHOCYTES FORMING ACTIVE ROSETTES IN CHRONIC 
MARIJUANA SMOKERS 

229039 01-15 
A PRELIMINARY REPORT ON CLINICAL RESPONSE AND BLOOD LEVELS OF 
CHLORPROMAZINE AND ITS SULFOXIDE DURING CHLORPROMAZINE 
THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS. 

229444 01-08 
INFLUENCE OF PSYCHOTROPIC DRUGS ON CHRONIC SCHIZOPHRENIC 
SYNDROMES - WITH SPECIAL EMPHASIS ON THE CHANGE IN CLINICAL 
PROCESS WITH A RELATIVELY HIGH DOSAGE OF SPIROPERIDOL, 

229761 01-08 
COGNITIVE DEFICITS ASSOCIATED WITH CHRONIC HEPATIC 
ENCEPHAIOPATHY AND THEIR RESPONSE TO LEVODOPA 

230580 01 15 
NEUROENDOCRINE EFFECTS OF HALOPERIDOL THfRAPY IN CHRONIC 
SCHIZOPHRENIA. 

230839 01 08 
TYROSINE-HYDROXYLASE ACTIVITY IN RAT BRAIN REGIONS AFTER 
CHRONIC TREATMENT WITH PLUS/MINUS PROPRANOLOL. 

230853 01-03 
SULPIRIDE IN CHRONIC PSYCHOSES OF THE PARANOID TYPE. 

230991 01 11 
THE RESOCIALIZING EFFECT OF CLOTHIAPINF IN CHRONIC PSYCHOSES. 

230993 01-11 
CYTOLOGIC STUDY OF CEREBROSPINAL FLUID IN CHRONIC PSYCHIATRIC 
PATIENTS TREATED WITH NEUROLEPTICS. 

230997 01-11 
THE PROBLEM OF CHRONIC SCHIZOPHRENIA: TREATMENT WITH DEPOT 
FLUPENTHIXOL, A LONG-ACTING NEUROLEPTIC. 

231367 01 08 
THE ASSESSMENT OF THIOTHIXENE IN CHRONIC SCHIZOPHRENIA: A 
DOUBLE-BLIND CONTROLLED TRIAL 

231609 01 08 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC LIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING. (UNPUBLISHED 
PAPER) 

231771 01-04 
BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AND AMPHETAMINE 
AFTER CHRONIC HIGH DOSE HALOPERIDOL TREATMEN 

232616 02-04 
RESPONSES OF CHRONIC SCHIZOPHRENIC FEMALES TO A COMBINATION 
OF DIPHENYLHYDANTOIN AND NEUROLEPTICS A DOUBLE BUND 
STUDY, 

232781 02 08 
A PLACEBO CONTROLLED STUDY OF LITHIUM COMBINED WITH 
NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC PATIENTS. 

232840 02-08 
ANTINUCLEAR ANTIBODIES IN CHRONIC PSYCHOTIC PATIENTS TREATED 
WITH CHLORPROMAZINE. 

232865 02- 1 5 
SCHEDULE-INDUCED ORAL NARCOTIC SELF ADMINISTRATION: ACUTE 
AND CHRONIC EFFECTS. 

233293 0204 
THYROTROPIN-RELEASING HORMONE IN CHRONIC SCHIZOPHRENIA. 

233817 0208 



EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN 
MONOAMINES AND SOME BEHAVIORAL AND PHYSIOLOGICAL 
FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS. 

233962 02-03 
A COMPARATIVE STUDY OF THIOTHIXENE AND CHLORPROMAZINE IN 
CHRONIC SCHIZOPHRENIC PATIENTS: APPLICATION OF SPECIAL 
PSYCHOMETRIC TEST BATTERY. 

235366 02-08 
CHANGES IN SERUM TRYPTOPHAN AND ALBUMIN BINDING OF 
TRYPTOPHAN IN CHLORPROAAAZINE TREATED CHRONIC 
SCHIZOPHRENICS ON WITHDRAWAL AND RESTORATION OF DRUG 
THERAPY. 

235629 02-08 
CHRONIC MARIHUANA INHALATION TOXICITY IN RATS. 

235671 02-05 
CEREBELLAR ATAXIA DUE TO DIPHENYLHYDANTOIN ADMINISTRATION - 
CLINICAL AND PATHOLOGICAL STUDIES ON TWO CASES OF CHRONIC 
DIPHENYLHYDANTOIN INTOXICATION. 

236696 02-15 
EVALUATION OF DISULFIRAM TREATMENT OF CHRONIC ALCOHOLISM. 

237026 02-11 
CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

237106 02-04 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

237109 02-04 
PROGRESSIVE CHANGES IN BEHAVIOR AND SEIZURES FOLLOWING 
CHRONIC COCAINE ADMINISTRATION: RELATIONSHIP TO KINDLING 
AND PSYCHOSIS. (UNPUBLISHED PAPER). 

237169 02-04 
BEHAVIORAL SUPERSENSITIVITY TO 5-HYDROXYTRYPTOPHAN-INDUCED 
BY CHRONIC METHYSERGIDE PRETREATMENT. 

237729 02-04 
EFFECTS OF MORPHINE ON THE TURNOVER OF BRAIN CATECHOLAMINES 
AND SEROTONIN IN RATS - CHRONIC MORPHINE ADMINISTRATION. 

237737 02-03 
A PRELIMINARY STUDY WITH PENFLURIDOL IN HOSPITALIZED CHRONIC 
SCHIZOPHRENIC PATIENTS. 

237897 0208 
LENPERONF: A CONTROLLED EVALUATION IN CHRONIC SCHIZOPHRENIC 
PATIENTS. 

237899 02-08 
EFFECT OF ACUTE AND CHRONIC IPRINDOLE ON SEROTONIN TURNOVER 
IN MOUSE BRAIN 

237922 02-03 
THE EFFECT OF CHRONIC CENTRAL ADRENERGIC DENERVATION ON 
LEARNING AND MEMORY OF AN AVERSIVE DISCRIMINATION TASK IN 
MICE: STUDIES WITH 6-HYDROXYDOPAMINE. (PHD, DISSERTATION). 

238157 02-03 
RESPONSFS OF FLEXOR REFLEX TO LSD, TRYPTAMINE (T), 5-HTP, 
METHOXAMINE (M) AND AMPHETAMINE (A) IN ACUTE AND 
CHRONIC SPINAL RATS. 

238704 03-04 
PROTECTION AGAINST STRESS-INDUCED DEPLETION OF BRAIN 
NOREPINEPHRINE AFTER PRIOR EXPOSURE TO CHRONIC STRESSES. 

238718 0304 
EFFECTS OF CHRONIC PRENATAL HYPOXIA ON PHYSIOLOGICAL, 
NEUROCHEMICAL AND BEHAVIORAL DEVELOPMENT. 

238722 03-04 
EFFECT OF CHRONIC BARBITAL ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL ON CATECHOLAMINE CONTENT AND TURNOVER IN RAT 
BRAIN. 

238790 03-03 
EFFECTS OF ACUTE AND CHRONIC PENTOBARBITAL ADMINISTRATION ON 

BRAIN GAMMA-AMINOBUTYRATE (GABA) AND GLUTAMATE (GLU) 
LEVELS IN THE MOUSE. 

238791 03 03 
THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE 

CONTROLLED BEHAVIOR IN THE RHESUS MONKEY. 

238794 03-04 
THE EFFECT OF CHRONIC MARIHUANA SMOKING ON THE BEAGLE DOG. 

238806 03-03 
CHRONIC CARDIOVASCULAR EFFECTS OF DELTA9- 

TETRAHYDROCANNABINOL (DELTA9-THC) IN THE MONGREL DOGS. 

238810 03-03 
BRAIN SYNAPTIC MEMBRANE NAK ATPASE FOLLOWING CHRONIC 
INJECTION OF DELTA9-TETRAHYDR0CANNABIN0L (THC). 

238812 03-03 
ENVIRONMENTAL INFLUENCES ON THE BEHAVIORAL RESPONSE TO ACUTE 
AND CHRONIC AMPHETAMINE ADMINISTRATION. 

238843 0304 
EFFECTS OF LITHIUM ON CHRONIC ETHANOL CONSUMPTION AND 
BEHAVIOR. 

238849 03-03 
ON THE MULTIFACTORIAL TREATMENT OF CHRONIC HEADACHES. 

238866 03-11 



S-74 



4 



VOLUME 14, SUBJECT INDEX 



Subject Index 



PLASMA AND ERYTHROCYTE MAGNESIUM LEVELS IN PATIENTS WITH 
PRIMARY AFFECTIVE DISORDER DURING CHRONIC LITHIUM 
TREATMENT. 

238977 03-15 
ACUTE AND CHRONIC EFFECTS OF VASOPRESSIN IN RATS WITH LITHIUM 
POLYURIA. 

239046 03-05 
ALTERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS AFTER CHRONIC HALOPERIOOL: INDIRECT EVIDENCE FOR 
CHOLINERGIC HYPOSENSITIVITY. 

239826 03 04 
ACUTE AND CHRONIC EFFECTS OF 4-CHLOROAMPHETAMINE ON 
MONOAMINE METABOLISM IN THE RAT BRAIN. 

239849 03-03 
COMPARISON BETWEEN CHRONIC CHLORDIAZEPOXIDE TREATMENT AND 
SHOCK REMOVAL IN A CONFLICT SITUATION IN RATS. 

239979 03-04 
P-CHLOROAMPHETAMINE (PCA): ACUTE AND CHRONIC EFFECTS ON 
HABITUATION AND SENSITIZATION OF THE ACOUSTIC STARTLE 
RESPONSE IN RATS. 

240062 03-04 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: II. ANTIPSYCHOTIC EFFECT OF HALOPERIDOL IN PATIENTS 
WITH CHRONIC ORGANIC BRAIN DAMAGE. 

240219 03-11 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER). 

240241 0304 
LORAZEPAM IN THE MANAGEMENT OF ANXIETY ASSOCIATED WITH 
CHRONIC GASTROINTESTINAL DISEASE: A DOUBLE-BLIND STUDY. 

241274 03-14 
LACK OF TOLERANCE OR SENSITIZATION TO THE EFFECTS OF CHRONIC D- 
AMPHETAMINE ON SUBSTANTIA-NIGRA SELF-STIMULATION. 

241307 03-04 
EFFECTS OF CHRONIC ADMINISTRATION OF MORPHINE ON 
PENTOBARBITAL RESPONSES IN THE MOUSE. 

241338 03-03 
THE EFFECT OF ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION 
ON SEIZURE SUSCEPTIBILITY AND BRAIN CATECHOLAMINES IN MICE 
(PH.D. DISSERTATION). 

241576 03-03 
BIOAVAILABILITY OF TWO CARBAMAZEPINE PREPARATIONS DURING 
CHRONIC ADMINISTRATION TO EPILEPTIC PATIENTS. 

242212 03-11 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER 

243024 04-17 
A TWO YEAR TRIAL OF LOXAPINE SUCCINATE IN CHRONIC PSYCHOTIC 
PATIENTS. 

244501 04-08 
PECULIAR CLINICOPHARMACOLOGICAL PROPERTIES OF CLOZAPINE 
REVEALED IN A GROUP OF CHRONIC SCHIZOPHRENICS. 

244587 04-08 
MOUSE-KILLING AND MOTOR ACTIVITY: EFFECTS OF CHRONIC DELTA9 
TETRAHYDROCANNABINOL AND PILOCARPINE. 

244682 04 04 
A DOUBLE-BLIND COMPARISON OF LOXITANE: LOXAPINE SUCCINATE 
AND TRIFLUOPERAZINE HYDROCHLORIDE IN CHRONIC SCHIZOPHRENIC 
PATIENTS. 

245014 04 08 
EFFECTS ON OFFSPRING OF CHRONIC MATERNAL METHAMPHETAMINE 
EXPOSURE. 

245405 04-05 
PERSISTENCE OF CHRONIC MORPHINE EFFECTS UPON ACTIVITY IN RATS 
8 MONTHS AFTER CEASING THE TREATMENT. 

245602 04 04 
HUMAN SLEEP DURING CHRONIC MORPHINE INTOXICATION. 

246304 04 1 3 
CAFFEINE AND CHLORDIAZEPOXIDE: EFFECTS ON MOTOR ACTIVITY IN 
THE CHRONIC THALAMIC RAT. 

246388 04-04 
CHRONIC MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 
HORMONE AND CORTICOSTERONE. 

246662 04-03 
THE EFFECTS OF CHRONIC GANGLION BLOCKADE AND CHRONIC 
CHOLINESTERASE INHIBITION ON THE SENSITIVITY OF RABBIT 
STOMACH MUSCULARIS TO CHOLINERGIC AND ADRENERGIC 
AGONISTS 

246842 04-03 
HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CSF 
OF PATIENTS AFTER A SEVERE HEAD INJURY. I. LUMBAR CSF 
CONCENTRATION IN CHRONIC BRAIN POSTTRAUMATIC SYNDROMES. 

246993 04- 13 
DIPSOGENIC EFFECTS OF INTRACELLULAR AND EXTRACELLULAR THIRST 
STIMULI BEFORE AND AFTER CHRONIC DFP TREATMENT. 

247209 04 04 
AN EARLY CLINICAL AND TOXICITY TRIAL OF EX-1 1-582A IN CHRONIC 
SCHIZOPHRENIA 

247481 04-07 



SUPERSENSITIVITY Tn D AMPHETAMINE AND APOMORPHINE INDUCED 
STEREOTYPED BEHAVIOR INDUCED BY CHRONIC D AMPHETAMINE 
ADMINISTRATION. 

247683 04-04 
NOREPINEPHRINE CONTENT OF VARIOUS RAT ORGANS AFTER CHRONIC 
ADMINISTRATION OF DESMETHYLIMIPRAMINE 

247777 04-03 
ENDOCRINE EFFECTS OF CHRONIC INTRAVENTRICULAR ADMINISTRATION 
OF DELTA9-TETRAHYDR0CANNABIN0L TO PREPUBERAL AND ADULT 
MALE RATS. 

248275 04-05 
MYELOID HYPERPLASIA IN GROWING RATS AFTER CHRONIC TREATMENT 
WITH DELTA9-THC AT BEHAVIORAL DOSES. 

248915 04-05 
CHANGES IN FIXED-INTERVAL BEHAVIOR DURING CHRONIC MORPHINE 
TREATMENT AND MORPHINE ABSTINENCE IN RATS. 

248959 04-04 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND CI4-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

248961 04-03 
THE EFFECT OF CHRONIC MARIHUANA USAGE ON THE IMMUNOLOGICAL 
STATUS OF RHESUS MONKEYS. 

249003 04-05 
PROGRESSIVE BEHAVIORAL CHANGES DURING CHRONIC IIDOCAINE 
ADMINISTRATION: RELATIONSHIP TO KINDLING. 

249005 04-04 
THE CONTRIBUTION OF LEARNING TO THE DEVELOPMENT OF CHRONIC 
ETHANOL TOLERANCE IN THE RAT. 

249264 04-04 
REVERSAL OF RESIDUAL TOLERANCE TO MORPHINE AND BLOCKADE OF 
EFFECTS OF MORPHINE WITH CHRONIC NALTREXONE 
ADMINISTRATION 

249268 0403 
EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN 
GLUTAMATE (GLU) AND GAMMA-AMINOBUTYRATE (GABA) LEVELS IN 
THE MOUSE. 

249292 04-03 
CHRONIC ETHANOL FEEDING AND BRAIN ADENYLCYCLASE AND 
PHOSPHODIESTERASE LEVELS IN MICE. 

249294 04-03 
EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVEAU ISOLE AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT 

249307 04-03 
CHANGES IN SENSITIVITY OF MORPHINE-INDUCED CIRCLING BEHAVIOUR 
AFTER CHRONIC TREATMENT AND PERSISTENCE AFTER WITHDRAWAL 
IN RATS. 

249485 04 04 
THIOTHIXENE IN THE TREATMENT OF GERIATRIC PATIENTS WITH 
CHRONIC ORGANIC BRAIN SYNDROME. 

249625 04-1) 
CHRONIC DELTA9-TETRAHYDR0CANNABIN0L TRANSIENT AND LASTING 
EFFECTS ON AVOIDANCE BEHAVIOR. 

250061 04-04 
POTENTIATION BY METYROSINE OF THIORIDAZINE EFFECTS IN CHRONIC 
SCHIZOPHRENICS: A LONG TERM TRIAL USING DOUBLE-BLIND 
CROSSOVER TECHNIQUE. 

251374 04-08 
SUPERSENSITIVITY OF CORTICAL NEURONES OF THE RAT TO 

ACETYLCHOIINE AND L-GLUTAMATE FOLLOWING CHRONIC MORPHINE 
TREATMENT 

251433 04-03 
A LONG-TERM STUDY OF PENFLURIDOL IN CHRONIC SCHIZOPHRENIA. 

251829 04-08 
EFFECTS OF ACUTE AND CHRONIC METHADONE TREATMENT ON THE 
UPTAKE OF 3H 5 HYDROXYTRYPTAMINE IN RAT HYPOTHALAMUS 
SLICES. 

252023 04-03 
POTENTIATION OF AMPHETAMINE-INDUCED HYPERACTIVITY BY ACUTE 
BUT NOT BY CHRONIC P-CHLOROPHENYLALANINE TREATMENT IN THE 
RAT 

252519 04-03 
THE DURATION OF MAINTENANCE THERAPY IN CHRONIC 
SCHIZOPHRENIA. 

252763 04-08 
A THREE-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS 
FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA. 

253048 04-08 
LITHIUM COMBINED WITH NEUROLEPTICS IN THE TREATMENT OF 

CHRONIC SCHIZOPHRENIA. 

253049 04-08 
THE EFFECTS OF THIOTHIXENE IN GERIATRIC PATIENTS WITH CHRONIC 

ORGANIC BRAIN-SYNDROMF 

253050 04-11 
ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE 

DRUGS TO PREPUBERTAL MAI E RATS. II. LSD. 

253700 04-03 










3E 



S-75 



Subject Index 



Psychopharmacology Abstracts 









CHRONICALIY 

DEVELOPMENT OF BRAIN CEREBROSIDES AND CEREBROSIDE SULFATE 
(SULFATIDE) IN OFFSPRING OF CONTROL RATS AND RATS 
CHRONICALLY TREATED WITH METHADONE. 

238723 03-03 
CEREBRAL AND CEREBELLAR NEUROCHEMICAL CHANGES AND 

BEHAVIORAL MANIFESTATIONS IN RATS CHRONICALLY EXPOSED TO 
MARIJUANA SMOKE. 

243181 04-04 
CHRONOTROPIC 

ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 
BROMAZEPAM IN CONSCIOUS TRAINED DOGS. 

240064 03-03 
CI-628 

EFFECTS OF ERGOCORNINE AND CI-628 ON FOOD INTAKE AND TASTE 
PREFERENCES. 

239290 03-04 
CIBA-34276-BA 

MAPROTILINE (LUDIOMIL, CIBA-34276-BA) AND IMIPRAMINE IN 
DEPRESSED OUTPATIENTS: A DOUBLE BLIND CLINICAL STUDY. 

242248 03-09 
A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF A NEW 
ANTIDEPRESSANT AGENT, MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE CHLORHYDRATE (CIBA 34276-BA) 

247554 04-09 
CICHIASOMA-NIGROFASCIATUM 

DIFFERENTIATION BY MORPHINE OF TWO TYPES OF AGGRESSIVE 
BEHAVIOR IN THE CONVICT CICHLID (CICHIASOMA- 
NIGROFASCIATUM). 

230865 01-04 
CICHLID 

DIFFERENTIATION BY MORPHINE OF TWO TYPES OF AGGRESSIVE 
BEHAVIOR IN THE CONVICT CICHLID (CICHLASOMA- 
NIGROFASCIATUM). 

230865 01-04 
CIGAREHE 

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE 
SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG 
SURVEILLANCE PROGRAM. 

225722 0115 
CINANSERIN 

ANTAGONISM BY METHYSERGID AND CINANSERIN OF THE 

ANTINOCICEPTIVE ACTION OF MORPHINE ADMINISTERED INTO THE 
PERIAQUEDUCTAL GRAY. 

239576 03-04 
CIRCADIAN 

CIRCADIAN CYCLES IN BINDING OF 3H-ALPREN0L0L TO BETA- 
ADRENERGIC RECEPTOR SITES IN RAT PINEAL 

234919 02-03 
CARBACHOL ELICITED MOUSE KILI ING BY RATS: CIRCADIAN RHYTHM 
AND DOSE RESPONSE. 

238006 02 04 
NEUROHUMORAL MECHANISMS RELATING TO CIRCADIAN SLEEP- 
WAKEFULNESS CYCLES OF HUMORAL EXPERIMENTAL ANIMALS. 

238971 03 03 
CIRCLING 

SPONTANEOUS AND DRUG-INDUCED ROTATION (CIRCLING BEHAVIOR) IN 
THE MONGOLIAN GERBIl (MERIONES-UNGUICULATUS). 

241311 03-04 
CIRCLING BEHAVIOUR PRODUCED BY UNILATERAL LESIONS IN THE 
REGION OF THE LOCUS COERULEUS IN RATS 

249076 04-04 
CHANGES IN SENSITIVITY OF MORPHINE INDUCED CIRCLING BEHAVIOUR 
AFTER CHRONIC TREATMENT AND PERSISTENCE AFTER WITHDRAWAL 
IN RATS. 

249485 04-04 
INHIBITION OF CIRCLING BEHAVIOR BY NEUROLEPTIC DRUGS IN MICE 
WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF THE STRIATUM. 

249679 04 04 
CIRCLING BEHAVIOUR PRODUCED BY ASYMMETRIC MEDIAL RAPHE 
NUCLEI LESIONS IN RATS, 

250358 04-04 
CIRCULAR 

METHADONE-INDUCED BEHAVIORAL CHANGES: CIRCULAR MOVEMENTS, 
AGGRESSION. AND ELECTROPHYSIOLOGICAL ASPECTS. 

229286 01-04 
MAGNETIC CIRCULAR DICHROISM OF SUBSTITUTED INDOLES. 

229493 01-06 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 
ALBUMIN - II, CIRCULAR DICHROISM STUDIES. 

251177 04-01 
CIRCULATION 

THE EFFECT OF CHLORPROMAZINE ON CEREBRAL CIRCULATION 

236234 02-03 
EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEG - DIAZEPAM, CLOMIPRAMINE. 
AND CHLORPROMAZINE. 

246319 04-03 



ROLE OF THE PROSTAGLANDINS IN THE REGULATION OF THE CEREBRAL 
BLOOD CIRCULATION, 

248552 04-03 
ADRENERGIC RECEPTORS AND VASCULAR RESISTANCE IN CEREBRAL 
CIRCULATION OF THE CAT, 

251820 04-03 
INTESTINAL ABSORPTION. DEMETHYLATION. AND ENTEROHEPATIC 
CIRCULATION OF IMIPRAMINE. 

252231 04-13 
CIRCULATORY 

PSYCHOPHARMACOLOGY OF THE CIRCULATORY SYSTEM. 

229471 01-13 
THE INFLUENCE OF IMIPRAMINE ON CIRCULATORY EFFECTS OF 
MIDODRINE. 

251415 04-03 
CIRRHOSIS 

NORMAL DISPOSITION OF OXAZEPAM IN ACUTE VIRAL HEPATITIS AND 
CIRRHOSIS. 

241730 03-13 
CLASS 

NATURE OF NEW CLASS OF CHLORPROAAAZINE (CPZ) METABOLITES IN 
PRIAAATE URINES. 

249328 04-01 
CLASSICAL 

CONDITIONED AND UNCONDITIONED DRUG EFFECTS IN A CLASSICAL 
CONDITIONING PARADIGM. 

238787 03-04 
CLASSIFICATION 

MODERN VIEWS ON DIAGNOSIS AND CLASSIFICATION OF DEPRESSIONS: 
II. UNITED-KINGDOM. 

227205 01-09 
SCANDINAVIAN STANDPOINT ON THE LIEGE CLASSIFICATION OF 
NEUROLEPTICS. 

227761 01 17 
HYPNOTICS AND SLEEP: CLASSIFICATION. METABOLISM, MECHANISM OF 
ACTION OF HYPNOTICS AND ALTERATIONS OF PHASES OF SLEEP BY 
HYPNOTICS. 

228094 01 14 
A PRACTICAL CLASSIFICATION OF UNTOWARD DRUG EFFECTS. 

248909 04-15 
A PRACTICAL CLASSIFICATION OF MORBID ANXIETY. 

251157 04-10 
CLASSIFICATIONS 

THE MAIN CLINICAL CLASSIFICATIONS OF NEUROLEPTICS. 

227764 01-06 
CLASSIFIED 

FENMETRAZOLE (DH-524): EUPHORIANT CLASSIFIED BY CEREBRAL 
ELECTROMETRY. 

230781 01-14 
CLASSROOM 

EFFECTS OF COMBINING METHYLPHENIDATE AND CLASSROOM TOKEN 
SYSTEM IN MODIFYING HYPERACTIVE BEHAVIOR. 

232807 02 11 
NON-MEDICATION MANAGEMENT OF HYPERKINETIC CHILDREN IN THE 
CLASSROOM. (PH.D. DISSERTATION). 

240977 03-11 
CLEFT 

ASSOCIATION BETWEEN CLEFT LIP WITH OR WITHOUT CLEFT PALATE 
AND PRENATAL EXPOSURE TO DIAZEPAM 

229349 01-17 
CLEFTS 

ASSOCIATION BETWEEN MATERNAL INTAKE OF DIAZEPAM AND ORAL 
CLEFTS. 

229350 01-15 
CLIMACTERIC 

THE TREATMENT OF CLIMACTERIC SYNDROME WITH TOFIZOPAM 
(GRANDAXIN). 

252450 04-1 1 
CLI/V\ACTERIUM 

THE PSYCHIATRY OF THE FEMALE CLIMACTERIUM: NEUROTIC OR 
PSYCHOTIC SYMPTOMS?. 

241875 03 09 
CLINIC 

DOXEPIN, A NEW ANTIDEPRESSANT DRUG FOR PATIENTS IN THE 
INTERNAL MEDICINE CLINIC. 

229515 01-10 
THE LITHIUM CLINIC: A NEW A/.ODEL FOR THE DELIVERY OF 
PSYCHIATRIC SERVICES 

234699 02-09 
THE USE OF PSYCHOTROPIC DRUGS IN A PAIN CLINIC. 

252144 04-17 
CLINICAL 

THIORIDAZINE PLASMA LEVELS AND CLINICAL RESPONSE. 

225932 01-08 
PLASMA CONCENTRATIONS OF L-DOPA AND 3-METHOXYDOPA AND 
IMPROVEMENT IN CLINICAL RATINGS AND MOTOR PERFORMANCE IN 
PATIENTS WITH PARKINSONISM TREATED WITH L-DOPA ALONE OR IN 
COMBINATION WITH AMANTADINE. 

226349 01 14 



4 



S-76 



OLUME 14, SUBJECT INDEX 



Subject Index 



TREATMENT WITH DISULFIRAAA IN HUNTINGTONS-CHOREA: A NEGATIVE 
CLINICAL AND PHARMACOLOGICAL STUDY. 

226430 01-07 
THE HAMILTON RATING SCALE. AN ASSESSMENT BASED ON A 
DOTHIEPIN (PROTHIADEN) VERSUS IMIPRAMINE (TOFRANIL) CLINICAL 
TRIAL 

226899 01-09 
EFFECTS OF CONTROL TECHNIQUES ON THERAPEUTIC OUTCOME IN A 
CONTROLLED CLINICAL TRIAL 

226902 01-16 
THE CLINICAL PHARMACOLOGY OF ANTIDEPRESSIVES. 

227209 01-17 
CLINICAL PHARMACOLOGY OF VILOXAZINE (VIVALAN). 

227210 01-07 
CLINICAL PHARMACY PRACTICE IN A COMMUNITY MENTAL-HEALTH 

CENTER. 

227560 01-17 
PHARMACOLOGICAL VS. CLINICAL PHYSIOGNOMY OF NEUROLEPTICS, 
WITH SPECIAL REFERENCE TO THEIR SEDATIVE AND ANTIPSYCHOTIC 
EFFECTS. 

227762 01 04 
BIOCHEMICAL VS CLINICAL PHYSIOGNOMY OF NEUROLEPTICS, WITH 

SPECIAL REFERENCE TO THEIR ANTIMANIC EFFECT. 

227763 01-04 
THE MAIN CLINICAL CLASSIFICATIONS OF NEUROLEPTICS. 

227764 01-06 
CLINICAL AND ELECTROENCEPHALOGRAPHICAL STUDIES OF THE 

THIOXANTHENES. 

227765 01-08 
CLINICAL PHYSIOGNOMY OF CHLORPROTHIXENE AND CLOPENTIXOL. 

227766 01-11 
CLINICAL PHYSIOGNOMY OF FLUPENTHIXOL. 

227772 01-14 
CLINICAL EXPERIENCE IN USING SULPIRIDE FOR INTERNAL 
PSYCHOSOMATIC ILLNESS. 

227806 01-11 
COMPREHENSIVE CLINICAL STUDIES WITH THIOTHIXENE. 

227820 01-14 
CLINICAL AND CNS EFFECTS OF ORAL AND I.V. THYROTROPIN-RELEASING 
HORMONE IN DEPRESSED PATIENTS. 

227826 01-09 
TRANQUILIZATION EFFECT OF BETA-BLOCKADE ALPRENOLOL; A CLINICAL 
STUDY. 

228311 01-11 
CLINICAL EXPERIENCE IN USING SULPIRIDE (FK 880) FOR DEPRESSION. 

228334 01-09 
CLINICAL EXPERIENCE IN USING CLOXAZOLAM (SEPAZON). 

229025 01-10 
CLINICAL PHARMACOLOGY OF SO 10996, A POTENTIAL ANTIDEPRESSIVE 
AGENT. 

229036 01-07 
THE CLINICAL APPLICATION OF LABORATORY ANIMAL EXPERIMENTAL 

FINDINGS: TREATMENT OF HYPERSEXUALIZED BEHAVIOR IN A MALE. 

229037 01-11 
PLASMA LEVELS OF IMIPRAMINE AND CLINICAL OUTCOME. 

229443 01 09 
A PRELIMINARY REPORT ON CLINICAL RESPONSE AND BLOOD LEVELS OF 

CHLORPROMAZINE AND ITS SULFOXIDE DURING CHLORPROMAZINE 
THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS. 

229444 01-08 
CHLORPROMAZINE METABOLISM AND CLINICAL RESPONSE IN ACUTE 

SCHIZOPHRENIA A PRELIMINARY REPORT, 

229445 01-08 
PLASMA LEVELS OF MESORIDAZINE AND ITS METABOLITES AND 

CLINICAL RESPONSES IN ACUTE SCHIZOPHRENIA AFTER A SINGLE 
INTRAMUSCULAR DRUG DOSE. 

229446 01-08 
THE CLINICAL EVALUATION OF A NEW MINOR TRANQUILIZER 

CLORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOMATIC DISEASE, NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BLIND CLINICAL STUDY. 

229504 01 II 
CLINICAL THERAPEUTIC EXPERIMENTS ON PSYCHOTIC PATIENTS WITH 
LONG-ACTING FLUPHENAZINE. 

229550 01 11 
CLINICAL EXPERIMENTS WITH FLUPHENAZINE DECANOATE IN 

HOSPITALIZED PATIENTS. 

229551 01 11 
CLINICAL EXPERIMENTATION OF THE LONG ACTING NEUROLEPTICS: 

METHODOLOGICAL PROBLEMS 

229554 0116 
PSYCHOMETRIC CLINICAL EVALUATION, THROUGH OVERALL AND 

GORHAMS TEST, OF THERAPY WITH FLUPHENAZINE DECANOATE 

229555 01 17 
ClINICAL THERAPEUTIC EXPERIMENTS WITH FLUPHENAZINE-DECANOATE 

IN TREATING DISSOCIATIVE SYNDROMES 

229560 01-11 
CLINICAL EXPERIENCE IN USING MENDON (DIPOTASSIUM CLORAZEPATE) 

229626 01-11 



CLINICAL EXPERIENCE IN USING MAPROTILINE, A NEW ANTIDEPRESSIVE 
MEDICINE. 

229760 01-09 
INFLUENCE OF PSYCHOTROPIC DRUGS ON CHRONIC SCHIZOPHRENIC 

SYNDROMES - WITH SPECIAL EMPHASIS ON THE CHANGE IN CLINICAL 
PROCESS WITH A RELATIVELY HIGH DOSAGE OF SPIROPERIDOL. 

229761 01-08 
TREATMENT OF THE MINIMAL-BRAIN DYSFUNCTION SYNDROME WITH 

PSYCHOPHARMACOTHERAPY (A CLINICAL STUDY WITH CAPTAGON). 

230002 01-11 
CLINICAL EXPERIENCES WITH ANTIDEPRESSANT DRUGS IN THE 
TREATMENT OF ANXIOUS PHOBIC PATIENTS. 

230015 01 10 
CLINICAL USE OF DRUGS FOR SLEEP DISTURBANCES. 

230119 01 17 
A CLINICAL TRIAL WITH NOMIFENSIN, A NEW ANTIDEPRESSANT DRUG. 

231035 01-09 
CLINICAL AND PHYSIOLOGICAL ASSESSMENT OF CHLORAZEPATE, 

DIAZEPAM AND PLACEBO IN ANXIOUS NEUROTICS. 

231036 01-10 
PREDICTABILITY IN PSYCHOPHARMACOLOGY: PRECLINICAL AND 

CLINICAL CORRELATIONS. 

23111201 17 
TRICYCLIC ANTIDEPRESSANT OVERDOSE: CLINICAL PRESENTATION AND 
PLASMA LEVELS. 

23131801-13 
CLINICAL PSYCHOPHARMACOLOGY AND PSYCHIATRY. 

231607 01-17 
CONCEPTS OF IMPULSIVITY: A CLINICAL NOTE. 

231610 01-09 
SEDATIVE HYPNOTIC PROPERTIES OF A NEW BENZODIAZEPINE IN 

COMPARISON WITH FLURAZEPAM: PHARMACOLOGICAL AND CLINICAL 
FINDINGS. 

232530 01-07 
PRACTICAL CLINICAL PSYCHOPHARMACOLOGY: IHE ANTIDEPRESSANTS 
AND LITHIUM. 

232762 02-17 
THE ROLE OF CLINICAL PSYCHIATRY IN THE DEVELOPMENT OF NEW 
PSYCHOTROPIC DRUGS. 

233684 02- 1 7 
CLINICAL STUDIES OF DOPAMINERGIC MECHANISMS. 

233975 02-11 
CLINICAL EXPERIENCE WITH CLOZAPINE. 

234419 02-11 
EFFECT OF L-5-HYDROXYTRYPTOPHAN ON BRAIN MONOAMINE 
METABOLISM AND EVALUATION OF ITS CLINICAL EFFECT IN 
DEPRESSED PATIENTS. 

234673 02-09 
CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
PSYCHOTROPIC DRUGS. 

234797 02-09 
ATROPINE COMA THERAPY IN PSYCHIATRY: CLINICAL OBSERVATIONS 
OVER A 20-YEAR PERIOD AND A REVIEW OF THE LITERATURE. 

234826 02-17 
6ENZ0CTAMINE IN THE TREATAylENT OF NEUROSIS - AN UNCONTROLLED 
CLINICAL STUDY 

235356 02-07 
ETAFENOXIN IN THE TREATMENT OF NEUROSIS AN UNCONTROLLED 

CLINICAL STUDY. 

235357 02 07 
LORAZEPAM IN THE TREATMENT OF NEUROSIS - AN UNCONTROLLED 

CLINICAL STUDY. 

235358 02 07 
TRAZODONE IN THE TREATMENT OF NEUROSIS - AN UNCONTROLLED 

CLINICAL STUDY. 

235359 02-07 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - 1. REPORT ON AN UNCONTROLLED CLINICAL 
TRIAL 

235360 02-07 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS • II REPORT ON A PLACEBO CONTROLLED 
CLINICAL TRIAL 

235361 02-09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - 111. STANDARD CONTROLLED CLINICAL 
TRIAL 

235362 02 09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - IV. A SUMMARY REPORT. 

235363 02-09 
PENFLURIDOL IN THE TREATMENT OF SCHIZOPHRENIA CLINICAL AND 

PSYCHOMETRIC FINDINGS 

235365 02-08 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES. II. BLOOD LEVELS 
AND THERAPEUTIC RESPONSIVENESS, 

235367 02-09 



09 






S-77 



Subject Index 



Psychopharmacology Abstracts 



■-im 



TRAZODONE: CLINICAL AND BIOCHtMICAL STUDIES: III. 

DEXAMETHASONE SUPPRESSION TEST RESULTS AND THERAPEUTIC 
RESPONSIVENESS. 

235368 0209 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES: I, AN 

UNCONTROLLED ClINICAL TRIAL IN DEPRESSION, 

235369 02-07 
THYROIROPIN RELEASING HORMONE IN DEPRESSION: CLINICAL AND 

ENDOCRINOLOGICAL FINDINGS. 

235370 02-09 
A CLINICAL CONTRIBUTION ON THE EFFECTS OF SUSPENDING 

ANTIPARKINSONIAN DRUGS IN PROLONGED TREATMENT WITH 
NEUROLEPTIC DRUGS, 

235992 02-11 
CLINICAL PSYCHOPHARMACOLOGY AND THE ELDERLY PATIENT. 

236300 02-17 
CLINICAL EVALUATION OF THE ANTIDEPRESSIVE ACTION OF THE 
PREPARATION AZAFEN 

236429 02-10 
CEREBELLAR ATAXIA DUE TO DIPHENYLHYDANTOIN ADMINISTRATION - 
CLINICAl AND PATHOLOGICAL STUDIES ON TWO CASES OF CHRONIC 
DIPHENYLHYDANTOIN INTOXICATION. 

236696 02-15 
EXCIT.ATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 
RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARAAACOLOGICAL, 
FUNCTIONAL AND CLINICAL DATA. 

237104 02-03 
CLINICAL USE OF ANTIANXIETY DRUGS. 

237165 02-10 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY. 

237458 02-10 
CLINICAL STUDIES WITH DOPAMINE RECEPTOR STIMULANTS. 

237725 02-08 
CLINICAL LABORATORY TEST STANDARDS FOR A SAMPLE OF 

SCHIZOPHRENICS. 

237726 02-08 
PRETREATMENT CPK AND CLINICAL RESPONSE TO ANTIPSYCHOTIC 

MEDICATION, (UNPUBLISHED PAPER), 

238489 02-08 
INFLUENCE OF THE ROUTE OF ADMINISTRATION OF THE CLINICAL 
ACTION OF DIAZEPAM. 

238531 02-13 
SLEEP AND HYPNOTIC DRUGS: THE PHYSIOLOGY, PHARMACOLOGY AND 
CLINICAL ASPECTS OF SLEEP. 

239029 03-14 
CLINICAL PHARMACOLOGY AND THE PRESCRIPTION OF PSYCHOTROPIC 
MEDICATION, 

239678 03-17 
RELATIONSHIP BETWEEN ANTIDEPRESSANT EFFECT AND PLASMA LEVEL 
OF NORTRIPTYLINE. CLINICAL STUDIES, 

240217 03-09 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: I INVESTIGATIONS WITH HALOPERIDOL. 

240218 03 08 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: II, ANTIPSYCHOTIC EFFECT OF HALOPERIDOL IN PATIENTS 
WITH CHRONIC ORGANIC BRAIN DAMAGE 

240219 03-11 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: III PRIMITIVE REFLEXES DURING NEUROLEPTIC 
TREATMENT 

240220 03-14 
CLINICAL ASPECTS OF COCAINE. ASSESSAAENT OF ACUTE AND CHRONIC 

EFFECTS IN ANIMALS AND MAN (UNPUBLISHED PAPER). 

240241 03-04 
DPH-INTOXICATION - CLINICAL AND NEUROPSYCHOLOGICAL 
EVALUATION OF A SLOW DPH ELIMINATION. 

240692 03-15 
A PRIMER ON THE ClINICAL EVALUATION OF PSYCHOTROPIC DRUGS, 

240838 03-17 
CONTROLLED CLINICAL AND QUANTITATIVE EEG STUDIES OF 

TRIFLUBAZAM (ORF-8063) IN PATIENTS WITH ANXIETY SYNDROME. 

241275 03-10 
DEPOT NEUROLEPTICS - PRACTICAL METBODS OF LONG-TERM 

TREATMENT AND METHODOLOGICAL PROBLEMS OF CLINICAL TRIALS. 

241761 03-08 
MAPROIILINE (LUDIOMIL. CIBA-34276-BA) AND IMIPRAMINE IN 
DEPRESSED OUTPATIENTS: A DOUBLE-BLIND CLINICAL STUDY 

242248 03-09 
A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL WITH MAPROTILINE 

(LUDIOMIL) AND IMIPRAMINE IN NEWLY-ADMITTED DEPRESSED 
PATIENTS 

242249 03-09 
CLINICAl RESEARCH WITH DEMETRIN IN SURGERY PATIENTS, 

242527 03-07 



CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANI/WALS AND MAN, (UNPUBLISHED PAPER 

243024 04- 1 7 
THE CLINICAL EFFECTIVENESS OF A CAVAIN-MAGNESIUM-OROTATE 
COMBINATION IN NURSING HOME PATIENTS IN A DOUBLE-BLIND 
STUDY, 

243180 04-11 
CLINICAL AND ELECTROENCEPHALOGRAPHICAL STUDIES OF THE NEW 
HYPNOSEDATIVE K-2004. 

243198 04- n 
DOPAMINE RECEPTOR BINDING PREDICTS CLINICAL AND 

PHARMACOLOGICAL POTENCIES OF ANTISCHIZOPHRENIC DRUGS. 

243483 04 03 
CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
PSYCHOTROPIC DRUGS. 

243819 04-13 
CLINICAL USE OF TRICYCLIC ANTIDEPRESSANTS. 

243861 04-09 
BIOCHEMICAL PHARMACOLOGICAL BASES FOR THE CLINICAL USE OF L- 
DIHYDROXYPHENYLALANINE IN PARKINSONS SYNDROME. 

244039 04-17 
CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, ICI-58834. 

244189 04-07 
INTERACTIONS OF HALLUCINOGENS AT THE CLINICAL LEVEL. 
(UNPUBLISHED PAPER). 

244195 04-12 
CLINICAL FINDINGS IN DISEASES IN THE ELDERLY WITH A CLEAR 
PSYCHOGENIC COMPONENT WITH PARTICULAR RESPECT TO THEIR 
PHARMACOLOGICAL TREATMENT. 

244476 04-11 
SERUM LITHIUM CURVE AND CLINICAL PSYCHOMETRIC VARIABLES: 
PRELIMINARY EXPERIMENTS 

244591 04-13 
STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAMAZEPINE 
IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 2- 
18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 
WITH BEHAVIOR AND CHARACTER. 

244958 04) 1 
CLINICAL EXPERIENCE WITH RO-5-3350 (BROMAZEPAM) 

245138 04-10 
CLINICAL OBSERVATIONS ON THE TREATMENT OF TARDIVE-DYSKINESIA 
WITH HALOPERIDOL. 

245967 0408 
LOGICAL ANALYSIS OF THE RESPECTIVE INFLUENCE OF THREE 

EXPERIMENTAL VARIABLES BY MEANS OF A DIAGRAM OF L. CARROLL. 
APPLICATION OF THIS METHOD TO A CLINICAL TRIAL OF TWO FORMS 
OF NOVERIL. 

245971 04-06 
PRACTICAL CLINICAL PSYCHOPHARMACOLOGY: THE TRANQUILIZERS. 

246033 04-17 
RECENT CLINICAL EXPERIENCE WITH TREATMENT OF DEPRESSION WITH 
GER0VITAL-H3 TABLETS. 

246425 04-09 
THE CLINICAL COURSE OF PRIAAARY RECURRENT DEPRESSION IN 
PHARMACOLOGICALLY TREATED FEMALE PATIENTS. 

246612 04-17 
CLONAZEPAM IN FACIAL NEURALGIA AND CLUSTER HEADACHE; 
CLINICAL AND ELECTROPHYSIOLOGICAL STUDY. 

246995 04-11 
CLINICAL EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE IN 
HYPERACTIVE CHILDREN. 

247380 04 14 
CLINICAL PHARMACOLOGICAL MANAGEMENT OF HYPERKINETIC 

CHILDREN. 

247381 04-17 
AN EARLY CLINICAL AND TOXICITY TRIAL OF EX-1 1-582A IN CHRONIC 

SCHIZOPHRENIA. 

247481 04-07 
A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF A NEW 

ANTIDEPRESSANT AGENT, MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE CHLORHYDRATE (CIBA-34276-BA). 

247554 04-09 
THE CLINICAL USES OF LEVODOPA 

247712 04-17 
CLINICAL EVALUATION OF CDP-CHOLINE (NICHOLIN): EFFICACY AS 
ANTIDEPRESSANT TREATMENT. 

247969 04-09 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEEN CLINICAL 
POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS. 

248466 04-03 
CLINICAL PHARMACOLOGY OF NABILONE, A CANNABINOL DERIVATIVE. 

248628 04-12 
CONTROLLED CLINICAL TRIAL OF A NEW ANTIDEPRESSANT (ORG-GB-94) 
OF NOVEL CHEMICAL FORMULATION 

248977 04-09 
THE CLINICAL PHARAMCOLOGY OF LILLY109514 IN NORMAL 
VOLUNTEERS. 

249260 04-07 



S-78 



OLUME 14, SUBJECT INDEX 



Subject Index 



A RELATIONSHIP BETWEEN CLINICAL EFFICACY AND VARIOUS 

BIOCHEMICAL PARAMETERS OF MONOAMINE-OXIDASE INHIBITORS 
(MAOIS)^ 

249308 04-03 
A CLINICAL TRIAL OF TEMAZEPAM. A SLEEP INDUCER, IN HOSPITAL 
PATIENTS. 

251006 04-07 
CLINICAL TRIALS OF OXPRENOLOL IN ANXIETY. 

251159 04-10 
CLINICAL EXPERIENCE WITH BETA-BLOCKERS IN CONSULTANT 
PSYCHIATRIC PRACTICE. 

251165 04-10 
ON THE CLINICAL RELEVANCE OF THE INTRACELLULAR RBC LITHIUAA 
CONCENTRATION. 

251417 04-15 
CLINICAL RESPONSE TO A POTENTIAL NONSEDATIVE ANXIOLYTIC. 

251719 04-07 
EFFECT OF FLURAZEPAM ON COMMON CLINICAL LABORATORY TESTS. 

251824 04-16 
A CLINICAL TRIAL OF TOFRANIL IN OSTEOARTHRITIS. 

252136 04-11 
A CLINICAL TRIAL OF TOFRANIL IN RHEUMATIC PAIN IN GENERAL 
PRACTICE. 

252139 04-17 
CLINICAL AND THERAPEUTICAL PROBLEMS OF MILD (NONPSYCHOTIC) 
MENTAL DEPRESSIONS. 

252447 04-10 
THE CLINICAL EVALUATION OF GRANDAXIN USED IN THE TREATMENT OF 

OUTPATIENTS (A MULTICENTRIC STUDY). 

252448 04 07 
CLINICAL APPLICATIONS OF A NEW RATIONALE IN THE TREATMENT OF 

ACUTE ALCOHOL WITHDRAWAL. 

252694 04-11 
AN UNCONTROLLED CLINICAL TRIAL OF TRAZODONE 

253054 04-11 
AN UNCONTROLLED CLINICAL TRIAL OF TRAZODONE. 

253055 04-11 
A COMPARISON OF TWO UNCONTROLLED CLINICAL TRIALS OF 

TRAZODONE, 

253056 04- 1 1 
A PLACEBO CONTROLLED CLINICAL TRIAL OF TRAZODONE. 

253057 04-11 
A STANDARD CONTROLLED CLINICAL TRIAL OF TRAZODONE ON 

GERIATRIC PATIENTS. 

253058 04-11 
TREATMENT OF DEPRESSION IN THE AGED WITH GER0VITAL-H3 

CLINICAL EFFICACY AND NEUROPHYSIOLOGICAL EFFECTS. 

253061 04-11 
DIGITALIS: CLINICAL IMPLICATIONS OF NEW FACTS ABOUT AN 01 D 
DRUG. 

253495 04-15 
ACUTE MANIA: CLINICAL AND GENETIC STUDY OF RESPONDERS AND 
NONRESPONDERS TO TREATMENTS 

253617 04 09 
INICAUY 

THE ANTINICOTINIC EFFECTS OF DRUGS WITH CLINICALLY USEFUl 
SEDATIVE ANTIANXIETY PROPERTIES. 

248009 04-03 
INICIAN 
PLASMA CONCENTRATION OF OIPHENYLHYDANTOIN IN THE EPILEPTIC: 
ITS INTEREST FOR THE CLINICIAN. 

240762 03-11 
INICO-CHEMICAl 
URINARY EXCRETION OF METABOLITES OF CHLORPROMAZINE: CLINICO- 
CHEMICAL CORRELATIONS. 

244050 04-08 
INICOPHARMACOLOGlCAl 
PECULIAR CLINICOPHARMACOLOGICAL PROPERTIES OF CLOZAPINE 
REVEALED IN A GROUP OF CHRONIC SCHIZOPHRENICS. 

244587 04-08 
OFIBRATE 
DOSE-RESPONSE RELATIONS IN DRUG-INDUCED INAPPROPRIATE 
SECRETION OF ADH: EFFECTS OF CLOFIBRATE AND CARBAMAZEPINE. 

232638 02 13 
OMACRAN 
CLOMACRAN IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS: A 
COMPARISON OF TWO ASSESSMENT METHODS 

231034 01-08 
CLOMACRAN IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS - A 
COMPARISON OF TWO ASSESSMENT METHODS 

235364 02-08 
OMIPRAMINE 
THE EFFECTS OF PROTRIPTYLINE AND CLOMIPRAMINE IN VITRO ON THE 
UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN HUMAN 
PLATELET-RICH PLASMA. 

227139 01-03 
A DOUBLE-BLIND CONTROLLED COMPARISON OF CLOMIPRAMINE 
(ANAFRANIL) AND IMIPRAMINE ON DEPRESSION. 

228327 01-09 



SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 
PSYCHIATRIC PATIENTS - I. REPORT ON AN UNCONTROLLED CLINICAL 
TRIAL. 

235360 02-07 
SYSTEAAATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - II. REPORT ON A PLACEBO CONTROLLED 
CLINICAL TRIAL. 

235361 02 09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - III STANDARD CONTROLLED CLINICAL 
TRIAL. 

235362 02-09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - IV. A SUMMARY REPORT, 

235363 02-09 
SYNTHESIS OF 3-CHL0R0-2-HYDR0XYIMIPRAMINE AND 3-CHL0R0-8- 

HYDROXYIMIPRAMINE (1), HYPOTHETICAL METABOLITES OF 
CLOMIPRAMINE. (UNPUBLISHED PAPER). 

237174 02-01 
A CONTROLIED COMPARATIVE TRIAL OF A COMBINATION OF 
OPIPRAMOI. AND CLOMIPRAMINE AND A HIGHER DOSE OF 
CLOMIPRAMINE ALONE. 

245468 04-09 
EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEG - DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE. 

246319 04-03 
CLONAL 

NEUROTRANSMITTER REGULATION OF ADENOSINE 3,5 MONOPHOSPHATE 
IN CLONAL NERVE, GLIA, AND MUSCIE CELL LINES. 

243482 04-03 
CLONAZEPAAA 

THE USE OF CLONAZEPAM IN TREATING CONVULSIVE MANIFESTATIONS 
WITH ENCEPHAIOPATHY IN CHILDREN: STUDY OF 28 CASES. 

229083 01-11 
ALTERED 5-HT METABOLISAA WITH CLONAZEPAM, DIAZEPAM AND 
OIPHENYLHYDANTOIN. 

230855 01-03 
LONG-TERM TREATMENT OF PETIT-MAL WITH CLONAZEPAM. 

231654 OT-TT 
INTENTION MYOCLONUS: SUCCESSFUL TREATMENT WITH CLONAZEPAM. 

237825 02-1 1 
CLONAZEPAM IN FACIAL NEURALGIA AND CLUSTER HEADACHE: 
CLINICAL AND ELECTROPHYSIOLOGICAL STUDY. 

246995 04- T I 
CLONAZEPAM IN THE TREATAAENT OF CHOREIFORM ACTIVITY 

250932 04-07 
ClONAZEPAM-INOUCED 

CLONAZEPAM INDUCED CHANGES IN 5-HYDROXYrRYPTAMINE (5-HT) 
METABOLISM IN ANIMALS AND MAN. 

237977 02-13 
CLONIC 

INHIBITORY EFFECTS IF 6-HYDROXYDOPAMINE ON THE CLONIC 
CONVULSIONS INDUCED BY ELECTROSHOCK AND DECAPITATION. 

245597 04-03 
CLONIDINE 

EFFECTS OF CLONIDINE AND BS 100-141 ON THE EEG SLEEP PATTERN IN 
RATS 

226728 01-03 
AUTOMUTILATION INDUCED BY CLONIDINE IN MICE. 

241398 03-04 
EFFECT OF THE NOREPINEPHRINE RECEPTOR STIMULATING AGENT 
CLONIDINE ON THE TURNOVER OF 5 HYDROXYTRYPTAMINE IN SOME 
AREAS OF THE RAT BRAIN. 

243777 04-03 
A STUDY OF THE CENTRAL EFFECTS OF SYMPATHOMIMETIC DRUGS: EEG 
AND BEHAVIOURAL INVESTIGATIONS ON CLONIDINE AND 
NAPHAZOLINE. 

246148 04-04 
POTENTIATING EFFECT OF LITHIUM CHLORIDE ON AGGRESSIVE 

BEHAVIOUR INDUCED IN MICE BY NIALAMIDE PLUS L-DOPA AND BY 
CLONIDINE. 

246664 04-04 
EFFECT OF CLONIDINE ON THE NOREPINEPHRINE (NE) SENSITIVE CYCLIC- 
AMP GENERATING SYSTEM IN SLICES OF RAT SPINAL CORD (SO, 
BRAINSTEM (BS) AND LIMBIC fOREBRAIN (LFB) AND ON MEDIAL 
FOREBRAIN BUNDLE (MFB) STIMULATION. 

249255 04-03 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE AND CLONIDINE 
FOLLOWING FRONTAL CORTICAL DAMAGE IN RATS. 

250089 04-04 
DIFFERENT ALPHA-ADRENORECEPTORS IN THE CENTRAL-NERVOUS- 
SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF 
CLONIDINE AND RECEPTOR BLOCKING AGENTS. 

251226 04-02 
CLOPENTIXOL 

CLINICAL PHYSIOGNOMY OF CHLORPROTHIXENE AND CLOPENTIXOL. 

227766 01 11 






ess 

OS 
I 



i 



S-79 



Subject Index 



Psychopharmacology Abstracts 



CIOPIMOZIDE 

CLOPIMOZIDE (R-29-764), A NEW HIGHLY POTENT AND ORALLY LONG- 
ACTING NEUROLEPTIC OF THE DIPHENYLBUTYLPIPERIDINE SERIES. 

232529 01-04 
CLORAZEPATE 

THE CLINICAL EVALUATION OF A NEW MINOR TRANQUILIZER 
CLORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOMATIC DISEASE, NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BLIND CLINICAL STUDY. 

229504 01-11 
CLINICAL EXPERIENCE IN USING MENDON (DIPOTASSIUM CLORAZEPATE). 

229626 01-11 
GLC DETERMINATION OF PLASMA DRUG LEVELS AFTER ORAL 
ADMINISTRATION OF CLORAZEPATE POTASSIUM SALTS. 

246968 04-03 
CLORAZEPATE DIPOTASSIUM (TRANXENE): A CONTROLLED EVALUATION 
IN ALCOHOLIC PATIENTS AFTER WITHDRAWAL. 

251718 04-11 
ClOTHIAPINE 

A CONTROLLED TRIAL OF CLOTHIAPINE AND CHLORPROMAZINE IN 
ACUTE SCHIZOPHRENIC SYNDROMES 

226412 01-08 
THE RESOCIALIZING EFFECT OF CLOTHIAPINE IN CHRONIC PSYCHOSES. 

230993 01-11 
CLOXAZOLAM 

CLINICAL EXPERIENCE IN USING CLOXAZOLAM (SEPAZON). 

229025 01-10 
CLOZAPINE 

CLOZAPINE INCREASES RAT SERUM PROLACTIN LEVELS. 

226869 01 03 
INHIBITION OF 4,ALPHA DIMETHYL-M-TYRAMINE H77-77 INDUCED 

HYPERMOBILITY IN RATS BY SINGLE AND REPEATED ADMINISTRATION 
OF CHLORPROMAZINE HALOPERIDOL, CLOZAPINE AND THIORIDAZINE. 

227129 01-04 
DETECTION OF THE NEUROLEPTIC PROPERTIES OF CLOZAPINE, SULPIRIDE, 
AND THIORIDAZINE. 

227135 01-04 
DIFFERENTIAL SENSITIVITY OF TWO DOPAMINERGIC STRUCTURES IN RAT 
BRAIN TO HALOPERIDOL AND TO CLOZAPINE. 

233291 02 03 
CLINICAL EXPERIENCE WITH CLOZAPINE. 

234419 02-11 
COMPARISON OF THE THERAPEUTIC EFFECT OF CLOZAPINE AND 

CHLORPROMAZINE 

234420 02-14 
AN EXPERIMENTAL STUDY OF THE SPECTRUM OF INDIVIDUAL 

PSYCHOTROPIC ACTIVITY OF CLOZAPINE (LEPONEX). 

236174 02-04 
EXTRAPYRAMIDAL SYMPTOMS UNDER CLOZAPINE: A CASUISTIC 
CONTRIBUTION. 

238855 03-15 
EFFECT OF CLOZAPINE ON THE METABOLISM OF SEROTONIN IN RAT 
BRAIN. 

239862 03 03 
IN VIVO ACTIONS OF CLOZAPINE AND HALOPERIDOL ON THE TURNOVER 
RATE OF ACETYLCHOLINE IN RAT STRIATUM 

241252 03-03 
EFFECTS OF A SINGLE ADMINISTRATION OF CLOZAPINE ON MOUSE 
BRAIN CATECHOLAMINES. 

241416 03-03 
COMPARISON TRIAL OF TWO ANTIPSYCHOTIC DRUGS: 
CHLORPROMAZINE AND CLOZAPINE 

241760 03 08 
ON THE MECHANISM OF ACTION OF CLOZAPINE ON THE ADRENERGIC 
NEURONE. 

241919 03 03 
ON THE MECHANISM OF ACTION OF CLOZAPINE ON THE ADRENERGIC 
NEURONE. 

243760 04-03 
EFFECT OF CLOZAPINE ON THE MENTAL AND PHYSICAL STATE OF 
PATIENTS. 

243986 04 08 
PECULIAR CLINICOPHARMACOLOGICAL PROPERTIES OF CLOZAPINE 
REVEALED IN A GROUP OF CHRONIC SCHIZOPHRENICS. 

244587 04-08 
CLOZAPINE AND THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA, A 
CRITICAL APPRAISAL 

246671 04-03 
ANIAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE APPLIED 
INTRACEREBRALLY TO THE NUCLEUS ACCUMBENS SEPTI BY TYPICAL 
NEUROLEPTICS AND BY CLOZAPINE, SULPIRIDE AND THIORIDAZINE. 

248290 04 06 
ACEIYLCHOLINE SYNTHESIS IN RAT BRAIN DISSIMILAR EFFECTS OF 
CLOZAPINE AND CHIORPROMAZINE 

248600 04-03 
LFFFCl OF THIORIDAZINE, CLOZAPINE AND OTHER ANTIPSYCHOTICS ON 
IHE KINETIC STATE OF TYROSINE HYDROXYLASE AND ON THE 



TURNOVER RATE OF DOPAMINE IN STRIATUM AND NUCLEUS- 
ACCUMBENS. 

248698 04-05 
INHIBITION OF TURNING BEHAVIOUR BY CLOZAPINE IN MICE WITH 
UNILATERAL DESTRUCTION OF DOPAMINERGIC NERVE TERMINALS 

249629 04-04 
CLOZAPINE IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC 
PATIENTS: A PILOT STUDY. 

251828 04-08 
AN EXAMPLE OF EUROPEAN MULTICENTER TRIALS: MULTISPECTRAL 
ANALYSIS OF CLOZAPINE. 

253052 04-08 
CLOZAPINE-INDUCED 

REVERSAL BY PHYSOSTIGMINE OF CLOZAPINE-INDUCED DELIRIUM. 

237647 02-14 
CLUSTER 

CLONAZEPAM IN FACIAL NEURALGIA AND CLUSTER HEADACHE: 
CLINICAL AND ELECTROPHYSIOLOGICAL STUDY. 

246995 04-11 
CNS 

INHIBITORY AND EXCITATORY EFFECTS OF CNS DEPRESSANTS ON 
INVERTEBRATE SYNAPSES 

226398 01-03 
SIMILARITY IN CNS SENSITIVITY TO HEXOBARBITAL IN THE RAT AND 
MOUSE AS DETERMINED BY AN ANALYTICAL, A PHARMACOKINETIC. 
AND AN ELECTROENCEPHALOGRAPHIC MEASURE. 

226865 01-03 
CLINICAL AND CNS EFFECTS OF ORAL AND I.V. THYROTROPIN-RELEASING 
HORMONE IN DEPRESSED PATIENTS. 

227826 01-09 
ONTOGENY OF BEHAVIORAL SENSITIVITY TO STRYCHNINE IN THE CHICK 
EMBRYO: EVIDENCE FOR THE EARLY ONSET OF CNS INHIBITION. 

228630 01-04 
STUDIES ON THE CNS AVAILABILITY OF AMPHETAMINE FROM 
AMPHETAMINIL. 

229041 01-03 
EVIDENCE FOR DRUG ACTIONS ON BOTH PRE- AND POSTSYNAPTIC 
CATECHOLAMINE RECEPTORS IN THE CNS. 

229431 01-03 
CNS STIMULANTS AND ANABOLIC SUBSTANCES IN GEROPSYCHIATRIC 
THERAPY. 

229459 01-11 
DISCOVERY OF SPECIFIC CNS EFFECTS OF LISURIDE HYDROGEN MALEATE 
- AN ANTIMIGRAINE COMPOUND 

229473 01-13 
BIOGENIC AMINE EFFECTS ON CNS PHOSPHOLIPID METABOLISM. 

229482 01-03 
SELF-ADMINISTRATION OF CNS STIMULANTS BY DOG. 

230879 01-04 
PHARMACOLOGICAL STUDIES OF DRUG ACTION ON CNS, WITH SPECIAL 
REFERENCE TO EFFECTS OF MAPROTILINE 

231316 01-04 
CNS EFFECTS OF NEUROLEPTIC AGENTS. 

231993 01 15 
NEW TRICYCLIC ENAMINE DERIVATIVES WITH CNS DEPRESSANT 
PROPERTIES. 

232528 01-02 
CNS TRANSMITTERS AND THE HYPOTHALAMUS 

238784 03 03 
6-HYDROXYDOPAMINE (6 OHDA) ADMINISTRATION TO NEONATAL RATS 
FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) IN THE CNS 

238826 03-03 
EFFECTS OF l,2-BENZISOXAZOLE-3-ACETAMIDOXIME HYDROCHLORIDE 
(PF-257) ON THE CNS WITH SPECIAL REFERENCE TO MONOAMINE 
METABOLISM. 

241393 03 03 
CNS PHOSPHOLIPID METABOLISM AND NEURONAL FUNCTION. 

244089 04 03 
A COMPARISON OF THE DISCRIMINABIE CNS EFFECTS OF KETAMINE, 
PHENCYCLIDINE AND PENTOBARBITAL. 

249025 04-04 
EFFECTS OF CHLORDIAZEPOXIDE, CNS STIMULANTS AND THEIR 

COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE. 

249026 04-04 
BACLOFEN (BE) AN UNUSUAL CNS ACTIVE AGENl 

249304 04-03 
COMBINATIONS OF SELECTED CNS DEPRESSANTS WITH D AMPHETAMINE 
OR MAZINDOL ON FOOD INTAKE AND MOTOR ACTIVITY OF RATS 

250080 04-03 
BEHAVIORAL EVIDENCE FOR THE RAPID RELEASE OF CNS SEROTONIN BY 
PCA AND FENFLURAMINE. 

250083 04 04 
A REVIEW OF THE CNS EFFECTS OF FENFLURAMINE, 780SE AND 
NORFENFLURAMINE ON ANIMALS AND MAN. 

250935 04 17 



S-80 



4 



LUME 14, SUBJECT INDEX 



Subject Index 



ALT 

APPEARANCE OF WET DOG SHAKE BEHAVIOR DURING COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT AND ITS SUPPRESSION BY 
RESERPINE. 

230836 01-04 
AIT-INDUCED 

NEUROCHEMICAL AND MORPHOLOGICAL CHANGES DURING THE 
DEVELOPMENT OF COBALT-INDUCED EPILEPSY IN THE RAT 

226399 01-03 
RA 

ALPHA-BUNGAROTOXIN, COBRA NEUROTOXIN AND EXCITATION OF 
RENSHAW CELLS BY ACETYLCHOLINE. 

244203 04-03 
AINE 

COMPARISON OF PROGRESSIVE-RATIO PERFORMANCE MAINTAINED BY 
COCAINE, METHYLPHENIDATE AND SECOBARBITAL. 

227137 01 04 
COCAINE AND AMPHETAMINE MODIFICATION OF CEREBRAL ENERGY 
METABOLISM IN VIVO, 

230834 01-03 
THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM), 2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE (DOET), D-AMPHETAMINE, AND 
COCAINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE 
STIMULUS. 

230837 01-04 
TIME COURSE FOR THE EFFECTS OF COCAINE ON FIXED-RATIO WATER 

REINFORCED RESPONDING IN RATS. 

230842 01-04 
PRETRIAL COCAINE AND PERFORMANCE IN RAT. 

237108 02-04 
PROGRESSIVE CHANGES IN BEHAVIOR AND SEIZURES FOLLOWING 
CHRONIC COCAINE ADMINISTRATION: RELATIONSHIP TO KINDLING 
AND PSYCHOSIS. (UNPUBLISHED PAPER). 

237169 02-04 
RESPONSES OF NORMAL AND ISOLATE MONKEYS TO D-AMPHETAMINE, 
COCAINE, CHLORPROMAZINE AND DIAZEPAM 

238694 03-04 
EFFECTS OF RO-4-1284, IPRONIAZID, METHYLPHENIDATE, COCAINE OR 
IMIPRAMINE ON SOUND AND PFNTYLENETETRAZOL-INDUCED SEIZURE 
IN THE RAT. 

238706 03-04 
CONCURRENT SCHEDULES OF COCAINE INJECTION IN RHESUS MONKEYS: 
DOSE VARIATIONS UNDER INDEPENDENT AND NON-INDEPENDENT 
VARIABLE-INTERVAL PROCEDURES 

240015 03-04 
CLINICAL ASPECTS OF COCAINE- ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER). 

240241 03-04 
AMT CATALEPSY AND HYPOKINESIA INTERACTION WITH MORPHINE 
AND COCAINE. 

241224 03-04 
CLINICAL ASPECTS OF COCAINE: ASSESSMENT OF ACUTE AND CHRONIC 
EFFECTS IN ANIMALS AND MAN. (UNPUBLISHED PAPER 

243024 04-17 
COMPARATIVE PSYCHOPHARMACOLOGV OF COCAINE AND 
AMPHETAMINE. 

243820 04-17 
NALTREXONE, MORPHINE AND COCAINE INTERACTIONS IN MICE. 

249269 04-04 
COMPARISON OF THE EFFECTS OF COCAINE AND AMPHETAMINE IN 

MONKEYS MAINTAINED ON NALTREXONE. 

249270 04 04 
EFFECTS OF ALCOHOL, CHLORDIAZEPOXIDE, COCAINE, AND 

PENTOBARBITAL ON RESPONDING MAINTAINED UNDER FIXED 
INTERVAL SCHEDULES OF FOOD OR SHOCK PRESENTATION 

2501 1 1 04 04 
COCAINE AND LITHIUM: NEUROBIOLOGICAL ANTAGONISM IN THE 
SEROTONIN BIOSYNTHETIC SYSTEM IN RAT BRAIN 

252514 04 03 

:ainestera$e 

resolution, purification and characterization of rabbit 
serum atropinesterase and cocainesterase 

251180 04-01 

:kroach 

effects of physostigmine on avoidance conditioning and 
retention in the isolated cockroach ganglion. (ph.d. 
dissertation). 

228503 01 04 
}EINE 
FURTHER STUDIES ON SELF ADMINISTRATION OF ANTIPYRETIC 
ANALGESICS AND COMBINATIONS OF ANTIPYRETIC ANALGESICS WITH 
CODEINE IN RHESUS MONKEYS 

246855 04-04 
FFEE 
THE MEDICAL EFfECIS OF COFFEE. 

248862 04-15 



COGNITIVE 

COGNITIVE EFFECTS OF METHYLPHENIDATE ON HYPERACTIVE CHILDREN. 
(PH.D. DISSERTATION). 

228431 01 II 
COGNITIVE AND PERCEPTUAL EFFECTS OF LONG-RANGE L-DOPA THERAPY 
IN PARKINSONISM. 

229165 01-11 
COGNITIVE DEFICITS ASSOCIATED WITH CHRONIC HEPATIC 
ENCEPHALOPATHY AND THEIR RESPONSE TO LEVODOPA. 

230580 01-15 
A REVIEW OF THE EFFECTS OF DIAZEPAM ON COGNITIVE AND 
PSYCHOMOTOR PERFORMANCE. 

235236 02-14 
COGNITIVE EFFECTS OF LONG TERM AAARIJUANA USE. (PH D, 
DISSERTATION). 

238085 02-14 

COLCHICINE 

ANATOMICAL AND BEHAVIORAL EFFECTS OF COLCHICINE 
ADMINISTRATION TO RATS LATE IN UTERO. 

252148 04-05 
COLD 

RESPONSE OF NIGRAL DOPAMINE NEURONS TO ACUTE AND PROLONGED 
MORPHINE TREATMENT: EFFECT OF EXPOSURE TO COLD, 
PHYSOSTIGMINE AND NICOTINE. 

237158 02-03 
RENAL LITHIUM, SODIUM, POTASSIUM, AND WATER EXCRETION AND 
PLASMA RENIN ACTIVITY IN RATS IN THE COLD. 

246673 04-03 
COLLABORATION 

AN ATTEMPT TO ESTABLISH QUALITY CONTROL IN DETERMINATION OF 
PLASMA CHLORPROMAZINE BY A MULTILABORATORY 
COLLABORATION 

229439 01-16 
COLLABORATIVE 

FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM 

CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE 
STUDY GROUP. 

225718 01-09 
DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE 
SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG 
SURVEILLANCE PROGRAM. 

225722 01-15 
COMPARISON OF EFFICACY OF LITHIUM CARBONATE AND 

CHLORPROMAZINE IN MANIA: REPORT OF COLLABORATIVE STUDY 
GROUP ON TREATMENT OF MANIA IN JAPAN 

228226 1 09 
OUTPATIENT PHENOTHIAZINE USE AND BONE MARROW DEPRESSION: A 
REPORT FROM THE DRUG EPIDEMIOLOGY UNIT AND THE BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM. 

253661 04-15 
COLLEGIUM 

NINTH CONGRESS OF THE INTERNATIONAL 

NEUROPSYCHOPHARMACOLOGICUM COLLEGIUM OR C.I.N. P. (PARIS. 
JULY 7-12, 1974). 

250266 04 17 
COLLICULUS 

DOPAMINE AGONIST INDUCED ASYMMETRY AFTER LESIONS OF 
SUPERIOR COLLICULUS IN RATS. 

238699 03-03 
ROLE OF SUPERIOR COLLICULUS SEROTONIN IN THE GROOMING 
BEHAVIOUR OF CATS. 

239978 03 04 
COLONIES 

BEHAVIORAL EVIDENCE OF THE INTERACTION OF PHENCYCLIDINE WITH 
CATECHOLAMINES IN PRIMATE SOCIAL COLONIES. 

238696 03-04 
MONOAMINE NEUROTOXINS: SELECTIVE AND DELAYED EFFECTS ON 
BEHAVIOR IN COLONIES OF LABORATORY RATS. 

25 1 063 04-04 
COLOR 

EYE COLOR AND TARDIVE-DYSKINESIA. 

253037 04 15 
COAAA 

ATROPINE COMA THERAPY IN PSYCHIATRY: CLINICAL OBSERVATIONS 
OVER A 20 YEAR PERIOD AND A REVIEW OF THE LITERATURE. 

234826 02-17 
COMBINATION 

PLASMA CONCENTRATIONS OF L DOPA AND 3 METHOXYDOPA AND 
IMPROVEMENT IN CLINICAL RATINGS AND MOTOR PERFORMANCE IN 
PATIENTS WITH PARKINSONISM TREATED WITH L DOPA ALONE OR IN 
COMBINATION WITH AMANTADINE 

226349 01 14 
A COMBINATION OF ANTIANXIETY DRUGS REPORT FROM THE GENERAL 
PRACTITIONER RESEARCH GROUP. 

228207 01 10 
EFFECT OF TWO WEEKS TREATMENT WITH CHLORDIAZEPOXIDE OR 
FLUPENTHIXOL, ALONE OR IN COMBINATION WITH ALCOHOL ON 
PSYCHOMOTOR SKILLS RELATED TO DRIVING 

229907 01 14 



09 

SO 





00 

I 



S-81 



Subject Index 



Psychopharmacology Abstract 



;Vv>^>;l 



'".v: 



STUDIES ON THF AtriON OF AN ANTICHOLINERGIC IN COMBINATION 
WITH A TRANQUILIZER ON GASTRIC JUICE SECRETION IN MAN, 

232503 01-13 
RESPONSES OF CHRONIC SCHIZOPHRENIC FEMALES TO A COMBINATION 
OF DIPHENYLHYDANTOIN AND NEUROLEPTICS: A DOUBLE BLIND 
STUDY. 

232781 02-08 
DRUGS IN COMBINATION WITH OTHER THERAPIES, 

234378 02-17 
TREATMENT OF ENDOGENOUS PSYCHOSES WITH DOMINAL AND 
DOMINAL FORTE IN COMBINATION WITH HIGHLY ACTIVE 
NEUROLEPriCS. 

235305 02-11 
PHARMACOKINETIC STUDIES IN ABSORPTION AND EXCRETION OF 
OXAZEPAM IN COMBINATION WITH ALCOHOL. 

237123 02-13 
PHARMACOLOGICAL DISSOCIATION BETWEEN VOCALIZATION AND 
BITING PRODUCED IN RATS BY THE COMBINATION OF IMIPRAMINE 
AND ISOCARBOXAZID 

237705 02-04 
TREATMENT OF SYDENHAMS CHOREA WITH A COMBINATION OF L-DOPA 
AND A PERIPHERAL DOPADECARBOXYLASE INHIBITOR. 

237733 02-11 
RELEASE OF NOREPINEPHRINE (NE) AND DOPAMINE-BEl A-HYDROXYLASE 
(DBH) EFFECT OF PHENOXYBENZAMINE (PBZ) ALONE AND IN 
COMBINATION WITH 8 BROMO-CGMP AND DIBUTYRYL-CAMP. 

238690 03-03 
ACUTE EFFECTS OF OXAZEPAM, DIAZEPAM AND METHYLPERONE, ALONE 
AND IN COMBINATION WITH ALCOHOL ON SEDATION, COORDINATION 
AND MOOD. 

239042 03- 14 
THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS AND BETA- 
ADRENERGIC BLOCKERS 

239783 03-15 
EXTRAPYRAMIDAl SYMPTOMS IN A COMBINATION OF LITHIUM LONG- 
TERM THERAPY WITH NORTRIPTYLINE; A CAUSISTIC REPORT ON 
PATHOGENESIS AND HYPOTHESIS FORMULATION. 

239835 03-15 
LITHIUM TREMOR - COMBINATION TREATMENT WITH BETA-RECEPTOR 
BLOCKERS?. 

240741 03-14 
COMBINATION OF IRICYCLIC ANTIDEPRESSANTS AND MAOI IN 
DEPRESSION 

240839 03-09 
THE EFFECT OF ETHANOL STRESS IN COMBINATION ON THE 

PHARMACOLOGIC ACTION OF HEXOBARBITAL. (PH.D. DISSERTATION). 

240933 03-03 
EFFECT OF SUBACUTE TREATMENT WITH HYPNOTICS, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON PSYCHOMOTOR SKILLS RELATED 
TO DRIVING. 

241417 03-15 
THE ClINICAL EFFECTIVENESS OF A CAVAIN MAGNESIUM-OROTATE 
COMBINATION IN NURSING HOME PATIENTS IN A DOUBLE BLIND 
STUDY. 

243180 04-1 1 
THE MORNING AFTER: RESIDUAL EEG EFFECTS OF TRIAZOLAM AND 
FLURAZEPAM, ALONE AND IN COMBINATION WITH ALCOHOL. 

244960 04-13 
A CONTROLIED COMPARATIVE TRIAL OF A COMBINATION OF 
OPIPRAMOL AND CLOMIPRAMINE AND A HIGHER DOSE OF 
CLOMIPRAMINE ALONE 

245468 04-09 
THE REIAIIVE ROLE OF BRAIN ACETYICHOLINE AND HISTAMINE IN 
PERPHENAZINE CATATONIA AND INFLUENCE OF ANTIDEPRESSANTS 
AND DIPHENHYDRAMINE ALONE AND IN COMBINATION. 

245593 04-05 
EFFECT OF TWO WEEKS TREATMENT WITH THIORIDAZINE 

CHLORPROMAZINE, SULPIRIDE AND BROMAZFPAM, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY IN MAN. 

246315 04-14 
COMBINATION DRUG THERAPY FOR THE PSYCHOGERIATRIC PATIENT: 
COMPARISON OF DOSAGE LEVELS OF THE SAME PSYCHOTROPIC 
DRUGS, USED SINGLY AND IN COMBINATION 

246694 04-11 
OXAZEPAM PROTRIPTYLINE: A DOUBLE BLIND PHASE II EVALUATION OF 
THE EFFICACY AND SAFETY OF THE COMBINATION VERSUS PLACEBO 
IN NEUROTIC, DEPRESSED AND ANXIOUS PSYCHIATRIC OUTPATIENTS. 

248975 04-10 
EEG AND BEHAVIORAL EFFECTS OF NARCOTIC ANTAGONISTS ALONE AND 
IN COMBINATION WITH OTHER PSYCHOACTIVE DRUGS IN MORPHINE- 
DEPENDENT MACACA MULATTA 

249267 04-04 
THE EFFECT OF CAFFEINE ON HUMAN PERFORMANCE, ALONE AND IN 
COMBINATION WITH ETHANOL. 

249674 04-14 
THE EFFECT OF TRYPTOPHAN AND A TRYPTOPHAN/5 

HYDROXYTRYPTOPHAN COMBINATION ON INDOLES IN THE BRAINS OF 
RATS FED A TRYPTOPHAN DEFICIENT DIET. 

249675 04-03 



AMPHETAMINE AND BARBITURATE EFFECTS ON TWO TASKS PERFORME 
SINGLY AND IN COMBINATION. 

253381 04-1 
COMBINATIONS 

THE PHARMACOLOGIC MEANING OF SUCCESSFUL ANTIPSYCHOTIC 
ANTIDEPRESSANT COMBINATIONS. 

230010 01-1 
ALTERATIONS IN DOPAMINE UPTAKE IN RAT CORPUS-STRIATUM 
INDUCED BY COMBINATIONS OF STRESS AND DELTA8- 
TETRAHYDROCANNABINOL (DELTA8-THC) 

241926 03-C 
FURTHER STUDIES ON SELF-ADMINISTRATION OF ANTIPYRETIC 
ANALGESICS AND COMBINATIONS OF ANTIPYRETIC ANALGESICS WITI 
CODEINE IN RHESUS MONKEYS. 

246855 04-C 
EFFECTS OF CHLORDIAZEPOXIDE, CNS STIMULANTS AND THEIR 
COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE. 

249026 04-C 
COMBINATIONS OF SELECTED CNS DEPRESSANTS WITH D-AMPHETAMIN 
OR MAZINDOL ON FOOD INTAKE AND MOTOR ACTIVITY OF RATS. 

250080 04-C 
COMBINED 

A PLACEBO CONTROLLED STUDY OF LITHIUM COMBINED WITH 
NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC PATIENTS. 

232840 02-C 
THE INFLUENCE OF ALCOHOL AND OTHER DRUGS ON MENTAL TASK 
PERFORAAANCES UNDER THEIR COMBINED ADMINISTRATION. 

233281 02-1 
TWO YEAR COMBINED THERAPY OF PARKINSONS DISEASE WITH L-DOP/ 
AND THE DECARBOXYLASE INHIBITOR BENSERAZID (RO-4 4602) 

233917 02-1 
IMPACT OF PSYCHOSOCIAI FACTORS ON THE CONDUCT OF COMBINED 
DRUG AND PSYCHOTHERAPY RESEARCH. 

235534 02-1 
EVALUATION OF COMBINED PHARMACOLOGICAL AND 

PSYCHOTHERAPEUTIC TREATMENT IN PATIENTS WITH FUNCTIONAL 
ABDOMINAL DISORDERS. 

235782 02-) 
THE DISTRIBUTION AND METABOLISM OF ETHANOL AND BARBITURATES 
IN THE ORGANISM DURING THEIR COMBINED USE (LITERATURE 
SURVEY). 

236717 02-0 
THE MEDICAL SAFETY OF THE COMBINED USAGE OF DISULFIRAM AND 
METHADONE: PHARMACOLOGICAL TREATMENT FOR ALCOHOLIC 
HEROIN ADDICTS. 

239943 03-1 
COMBINED EFFECTS OF METHAMPHETAMINE, CAFFEINE, DIAZEPAM, AN! 
PENTOBARBITAL ON DRL PERFORMANCE IN RATS. 

241400 03-0 
DEPENDENCY ON COMBINED METHAQUALONE DIPHENHYDRAMINE. 

241870 03-1 
EFFECTS OF MARIHUANA COMBINED WITH SECOBARBITAL. 

245648 04-] 
COMBINED THERAPY WITH TETRABENAZINE AND PIMOZIDE IN 
HUNTINGTONS-CHOREA: PILOT STUDY. 

248172 04-1 
COMPARISON OF DOPADECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE IN PARKINSONS 
DISEASE. 

248612 04-1 
COMPARISON OF DOPADECARBOXYLASE INHIBITOR (CARBIDOPA) 

COMBINED WITH LEVODOPA AND LEVODOPA ALONE ON THE 
CARDIOVASCULAR SYSTEM OF PATIENTS WITH PARKINSONS DISEASE, 

248613 04-1 
ELICITATION OF MOUSE JUMPING BY COMBINED TREATMENT WITH 

AMPHETAMINE AND L-DOPA: BLOCKADE BY KNOWN NEUROLEPTICS. 

249272 04-0' 
APPROACH TO A COMBINED PHARMACOLOGIC THERAPY OF CHILDHOOD 
HYPERKINESIS. 

249772 04-1 
LITHIUM COMBINED WITH NEUROLEPTICS IN THE TREATMENT OF 
CHRONIC SCHIZOPHRENIA. 

253049 04-Of 
COMBINING 

EFFECTS OF COMBINING METHYLPHENIDATE AND CLASSROOM TOKEN 
SYSTEM IN MODIFYING HYPERACTIVE BEHAVIOR. 

232807 02-11 
COMMUNITY 

CLINICAL PHARMACY PRACTICE IN A COMMUNITY MENTAL-HEALTH 
CENTER. 

227560 01-1/ 
LONG-ACTING PHENOTHIAZINE AND SOCIAL THERAPY IN THE 
COMMUNITY TREATMENT OF ACUTE SCHIZOPHRENICS. 

229448 01 -0£ 
COMPARED 

SHORT-TERM EFFECTS OF VILOXAZINE (VIVALAN) COMPARED WITH 
PLACEBO IN DEPRESSION: A DOUBLE-BLIND STUDY. 

227214 01 05 



S-82 



* 



UME 14, SUBJECT INDEX 



Subject Index 



.ORAZEPAM COMPARED WITH PENTOBARBITAL FOR NIGHTTIME 
SEDATION 

232622 02-14 
'ERORAL AND PARENTERAL ADMINISTRATION OF LONG-ACTING 
NEUROLEPTICS: A DOUBLE-BLIND STUDY OF PENFLURIDOL COMPARED 
TO FLUPENTHIXOL-DECANOATE IN THE TREATMENT OF 
SCHIZOPHRENIA 

239023 03-08 
FRAZODONE: THERAPEUTIC EFFECTIVENESS IN ENDOGENOUS 
DEPRESSION, COMPARED WITH BLOOD LEVELS. 

244588 04-09 
IFFECTS OF THIENODIAZEPINE DERIVATIVES ON HUMAN SLEEP AS 
COMPARED TO THOSE OF BENZODIAZEPINE DERIVATIVES. 

246309 04-07 
ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED WITH THREE OTHER DRUGS. 

248283 04-02 
PARING 

fHERAPY OF ANXIETY IN PATIENTS WITH RHEUMATIC DISEASE: 
CROSSOVER DOUBLE-BLIND STUDY COMPARING LORAZEPAM WITH 
PLACEBO. 

228241 01-11 
.(QUID LITHIUM VS. SOLID LITHIUM: AN OPEN, CROSSOVER, PILOT 
STUDY COMPARING ORAL PREPARATIONS. 

247877 04-07 
PARISON 

\ DOUBLE-BLIND COMPARISON BETWEEN DOXEPIN AND DIAZEPAM IN 
THE TREATMENT OF STATES OF ANXIETY. 

226410 01-10 
\ COMPARISON BETWEEN LITHIUM, PLACEBO AND A DIURETIC IN 
PREMENSTRUAL TENSION. 

226414 01-11 
:OMPARISON OF PROGRESSIVE-RATIO PERFORMANCE MAINTAINED BY 
COCAINE, METHYLPHENIDATE AND SECOBARBITAL 

227137 01-04 
i/ILOXAZINE (VIVALAN) COMPARISON WITH IMIPRAMINE. 

227215 01-09 
:AFFEINE VERSUS METHYLPHENIDATE AND D-AMPHETAMINE IN 
MINIMAL-BRAIN-DYSFUNCTION: A DOUBLE-BLIND COMPARISON 

227571 01-11 
COMPARISON OF CENTRAL EFFECTS OF NORADRENALINE AND DOPAMINE 
INJECTED INTO THE LATERAL BRAIN VENTRICLE IN RATS. 

227636 01 04 
3ENZ0DIAZEPINES: A COMPARISON OF THEIR EFFECTS IN MICE ON THE 
MAGNITUDE OF THE PALMAR SKIN CONDUCTIVITY RESPONSE AND ON 
PENTYLENETETRAZOL-INDUCED SEIZURES. 

227694 01-03 
COMPARISON OF EFFICACY OF LITHIUM CARBONATE AND 
CHLORPROMAZINE IN MANIA: REPORT OF COLLABORATIVE STUDY 
GROUP ON TREATMENT OF MANIA IN JAPAN. 

228226 01-09 
^ DOUBLE BLIND CONTROLLED COMPARISON OF CLOMIPRAMINE 
(ANAFRANIL) AND IMIPRAMINE ON DEPRESSION. 

228327 01-09 
^ DOUBLE-BLIND COMPARISON OF PENFLURIDOL (EASER) WITH 
PIMOZIDE IN SCHIZOPHRENIA. 

229026 01 07 
RESPONSE SUPPRESSION IN RATS: A COMPARISON OF RESPONSE 
CONTINGENT AND NONCONTINGENT PUNISHMENT AND THE EFFECT OF 
THE MINOR TRANQUILLIZER, CHLORDIAZEPOXIDE. 

230831 01-04 
■FENFLURAMINE AND N-ETHYLAMPHETAMINE: COMPARISON OF THE 
REINFORCING AND RATE-DECREASING ACTIONS IN THE RHESUS 
MONKEY. 

230874 01-04 
CLOMACRAN IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS: A 
COMPARISON OF TWO ASSESSMENT METHODS. 

231034 01-08 
^ COMPARISON OF FENFLURAMINE AND AMPHETAMINE IN MAN. 

23131901-13 
COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 

232483 01-04 
SEDATIVE HYPNOTIC PROPERTIES OF A NEW BENZODIAZEPINE IN 
COMPARISON WITH FLURAZEPAM: PHARMACOLOGICAL AND CLINICAL 
FINDINGS. 

232530 01-07 
^ COMPARISON OF THE POTENCIES OF A SERIES OF BARBITURATES AT 
THE NEUROMUSCULAR JUNCTION AND ON THE CENTRAL-NERVOUS- 
SYSTEM. 

233289 02-03 
COMPARISON OF SERUM LEVELS AND URINARY EXCRETION OF THREE 
MAJOR ANTICONVULSANTS BETWEEN CHILDREN AND ADULTS 

233832 02-13 
ALLEVIATING AGITATION, APPREHENSION, AND RELATED SYMPTOMS IN 
GERIATRIC PATIENTS: A DOUBLE-BLIND COMPARISON OF A 
PHENOTHIAZINE AND A BENZODIAZEPINE, 

234114 02-11 



COMPARISON OF THE THERAPEUTIC EFFECT OF CLOZAPINE AND 
CHLORPROMAZINE. 

234420 02 14 
CLOMACRAN IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS - A 
COMPARISON OF TWO ASSESSMENT METHODS. 

235364 02 08 
A COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF R 
2,5 DIMETHOXY-4-METHYLAMPHETAMINE (ROOM) AND S 
AMPHETAMINE IN THE RAT. 

237717 02-04 
COMPARISON OF BICUCULLINE METHOCHLORIDE WITH BICUCULLINE 
AND PICROTOXIN AS ANTAGONISTS OF AMINO-ACID AND 
MONOAMINE DEPRESSION OF NEURONES IN THE RAT BRAINSTEM. 

237783 02-03 
A DOUBLE-BLIND COMPARISON OF LOXAPINE SUCCINATE AND 

TRIFLUOPERAZINE IN NEWLY ADMITTED SCHIZOPHRENIC PATIENTS 

237828 02-08 
COMPARISON OF THE EFFECTS OF LESION IN THE 0B9 CELL BODY GROUP 
AND P-CHLOROAMPHETAMINE ON TRYPTOPHAN-HYDROXYLASE AND 
5-HYDROXYTRYPTAMINE IN RAT BRAIN NUCLEI. 

237863 02-03 
METABOLISM OF DELTAl -TETRAHYDROCANNABINOL BY THE ISOLATED 
PERFUSED DOG LUNG. COMPARISON WITH IN VITRO LIVER 
METABOLISM. 

238316 02 03 
TRYPTOPHAN-HYDROXYLASE IN DISCRETE NUCLEI: COMPARISON OF 
ACTIVITY IN VITRO AND IN VIVO. 

238678 03 03 
COMPARISON OF THYROID-RELEASING HORMONE (TRH) AND 

AMPHETAMINE (AMP) ON CHANGES IN ACTIVITY LEVELS OF RATS 
FOLLOWING INJECTIONS INTO THE CAUDATE-NUCLEUS, SEPTUM, AND 
HYPOTHALAMUS. 

238744 03 04 
DISCRIMINATIVE PENTOBARBITAL STIMULUS AFTER INTRAVENOUS 
ADMINISTRATION: A COMPARISON WITH THE INTRAPERITONEAL 
ROUTE. 

238756 03-04 
A COMPARISON OF THf BIOCHEMICAL EFFECT OF TWO CATALYTIC 
INHIBITORS OF MAMMALIAN BRAIN GABA-TRANSAMINASE: GAMMA- 
VINYL-GABA (AMINO-4 HEX 5 ENOIC ACID) AND GAMMA-ACETYLENIC- 
GABA (AMINO-4 HEX-5-YN0IC-ACID). 

238782 03 03 
A QUANTITATIVE COMPARISON OF RELATIONSHIPS BETWEEN PLASMA 
TESTOSTERONE (T) AND TWO CENTRAL FUNCTIONS: LH FEEDBACK 
AND SEX BEHAVIOR. 

238800 03 04 
THE EFFECT OF DL-254 ON THE PHARMACOLOGICAL ACTIVITIES OF D- 
AMPHETAMINE AND APOMORPHINE: A COMPARISON WITH 
ANTIANXIETY AND NEUROLEPTIC AGENTS. 

238846 03-03 
A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE-DECANOATE AND 
FLUPENTHIXOL-DECANOATE IN THE TREATMENT OF ACUTE 
SCHIZOPHRENIA. 

238996 03-08 
DOUBLE-BLIND COMPARISON OF MAPROTILINE WITH AMITRIPTYLINE IN 
THE TREATMENT OF DEPRESSIVE ILLNESS, 

239818 03 10 
A CONTROLLED COMPARISON OF CYCLAZOCINE AND NALOXONE 
TREATMENT OF THE PAROLED NARCOTIC ADDICT. 

239824 03- 1 1 
COMPARISON OF WITHDRAWAL PRECIPTATING PROPERTIES OF VARIOUS 
MORPHINE ANTAGONISTS AND PARTIAL AGONISTS IN RELATION TO 
THEIR STEREOSPECIFIC BINDING TO BRAIN HOMOGENATES. 

239854 03 03 
COMPARISON BETWEEN CHRONIC CHLORDIAZEPOXIDE TREATMENT AND 
SHOCK REMOVAL IN A CONFLICT SITUATION IN RATS. 

239979 03-04 
EFFECTS OF SULTHIAME UPON INTELLECTUAL, NEUROPSYCHOLOGICAL, 
AND SOCIAL FUNCTIONING ABILITIES AMONG ADULT EPILEPTICS: 
COMPARISON WITH DIPHENYLHYDANTOIN. 

240475 03-14 
COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY 
SHORT SENSORY DEPRIVATION AND BY DELTA9-TRANS- 
TETRAHYDROCANNABINOL. 

240645 03-14 
SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF 
PHYSICAL DEPENDENCE IN RATS: I. COMPARISON OF PRECIPITATED 
MORPHINE WITHDRAWAL AFTER INTRAPERITONEAL AND 
INTRAVENTRICULAR INJECTION OF MORPHINE ANTAGONISTS 

241223 03 04 
CONTROLLED COMPARISON OF ESTAZOLAM AND NITRAZEPAM AS 
HYPNOTICS ON THE PREOPERATIVE NIGHT SLEEP. 

241273 03 14 
COMPARISON OF THE INHIBITORY EFFECTS OF NEUROLEPTIC DRUGS ON 
ADENYLATE-CYCLASE IN RAT TISSUES STIMULATED BY DOPAMINE, 
NORADRENALINE AND GLUCAGON 

241347 03 03 



09 

s 
S 






S-83 



Subject Index 



Psychophormacology Abstrac 



COMPARISON OF THE EfFECTS OF NEUROLEPTICS ON SELF-STIMULATION 
AND CONDITIONED AVOIDANCE RESPONSE IN RATS. 

241375 03-04 
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS. 4TH 
REPORT. COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
COMPARISON TRIAL OF TWO ANTIPSYCHOTIC DRUGS: 
CHLORPROMAZINE AND CLOZAPINE. 

241760 03-08 
EXCITATORY EFFECTS OF 5-HYDROXYTRYPTAMINE. HISTAMINE AND 
POTASSIUM IONS ON MUSCULAR GROUP IV AFFERENT UNITS- A 
COMPARISON WITH BRADYKININ. 

241798 03-03 
EFFECT OF METHADONE AND DEXTROMORAMIDE ON DOPAMINE 
METABOLISM COMPARISON WITH HALOPERIDOL AND 
AMPHETAMINE. 

244513 04-03 
A COMPARISON OF THE EFFECTS OF FLURAZEPAM 30 MG AND 
TRIAZOLAM 0.5 MG ON THE SLEEP OF INSOMNIACS. 

244686 04-11 
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOUR 

IN MICE: COMPARISON BETWEEN TWO VEHICLES 

244687 04-04 
A DOUBLE-BLIND COMPARISON OF LOXITANE: LOXAPINE SUCCINATE 

AND TRIFLUOPERAZINE HYDROCHLORIDE IN CHRONIC SCHIZOPHRENIC 
PATIENTS. 

245014 04-08 
COMBINATION DRUG THERAPY FOR THE PSYCHOGERIATRIC PATIENT- 
COMPARISON OF DOSAGE LEVELS OF THE SAME PSYCHOTROPIC 
DRUGS, USED SINGLY AND IN COMBINATION. 

246694 04-11 
A COMPARISON OF DEXTROAMPHETAMINE AND RACEMIC 

AMPHETAMINE IN THE TREATMENT OF THE HYPERKINETIC SYNDROME 
OR MINIMAL-BRAIN-DYSFUNCTION 

247878 04-11 
ROLE OF DA IN THE STIMULANT EFFECT OF DITA IN MICE; COMPARISON 
WITH D-AMPHETAMINE. 

248284 04-03 
A COMPARISON OF 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL AND TETRAHYDROPAPAVEROLINE AN INHIBITORS OF 
MONOAMINE OXIDASE WITHIN THE ADRENERGIC NERVE PLEXUS OF 
THE ISOLATED MOUSE ATRIUM 

248603 04-03 
COMPARISON OF DOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE IN PARKINSONS 
DISEASE 

248612 04- 11 
COMPARISON OF DOPA DECARBOXYLASE INHIBITOR (CARBIDOPA) 

COMBINED WITH LEVODOPA AND LEVODOPA ALONE ON THE 
CARDIOVASCULAR SYSTEM OF PATIENTS WITH PARKINSONS DISEASE. 

248613 04-11 
A COMPARISON OF THE DISCRIMINABLE CNS EFFECTS OF KETAMINE 

PHENCYCLIDINE AND PENTOBARBITAL. 

249025 04-04 
A COMPARISON OF NARCOTIC ANALGESICS WITH NEUROLEPTICS ON 
BEHAVIORAL MEASURES OF DOPAMINERGIC ACTIVITY 

249139 04-04 
COMPARISON OF THE EFFECTS OF COCAINE AND AMPHETAMINE IN 
MONKEYS MAINTAINED ON NALTREXONE 

249270 04-04 
COMPARISON OF THE MONOMETHOXYAMPHETAMINES ON THE UPTAKE 
AND RELEASE OF BIOGENIC AMINES IN BRAIN TISSUE. 

249315 0403 
BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE: 
COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N,N 
DIMETHYLTRYPTAMINE AND S-METHOXY-N.N DIMETHYLTRYPTAMINE. 

249317 04-05 
STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE 
RECEPTORS IN COMPARISON TO APOMORPHINE, ( i ) AMPHETAMINE 
AND L DOPA 

249419 04-04 
COMPARISON BETWEEN INTRAVENOUS AND INTRAGASTRIC ALCOHOL 
SELF ADMINISTRATION 

250021 04-04 
A COMPARISON BETWEEN A MELANOCYTE STIMULATING HORMONE 
INHIBirORY FACTOR (MIF I) AND SUBSTANCES KNOWN TO ACTIVATE 
(LNIRAI DOPAMINE RECEPTORS 

250082 04-03 
ANIIACITYLCHOIINE ACTIVITIES OF PSYCHOACTIVE DRUGS: A 

( OMPARISON OF THE (3H)QUINUCLIDINYL BENZILATE BINDING ASSAY 
WITH CONVENTIONAL METHODS 

250360 04-02 
COMPARISON OF THE APPARENT ANTIDEPRESSANT ACTIVITY OF (-) AND 
( I ) TRANYLCYPROMINE IN AN ANIMAL MODEL. 

250376 04 03 
COMPARISON OF LOW DOSES OF HALOPERIDOL AND DIAZEPAM IN 
ANXIETY STATES 

250491 04-10 



COMPARISON OF A NEW ANTIDEPRESSIVE, LOFEPRAMINE WITH 
IMIPRAMINE IN A DOUBLE-BLIND MULTICENTRE TRIAL. 

251118 04 
CARBAMAZEPINE (TEGRETOL) - A DOUBLE-BLIND COMPARISON WITH 
PHENYTOIN (DILANTIN). 

251937 04 
COMPARISON OF THE EFFECTS OF MORPHINE, PENTAZOCINE 
CYCLAZOCINE AND AMPHETAMINE ON INTRACRANIAL SELF- 
STIMULATION IN THE RAT. 

251975 04 
COMPARISON OF DEPOT FLUPHENAZINES: DURATION OF ACTION AND 
INCIDENCE OF SIDE-EFFECTS, 

252006 04 
SERUM CONCENTRATION OF CARBAMAZEPINE: COMPARISON OF 
HERRMANNS SPECTROPHOTOMETRIC METHOD AND A NEW GLC 
METHOD FOR THE DETERMINATION OF CARBAMAZEPINE. 

25301 1 04 
COMPARISON OF FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, 
AND PLACEBO IN REMITTED OUTPATIENT SCHIZOPHRENICS. 

253047 04 
A CONTROLLED DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE ANC 
HALOPERIDOL IN ACUTE NEWLY HOSPITALIZED SCHIZOPHRENIC 
PATIENTS. 

253051 04 
A COMPARISON OF TWO UNCONTROLLED CLINICAL TRIALS OF 
TRAZODONE. 

253056 04 
A COMPARISON OF ANTIDEPRESSANT MEDICATIONS IN NEUROTIC AN( 
PSYCHOTIC PATIENTS. 

253641 04 
COMPARISONS 

BARBITURATE REINFORCED RESPONDING IN RHESUS MONKEYS: 

COMPARISONS OF DRUGS WITH DIFFERENT DURATIONS OF ACTION. 

237874 02 
COMPARISONS BETWEEN THE BEHAVIOURAL AND ANOREXIC EFFECTS 
780SE AND OTHER PHENYLETHYLAMINES IN THE RAT. 

250939 04 
COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYl 
CYCLIC-AMP AND ANALEPTIC DRUGS ON AMOBARBITAL INDUCED 
NARCOSIS IN THE RAT. 

252221 04 
COMPARTMENT 

RELATIONSHIP BETWEEN SEROTONIN IN THE INTACT BRAIN AND 
RELEASE OF PROTEIN INTO THE PERFUSED CEREBROSPINAL FLUID 
COMPARTMENT OF CONSCIOUS AND ANESTHETIZED RABBITS, 

238681 03- 
COMPENDIUM 

COMPENDIUM OF PHARMACOLOGY DRUG CHARTS. 

249768 04 
COMPETENT 

FUGUE STATES - EPILEPSY - MEDICATION - HELD COMPETENT TO 
STAND TRIAL: PEOPLE V. PARSONS, 371 N.Y.S.2D 840, (NEW-YORK), 
NASSAU COUNTY COURT AUGUST 1, 1975. 

237476 02- 
COMPETING 

THE EFFECTS OF AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE 

BUTYROPHENONE SERIES, ON DOMINANT SUBORDINATE BEHAVIOUR 
IN WISTAR RATS COMPETING FOR FOOD. 

225571 01- 
COMPETITION 

EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON SQUIRREL-MONKEY 
INCENTIVE COMPETITION BEHAVIOR. (PH.D. DISSERTATION). 

241668 03- 
COMPETITIVE 

A SIMPLE METHOD OF EVALUATING THE COMPETITIVE INTERACTION 
REVERSIBLE INHIBITORS WITH CHOLINESTERASES 

23T072 01-I 
DRUG RECEPTOR INTERACTIONS OF MORPHINE AND NALORPHINE: 
COMPETITIVE DUALISM VERSUS RECEPTOR DUALISM. (PH.D. 
DISSERTATION) 

240934 03-1 
COMPLEX 

DRUG-INDUCED RHYTHM.ICAL ACTIVITY IN THE INFERIOR OLIVARY 
COMPLEX OF THE RAT 

235866 02-1 
INTRODUCTION: COMPLEX SCHEDULES OF DRUG INJECTION, 

240012 03-( 
TERMINATION OF A SCHEDULE COMPLEX ASSOCIATED WITH 

INTRAVENOUS INJECTIONS OF NALORPHINE IN MORPHINEDEPENDEN 
RHESUS MONKEYS. 

240019 03-( 
THE NATURE OF THE 455-NM ABSORBING COMPLEX FORMED DURING 
THE CYTOCHROME-P450 DEPENDENT OXIDATIVE METABOLISM OF 
AMPHETAMINE. 

241350 03-( 
ON MONOAMINERGIC MECHANISMS OF THE AMYGDALA COMPLEX 
IMPLEMENTING CONDITIONED REFLEXES OF VARIOUS BIOLOGICAL 
MODALITIES. 

241980 03-C 



S-84 



LUME 14, SUBJECT INDEX 



Subject Index 



THE NARCOTIC DISCRIMINATIVE STIMULUS COMPLEX: RELATION TO 
ANALGESIC ACTIVITY. 

250355 04-03 
EFFECT OF MORPHINE ON SINGLE UNIT RESPONSES IN VENTROBASAL 
COMPLEX (VB) AND POSTERIOR NUCLEAR GROUP (PO) FOLLOWING 
TOOTH PULP STIMULATION. 

25)070 04-03 
tPUCATING 
FATAL PARALYTIC ILEUS COMPLICATING PHENOTHIAZINE THERAPY 

235286 02-15 
IPIICATION 

PAVOR-NOCTURNUS: A COMPLICATION OF SINGLE DAILY TRICYCLIC OR 
NEUROLEPTIC DOSAGE. 

252955 04-17 
IPLICATIONS 

COMPLICATIONS OF PSYCHOACTIVE DRUGS AS SEEN BY FAMILY 
PRACTITIONERS. 

248851 04-15 
[POSITION 

THE EFFECTS OF LONG-TERM STIMULANT MEDICATION ON GROWTH AND 
BODY COMPOSITION OF HYPERACTIVE CHILDREN. 

253041 04-15 
IPREHENSIVE 
COMPREHENSIVE CLINICAL STUDIES WITH THIOTHIXENE. 

227820 01-14 
IPUISIVE 

DUAL ACTION OF MORPHINE AND RELATED DRUGS ON COMPULSIVE 
GNAWING OF RATS. 

239860 03-04 
IPUTERIZED 
COMPUTERIZED ELECTROENCEPHALOGRAM: A MODEL OF 

UNDERSTANDING THE BRAIN FUNCTION IN CHILDHOOD PSYCHOSIS 
AND ITS TREATMENT. 

232635 02-11 
ICENTRATION 

INFLUENCE OF DRUGS ON STRIATAL AND LIMBIC HOMOVANILLIC-ACID 
CONCENTRATION IN THE RAT BRAIN. 

226727 01-03 
EFFECT OF ECT AND IMIPRAMINE TREATMENT ON THE CONCENTRATION 
OF 5-HYDROXYINDOLEACETIC-ACID (5-HIAA) AND HOMOVANILLIC- 
ACID (HVA) IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS. 

230827 01-09 
THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON BRAIN AMINE 
CONCENTRATION AND TURNOVER IN WHOLE RAT BRAIN AND IN 
VARIOUS REGIONS OF THE BRAIN. 

230856 01-03 
A GAS CHROMATOGRAPHIC METHOD FOR DETERMINING HALOPERIDOL: 
A SENSITIVE PROCEDURE FOR STUDYING SERUM CONCENTRATION 
AND PHARMACOKINETICS OF HALOPERIDOL IN PATIENTS. 

237152 02-16 
PLASMA CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES AFTER 
PERORAL, INTRAMUSCULAR, AND RECTAL ADMINISTRATION: 
CORRELATION BETWEEN PLASMA CONCENTRATION AND SEDATORY 
EFFECT OF DIAZEPAM. 

237735 02-13 
CATECHOLAMINE CONCENTRATION OF DISCRETE BRAIN AREAS 

FOLLOWING SELF-STIMULATION IN THE VENTROMEDIAL TEGMENTUM 
OF THE RAT. 

237862 02-03 
SERUM CONCENTRATION AND ELIMINATION OF THIORIDAZINE IN 
PSYCHIATRIC PATIENTS. 

238552 02-13 
CATECHOLAMINE CONCENTRATION IN DISCRETE AREAS OF BRAIN OF 
SEVERAL STRAINS OF MICE: CORRELATION WITH AGGRESSIVITY. 

238673 03-03 
PLASMA CONCENTRATION OF DIPHENYLHYDANTOIN IN THE EPILEPTIC: 
ITS INTEREST FOR THE CLINICIAN. 

240762 03-11 
REDUCTION OF TRYPTOPHAN-HYDROXYLASE ACTIVITY AND 5- 
HYDROXYTRYPTAMINE CONCENTRATION IN CERTAIN RAT BRAIN 
NUCLEI AFTER P CHLOROAMPHETAMINE. 

241253 03-03 
CONCENTRATION OF AMPHETAMINE ISOMERS IN BRAIN AND HEART OF 
ADULT AND DEVELOPING MICE. 

241414 03-03 
ORAL DIAZEPAM IN HOSPITALIZED ANXIETY PATIENTS (WITH 
OBSERVATIONS ON CONCENTRATION EFFECT RELATIONSHIPS). 

241427 03-10 
DRUG-INDUCED CHANGES IN BEHAVIOUR AND GANGLIONIC 
ACETYLCHOLINE CONCENTRATION OF THE LEECH. 

245595 04-03 
THE CONCENTRATION OF 5-METHOXYTRYPTAMINE IN RAT BRAIN AND 
ITS EFFECTS ON BEHAVIOUR FOLLOWING ITS PERIPHERAL INJECTION. 

245600 04-04 
HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CSF 
OF PATIENTS AFTER A SEVERE HEAD INJURY. I. LUMBAR CSF 
CONCENTRATION IN CHRONIC BRAIN POSTTRAUMATIC SYNDROMES. 

246993 04- 13 



THE EFFECT OF PRETREATMENT WITH 6-HYDROXYDOPAMINE ON THE 
NOREPINEPHRINE CONCENTRATION AND SENSITIVITY OF THE RAT 
VAS-DEFERENS. 

248413 04-03 
ON THE CLINICAL RELEVANCE OF THE INTRACELLULAR RBC LITHIUM 
CONCENTRATION. 

251417 04 15 
SERUM CONCENTRATION OF CARBAMAZEPINE: COMPARISON OF 
HERRMANNS SPECTROPHOTOMETRIC METHOD AND A NEW GLC 
METHOD FOR THE DETERMINATION OF CARBAMAZEPINE. 

25301 1 04 07 
USE OF 300-MSEC MICROWAVE IRRADIATION FOR ENZYME 

INACTIVATION: A STUDY OF EFFECTS OF SODIUM PENTOBARBITAL ON 
ACETYLCHOLINE CONCENTRATION IN MOUSE BRAIN REGIONS. 

253106 04-03 
CONCENTRATIONS 

PLASMA CONCENTRATIONS OF L-DOPA AND 3-METHOXYDOPA AND 
IMPROVEMENT IN CLINICAL RATINGS AND MOTOR PERFORMANCE IN 
PATIENTS WITH PARKINSONISM TREATED WITH L-DOPA ALONE OR IN 
COMBINATION WITH AMANTADINE. 

226349 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 
APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. III. THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAMATE IN THE BLOOD 
AND THEIR EFFECTS ON PERFORMANCE, APPLICATION OF 
MATHEAAATICAL MODELS. 

232519 01 14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUAAAN SUBJECTS. IV. THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAMATE IN THE BLOOD. 

232520 01-13 
THE EFFECT OF SMALL CONCENTRATIONS OF SODIUM PENTOBARBITAL 

ON AUDITORY EVOKED RESPONSES. 

234682 02-03 
EFFECT OF NOMIFENSINE ON MOTOR ACTIVITY, DOPAMINE TURNOVER 
RATE AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE 
CONCENTRATIONS OF RAT STRIATUM. 

237156 02-04 
PLASMA CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES AFTER 
PERORAL, INTRAMUSCULAR, AND RECTAL ADMINISTRATION: 
CORRELATION BETWEEN PLASMA CONCENTRATION AND SEDATORY 
EFFECT OF DIAZEPAM. 

237735 02-13 
EFFECT OF CATECHOL-0-METHYLTRANSFERASE INHIBITORS ON BRAIN 
APOMORPHINE CONCENTRATIONS AND STEREOTYPED BEHAVIOUR IN 
THE RAT. 

237747 02-03 
SERUM CREATINE-PHOSPHOKINASE CONCENTRATIONS AFTER 
INTRAMUSCULAR CHLORDIAZEPOXIDE AND ITS SOLVENT. 

237928 02-15 
FURTHER STUDIES ON BRAIN CONCENTRATIONS OF AMPHETAMINE AND 
ITS METABOLITES IN STRAINS OF MICE SHOWING DIFFERENT 
SENSITIVITY TO PHARMACOLOGICAL EFFECTS OF AMPHETAMINE. 

238322 02-03 
MARIJUANA-INDUCED ALTERATIONS IN FEEDING BEHAVIOR AND 
HYPOTHALAMIC CONCENTRATIONS OF NOREPINEPHRINE AND 
SEROTONIN IN THE RAT. 

238720 03-04 
PHARMACOKINETIC MODEL TO DESCRIBE SELF-INDUCED DECREASES IN 
STEADY-STATE CONCENTRATIONS OF CARBAMAZEPINE. 

239658 03-13 
DETERMINATIONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESIS IN 
A SINGLE MOUSE BRAIN: BIPHASIC EFFECTS OF ( + ) AMPHETAMINE. 

241257 03-03 
CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04-03 
HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CSF 
OF PATIENTS AFTER A SEVERE HEAD INJURY. II. VENTRICULAR CSF 
CONCENTRATIONS IN ACUTE BRAIN POSTTRAUMATIC SYNDROMES. 

246994 04 13 
STEADY-STATE CONCENTRATIONS OF CHOLINE AND ACETYLCHOLINE IN 
RAT BRAIN PARTS DURING A CONSTANT RATE INFUSION OF 
DEUTERATED CHOLINE. 

247146 04-03 
EFFECTS OF BENZODIAZEPINES ON THE BINDING OF TRYPTOPHAN IN 
SERUM. CONSEQUENCES ON 5-HYDROXYINDOLES CONCENTRATIONS IN 
THE RAT BRAIN. 

247213 04-03 
MEASUREMENTS OF BRAIN AMOBARBITAL CONCENTRATIONS IN RATS 
ANESTHETIZED AND OVERDOSED WITH AMOBARBITAL AND TREATED 
CENTRALLY WITH DIBUTYRYL CYCLIC-AMP. 

248276 04-03 



09 

CP 



as 

s 

I 

Si; 

7»-~ 



S-85 



Subject Index 



Psychopharmacology Abstra 



SELf INHIBITING ACTION OF NORTRIPTYLINE ANTIDEPRESSIVE EFFECT AT 
HIGH PIASMA LEVELS: A RANDOMIZED, DOUBLE-BLIND STUDY 
CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION, 

248955 04-10 
CORRELATION BETWEEN NEUROLEPTIC-INDUCED SUPPRESSION OF 

STEREOTYPED BEHAVIOUR AND HVA CONCENTRATIONS IN RAT BRAIN 

252523 04-03 
THE UPTAKE OF LOW CONCENTRATIONS OF LITHIUM IONS INTO RAT 
CEREBRAL CORTEX SLICES AND ITS DEPENDENCE ON CATIONS. 

253411 04-03 
CONCEPT 

EXCITATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 
RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL 
FUNCTIONAL AND CLINICAL DATA, 

237104 02-03 
CONCEPTS 

CONCEPTS OF IMPULSIVITY: A CLINICAL NOTE 

231610 01-09 
CONCEPTUAL 

CONCEPTUAL IMPLICATIONS OF DRUG AND NONSOMATIC TREATMENT 
INTERACTION STUDIES. 

229452 CM 7 
PSYCHOTHERAPY AND PHARMACOTHERAPY: CONCEPTUAL ISSUES 
(UNPUBIISHED PAPER). 

238493 02 17 
CONDITION 

THE EFFECTS OF TEST ENVIRONMENT AND REARING CONDITION ON 
AMPHETAMINE-INDUCED STEREOTYPY IN THE GUINEA-PIG. 

237712 02-04 
CONDITIONAL 

REDUCTION OF MORPHINE WITHDRAWAL BODY SHAKES BY A 
CONDITIONAL STIMULUS IN THE RAT, 

232617 02-03 
NALOXONE ANTAGONISM OF CONDITIONAL REVERSAL OF NARCOTIC 
WITHDRAWAL SIGNS AND CONDITIONAL MORPHINE HYPERTHERMIA- 
AN INDIRECT EVIDENCE FOR RELEASE OF ENDOGENOUS OPIOID-LIKE 
SUBSTANCE IN THE RAT. 

238713 03-04 
CONDITIONED 

THE EFFECTS OF NEUROLEPTICS AND NIALAMIDE ON DEFENSIVE 
CONDITIONED REFLEX IN RATS. 

227637 01-04 
EFFECT OF 5,5 DIPHENYLHYDANTOIN ON FIXED CONDITIONED REFLEXES 
IN CATS 

229681 01-04 
RELATIONS BETWEEN ORIENTING, PSEUDOCONDITIONED AND 
CONDITIONED RESPONSES IN THE SHUTTLEBOX - A 
PHARMACOLOGICAL ANALYSIS BY MEANS OF LSD AND DIBENAMINE. 

230570 01 04 
EFFECTS OF DRUG EXPERIENCE ON DRUG-INDUCED CONDITIONED TASTE 
AVERSIONS. STUDIES WITH AMPHETAMINE AND FENFLURAMINE 

230829 01-04 
STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 
EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT 

230860 01 03 
THE EFFECT OF PSYCHOTROPIC DRUGS ON CONDITIONED REFLEXES 
AFTER AN EMOTIONAL STRESS IN CATS. 

231069 01-04 
THE INFLUENCE OF D.L-AMPHETAMINE AND CAFFEINE ON CAUDATE 
INHIBITION OF CONDITIONED AVOIDANCE REACTIONS IN CATS 

231248 01-04 
MONOAMINERGIC INFLUENCES OF THE CAUDATE NUCLEUS ON 
CONDITIONED FOOD PROCURING REACTIONS IN RATS. 

231251 01-04 
CONDITIONED AVERSION BY PSYCHOACTIVE DRUGS: DOES IT HAVE 
SIGNIFICANCE FOR AN UNDERSTANDING OF DRUG DEPENDENCE 

233488 02-14 
THE DEPENDENCE OF THE MAGNITUDE OF CONDITIONED SALIVATION IN 
DOGS ON DOSES OF CAFFEINE 

236249 02-03 
ON NEUROCHEMICAL MECHANISMS OF THE INHIBITORY INFLUENCE OF 
THE HIPPOCAMPUS ON THE RAT FOOD PROCURING CONDITIONED 
REACTION 

236257 02-04 
PARTICIPATION OF ADRENO, DOPAMINE, AND SEROTONERGIC 
MECHANISMS OF THE SEPTUM IN CONDITIONED REFLEX REACTIONS 
TO VARIOUS BIOLOGICAL MODALITIES IN RATS 

236828 02 04 
THE POTENTIATION OF CONDITIONED REINFORCEMENT BY 
PSYCHOMOTOR STIMULANT DRUGS A TEST OF HILLS HYPOTHESIS, 

23771 1 02-04 
ATTENUATION BY ALPHA METHYLTYROSINE OF AMPHETAMINE-INDUCED 
CONDITIONED TASTE AVERSION IN RATS 

237713 02-04 
IHf EFFECTS OF N OIPROPYLACETATt ON THE ACQUISITION OF 

CONDITIONED BEHAVIOUR WITH NEGATIVE REINFORCEMENT IN MICE. 

237723 02-04 



CONDITIONED AND UNCONDITIONED DRUG EFFECTS IN A CLASSICAL 
CONDITIONING PARADIGM. 

238787 O: 
EFFECT OF SOME INTRACEREBRALLY ADMINISTERED DRUGS ON A 
CONDITIONED REFLEX IN THE CAT. 

239275 O: 
CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING DRUG 
AS CONDITIONED STIMULI. (PH.D. DISSERTATION). 

239523 O: 
COMPARISON OF THE EFFECTS OF NEUROLEPTICS ON SELF-STIMULATI 
AND CONDITIONED AVOIDANCE RESPONSE IN RATS. 

241375 0: 
FORMATION AND RETENTION OF CONDITIONED TASTE AVERSIONS AN 
UCS HABITUATION. 

241521 a 
ON MONOAMINERGIC MECHANISMS OF THE AMYGDALA COMPLEX 
IMPLEMENTING CONDITIONED REFLEXES OF VARIOUS BIOLOGICAL 
MODALITIES 

241980 0: 
DRUG-INDUCED CONDITIONED SUPPRESSION: SPECIFICITY DUE TO DR 
EMPLOYED AS UCS 

242750 a 
CHARACTERISTIC CHANGES IN CONDITIONED DEFENSIVE REFLEXES 
CAUSED BY TRIFLUOPERAZINE, CARBAMAZEPINE AND 
CHLORPROMAZINE. 

244352 0. 
EFFECTS OF SELECTED DRUGS ON AN AUDITORY OR THALAMIC 
CONDITIONED STIMULUS ELICITING RECRUITMENT IN THE CAT. 

246967 0. 
MODIFICATION OF CONDITIONED AVOIDANCE AND TURNING BEHAVK 
BY BACLOFEN AND ITS INFLUENCE ON CHOLINERGIC DOPAMINERGI 
NERVOUS SYSTEM. 

251397 0. 
INFLUENCE OF PHAR/\AACOLOGICALLY ACTIVE SUBSTANCES ON A 
CONDITIONED BLOOD-PRESSURE INCREASE IN SQUIRREL-MONKEYS. 

251414 0- 
ANOREXIA AND CONDITIONED TASTE AVERSIONS IN THE RAT. 

251629 0- 
HORMONAL INFLUENCES ON THE EXTINCTION OF CONDITIONED TASTI 
AVERSION 

251980 0' 
ACUTE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE 

ACQUISITION OF SHUTTLEBOX CONDITIONED AVOIDANCE RESPONSI 

251989 0' 
CONDITIONING 

THE EFFECT OF ADRENALINE, TYRAMINE AND GUANETHIDINF ON TWC 
WAY AVOIDANCE CONDITIONING AND ON PSEUDOCONDITIONING. 

227138 01 
EFFECTS OF PHYSOSTIGMINE ON AVOIDANCE CONDITIONING AND 
RETENTION IN THE ISOLATED COCKROACH GANGLION. (PH.D. 
DISSERTATION). 

228503 01 
CONDITIONED AND UNCONDITIONED DRUG EFFECTS IN A CLASSICAL 
CONDITIONING PARADIGM. 

238787 O; 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L AND PENTOBARBITAL 
A CORTICAL RESPONSE EVOKED DURING CONDITIONING. 

244693 OA 
DIFFERENTIAL POTENCY OF TASTE AND AUDIOVISUAL STIMULI IN THE 
CONDITIONING OF MORPHINE WITHDRAWAL IN RATS 

251978 04 
CONDITIONS 

BIOTRANSFORMAnON AND BILIARY EXCRETION OF IMIPRAMINE IN 
RATS UNDER VARIOUS EXPERIMENTAL CONDITIONS. 

226928 01 
EFFECT OF SODIUM OXYBUTYRATE, AMPHETAMINE, TRAN5AMINE, L- 
DOPA ON THE PROCESSES OF RESTORATION OF WORKING CAPACI? 
UNDER CONDITIONS OF MINIMAL REST, 

236372 02 

THE INTERACTIVE EFFECTS OF PRENATAL IMIPRAMINE EXPOSURE AND 

POSTNATAL REARING CONDITIONS ON BEHAVIOUR AND HISTOLOGY 

237721 02 
ANALYSIS OF THE DISCREPANCY IN MAN-MACHINE TRACKING SYSTEA 
UNDER CONDITIONS OF DELAYED FEEDBACK. 

242702 03 
NORADRENALINE SYNTHESIS AND UTILIZATION: CONTROL BY NERVE 
IMPULSE FLOW UNDER NORMAL CONDITIONS AND AFTER TREATME 
WITH ALPHA-ADRENORECEPTOR BLOCKING AGENTS. 

251227 04 
THE USE OF PSYCHOTROPIC DRUGS IN OTHER PAINFUL CONDITIONS. 

252142 04 
CONDUCT 

IMPACT OF PSYCHOSOCIAL FACTORS ON THE CONDUCT OF COMBINED 
DRUG AND PSYCHOTHERAPY RESEARCH. 

235534 02 



S-86 



>LUME 14, SUBJECT INDEX 



Subject Index 



NDUCTANCE 

HABITUATION TO ITERATIVE PHOTOSTIMULATION IN THE PALMAR SKIN 
CONDUCTANCE RESPONSE OF MICE, ITS DELAY BY 
PSYCHOANALEPTICS 

248514 04-04 
MDUCTIVITY 
BENZODIAZEPINES: A COMPARISON OF THEIR EFFECTS IN MICE ON THE 
MAGNITUDE OF THE PALMAR SKIN CONDUCTIVITY RESPONSE AND ON 
PENTYLENETETRAZOL-INDUCED SEIZURES. 

227694 01-03 
*IFINEMENT 
FENFLURAMINE-INDUCED ENHANCEMENT OF CONFINEMENT MOTOR 
ACTIVITY: AN INDIRECT 5-HYDROXYTRYPTAMINE LIKE ACTION?. 

24491 1 04-04 
«1FIRME0 
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN 
CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY 
DESTRUCTION OF INTERNEURONS, (UNPUBLISHED PAPER). 

240242 03-03 
^JFLICT 
EFFECTS OF BENZODIAZEPINE ANTIANXIETY AGENTS ON PUNISHED 
(CONFLICT) AND UNPUNISHED BEHAVIOR IN DRUG-NAIVE RATS. 

238697 03-04 
COMPARISON BETWEEN CHRONIC CHLORDIAZEPOXIDE TREATMENT AND 
SHOCK REMOVAL IN A CONFLICT SITUATION IN RATS. 

239979 03-04 
»JFORMANT 
""HE INFLUENCE OF PSYCHOTROPIC AND ANTICONVULSANT AGENTS ON 
CONFORMANT TRANSITIONS IN THE TRANSPORT ATPASE. 

236715 0203 
MFORMATIONAl 

CONFORMATIONAL REQUIREMENTS FOR BLOCKING UPTAKE OF 
CATECHOLAMINES AND SEROTONIN INTO CRUDE RAT BRAIN 
SYNAPTOSOMES. 

238738 03-01 
MFORMATIONALIY 
CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE II. 

233361 02-01 
CONFORMATIONALLY RIGID AMPHETAMINE ANALOGS AS INHIBITORS OF 
MONOAMINE UPTAKE BY BRAIN SYNAPTOSOMES. 

251700 04-03 
>JFRONTATION 
MODEL OF CAUSAL CONFRONTATION IN INTEGRATIVE PSYCHOTHERAPY. 

234503 02 14 
MFUSED 
DOUBLE-BLIND EVALUATION OF NAFTIDROFURYL IN TREATING ELDERLY 
CONFUSED HOSPITALISED PATIENTS. 

229368 01 11 
hJFUSIONAL 
ACUTE CONFUSIONAL STATES. 

239607 03-17 
rjGENERS 
CONGENERS OF PHENOTHIAZINE TRANQUILIZERS. (PH.D. DISSERTATION). 

240937 03-02 
^IGENITAL 
CONGENITAL MALFORMATIONS WITH PSYCHOPHARMACOLOGIC 
AGENTS. 

230012 0115 
»JGRESS 
NINTH CONGRESS OF THE INTERNATIONAL 
NEUROPSYCHOPHARMACOLOGICUM COLLEGIUM OR C.I.N. P. (PARIS, 
JULY 7-12, 1974). 

250266 04- 1 7 
MJUGATION 

CONJUGATION OF L DOPA AND ITS METABOLITES AFTER ORAL AND 
INTRAVENOUS ADMINISTRATION TO PARKINSONIAN PATIENTS. 

249232 04- 1 5 
STUDIES ON SULFATE CONJUGATION OF ESTROGENS IN BRAIN AND 
LIVER. 

249245 04-03 
*4NECTIONS 
THE SEROTONERGIC SYSTEM IN THE BRAIN AND ITS POSSIBLE 
FUNCTIONAL CONNECTIONS WITH OTHER AMINERGIC SYSTEMS. 

248159 04-03 
MNERS 

CONNERS TEACHER RATING SCALE FOR USE IN DRUG STUDIES WITH 
CHILDREN -- AN EMPIRICAL STUDY. 

248593 04-1 1 
MSCIOUS 
DFITA9 TETRAHYDROCANNABINOL ALTERS FLOW OF BLOOD TO 
SUBCORTICAL AREAS OF THE CONSCIOUS RAT BRAIN. 

226874 01-04 
RELATIONSHIP BETWEEN SEROTONIN IN THE INTACT BRAIN AND 
RELEASE OF PROTEIN INTO THE PERFUSED CEREBROSPINAL FLUID 
COMPARTMENT OF CONSCIOUS AND ANESTHETIZED RABBITS 

238681 03-03 
ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 
8R0MAZEPAM IN CONSCIOUS TRAINED DOGS. 

240064 03 03 



CONSCIOUSNESS 

COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY 
SHORT SENSORY DEPRIVATION AND BY DELTA9 TRANS 
TETRAHYDROCANNABINOL. 

240645 03-14 
CONSENT 

DRUG RESEARCH AND THE QUESTION OF CONSENT. 

252314 04-17 
CONSOLIDATION 

THE EFFECTS OF NOREPINEPHRINE BIOSYNTHESIS INHIBITION ON THE 
CONSOLIDATION OF TWO DISCRIMINATED ESCAPE RESPONSES. 

241301 03-04 
CONSTANT 

STEADY-STATE CONCENTRATIONS OF CHOLINE AND ACETYLCHOLINE IN 
RAT BRAIN PARTS DURING A CONSTANT RATE INFUSION OF 
DEUTERATFD CHOLINE 

247146 04-03 
CONSTRAINED 

CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE II. 

233361 02-01 
CONSTRICTION 

EFFECT OF CANNABINOIDS ON THE ABDOMINAL CONSTRICTION 
RESPONSE IN MICE: WITHIN CANNABINOID INTERACTIONS. 

239859 03-03 
CONSULTANT 

CLINICAL EXPERIENCE WITH BETA-BLOCKERS IN CONSULTANT 
PSYCHIATRIC PRACTICE. 

251165 04-10 
CONSUMMATORY 

CHOLINERGIC MEDIATION OF INSTRUMENTAL AND CONSUMMATORY 
BEHAVIORS. 

233448 02-04 
CONSUMPTION 

THE INFLUENCE OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABINOL 
AND CANNABIDIOL ON TISSUE OXYGEN CONSUMPTION. 

231010 01-03 
LONG TERM CONSUMPTION OF A TRYPTOPHAN POOR DIFT ALTERS THE 
BEHAVIORAL RESPONSE TO DRUGS. 

238741 03-03 
DOSE-RESPONSE STUDIES ON EFFECTS OF AMPHETAMINE ON ACTIVITY 
AND OXYGEN CONSUMPTION IN DOG AND CAT MODELS OF 
HYPERKINESIS (HYPOINHIBITORY SYNDROME). 

238825 03 03 
EFFECTS OF LITHIUM ON CHRONIC FTHANOL CONSUMPTION AND 
BEHAVIOR. 

238849 03 03 
CHANGE IN FTHANOL CONSUMPTION BY ALBINO RATS UNDER THE 
EFFECT OF NEUROLEPTICS AND TRANQUILIZERS. 

241987 03-03 
PATTERNS AND PROBLEMS OF DRUG CONSUMPTION IN A DEVELOPING 

COUNTRY 

252990 04 17 
CONTINGENT 

CONTINGENT NALOXONE (N-ALLYLNOROXYMORPHONE) TREATMENT OF 
THE PAROLED NARCOTIC ADDICT. 

226901 01-14 
RESPONSE SUPPRESSION IN RATS: A COMPARISON OF RESPONSE 

CONTINGENT AND NONCONTINGENT PUNISHMENT AND THE EFFECT OF 
THE MINOR TRANQUILLIZER, CHLORDIAZEPOXIDE. 

230831 01-04 
CHLORPROMAZINE EFFECTS ON BRAIN ACTIVITY (CONTINGENT NEGATIVE 
VARIATION) AND REACTION TIME' IN NORMAL WOMEN. 

230863 01-14 
EFFECTS OF ALCOHOL AND LITHIUM HABITUATION ON THE 

DEVELOPMENT OF ALCOHOL AVERSIONS THROUGH CONTINGENT 
LITHIUM INJECTION 

246093 04-04 
CONTRACTION 

EFFECT OF AMPHETAMINE AND GUTIMIN ON ADAPTIVE CHANGES IN 
ARTERIAL PRESSURE ARISING IN RESPONSE TO CONTRACTION OF THE 
SKELETAL MUSCLES. 

241988 03-03 
DIFFERENTIAL EFFECTS OF ETHYLALCOHOL ON CONTRACTION OF 

ARTERIAL SMOOTH MUSCLE 

251905 04-03 
DIFFERENTIAL EFFECTS OF ETHANOL AND MANNITOL ON CONTRACTION 
OF ARTERIAL SMOOTH MUSCLE 

2.S3I13 04-03 
CONTRACTIONS 

CEREBRAL ARTERIAL SPASM. PART 4: IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAl 
CONCENTRATIONS OF SEROIONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04 03 
CONTRACTOR 

CONTRACTOR EFFECT OF BARBITURATES ON SMOOTH MUSCLE. 

2304.54 01 03 









I 

SI. 



S-87 



Subject Index 



Psychopharmacology Abstrai 



CONTRALATERAL 

A TELENCEPHALIC LESION SITE FOR D-AMPHETAfvMME-INDUCED 
CONTRALATERAL ROTATION IN RATS, 

231301 01 04 
CONTRASTING 

CONTRASTING EFFECTS OF MORPHINE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN THE CHIMPANZEE AND BABOON. 

246854 04-02 
CONTROL 

EFFECTS OF CONTROL TECHNIQUES ON THERAPEUTIC OUTCOME IN A 
CONTROLLED CLINICAL TRIAL 

226902 01-16 
SCOPOLAMINE AND AMPHETAMINE EFFECTS ON DISCRIMINATION: 
INTERACTION WITH STIMULUS CONTROL. 

227131 01-04 
LOSS OF INHIBITORY MOTOR CONTROL FOLLOWING A SUBANESTHETIC 
DOSE OF THIOBARBITURATE IN RHESUS MONKEYS. 

228139 01-04 
AN ATTEMPT TO ESTABLISH QUALITY CONTROL IN DETERMINATION OF 
PLASMA CHLORPROMAZINE BY A MULTILABORATORY 
COLLABORATION. 

229439 01-16 
SCOPOLAMINE EFFECTS ON VISUAL DISCRIMINATION: MODIFICATIONS 
RELATED TO STIMULUS CONTROL. 

231005 01-04 
A DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR BY INTRAVENOUS 
ADMINISTRATION OF DRUGS IN RATS. 

237701 02-04 
DIFFERENTIAL RESPONSE CONTROL BY ISOPROPAMIDE; A PERIPHERALLY 
INDUCED DISCRIMINATIVE CUE. 

237744 02-04 
SCHIZOPHRENIA RELATIONSHIPS TO DOPAMINE TRANSMISSION, MOTOR 
CONTROL, AND FEATURE EXTRACTION. 

238464 02-08 
DEVELOPMENT OF BRAIN CEREBROSIDES AND CEREBROSIDE SULFATE 
(SULFATIDE) IN OFFSPRING OF CONTROL RATS AND RATS 
CHRONICALLY TREATED WITH METHADONE. 

238723 03-03 
INTRODUCTION: THE CONTROL OF BEHAVIOR BY CONSEQUENT DRUG 
INJECTIONS. 

240009 03-04 
STIMULI ASSOCIATED WITH DRUG INJECTIONS AS EVENTS THAT 
CONTROL BEHAVIOR. 

24001 1 03-04 
DRUG EFFECTS AND THE ENVIRONMENTAL CONTROL OF BEHAVIOR. 

240021 03-04 
TRIAL OF A NEW THERAPEUTIC AGENT, PERVINCAMINE, IN THE 

POSTCONCUSSION SYNDROME OF CRANIAL TRAUMAS: APPLICATION 
OF A DOUBLE-BLIND CONTROL AND SEQUENTIAL ANALYSIS. 

240033 03-11 
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN 
CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY 
DESTRUCTION OF INTERNEURONS. (UNPUBLISHED PAPER). 

240242 03-03 
THE CHEMICAL CONTROL OF NEURONAL ACTIVITY. (UNPUBLISHED 
PAPER). 

243183 04-17 
REGULATION OF ADRENAL TYROSINE-HYDROXYLASE ACTIVITY: 

NEURONAL VERSUS LOCAL CONTROL STUDIED WITH APOMORPHINE. 

244314 04-03 
TOXICOLOGY UPDATE OF THE ARKANSAS POISON CONTROL DRUG- 
INFORMATION CENTER: THE TRICYCLIC ANTIDEPRESSANTS. 

245822 04-13 
FRONTAL-STRIATAL CONTROL OF BEHAVIORAL INHIBITION IN THE RAT. 

251138 04-04 
BETA-ADRENERGIC BLOCKADE IN THE CONTROL OF SCHIZOPHRENIC 
SYMPTOMS - A CASE FOR CONTROLLED STUDIES. 

251164 04-08 
NORADRENALINE SYNTHESIS AND UTILIZATION: CONTROL BY NERVE 
IMPULSE FLOW UNDER NORMAL CONDITIONS AND AFTER TREATMENT 
WITH ALPHA-ADRENORECEPTOR BLOCKING AGENTS. 

251227 04-02 
CONTROL OF LITHIUM TREMOR WITH PROPRANOLOL. 

25I43I 04-15 
CONTROLLED 

LOXAPINE SUCCINATE: A CONTROLLED DOUBLE-BLIND STUDY IN 
CHRONIC SCHIZOPHRENIA 

225867 01-08 
FLUPENTHIXOL DECANOATE - CONTROLLED INVESTIGATION CONCERNING 
DOSAGE 

226408 01-08 
A CONTROLLED TRIAL OF CLOTHIAPINE AND CHLORPROMAZINE IN 
ACUTE SCHIZOPHRENIC SYNDROMES. 

226412 01-08 
EFFECTS OF CONTROL TECHNIQUES ON THERAPEUTIC OUTCOME IN A 
CONTROLLED CLINICAL TRIAL. 

226902 01-16 



A CONTROLLED MULTICENTRE THERAPEUTIC TRIAL OF VILOXAZINE 
(VIVALAN). 

227216 01 
A DOUBLE-BLIND CONTROLLED COMPARISON OF CLOMIPRAMINE 
(ANAFRANIL) AND IMIPRAMINE ON DEPRESSION. 

228327 
DOUBLE-BLIND CONTROLLED STUDY OF L-DOPA THERAPY IN 
SCHIZOPHRENIA. 

229064 
A CONTROLLED TRIAL OF CHLORMETHIAZOLE AND CHLORDIAZEPOXIt 
IN THE TREATMENT OF THE ACUTE WITHDRAWAL PHASE OF 
ALCOHOLISM. 

230104 
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN 
ANXIETY NEUROSIS. 

230907 
A CONTROLLED TRIAL OF MAPROTILINE (LUDIOMIL) IN DEPRESSED 
OUTPATIENTS. 

231401 
THE ASSESSMENT OF THIOTHIXENE IN CHRONIC SCHIZOPHRENIA: A 
DOUBLE-BLIND CONTROLLED TRIAL. 

231609 
A PLACEBO CONTROLLED STUDY OF LITHIUM COMBINED WITH 
NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC PATIENTS. 

232840 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 
PSYCHIATRIC PATIENTS - II. REPORT ON A PLACEBO CONTROLLED 
CLINICAL TRIAL. 

235361 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - III. STANDARD CONTROLLED CLINICAL 
TRIAL. 

235362 
CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY OF THE COMPARA' 

EFFECTIVENESS OF MEPIPRAZOL (EMD-16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 
LENPERONE: A CONTROLLED EVALUATION IN CHRONIC SCHIZOPHREN 
PATIENTS. 

237899 
PIPAMPERONE (DIPIPERON, R-3-345) IN TROUBLESOME MENTAL 
RETARDATES: A DOUBLE-BLIND PLACEBO CONTROLLED CROSSOVEF 
STUDY WITH LONG-TERM FOLLOW-UP. 

238982 
A CONTROLLED COMPARISON OF CYCLAZOCINE AND NALOXONE 
TREATMENT OF THE PAROLED NARCOTIC ADDICT. 

239824 
A MULTIPLE DOSE, CONTROLLED STUDY OF PHENELZINE IN DEPRESSI 
ANXIETY STATES. 

239938 
CHARACTERISTICS OF BEHAVIOR CONTROLLED BY SCHEDULED 
INJECTIONS OF DRUGS 

240010 
CONTROLLED COMPARISON OF ESTAZOLAM AND NITRAZEPAM AS 
HYPNOTICS ON THE PREOPERATIVE NIGHT SLEEP. 

241273 
CONTROLLED CLINICAL AND QUANTITATIVE EEG STUDIES OF 

TRIFLUBAZAM (ORF-8063) IN PATIENTS WITH ANXIETY SYNDROME 

241275 
PERSONALITY FACTORS AND DRUG EFFECTS IN A CONTROLLED STUD 
OF CYCLAZOCINE. 

244298 
A CONTROLLED TRIAL OF AMANTADINE IN DRUG-INDUCED 
EXTRAPYRAMIDAL DISORDERS. 

244701 
A PLACEBO CONTROLLED TRIAL OF VILOXAZINE WITH AND WITHOUl 
TRANQUILLIZERS IN DEPRESSIVE ILLNESS. 

245137 
A CONTROLLED COMPARATIVE TRIAL OF A COMBINATION OF 
OPIPRAMOL AND CLOMIPRAMINE AND A HIGHER DOSE OF 
CLOMIPRAMINE ALONE. 

245468 C 
CONTROLLED TRIAL OF METHYLPHENIDATE IN PRESCHOOL CHILDREN 
WITH MINIMAL-BRAIN-DYSFUNCTION. 

247375 
A CONTROLLED EVALUATION OF LOXITANE IN SEVENTY-FIVE 
ADOLESCENT SCHIZOPHRENIC PATIENTS. 

247483 
DOUBLE-BLIND PLACEBO CONTROLLED EFFICACY STUDY OF KETAZOL 
(U-28774). 

248532 
SELF-INHIBITING ACTION OF NORTRIPTYLINE ANTIDEPRESSIVE EFFECT 
HIGH PLASMA LEVELS: A RANDOMIZED, DOUBLE-BLIND STUDY 
CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION. 

248955 
CONTROLLED CLINICAL TRIAL OF A NEW ANTIDEPRESSANT (ORG-GB-' 
OF NOVEL CHEMICAL FORMULATION. 

248977 



S-88 



VOLUME 14, SUBJECT INDEX 



Subject Index 



A STATISTICAL REVIEW OF CONTROLLED TRIALS OF IMIPRAMINE AND 
PLACEBO IN THE TREATMENT OF DEPRESSIVE ILLNESSES. 

249536 04-16 
THE OBJECTIVE MEASUREMENT OF MENTAL PERFORMANCE IN 
CEREBROVASCULAR DISEASE: A DOUBLE-BLIND CONTROLLED STUDY 
USING A GRADED-RELEASE PREPARATION OF ISOXSUPRINE. 

250414 04-11 
BETA-ADRENERGIC BLOCKADE IN THE CONTROL OF SCHIZOPHRENIC 
SYMPTOMS - A CASE FOR CONTROLLED STUDIES. 

251164 04-08 
CLORAZEPATE DIPOTASSIUM (TRANXENE): A CONTROLLED EVALUATION 
IN ALCOHOLIC PATIENTS AFTER WITHDRAWAL. 

251718 04-11 
A CONTROLLED DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE AND 
HALOPERIDOL IN ACUTE NEWLY HOSPITALIZED SCHIZOPHRENIC 
PATIENTS. 

253051 04-08 
A PLACEBO CONTROLLED CLINICAL TRIAL OF TRAZODONE. 

253057 04-11 
A STANDARD CONTROLLED CLINICAL TRIAL OF TRAZODONE ON 

GERIATRIC PATIENTS. 

253058 04-1 1 
ANTIDEPRESSANT TREATMENT WITH MAPROTILINE IN THE 

MANAGEMENT OF EMOTIONAL DISTURBANCES IN PATIENTS WITH 
ACUTE MYOCARDIAL INFARCTION: A CONTROLLED STUDY. 

253684 04-11 
CONTROLLING 

CONTROLLING INCONTINENCE AMONG GERIATRIC PATIENTS: A PILOT 
STUDY MADE IN A STATE MENTAL HOSPITAL. 

237271 02-14 
CONVERGENCE 

USES OF DOUBLE-PULSE STIMULATION BEHAVIORALLY TO INFER 
REFRACTORINESS, SUMMATION. CONVERGENCE, AND TRANSMITTER 
CHARACTERISTICS OF HYPOTHALAMIC REWARD SYSTEMS. 

250278 04-03 
CONVERSION 

ENZYMATIC CONVERSION OF MORPHINE TO PSEUDOMORPHINE. 

243780 04-03 
CONVICT 

DIFFERENTIATION BY MORPHINE OF TWO TYPES OF AGGRESSIVE 
BEHAVIOR IN THE CONVICT CICHLID (CICHLASOMA- 
NIGROFASCIATUM). 

230865 01-04 
CONVICTS 

TREATMENT OF PSYCHOLOGICAL PROBLEMS OF CONVICTS. 

233079 02-11 
CONVULSANT 

DIFFERENTIAL REGIONAL EFFECTS OF THE CONVULSANT METHIONINE 
SULFOXIMINE ON SEROTONIN TURNOVER IN THE RAT BRAIN. 

227387 01-03 
EFFECTS OF ANTICONVULSANT AND CONVULSANT DRUGS ON THE 
ATPASE ACTIVITIES OF SYNAPTOSOMES AND THEIR COMPONENTS. 

243801 04-03 
SPECIFIC AXONAL EFFECTS OF A CONVULSANT BARBITURATE. 

249258 04-03 
CONVULSION 

SUSCEPTIBILITY TO ELECTROSHOCK CONVULSION AFTER BARBITURATE 
PELLET IMPLANTATION IN THE MOUSE. 

249254 04-05 
CONVULSIONS 

TWO CASES OF CONVULSIONS DURING LITHIUM THERAPY. 

228072 01-15 
RELATIONSHIPS BETWEEN ANESTHETIC SUBSTANCES, CONVULSIONS, 
AND PSYCHIC DISTURBANCES. 

229118 01-15 
MODIFICATION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS BY 
DRUGS WHICH ALTER BRAIN CATECHOLAMINE LEVELS OR STIMULATE 
CATECHOLAMINE RECEPTORS. 

238734 03-03 
THE ROLE OF DOPAMINE (DA) AND SEROTONIN (5-HT) IN THE 

PROLONGATION OF POST DECAPITATION CONVULSIONS (PDC) IN MICE. 

238737 03-03 
EFFECT OF CONVULSIONS AND ANTICONVULSIVE DRUGS ON 
CEREBROSPINAL FLUID CYCLIC-AMP IN RABBITS. 

239090 03-03 
INTERACTION OF DELTA9-TETRAHYDR0CANNABIN0L AND CANNABIDIOL 
WITH PHENOBARBITONE IN PROTECTING MICE FROM ELECTRICALLY- 
INDUCED CONVULSIONS. 

244894 04-04 
INHIBITORY EFFECTS IF 6-HYDROXYDOPAMINE ON THE CLONIC 
CONVULSIONS INDUCED BY ELECTROSHOCK AND DECAPITATION. 

245597 04-03 
FAILURE OF PHENOBARBITONE TO PREVENT FEBRILE CONVULSIONS. 

251103 04-11 
CONVULSIVE 

THE USE OF CLONAZEPAM IN TREATING CONVULSIVE MANIFESTATIONS 
WITH ENCEPHALOPATHY IN CHILDREN: STUDY OF 28 CASES. 

229083 01-11 



ANESTHESIOLOGIC CONSIDERATIONS IN PSYCHIATRIC CONVULSIVE 
THERAPY. 

249765 04-17 
COOMBS-POSITIVE 

COOMBS-POSITIVE HEMOLYTIC ANEMIA PROVOKED BY 
CHLORPROMAZINE. 

237161 02-15 
COORDINATION 

ACUTE EFFECTS OF OXAZEPAM, DIAZEPAM AND METHYLPERONE, ALONE 
AND IN COMBINATION WITH ALCOHOL ON SEDATION, COORDINATION 
AND MOOD. 

239042 03-14 
CORD 

THE EFFECTS OF BETA-CARBOLINES ON RESPONSES TO ACETYLCHOLINE, 
NORADRENALINE, 5-HYDROXYTRYPTAMINE AND AMINO-ACIDS IN THE 
RAT SPINAL CORD. 

235863 02-03 
ACTIONS OF METHOXAMINE AND TRYPTAMINE AND THEIR 

INTERACTIONS WITH CYPROHEPTADINE AND PHENOXYBENZAMINE ON 
CAT SPINAL CORD SEGMENTAL REFLEXES. 

237752 02-03 
LOSS OF INHIBITION IN SPINAL CORD DURING BARBITURATE 
WITHDRAWAL. 

238770 03-03 
EFFECTS OF MORPHINE ON ACETYLCHOLINE RELEASE FROM THE FROG 
SPINAL CORD. 

241922 03-03 
EFFECT OF CLONIDINE ON THE NOREPINEPHRINE (NE) SENSITIVE CYCLIC- 
AMP GENERATING SYSTEM IN SLICES OF RAT SPINAL CORD (SO, 
BRAINSTEM (BS) AND LIMBIC FOREBRAIN (LFB) AND ON MEDIAL 
FOREBRAIN BUNDLE (MFB) STIMULATION. 

249255 04-03 
CORN-FED 

RAPID REPLETION OF BRAIN SEROTONIN IN MALNOURISHED CORN-FED 
RATS FOLLOWING L-TRYPTOPHAN INJECTION. 

226873 01-03 
STIMULATION OF BRAIN SEROTONIN {5-HT) SYNTHESIS BY L- 

TRYPTOPHAN (TRP) INJECTION IN MALNOURISHED, CORN-FED RATS. 

238676 03-03 
CORNEA 

DEPOSITS IN THE LENS AND CORNEA OF THE EYE DURING LONG-TERM 
CHLORPROMAZINE MEDICATION. 

240048 03-15 
CORPUS-STRIATUM 

AMPHETAMINE AND APOMORPHINE RESPONSES IN THE RAT FOLLOWING 
6-OHDA LESIONS OF THE NUCLEUS ACCUMBENS SEPT! AND CORPUS- 
STRIATUM. 

226937 01-04 
RELEASE OF H3-ALPHA-METHYL-TYRAMINE FROM CORPUS-STRIATUM IN 
VITRO AND THE EFFECTS OF GLUCOSE DEPRIVATION. 

23873! 03-03 
A STUDY OF THE METABOLISM AND RELEASE OF DOPAMINE AND 

AMINO-ACIDS FROM NERVE ENDINGS ISOLATED FROM SHEEP CORPUS- 
STRIATUM. 

241206 03-03 
ALTERATIONS IN DOPAMINE UPTAKE IN RAT CORPUS-STRIATUM 
INDUCED BY COMBINATIONS OF STRESS AND DELTA8- 
TETRAHYDROCANNABINOL (DELTA8-THC). 

241926 03-03 
THE EFFECT OF LONG-TERM PENFLURIDOL TREATMENT ON THE 
SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS- 
ACCUMBENS AND IN THE CORPUS-STRIATUM. 

249670 04-04 
EFFECT OF ETHANOL ON DOPAMINE SYNTHESIS AND RELEASE FROM RAT 
CORPUS-STRIATUM. 

251178 04-03 
CORRECTION 

FOR SENILE DEMENTIA: CHEMICAL CORRECTION?. 

249351 04-11 
CORRECTIVES 

ON HYPOTENSION AS A RESULT OF PSYCHOTROPIC MEDICATION: 
COMPARATIVE STUDY OF TWO CORRECTIVES (ETILEFRINE AND 
DIHYDROERGOTAMINE). 

241763 03-15 
CORRELATE 

AN ATTEMPT TO CORRELATE ANALGESIA TO CHANGES IN BRAIN 
NEUROMEDIATORS IN RATS. 

233336 02-03 
CORRELATES 

BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF REPEATED D- 
AMPHETAMINE ADMINISTRATION. 

234809 02-04 
CORRELATES OF PLACEBO REACTION IN AN OUTPATIENT POPULATION. 

235628 02-17 
THE ANXIOLYTIC EFFECT OF SAAALL CUMULATIVE DOSES OF OXYPERTIN 
IN RATS IN AN ANXIETY TEST AND THE POSSIBLE NEUROCHEMICAL 
CORRELATES IN THE HYPOTHALAMUS AND STRIATUM. 

239834 03-04 



2 



•ST'- 

I 

S3t;.. 



S-89 



Subject Index 



Psychopharmacology Abstracts 



PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER- 
DISCHARGES IN RATS: INCREMENTAL DOSE, HIPPOCAMPAL EEC AND 
BEHAVIORAL ACTIVITY CORRELATES 

239858 0303 
NEUROCHEMICAL CORRELATES OF BEHAVIOUR ■• CONTENT OF 
TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, SEROTONIN, 5- 
HYDROXYINDOLEACETIC ACID, TYROSINE, DOPAMINE AND 
NOREPINEPHRINE IN FOUR BRAIN PARTS OF THE PIGEON DURING 
BEHAVIOURAL DEPRESSION FOLLOWING AN INJECTION. 

241205 03-04 
THE GENETIC, BIOCHEMICAL AND PHARMACOLOGICAL CORRELATES OF 
RESPONSES TO PRIMING IN MICE. (PH.D. DISSERTATION). 

241687 03-04 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACIDS 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG-INDUCED 
BEHAVIORAL EXCITATION. 

250067 04-04 
CORRELATION 

CORRELATION OF CHLORPROMAZINE LEVELS IN RAT BRAIN AND SERUM 
WITH ITS HYPOTHERMIC EFFECT. 

236527 02-03 
PLASMA CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES AFTER 
PERORAL, INTRAMUSCULAR, AND RECTAL ADMINISTRATION: 
CORRELATION BETWEEN PLASMA CONCENTRATION AND SEDATORY 
EFFECT OF DIAZEPAM. 

237735 02-13 
GAMMA-HYDROXYBUTYRATE: CORRELATION OF SERUM AND 

CEREBROSPINAL FLUID LEVELS WITH ELECTROENCEPHALOGRAPHIC 
AND BEHAVIORAL EFFECTS. 

237826 02-03 
THE INCREASE IN BRAIN TRYPTOPHAN CAUSED BY AMPHETAMINE-LIKE 
DRUGS: CORRELATION WITH AN INCREASE IN BODY TEMPERATURE. 

237891 02-03 
AAJ-9022: CORRELATION BETWEEN NEUROLEPTIC POTENTIAL AND 
STEREOTYPY. 

237903 02-08 
CATECHOLAMINE CONCENTRATION IN DISCRETE AREAS OF BRAIN OF 
SEVERAL STRAINS OF MICE: CORRELATION WITH AGGRESSIVITY 

238673 03-03 
CORRELATION BETWEEN THE EFFECTS OF SEVERAL CANNABINOIDS ON 
CATECHOLAMINE SYNTHESIS, BODY TEMPERATURE, AND BEHAVIOR. 

238769 03-03 
STUDIES ON THE CORRELATION BETWEEN BEHAVIOR AND BRAIN AMINES 
WITH PSYCHOTROPIC DRUGS 

241378 03-04 
CORRELATION BETWEEN THE 5-HYDROXYTRYPTAMINE CONTENTS IN THE 
BRAIN AND DEGREES OF SENSORY, AND lOCOMOrOR ACTIVITIES IN 
THE RAT. 

242205 03-04 
CORRELATION BETWEEN BRAIN LEVELS AND BIOCHEMICAL EFFECTS ON 
THE OPTICAL ISOMERS OF P-CHLOROAMPHETAMINE 

246851 04-03 
CORRELATION BETWEEN STRUCTURE, BEHAVIORAL ACTIVITY AND RATE 
OF BIOTRANSFORMATION OF SOME ACTH4-9 ANALOGS. 

246853 04 04 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEFN CLINICAL 
POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS 

248466 0403 
CORRELATION OF THE INCREASE IN BRAIN TRYPTOPHAN PRODUCED BY 
AMPHETAMINE LIKE DRUGS WITH AN INCREASE IN BODY 
TEMPERATURE. 

249316 04-03 
CORRELATION BETWEEN DISSOLUTION CHARACTERISTICS AND 
ABSORPTION OF METHAQUALONE FROM SOLID DOSAGE FORMS. 

250332 04-06 
LACK OF CORRELATION BETWEEN CHANGES IN CYCLIC NUCLEOTIDES 
AND SUBSEQUENT INDUCTION OF TYROSINE-HYDROXYI ASE IN RAT 
ADRENAL MEDULLA. 

251434 04-03 
CORRELATION BETWEEN NEUROLEPTIC-INDUCED SUPPRESSION OF 

STEREOTYPED BEHAVIOUR AND HVA CONCENTRATIONS IN RAT BRAIN. 

252523 04-03 
CORRELATIONS 

PREDICTABILITY IN PSYCHOPHARMACOLOGY: PRECLINICAL AND 
CLINICAL CORRELATIONS 

23111201 17 
CORRELATIONS BETWEEN THE EFFECTS OF DL AMPHETAMINE AND 
RESERPINE ON THE MODEL OF THE CAUDATE REACTION OF 
RETARDATION 

236235 02 03 
ELECTROCLINICAL CORRELATIONS IN PSYCHOPATHIES, 

236793 02-14 
URINARY EXCRETION OF METABOLITES OF CHLORPROMAZINE: CLINICO- 
CHEMICAL CORRELATIONS 

244050 04-08 
EFFECTS OF CHLORIMIPRAMINE AND LYSERGIC ACID DIETHYLAMIDE ON 
EFFLUX OF PRECURSOR FORMED 3H-SER0T0NIN: CORRELATIONS WITH 
SEROTONERGIC IMPULSE FLOW. 

246846 04-03 



CORRELATIONS BETWEEN THE ACTIVITY OF DIMETHYLTRYPTAMINES AS 
5-HYDROXYTRYPTAMINE ANTAGONISTS AND THEIR QUANTUM 
CHEMICAL PARAMETERS, 

249318 04-0: 
CORRELATIVE 

BENZODIAZEPINE-INDUCED STATE-DEPENDENT LEARNING: A 
CORRELATIVE OF ABUSE POTENTIAL?. 

252674 04-0 
CORTEX 

A STUDY OF INHIBITORY ANTAGONISM IN CAT VISUAL CORTEX. 

226397 01-0 
INCREASED TYROSINE-HYDROXYLASE ACTIVITY IN FRONTAL CORTEX 
AND CEREBELLUM AFTER RESERPINE. 

226935 01-0 
A DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN ANTERIOR LIMBIC 
CORTEX AND MESOLIMBIC REGION OF PRIMATE BRAIN. 

231304 01-0 
BARBITURATE SPINDLE ACTIVITY IN THE THALAMIC LATERAL 
VENTROPOSTERIOR NUCLEUS AND THE SECOND SOMATOSENSORY 
AREA OF THE CORTEX. 

232607 02-0 
THE EFFECT OF ^IHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE 01 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

237109 02-0 
EFFECTS OF DIPHENYLHYDANTOIN AND PHENOBARBITAL ON PROTEIN 
METABOLISM IN THE RAT CEREBRAL CORTEX. 

237243 O2-0 
NORADRENERGIC SUBSENSITIVITY AND SUPERSENSITIVITY OF THE 
CEREBRAL CORTEX AFTER RESERPINE TREATMENT. 

237756 02-0 
LOCAL ANESTHETICS AND BARBITURATES: EFFECTS ON EVOKED 
POTENTIALS IN ISOLATED MAMMALIAN CORTEX. 

237875 02-0 
ELECTROCONVULSIVE SHOCK RAISES PROSTAGLANDINS-F IN RAT 
CEREBRAL CORTEX. 

237921 O2-0 
DEPRESSION OF NEURONES IN THE RAT CEREBRAL CORTEX BY LEPTAZOI 

237925 02-C 
CELLULAR LOCALIZATION AND KINESTIC PROPERTIES OF GAMMA- 
GIUTAMYL TRANSPEPTIDASE IN RAT CEREBRAL CORTEX, 

238680 03-C 
EFFECT OF MONOAMINE-OXIDASE INHIBITORS ON RELEASE AND UPTAKE 
OF H3-N0REPINEPHRINE IN RAT CEREBRAL CORTEX IN VITRO. 

238689 03-C 
ALTERATIONS IN CA45 UPTAKE AND EFFLUX IN RAT CORTEX, STRIATU^ 
AND HYPOTHALAMUS SLICES. 

238714 03-C 
INTRACRANIAL SELF-STIMULATION DERIVED FROM ENTORHINAL CORTE) 

238757 03-C 
INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS ON THE ADENYLATE- 
CYCLASE PHOSPHODIESTERASE SYSTEM IN THE RAT CORTEX. 

239085 03-C 
ACTION OF NEUROLEPTIC AGENTS ON HISTAMINE SENSITIVE ADENYLATI 
CYCLASE IN RABBIT CEREBRAL CORTEX 

239582 03-C 
RESPONSES OF NEURONES IN THE CEREBRAL CORTEX AND CAUDATE- 
NUCLEUS TO AMANTADINE, AMPHETAMINE AND DOPAMINE. 

243805 04-C 
BEHAVIORAL EFFECTS OF AMPHETAMINE IN A GROUP OF RHESUS 
MONKEYS WITH LESIONS OF DORSOLATERAL FRONTAL CORTEX 

244684 04-C 
AMPHETAMINE: EVALUATION OF D-ISOMERS AND L-ISOMERS AS 

RELEASING AGENTS AND UPTAKE INHIBITORS FOR 3H-D0PAMINE AN! 
3H NOREPINEPHRINE IN SLICES OF RAT NEOSTRIATUM AND CEREBRAI 
CORTEX. 

248699 04C 
ON THE SPECIFICITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS IN THE 
RAT CEREBRAL CORTEX. 

248725 04-C 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN 

248961 04-C 
MORPHINE TOLERANCE AND DEPENDENCE IN NORADRENALINE 
NEURONES OF THE RAT CEREBRAL CORTEX. 

248979 04-C 
INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF 

NORADRENALINE FROM RAT CEREBELLAR CORTEX SLICES, 

248980 04-C 
ACTION OF PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE 

CEREBRAL CORTEX AND LUNG FOLLOWING MICROWAVE 
IRRADIATION, 

249286 04-C 
STIMULATION BY MORPHINE OF ACETYLCHOLINE OUTPUT FROM THE 
CEREBRAL CORTEX OF SEPTAL RATS. 

249664 04-C 



S-90 



VOLUME 14, SUBJECT INDEX 



Subject Index 



LOCALIZATION OF DOPAMINE RECEPTORS IN THE RAT CEREBRAL 
CORTEX 

250356 04-03 
EFFECTS OF ALPHA-RECEPTOR BLOCKERS AND ANTIDEPRESSANT DRUGS 
ON THE PRESYNAPTIC ALPHA-RECEPTOR OF RAT CEREBRAL CORTEX^ 

251394 04-03 
UPTAKE AND RELEASE OF NOREPINEPHRINE BY SLICES OF RAT CEREBRAL 
CORTEX; EFFECTS OF AGENTS WHICH INCREASE CYCLIC-AMP LEVELS. 

251964 04-03 
THE UPTAKE OF LOW CONCENTRATIONS OF LITHIUM IONS INTO RAT 
CEREBRAL CORTEX SLICES AND ITS DEPENDENCE ON CATIONS. 

25341 1 04-03 
THE EFFECT OF VARIOUS PHENOTHIAZINES AND TRICYCLIC 
ANTIDEPRESSANTS ON THE ACCUMULATION AND RELEASE OF 3H- 
NOREPINEPHRINE AND 3H-5-HYDROXYTRYPTAMINE IN SLICES OF RAT 
OCCIPITAL CORTEX. 

253691 04-03 
CORTICAL 

THE EFFECT OF D.LAMPHETAMINE ON THE REACTION OF CORTICAL 
NEURONS EVOKED BY STIMULATION OF MESODIENCEPHALIC 
STRUCTURES. 

228546 01-03 
BARBITURATE SPINDLE ACTIVITY IN FUNCTIONALLY CORRESPONDING 
THALAMIC AND CORTICAL SOMATOSENSORY AREAS IN THE CAT. 

232606 02-03 
THE EFFECTS OF DIMETHYLAMINOETHANOL (DEANOL) ON CEREBRAL 
CORTICAL NEURONS. 

23262! 02-03 
CORTICAL AND SUBCORTICAL PROJECTED FOCI IN CATS: INHIBITORY 
ACTION OF TAURINE. 

233299 02-03 
THE NATURE OF BACKGROUND SPIKE ACTIVITY OF CORTICAL NEURONS 
UNDER THE ACTION OF PSYCHOTROPIC DRUGS. 

236265 02-03 
CORTICAL OISINHIBITION: A POSSIBLE MECHANISM FOR DRUG-INDUCED 
HALLUCINATIONS. 

238830 03-03 
DIPHENYLHYDANTOIN INCREASES CORTICAL POSTSYNAPTIC INHIBITION. 

241805 03-03 
EFFECTS OF FRONTAL POLAR CORTICAL ABLATION AND CYCLOHEXIMIDE 
ON ETHANOL TOLERANCE IN RATS. 

242741 03-03 
EFFECTS OF 0ELTA9-TETRAHYDR0CANNABIN0L AND PENTOBARBITAL ON 
A CORTICAL RESPONSE EVOKED DURING CONDITIONING. 

244693 04-03 
EFFECTS OF ETHANOL ON NEUROTRANSMITTER RELEASE BY RAT BRAIN 
CORTICAL SLICES. 

246850 04-03 
THE EFFECT OF ATROPINE UPON ACETYLCHOLINE RELEASE FROM CAT 
SUPERIOR CERVICAL GANGLIA AND RAT CORTICAL SLICES; 
MEASUREMENT BY A RADIOENZYMIC METHOD 

248724 04-03 
ELECTRICALLY-INDUCED HIPPOCAMPAL AND CORTICAL SEIZURES AND 
THEIR EFFECTS ON OPERANT BEHAVIOR. 

249241 04-06 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE AND CLONIDINE 
FOLLOWING FRONTAL CORTICAL DAMAGE IN RATS. 

250089 04 04 
SUPERSENSITIVITY OF CORTICAL NEURONES OF THE RAT TO 

ACETYLCHOLINE AND L-GLUTAMATE FOLLOWING CHRONIC MORPHINE 
TREATMENT. 

251433 04-03 
CORTICOIDS 

PLASMA CORTICOIDS AND BRAIN TRYPTOPHAN AFTER ACUTE AND 
TOLERANCE DOSAGE OF LSD, 

234311 02-03 
CORTICOSTEROID 

UNWANTED CORTICOSTEROID EFFECTS IN CHILDHOOD BONE MARROW 
FAILURE, RENAL FAILURE AND BRAIN DAMAGE; CASE REPORT. 

245856 04-13 
CORTICOSTEROIOOGENESIS 

INHIBITION OF CORTICOSTEROIOOGENESIS BY CANNABINOIDS. 

238808 03-03 
CORTICOSTEROIDS 

INVOLVEMENT OF CORTICOSTEROIDS IN ACOUSTIC INDUCTION OF 
AUDIOGENIC SEIZURE SUSCEPTIBILITY IN MICE. 

237706 02-03 
CORTICOSTERONE 

ACUTE MORPHINE EFFECTS ON REGIONAL BRAIN AMINES. GROWTH 
HORMONE AND CORTICOSTERONE. 

246661 04 03 
CHRONIC MORPHINE EFFECTS ON REGIONAL BRAIN AMINES, GROWTH 

HORMONE AND CORTICOSTERONE. 

246662 04 03 
THE ROLE OF ADRENAL CATECHOLAMINES IN THE RELEASE OF 

CORTICOSTERONE AND FATTY-ACIDS BY NICOTINE IN THE RAT. 

247731 04-03 



CORTISOL 

EFFECTS OF CHLORPkOMAZINE ON FEAR MOTIVATED BEHAVIOR, 
URINARY CORTISOL, URINARY VOLUME, AND HEARTRATE IN THE 
DOG. 

240916 03-04 
DEPRESSION OF GROWTH HORMONE AND CORTISOL RESPONSE TO 
INSULIN-INDUCED HYPOGLYCEMIA AFTER PROLONGED ORAL DELTA9- 
TETRAHYDROCANNABINOL ADMINISTRATION IN MAN, 

252327 04-13 
CORTISONE 

EFFECT OF CORTISONE, ALDOSTERONE AND NIALAMIDE ON 
AMPHETAMINE STEREOTYPES AND BRAIN METHAMPHETAMINE LEVELS 
OF ADRENALECTOMIZED RATS, 

251990 04-04 
COUNCILS 

A CRITICISM OF WILLIAM SARGANTS ATTACK ON THE MEDICAL 
RESEARCH COUNCILS STUDY OF MODITEN. 

235429 02-08 
COUNSELING 

COUNSELING, PEAK EXPERIENCES AND THE HUAAAN ENCOUNTER WITH 
DEATH; AN EMPIRICAL STUDY OF THE EFFICACY OF DPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH.D. 
DISSERTATION). 

228686 01-11 
47-XYY AND 46-XY MALES WITH ANTISOCIAL AND/OR SEX OFFENDING 
BEHAVIOR; ANTIANDROGEN THERAPY PLUS COUNSELING. 

248222 04-10 
COUNTERACT 

DOES PIRACETAM COUNTERACT THE ECT-INDUCED MEMORY 
DYSFUNCTIONS IN DEPRESSED PATIENTS?. 

239002 03-09 
COUNTRY 

PATTERNS AND PROBLEMS OF DRUG CONSUMPTION IN A DEVELOPING 
COUNTRY. 

252990 04-17 
COURT 

FUGUE STATES - EPILEPSY - MEDICATION - HELD COMPETENT TO 
STAND TRIAL; PEOPLE V. PARSONS, 371 N.Y.S.2D 840, (NEW-YORK), 
NASSAU COUNTY COURT AUGUST 1, 1975, 

237476 02-17 



CPK 



PRETREATMENT CPK AND CLINICAL RESPONSE TO ANTIPSYCHOTIC 
MEDICATION, (UNPUBLISHED PAPER). 

238489 02-08 
CPZ 

SMOOTH PURSUIT EYE MOVEMENTS, AND DIAZEPAM, CPZ, AND 
SECOBARBITAL 

246303 04-14 
NATURE OF NEW CLASS OF CHIORPROAAAZINE (CPZ) METABOLITES IN 
PRIMATE URINES. 

249328 04-01 
CRANIAL 

TRIAL OF A NEW THERAPEUTIC AGENT, PERVINCAMINE, IN THE 

POSTCONCUSSION SYNDROME OF CRANIAL TRAUMAS; APPLICATION 
OF A DOUBLE-BLIND CONTROL AND SEQUENTIAL ANALYSIS. 

240033 03-11 
CREATINE-PHOSPHOKINASE 

PLASMA CREATINE-PHOSPHOKINASE LEVELS IN RATS FOLLOWING 
LYSERGIC-ACID-DIETHYLAMIDE 

230826 01-03 
SERUM CREATINE-PHOSPHOKINASE CONCENTRATIONS AFTER 
INTRAMUSCULAR CHLORDIAZEPOXIDE AND ITS SOLVENT, 

237928 02-15 
CRICKET 

PSYCHOPHARMACOLOGICAL CHARACTERIZATION OF A DRUG-INDUCED 
GROOMING BEHAVIOR IN THE CRICKET, ACHETA-DOMESTICUS 
(INSECTA, ORTHOPTERA). (PH.D. DISSERTATION), 

241994 03-04 
CRISIS 

INTRAVENOUS LORAZEPAM IN THE ACUTE ANXIETY CRISIS; A 
PRELIMINARY REPORT ON 60 CASES, 

242250 03-10 
CRITERIA 

CRITERIA FOR AND PITFALLS IN THE IDENTIFICATION OF RECEPTORS, 

229436 01-03 
CRITICISM 

A CRITICISM OF WILLIAM SARGANTS ATTACK ON THE MEDICAL 
RESEARCH COUNCILS STUDY OF MODITEN. 

235429 02-08 
CRITIQUE 

A CRITIQUE OF OBSTETRICAL PAIN RELIEVING DRUGS AS PREDICTORS OF 
INFANT BEHAVIOR VARIABILITY. 

250175 04-15 
CROSS-TOLERANCE 

ELECTROENCEPHALOGRAPHIC STUDIES ON THE DEVELOPMENT OF 
TOLERANCE AND CROSS TOLERANCE TO MESCALINE IN THE RAT. 

230880 01-04 






a;: 



S-91 



Subject Index 



Psychopharmacology Abstract 






BARBITAL-INDUCED CROSS-TOLERANCE TO BARBITURATES BY THE 
INTRACISTERNAL ROUTE OF ADMINISTRATION. 

231011 01-03 
ANALGETIC EFFECTS OF LANTHANUM: CROSS-TOLERANCE WITH 
MORPHINE. 

237870 02-03 
DEVELOPMENT OF CROSS-TOLERANCE BETWEEN DELTA9- 
TETRAHYDROCANNABINOL AND ETHANOL. 

249263 04-03 
CROSS-TOLERANCE BETWEEN MORPHINE AND OTHER ANALGESICS. 

251408 04-17 
CROSSOVER 

THERAPY OF ANXIETY IN PATIENTS WITH RHEUMATIC DISEASE; 
CROSSOVER DOUBLE-BLIND STUDY COMPARING LORAZEPAM WITH 
PLACEBO. 

228241 0111 
THE EFFECT OF L-DOPA ON YOUNG PATIENTS WITH SIMPLE 

SCHIZOPHRENIA, TREATED WITH NEUROLEPTIC DRUGS: A DOUBLE- 
BLIND CROSSOVER TRIAL WITH MADOPAR AND PLACEBO. 

230823 01-08 
CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY OF THE COMPARATIVE 
EFFECTIVENESS OF MEPIPRAZOL (EMD-16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 02-10 
PIPAMPERONE (DIPIPERON, R-3-345) IN TROUBLESOME MENTAL 
RETARDATES: A DOUBLE-BLIND PLACEBO CONTROLLED CROSSOVER 
STUDY WITH LONG-TERM FOLLOW-UP. 

238982 03-11 
A PLACEBO CROSSOVER STUDY OF CAFFEINE TREATMENT OF 
HYPERKINE1IC CHILDREN. 

247379 04-14 
LEVODOPA AND LEVOAMPHETAMINE: A CROSSOVER STUDY IN YOUNG 
SCHIZOPHRENIC CHILDREN. 

247480 04-08 
LIQUID LITHIUM VS. SOLID LITHIUM: AN OPEN, CROSSOVER, PILOT 
STUDY COMPARING ORAL PREPARATIONS. 

247877 04-07 
LORAZEPAM IN GASTROINTESTINAL DISORDERS WITH ANXIETY OVERLAY 
(A DOUBLE-BLIND CROSSOVER STUDY) 

250193 04-14 
POTENTIATION BY METYROSINE OF THIORIDAZINE EFFECTS IN CHRONIC 
SCHIZOPHRENICS: A LONG-TERM TRIAL USING DOUBLE-BLIND 
CROSSOVER TECHNIQUE. 

251374 04-08 
CRUCIAL 

SEROTONIN: THE CRUCIAL SUBSTANCE THAT TURNS DREAMS ON AND 
OFF. 

241505 03-12 
CRUDE 

CONFORMATIONAL REQUIREMENTS FOR BLOCKING UPTAKE OF 
CATECHOLAMINES AND SEROTONIN INTO CRUDE RAT BRAIN 
SYNAPTOSOMES. 

238738 03-01 
CRYSTAUOGRAPHIC 

DOPAMINE RECEPTOR BLOCKADE AND THE NEUROLEPTICS, A 
CRYSTALLOGRAPHIC STUDY. 

226761 01-03 



CSF 



CUE 



PROBENECID: DOSAGE, LEVELS IN PLASMA AND CEREBROSPINAL FLUID 
(CSF) AND INFLUENCE UPON CSF LEVELS OF HOMOVANILLIC-ACID 
(HVA) AND 5-HYDROXYINDOLEACETIC-ACID (5 HIAA) IN THE RABBIT. 

230877 01-06 

HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CSF 
OF PATIENTS AFTER A SEVERE HEAD INJURY. I. LUMBAR CSF 
CONCENTRATION IN CHRONIC BRAIN POSTTRAUMATIC SYNDROMES. 

246993 04-13 
HOMOVANILLIC-ACID AND 5-HYDROXYINDOLEACETIC-ACID IN THE CSF 

OF PATIENTS AFTER A SEVERE HEAD INJURY. II VENTRICULAR CSF 
CONCENTRATIONS IN ACUTE BRAIN POSTTRAUMATIC SYNDROMES. 

246994 04-13 
THE INFLUENCE OF PYRITHIOXINE HYPERVENTILATION ASSOCIATION ON 

CSF LACTATE IN CEREBRAL INFARCTION PATIENTS. 

252713 04-11 

DIFFERENTIAL RESPONSE CONTROL BY ISOPROPAMIDE: A PERIPHERALLY 
INDUCED DISCRIMINATIVE CUE. 

237744 02-04 
PHYSOSTIGMINE AS A DISCRIMINATIVE CUE IN RATS. 

241258 03-04 
ON THE ABILITY OF NARCOTIC ANTAGONISTS TO PRODUCE THE 
NARCOTIC CUE. 

251429 04-03 



CUES 



STATE-DEPENDENT ACCESSIBILITY OF RETRIEVAL CUES IN THE 
RETENTION OF A CATEGORIZED LIST. 

243013 04-04 



CULTURE 

A STUDY ON THE DEVELOPMENT OF BARBITURATE-TOLERANCE AND 
DEPENDENCE IN HAMSTER GLIAL CELLS IN CULTURE. 

241348 03-C 
THE EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON THE RESTING 
MEMBRANE POTENTIAL OF DISSOCIATED BRAIN NEURONS IN 
CULTURE. 

244199 04-C 
CULTURE, MORBIDITY, AND THE EFFECTS OF DRUGS. 

252991 04-1 
CULTURED 

THE EFFECTS OF GABA, PICROTOXIN AND BICUCULLINE ON THE 
SPONTANEOUS BIOELECTRIC ACTIVITY OF CULTURED CEREBELLAR 
PURKINJE CELLS. 

232906 02-C 
CULTURES 

OPIATE RECEPTORS IN CELL CULTURES. (UNPUBLISHED PAPER). 

239787 03-C 
MECHANISMS OF TRANS-SYNAPTIC INDUCTION OF TYROSINE- 
HYDROXYLASE (TH) AND DOPAMINE-BETA-HYDROXYLASE (DBH) IN 
ORGAN CULTURES OF RAT SYMPATHETIC GANGLIA: ROLE OF 
DEPOLARIZATION OF THE POSTSYNAPTIC MEMBRANE. 

251393 04-( 
CUMULATIVE 

THE ANXIOLYTIC EFFECT OF SMALL CUMULATIVE DOSES OF OXYPERTIN 
IN RATS IN AN ANXIETY TEST AND THE POSSIBLE NEUROCHEMICAL 
CORRELATES IN THE HYPOTHALAMUS AND STRIATUM. 

239834 03-( 
CURARIZED 

DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: I. PGO WAVE ACTIVITY INDUCED BY RO-4-1284 ANI 
BY P-CHLOROPHENYLALANINE (PCPA) AS A BASIS FOR 
NEUROPHARMACOLOGICAL STUDIES. 

241315 03-( 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: II. PGO WAVE ACTIVITY AND BRAIN 5- 
HYDROXYTRYPTAMINE. 

241316 03-C 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: III. PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES. 

241317 03-C 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: IV. THE EFFECTS OF ACETYLCHOLINE. GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY. 

241318 03-C 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: V. MISCELLANEOUS COMPOUNDS. SYNOPSIS OF THi 
ROLE OF CENTRAL NEUROTRANSMITTERS ON PGO WAVE ACTIVITY. 

241319 03-C 
HYPOTHALAMIC CHEMOSTIMULATION AND AUTONOMIC CHANGES IN 

CURARIZED RATS. 

244691 04-C 
HIPPOCAMPAL THETA-RHYTHM. I. DEPTH PROFILES IN THE CURARIZED 
RAT. 

251061 04-C 
CURB 

CURB ON BARBITURATES. 

231749 01-1 
CURE 

MAINTENANCE ANTIPSYCHOTIC THERAPY: IS THE CURE WORSE THAN 
THE DISEASE'. 

236307 02-C 
DRUGS HELP, BUT WONT CURE, MOST HYPERACTIVE CHILDREN. 

247143 04-1 
CURVE 

SERUM LITHIUM CURVE AND CLINICAL PSYCHOMETRIC VARIABLES: 
PRELIMINARY EXPERIMENTS. 

244591 04-1 
CYCLANDELATE 

CYCLANOELATE CHECKS MENTAL DECAY: AGED PATIENTS IQ AND 
MEMORY PRESERVED WITH USE OF VASODILATOR. 

247022 04-1 
CYCLAZOCINE 

A CONTROLLED COMPARISON OF CYCLAZOCINE AND NALOXONE 
TREATMENT OF THE PAROLED NARCOTIC ADDICT. 

239824 03-1 
PERSONALITY FACTORS AND DRUG EFFECTS IN A CONTROLLED STUDY 
OF CYCLAZOCINE. 

244298 04-1 
COMPARISON OF THE EFFECTS OF MORPHINE, PENTAZOCINE, 
CYCLAZOCINE AND AMPHETAMINE ON INTRACRANIAL SELF- 
STIMULATION IN THE RAT. 

251975 04-0 
CYCLE 

CHANGE OF THE HEARTRATE AND SLEEP-WAKEFULNESS CYCLE AFTER 
ISOPROTERENOL ADMINISTRATION IN WHITE RATS. 

244449 04-0 



S-92 



LUME 14, SUBJECT INDEX 



Subject Index 



LES 

CIRCADIAN CYCLES IN BINDING OF 3H-ALPREN0L0L TO BETA- 
ADRENERGIC RECEPTOR SITES IN RAT PINEAL. 

234919 02-03 
NEUROHUMORAL MECHANISMS RELATING TO CIRCADIAN SLEEP- 
WAKEFULNESS CYCLES OF HUMORAL EXPERIMENTAL ANI/WALS. 

238971 03-03 
INFLUENCE OF DIURNAL CYCLES ON BIOCHEMICAL PARAMETERS OF 
DRUG SENSITIVITY: THE PINEAL GLAND AS A MODEL. 

241471 03-17 
EFFECT OF 10 DAYS RESERPINE OR APOMORPHINE ADMINISTRATION ON 
SLEEP CYCLES IN RATS 

242732 03-04 
THE EFFECT OF PROLONGED ADMINISTRATION OF NITRAZEPAM ON 
SLEEP CYCLES IN RATS. 

, 244456 04-04 
ACTION OF ALPHA-METHYL-DOPA ON WAKING-SLEEP CYCLES IN TWO 
INBRED STRAINS OF MICE, C57BR AND C57BL/6. 

249676 04-04 
Lie 

NEUROTRANSMITTERS INCREASE CYCLIC NUCLEOTIDES IN 
POSTGANGLIONIC NEURONS: IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318 01-03 
REGULATION OF PROTEIN PHOSPHORYLATION AND MEMBRANE 
PERMEABILITY BY BETA-ADRENERGIC AGENTS AND CYCLIC ADENOSINE 
3:5,-MONOPHOSPHATE IN THE AVIAN ERYTHROCYTE. 

231014 01-03 
CYCLIC NUCLEOTIDES, PROTEIN PHOSPHORYLATION, AND NEURONAL 
FUNCTION. 

231021 01-17 
CYCLIC EEG CHANGES IN SUBACUTE SPONGIFORM AND ANOXIC 
ENCEPHALOPATHY. 

235563 02-13 
EFFECT OF NOMIFENSINE ON MOTOR ACTIVITY, DOPAMINE TURNOVER 
RATE AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE 
CONCENTRATIONS OF RAT STRIATUM. 

237156 02-04 
CYCLIC NUCLEOTIDES AND THEIR POSSIBLE RELEVANCE TO DISORDERS 
OF NERVOUS SYSTEM FUNCTION. (UNPUBLISHED PAPER). 

237171 02-03 
CYCLIC ADENOSINE MONOPHOSPHATE IN CEREBROSPINAL FLUID: 
EFFECTS OF THEOPHYLLINE, L-DOPA AND A DOPAMINE RECEPTOR 
STIMULANT IN RATS. 

240447 03-03 
EFFECTS OF STIMULATORY AND DEPRESSANT DRUGS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE LEVELS IN MOUSE BRAIN, 

241246 03-03 
CENTRAL GAMMA-AMINOBUTYRIC-ACID RECEPTORS AND THE 

REGULATION OF 35 CYCLIC ADENOSINE MONOPHOSPHATE CONTENT 
IN RAT PITUITARY. (UNPUBLISHED PAPER). 

243041 04-03 
EFFECTS OF ARECOLINE AND CHOLINESTERASE INHIBITORS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE IN MOUSE BRAIN. 

246389 04-03 
THE EFFECT OF LITHIUM ON UNSTIMULATED AND GLUCAGON 
STIMULATED URINARY CYCLIC AMP EXCRETION IN RAT AND MAN. 

251129 04-17 
EFFECTS OF DOPAMINERGIC STIMULANTS ON CYCLIC NUCLEOTIDE 
LEVELS IN MOUSE BRAIN IN VIVO. 

251432 04-03 
LACK OF CORRELATION BETWEEN CHANGES IN CYCLIC NUCLEOTIDES 
AND SUBSEQUENT INDUCTION OF TYROSINE-HYDROXYLASE IN RAT 
ADRENAL MEDULLA. 

251434 04-03 
.IC-AMP 

SUBSENSITIVITY OF NORADRENALINE STIMULATED CYCLIC-AMP 
ACCUMULATION IN BRAIN SLICES OF D-AMPHETAMINE TREATED 
MICE. 

226651 01-02 
MODULATORS OF CYCLIC-AMP SYSTEMS. 

229464 01-03 
DOPAMINE-INDUCED INCREASES IN CYCLIC-AMP, AND CYCLIC-AMP 
DEPENDENT PROTEIN PHOSPHORYLATION, IN THE RAT CAUDATE- 
NUCLEUS. (PH.D. DISSERTATION). 

238080 02-13 
A DOPAMINE INDUCED NEURONAL MEMORY TRACE, MEDIATED BY 
CYCLIC AMP AND DISRUPTABLE BY CYCLIC GMP. 

238717 03-04 
CENTRAL DEPLETION OF NOREPINEPHRINE IN GUINEA PIG: LACK OF 
EFFECT ON NOREPINEPHRINE SENSITIVE CYCLIC-AMP GENERATING 
SYSTEMS. 

238798 03-03 
CHL0RPR0MA2INE AND HORMONAL ELEVATION OF CYCLIC-AMP 
CONTENTS IN TURKEY ERYTHROCYTES AND PERFUSED RAT HEART 
AND LIVER. 

239044 03-03 



EFFECT OF CONVULSIONS AND ANTICONVULSIVE DRUGS ON 
CEREBROSPINAL FLUID CYCLIC-AMP IN RABBITS. 

239090 03-03 
INHIBITORY ACTION OF NORADRENALINE AND CYCLIC-AMP IN EXPLANTS 
OF RAT CEREBELLUM. 

239836 0303 
BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN 
CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY 
DESTRUCTION OF INTERNEURONS. (UNPUBLISHED PAPER). 

240242 03-03 
CYCLIC-AMP AS A POSSIBLE MEDIATOR IN DOPAMINERGIC 

STIMULATION-INDUCED ROTATIONAL BEHAVIOR OF RATS LESIONED 
UNILATERALLY IN SUBSTANTIA-NIGRA. 

241382 03-04 
CYCLIC-AMP IN CEREBROSPINAL FLUID IN PATIENTS WITH AFFECTIVE 
ILLNESS: EFFECTS OF PROBENECID, ACTIVITY, AND PSYCHOTROPIC 
MEDICATIONS. (UNPUBLISHED PAPER 

243023 04-09 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VIVO 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE. 

244514 04-03 
ACTION OF VARIOUS ANTIDEPRESSANT TREATMENTS REDUCES 

REACTIVITY OF NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM 
IN LIMBIC FOREBRAIN. 

245115 04-03 
EFFECT OF CLONIDINE ON THE NOREPINEPHRINE (NE) SENSITIVE CYCLIC- 
AMP GENERATING SYSTEM IN SLICES OF RAT SPINAL CORD (SO, 
BRAINSTEM (BS) AND LIMBIC FOREBRAIN (LFB) AND ON MEDIAL 
FOREBRAIN BUNDLE (MFB) STIMULATION. 

249255 04-03 
ACTION OF PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE 
CEREBRAL CORTEX AND LUNG FOLLOWING MICROWAVE 
IRRADIATION. 

249286 04-03 
ON THE MECHANISM OF THE INHIBITION OF BRAIN CYCLIC-AMP 

PHOSPHODIESTERASE BY PSYCHOTROPIC AGENTS. 

249287 04-03 
CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 

ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
UPTAKE AND RELEASE OF NOREPINEPHRINE BY SLICES OF RAT CEREBRAL 
CORTEX: EFFECTS OF AGENTS WHICH INCREASE CYCLIC-AMP LEVELS. 

251964 04-03 
EFFECT OF NARCOTIC DEPENDENCE AND WITHDRAWAL ON STRIATAL 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND SYNAPTOSOMAL 
CYCLIC-AMP METABOLISM. 

253135 04-03 
CYCLIC-GMP 

A DOPAMINE-INDUCED NEURONAL MEMORY TRACE, MEDIATED BY 
CYCLIC-AMP AND DISRUPTABLE BY CYCLIC-GMP. 

238717 03-04 
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE- 
CYCLASE AND ON CYCLIC-GMP FORMATION IN MONKEY BRAIN 
AMYGDALA. 

238739 03-03 
CYCLOAIKANOL 

SUBSTITUTED CYCLOALKANOL ETHERS OF PSYCHOSTIMULANT ACTIVITY: 
STUDIES ON QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS. 

231008 01-03 
CYCLOBARBITAL 

EFFECT OF ANTIPHENOBARBITAL ANTIBODIES ON SLEEPING TIME 
INDUCED BY CYCLOBARBITAL TO MICE. 

241403 03-03 
CYCLOBARBITAL-INDUCED 

EFFECTS OF PASSIVE IMMUNIZATION WITH RABBIT 

ANTIPHENOBARBITAL IGG ON CYCLOBARBITAL-INDUCED SLEEPING 
TIME AND HEPATIC ENZYME ACTIVITIES OF C3H MICE. 

242201 03-03 
CYCLOCHOUNE 

SOME PHARMACOLOGICAL PROPERTIES OF CYCLOCHOLINE, A REACTIVE 
ANALOG OF CHOLINE. 

238828 03-03 
CYCLOHEXIMIDE 

DIFFERENTIAL BEHAVIORAL AND BIOCHEMICAL EFFECTS OF REGIONAL 
INJECTION OF CYCLOHEXIMIDE INTO MOUSE BRAIN. 

235320 02-04 
EFFECTS OF ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE ON THE 
INCORPORATION OF AMINO-ACIDS INTO PROTEINS OF MOUSE BRAIN 
SUBCELLULAR FRACTIONS. 

237155 02-03 
EFFECTS OF FRONTAL POLAR CORTICAL ABLATION AND CYCLOHEXIMIDE 
ON ETHANOL TOLERANCE IN RATS. 

242741 03 03 
INTRACRANIAL CYCLOHEXIMIDE: EFFECT ON MALE MOUSE SEXUAL 
BEHAVIOR AND PLASMA TESTOSTERONE. 

242743 03-04 






'5P- 
I 



S-93 



Subject Index 



Psychopharmacology Abstraci 



CYCLOHEXIMIDE-INDUCED 

CYCLOHEXIMIDE-INDUCED AMNESIA FOR TASTE AVERSION MEMORY IN 
RATS 

242742 0304 
EFFECT OF AGE OF HABIT ON SUSCEPTIBILITY TO CYCLOHEXIMIDE- 
INDUCED AMNESIA IN MICE. 

245614 04-02 
CYCLOPHOSPHAMIDE 

DEVELOPMENT AND ADULT BEHAVIORAL ABNORMALITIES IN MICE 
TREATED NEONATALLY WITH CYCLOPHOSPHAMIDE, 

249296 04-02 
CYCLOPHRENIA 

LITHIUM SALTS IN CYCLOPHRENIA (MANIC-DEPRESSIVE PSYCHOSIS). 

237013 02-09 
CYCLOPROPANE 

INHIBITION BY CYCLOPROPANE OF RELEASE OF NOREPINEPHRINE. BUT 
NOT OF DOPAMINE-BETA-HYDROXYLASE FROM GUINEA-PIG VAS- 
DEFERENS (UNPUBLISHED PAPER). 

247028 04-03 
CYCLOTHYMIC 

PSYCHOVEGETATIVE DISORDERS IN CASES OF CYCLOTHYMIC 
DEPRESSION 

226777 01-09 
THE LITTLE KNOWN THERAPEUTIC PROPERTIES OF IMIPRAMINE IN 
MANIC STATES OF CYCLOTHYMIC PSYCHOSES. 

231368 01-09 
CYNOMYS-LUOOVICIANUS 

TOLERANCE IN METHYLPHENIDATE-INDUCED LOCOMOTION IN PRAIRIE 
DOGS (CYNOMYS LUDOVICIANUS). 

239863 03-04 
CYPROHEPTADINE 

ACTIONS OF METHOXAMINE AND TRYPTAMINE AND THEIR 

INTERACTIONS WITH CYPROHEPTADINE AND PHENOXYBENZAMINE ON 
CAT SPINAL CORD SEGMENTAL REFLEXES. 

237752 02-03 
CYPROHEPTADINE: WEIGHT GAIN AND APPETITE STIMULATION IN 
ESSENTIAL ANOREXIC ADULTS 

237900 02-10 
THERAPEUTIC DOSES OF CYPROHEPTADINE DO NOT INHIBIT 
MONOAMINE-OXIDASE IN MAN. 

237927 02-13 
CYTOCHEMICAL 

CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN 
THE CAUDATE-NUCLEUS. (UNPUBLISHED PAPER). 

238471 02-03 
CYTOCHROME-P450 

THE NATURE OF THE 455-NM ABSORBING COMPLEX FORMED DURING 
THE CYTOCHROME-P450 DEPENDENT OXIDATIVE METABOLISM OF 
AMPHETAMINE. 

241350 03-01 
CYTOLOGIC 

CYTOLOGIC STUDY OF CEREBROSPINAL FLUID IN CHRONIC PSYCHIATRIC 
PATIENTS TREATED WITH NEUROLEPTICS. 

230997 01-11 
C14-LEUCINE 

THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

237109 02-04 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

248961 04-03 
C14-METHAQUALONE 

PLACENTAL TRANSFER AND MATERNAL AND FETAL TISSUE 
DISTRIBUTION OF C14-METHAQUAL0NE IN MICE 

238764 03-03 
CI 4-5-HYDROXYTRYPT AMINE 

EFFECT OF ANGIOTENSIN II AND ITS ANALOGS ON UPTAKE AND RELEASE 
OF C14-5-HYDROXYTRYPTAMINE BY RAT BRAIN. 

237739 02-03 
D-AMPHETAMINE 

SUBSENSITIVITY OF NORADRENALINE STIMULATED CYCLIC-AMP 
ACCUMULATION IN BRAIN SLICES OF D-AMPHETAMINE TREATED 
MICE. 

226651 01-02 
RELATIONSHIP OF RATS SPATIAL PREFERENCES TO EFFECTS OF D- 
AMPHETAMINE ON TIMING BEHAVIOR. 

226729 01-04 
EFFECTS OF D-AMPHETAMINE ON THE BEHAVIOR OF PIGEONS 

MAINTAINED BY A SECOND-ORDER SCHEDULE OF REINFORCEMENT 

226852 01-04 
A STUDY OF THE EFFECT OF D-AMPHETAMINE ON THE TOXICITY, 
ANALGESIC POTENCY AND SWIMMING IMPAIRMENT CAUSED BY 
POTENT ANALGESICS IN MICE. 

226926 01 04 



1 



OLFACTORY BULB REMOVAL IN MICE: ACTIVITY LEVELS AND 

RESPONSIVENESS TO THE LOCOMOTOR STIMULANT AND ANOREXIC 
PROPERTIES OF D-AMPHETAMINE SULFATE. (PH.D. DISSERTATION). 

227074 01 04 

FOOD AND DRUG-REINFORCED RESPONDING: EFFECTS OF DITA AND D- 
AMPHETAMINE. 

227127 01-04 
CAFFEINE VERSUS METHYLPHENIDATE AND D-AMPHETAMINE IN 
MINIMAL-BRAIN-DYSFUNCTION: A DOUBLE-BLIND COMPARISON. 

227571 0111 
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE IN MATURE AND IMMATURE 
RATS. 

228160 01-04 
EFFECTS OF D-AMPHETAMINE, CHLORPROMAZINE, AND 

CHLORDIAZEPOXIDE ON INTERCURRENT BEHAVIOR DURING SPACED 
RESPONDING SCHEDULES. 

229639 01-04 
THE EFFECTS OF 2.5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM). 2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE (DOET), D-AMPHETAMINE, AND 
COCAINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE 
STIMULUS. 

230837 01-04 
BEHAVIORAL AND NEUROCHEMICAL CORRELATES OF REPEATED D- 
AMPHETAMINE ADMINISTRATION. 

234809 02-04 
INTERACTION EFFECTS OF D-AMPHETAMINE TREATMENT AND AMBIENT 
TEMPERATURE ON RATS FOOD INTAKE. 

237097 02-03 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE. LOCOMOTOR ACTIVITY. AND C14-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

237109 02-04 
EFFECTS OF D-AMPHETAMINE ON F-l SHOCK PRESENTATION WITH 
SDELTA PROBE. 

237699 02-04 
EFFECTS OF SCOPOLAMINE. D-AMPHETAMINE AND OTHER DRUGS 
AFFECTING CATECHOLAMINES ON SPONTANEOUS ALTERNATION AND 
LOCOMOTOR ACTIVITY IN MICE. 

237703 02-04 
ATTENUATION OF THE EUPHORIANT AND ACTIVATING EFFECTS OF D- 
AMPHETAMINE AND AND L-AMPHETAMINE BY LITHIUM CARBONATE 
TREATMENT. 

237716 02-14 
RESPONSES OF NORMAL AND ISOLATE MONKEYS TO D-AMPHETAMINE. 
COCAINE. CHLORPROMAZINE AND DIAZEPAM. 

238694 03-04 
RESPONSES OF FLEXOR REFLEX TO LSD, TRYPTAMINE (T). 5-HTP. 
METHOXAMINE (M) AND D-AMPHETAMINE (A) IN ACUTE AND 
CHRONIC SPINAL RATS. 

238704 0304 
NECESSITY OF HYPERTHERMIA FOR L-DOPA OR O-AMPHETAMINE TO 
DISAGGREGATE RAT BRAIN POLYSOMES. 

238719 03-03 
ANTAGONISMS BY NEUTRAL AMINO-ACIDS (NAA) OF THE HYPOTHERMIC 
EFFECT OF D-AMPHETAMINE (AMP). 

238726 03-03 
MODULATION BY RESPONSE REQUIREMENTS OF THE EFFECTS AND 
INTERACTIONS OF D-AMPHETAMINE AND ALPHA-METHYL-P-TYROSINE 
ON SCHEDULE-CONTROLLED PERFORAAANCE IN RATS. 

238844 03-04 
THE EFFECT OF DL-254 ON THE PHARMACOLOGICAL ACTIVITIES OF D- 
AMPHETAMINE AND APOMORPHINE: A COMPARISON WITH 
ANTIANXIETY AND NEUROLEPTIC AGENTS. 

238846 03 03 
D-AMPHETAMINE AND L-AMPHETAMINE DIFFERENTIALLY MEDIATES 
SELF-STIMULATION IN RAT DORSAL MIDBRAIN AREA. 

239272 03-04 
TEMPORAL PARAMETERS OF D-AMPHETAMINE AS A DISCRIMINATIVE 
STIMULUS IN THE RAT. 

239856 03-04 
PERFORMANCE ENHANCEMENT EFFECTS OF D-AMPHETAMINE. 

METHYLPHENIDATE. PIPRADROL AND PHENINDAMINE IN RATS. 

239857 03-04 
INFLUENCE OF PRENATAL D-AMPHETAMINE ADMINISTRATION ON 

DEVELOPMENT AND BEHAVIOR OF RATS. 

241245 03-04 
LACK OF TOLERANCE OR SENSITIZATION TO THE EFFECTS OF CHRONIC D- 
AMPHETAMINE ON SUBSTANTIA-NIGRA SELF-STIMULATION, 

241307 03 04 
TOLERANCE TO THE ACTIVITY ENHANCING EFFECT OF D-AMPHETAMINE. 
(PH.D. DISSERTATION). 

241575 03-03 
TASTE AVERSIONS INDUCED BY D-AMPHETAMINE: DOSE-RESPONSE 
RELATIONSHIP, 

242882 0404 
EFFECTS OF IMIPRAMINE. D-AMPHETAMINE. AND TRIPELENNAMINE ON 
MOUSE-KILLING AND FROG-KILLING BY THE RAT. 

243346 04-04 



S-94 



HUME 14, SUBJECT INDEX 



Subject Index 



EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE ON OBSERVING 
RESPONSES DURING A FIXED-INTERVAL SCHEOULE^ 

245303 04-04 
DOSE-RESPONSE EFFECTS OF D-AMPHETAMINE ON PASSIVE AVOIDANCE 
LEARNING IN THE RAT 

2463 1 3 0404 
D-AMPHETAMINE AS A RELEASER OR REUPTAKE INHIBITOR OF BIOGENIC 
AMINES IN SYNAPTOSOMES. 

246665 04-03 
INVOLVEMENT OF CENTRAL DOPAMINE IN THE HYPERTHERMIA IN RATS 
PRODUCED BY D-AMPHETAMINE. 

246820 04-04 
D-AMPHETAMINE AND L-AMPHETAMINE STEREOISOMERS: COMPARATIVE 
POTENCIES IN AFFECTING THE FIRING OF CENTRAL DOPAMINERGIC 
AND NORADRENERGIC NEURONS. 

247211 04-03 
SUPERSENSITIVITY TO D-AMPHETAMINE AND APOMORPHINE-INDUCED 
STEREOTYPED BEHAVIOR INDUCED BY CHRONIC D-AMPHETAMINE 
ADMINISTRATION. 

24/683 04 04 
ROLE OF DA IN THE STIMULANT EFFECT OF DITA IN MICE, COMPARISON 
WITH D-AMPHETAMINE. 

248284 04-03 
THE EFFECT OF CHRONIC SELF-ADMINISTRATION OF D-AMPHETAMINE ON 
FOOD INTAKE, LOCOMOTOR ACTIVITY, AND CI4-LEUCINE 
INCORPORATION INTO CEREBRAL CORTEX PROTEIN. 

248961 04-03 
EFFECTS OF MONOAMINE-OXIDASE INHIBITORS (MAOIS) ON 

SPONTANEOUS AND D-AMPHETAMINE STIMULATED LOCOMOTOR 
ACTIVITY. 

249273 04-03 
EFFECTS OF D-AMPHETAMINE, MONOMETHOXN AMPHETAMINES AND 
MESCALINE ON FIXED-INTERVAL RESPONDING IN RATS. 

249275 04-04 
EFFECT OF D-AMPHETAMINE AND D,L P-CHLOROAMPHETAMINE ON 
REGIONAL LEVELS OF CHOLINE AND ACETYLCHOLINE IN RAT BRAIN. 

249300 04-03 
AMANTADINE DECREASES D-AMPHETAMINE STIMULATION AND 
INCREASES D-AMPHETAMINE ANOREXIA IN MICE. 

249459 04-03 
EFFECTS OF D-AMPHETAMINE ON THE INCORPORATION OF CARBON 
ATOMS OF D-GLUCOSE INTO THE BRAINS OF DIFFERENTIALLY HOUSED 
MICE. 

249672 04-04 
ROLE OF STIMULUS LOCALE ON STRAIN DIFFERENCES IN ACTIVE 
AVOIDANCE AFTER SCOPOLAMINE OR D-AMPHETAMINE TREATMENT. 

2500/4 04-04 
COMBINATIONS OF SELECTED CNS DEPRESSANTS WITH D-AMPHETAMINE 
OR MAZINDOL ON FOOD INTAKE AND MOTOR ACTIVITY OF RATS. 

250080 04-03 
THE EFFECTS OF PHENCYCLIDINE, KETAMINE, D AMPHETAMINE AND 
PENTOBARBITAL ON SCHEDULE-CONTROLLED BEHAVIOR IN THE 
MOUSE. 

250112 04-04 
SOME EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL ON 
PERFORMANCE UNDER A LONG FIXED-INTERVAL SCHEDUIE 

252816 04-04 
EFFECTS OF INTERMITTENT AND REPEATED ADMINISTRATION OF D- 
AMPHETAMINE ON RESTRICTED WATER INTAKE IN RATS. 

253111 04-04 
EFFECT OF AROUSAL BY SOCIAL ISOLATION, GROUPING, AND D- 
AMPHETAMINE ON INTER-MALE AGGRESSION IN MICE (MUS- 
MUSCULUS). 

253485 04-04 
VMPHETAMINEINDUCED 
A TELENCEPHALIC LESION SITE FOR D-AMPHETAMINEINDUCED 
CONTRALATERAL ROTATION IN RATS 

231301 01-04 
ANTAGONISM OF APOMORPHINE AND D-AMPHETAMINE-INDUCED 
STEREOTYPED BEHAVIOUR BY INJECTION OF LOW DOSES OF 
HALOPERIDOL INTO THE CAUDATE-NUCLEUS AND THE NUCLEUS- 
ACCUMBENS. 

237704 02-04 
2-PHENYLETHYLAMINE (PEA) IN D-AMPHETAMINE-INDUCED 
EXTRAPYRAMIDAL DISORDERS. 

23884) 03-03 
DAMPHETAMINE-INDUCED INHIBITION OF CENTRAL DOPAMINERGIC 
NEURONS; MEDIATION BY A STRIATO-NIGRAL FEEDBACK PATHWAY. 

243882 04-03 
VMPHETAMINES 
INHIBITION OF SYNAPTOSOMAL ACCUMULATION OF L-NOREPINEPHRINE 
II: N-ARYLOXYALKYLPHENTERMINES, QUATERNARY D-AMPHETAMINES, 
AND 3ARYL0XYPR0PYLAMINES. 

248637 04-01 
HUCOSE 
EFFECTS OF D-AMPHETAMINE ON THE INCORPORATION OF CARBON 
ATOMS OF 0-GLUCOSE INTO THE BRAINS OF DIFFERENTIALLY HOUSED 
MICE. 

249672 04-04 



0-GLUCOSE- 14C 

DRUG-INDUCED PARKINSONISM IN THE RAT - A MODEL FOR 

BIOCHEMICAL INVESTIGATION OF THE PARKINSON SYNDROME: III: 
THE INCORPORATION OF D-GLUC0SE14C(U) IN AMINO-ACIDS OF 
BRAIN AND LIVER FROM RATS PRETREATED WITH RESERPINE OR 
WITH PHENOTHIAZINES. 

244692 04-03 
D-ISOMERS 

EFFECTS OF THE D-ISOMERS AND L-ISOMERS OF AMPHETAMINE ON 
UPTAKE, RELEASE AND CATABOLISM OF NOREPINEPHRINE, DOPAMINE 
AND 5-HYDROXYTRYPTAMINE IN SEVERAL REGIONS OF RAT BRAIN. 

241345 03-03 
AMPHETAMINE: EVALUATION OF D-ISOMERS AND L-ISOMERS AS 

RFI EASING AGENTS AND UPTAKE INHIBITORS FOR 3H-D0PAMINE AND 
3H-N0REPINEPHRINE IN SLICES OF RAT NEOSTRIATUM AND CEREBRAL 
CORTEX 

248699 04-03 
D-LSO 

THE DOPAMINE RECEPTOR: DIFFERENTIAL BINDING OF D-LSD AND 
RELATED AGENTS TO AGONIST AND ANTAGONIST STATES. 

247862 04-03 
D-LYSERGIC 

ANTAGONISM OF D-LYSERGIC ACID DIETHYLAMIDE AND MESCALINE BY 
1 METHYL 1,2,5,6 TETRAHYDROPYRIDINE N.N DIETHYLCARBOXAMIDE 
(TMPC). 

230453 01-03 
D-LYSERGIC-AC(D-DIETHYLAMIDE 

STEREOSPECIFIC BINDING OF D-LYSERGIC-ACID-DIETHYLAMIDE (LSD) TO 
BRAIN MEMBRANES: RELATIONSHIP TO SEROTONIN RECEPTORS. 

226936 01-12 
D-TRYPTOPHAN 

REDUCED SPONTANEOUS LOCOMOTOR ACTIVITY EVOKED BY L- 
TRYPTOPHAN & PREVENTED BY D-TRYPTOPHAN. 

238698 03-04 
DAILY 

BEHAVIORAL EFFECTS OF REDUCING THE DAILY FREQUENCY OF 
PHENOTHIAZINE ADMINISTRATION. 

228224 01-08 
LITHIUM MAINTENANCE TREATMENT OF MANIC-MELANCHOLIC 
PATIENTS: ITS ROLE IN THE DAIIY ROUTINE. 

240055 03-09 
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION: DAILY 
MORPHINE AND LATERAL HYPOTHALAMIC SELF-STIMULATION. 

250019 04-04 
PAVOR-NOCTURNUS: A COMPLICATION OF SINGLE DAILY TRICYCLIC OR 
NEUROLEPTIC DOSAGE. 

252955 04-17 
DAMAGE 

AN INVESTIGATION INTO THE POSSIBILITY OF IRREVERSIBLE CENTRAL- 
NERVOUS-SYSTEM DAMAGE AS A RESULT OF LONG-TERM 
CHLORPROMAZINE MEDICATION. 

229169 0M5 
CLINICAL AND BIOCHEMICAL PARAMETERS DURING NEUROLEPTIC 

TREATMENT: II. ANTIPSYCHOTIC EFFECT OF HALOPERIDOL IN PATIENTS 
WITH CHRONIC ORGANIC BRAIN DAMAGE. 

240219 03-11 
UNWANTED CORTICOSTEROID EFFECTS IN CHILDHOOD BONE MARROW 
FAILURE, RENAL FAILURE AND BRAIN DAMAGE: CASE REPORT. 

245856 04-13 
CAN PHENYTOINS CAUSE FETAL DAMAGE?. 

248097 04-13 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE AND CLONIDINE 
FOLLOWING FRONTAI CORTICAL DAMAGE IN RATS. 

250089 04-04 
DAMAGED 

THERMOREGULATORY RESPONSES TO INTRAVENTRICULAR 

NOREPINEPHRINE IN NORMAL AND HYPOTHALAMIC DAMAGED RATS. 

252174 04-03 
DAPOTUM-D 

EXPERIENCES WITH A DEPOT NEUROLEPTIC (DAPOTUM-D). 

242503 03-08 
DATA 

ANALYSIS AND DISPLAY OF PSYCHOPHARMACOLOGICAL DATA. 

228978 01-17 
PHARMACOLOGICAL RESPONSE DATA FOR COMPARATIVE 

BIOAVAILABILITY STUDIES OF CHLORPROMAZINE ORAL DOSAGE 
FORMS IN HUMANS: I. PUPILOMETRY. 

232623 02-13 
EXCITATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 
RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL. 
FUNCTIONAL AND CLINICAL DATA. 

237104 02-03 
DIFFERENTIAL EFFECTS OF AN INHIBITOR OF DECARBOXYLASE ON L- 
OOPA AND L 5-HTP: POLYGRAPHIC AND BIOCHEMICAL DATA. 

237709 02-03 
PERFUSION WITH L-5-HTP, ALONG WITH A DECARBOXYLASE INHIBITOR, 

IN THE RABBIT. POLYGRAPHIC AND BIOCHEMICAL DATA. 

237710 02-03 






-re 



'5P- 
I 

2E 

3St 



S-95 



Subject Index 



Psychopharmacology Abstracts 



BIOAVAILABILITY ANALYSIS OF CHLORPROMAZINE IN HUMANS FROM 
PUPILOMETRIC DATA. 

237872 02-13 
RAT DATA WHICH SUGGEST ALCOHOLIC BEVERAGES SHOULD BE 
SWALLOWED DURING CHEMICAL AVERSION THERAPY, NOT JUST 
TASTED 

252859 04-17 
DAYS 

EFFECT OF 10 DAYS RESERPINE OR APOMORPHINE ADMINISTRATION ON 
SLEEP CYCLES IN RATS. 

242732 03-04 
DBH 

RELEASE OF NOREPINEPHRINE (NE) AND DOPAMINE-BETA-HYDROXYLASE 
(DBH): EFFECT OF PHENOXYBENZAMINE (PBZ) ALONE AND IN 
COMBINATION WITH 8-BROMO-CGMP AND DIBUTYRYL-CAMP. 

238690 03-03 
MECHANISMS OF TRANS-SYNAPTIC INDUCTION OF TYROSINE- 
HYDROXYLASE (TH) AND DOPAMINE-BETA-HYDROXYLASE (DBH) IN 
ORGAN CULTURES OF RAT SYMPATHETIC GANGLIA: ROLE OF 
DEPOLARIZATION OF THE POSTSYNAPTIC MEMBRANE. 

251393 04-03 
OEAMINATION 

PREFERENTIAL DEAMINATION OF DOPAMINE BY AN A TYPE 
MONOAMINE-OXIDASE IN RAT BRAIN. 

251225 04-03 
DEANOl 

DEANOL IN THE TREATMENT OF TARDIVE-DYSKINESIA. 

227570 01-11 
THE EFFECTS OF DIMETHYLAMINOETHANOL (DEANOL) ON CEREBRAL 
CORTICAL NEURONS. 

232621 02-03 
DEATH 

COUNSELING. PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH: AN EMPIRICAL STUDY OF THE EFFICACY OF DPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH D 
DISSERTATION). 

228686 01-11 
SUDDEN UNEXPLAINED DEATH IN A PSYCHIATRIC PATIENT TAKING 
THIORIDAZINE. 

240243 03-15 
DEATH AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL. 

243716 04-15 
DECANOATE 

PHARMACOKINETICS OF FLUPENTHIXOL-DECANOATE. DECANOATE. 

227767 01-08 
FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE, WITH SPECIAL 
REFERENCE TO THEIR ANTIPSYCHOTIC EFFECT. 

227770 01-08 
ANTIPARKINSONIAN AGENTS AND FLUPHENAZINE-DECANOATE 
DECANOATE. 

236317 02-15 
DECAPITATION 

INHIBITORY EFFECTS IF 6-HYDROXYDOPAMINE ON THE CLONIC 
CONVULSIONS INDUCED BY ELECTROSHOCK AND DECAPITATION. 

245597 0403 
DECARBOXYLASE 

EFFECT OF PERIPHERAL DECARBOXYLASE INHIBITION ON HVA AND 5- 
HIAA IN CEREBROSPINAL FLUID OF DEPRESSED PATIENTS. 

226915 01-09 
TWO YEAR COMBINED THERAPY OF PARKINSONS DISEASE WITH L-DOPA 
AND THE DECARBOXYLASE INHIBITOR BENSERAZID (RO-4-4602). 

233917 02-11 
DIFFERENTIAL EFFECTS OF AN INHIBITOR OF DECARBOXYLASE ON L- 
DOPA AND L-5-HTP: POLYGRAPHIC AND BIOCHEMICAL DATA. 

237709 02-03 
PERFUSION WITH L-5 HTP, ALONG WITH A DECARBOXYLASE INHIBITOR, 

IN THE RABBIT. POLYGRAPHIC AND BIOCHEMICAL DATA. 

237710 02-03 
INTERACTIONS OF LEVODOPA WITH INHIBITORS OF MONOAMINE- 
OXIDASE AND L-AROMATIC AMINO ACID DECARBOXYLASE, 

245647 04 13 
THE INFLUENCE OF THE DECARBOXYLASE INHIBITOR 8ENSERAZIDE ON 
ANTIHYPERTENSIVE EFFECT AND METABOLISM OF METHYLDOPA IN 
HYPERTENSIVE PATIENTS. 

251418 04-11 
DECAY 

CYCLANDELATE CHECKS MENTAL DECAY: AGED PATIENTS IQ AND 
MEMORY PRESERVED WITH USE OF VASODILATOR. 

247022 04-11 
DECOMPOSITION 

DECOMPOSITION OF AMITRIPTYLINE HYDROCHLORIDE IN AQUEOUS 
SOLUTION: IDENTIFICATION OF DECOMPOSITION PRODUCTS. 

246317 04-01 
DEFECATION 

STUDIES ON BIOGENIC AMINES AND BEHAVIOR (I). RELATIONSHIP 
BETWEEN BRAIN MONOAMINES AND DEFECATION IN RATS, 

241370 03-04 



STUDIES ON BIOGENIC AMINES AND BEHAVIOR (II). RELATIONSHIP 
BETWEEN EMOTIONALITY AND DEFECATION. 

241371 03-04 
DEFENSIVE 

THE EFFECTS OF NEUROLEPTICS AND NIALAMIDE ON DEFENSIVE 
CONDITIONED REFLEX IN RATS. 

227637 01-04 
COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 

232483 01 04 
CHARACTERISTIC CHANGES IN CONDITIONED DEFENSIVE REFLEXES 
CAUSED BY TRIFLUOPERAZINE, CARBAAAAZEPINE AND 
CHLORPROMAZINE. 

244352 04-04 
DEFICIENT 

AVOIDANCE BEHAVIOR IN VITAMIN-B6 DEFICIENT RATS. 

232639 0204 
THE EFFECT OF TRYPTOPHAN AND A TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN COMBINATION ON INDOLES IN THE BRAINS OF 
RATS FED A TRYPTOPHAN DEFICIENT DIET. 

249675 04-03 
DEFICIT 

NEONATAL HYPERTHYROIDISM: MATURATIONAL ACCELERATION AND 
LEARNING DEFICIT IN TRIIODOTHYRONINE STIMULATED RATS. 

228143 01-04 
MEASUREMENT OF ATTENTION DEFICIT IN THE COURSE OF 
INTOXICATIONS. 

244896 04-14 
DEFICITS 

NEUROLEPTIC-INDUCED DEFICITS IN FOOD AND WATER REGULATION: 
SIMILARITIES TO THE LATERAL HYPOTHALAMIC SYNDROME. 

227134 01-03 
COGNITIVE DEFICITS ASSOCIATED WITH CHRONIC HEPATIC 
ENCEPHALOPATHY AND THEIR RESPONSE TO LEVODOPA. 

230580 01-15 
THERMOREGULATORY DEFICITS IN THE MONKEY PRODUCED BY 5,6 
DIHYDROXYTRYPTAMINE INJECTED INTO THE HYPOTHALAMUS. 

239087 03-03 
LONG-TERM DEFICITS IN STIMULATION-INDUCED BEHAVIORS AND SELF- 
STIMULATION AFTER 6-HYDROXYDOPAMINE ADMINISTRATION IN 
RATS. 

241300 03-04 
DECREASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR 
6-HYDROXYDOPAMINE: EVIDENCE FOR MEDIATION BY MOTOR 
DEFICITS RATHER THAN BY REDUCED REWARD. 

244676 04-04 
PIMOZIDE-INDUCED EXTINCTION OF INTRACRANIAL SELF-STIMULATION: 
RESPONSE PATTERNS RULE OUT MOTOR OR PERFORMANCE DEFICITS. 

249749 04-03 
DEFINED 

PSYCHOTOGENIC DRUG ACTION ON CHEMICALLY DEFINED NEURONS. 

244072 04-03 
DEFINING 

USE OF SYNTHESIS INHIBITORS IN DEFINING A ROLE FOR BIOGENIC 
AMINES DURING IMIPRAMINE TREATMENT IN DEPRESSED PATIENTS. 

247216 04-09 
DEGENERATION 

BEHAVIOURAL SEQUELAE OF DOPAMINERGIC DEGENERATION: 
POSTSYNAPTIC SUPERSENSITIVITY? 

229434 01-03 
SPECIFICITY OF DOPAMINERGIC NEURONAL DEGENERATION INDUCED BY 
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE IN THE 
NIGROSTRIATAL DOPAMINE SYSTEM. 

249899 04-03 
DEGRADATION 

EFFECTS OF A CHOLINE-DEFICIENT DIET ON THE INDUCTION OF DRUG 
AND ETHANOL METABOLIZING ENZYMES AND ON THE ALTERATION OF 
RATES OF ETHANOL DEGRADATION BY ETHANOL AND 
PHENOBARBITAL. 

247032 04-03 
DEHYDRATED 

THE UPTAKE OF 35S BY HYPOTHALAMIC AND NEUROHYPOPHYSIAL 
PROTEINS FOLLOWING INTRAVENTRICULAR INJECTION OF L-CYSTEINE- 
35S-HYDROCHLORIDE IN RATS DEHYDRATED AND RESERPINIZED. 

248952 04-03 
DEIAGRANGE 

TREATMENT OF UNSELECTED INDONESIAN PSYCHOTIC PATIENTS WITH 
DOGMATIL (DEIAGRANGE), 

239269 03- 1 1 
DELAY 

HABITUATION TO ITERATIVE PHOTOSTIMULATION IN THE PALMAR SKIN 
CONDUCTANCE RESPONSE OF MICE, ITS DELAY BY 
PSYCHOANALEPTICS. 

248514 04-04 
DELAYED 

AMITRIPTYLINE PERPHENAZINE OVERDOSE PRODUCING DELAYED 
HYPOMANIA IN MANIC-DEPRESSIVE ILLNESS. 

227572 01 09 



S-96 



IME 14, SUBJECT INDEX 



Subject Index 



^ECTS OF MAGNESIUM PEMOLINE ON A DELAYED MATCH-TO-SAMPLE 
TASK IN MONKEYS. 

230577 01-04 
lALYSIS Of THE DISCREPANCY IN MAN-MACHINE TRACKING SYSTEMS 
UNDER CONDITIONS OF DELAYED FEEDBACK. 

242702 03-14 
LAYED SEVERE EXTRAPYRAMIDAL DISTURBANCE FOLLOWING 
FREQUENT DEPOT PHENOTHIAZINE ADMINISTRATION. 

245789 04-15 
LAYED AND INSIDIOUS ONSET OF DIPHENYLHYDANTOIN TOXICITY. 

246932 04-15 
)NOAMINE NEUROTOXINS: SELECTIVE AND DELAYED EFFECTS ON 
BEHAVIOR IN COLONIES OF LABORATORY RATS. 

251063 04-04 
ATION 

\\P\ DELINEATION Of A SUBGROUP OF DEPRESSED PATIENTS 
REFRACTORY TO LITHIUM CARBONATE THERAPY. 

253595 04-09 
lUENT 

YCHOPHARMACOLOGY IN THE PREVENTION OP ANTISOCIAL AND 
DELINQUENT BEHAVIOR. 

247385 04-17 
IM 
^ERSAL BY PHYSOSTIGMINE OF CLOZAPINE-INDUCED DELIRIUM. 

237647 02-14 
lY 

E LITHIUM CLINIC: A NEW MODEL FOR THE DELIVERY OF 
PSYCHIATRIC SERVICES. 

234699 02-09 

UGS DERIVED FROM CANNABINOIDS. 5. DELTA 
TETRAHYDROCANNABINOL AND HETEROCYCLIC ANALOGS 
CONTAINING AROMATIC SIDE-CHAINS. 

248648 04-02 
-TETRAHYDROCANNABINOL 
TERATION OF MEMBRANE INTEGRITY OF DELTAI- 
TETRAHYDROCANNABINOL. 

229035 01-03 
.NNABIDIOL AND ITS PHARMACOKINETIC INTERACTION WITH DELTAl- 
TETRAHYDROCANNABINOL. 

233279 02-03 
JTABOLISM OF DELTAl-TETRAHYDROCANNABINOL BY THE ISOLATED 
PERFUSED DOG LUNG. COMPARISON WITH IN VITRO LIVER 
METABOLISM. 

238316 02-03 
lARACTERIZATION OF THREE MONOHYDROXYACID AND TWO 
DIHYDROXYACID METABOLITES OF DELTAl-TETRAHYDROCANNABINOL 
IN MOUSE LIVER. 

243787 04-03 
E UPTAKE OF TRITIATED DELTAl-TETRAHYDROCANNABINOL BY THE 
ISOLATED VASDEFERENS OF THE RAT. 

252200 04-03 
i-TETRAHYDROCANNABINOl 

TERATIONS IN DOPAMINE UPTAKE IN RAT CORPUS STRIATUM 
INDUCED BY COMBINATIONS OF STRESS AND DELTA8- 
TETRAHYDROCANNABINOL (DELTA8-THC). 

241926 03-03 
l-THC 

TERATIONS IN DOPAMINE UPTAKE IN RAT CORPUS STRIATUM 
INDUCED BY COMBINATIONS OF STRESS AND DELTAS 
TETRAHYDROCANNABINOL (DELTA8-THC). 

241926 03-03 
-TETRAHYDROCANNABINOL 

ARMACOLOGICAL INTERACTION BETWEEN CANNABINOL AND DELTA9- 
TETRAHYDROCANNABINOL. 

225570 01-03 
TERACTIONS OF DELTA9-TETRAHYDR0CANNABIN0L, ADRENAL 
STEROIDS, AND ETHANOL 

226763 01-03 
E EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABIDIOL AND 
CANNABINOL ON ETHER ANAESTHESIA IN MICE. 

226764 01-04 
LTA9 TETRAHYDROCANNABINOL ALTERS FLOW OF BLOOD TO 
SUBCORTICAL AREAS OF THE CONSCIOUS RAT BRAIN. 

226874 01-04 
FECTS OF DELTA9 TETRAHYDROCANNABINOL ON MOUSE SPLEENS. 

226944 01-05 
'LERANCE TO THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL IN 
MICE ON INTESTINAL MOTILITY, TEMPERATURE AND LOCOMOTOR 
ACTIVITY. 

227130 01-04 
E EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON BRAIN AMINE 
CONCENTRATION AND TURNOVER IN WHOLE RAT BRAIN AND IN 
VARIOUS REGIONS OF THE BRAIN 

230856 01-03 
■LUENCE OF DELTA9 TETRAHYDROCANNABINOL ON PARTIAL 
REINFORCEMENT EFFECTS. 

230875 01-04 



THE INFLUENCE OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABINOL 
AND CANNABIDIOL ON TISSUE OXYGEN CONSUMPTION 

231010 01-03 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON SOCIAL BEHAVIOUR 
IN THE LABORATORY MOUSE AND RAT. 

237727 02-04 
AN INHALATION AEROSOL OF DELTA9-TETRAHYDR0CANNABIN0L. 

237787 02-16 
EFFECTS OF (-)DELTA9-TETRAHYDR0CANNABIN0L ON REGIONAL BRAIN 
ACETYLCHOLINE IN THE RAT. 

238709 03-03 
RESPONSE TO DELTA9-TETRAHYDR0CANNABIN0L, BARBITURATES AND 
ETHANOL IN LACTATING, VIRGIN FEMALE, AND MALE MICE. 

238766 03-03 
STRUCTURE-ACTIVITY RELATIONSHIPS IN ANALOGS OF DELTA9- 
TETRAHYDROCANNABINOL: TACHYCARDIA VS. ANALGESIA. 

238805 03-02 
MECHANISM OF VASOCONSTRICTOR ACTION OF DELTA9 

TETRAHYDROCANNABINOL IN PITHED AND ANESTHETIZED RATS. 

238809 03-03 
CHRONIC CARDIOVASCULAR EFFECTS OF DELTA9- 

TETRAHYDROCANNABINOL (DELTA9-THC) IN THE MONGREL DOGS. 

238810 03-03 
BRAIN SYNAPTIC MEMBRANE NAK-ATPASE FOLLOWING CHRONIC 

INJECTION OF DELTA9-TETRAHYDR0CANNABIN0L (THC). 

238812 03-03 
DELTA9-TETRAHYDR0CANNABIN0L (DELTA9-THC) AND 1 1-0H-DELTA9- 

THC: ONSET, PATTERN AND DURATION OF BEHAVIORAL EFFECTS AND 
TOLERANCE IN RATS. 

238813 03-04 
THE MECHANISM BY WHICH DELTA9-TETRAHYDR0CANNABIN0L (THC) 

PRODUCES A DECREASE IN SALIVARY FLOW FOLLOWING ELECTRICAL 
STIMULATION. 

238815 03-03 
CELLULAR MEDIATED DECREASES IN SENSITIVITY TO THE INHIBITORY 

EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L (DELTA9-THC). 

238816 03-03 
THE EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON ACTION 

POTENTIALS IN THE MOLLUSC APLYSIA. 

239261 03-03 
RELATIONSHIP BETWEEN THE SUBCELLULAR DISTRIBUTION OF DELTA9- 
TETRAHYDROCANNABINOL AND ITS METABOLITES IN RAT BRAIN AND 
THE DURATION OF THE EFFECT ON MOTOR ACTIVITY. 

241242 03-03 
EFFECT OF DELTA9-TETRAHY0R0CANNABIN0L ON THE METABOLISM OF 
BRAIN MONOAfilNES WITH SPECIAL REFERENCE TO THE 
RELATIONSHIP BETWEEN NORADRENALINE CONTENTS OF THE 
OLFACTORY BULB AND MURICIDE BEHAVIOR. 

241373 03 04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON SQUIRREL-MONKEY 
INCENTIVE COMPETITION BEHAVIOR, {PH.D. DISSERTATION), 

241668 03-04 
INFLUENCE OF CANNABIDIOL OF DEL rA9 TETRAHYDROCANNABINOL 
EFFECTS. 

243087 04 14 
IN VIVO AND IN VITRO EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L 
ON RAT LIVER MICROSOMAL DRUG METABOLIZING ENZYMES. 

243182 04-03 
TOLERANCE TO THE CARDIOVASCULAR EFFECTS OF DELTA9 
TETRAHYDROCANNABINOL IN THE RAT. 

243800 04-03 
UTEROTROPHIC EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L IN 
OVARIECTOMIZED RATS 

243865 04-03 
COMPARATIVE AUTORADIOGRAPHIC AND METABOLIC STUDY OF 
DELTA8- AND DELTA9-TETRAHYDR0CANNABIN0L IN THE BRAIN OF 
THE MARMOSET CALLITHRIX JACCHUS. 

244681 04-03 
MOUSE-KILLING AND MOTOR ACTIVITY: EFFECTS OF CHRONIC DELTA9- 

TETRAHYDROCANNABINOL AND PILOCARPINE. 

244682 04-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON SOCIAL BEHAVIOUR 

IN MICE: COMPARISON BETWEEN TWO VEHICLES. 

244687 04-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L AND PENTOBARBITAL ON 
A CORTICAL RESPONSE EVOKED DURING CONDITIONING, 

244693 04 03 
INTERACTION OF DELTA9-TETRAHYDR0CANNABIN0L AND CANNABIDIOL 
WITH PHENOBARBITONE IN PROTECTING MICE FROM ELECTRICALLY 
INDUCED CONVULSIONS, 

244894 04-04 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L ON ACTIVE AVOIDANCE 
ACQUISITION AND PASSIVE AVOIDANCE RETENTION IN RATS WITH 
AMYGDALOID LESIONS. 

246819 04 04 
ENDOCRINE EFFECTS OF CHRONIC INTRAVENTRICULAR ADMINISTRATION 
OF DELTA9-TETRAHYDR0CANNABIN0L TO PREPUBERAL AND ADULT 
MALE RATS. 

248275 04 05 



00 



-n 



3B^ 



S-97 



Subject Index 



Psychopharmacology Abstract! 



ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED WITH THREE OTHER DRUGS. 

248283 04-02 
DISTRIBUTION STUDIES OF (14C)DELTA9-TETRAHYDR0CANNABIN0L IN 
MICEr EFFECT OF VEHICLE, ROUTE OF ADMINISTRATION, AND 
DURATION OF TREATMENT 

249223 04-03 
DEVELOPMENT OF CROSS-TOLERANCE BETWEEN DELTA9- 
TETRAHYDROCANNABINOL AND ETHANOL 

249263 04-03 
EVIDENCE FOR 2-PHENYLETHYLAMINE (PEA) AS A MEDIATOR FOR THE 
CENTRAL STIMULANT AND ANTITREMORGENIC ACTIONS OF DELTA9- 
TETRAHYDROCANNABINOL (THC) 

249309 04-03 
TOLERANCE TO THE CARDIOVASCULAR EFFECTS OF DELTA9- 
TETRAHYDROCANNABINOL IN THE RAT. 

249418 04-03 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L AND CANNABINOL IN 
MAN. 

249622 04-07 
CHRONIC DELTA9TETRAHYDR0CANNABIN0L. TRANSIENT AND LASTING 
EFFECTS ON AVOIDANCE BEHAVIOR. 

250061 04-04 
DELTA9-TETRAHYDR0CANNABIN0L: EFFECT ON MACROMOLECULAR 
SYNTHESIS IN HUMAN AND OTHER MAM/WALIAN CELLS. 

251420 04-13 
EFFECTS ON VISUAL TRACKING OF DELTA9-TETRAHYDR0CANNABIN0L 
AND PENTOBARBITAL. 

251825 04-14 
DELTA9-TETRAHYDR0CANNABIN0L, ETHANOL, AND AMPHETAMINE AS 
DISCRIMINATIVE STIMULI GENERALIZATION TESTS WITH OTHER 
DRUGS. 

251977 04-04 
THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L AND LSD ON THE 
ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN THE RAT 

251979 04-04 
DEPRESSION OF GROWTH HORMONE AND CORTISOL RESPONSE TO 
INSULIN-INDUCED HYPOGLYCEMIA AFTER PROLONGED ORAL DELTA9- 
TETRAHYDROCANNABINOL ADMINISTRATION IN MAN, 

252327 04-13 
PHYTOHEMAGLUTININ-INDUCED LYMPHOCYTE TRANSFORMATION IN 
HUMANS RECEIVING DELTA9-TETRAHYDR0CANNABIN0L, 

252825 04-13 
EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L ON GANGLIOSIDES AND 
SIALOGLYCOPROTEINS IN SUBCELLULAR FRACTIONS OF RAT BRAIN. 

/ 253406 04-03 

CARDIOVASCULAR EFFECTS OF PROLONGED DELTA9- 
TETRAHYDROCANNABINOL INGESTION. 

253609 04-13 
DELTA9-THC 

EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9-TRANS- 
TETRAHYDROCANNABINOL (DELTA9-THC) IN GUINEA-PIGS. 

229033 01-03 
ATTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE 
DEPENDENT RATS BY DELTA9-THC. 

232615 02-04 
THE EFFECT OF DELTA9-THC ON HIGH AND LOW AFFINITY UPTAKE OF 
CHOLINE AND ITS RELATIONSHIP TO TURNOVER OF ACETYLCHOLINE IN 
MOUSE BRAIN. 

238765 03-03 
CHRONIC CARDIOVASCULAR EFFECTS OF DELTA9- 

TETRAHYDROCANNABINOL (DELTA9-THC) IN THE MONGREL DOGS. 

238810 03-03 
EFFECT OF DELTA9-THC ON PHYSICAL SYMPTOMS AND EEG IN THE 

NATURALLY EPILEPTIC BEAGLE 

238811 03-04 
DELTA9-TETRAHYDR0CANNABIN0L (DELTA9-THC) AND n-0H-DELTA9- 

THC: ONSET, PATTERN AND DURATION OF BEHAVIORAL EFFECTS AND 
TOLERANCE IN RATS. 

238813 03-04 
CELLULAR MEDIATED DECREASES IN SENSITIVITY TO THE INHIBITORY 
EFFECTS OF DELTA9TETRAHYDR0CANNABIN0L (DELTA9-THC) 

238816 03-03 
MYELOID HYPERPLASIA IN GROWING RATS AFTER CHRONIC TREATMENT 
WITH DELTA9-THC AT BEHAVIORAL DOSES. 

248915 04-05 
INTERACTIONS BETWEEN CANNABIDIOL AND DELTA9-THC DURING 
ABSTINENCE IN MORPHINE-DEPENDENT RATS. 

249001 04-04 
DELTA9-TRANS-TETRAHY0ROCANNABINOI 

EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9TRANS- 
TETRAHYDROCANNABINOL (DELTA9-THC) IN GUINEA-PIGS. 

229033 01-03 
COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY 
SHORT SENSORY DEPRIVATION AND BY DELTA9-TRANS- 
TETRAHYDROCANNABINOL 

240645 03-14 



DELUSION 

DEPRESSION, DELUSION AND DRUG RESPONSE. 

245784 04-0 
DELUSIONS 

PENTAZOCINE PSYCHOSIS: A CASE OF PERSISTENT DELUSIONS. 

225873 01-1 
DEMENTIA 

TREATABLE ASPECTS OF THE DEMENTIA SYNDROME. 



PARKINSONISM AND DEMENTIA: EFFECTS OF LEVODOPA. 
FOR SENILE DEMENTIA: CHEMICAL CORRECTION?. 
TREATMENT OF DIALYSIS DEMENTIA WITH THIAMINE. 
DEMENTIA INDUCED BY METHYLDOPA WITH HALOPERIDOL 



4 



240614 03-1 

245235 04-1 

249351 04-1 

251966 04-1 

253391 04-1 
DEMETHYLATION 

INTESTINAL ABSORPTION, DEMETHYLATION, AND ENTEROHEPATIC 
CIRCULATION OF IMIPRAMINE. 

252231 04-1 
DEMETRIN 

CLINICAL RESEARCH WITH DEMETRIN IN SURGERY PATIENTS. 

242527 03-0 
DEMONSTRATION 

NEUROTRANSMITTERS INCREASE CYCLIC NUCLEOTIDES IN 
POSTGANGLIONIC NEURONS: IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318 01-0 
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE 
DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING 
NEURONS AND AXONS BY GLYOXYLIC-ACID INDUCED FLUORESCENCE: 
II. A DETAILED DESCRIPTION OF METHODOLOGY. (UNPUBLISHED 
PAPER). 

236875 02-0 
DEMONSTRATION OF AN INVERSELY PROPORTIONAL RELATIONSHIP 
BETWEEN DOPAMINE AND SEROTONIN IN CERTAIN CEREBRAL 
STRUCTURES: NEUROCHEMICAL AND MORPHOLOGICAL ASPECTS. 

244638 04-0: 
OENERVATED 

REINSTATEMENT OF EATING BY DOPAMINE AGONISTS IN APHAGIC 
DOPAMINE DENERVATED RATS 

243348 04-0 
DENERVATION 

THE EFFECT OF CHRONIC CENTRAL ADRENERGIC DENERVATION ON 
LEARNING AND MEMORY OF AN AVERSIVE DISCRIMINATION TASK IN 
MICE: STUDIES WITH 6-HYDROXYDOPAMINE. (PH.D. DISSERTATION). 

238157 02-0 
CHANGES IN BRAINSTEM MONOAMINE NEURONS AFTER SURGICAL AND 
CHEMICAL DENERVATION OF THE OLFACTORY BULB (OB) IN RATS. 

241369 03-0 
DEPARTMENT 

ABUSE OF PSYCHOPHARMACEUTICAL AGENTS IN DRUG DEPENDENCE 
(ANALYSIS OF CASES HOSPITALIZED IN A PSYCHIATRIC DEPARTMENT 
IN THE YEARS 1970 TO 1973). 

234653 02-1 ; 
DEPARTMENT SEEKS ADVICE ON SAFETY OF PSYCHOTROPICS. 

251232 04-1 : 
DEPENDENCE 

NITRAZEPAM (MOGADON) DEPENDENCE. 

225699 01 -li 
SELECTED BIBLIOGRAPHY ON DETECTION OF DEPENDENCE PRODUCING 
DRUGS IN BODY FLUIDS. 

229112 01-1; 
CONDITIONED AVERSION BY PSYCHOACTIVE DRUGS: DOES IT HAVE 
SIGNIFICANCE FOR AN UNDERSTANDING OF DRUG DEPENDENCE 

233488 02-1' 
ABUSE OF PSYCHOPHARMACEUTICAL AGENTS IN DRUG DEPENDENCE 
(ANALYSIS OF CASES HOSPITALIZED IN A PSYCHIATRIC DEPARTMENT 
IN THE YEARS 1970 TO 1973). 

234653 02- 1; 
DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON ENDOGENOUS 
NEUROTRANSMITTERS. 

234798 02-Of 
THE DEPENDENCE OF THE MAGNITUDE OF CONDITIONED SALIVATION IN 
DOGS ON DOSES OF CAFFEINE. 

236249 02-0; 
METHAQUALONE: TOLERANCE AND PHYSICAL DEPENDENCE IN MICE 

237731 02-0' 
A NOVEL METHOD FOR RAPID DEVELOPMENT OF BARBITURATE- 
TOLERANCE AND PHYSICAL DEPENDENCE IN MICE. 

238701 03-03 
STUDY OF DEVELOPMENT OF TOLERANCE TO AND BARBITURATE-LIKE 
PHYSICAL DEPENDENCE ON THE TRANQUILLIZER TEMPIDON. 

240205 03-0.' 
REDUCTION IN MORPHINE TOLERANCE AND PHYSICAL DEPENDENCE ANO 
OPIOID SEEKING BEHAVIOR BY INTRACEREBRAL 6- 
HYDROXYDOPAMINE. (PH.D. DISSERTATION). 

241100 03-03 



S-98 



JME 14, SUBJECT INDEX 



Subject Index 



TES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF 
PHYSICAL DEPENDENCE IN RATS: I. COMPARISON OF PRECIPITATED 
MORPHINE WITHDRAWAL AFTER INTRAPERITONEAL AND 
INTRAVENTRICULAR INJECTION OF MORPHINE ANTAGONISTS' 

241223 03-04 
1ARMAC0L0GICAL ASPECTS OF PHYSICAL DEPENDENCE ON ETHANOL. 

241240 03-17 
STUDY ON THE DEVELOPMENT OF BARBITURATE-TOLERANCE AND 
DEPENDENCE IN HAMSTER GLIAL CELLS IN CULTURE, 

241348 03-03 
3LERANCE, PHYSICAL DEPENDENCE AND OPIOID SEEKING BEHAVIOR; 
DEPENDENCE ON DIENCEPHALIC NOREPINEPHRINE. 

244202 04-04 
METHOD FOR BIOASSAY OF PHYSICAL DEPENDENCE ON SEDATIVE 
DRUGS IN DOG 

244674 04-06 
INTAZOCINE DEPENDENCE - TRUTH AND FICTION?. 

246707 04- 1 5 
ECTROPHYSIOLOGICAL EVIDENCE FOR A NEUROHORMONAL 
DEPENDENCE IN THE CHANGES OF THE LATE GLABELLAR RESPONSE IN 
MAN. 

246992 04-13 
;NFLURID0L blockade of APOMORPHINE: dependence OF DURATION 
ON SPECIES AND ENDPOINT. 

248406 04-02 
EPENDENCE ON AGE OF METHAMPHETAMINE PRODUCED CHANGES IN 
THERMOREGULATION AND METABOLISM. 

248951 04-03 
lORPHINE TOLERANCE AND DEPENDENCE IN NORADRENALINE 
NEURONES OF THE RAT CEREBRAL CORTEX. 

248979 04 03 
HARACTERISTICS OF NARCOTIC DEPENDENCE PRODUCED BY ORAL 
INGESTION OF FENTANYL SOLUTIONS IN RATS. 

249289 04-04 
lORPHINE TOLERANCE AND PHYSICAL DEPENDENCE: INFLUENCE OF 
CHOLINERGIC AGONISTS AND ANTAGONISTS. 

250079 0404 
DME PHARMACOLOGICAL ASPECTS OF DRUG DEPENDENCE. 

251561 04-13 
:FECT of NARCOTIC DEPENDENCE AND WITHDRAWAL ON STRIATAL 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND SYNAPTOSOMAL 
CYCLIC-AMP METABOLISM. 

253135 04-03 
HE UPTAKE OF LOW CONCENTRATIONS OF LITHIUM IONS INTO RAT 
CEREBRAL CORTEX SLICES AND ITS DEPENDENCE ON CATIONS 

253411 04-03 
IDENCY 
EPENDENCY ON COMBINED METHAQUALONE DIPHENHYDRAMINE. 

241870 03-17 
IDENT 

TTENUATION OF PRECIPITATED ABSTINENCE IN METHADONE 
DEPENDENT RATS BY DELTA9-THC. 

232615 02-04 
OPAMINE-INDUCED INCREASES IN CYCLIC-AMP, AND CYCLIC-AMP 
DEPENDENT PROTEIN PHOSPHORYLATION, IN THE RAT CAUDATE 
NUCLEUS. (PH.D. DISSERTATION). 

238080 02-13 
AURINE: A SODIUM DEPENDENT HIGH AFFINITY UPTAKE SYSTEM INTO 
SYNAPTOSOMES OF RAT BRAIN. 

238715 03-03 
NDOGENOUS DOPAMINE RELEASE DEPENDENT AND INDEPENDENT 
ACTIVATION OF DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL 
SYNAPTOSOMES. 

238729 03-03 
NTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF 
NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL PHENOTHIAZINES. 

239662 03-03 
HE NATURE OF THE 455-NM ABSORBING COMPLEX FORMED DURING 
THE CYTOCHROME-P450 DEPENDENT OXIDATIVE METABOLISM OF 
AMPHETAMINE. 

241350 03-01 
ATE DEPENDENT DRUG EFFECTS: POSSIBLE STATE-DEPENDENCY. 

242739 03-04 
ODIUM DEPENDENT HIGH AFFINITY CHOLINE UPTAKE AS A 
REGULATORY STEP IN ACETYLCHOLINE SYNTHESIS. 

249303 04-03 
ISONALIZATION 
. CASE OF PHOBIC ANXIETY DEPERSONALIZATION SYNDROME (ROTH). 

243094 04- 1 7 
TED 

HE EFFECTS OF ACETYLCHOLINE AND DOPAMINE ON THE CAUDATE- 
NUCLEUS DEPLETED OF BIOGENIC AMINES. 

230457 01-03 
TION 

LABILITY OF AN INHIBITOR OF AMINE UPTAKE (LILLY-1 10140) TO 
BLOCK DEPLETION OF BRAIN 5-HYDROXYTRYPTAMINE BY L-DOPA. 

226765 01-03 



DEPLETION OF S-ADENOSYL-L-METHIONINE IN MOUSE BRAIN BY 
ANTIDEPRESSIVE DRUGS 

226850 01-03 
EFFECT OF MINOR TRANQUILLISERS ON HIPPOCAMPAL THETA-RHYTHM 
MIMICKED BY DEPLETION OF FOREBRAIN NORADRENALINE. 

234918 02-03 
RESERPINE-INDUCED CATECHOLAMINE DEPLETION FROM SMALL CELLS IN 
RAT SYMPATHETIC GANGLIA. 

237738 02 03 
THE EFFECT OF NOMIFENSINE ON THE DEPLETION OF BRAIN SEROTONIN 
AND CATECHOLAMINES INDUCED RESPECTIVELY BY FENFLURAMINE 
AND 6-HYDROXYDOPAMINE IN RATS. 

237743 02-03 
FAILURE OF DEPLETION OF RAT BRAIN 5-HYDROXYTRYPTAMINE TO 
ALTER FENFLURAMINE-INDUCED ANOREXIA. 

237748 02-03 
STUDIES ON THE MECHANISM OF DEPLETION OF STRIATAL DOPAMINE 
BY ALPHA-METHYL-M-TYROSINE. 

237873 02-03 
PROTECTION AGAINST STRESS-INDUCED DEPLETION OF BRAIN 
NOREPINEPHRINE AFTER PRIOR EXPOSURE TO CHRONIC STRESSES. 

238718 03 04 
CENTRAL DEPLETION OF NOREPINEPHRINE IN GUINEA-PIG: LACK OF 
EFFECT ON NOREPINEPHRINE SENSITIVE CYCLIC-AMP GENERATING 
SYSTEMS. 

238798 03-03 
INABILITY OF METHADONE TO PREVENT THE DEPLETION OF BRAIN 5- 
HYDROXYINDOLES BY P-CHLOROAMPHETAMINE. 

241339 03-03 
HYPERPHAGIA AND OBESITY FOLLOWING SEROTONIN DEPLETION BY 
INTRAVENTRICULAR P-CHLOROPHENYLALANINE. 

243878 0404 
EFFECT OF 3-P TRIFLUOROMETHYLPHENOXY-N-METHYL-3- 

PHENYLPROPYLAMINE ON THE DEPLETION OF BRAIN SEROTONIN BY 4- 
CHLOROAMPHETAMINE. 

246847 04-03 
FENFLURAMINE: EVIDENCE FOR A NEUROTOXIC ACTION ON MIDBRAIN 
AND A LONG-TERM DEPLETION OF SEROTONIN. 

247214 04-05 
EFFECT OF MORPHINE ON INTRACRANIAL SELF-STIMULATION BEHAVIOR 
FOLLOWING BRAIN AMINE DEPLETION. 

249138 04-04 
DEPOLARISING 

EFFECT OF MORPHINE ON A DEPOLARISING DOPAMINE RESPONSE. 

246998 04-03 
DEPOLARIZATION 

DIAZEPAM DEPOLARIZATION OF PRESYNAPTIC TERMINALS IN BULLFROG 
SYMPATHETIC GANGLIA: MEDIATION THROUGH GABA? 

229463 01-03 
MECHANISMS OF TRANS-SYNAPTIC INDUCTION OF TYROSINE- 
HYDROXYLASE (TH) AND DOPAMINE-BETA-HYDROXYLASE (DBH) IN 
ORGAN CULTURES OF RAT SYMPATHETIC GANGLIA: ROLE OF 
DEPOLARIZATION OF THE POSTSYNAPTIC MEMBRANE. 

251393 04-03 
DEPOLARIZED 

BARBITURATES BLOCK CALCIUM UPTAKE BY STIMULATED AND 
POTASSIUM DEPOLARIZED RAT SYMPATHETIC GANGLIA. 

237751 02-03 
DEPOSITS 

DEPOSITS IN THE LENS AND CORNEA OF THE EYE DURING LONG-TERM 
CHLORPROMAZINE MEDICATION. 

240048 03 15 
DEPOT 

ON THE PHARMACOLOGY OF DEPOT PHTHORPHENAZINE. 

228547 01-04 
THE PROBLEM OF CHRONIC SCHIZOPHRENIA: TREATMENT WITH DEPOT 
FLUPENTHIXOL, A LONG-ACTING NEUROLEPTIC. 

231367 01-08 
DEPOT NEUROLEPTICS - PRACTICAL METHODS OF LONG-TERM 

TREATMENT AND METHODOLOGICAL PROBLEMS OF CLINICAL TRIALS. 

241761 03-08 
EXPERIENCES WITH A DEPOT NEUROLEPTIC (DAPOTUM-D). 

242503 03-08 
FIVE YEARS OF DEPOT FLUPHENAZINE THERAPY. 

244620 04-08 
DELAYED SEVERE EXTRAPYRAMIDAL DISTURBANCE FOLLOWING 
FREQUENT DEPOT PHENOTHIAZINE ADMINISTRATION. 

245789 04-15 
DEPOT FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE-DECANOATE: 
COMPARATIVE RATES OF RELEASE IN DOGS. 

247130 04-03 
COMPARISON OF DEPOT FLUPHENAZINES: DURATION OF ACTION AND 
INCIDENCE OF SIDE-EFFECTS. 

252006 04-08 
DEPRENYL 

THE MONOAMINE-OXIDASE B INHIBITOR DEPRENYL POTENTIATES 
PHENYLETHYLAMINE BEHAVIOUR IN RATS WITHOUT INHIBITION OF 
CATECHOLAMINE METABOLITE FORMATION. 

253643 04-04 



DC 









S-99 



Subject Index 



Psychopharmacology Abstracts 



DEPRESSANT 

A CENTRALNERVOUSSYSTEM DEPRESSANT ANTIDEPRESSANT. 

227695 01-02 
NEW TRICYCLIC ENAMINE DERIVATIVES WITH CNS DEPRESSANT 
PROPERTIES. 

232528 01-02 
LACK OF A RELATION BETWEEN THE ANTIPSYCHOTIC AND THE 

EXCITABILITY DEPRESSANT PROPERTIES OF MAJOR TRANQUILIZERS. 

238710 03-03 
EFFECTS OF STIMULATORY AND DEPRESSANT DRUGS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3,5 
MONOPHOSPHATE LEVELS IN MOUSE BRAIN. 

241246 03-03 
SYNTHESIS AND CENTRAL-NERVOUS- SYSTEM DEPRESSANT ACTIVITY OF 
SOME BICYCLIC AMIDES. 

248539 04-02 
DEPRESSANTS 

INHIBITORY AND EXCITATORY EFFECTS OF CNS DEPRESSANTS ON 
INVERTEBRATE SYNAPSES. 

226398 01-03 
CENTRAL NERVOUS-SYSTEM DEPRESSANTS, 13. S- 
TRIAZOLOBENZODIAZEPIN-5-ONES. 

238478 02-0! 
COMBINATIONS OF SELECTED CNS DEPRESSANTS WITH D-AMPHETAMINE 
OR MAZINDOL ON FOOD INTAKE AND MOTOR ACTIVITY OF RATS, 

250080 04-03 
DEPRESSED 

EFFECT OF PERIPHERAL DECARBOXYLASE INHIBITION ON HVA AND 5- 
HIAA IN CEREBROSPINAL FLUID OF DEPRESSED PATIENTS. 

226915 01-09 
THE METHODOLOGY OF TRIALS OF ANTIDEPRESSANTS FOR DEPRESSED 
INPATIENTS 

227213 01-16 
CLINICAL AND CNS EFFECTS OF ORAL AND I.V. THYROTROPIN-RELEASING 
HORMONE IN DEPRESSED PATIENTS. 

227826 01-09 
PHARMACODYNAMICS OF IMIPRAMINE IN DEPRESSED PATIENTS. 

229437 01-09 
PREDICTION OF RESPONSE TO DRUG AND GROUP PSYCHOTHERAPY IN 
DEPRESSED OUTPATIENTS. 

229449 01-09 
EFFECT OF ECT AND IMIPRAMINE TREATMENT ON THE CONCENTRATION 
OF 5-HYDROXYINDOLEACETIC-ACID (5-HIAA) AND HOMOVANILLIC- 
ACID (HVA) IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS. 

230827 01-09 
A CONTROLLED TRIAL OF MAPROTILINE (LUDIOMIL) IN DEPRESSED 
OUTPATIENTS. 

231401 01-09 
EFFECT OF L-5-HYDROXYTRYPTOPHAN ON BRAIN MONOAMINE 
METABOLISM AND EVALUATION OF ITS CLINICAL EFFECT IN 
DEPRESSED PATIENTS. 

234673 02-09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 
PSYCHIATRIC PATIENTS - I. REPORT ON AN UNCONTROLLED CLINICAL 
TRIAL. 

235360 02-07 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - II. REPORT ON A PLACEBO CONTROLLED 
CLINICAL TRIAL. 

235361 02-09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - III. STANDARD CONTROLLED CLINICAL 
TRIAL. 

235362 02-09 
SYSTEMATIC CLINICAL STUDIES WITH CLOMIPRAMINE IN DEPRESSED 

PSYCHIATRIC PATIENTS - IV. A SUMMARY REPORT. 

235363 02-09 
CHOLINESTERASE ACTIVITY AND CONTENT OF ADENOSINE 

TRIPHOSPHATE IN DEPRESSED PATIENTS AND THEIR CHANGES UNDER 
THE INFLUENCE OF MONOCHLORIMIPRAMINE, 

236364 02-10 
PITUITARY ADRENAL FUNCTION IN DEPRESSED PATIENTS: RESISTANCE 
TO DEXAMETHASONE SUPPRESSION, 

236801 02-13 
A DOUBLE BLIND TRIAL OF MAPROTILINE (LUDIOMIL) AND 
AMITRIPTYLINE IN DEPRESSED OUTPATIENTS, 

238981 03-10 
DOES PIRACETAM COUNTERACT THE ECT INDUCED MEMORY 
DYSFUNCTIONS IN DEPRESSED PATIENTS?. 

239002 03-09 
DEPRESSED 5 HYDROXYINDOLE LEVELS ASSOCIATED WITH HYPERACTIVE 
AND AGGRESSIVE BEHAVIOR; RELATIONSHIP TO DRUG RESPONSE. 

239936 03-13 
EVIDENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
MOTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS 

241203 03-03 
EARLY STRATEGIES IN TREATMENT OF THE DEPRESSED PATIENT. 

241435 03-17 



MAPROTILINE (LUDIOMIL, CIBA-34276BA) AND IMIPRAMINE IN 
DEPRESSED OUTPATIENTS: A DOUBLE-BLIND CLINICAL STUDY. 

242248 03-09 
A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL WITH MAPROTILINE 

(LUDIOMIL) AND IMIPRAMINE IN NEWLY-ADMITTED DEPRESSED 
PATIENTS. 

242249 03-09 
INTRAVENOUS L-DOPA PLUS CARBIDOPA IN DEPRESSED PATIENTS: 

AVERAGE EVOKED RESPONSE, LEARNING, AND BEHAVIORAL CHANGES. 

244664 04-09 
USE OF SYNTHESIS INHIBITORS IN DEFINING A ROLE FOR BIOGENIC 
AMINES DURING IMIPRAMINE TREATMENT IN DEPRESSED PATIENTS. 

247216 04-09 
DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF 
DEPRESSED PATIENTS. 

248)60 04-10 
OXAZEPAM PROTRIPTYLINE: A DOUBLE-BLIND PHASE II EVALUATION OF 
THE EFFICACY AND SAFETY OF THE COMBINATION VERSUS PLACEBO 
IN NEUROTIC, DEPRESSED AND ANXIOUS PSYCHIATRIC OUTPATIENTS, 

248975 04-10 
PLASAAA RENIN ACTIVITY IN DEPRESSED PATIENTS TREATED WITH 
INCREASING DOSES OF LITHIUM CARBONATE. 

249673 04-13 
THE RELATIONSHIP BETWEEN ACETYLATOR STATUS AND INHIBITION OF 
MONOAMINE-OXIDASE, EXCRETION OF FREE DRUG AND 
ANTIDEPRESSANT RESPONSE IN DEPRESSED PATIENTS ON PHENELZINE. 

251985 04-10 
MMPI DELINEATION OF A SUBGROUP OF DEPRESSED PATIENTS 
REFRACTORY TO LITHIUM CARBONATE THERAPY 

253595 04-09 
DEPRESSION 

INTRAVENOUS TYRAMINE PRESSOR RESPONSE IN DEPRESSION. 

226187 01-10 
PSYCHOVEGETATIVE DISORDERS IN CASES OF CYCLOTHYMIC 
DEPRESSION. 

226777 01-09 
THE CAUSES AND TREATMENT OF DEPRESSION. 

226794 01-09 
SHORT-TERM EFFECTS OF VILOXAZINE (VIVALAN) COMPARED WITH 
PLACEBO IN DEPRESSION: A DOUBLE-BLIND STUDY. 

227214 01-09 
A DOPAMINE RECEPTOR STIMULATOR IN DEPRESSION. (UNPUBLISHED 
PAPER). 

227785 01-09 
THE NATURE AND TREATMENT OF DEPRESSION. 

228037 01-09 
DEPRESSION AND THE ACUTE SCHIZOPHRENIC PROCESS. 

228240 01-08 
IMIPRAMINE PAMOATE IN DEPRESSION. 

228243 01-11 
A DOUBLE-BLIND CONTROLLED COMPARISON OF CLOMIPRAMINE 
(ANAFRANIL) AND IMIPRAMINE ON DEPRESSION. 

228327 01-09 
CLINICAL EXPERIENCE IN USING SULPIRIDE (FK-880) FOR DEPRESSION. 

228334 01-09 
TREATMENT OF DEPRESSION IN GERIATRICS WITH ANAFRANIL. 

229370 01 11 
DRUGS AND PSYCHOTHERAPY IN DEPRESSION REVISITED: ISSUES IN THE 
ANALYSIS OF LONG-TERM TRIALS. 

229450 01-09 
A DOUBLE-BLIND TRIAL OF INTRAVENOUS THYROTROPIN-RELEASING 
HORMONE IN THE TREATMENT OF REACTIVE DEPRESSION. 

229693 01-09 
THERAPY OF DEPRESSION BY PHENYLALANINE: PRELIMINARY NOTE. 

229827 01-09 
DOUBLE-BLIND TRIAL OF SINTAMIL IN DEPRESSION. 

231603 01-10 
EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON THE 

ELECTROCARDIOGRAMS OF PATIENTS WITH ENDOGENOUS DEPRESSION 
(INTRODUCTORY REPORT). 

234046 02-09 
LITHIUM CARBONATE IN AFFECTIVE DISORDERS: IV. A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS IN UNIPOLAR RECURRENT DEPRESSION 

234203 02-09 
ATYPICAL AND SEVERE FORMS OF DEPRESSION. 

234597 02-09 
PRELIMINARY EXPERIENCE WITH PARENTERAL SINTAMIL IN TREATMENT 
OF DEPRESSION. 

235348 02-09 
TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES: I. AN 
UNCONTROLLED CLINICAL TRIAL IN DEPRESSION. 

235369 0207 
THYROTROPIN-RELEASING HORMONE IN DEPRESSION: CLINICAL AND 

ENDOCRINOLOGICAL FINDINGS. 

235370 0209 
COMPARISON OF BICUCULLINE METHOCHLORIDE WITH BICUCULLINE 

AND PICROTOXIN AS ANTAGONISTS OF AMINO-ACID AND 
MONOAMINE DEPRESSION OF NEURONES IN THE RAT BRAINSTEM. 

237783 02-03 



S-100 



iLUME 14, SUBJECT INDEX 



DEPRESSION OF NEURONES IN THE RAT CEREBRAL CORTEX BY LEPTAZOL. 

237925 02-03 
METHAMPHETAMINE WITHDRAWAL AS A MODEL FOR THE DEPRESSIVE 
STATE: ANTAGONISM OF POST-AMPHETAMINE DEPRESSION BY 
IMIPRAMINE. 

237976 02-03 
TREATMENT OF UNIPOLAR DEPRESSION. 

237994 02-10 
CESIUM ION: ANTAGONISM TO CHLORPROMAZINE AND L-DOPA 
PRODUCED BEHAVIOURAL DEPRESSION IN AAICE. 

238318 02-04 
AMPHETAMINE AND THE REWARD SYSTEM: EVIDENCE FOR TOLERANCE 
AND POST-DRUG DEPRESSION. 

239850 03-04 
A MULTIPLE DOSE, CONTROLLED STUDY OF PHENELZINE IN DEPRESSION 
ANXIETY STATES. 

239938 03-10 
TREATMENT OF DEPRESSION WITH TRICYCLIC DRUGS - 
PHARMACOKINETIC AND PHARMACODYNAMIC ASPECTS. 

2402)6 03-09 
TRYPTOPHAN AND DEPRESSION. 

240773 03-09 
COMBINATION OF TRICYCLIC ANTIDEPRESSANTS AND AAAOI IN 
DEPRESSION 

240839 03-09 
NEUROCHEMICAL CORRELATES OF BEHAVIOUR - CONTENT OF 
TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, SEROTONIN, 5- 
HYDROXYINDOLEACETIC-ACID, TYROSINE, DOPAMINE AND 
NOREPINEPHRINE IN FOUR BRAIN PARTS OF THE PIGEON DURING 
BEHAVIOURAL DEPRESSION FOLLOWING AN INJECTION. 

241205 03-04 
THE PSYCHOPHARMACEUTICAL THERAPY OF DEPRESSION. 

241762 03-09 
CHANGING PATTERNS IN THE MANAGEMENT OF DEPRESSION. 

243863 04-09 
PROBLEMS OF POLYPHARMACY IN DEPRESSION. 

243864 04-09 
PHARMACEUTICAL THERAPY OF MASKED DEPRESSION. 

244040 04-10 
TRAZODONE: THERAPEUTIC EFFECTIVENESS IN ENDOGENOUS 
DEPRESSION, COMPARED WITH BLOOD LEVELS. 

244588 04-09 
RESERPINE AND THE INDUCTION OF DEPRESSION: A CASE REPORT. 

245016 04-09 
TREATMENT OF DEPRESSION IN ALCOHOLICS. 

245521 04-09 
DEPRESSION AND ANTIDEPRESSANT DRUGS. 

245646 04-09 
DEPRESSION, DELUSION AND DRUG RESPONSE. 

245784 04-09 
RECENT CLINICAL EXPERIENCE WITH TREATMENT OF DEPRESSION WITH 
GER0VITAL-H3 TABLETS. 

246425 04-09 
THE CLINICAL COURSE OF PRIMARY RECURRENT DEPRESSION IN 
PHARMACOLOGICALLY TREATED FEMALE PATIENTS. 

246612 04-17 
TRYPTOPHAN/IMIPRAMINE IN DEPRESSION. 

246623 04-09 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
0-METHYLTRANSFERASE, AND FAMILY HISTORY. 

246629 04-09 
ANXIETY/DEPRESSION IN ELDERLY PATIENTS: A DOUBLE-BLIND 
COMPARATIVE STUDY OF FLUPHENAZINE/NORTRIPTYLINE AND 
PROMAZINE. 

247030 04-11 
ORAL PROTIRELIN (TRH) IN DEPRESSION. 

247482 04-09 
LITHIUM CARBONATE AND AFFECTIVE DISORDERS. V: A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS OF DEPRESSION IN BIPOLAR ILLNESS. 

247582 04-09 
MEMORY FUNCTIONS IN DEPRESSION: IMPROVEMENT WITH 
ANTIDEPRESSANT MEDICATION. 

248583 04-09 
SELF-INHIBITING ACTION OF NORTRIPTYLINE ANTIDEPRESSIVE EFFECT AT 
HIGH PLASMA LEVELS: A RANDOMIZED, DOUBLE-BLIND STUDY 
CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION. 

248955 04-10 
RAPHE NEURONS: DEPRESSION OF ACTIVITY BY L-5- 
HYDROXYTRYPTOPHAN. 

249078 04-03 
DEPRESSION OF DOPAMINE RELEASE DURING THE ETHANOL 
WITHDRAWAL SYNDROME. 

249293 04-03 
DEPRESSION OF GROWTH HORMONE AND CORTISOL RESPONSE TO 
INSULIN-INDUCED HYPOGLYCEMIA AFTER PROLONGED ORAL DELTA9- 
TETRAHYDROCANNABINOL ADMINISTRATION IN MAN. 

252327 04-13 



Subject Index 

DRUG AND PSYCHOTHERAPY INTERACTIONS IN DEPRESSION. 

252941 04-09 
RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM 
PROPHYLAXIS IN RECURRENT DEPRESSION. 

252954 04-09 
TREATMENT OF DEPRESSION IN THE AGED WITH GER0VITAL-H3: 
CLINICAL EFFICACY AND NEUROPHYSIOLOGICAL EFFECTS. 

253061 04-11 
BEHAVIORAL DEPRESSION IN SIDMAN AVOIDANCE LEARNING INDUCED 
BY DOPAMINE-BETA HYDROXYLASE INHIBITORS. 

253450 04-04 
OUTPATIENT PHENOTHIAZINE USE AND BONE MARROW DEPRESSION: A 
REPORT FROM THE DRUG EPIDEMIOLOGY UNIT AND THE BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM. 

253661 04-15 
DEPRESSIONS 

MODERN VIEWS ON DIAGNOSIS AND CLASSIFICATION OF DEPRESSIONS: 
II. UNITED-KINGDOM. 

227205 01-09 
THE PROBLEM OF POST-PSYCHOTIC SCHIZOPHRENIC DEPRESSIONS AND 
THEIR PHARMACOLOGICAL INDUCTION: LONG-TERM STUDIES WITH 
FLUSPIRILENE AND PENFLURIDOL AND SINGLE-BLIND TRIAL WITH 
FLUPHENAZINE-DECANOATE AND FLUPENTHIXOL DECANOATE. 

239823 03-08 
CLINICAL AND THERAPEUTICAL PROBLEMS OF MILD (NONPSYCHOTIC) 
MENTAL DEPRESSIONS. 

252447 04-10 
DEPRESSIVE 

SULPIRIDE IN DEPRESSIVE SCHOOL PHOBIC CHILDREN. 

227141 01-10 
THE CLINICAL EVALUATION OF A NEW MINOR TRANQUILIZER 
CLORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOAAATIC DISEASE, NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BLIND CLINICAL STUDY. 

229504 01-11 
THE EFFECT OF LITHIUM TREATMENT ON MANIC SYMPTOMS AND 
LEVELS OF MONOAMINE METABOLITES IN CEREBROSPINAL FLUID OF 
MANIC DEPRESSIVE PATIENTS. 

230824 01-09 
TREATMENT OF DEPRESSIVE SYNDROMES IN INVOLUTIONAL SUBJECTS. 

230990 01-09 
A CONTRIBUTION TO TREATMENT OF DEPRESSIVE SYNDROMES: USE OF 
TRAZODONE INTRAVENOUSLY. 

230992 01-09 
DEPRESSIVE EFFECTS OF MORPHINE UPON LAMINA V CELLS ACTIVITIES 
IN THE DORSAL HORN OF THE SPINAL CAT. 

232328 01-03 
DEPRESSIVE STATE AND DIMENSIONS OF THE MAN ON GOODENOUGHS 
DRAW-A-MAN TEST IN CHILDREN. 

235998 02-10 
ISONIAZID (INH) IN THE TREATMENT OF DEPRESSIVE SYNDROME: A 
PILOT TRIAL. 

236665 02-09 
THE USE OF DOTHIEPIN IN THE TREATMENT OF PSYCHONEUROTIC 
ANXIETY WITH DEPRESSIVE FEATURES. 

237774 02-10 
METHAMPHETAMINE WITHDRAWAL AS A MODEL FOR THE DEPRESSIVE 
STATE: ANTAGONISM OF POST-AMPHETAMINE DEPRESSION BY 
IMIPRAMINE 

237976 02-03 
DOUBLE-BLIND COMPARISON OF MAPROTILINE WITH AMITRIPTYLINE IN 
THE TREATMENT OF DEPRESSIVE ILLNESS. 

239818 03-10 
DOUBLE-BLIND TRIAL OF DIFFUCAPS AMITRIPTYLINE AND ORDINARY 
AMITRIPTYLINE IN SLEEP DISORDERS OF DEPRESSIVE ORIGIN. 

240032 03-09 
CENTRAL NERVOUS DEPRESSIVE ACTIONS OF NEUROTROPIN ON MICE 
AND RATS. 

241374 03-04 
INTRAVENOUS TRAZODONE WITH DEPRESSIVE SYNDROMES. 

244589 04-09 
A PLACEBO CONTROLLED TRIAL OF VILOXAZINE WITH AND WITHOUT 
TRANQUILLIZERS IN DEPRESSIVE ILLNESS. 

245137 04-10 
IS THERE AN INCREASE IN MONOAMINE-OXIDASE ACTIVITY IN 
DEPRESSIVE ILLNESS?. 

245233 04-13 
SINGLE DOSE IMIPRAMINE PAMOATE IN THE TREATMENT OF DEPRESSIVE 
NEUROSIS. 

246300 04-10 
STUDIES ON THYROID THERAPY AND THYROID FUNCTION IN DEPRESSIVE 
PATIENTS. 

249123 04-13 
A STATISTICAL REVIEW OF CONTROLLED TRIALS OF IMIPRAMINE AND 
PLACEBO IN THE TREATMENT OF DEPRESSIVE ILLNESSES. 

249536 04-16 
THIORIDAZINE IN THE TREATMENT OF DEPRESSIVE PATIENTS. 

252760 04-09 



00- 



ffi) 
-n 



I 



S-101 



Subject Index 



Psychopharmacology Abstf^! 



DEPRIVATION 

TOTAL SUPPRESSION OF IRRITABLE AGGRESSION IN RATS BY SENSORY 
DEPRIVATION 

233418 02-03 
RELEASE OF H3-ALPHA-METHYLTYRAMINE FROM CORPUS-STRIATUM IN 
VITRO AND THE EFFECTS OF GLUCOSE DEPRIVATION. 

238731 03-03 
COMPARISON OF ALTERED STATES OF CONSCIOUSNESS INDUCED BY 
SHORT SENSORY DEPRIVATION AND BY DELTA9-TRANS- 
TETRAHYDROCANNABINOL 

240645 03- 14 
PITRESSIN-INDUCED INHIBITION OF DRINKING FOLLOWING WATER 
DEPRIVATION IN THE SWR-J MOUSE, 

242746 04-04 
EFFECTS OF AMPHETAMINE, FOOD DEPRIVATION AND CURRENT 
INTENSITY ON SELF-STIMULATION IN THE RAT. 

244214 0404 
BICUCULLINE REVERSAL OF DEPRIVATION AMBLYOPIA IN THE CAT 

249983 04-03 
Y-MAZE LEARNING IN TWO INBRED STRAINS OF MICE. EFFECTS OF 
INSTRUMENTAL AND PHARMACOLOGICAL DEPRIVATION OF SLEEP. 

252171 04-04 
DERIVATIVE 

A PHENOTHIAZINE DERIVATIVE IN THE TREATMENT OF SPASTICITY. 

226960 01 11 
EFFECTS OF A NEW BUTYROPHENONE DERIVATIVE (BURONIL) ON 
NOCTURNAL SLEEP IN NORMAL MAN. 

227140 01-14 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY. 

237458 02-10 
RELEASE OF NOREPINEPHRINE AND DOPAMINEBETA-HYDROXYLASE BY 
NERVE STIMULATION. V. ENHANCED RELEASE ASSOCIATED WITH A 
GRANULAR EFFECT OF A BENZOQUINOLIZINE DERIVATIVE WITH 
RESERPINELIKE PROPERTIES. 

246844 04-03 
MEASUREMENT OF DESIPRAMINE IN BRAIN TISSUE BY A RADIOISOTOPE 
DERIVATIVE TECHNIQUE. 

247131 04-03 
CLINICAL PHARMACOLOGY OF NABILONE. A CANNABINOL DERIVATIVE. 

248628 04-12 
DIRECT DOPAMINERGIC ACTION OF LISURIDE HYDROGEN MALEATE, AN 
ERGOT DERIVATIVE, IN MICE. 

252028 04-04 
DERIVATIVES 

NEW TRICYCLIC ENAMINE DERIVATIVES WITH CNS DEPRESSANT 
PROPERTIES 

232528 01-02 
BASIC DERIVATIVES OF 6,7 DIHYDROINDOLOBENZAZEPINE AND 6H 
INDOLOBENZOXAZEPINE AS POTENTIAL ANTIDEPRESSANT AGENTS. 

237834 02-02 
DISSOCIATION BY THE APOMORPHINE DERIVATIVES OF THE 

STEREOTYPIC AND HYPERACTIVITY RESPONSES RESULTING FROM 
INJECTIONS INTO THE NUCLEUS-ACCUMBENS SEPTI. 

238319 02-04 
STUDIES ON MODE OF ANTAGONISM BETWEEN ADRENERGIC BETA- 
MIMETICS AND BETA-BLOCKING AGENTS (I), BETA-BLOCKING ACTION 
OF MESCALINE AND ITS DERIVATIVES 

238563 02-03 
EFFECTS OF DOPAMINE (DA) DERIVATIVES ON CENTRAL DOPAMINERGIC 
MECHANISMS 

238700 0303 
EFFECTS OF BETA HYDROXYLATED PHENOTHIAZINE DERIVATIVES ON 
ISOLATED BRAIN MITOCHONDRIA. 

238777 03-03 
WET DOG SHAKE BEHAVIOR IN NORMAL RATS, ELICITED BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID DERIVATIVES. 

241231 0304 
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIMALS. 4TH 
REPORT COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
DIFFERENTIAL PHARMACOTHERAPY FOR NEUROTIC STATES 
(COMPARATIVE EFFECTIVENESS OF BENZODIAZEPINE DERIVATIVES). 

244349 04- 10 
EFFECTS OF THIENODIAZEPINE DERIVATIVES ON HUMAN SLEEP AS 
COMPARED TO THOSE OF BENZODIAZEPINE DERIVATIVES. 

246309 04-07 
THE EFFECT OF VARIOUS CHLORPROMAZINE DERIVATIVES ON THE 
APOMORPHINE-ELICITEO INHIBITION OF SYNAPTOSOMAL TYROSINE- 
HYDROXYLASE ACTIVITY 

247212 04-03 
ON THE IN VIVO AND IN VITRO ACTIONS OF FENFLURAMINE AND ITS 
DERIVATIVES ON CENTRAL MONOAMINE NEURONS, ESPECIALLY 5 
HYDROXYTRYPTAMINE NEURONS, AND THEIR RELATION TO THE 
ANORECTIC ACTIVITY OF FENFLURAMINE. 

250937 04-03 



SOME EFFECTS OF FENFLURAMINE AND ITS DERIVATIVES ON THE 
CENTRAL CATECHOLAMINERGIC SYSTEMS OF MICE. 

250940 a 
EFFECT OF ACETYLATED DERIVATIVES OF SOME SYMPATHOMIMETIC 
AMINES ON THE ACUTE TOXICITY, LOCOMOTOR ACTIVITY AND 
BARBITURATE ANESTHESIA TIME IN MICE. 

251130 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERU/ 
ALBUMIN ■■ I, GEL FILTRATION STUDIES. 

251176 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUI 

ALBUMIN - 11. CIRCULAR DICHROISM STUDIES. 

251177 
DIESTER DERIVATIVES AS APOMORPHINE PRODRUGS. 

251699 
THE STRUCTURE-ACTION RELATIONSHIP AND KINETICS OF SOME 
NALOXONE AND NALTREXONE DERIVATIVES. 

252223 
DERIVED 

INTRACRANIAL SELF-STIMULATION DERIVED FROM ENTORHINAL COR 

238757 
NEUROAMINE DERIVED ALKALOIDS; SUBSTRATE PREFERRED INHIBITC 
OF RAT BRAIN MONOAMINE-OXIDASE IN VITRO. 

243778 C 
DRUGS DERIVED FROM CANNA8IN0IDS. 1. NITROGEN ANALOGS, 
BENZOPYRANOPYRIDINES AND BENZOPYRANOPYRROLES. 

248646 C 
DRUGS DERIVED FROM CANNABINOIDS. 2. BASIC ESTERS OF NITROG 

AND CARBOCYCLIC ANALOGS. 

248647 C 

DRUGS DERIVED FROM CANNABINOIDS. 5, DELTA 

TETRAHYDROCANNABINOL AND HETEROCYCLIC ANALOGS 
CONTAINING AROMATIC SIDE-CHAINS. 

248648 C 
DRUGS DERIVED FROM CANNABINOIDS. 3. SULFUR ANALOGS, 

THIOPYRANOBENZOPYRANS AND THIENOBENZOPYRANS. 

248651 C 
DRUGS DERIVED FROM CANNABINOIDS. 4. EFFECT OF ALKYL 

SUBSTITUTION IN SULFUR AND CARBOCYCLIC ANALOGS. 

248652 C 
DESCRIBE 

PHARMACOKINETIC MODEL TO DESCRIBE SELF-INDUCED DECREASES 
STEADY-STATE CONCENTRATIONS OF CARBAMAZEPINE, 

239658 C 
DESIGN 

ANXIETY IN SCHIZOPHRENIA: THE RESPONSES TO CHLORDIAZEPOXID 
AN INTENSIVE DESIGN STUDY, 

228221 C 
SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE 
SPECIFIC INHIBITORS OF MONOAMINE-OXIDASE. 

233946 ( 
DESIPRAAAINE 

SIMULTANEOUS MEASUREMENT OF IMIPRAMINE AND DESIPRAMINE 
SELECTED ION RECORDING WITH DEUTERATED INTERNAL STANOAI 
(UNPUBLISHED PAPER). 

237274 ( 
PLASMA LEVELS OF IMIPRAMINE AND DESIPRAMINE IN MAN AFTER 
DIFFERENT ROUTES OF ADMINISTRATION. 

246387 ( 
MEASUREMENT OF DESIPRAMINE IN BRAIN TISSUE BY A RADIOISOTI 
DERIVATIVE TECHNIQUE 

247131 ( 
TREATMENT OF EXPERIMENTAL IMIPRAMINE AND DESIPRAMINE 
POISONING IN THE RAT 

251419( 
POTENTIATION BY DESIPRAMINE OF NEURONAL RESPONSES TO 
MESCALINE. 

251705 ( 
CATECHOLAMINE RELEASE BY INTRACEREBRAL PERFUSION OF 6 
HYDROXYDOPAMINE AND DESIPRAMINE. 

252024 ( 
DESMETHYUMIPRAMINE 

RADIOIMMUNOASSAY FOR DESMETHYLIMIPRAMINE. 

236526 ( 
A SENSITIVE GLC METHOD FOR THE DETERMINATION OF IMIPRAMIN 
AND DESMETHYLIMIPRAMINE USING A NITROGEN DETECTOR. 

236529 ( 
INFLUENCE OF DESMETHYLIMIPRAMINE ON SOME NEUROCHEMICAL 
ALTERATIONS DURING EXPERIMENTAL HYPOTHYROIDISM. 

2461 52 ( 
NOREPINEPHRINE CONTENT OF VARIOUS RAT ORGANS AFTER CHRON 
ADMINISTRATION OF DESMETHYLIMIPRAMINE. 

247777 { 
DIFFERENCES BETWEEN THE EFFECTS OF ACUTE AND LONG-TERM 
TREATMENT WITH DESMETHYLIMIPRAMINE ON RESERPINEINDUCl 
RELEASE OF AMINES FROM RAT BRAIN. 

249233 ( 



S-102 



LUME 14, SUBJECT INDEX 



Subject Index 



>AIR 

PROTEST DESPAIR RESPONSE TO PEER SEPARATION IN RHESUS MONKEYS 
AND ITS POTENTIATION BY ALTERATION OF CATECHOLAMINE 
METABOLISM. 

248437 04-04 
rRUCTION 

BETA-ADRENERGIC CONTROL OF CYCLIC-AMP GENERATING SYSTEMS IN 
CEREBELLUM: PHARMACOLOGICAL HETEROGENEITY CONFIRMED BY 
DESTRUCTION OF INTERNEURONS. (UNPUBLISHED PAPER). 

240242 03-03 
BEHAVIORAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN AFTER 
DESTRUCTION OF ASCENDING SEROTONERGIC PATHWAYS IN THE RAT: 
THE ROLE OF CATECHOLAMINERGIC NEURONS. 

241251 03-04 
INHIBITION OF TURNING BEHAVIOUR BY CLOZAPINE IN MICE WITH 
UNILATERAL DESTRUCTION OF DOPAMINERGIC NERVE TERMINALS. 

249629 04-04 
FRUCTIVE 

DESTRUCTIVE ACTION OF SYSTEMICALLY ADMINISTERED 6- 
HYDROXYDOPAMINE ON THE RAT AREA POSTREMA. 

239832 03-03 
iCT 

FURTHER STUDIES ON THE SENSITIVITY OF OPERANT BEHAVIOR TO 
DETECT OPIATE WITHDRAWAL IN RATS. 

249247 04-04 
ICTING 

CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
NEW METHOD FOR DETECTING AND QUANTITATING PHARMACOKINETIC 
DRUG DRUG INTERACTIONS APPLIED TO ETHANOL PROPRANOLOL. 

247846 04-06 
ICTION 

DETECTION OF THE NEUROLEPTIC PROPERTIES OF CLOZAPINE, SULPIRIDE, 
AND THIORIDAZINE. 

227135 01-04 
SELECTED BIBLIOGRAPHY ON DETECTION OF DEPENDENCE PRODUCING 
DRUGS IN BODY FLUIDS. 

22911201-17 
MEASUREMENT OF ANXIETY IN OUTPATIENT TRIALS: DETECTION OF BIAS 
IN PATIENT AND DOCTOR RATINGS. 

253043 04-16 
■CTOR 

A SENSITIVE GLC METHOD FOR THE DETERMINATION OF IMIPRAMINE 
AND OESMETHYLIMIPRAMINE USING A NITROGEN DETECTOR. 

236529 02-06 
■RMINANT 

DRUGS AND PUNISHED RESPONDING Vh BODY WEIGHT AS A 
DETERMINANT OF DRUG EFFECTS. 

247845 04-04 
■RMINANTS 

INDIVIDUAL DIFFERENCES AND SETTING AS DETERMINANTS OF ACUTE 
ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, 

233377 02-12 
ERMINATION 

AN ATTEMPT TO ESTABLISH QUALITY CONTROL IN DETERMINATION OF 
PLASMA CHLORPROMAZINE BY A MULTILABORATORY 
COLLABORATION. 

229439 01-16 
A NOVEL APPROACH TO QUANTITATIVE DETERMINATION OF 
SUBNANOMOLES OF PSYCHOACTIVE DRUGS IN BLOOD. 

229441 01-16 
DETERMINATION OF BROMAZEPAM IN PLASMA WITH AN INTERNAL 
STANDARD BY GAS-LIQUID CHROMATOGRAPHY 

229906 01-16 
QUANTITATIVE GLC DETERMINATION OF PENTYLENETETRAZOL IN 
BIOLOGICAL FLUIDS. 

233277 02-06 
A SENSITIVE GLC METHOD FOR THE DETERMINATION OF IMIPRAMINE 
AND OESMETHYLIMIPRAMINE USING A NITROGEN DETECTOR. 

236529 02-06 
CURRENT DETERMINATION OF LITHIUM INDUCED MINIMUM SODIUM 
REQUIREMENT IN RATS. 

237110 02-04 
QUANTITATIVE DETERMINATION OF THIORIDAZINE AND 

NONCONJUGATED THIORIDAZINE METABOLITES IN SERUM AND URINE 
OF PSYCHIATRIC PATIENTS 

237902 02- 13 
GLC IDENTIFICATION AND DETERMINATION OF 3,4 
METHYLENEDIOXYAMPHETAMINE (MDA) FROM PLASMA AND URINE, 

238484 02-06 
PKA DETERMINATION OF METHAQUALONE. 

239659 03-01 
DETERMINATION AND CHARACTERIZATION OF THE ANTINOCICEPTIVE 
ACTIVITY OF INTRAVENTRICULARLY ADMINISTERED ACETYLCHOLINE 
IN MICE. 

246852 04-04 



GLC DETERMINATION OF PLASMA DRUG LEVELS AFTER ORAL 
ADMINISTRATION OF CLORAZEPATE POTASSIUM SALTS. 

246968 04-03 
EXTINCTION RESPONDING FOLLOWING AMPHETAMINE SELF- 
ADMINISTRATION: DETERMINATION OF REINFORCEMENT AAAGNITUD 

250010 04-04 
CHLORPROMAZINE METABOLISM VII: NEW QUANTITATIVE 

FLUOROMETRIC DETERMINATION OF CHLORPROMAZINE AND ITS 
SULFOXIDE 

251777 04-06 
SERUM CONCENTRATION OF CARBAMAZEPINE: COMPARISON OF 
HERRMANNS SPECTROPHOTOMETRIC METHOD AND A NEW GLC 
METHOD FOR THE DETERMINATION OF CARBAMAZEPINE. 

25301 1 04-07 
DETERMINATIONS 

DETERMINATIONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESIS IN 
A SINGLE MOUSE BRAIN: BIPHASIC EFFECTS OF ( -i ) AMPHETAMINE. 

241257 03-03 
DETERMINED 

SIMILARITY IN CNS SENSITIVITY TO HEXOBARBITAL IN THE RAT AND 
MOUSE AS DETERMINED BY AN ANALYTICAL, A PHARMACOKINETIC, 
AND AN ELECTROENCEPHALOGRAPHIC MEASURE. 

226865 01-03 
STEREOSPECIFIC BINDING OF ETORPHINE IN ISOLATED NEURAL CELLS 
AND IN RETINA, DETERMINED BY A SENSITIVE MICROASSAY. 

252178 04-03 
DETOXIFICATION 

PSYCHIATRIC EMERGENCY CAUSED BY ACUTE INTOXICATION AND 
DETOXIFICATION SYNDROMES. 

242751 04-17 
DEUTERATED 

SIMULTANEOUS MEASUREMENT OF IMIPRAMINE AND DESIPRAMINE BY 
SELECTED ION RECORDING WITH DEUTERATED INTERNAL STANDARDS. 
(UNPUBLISHED PAPER). 

237274 02-16 
STEADY-STATE CONCENTRATIONS OF CHOLINE AND ACETYLCHOLINE IN 
RAT BRAIN PARTS DURING A CONSTANT RATE INFUSION OF 
DEUTERATED CHOLINE. 

247146 04-03 
DEUTEROPATHY 

DEUTEROPATHY AFTER STOPPING PSYCHIATRIC MEDICATION FOR 
CHRONIC SCHIZOPHRENIA. 

228325 01-08 
DEVELOPING 

BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5,7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 
ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02-04 
EFFECTS OF CATECHOLAMINE RECEPTOR BLOCKING AGENTS ON 
TOXICITY AND THERMAL RESPONSES INDUCED BY AMPHETAMINE 
ISOMERS IN ADULT AND DEVELOPING MICE. 

239043 03-05 
ACTIONS OF 6-HYDROXYDOPAMINE INJECTED INTRAVENTRICULARLY 
INTO DEVELOPING RATS (2). INFLUENCE ON MOTOR ACTIVITIES AND 
AGGRESSIVE BEHAVIOR. 

241372 03-04 
CONCENTRATION OF AMPHETAMINE ISOMERS IN BRAIN AND HEART OF 
ADULT AND DEVELOPING MICE. 

241414 03-03 
MANIPULATION OF ACETYLCHOLINE LEVELS IN DEVELOPING RAT BRAIN: 
BIOCHEMICAL AND BEHAVIORAL CONSIDERATIONS. (PHD, 
DISSERTATION), 

241680 03-04 
IN VIVO REVERSAL OF THYROXINE INDUCTION OF DNA SYNTHESIS BY 
DIBUTYRYL-CYCLIC-AMP IN DEVELOPING RAT CEREBELLUM, 

243814 04-03 
A PARADOXICAL RESPONSE TO AMPHETAMINE IN DEVELOPING RATS 
TREATED WITH 6-HYDROXYDOPAMINE. 

251951 04-04 
PATTERNS AND PROBLEMS OF DRUG CONSUMPTION IN A DEVELOPING 
COUNTRY, 

252990 04-17 
DEVELOPMENT 

NEUROCHEMICAL AND MORPHOLOGICAL CHANGES DURING THE 
DEVELOPMENT OF COBALT-INDUCED EPILEPSY IN THE RAT. 

226399 01-03 
THE EFFECT OF CHRONIC INJECTIONS OF CHLORPROAAAZINE ON 
OOGENESIS AND PROGENY DEVELOPMENT IN ALBINO MICE. 

228554 01-05 
STRATEGIES OF BASIC RESEARCH IN DEVELOPMENT OF DRUGS. 

229429 01-06 
ELECTROENCEPHALOGRAPHIC STUDIES ON THE DEVELOPMENT OF 
TOLERANCE AND CROSS-TOLERANCE TO MESCALINE IN THE RAT. 

230880 01-04 
THE ROLE OF CLINICAL PSYCHIATRY IN THE DEVELOPMENT OF NEW 
PSYCHOTROPIC DRUGS 

233684 02-17 



PS' 



-r6 









S-103 



Subject Index 



Psychopharmacology Abstra 



DEVELOPMENT OF TOLERANCE TO ANn DEPENDENCE ON ENDOGENOUS 
NEUROTRANSMITTERS 

234798 02-08 
A NOVEL METHOD FOR RAPID DEVELOPMENT OF BARBITURATE- 
TOLERANCE AND PHYSICAL DEPENDENCE IN MICE. 

238701 03-03 
EFFECTS OF CHRONIC PRENATAL HYPOXIA ON PHYSIOLOGICAL, 
NEUROCHEMICAL AND BEHAVIORAL DEVELOPMENT. 

238722 03-04 
DEVELOPMENT OF BRAIN CEREBROSIDES AND CEREBROSIDE SULFATE 

(SULFATIDE) IN OFFSPRING OF CONTROL RATS AND RATS 
CHRONICALLY TREATED WITH METHADONE. 

238723 03-03 
6HYDR0XYD0PAMINE (6-OHDA) ADMINISTRATION TO NEONATAL RATS 

FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH). CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) IN THE CNS. 

238826 03-03 
IMPAIRED DEVELOPMENT OF TOLERANCE TO MORPHINE ANALGESIA IN 
RATS WITH HEREDITARY DIABETES-INSIPIOUS. 

239851 03-03 
STUDY OF DEVELOPMENT OF TOLERANCE TO AND BARBITURATE-LIKE 
PHYSICAL DEPENDENCE ON THE TRANQUILLIZER TEMPIDON. 

240205 03-05 
SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF 
PHYSICAL DEPENDENCE IN RATS: I. COMPARISON OF PRECIPITATED 
MORPHINE WITHDRAWAL AFTER INTRAPERITONEAL AND 
INTRAVENTRICULAR INJECTION OF MORPHINE ANTAGONISTS. 

241223 03-04 
INFLUENCE OF PRENATAL D-AMPHETAMINE ADMINISTRATION ON 
DEVELOPMENT AND BEHAVIOR OF RATS, 

241245 03-04 
A STUDY ON THE DEVELOPMENT OF BARBITURATE-TOLERANCE AND 
DEPENDENCE IN HAMSTER GLIAL CELLS IN CULTURE. 

241348 03-03 
SPONTANEOUS AND GUANETHIDINE-INDUCED CHANGES OF REGIONAL 
MONOAMINE CONTENT AND MONOAMINE UPTAKE DURING 
POSTNATAL DEVELOPMENT OF THE PJkJ BRAIN. 

241366 03-03 
DEVELOPMENT OF DRUG SENSITIVE SYMPTOM RATING SCALES. 

244063 04-17 
EFFECTS OF ALCOHOL AND LITHIUM HABITUATION ON THE 

DEVELOPMENT OF ALCOHOL AVERSIONS THROUGH CONTINGENT 
LITHIUM INJECTION. 

246093 04-04 
POSTNATAL ELEVATION OF BRAIN TYROSINE-HYDROXYLASE ACTIVITY, 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 
CATECHOLAMINE LEVELS, RESULTING FROM DL-ALPHA METHYL-P- 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 04-03 
DEVELOPMENT OF CROSS-TOLERANCE BETWEEN DELTA9- 
TETRAHYDROCANNABINOL AND ETHANOL. 

249263 04-03 
THE CONTRIBUTION OF LEARNING TO THE DEVELOPMENT OF CHRONIC 

ETHANOL TOLERANCE IN THE RAT. 

249264 04-04 
STUDIES ON SINGLE DOSE TOLERANCE DEVELOPMENT TO MORPHINE IN 

MICE. 

249288 04-04 
DEVELOPMENT AND ADULT BEHAVIORAL ABNORMALITIES IN MICE 
TREATED NEONATALLY WITH CYCLOPHOSPHAMIDE. 

249296 04-02 
DEVELOPMENT OF THE INFLUENCES OF SODIUM, CATECHOLAMINE AND 
TRICYCLIC ANTIDEPRESSANT DRUG ON THE UPTAKE OF 3H-5- 
HYDROXYTRYPTAMINE BY RAT BRAIN SYNAPTOSOMES. 

249667 04-03 
POSTNATAL DEVELOPMENT OF DOPAMINERGIC AND CHOLINERGIC 
CATALEPSY IN THE RAT. 

250084 04-03 
EFFECTS OF PRENATAL RESERPINE ADMINISTRATION ON DEVELOPMENT 
OF THE RAT ADRENAL MEDULLA AND CENTRAL-NERVOUS-SYSTEM. 

253110 04-03 
DEVELOPMENTAL 

NUTRITION AND DRUG THERAPY FOR PERSONS WITH DEVELOPMENTAL 
DISABILITIES, 

232815 02-15 
DEVELOPMENTS 

RECENT DEVELOPMENTS IN THE TREATMENT OF SCHIZOPHRENIA. 

235803 02-08 
RECENT DEVELOPMENTS IN THE DRUG TREATMENT OF SCHIZOPHRENIA. 

236751 0208 
NEW DEVELOPMENTS IN THE USE OF PHENOBARBITAL IN PEDIATRICS. 

240723 03-17 
CURRENT DEVELOPMENTS IN PSYCHOPHARMACOLOGY, VOLUME I. 

245873 04-17 



DEVICE 

CHEMISTOR: A REUSABLE TELESTIMULATION DEVICE FOR DIRECT 
CHEMICAL STIMULATION OF THE NONHUMAN PRIMATE BRAIN IN 
FREELY MOVING ANIMALS. 

237270 
DEVOID 

MESOLIMBIC AREA AND C. STRIATUM: RELATIVE INCREASES IN 
DOPAMINE TURNOVER BY NEUROLEPTIC AND RELATED COMPOUNt 
DEVOID OF ANTIPSYCHOTIC ACTIVITY. 

251395 
DEXAMETHASONE 

TRAZODONE: CLINICAL AND BIOCHEMICAL STUDIES: III. 

DEXAMETHASONE SUPPRESSION TEST RESULTS AND THERAPEUTIC 
RESPONSIVENESS. 

235368 
PITUITARY ADRENAL FUNCTION IN DEPRESSED PATIENTS: RESISTANC 
TO DEXAMETHASONE SUPPRESSION. 

236801 C 
THE AUTORADIOGRAPHIC LOCALIZATION OF (3H)DEXAMETHAS0NE II 
THE BRAIN AND PITUITARY OF THE RAT. 

237864 
DEXAMPHET AMINE- 1 4C 

5-HYDROXYTRYPTAMINE-MC AND DEXAMPHETAMINE-14C UPTAKE B 
FUNDAL SARCOLEMMA PREPARATIONS: EFFECT OF THERAAAL AND 
CHEMICAL ALTERATIONS AS INDIRECT APPROACH TO THE PROBLE 
OF THE COMMON RECEPTOR. 

226827 C 
DEXETIMIDE 

THE EFFECTS OF DEXETIMIDE ON PIMOZIDE, AND HALOPERIDOL AND 
PIPAMERONE-INDUCED INHIBITION OF BRAIN SELF-STIMULATION II 
RATS. 

230452 C 
DEXTROAMPHETAMINE 

EFFECT OF DEXTROAMPHETAMINE ON IDENTIFIED CHOLINOCEPTIVE 
CELLS OF THE SNAIL BRAIN. 

238740 C 
LEVOAMPHETAMINE VS DEXTROAMPHETAMINE IN MINIMAL-BRAIN- 
DYSFUNCTION: REPLICATION, TIME RESPONSE, AND DIFFERENTIAL 
EFFECT BY DIAGNOSTIC GROUP AND FAMILY RATING. 

239932 C 
METHYLPHENIDATE, DEXTROAMPHETAMINE, AND LEVAMFETAMINE: 

EFFECTS ON SCHIZOPHRENIC SYMPTOMS. 

239933 C 
A COMPARISON OF DEXTROAMPHETAMINE AND RACEMIC 

AMPHETAMINE IN THE TREATMENT OF THE HYPERKINETIC SYNDR( 
OR MINIMAL-BRAIN-DYSFUNCTION. 

247878 
DEXTROMORAMIDE 

EFFECT OF METHADONE AND DEXTROMORAMIDE ON DOPAMINE 
METABOLISM: COMPARISON WITH HALOPERIDOL AND 
AMPHETAMINE. 

244513 
DFP 

DIPSOGENIC EFFECTS OF INTRACELLULAR AND EXTRACELLULAR THIR: 
STIMULI BEFORE AND AFTER CHRONIC DFP TREATMENT. 

247209 
DH-524 

FENMETRAZOLE (DH-524): EUPHORIANT CLASSIFIED BY CEREBRAL 
ELECTROMETRY. 

230781 
DI-N-PROPYLACETATE 

THE MODIFICATION OF THE ETHANOL WITHDRAWAL SYNDROME IN 
RATS BY DI-N-PROPYLACETATE. 

241222 
DIABETES 

INVESTIGATION OF THE INCIDENCE OF DIABETES IN PATIENTS IN THE 
LUCCA PSYCHIATRIC HOSPITAL: PATHOGENIC CONSIDERATIONS. 

235988 
DIABETES-INSIPIDUS 

IMPAIRED DEVELOPMENT OF TOLERANCE TO MORPHINE ANALGESIA I 
RATS WITH HEREDITARY DIABETES-INSIPIDUS. 

239851 
DIAGNOSES 

NATURALISTIC ASSESSMENT OF NEUROLOGICAL DIAGNOSES AND 
PHARMACOLOGICAL INTERVENTION. 

251149 
DIAGNOSIS 

MODERN VIEWS ON DIAGNOSIS AND CLASSIFICATION OF DEPRESSId 
II. UNITED-KINGDOM. 

227205 C 
ANTINUCLEAR ANTIBODIES IN PSYCHIATRIC ILLNESS: THEIR 
RELATIONSHIP TO DIAGNOSIS AND DRUG TREATMENT. 

228208 
THE LEARNING DISABLED OR HYPERACTIVE CHILD: DIAGNOSIS AND 
TREATMENT, 

233513 0: 
ON THE DIFFERENTIAL DIAGNOSIS OF ACUTE EXTRAPYRAMIDAL MOTi 
DISTURBANCES IN CHILDHOOD: CASUISTIC ACCOUNT. 

234291 O: 



S-104 



OLUME 14, SUBJECT INDEX 



Subject Index 



DIAGNOSIS AND MANAGEMENT OF ETHANOL WITHDRAWAL 
SYNDROMES. 

244107 04-11 
THE RELEVANCE TO DIFFERENTIAL DIAGNOSIS OF THE DISTRIBUTION OF 
EXTRAPYRAMIDAL SYMPTOMS RESULTING FROM NEUROLEPTIC 
THERAPY IN PSYCHIATRIC PRACTICE. 

244355 04-15 
AGNOSTIC 

LEVOAMPHETAMINE VS DEXTROAMPHETAMINE IN MINIMAL-BRAIN- 
DYSFUNCTION: REPLICATION, TIME RESPONSE, AND DIFFERENTIAL 
EFFECT BY DIAGNOSTIC GROUP AND FAMILY RATING. 

239932 03-1 1 
AGRAM 

LOGICAL ANALYSIS OF THE RESPECTIVE INFLUENCE OF THREE 

EXPERIMENTAL VARIABLES BY MEANS OF A DIAGRAM OF L CARROLL 
APPLICATION OF THIS METHOD TO A CLINICAL TRIAL OF TWO FORMS 
OF NOVERIL. 

245971 04-06 
ALYSIS 

TREATMENT OF DIALYSIS DEMENTIA WITH THIAMINE. 

251966 04-11 
AZEPAM 

A DOUBLE-BLIND COMPARISON BETWEEN DOXEPIN AND DIAZEPAM IN 
THE TREATMENT OF STATES OF ANXIETY. 

226410 01-10 
EVIDENCE FOR AN INVOLVEMENT OF GABA IN THE MEDIATION OF THE 
CEREBELLAR CGMP DECREASE AND THE ANTICONVULSANT ACTION OF 
DIAZEPAM. 

226857 01-03 
DIAZEPAM, ETHANOL AND DRUG METABOLIZING ENZYMES IN RAT 
LIVER. 

226927 01-03 
INHIBITION OF DRUG METABOLIZING ENZYMES BY DIAZEPAM IN RAT 
LIVER. 

227696 01-03 
THE EFFECT OF DIAZEPAM AND TRIFLUOPERAZINE ON BLOOD SUPPLY 
AND CARDIAC ACTIVITY. 

228553 01-03 
SERUM GROWTH HORMONE, SERUM IMMUNOREACTIVE INSULIN AND 
BLOOD GLUCOSE RESPONSE TO ORAL AND INTRAVENOUS DIAZEPAM 
IN MAN. 

229042 01-13 
ASSOCIATION BETWEEN CLEFT LIP WITH OR WITHOUT CLEFT PALATE 
AND PRENATAL EXPOSURE TO DIAZEPAM. 

229349 01-17 
ASSOCIATION BETWEEN MATERNAL INTAKE OF DIAZEPAM AND ORAL 

CLEFTS 

229350 01-15 
DIAZEPAM AND PLASMA TESTOSTERONE LEVELS. 

229369 01-15 
BLOOD LEVEL, MOOD, AND MHPG RESPONSES TO DIAZEPAM IN MAN. 

229440 01-14 
DIAZEPAM DEPOLARIZATION OF PRESYNAPTIC TERMINALS IN BULLFROG 
SYMPATHETIC GANGLIA: MEDIATION THROUGH GABA? 

229463 01-03 
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN ELDERLY VOLUNTEERS: 
EFFECT OF DIAZEPAM IN MALES. 

229840 01-11 
MISUSE AND ABUSE OF DIAZEPAM: AN INCREASINGLY COMMON 
MEDICAL PROBLEM. 

229852 01-17 
DIAZEPAM AND ACTIVE METABOLITE IN BREAST MILK AND THEIR 
TRANSFER TO THE NEONATE. 

230424 01-15 
THE EFFECT OF DIAZEPAM AND FENTANYL ON MENTAL, PSYCHOMOTOR 
AND ELECTROENCEPHALOGRAPHIC FUNCTIONS AND THEIR RATE OF 
RECOVERY 

230830 01-14 
ALTERED 5-HT METABOLISM WITH CLONAZEPAM, DIAZEPAM AND 
DIPHENYLHYDANTOIN. 

230855 01-03 
EFFECTS OF DIAZEPAM ON THE ISOLATED CHICK EMBRYO HEART. 

230862 01-03 
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN 
ANXIETY NEUROSIS. 

230907 01-08 
EFFECT OF ETHANOL ON DIAZEPAM DISTRIBUTION IN RAT. 

231007 01-03 
CLINICAL AND PHYSIOLOGICAL ASSESSMENT OF CHLORAZEPATE, 
DIAZEPAM AND PLACEBO IN ANXIOUS NEUROTICS. 

231036 01-10 
INHIBITION OF CENTRALLY EVOKED PRESSOR RESPONSES BY DIAZEPAM: 
EVIDENCE FOR AN EXCLUSIVELY SUPRAMEDULLARY ACTION. 

231039 01-03 
EVIDENCE FOR GABA INVOLVEMENT IN THE ACTION OF DIAZEPAM ON 
PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC 
GANGLIA. 

232513 01-03 



THE EFFECT OF DIAZEPAM, FLUNITRAZEPAM AND DROPERIDOL WITH AN 
ANALGESIC ON BLOOD-PRESSURE AND HEARTRATE IN AAAN. 

232531 01-13 
EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON 
THE METABOLISM OF METHYLPREDNISOLONE AND ITS SODIUM 
SUCCINATE. 

233001 02-13 
A REVIEW OF THE EFFECTS OF DIAZEPAM ON COGNITIVE AND 
PSYCHOMOTOR PERFORMANCE. 

235236 02-14 
ON THE INTRACELLULAR MECHANISM OF ACTION OF IMIPRAMINE AND 
DIAZEPAM. 

236232 02-03 
LORAZEPAM AND DIAZEPAM IN THE TREATMENT OF NEUROTIC 
ANXIETY: DOUBLE-BLIND TRIAL. 

236658 02-10 
CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY OF THE COMPARATIVE 
EFFECTIVENESS OF MEPIPRAZOL (EMD-16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 02-10 
EFFECTS OF DIAZEPAM AND SCOPOLAMINE ON STORAGE, RETRIEVAL 
AND ORGANIZATIONAL PROCESSES IN MEMORY. 

237722 02-14 
PLASMA CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES AFTER 
PERORAL, INTRAMUSCULAR, AND RECTAL ADMINISTRATION: 
CORRELATION BETWEEN PLASMA CONCENTRATION AND SEDATORY 
EFFECT OF DIAZEPAM. 

237735 02-13 
GAS CHROMATOGRAPHIC SEPARATION OF CHLORPROMAZINE, 
DIAZEPAM AND N-DESMETHYLDIAZEPAM. 

237750 02-06 
ROLE OF DIAZEPAM IN THE MANAGEMENT OF ECLAMPSIA. 

237898 02-11 
APPARENT PHARAAACOKINETIC INTERACTION OF DIAZEPAM AND 
AMITRIPTYLINE IN PSYCHIATRIC PATIENTS: A PILOT STUDY. 

237901 02-13 
DRUG PERMEATION THROUGH MEMBRANES V: INTERACTION OF 
DIAZEPAM WITH COMMON EXCIPIENTS. 

238485 02-02 
INFLUENCE OF THE ROUTE OF ADMINISTRATION OF THE CLINICAL 
ACTION OF DIAZEPAM. 

238531 02-13 
RESPONSES OF NORMAL AND ISOLATE MONKEYS TO D-AMPHETAMINE, 
COCAINE, CHLORPROMAZINE AND DIAZEPAM. 

238694 03-04 
INFLUENCE OF DIAZEPAM (VALIUM) ON HUMAN LEARNING AND 
MEMORY PROCESSES. 

238711 03-14 
ACUTE EFFECTS OF OXAZEPAM, DIAZEPAM AND METHYLPERONE, ALONE 
AND IN COMBINATION WITH ALCOHOL ON SEDATION, COORDINATION 
AND MOOD. 

239042 03-14 
EFFECTS OF DIPHENYLHYDANTOIN AND DIAZEPAM ON HIPPOCAMPAL 
EVOKED RESPONSES. 

239961 03-03 
EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON SELF-STIMULATION IN 
POSTERIOR HYPOTHALAMIC AND PREOPTIC REGIONS AND ON THE 
THERMOREGULATORY RESPONSES TO REWARDING BRAIN 
STIMULATION. 

239980 03-04 
EFFECTIVENESS OF MORPHINE AND INEFFECTIVENESS OF DIAZEPAM AND 

PHENOBARBITAL ON THE MOTIVATIONAL PROPERTIES OF 
HYPOTHALAMIC SELF-STIMULATION BEHAVIOUR. 

239981 03-04 
THE EFFECT OF DIAZEPAM AND PICROTOXIN ON BRAINSTEM EVOKED 

DORSAL ROOT POTENTIALS. 

239982 03-03 
ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 

BROMAZEPAM IN CONSCIOUS TRAINED DOGS. 

240064 03-03 
DIAZEPAM USE IN MILITARY SICK CALL. 

240278 03-17 
CAMAZEPAM (SB-5833) IN PREPARATION FOR ENDOSCOPY INSPECTION: 
OPEN AND DOUBLE-BLIND STUDY VERSUS DIAZEPAM. 

241276 03-14 
COMBINED EFFECTS OF METHAMPHETAMINE, CAFFEINE, DIAZEPAM, AND 
PENTOBARBITAL ON DRL PERFORMANCE IN RATS. 

241400 03-04 
ORAL DIAZEPAM IN HOSPITALIZED ANXIETY PATIENTS (WITH 
OBSERVATIONS ON CONCENTRATION EFFECT RELATIONSHIPS). 

241427 03-10 
DIAZEPAM AND CHLORDIAZEPOXIDE: POWERFUL GABA ANTAGONISTS IN 
EXPLANTS OF RAT CEREBELLUM. 

244205 04-03 
EFFECT OF INTRAVENOUS DIAZEPAM ON RENAL FUNCTION. 

246273 04-15 
SMOOTH PURSUIT EYE MOVEMENTS, AND DIAZEPAM, CPZ, AND 
SECOBARBITAL. 

246303 04-14 



■so 










S-105 



Subject Index 



Psychopharmacology Abstracts 



EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEC - DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE 

2463)9 04-03 
PLASMA LEVELS OF DIAZEPAM AFTER PARENTERAL AND RECTAL 
ADMINISTRATION IN CHILDREN. 

246891 04- n 
ASSESSMENT OF DIAZEPAM AFTER THREE YEARS USE IN CHILD 
PSYCHIATRY. 

249144 04-n 
EFFECTS OF DIAZEPAM ON SIX DRUG-INDUCED LOCOMOTOR 
HYPERACTIVITIES IN MICE. 

249677 0404 
WITHDRAWAL OF DIAZEPAM. 

250056 04-15 
BILIARY ELIMINATION OF DIAZEPAM IN MAN 

250423 04-13 
COMPARISON OF LOW DOSES OF HALOPERIDOL AND DIAZEPAM IN 
ANXIETY STATES. 

250491 04-10 
EFFECTS OF THIORIDAZINE AND DIAZEPAM ON THE PHARMACOKINETICS 
OF (14C)IMIPRAMINE IN RAT: ACUTE STUDY. 

250655 04 03 
EXPOSURE IN VIVO OF AGORAPHOBICS: CONTRIBUTIONS OF DIAZEPAM, 
GROUP EXPOSURE, AND ANXIETY EVOCATION. 

250727 04-10 
DIAZEPAM-INOUCED 

CHLORDIAZEPOXIDE AND DIAZFPAM-INDUCED MOUSE-KILLING BY RATS. 

230838 01-04 
DIAZOXIDE 

ENHANCEMENT BY CHLORPROMAZINE OF HYPERGYLCEMIC ACTION OF 
DIAZOXIDE. 

247715 04-15 
DIBENAMINE 

RELATIONS BETWEEN ORIENTING. PSEUDOCONDITIONFD AND 
CONDITIONED RESPONSES IN THE SHUTTLEBOX ■■ A 
PHARMACOLOGICAL ANALYSIS BY MEANS OF LSD AND DIBENAMINE. 

230570 01-04 
DIBt^NZOOIAZEPINES 

ANTIDOPAMINERGIC AND ANTIMUSCARINIC EFFECTS OF 
DIBENZ0DIA7EPINES: RELATIONSHIP TO DRUG INDUCED 
PARKINSONISM. 

241248 03-03 
DIBUTYRYl-CAMP 

RELEASE OF NOREPINEPHRINE (NE) AND DOPAMINE BETA-HYDROXYLASE 
(DBH): EFFECT OF PHENOXYBENZAMINE (PBZ) ALONE AND IN 
COMBINATION WITH 8-BROMO-CGMP AND DIBUTYRYL-CAMP. 

238690 03-03 
DIBUTYRYI-CYCIIC-AMP 

BEHAVIORAL EFFECTS OF DIBUTYRYL-CYCLIC-AMP AND BIOGENIC 
AMINES IN RATS. 

232484 01-04 
IN VIVO REVERSAL OF THYROXINE INDUCTION OF DNA SYNTHESIS BY 
DIBUTYRYL-CYCLIC-AMP IN DEVELOPING RAT CEREBELLUM. 

243814 04-03 
MEASUREMENTS OF BRAIN AMOBARBITAL CONCENTRATIONS IN RATS 
ANESTHETIZED AND OVERDOSED WITH AMOBARBITAL AND TREATED 
CENTRALLY WITH DIBUTYRYL-CYCLIC-AMP. 

248276 04-03 
COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYL- 
CYCLIC-AMP AND ANAIFPTIC DRUGS ON AMOBARBITAL-INDUCED 
NARCOSIS IN THE RAT. 

252221 04-03 
OICHIORVOS 

DICHLORVOS AND THE CHOLINERGIC SYSTEM: EFFECTS ON 
CHOLINESTERASE AND ACETYLCHOLINE AND CHOLINE CONTENTS OF 
RAT TISSUES. 

230451 01-03 
DICHROISM 

MAGNETIC CIRCULAR DICHROISM OF SUBSTITUTED INDOLES. 

229493 01-06 
INTERACTION OF BENZODIAZEPINE DERIVATIVES WITH BOVINE SERUM 
ALBUMIN - II. CIRCULAR DICHROISM STUDIES. 

251177 04-01 
DIDEHYDRO-METHYL-SBETA-PYRIOYLTHIOMETHYLERGOIINE 

CF 25-397, DIDEHYDR0-METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINF, A 
NEW CENTRAL DOPAMINE RECEPIOR AGONIST. 

241927 03-04 
DIEIORIN 

THE EFFECTS OF LOW-LEVEL DIELDRIN EXPOSURE ON THE EEG AND 
LEARNING ABILITY OF THE SQUIRREL-MONKEY. 

227385 01-04 
NEUROTOXICITY OF DIELDRIN IN RELATION TO THE SEROTONIN 
METABOLISM AND ACID TRANSPORT IN MOUSE BRAIN. 

249265 04-05 
OIENCEPHAIIC 

EFFECTS OF INTRAVENTRICULAR 6-HYDROXYDOPAMINE AND 

REPLACEMENT THERAPY WITH NOREPINEPHRINE, DOPAMINE, AND 



SEROTONIN ON SELF-STIMULATION IN DIENCEPHALIC AND 
MESENCEPHALIC REGIONS IN THE RAT. 

232332 01-04 
TOLERANCE, PHYSICAL DEPENDENCE AND OPIOID-SEEKING BEHAVIOR: 
DEPENDENCE ON DIENCEPHALIC NOREPINEPHRINE. 

244202 04-04 
CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 
ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
DIESTER 

DIESTER DERIVATIVES AS APOMORPHINE PRODRUGS. 

251699 04-04 
DIET 

LONG-TERM CONSUMPTION OF A TRYPTOPHAN POOR DIET ALTERS THE 
BEHAVIORAL RESPONSE TO DRUGS. 

238741 03-03 
EFFECTS OF A CHOLINE-DEFICIENT DIET ON THE INDUCTION OF DRUG 
AND ETHANOL METABOLIZING ENZYMES AND ON THE ALTERATION OF 
RATES OF ETHANOL DEGRADATION BY ETHANOL AND 
PHENOBARBITAL. 

247032 04-03 
THE EFFECT OF TRYPTOPHAN AND A TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN COMBINATION ON INDOLES IN THE BRAINS OF 
RATS FED A "..^YPTOPHAN DEFICIENT DIET. 

249675 04-03 
INTERACTION OF DIET AND DRUGS IN THE REGULATION OF BRAIN 5- 
HYDROXYINDOLES AND THE RESPONSE TO PAINFUL ELECTRIC SHOCK. 

252516 04-03 
DIETARY 

THE INFLUENCE OF DIETARY IODINE ON LITHIUM BLOOD LEVEL, SERUM 
0T4 AND THYROID GLAND WEIGHT. 

236528 02-03 
DIETHYLCARBOXAMIDE 

BLOCKAGE OF LSD BINDING AT ITS HIGH AFFINITY SITE ON 
SYNAPTOSOMAL MEMBRANES BY 1 METHYL 1,2,5,6 
TETRAHYOROPYRIDINE N,N DIETHYLCARBOXAMIDE. 

227692 01-03 
ANTAGONISM OF D-LYSERGIC ACID-DIETHYLAMIDE AND MESCALINE BY 
1 METHYL 1,2,,5,6 TETRAHYOROPYRIDINE N,N DIETHYLCARBOXAMIDE 
(THPC). 

230453 01-03 
DIETHYLDITHIOCARBAMATE 

EFFECTS OF DIETHYLDITHIOCARBAMATE ON THE CATABOLISM OF 
TYROSINE IN THE RAT BRAIN. 

241249 03-05 
DIFFERENTIALLY 

BINDING OF GLYCINE AND GAMMA-AMINOBUTYRIC-ACID TO 

SYNAPTOSOMAL FRACTIONS OF THE BRAINS OF DIFFERENTIALLY 
HOUSED MICE 

238349 02-03 
D-AMPHETAMINE AND L-AMPHETAMINE DIFFERENTIALLY MEDIATES 
SELF-STIMULATION IN RAT DORSAL MIDBRAIN AREA. 

239272 03-04 
SALSOLINOL DIFFERENTIALLY AFFECTS MICE SELECTED FOR SENSITIVITY 
TO ALCOHOL. 

244680 04-04 
LITHIUM DIFFERENTIALLY ANTAGONISES SELF-STIMULATION 
FACILITATED BY MORPHINE AND (4 ) AMPHETAMINE. 

249486 04-03 
EFFECTS OF D-AMPHETAMINE ON THE INCORPORATION OF CARBON 
ATOMS OF D-GLUCOSE INTO THE BRAINS OF DIFFERENTIALLY HOUSED 
MICE 

249672 04-04 
DIFFERENTIATION 

DIFFERENTIATION BY MORPHINE OF TWO TYPES OF AGGRESSIVE 
BEHAVIOR IN THE CONVICT CICHLID (CICHLASOMA- 
NIGROFASCIATUM). 

230865 01-04 
CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIOERAriON OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
DIFFERENTIATION OF SENSORY-MOTOR MECHANISMS IN PERIPHERAL 
NERVE BLOCK BY MODIFIED RAT SCIATIC BLOCK METHOD. 

238724 03 03 
DIFFICULTIES 

FLUPHENAZINE: DIFFICULTIES AND LIMITATIONS IN ANIMAL 
EXPERIMENTATION WITH NEUROLEPTIC SUBSTANCES. 

247151 04-04 
DIFFUCAPS 

DOUBLE-BLIND TRIAL OF DIFFUCAPS AMITRIPTYLINE AND ORDINARY 
AMITRIPTYLINE IN SLEEP DISORDERS OF DEPRESSIVE ORIGIN. 

240032 03-09 
DIGITALIS 

DIGITALIS: CLINICAL IMPLICATIONS OF NEW FACTS ABOUT AN OLD 
DRUG. 

253495 04-15 



S-106 



OLUME 14, SUBJECT INDEX 



Subject Index 



IGITOXIN 

THE EFFECT OF OUABAIN AND DIGITOXIN ON HEXOBARBITONE SLEEPING 
TIME IN THE MOUSE. 

225574 01-03 
IGOXIN 

TRIAL OF DIGOXIN IN MANIA. 

24771 1 04-09 
IHYDROERGOTAMINE 

ON HYPOTENSION AS A RESULT OF PSYCHOTROPIC MEDICATION: 
COMPARATIVE STUDY OF TWO CORRECTIVES (ETILEFRINE AND 
DIHYDROERGOTAMINE). 

241763 03-15 
IHYDROINDOIOBENZAZEPINE 

BASIC DERIVATIVES OF 6,7 DIHYDROINDOLOBENZAZEPINE AND 6H 
INDOLOBENZOXAZEPINE AS POTENTIAL ANTIDEPRESSANT AGENTS. 

237834 02-02 
IHYDROMORPHINE 

SATURABLE BINDING OF DIHYDROMORPHINE AND NALOXONE TO RAT 
BRAIN TISSUE IN VITRO. 

230919 01-03 
IHYDROXYACID 

CHARACTERIZATION OF THREE MONOHYDROXYACID AND TWO 

DIHYDROXYACID METABOLITES OF DELTAl -TETRAHYDROCANNABINOL 
IN MOUSE LIVER. 

243787 04-03 
IHYDROXYCHLORPROMAZINE 

EFFECTS OF SUPEROXIDE DISMUTASE ON THE AUTOOXIDATION OF 7,8 
DIHYDROXYCHLORPROMAZINE IN THE PRESENCE OF RAT BRAIN 
MITOCHONDRIA. 

236521 02-03 
IHYDROXYPEHNYLPtPERAZINE 

MECHANISMS OF A DYSKINESIA INDUCTION BY 1-3,4 
DIHYDROXYPEHNYLPIPERAZINE IN THE RAT. 

239964 03-04 
IHYDROXYPHENYIACETIC-ACID 

CENTRAL DOPAMINERGIC NEURONS: EFFECTS OF ALTERATIONS IN 
IMPULSE FLOW ON THE ACCUMULATION OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085 04-03 
IHYOROXYPHENYLAMINO 

3,4 DIHYDROXYPHENYLAMINO 2 IMIDAZOLINE (DPI), A NEW POTENT 
AGONIST AT DOPAMINE RECEPTORS MEDIATING NEURONAL 
INHIBITION. 

238321 02-03 
IHYOROXYTETRAHYDROISOQUINOLINE 

A COMPARISON OF 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL AND TETRAHYDROPAPAVEROLINE AN INHIBITORS OF 
MONOAMINE-OXIDASE WITHIN THE ADRENERGIC NERVE PLEXUS OF 
THE ISOLATED MOUSE ATRIUM. 

248603 04-03 
IHYDROXYTRYPTAMINE 

IMPAIRMENT OF THERMOREGULATION, FOOD AND WATER INTAKES IN 
THE RAT AFTER HYPOTHALAMIC INJECTIONS OF 5,6 
DIHYDROXYTRYPTAMINE. 

226938 01-04 
BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5,7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 
ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02-04 
EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON TYROSINE-HYDROXYLASE 
ACTIVITY IN CENTRAL CATECHOLAMINERGIC NEURONS OF THE RAT. 

232624 02-03 
THERMOREGULATORY DEFICITS IN THE MONKEY PRODUCED BY 5,6 
DIHYDROXYTRYPTAMINE INJECTED INTO THE HYPOTHALAMUS. 

239087 03-03 
EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON AN IDENTIFIED 5- 
HYDROXYTRYPTAMINE CONTAINING NEURONE IN THE CENTRAL- 
NERVOUS-SYSTEM OF THE SNAIL HELIX POMATIA. 

243799 04-03 
HYPERPHAGIA AND INCREASED GROWTH IN RATS AFTER 

INTRAVENTRICULAR INJECTION OF 5,7 DIHYDROXYTRYPTAMINE. 

243879 04-04 
ACTIVITY, AVOIDANCE LEARNING AND REGIONAL 5- 

HYDROXYTRYPTAMINE FOLLOWING INTRABRAIN STEM 5,7 
DIHYDROXYTRYPTAMINE AND ELECTROLYTIC MIDBRAIN RAPHE 
LESIONS IN THE RAT. 

252173 04-03 
IHYDHOXYTRYPTOPHAN 

EFFECTS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTOPHAN 
TREATMENT ON SPONTANEOUS MOTOR ACTIVITY AND BRAIN 
MONOAMINES IN MICE. 

238565 02-03 
lUNTIN 

INCREASE IN HYPOTHALAMIC SENSITIVITY TO THE INHIBITORY ACTION 
OF ESTROGENS CAUSED BY THE USE OF L-DOPA, DILANTIN, 
EPITHALAMIN, AND PHENOFORMIN IN OLD RATS. 

241983 03-05 



CARBAMAZEPINE (TEGRETOL) - A DOUBLE-BLIND COMPARISON WITH 
PHENYTOIN (DILANTIN). 

251937 04-13 
DIMENSIONS 

DEPRESSIVE STATE AND DIMENSIONS OF THE MAN ON GOODENOUGHS 
DRAW-A-MAN TEST IN CHILDREN. 

235998 02-10 
DIMETHOXY-4-ETHYLAMPHET AMINE 

THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM), 2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE (DOET), D-AMPHETAMINE, AND 
COCAINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE 
STIMULUS. 

230837 01-04 
DIMETHOXY-4-METHYlAMPHETAMINE 

THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM), 2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE (DOET), D-AMPHETAMINE, AND 
COCAINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE 
STIMULUS. 

230837 01-04 
A COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF R- 
2,5 DIMETHOXY-4-METHYLAMPHETAMINE (R-DOM) AND S- 
AMPHETAMINE IN THE RAT. 

237717 02-04 
BEHAVIORAL AND NEUROPHARAAACOLOGICAL ANALYSIS OF 

AMPHETAMINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN 
RATS. 

237718 02-04 
DIMETHOXY-4-METHYLPHENYl 

METABOLIC 0-DEMETHYLATION OF THE PSYCHOTOMIMETIC AMINE 1 2.5 
DIMETHOXY-4-METHYLPHENYL 2 AMINOPROPANE. 

236520 02-03 
DIMETHOXYMETHYl-PHENOBARBITAL 

METABOLISM, DISTRIBUTION AND ANTICONVULSANT PROPERTIES OF 
N,N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT. 

237758 02-03 
DIMETHYL-M-TYRAMINE 

INHIBITION OF 4,ALPHA DIMETHYL-M-TYRAMINE H77-77 INDUCED 

HYPERMOBILITY IN RATS BY SINGLE AND REPEATED ADMINISTRATION 
OF CHLORPROAAAZINE HALOPERIDOL, CLOZAPINE AND THIORIDAZINE. 

227129 01-04 
DIMETHYL-5-AMINOADAMANTAN 

NEUROPHARMACOLOGICAL STUDIES ON D145 (1,3 DIMETHYL-5- 
AMINOADAMANTAN). 

227133 01-03 
DIMETHYLAMINOETHANOL 

THE EFFECTS OF DIMETHYLAMINOETHANOL (DEANOL) ON CEREBRAL 
CORTICAL NEURONS. 

232621 02-03 
DIMETHYIDOPAMINE 

ESTERS OF APOMORPHINE AND N,N DIMETHYLDOPAMINE AS AGONISTS 
OF DOPAMINE RECEPTORS IN THE RAT BRAIN IN VIVO. 

246150 04-04 
DIMETHYL5ULFOXIDE 

EFFECTS OF DIMETHYLSULFOXIDE ON METABOLISM OF ISOLATED 
PERFUSED RAT BRAIN. 

243782 04-03 
DIMETHYLTRYPTAMINE 

5 METHOXY N,N:DIMETHYLTRYPTAMINE (5-MEO-DMT) SHARES 

INHIBITORY EFFECTS WITH MESCALINE BUT NOT EXCITATORY EFFECTS 
ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS. (UNPUBLISHED PAPER). 

227802 01-04 
THE PSYCHEDELIC MODEL OF SCHIZOPHRENIA: THE CASE OF N,N 
DIMETHYLTRYPTAMINE. 

236750 02-08 
BRAIN BUFOTENINE FROM ADMINISTERED ACETYLBUFOTENINE: 
COMPARISON OF ITS TREMORGENIC ACTIVITY WITH THAT OF N,N 
DIMETHYLTRYPTAMINE AND 5-METHOXY-N.N DIMETHYLTRYPTAMINE. 

249317 04-05 
DIMETHYLTRYPT AMINES 

CORRELATIONS BETWEEN THE ACTIVITY OF DIMETHYLTRYPTAMINES AS 
5-HYDROXYTRYPTAMINE ANTAGONISTS AND THEIR QUANTUM 
CHEMICAL PARAMETERS. 

249318 04-03 
DINUCLEOTIDE 

ANTICONVULSANT ACTIVITY AND SELECTIVE INHIBITION OF 

NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL PHENOTHIAZINES. 

239662 03-03 
DIPHENHYDRAMINE 

DEPENDENCY ON COMBINED METHAQUALONE DIPHENHYDRAMINE. 

241870 03-17 
THE RELATIVE ROLE OF BRAIN ACETYLCHOLINE AND HISTAMINE IN 
PERPHENAZINE CATATONIA AND INFLUENCE OF ANTIDEPRESSANTS 
AND DIPHENHYDRAMINE ALONE AND IN COMBINATION, 

245593 04-05 
THE EFFECTIVENESS OF DIPHENHYDRAMINE HCL IN PEDIATRIC SLEEP 
DISORDERS. 

251827 04-14 



as 



St: 



S-107 



Subject Index 

DIPHENYLBUTYLPIPERIDINE 

CLOPIMOZIOE (R-29-764), A NEW HIGHLY POTENT AND ORALLY LONG- 
ACTING NEUROLEPTIC OF THE DIPHENYLBUTYLPIPERIDINE SERIES. 

232529 01-04 
DIPHENYLHYDANTOIN 

EFFECT OF 5,5 DIPHENYLHYDANTOIN (DPH) ON LEARNING AND MEMORY 
IN CATS. 

229680 01-04 
EFFECT OF 5,5 DIPHENYLHYDANTOIN ON FIXED CONDITIONED REFLEXES 

IN CATS. 

229681 01-04 
ALTERED 5-HT METABOLISM WITH CLONAZEPAM, DIAZEPAM AND 

DIPHENYLHYDANTOIN. 

230855 01-03 
DIPHENYLHYDANTOIN POTENCY AND PLASMA PROTEIN BINDING. 

231003 01-03 
RESPONSES OF CHRONIC SCHIZOPHRENIC FEMALES TO A COMBINATION 
OF DIPHENYLHYDANTOIN AND NEUROLEPTICS: A DOUBLE-BUND 
STUDY. 

232781 02-08 
DIPHENYLHYDANTOIN INHIBITS IONIC EXCITATION OF MOUSE 
NEUROBLASTOMA CELLS 

232917 02-03 
EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON 
THE METABOLISM OF METHYLPREDNISOLONE AND ITS SODIUM 
SUCCINATE. 

233001 02-13 
PAROXYSMAL NIGHTMARES: SEQUEL OF A STROKE RESPONSIVE TO 
DIPHENYLHYDANTOIN. 

233295 02-14 
CEREBELLAR ATAXIA DUE TO DIPHENYLHYDANTOIN ADMINISTRATION - 
CLINICAL AND PATHOLOGICAL STUDIES ON TWO CASES OF CHRONIC 
DIPHENYLHYDANTOIN INTOXICATION. 

236696 02-15 
EFFECTS OF DIPHENYLHYDANTOIN AND PHENOBARBITAL ON PROTEIN 
METABOLISM IN THE RAT CEREBRAL CORTEX. 

237243 02-03 
EFFECTS OF DIPHENYLHYDANTOIN AND DIAZEPAM ON HIPPOCAMPAL 
EVOKED RESPONSES. 

239961 03-03 
EVIDENCE THAT DIPHENYLHYDANTOIN DOES NOT AFFECT ADENOSINE 

TRIPHOSPHATASES FROM BRAIN. 

239962 03-03 
DIPHENYLHYDANTOIN SERUM LEVELS, TOXICITY, AND 

NEUROPSYCHOLOGICAL PERFORMANCE IN PATIENTS WITH EPILEPSY. 

240473 03-15 
EFFECTS OF SULTHIAME UPON INTELLECTUAL, NEUROPSYCHOLOGICAL 
AND SOCIAL FUNCTIONING ABILITIES AMONG ADULT EPILEPTICS- 
COMPARISON WITH DIPHENYLHYDANTOIN. 

240475 03-14 
EFFECT OF DIPHENYLHYDANTOIN ON THE ENDOGENOUS 
PHOSPHORYLATION OF BRAIN PROTEIN. 

240746 03-03 
PLASMA CONCENTRATION OF DIPHENYLHYDANTOIN IN THE EPILEPTIC- 
ITS INTEREST FOR THE CLINICIAN. 

240762 03-1 1 
DIPHENYLHYDANTOIN INCREASES CORTICAL POSTSYNAPTIC INHIBITION. 

241805 03-03 
DELAYED AND INSIDIOUS ONSET OF DIPHENYLHYDANTOIN TOXICITY. 

246932 04-15 
DIPHENYLHYDANTOIN FACILITATION OF LABILE, PROTEIN INDEPENDENT 
MEMORY. 

253290 04-04 
OIPHOSPHONATE 

EFFECT OF HYDROCHLOROTHIAZIDE ON PHOSPHORUS DURING 
TREATMENT WITH OIPHOSPHONATE. 

245651 04-13 
DIPIPERON 

PIPAMPERONE (DIPIPERON, R-3-345) IN TROUBLESOME MENTAL 
RETARDATES: A DOUBLE-BLIND PLACEBO CONTROLLED CROSSOVER 
STUDY WITH LONG-TERM FOLLOW-UP. 

238982 03-11 
DIPOTASSIUM 

THE CLINICAL EVALUATION OF A NEW MINOR TRANQUILIZER 
CLORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOMATIC DISEASE, NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BLIND CLINICAL STUDY. 

229504 01-11 
CLINICAL EXPERIENCE IN USING MENDON (DIPOTASSIUM CLORAZEPATE). 

229626 01-11 
CLORAZEPATE DIPOTASSIUM (TRANXENE): A CONTROLLED EVALUATION 
IN ALCOHOLIC PATIENTS AFTER WITHDRAWAL. 

251718 04-11 
DIPROPYLACETATE 

THE EFFECTS OF N DIPROPYLACETATE ON THE ACQUISITION OF 

CONDITIONED BEHAVIOUR WITH NEGATIVE REINFORCEMENT IN MICE. 

237723 02-04 



Psychopharmacology Abstracts 



DIPROPYLTRYPTAMINE 

DIPROPYLTRYPTAMINE IN PSYCHOTHERAPY. 

251752 04- 17 
DIPSOGENIC 

DIPSOGENIC EFFECTS OF INTRACELLULAR AND EXTRACELLULAR THIRST 
STIMULI BEFORE AND AFTER CHRONIC DFP TREATMENT. 

247209 04-04 
DIRECT 

BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC 
AGONISTS. 

233973 02-03 
CHEMISTOR: A REUSABLE TELESTIMULATION DEVICE FOR DIRECT 
CHEMICAL STIMULATION OF THE NONHUMAN PRIMATE BRAIN IN 
FREELY MOVING ANIMALS. 

237270 02-06 
ON THE DIRECT OR INDIRECT INFLUENCE OF APOMORPHINE ON CENTRAL 
SEROTONIN NEURONS. 

237785 02-03 
DECREASE IN RAT STRIATAL ACETYLCHOLINE LEVELS BY SOME DIRECT 
AND INDIRECT ACTING DOPAMINERGIC ANTAGONISTS. 

248410 04-03 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEEN CLINICAL 
POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS. 

248466 04-03 
THE TOXICITY OF DIRECT ACTING DOPAMINE AGONISTS: IMPLICATIONS 
FOR THE THERAPY OF PARKINSONISM. 

251959 04-05 
DIRECT DOPAMINERGIC ACTION OF LISURIDE HYDROGEN MALEATE, AN 
ERGOT DERIVATIVE, IN MICE. 

252028 04-04 
DISABILITIES 

NUTRITION AND DRUG THERAPY FOR PERSONS WITH DEVELOPMENTAL 
DISABILITIES. 

232815 02-15 
THE USE OF MEGAVITAMIN TREATMENT IN CHILDREN WITH LEARNING 
DISABILITIES. 

235676 02-11 
DISABILITY 

PSYCHIATRIC SYMPTOMS DURING L-DOPA THERAPY FOR PARKINSONS 
DISEASE AND THEIR RELATIONSHIP TO PHYSICAL DISABILITY. 

250722 04-15 
DISABLED 

THE LEARNING DISABLED OR HYPERACTIVE CHILD: DIAGNOSIS AND 
TREATMENT. 

233513 02-17 
DISAGGREGATE 

NECESSITY OF HYPERTHERMIA FOR L-DOPA OR D-AMPHETAMINE TO 
DISAGGREGATE RAT BRAIN POLYSOMES. 

238719 03-03 
DISASTER 

LITHIUM - FUTILITY, DISASTER AND TRIUMPH. 

227411 01-17 
DISCHARGE 

THE NONCONTRIBUTION OF DRUGS TO THE DISCHARGE OF THE LONG- 
STAY PSYCHIATRIC PATIENT. 

227461 01-17 
NEURAL DISCHARGE ASSOCIATED WITH TAIL PINCH INDUCED 
STEREOTYPED BEHAVIOR. 

238819 03-04 
DISCONTINUITY 

EFFECTS OF DISCONTINUITY OF MEDICATION ON THE RESULTS OF A 
DOUBLE-BLIND DRUG STUDY IN OUTPATIENT ALCOHOLICS. 

229091 OI-U 
DISCOURSE 

DISCOURSE ON THE DOUBLE-BLIND METHOD. INSTITUTION AND 
EXPERIMENTATION: 19366-RP. 

229078 01-16 
DISCOVERY 

DISCOVERY OF SPECIFIC CNS EFFECTS OF LISURIDE HYDROGEN MALEATE 
- AN ANTIMIGRAINE COMPOUND. 

229473 01-13 
DISCREPANCY 

ANALYSIS OF THE DISCREPANCY IN /WAN-MACHINE TRACKING SYSTEMS 
UNDER CONDITIONS OF DELAYED FEEDBACK. 

242702 03-14 
DISCRIMINABLE 

BEHAVIORALLY INDUCED SENSITIVITY TO THE DISCRIMINABLE 
PROPERTIES OF LSD. 

230876 01-04 
A COMPARISON OF THE DISCRIMINABLE CNS EFFECTS OF KETAMINE, 
PHENCYCLIDINE AND PENTOBARBITAL. 

249025 04-04 
DISCRIMINATED ^ 

THE EFFECTS OF NOREPINEPHRINE BIOSYNTHESIS INHIBITION ON THE H 
CONSOLIDATION OF TWO DISCRIMINATED ESCAPE RESPONSES. T 

241301 03-04 



S-108 



OLUME 14, SUBJECT INDEX 



Subject Index 



SCRIMINATION 

SCOPOLAMINE AND AMPHETAMINE EFFECTS ON DISCRIMINATION: 
INTERACTION WITH STIMULUS CONTROL. 

227)31 01-04 
PARATHION ADMINISTRATION IN THE MONKEY: TIME COURSE OF 

INHIBITION AND RECOVERY OF BLOOD CHOLINESTERASES AND VISUAL 
DISCRIMINATION PERFORMANCES. 

227384 01-03 
SCOPOLAMINE EFFECTS ON VISUAL DISCRIMINATION: MODIFICATIONS 
RELATED TO STIMULUS CONTROL. 

231005 01-04 
EFFECTS OF METHYLPHENIDATE ON AUDITORY INTENSITY 

DISCRIMINATION AND GENERALIZATION IN THE IMAAATURE RAT. 
(PH.D. DISSERTATION). 

231533 01-04 
THE EFFECT OF CHRONIC CENTRAL ADRENERGIC DENERVATION ON 
LEARNING AND MEMORY OF AN AVERSIVE DISCRIMINATION TASK IN 
MICE: STUDIES WITH 6-HYDROXYDOPAMINE. (PH.D. DISSERTATION). 

238157 02-03 
DRUG EFFECTS ON LEARNING: A TWO STAGE DRUG SCREEN UTILIZING 
FIXED-RATIO AND SERIAL DISCRIMINATION REVERSAL LEARNING. 
(PH.D. DISSERTATION). 

239533 03-04 
THEORETICAL AND METHODOLOGICAL CONSIDERATIONS ON DRUG 
DISCRIMINATION LEARNING. 

241228 03-04 
DRUG DISCRIMINATION IN RATS: EFFECTS OF MIXTURES OF DITRAN AND 
CHOLINESTERASE INHIBITORS. 

242737 03-04 
EFFECTS OF DRUG STATE CHANGE ON DISCRIMINATION PERFORAAANCE. 

244679 04-04 
DRUG DISCRIMINATION IN RATS: THE EFFECTS OF PHENCYCLIDINE AND 
DITRAN. 

245297 04-04 
EFFECT OF PHYSOSTIGMINE ON Y-MAZE DISCRIMINATION RETENTION IN 
THE RAT. 

251982 04-04 
SCRIMINATIVE 

THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM), 2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE (DOET), D-AMPHETAMINE, AND 
COCAINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE 
STIMULUS. 

230837 01-04 
A DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR BY INTRAVENOUS 
ADMINISTRATION OF DRUGS IN RATS. 

237701 02-04 
A COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF R- 
2,5 DIMETHOXY-4-METHYLAMPHETAMINE (R-DOM) AND S- 
AMPHETAMINE IN THE RAT. 

237717 02-04 
DIFFERENTIAL RESPONSE CONTROL BY ISOPROPAMIDE: A PERIPHERALLY 
INDUCED DISCRIMINATIVE CUE. 

237744 02-04 
DISCRIMINATIVE PENTOBARBITAL STIMULUS AFTER INTRAVENOUS 
ADMINISTRATION: A COMPARISON WITH THE INTRAPERITONEAL 
ROUTE. 

238756 03-04 
TEMPORAL PARAMETERS OF D-AMPHETAMINE AS A DISCRIMINATIVE 
STIMULUS IN THE RAT. 

239856 03-04 
PHYSOSTIGMINE AS A DISCRIMINATIVE CUE IN RATS. 

241258 03-04 
THE ROLE OF SEROTONIN IN THE DISCRIMINATIVE STIMULUS 
PROPERTIES OF MESCALINE. (PH.D. DISSERTATION). 

241573 03-03 
LONG-TERM EFFECTS OF BARBITAL ON SPONTANEOUS ACTIVITY OF RATS 
TRAINED TO USE THE DRUG AS A DISCRIMINATIVE STIMULUS. 

245299 04-04 
DISCRIMINATIVE STIMULUS PROPERTIES OF ETHANOL AND BARBITAL. 

249262 0404 
THE NARCOTIC DISCRIMINATIVE STIMULUS COMPLEX: RELATION TO 
ANALGESIC ACTIVITY. 

250355 04-03 
DELTA9-TETRAHYDR0CANNABIN0L. ETHANOL, AND AMPHETAMINE AS 
DISCRIMINATIVE STIMULI GENERALIZATION TESTS WITH OTHER 
DRUGS. 

251977 04-04 
DISCRIMINATIVE STIMULUS PROPERTIES OF ANALGESIC DRUGS: 
NARCOTIC VERSUS NONNARCOTIC ANALGESICS. 

253394 04-04 
SCUSSIONS 

SUMMARY OF THE DISCUSSIONS AT THE SYMPOSIUM PSYCHOSIS AND 
FREEDOM. 

246126 04-17 
SEASE 

THERAPY OF ANXIETY IN PATIENTS WITH RHEUMATIC DISEASE: 
CROSSOVER DOUBLE-BLIND STUDY COMPARING LORAZEPAM WITH 
PLACEBO. 

228241 OMl 



THE CLINICAL EVALUATION OF A NEW MINOR TRANQUILIZER 
CLORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOAAATIC DISEASE, NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BLIND CLINICAL STUDY. 

229504 01-11 
TWO YEAR COMBINED THERAPY OF PARKINSONS DISEASE WITH L-DOPA 
AND THE DECARBOXYLASE INHIBITOR BENSERAZID (RO-4-4602). 

233917 02-11 
THE USE OF A DOPAMINERGIC RECEPTOR STIMULATING AGENT 
(PIRIBEDIL, ET-495) IN PARKINSONS DISEASE. 

233974 02-11 
MAINTENANCE ANTIPSYCHOTIC THERAPY: IS THE CURE WORSE THAN 
THE DISEASE?. 

236307 02-08 
TREATMENT OF PARKINSONS DISEASE WITH APORPHINES: POSSIBLE 
ROLE OF GROWTH HORMONE. 

237253 02-1 1 
NEUROPSYCHOLOGICAL INVESTIGATIONS ON THE SHORT-TERM EFFECTS 
OF BIPERIDEN (AKINETON) IN PARKINSONS DISEASE. 

238516 02-11 
LORAZEPAM IN THE MANAGEMENT OF ANXIETY ASSOCIATED WITH 
CHRONIC GASTROINTESTINAL DISEASE: A DOUBLE-BLIND STUDY. 

24)274 03-14 
COMPARISON OF OOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE IN PARKINSONS 
DISEASE. 

2486)2 04-]) 
COMPARISON OF DOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE ON THE 
CARDIOVASCULAR SYSTEM OF PATIENTS WITH PARKINSONS DISEASE. 

2486)3 04-)) 
THE OBJECTIVE MEASUREMENT OF MENTAL PERFORMANCE IN 

CEREBROVASCULAR DISEASE: A DOUBLE-BLIND CONTROLLED STUDY, 
USING A GRADED-RELEASE PREPARATION OF ISOXSUPRINE. 

2504)4 04-)) 
PSYCHIATRIC SYMPTOMS DURING L-DOPA THERAPY FOR PARKINSONS 
DISEASE AND THEIR RELATIONSHIP TO PHYSICAL DISABILITY. 

250722 04) 5 
FIVE YEARS TREATMENT OF PARKINSONS DISEASE WITH LEVODOPA: 
THERAPEUTIC RESULTS AND SURVIVAL OF )00 PATIENTS. 

250927 04-)) 
BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF FENFLURAMINE IN 
PATIENTS WITH NEUROLOGIC DISEASE 

250942 04-)) 
BROMOCRIPTINE TREATMENT IN PARKINSONS DISEASE. 

25)239 04-)) 
SIX-YEAR RESULTS OF TREATMENT WITH LEVODOPA PLUS BENSERAZIDE 
IN PARKINSONS DISEASE. 

25)648 04-)) 
DISEASES 

AN ELECTROENCEPHALOGRAPHIC STUDY OF THE VALUE OF ACTIVATION 
BY MEGIMID IN PSYCHIATRIC DISEASES. 

2291)50)13 
CLINICAI FINDINGS IN DISEASES IN THE ELDERLY WITH A CLEAR 
PSYCHOGENIC COMPONENT WITH PARTICULAR RESPECT TO THEIR 
PHARMACOLOGICAL TREATMENT 

244476 04) 1 
DISINHIBITING 

THE DISINHIBITING EFFECT OF N (l-ETHYL-2-PYRROLIDINYL-METHYL 2- 
METHOXY-5-SULFAMIDOBENZAMIDE (SULPIRIDE). II. 

229529 0)-)4 
OISINHIBITION 

CORTICAL OISINHIBITION: A POSSIBLE MECHANISM FOR DRUG-INDUCED 
HALLUCINATIONS. 

238830 03-03 
BEHAVIORAL OISINHIBITION BY MESCALINE. 

24)243 03-04 
DISINHIBITORY 

DISINHIBITORY EFFECTS OF SEPTAL LESIONS AND SCOPOLAMINE 
HYDROBROMIDE. (PHD, DISSERTATION). 

227099 0) -04 
DISMUTASE 

EFFECTS OF SUPEROXIDE DISMUTASE ON THE AUTOOXIDATION OF 7,8 
DIHYDROXYCHLORPROMAZINE IN THE PRESENCE OF RAT BRAIN 
MITOCHONDRIA. 

23652) 02-03 
DISORDER 

PLASMA AND ERYTHROCYTE MAGNESIUM LEVELS IN PATIENTS WITH 
PRIMARY AFFECTIVE DISORDER DURING CHRONIC LITHIUM 
TREATMENT. 

238977 03) 5 
TREATMENT OF STUDENTS WITH MENTAL DISORDER. 

243092 04) 7 
THOUGHT DISORDER IN AMPHETAMINE PSYCHOSIS: A CASE REPORT. 

250)96 04) 3 
DISORDERS 

DRUGS IN THE MANAGEMENT OF LEARNING AND BEHAVIOR DISORDERS 
IN SCHOOLCHILDREN. 

225783 0) 14 



35; 



-re 



ftmm 

a. 



S-109 



Subject Index 



THE LONG-TERM LITHIUM TREATMENT OF AFFECTIVE DISORDERS. LONG- 
TERM EFFECTS AND SIDE-EFFECTS. 

226612 01-09 

UTILIZATION OF CELLULAR STUDIES OF NEUROTRANSMITTER RELATED 
ENZYMES AND TRANSPORT PROCESSES IN MAN FOR THE 
INVESTIGATION OF BIOLOGICAL FACTORS IN BEHAVIORAL DISORDERS. 
(UNPUBLISHED PAPER). 

226731 01-13 

PSYCHOVEGETATIVE DISORDERS IN CASES OF CYCLOTHYMIC 
DEPRESSION. 

226777 01-09 
PHARMACOTHERAPY IN PSYCHOVEGETATIVE DISORDERS. 

226778 01-09 
DRUGS FOR MENTAL DISORDERS OF OLD AGE. 

229315 01-11 
EFFECT OF LITHIUM ON HYPOTHALAMIC PITUITARY THYROID FUNCTION 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

230763 01-13 
DRUG TREATMENT OF MENTAL DISORDERS. 

23111301-17 
DRUGS FOR EMOTIONAL DISORDERS: CURRENT PROBLEMS. 

233514 02-17 
ELECTROENCEPHALOGRAPHIC STUDIES IN PATIENTS WITH AFFECTIVE 
DISORDERS DURING PROPHYLACTIC TREATMENT WITH LITHIUM 
CARBONATE. 

234044 02-09 
LITHIUM CARBONATE IN AFFECTIVE DISORDERS: IV. A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS IN UNIPOLAR RECURRENT DEPRESSION, 

234203 02-09 
POSSIBILITIES FOR PHARMACOTHERAPY IN THE COURSE OF 
PSYCHOTHERAPY FOR MENTAL DISORDERS. 

234438 02-17 
EVALUATION OF COMBINED PHARMACOLOGICAL AND 

PSYCHOTHERAPEUTIC TREATMENT IN PATIENTS WITH FUNCTIONAL 
ABDOMINAL DISORDERS. 

235782 02-11 
OVERVIEW: MAINTENANCE THERAPY IN PSYCHIATRY: II. AFFECTIVE 
DISORDERS. 

236303 02 17 
THE COURSE OF TREATMENT IN SCHIZOPHRENIA AS RELATED TO THE 
APPEARANCE OF AFFECTIVE DISORDERS. 

236421 02-08 
CONTROLLED, DOUBLE BLIND, CROSSOVER STUDY OF THE COMPARATIVE 
EFFECTIVENESS OF MEPIPRAZOL (EMD-16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 02-10 
CYCLIC NUCLEOTIDES AND THEIR POSSIBLE RELEVANCE TO DISORDERS 
OF NERVOUS SYSTEM FUNCTION, {UNPUBLISHED PAPER) 

237171 02-03 
2-PHENYLETHYLAMINE (PEA) IN D-AMPHETAMINE-INDUCED 
EXTRAPYRAMIDAL DISORDERS. 

238841 03-03 
PROPHYLAXIS OF AFFECTIVE DISORDERS: CURRENT STATUS OF 
KNOWLEDGE. 

239937 03-09 
DOUBLE-BLIND TRIAL OF DIFFUCAPS AMITRIPTYLINE AND ORDINARY 
AMITRIPTYLINE IN SLEEP DISORDERS OF DEPRESSIVE ORIGIN. 

240032 03-09 
BEHAVIOR DISORDERS IN CHILDHOOD AND THEIR TREATMENT. 

240711 03-11 
BIOGENIC AMINES AND AFFECTIVE DISORDERS. 

241937 03-09 
THE EFFECT OF LITHIUM ON RED BLOOD CELL CHOLINESTERASE ACTIVITY 
IN PATIENTS WITH AFFECTIVE DISORDERS. 

244495 04-09 
THE DRUG TREATMENT OF MOOD DISORDERS. PART II: ANTIMANIC AND 
ANTIDEPRESSANT AGENTS, MAINTENANCE TREATMENT, AND RECENT 
ADVANCES. (UNPUBLISHED PAPER). 

244574 04-09 
A CONTROLLED TRIAL OF AMANTADINE IN DRUG-INDUCED 
EXTRAPYRAMIDAL DISORDERS. 

244701 04-15 
LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS, 

245416 04-09 
LITHIUM CARBONATE AND AFFECTIVE DISORDERS. V: A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS OF DEPRESSION IN BIPOLAR ILLNESS. 

247582 04-09 
LORAZEPAM IN GASTROINTESTINAL DISORDERS WITH ANXIETY OVERLAY 
(A DOUBLE-BLIND CROSSOVER STUDY). 

250193 04-14 
PSYCHOTROPIC DRUGS IN SOMATIC DISORDERS. 

250856 04-17 
THE EFFECTIVENESS OF DIPHENHYDRAMINE HCL IN PEDIATRIC SLEEP 
DISORDERS 

251827 04-14 
LONG-TERM THERAPY OF NEUROLOGIC DISORDERS WITH L-5- 
HYDROXYTRYPTOPHAN. 

251960 04-13 



J 
Psychopharmacoiogy Abstracts' 

TETRABENAZINE IN THE TREATMENT OF HYPERKINETIC MOVEMENT 
DISORDERS. 

251961 04-11 
TREATMENT OF PSYCHIC DISORDERS ACCOMPANYING MYASTHENIA- 
GRAVIS: (GRANDAXIN, A NEW, NONRELAXANT TRANQUILLIZER). 

252449 04-07 
DISPERSED 

SELF-STIMULATION AND NORADRENALINE: EVIDENCE THAT INHIBITION 
OF SYNTHESIS ABOLISHES RESPONDING ONLY IF THE RESERVE POOL IS 
DISPERSED FIRST. 

246774 04-03 
DISPLAY 

ANALYSIS AND DISPLj'VY OF PSYCHOPHARAAACOLOGICAL DATA. 

228978 01-17 
DISPOSITION 

PHENOBARBITAL (PB) DISPOSITION IN MAN: PRESUMPTIVE EVIDENCE 
FOR SEVERAL METABOLITES. 

238796 03-13 
NORMAL DISPOSITION OF OXAZEPAM IN ACUTE VIRAL HEPATITIS AND 
CIRRHOSIS. 

241730 03-13 
OISRUPTABLE 

A DOPAMINE-INDUCED NEURONAL MEMORY TRACE, MEDIATED BY 
CYCLIC-AMP AND DISRUPTABLE BY CYCLIC-GMP. 

238717 03-04 
DISRUPTION 

FACILITATION AND DISRUPTION BY MESCALINE OF SHUTTLEBOX 
AVOIDANCE IN RATS. (PH.D. DISSERTATION). 

226991 01-12 
DISRUPTION OF BRAIN STIMULATION-INDUCED FEEDING BY DOPAMINE 
RECEPTOR BLOCKADE. 

235587 02-04 
DOES INCREASING STRESS CHANGE THE BEHAVIORAL ACTION OF 
MESCALINE FROM DISRUPTION TO FACILITATION?. 

237732 02-04 
PREVENTION OF REVERSAL OF OPERANT BEHAVIORAL DISRUPTION 
DURING PRECIPITATED WITHDRAWAL BY TREATMENT WITH 
MORPHINE BEFORE OR AFTER NALOXONE. 

238687 03-04 
DISSIMILAR 

ACETYLCHOLINE SYNTHESIS IN RAT BRAIN: DISSIMILAR EFFECTS OF 
CLOZAPINE AND CHLORPROMAZINE. 

248600 04-03 
DISSOCIATED 

RAPID AND DISSOCIATED CHANGES IN SENSITIVITIES OF DIFFERENT 
DOPAMINE RECEPTORS IN MOUSE BRAIN. 

227996 01-03 
THE EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON THE RESTING 
MEMBRANE POTENTIAL OF DISSOCIATED BRAIN NEURONS IN 
CULTURE. 

244199 04-03 
DISSOCIATION 

PHAR/WACOLOGICAL DISSOCIATION BETWEEN VOCALIZATION AND 
BITING PRODUCED IN RATS BY THE COMBINATION OF IMIPRAMINE 
AND ISOCARBOXAZID. 

237705 02-04 
DISSOCIATION OF RAT BRAIN POLYRIBOSOMES IN VIVO BY 
AMPHETAMINES. 

237871 02-03 
DRUG DISSOCIATION OF NEUROELECTRICAL AND BEHAVIORAL 
RESPONSES IN MICE. (PH.D. DISSERTATION). 

238159 02-03 
DISSOCIATION BY THE APOMORPHINE DERIVATIVES OF THE 

STEREOTYPIC AND HYPERACTIVITY RESPONSES RESULTING FROM 
INJECTIONS INTO THE NUCLEUS-ACCUMBENS SEPTI. 

238319 02-04 
METHSCOPOLAMINE: SUPPRESSION OF SLEEP RELATED GROWTH 

HORMONE SECRETION AND DISSOCIATION FROM SLOW WAVE SLEEP. 

243822 04-14 
DISSOCIATION OF STEREOTYPED BITING RESPONSES AND ORO-BUCCO- 
LINGUAL DYSKINESIAS. 

252031 04-03 
DISSOCIATIVE 

CLINICAL THERAPEUTIC EXPERIMENTS WITH FLUPHENAZINE-DECANOATE 
IN TREATING DISSOCIATIVE SYNDROMES, 

229560 01-11 
STATE-DEPENDENT (DISSOCIATIVE) EFFECTS OF METHADONE ON HUMAN 
RETENTION. (PH.D. DISSERTATION). 

242151 03-14 
DISSOLUTION 

CORRELATION BETWEEN DISSOLUTION CHARACTERISTICS AND 
ABSORPTION OF METHAQUALONE FROM SOLID DOSAGE FORMS. 

250332 04-06 
DISTIGMINBROMIDE 

THERAPY OF PSYCHOPHARMACEUTICAL SIDE-EFFECTS WITH 
DISTIGMINBROMIDE (UBRETID, BC-51). 

239782 03-15 



S-110 



OLUME 14, SUBJECT INDEX 



Subject Index 



STRACTION 

ARE CENTRAL CHOLINERGIC PATHWAYS INVOLVED IN THE HABITUATION 
OF EXPLORATION AND DISTRACTION?. 

241932 0304 
STRIBUTION 

REGIONAL DISTRIBUTION OF POSTSYNAPTIC RECEPTOR BINDING FOR 
GAMMA-AMINOBUTYRIC-ACID (GABA) IN MONKEY BRAIN. 

226407 01-03 
SYNTHESIS, RELEASE AND DISTRIBUTION OF ACETYLCHOLINE IN THE 
BRAIN OF RATS UNDER THE INFLUENCE OF CHOLINERGIC AGENTS. 

228550 01-03 
DISTRIBUTION OF CHLORPROMAZINE IN THE GASTROINTESTINAL TRACT 
OF THE RAT AND ITS EFFECT ON ABSORPTIVE FUNCTION. 

230918 01-03 
EFFECT OF ETHANOL ON DIAZEPAM DISTRIBUTION IN RAT. 

231007 01-03 
H3-P-CHL0R0AMPHETAMINE: CEREBRAL LEVELS AND DISTRIBUTION. 

232614 02-03 
THE DISTRIBUTION AND METABOLISM OF ETHANOL AND BARBITURATES 
IN THE ORGANISM DURING THEIR COMBINED USE (LITERATURE 
SURVEY). 

236717 02-03 
3H-DELTA9-TETRAHYDROCANNABINOL TISSUE AND SUBCELLULAR 
DISTRIBUTION IN THE CENTRAL-NERVOUS-SYSTEM AND TISSUE 
DISTRIBUTION IN PERIPHERAL ORGANS OF TOLERANT AND 
NONTOLERANT DOGS. 

237753 02-03 
METABOLISM, DISTRIBUTION AND ANTICONVULSANT PROPERTIES OF 
N,N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT. 

237738 02-03 
DISTRIBUTION OF TYPE A AND B MONOAMINE OXIDASE ACTIVITIES IN 
THE CENTRAL-NERVOUS-SYSTEM OF RAT AND CHICK 

237923 02-03 
PLACENTAL TRANSFER AND MATERNAL AND FETAL TISSUE 
DISTRIBUTION OF C14-METHAQUAL0NE IN MICE. 

238764 03-03 
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF H3- 
TRIMETHOXY-BETA-PHENYLETHYLAMINE IN THE MOUSE. 

239855 03-03 
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF H3-MESCALINE 
IN THE BRAIN OF THE MARMOSET, CALLITHRIX JACCHUS. 

239864 03-03 
5-HYDROXY-L-TRYPTOPHAN-DECARBOXYLASE ACTIVITY; MICROASSAY 
AND DISTRIBUTION IN DISCRETE RAT BRAIN NUCLEI. 

241208 03-03 
RELATIONSHIP BETWEEN THE SUBCELLULAR DISTRIBUTION OF DEI TA9- 
TETRAHYDROCANNABINOL AND ITS METABOLITES IN RAT BRAIN AND 
THE DURATION OF THE EFFECT ON MOTOR ACTIVITY, 

241242 03-03 
THE RELEVANCE TO DIFFERENTIAL DIAGNOSIS OF THE DISTRIBUTION OF 
EXTRAPYRAMIDAL SYMPTOMS RESULTING FROM NEUROLEPTIC 
THERAPY IN PSYCHIATRIC PRACTICE. 

244355 04-15 
DISTRIBUTION OF 3H-ALPHA-MSH IN RAT BRAIN 

248349 04-03 
RADIOPHARMACEUTICALS. 16. HALOGENATED DOPAMINE ANALOGS. 
SYNTHESIS AND RADIOLABELING OF 6-IODODOPAMINE AND TISSUE 
DISTRIBUTION STUDIES IN ANIMALS. 

248537 04-01 
ABSORPTION, DISTRIBUTION AND EXCRETION OF TRIFLUOPERAZINE IN 
RATS. 

249036 04-03 
DISTRIBUTION STUDIES OF (14C)DELTA9-TETRAHYDR0CANNABINOL IN 
MICE: EFFECT OF VEHICLE, ROUTE OF ADMINISTRATION, AND 
DURATION OF TREATMENT. 

249223 04-03 
EXTRAPINEAL AMINE N-ACETYLATION IN RAT BRAIN: REGIONAL AND 
SUBCELLULAR DISTRIBUTION AND ENZYME KINETICS. 

250377 0401 
IDENTIFICATION AND DISTRIBUTION OF BENZYLAMINE IN TISSUE 
EXTRACTS ISOLATED FROM RATS PRETREATED WITH PARGYLINE 

250379 04-03 
THE REGIONAL DISTRIBUTION OF A MORPHINE-LIKE FACTOR ENKEPHALIN 
IN MONKEY BRAIN. 

252219 04-03 
AUTORADIOGRAPHIC DISTRIBUTION STUDY OF 14C-D0PA IN CAT BRAIN. 

253393 04-03 
5TRIBUTIONS 

REM SLEEP DISTRIBUTIONS IN POSTAODICT RAT RELAPSING TO 
MORPHINE SELF-ADMINISTRATION: EFFECTS OF NALOXONE 
SUBCUTANEOUS PELLETS. 

251533 04-04 
STURBANCE 
MENTAL AND EMOTIONAL DISTURBANCE WITH PENTAZOCINE (TALWIN) 
USE. 

233828 02-15 
DELAYED SEVERE EXTRAPYRAMIDAL DISTURBANCE FOLLOWING 
FREQUENT DEPOT PHENOTHIAZINE ADMINISTRATION. 

245789 04-15 



DISTURBANCES 

TREATMENT WITH ACETAZOLAMIDE OF BRAINSTEM AND SPINAL 
PAROXYSMAL DISTURBANCES IN MULTIPLE SCLEROSIS. 

226351 01-13 
SLEEP AND ITS DISTURBANCES IN THE CHILD: CONTRIBUTIONS OF 
ELECTROPHYSIOLOGY 

228091 01-11 
RELATIONSHIPS BETWEEN ANESTHETIC SUBSTANCES, CONVULSIONS, 
AND PSYCHIC DISTURBANCES 

229118 01-15 
CLINICAL USE OF DRUGS FOR SLEEP DISTURBANCES. 

230119 01-17 
THE THERAPY OF AUTONOMIC REGULATORY DISTURBANCES THROUGH 
DRUGS. 

232260 01-15 
TWO CASES OF PSYCHIC DISTURBANCES 

232545 01-17 
ON THE DIFFERENTIAL DIAGNOSIS OF ACU1E EXTRAPYRAMIDAL MOTOR 
DISTURBANCES IN CHILDHOOD: CASUISTIC ACCOUNT. 

234291 02-11 
BETA-PHENYLETHYLAMINE (PEA) AND THE NEUROPSYCHIATRIC 
DISTURBANCES. (UNPUBLISHED PAPER). 

241474 03-14 
PROPHYLACTIC EFFECTIVENESS OF LITHIUM IN PATIENTS WITH 
AFFECTIVE DISTURBANCES. 

243985 04-09 
ANTIDEPRESSANT TREATMENT WITH AMPROTILINE IN THE 

MANAGEMENT OF EMOTIONAL DISTURBANCES IN PATIENTS WITH 
ACUTE MYOCARDIAL INFARCTION: A CONTROLLED STUDY. 

253684 04-11 
DISTURBED 

SUCCESS WITH LITHIUM IN A DISTURBED CHILD. 

236118 02-11 
DISTURBING 

STIMULANT DRUGS FOR HYPERACTIVITY: SOME ADDITIONAL 
DISTURBING QUESTIONS. 

240599 03-17 
DISULFIDE 

EFFECTS OF CARBON DISULFIDE ON OPERANT BEHAVIOR IN PIGEONS. 
(PH.D. DISSERTATION). 

238081 02-04 
THE EFFECT OF CARBON DISULFIDE ON THE STEREOTYPIC EFFECT OF 
DOPAMINE AGONISTS. 

250090 04-04 
DISULFIRAM 

TREATMENT WITH DISULFIRAM IN HUNTINGTONS-CHOREA: A NEGATIVE 
CLINICAL AND PHARMACOLOGICAL STUDY. 

226430 01-07 
EVALUATION OF DISULFIRAM TREATMENT OF CHRONIC ALCOHOLISM. 

237026 02-1 1 
TREATMENT OF ALCOHOLIC METHADONE /MAINTENANCE PATIENTS WITH 
DISULFIRAM. 

237624 02-11 
THE MEDICAL SAFETY OF THE COMBINED USAGE OF DISULFIRAM AND 
METHADONE: PHARMACOIOGICAL TREATMENT FOR ALCOHOLIC 
HEROIN ADDICTS. 

239943 03-15 
DITA 

FOOD AND DRUG-REINFORCED RESPONDING: EFFECTS OF DITA AND D- 
AMPHETAMINE. 

227127 01-04 
ROLE OF DA IN THE STIMULANT EFFECT OF DITA IN MICE,- COMPARISON 
WITH DAMPHETAMINE, 

248284 04-03 
DITRAN 

DRUG DISCRIMINATION IN RATS: EFFECTS OF MIXTURES OF DITRAN AND 
CHOLINESTERASE INHIBITORS. 

242737 03-04 
DRUG DISCRIMINATION IN RATS: THE EFFECTS OF PHENCYCLIDINE AND 
DITRAN 

245297 04-04 
DIURETIC 

A COMPARISON BETWEEN LITHIUM, PLACEBO AND A DIURETIC IN 
PREMENSTRUAL TENSION. 

22641401-11 
DIURNAL 

INFLUENCE OF DIURNAL CYCLES ON BIOCHEMICAL PARAMETERS OF 
DRUG SENSITIVITY: THE PINEAL GLAND AS A MODEL. 

241471 03-17 
DIURNAL VARIATION IN THE REQUIREMENT FOR RNA SYNTHESIS IN THE 
INDUCTION OF PINEAL N-ACETYLTRANSFERASE. 

243795 04-03 
DIURNAL ACTION OF KETAMINE IN THE YOUNG CHICK: INFLUENCE BY 
PINEAL METABOLITES. 

249240 04-03 
DIV-154 

CHEMISTRY AND PHARMACOLOGY OF DIV-154, A NEW POTENTIAL 
NONTRICYCLIC ANTIDEPRESSANT COMPOUND. 

251407 04-17 









36: 



s-ni 



Subject Index 



Psychopharmacology Abstracts 



DIVIDED 

DIVIDED ATTENTION PERFORMANCE OF CANNABIS USERS AND 
NONUSERS FOLLOWING CANNABIS AND ALCOHOL. 

246305 04-13 
Dl-AIPHA-METHYL-P-TYROSINE 

POSTNATAL ELEVATION OF BRAIN TYROSINE-HYDROXYLASE ACTIVITY, 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 
CATECHOLAMINE LEVELS, RESULTING FROM DL-ALPHA-METHYL-P- 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 04-03 
DL-AMPHET AMINE 

CORRELATIONS BETWEEN THE EFFECTS OF DL-AMPHETAMINE AND 
RESERPINE ON THE MODEL OF THE CAUDATE REACTION OF 
RETARDATION. 

236235 02-03 
DL-AMPHETAMINES 

INHIBITION OF SYNAPTOSOAAAL ACCUMULATION OF L-NOREPINEPHRINE 
I: N-ARYLALKYL AND N-ARYLOXYALKYL DL-AMPHETAMINES AND 
RELATED COMPOUNDS. 

246316 04-03 
Dl-254 

THE EFFECT OF DL 254 ON THE PHARMACOLOGICAL ACTIVITIES OF D- 
AMPHETAMINE AND APOMORPHINE: A COMPARISON WITH 
ANTIANXIETY AND NEUROLEPTIC AGENTS. 

238846 03-03 
DMT 

THE TRANSCALLOSALLY EVOKED POTENTIAL (TEP) FOLLOWING 
ADMINISTRATION OF LSD, MESCALINE, DMT, APOMORPHINE AND 
METHOXAMINE IN THE DOG. 

238703 03-03 
ONA 

IN VIVO REVERSAL OF THYROXINE INDUCTION OF DNA SYNTHESIS BY 
DIBUTYRYL-CYCLIC-AMP IN DEVELOPING RAT CEREBELLUM. 

243814 04-03 
DOCTOR 

MEASUREMENT OF ANXIETY IN OUTPATIENT TRIALS: DETECTION OF BIAS 
IN PATIENT AND DOCTOR RATINGS. 

253043 04-16 
DOET 

THE EFFECTS OF 2,5 DIMETKOXY-4-METHYLAMPHETAMINE (DOM) 2 5 
DIMETHOXY-4-ETHYLAMPHETAMINE (DOET), D-AMPHETAMINE, AND 
COCAINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE 
STIMULUS. 

230837 01-04 
DOG 

HALOPERIDOL AND PROPRANOLOL IN THE TREATMENT OF ACUTE 
AMPHETAMINE INTOXICATION IN THE DOG. 

227389 01-03 
APPEARANCE OF WET DOG SHAKE BEHAVIOR DURING COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT AND ITS SUPPRESSION BY 
RESERPINE. 

230836 01-04 
SELF-ADMINISTRATION OF CNS STIMULANTS BY DOG. 

230879 01-04 
THE INFLUENCE OF IMIPRAMINE ON DOPAMINE-INDUCED GANGLIONIC 
INHIBITION AND NEUROGENIC VASODILATION IN THE DOG. 

237160 02-03 
METABOLISM OF DELTAl-TETRAHYDROCANNABINOL BY THE ISOLATED 
PERFUSED DOG LUNG. COMPARISON WITH IN VITRO LIVER 
METABOLISM. 

238316 02-03 
BIOTRANSFORMATION OF AMITRIPTYLINE IN THE DOG. 

238684 03-03 
THE TRANSCALLOSALLY EVOKED POTENTIAL (TEP) FOLLOWING 
ADMINISTRATION OF LSD, MESCALINE, DMT, APOMORPHINE AND 
METHOXAMINE IN THE DOG. 

238703 03-03 
CENTRAL ACTION OF AMPHETAMINE-INDUCED MYDRIASIS IN THE DOG. 

238772 03-03 
THE EFFECT OF CHRONIC MARIHUANA SMOKING ON THE BEAGLE DOG. 

238806 03-03 
DOSE-RESPONSE STUDIES ON EFFECTS OF AMPHETAMINE ON ACTIVITY 
AND OXYGEN CONSUMPTION IN DOG AND CAT MODELS OF 
HYPERKINESIS (HYPOINHIBITORY SYNDROME) 

238825 03-03 
EFFECTS OF CHLORPROMAZINE ON FEAR MOTIVATED BEHAVIOR, 
URINARY CORTISOL, URINARY VOLUME, AND HEARTRATE IN THE 
DOG. 

240916 03-04 
WET DOG SHAKE BEHAVIOR IN NORMAL RATS, ELICITED BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID DERIVATIVES. 

241231 03-04 
A METHOD FOR BIOASSAY OF PHYSICAL DEPENDENCE ON SEDATIVE 
DRUGS IN DOG. 

244674 04-06 
DOGMATIl 

DOGMATIL OR SULPIRIDE: AN ATTEMPT AT SPECIFICATION. 

237015 02-17 



TREATMENT OF UNSELECTED INDONESIAN PSYCHOTIC PATIENTS WITH 
DOGMATIL (DELAGRANGE). 

239269 03- n 
DOG/WATIL AND BEHAVIORAL PROBLEMS IN MIGRANT WORKERS. 

249693 04-11 
DOGS 

THE DEPENDENCE OF THE /WAGNITUDE OF CONDITIONED SALIVATION IN 
DOGS ON DOSES OF CAFFEINE. 

236249 02 03 
3H-DELTA9-TETRAHYDR0CANNABIN0L TISSUE AND SUBCELLULAR 
DISTRIBUTION IN THE CENTRAL-NERVOUS-SYSTEM AND TISSUE 
DISTRIBUTION IN PERIPHERAL ORGANS OF TOLERANT AND 
NONTOLERANT DOGS. 

237753 02-03 
CHRONIC CARDIOVASCULAR EFFECTS OF DELTA9- 

TETRAHYDROCANNABINOL (DELTA9-THC) IN THE MONGREL DOGS. 

238810 03-03 
TOLERANCE IN METHYLPHENIDATE-INDUCED LOCOMOTION IN PRAIRIE 
DOGS (CYNOMYS-LUDOVICIANUS). 

239863 03-04 
ANALYSIS OF CARDIAC CHRONOTROPIC RESPONSES TO DIAZEPAM AND 
BROMAZEPAM IN CONSCIOUS TRAINED DOGS. 

240064 03-03 
THE MODIFICATION OF INOTROPIC ACTION OF OUABAIN BY 6- 
HYDROXYDOPAMINE AND ALPHA-METHYL-P-TYROSINE IN DOGS. 

242200 03-03 
DEPOT FLUPHENAZINE-ENANTHATE AND FLUPHENAZINE-DECANOATE: 
COMPARATIVE RATES OF RELEASE IN DOGS. 

247130 04-03 
DOMESTIC 

EFFECTS OF TESTOSTERONE ON THE BEHAVIOUR OF THE DOMESTIC 
CHICK. I. EFFECTS PRESENT IN MALES BUT NOT IN FEMALES. 

245712 04-04 
EFFECTS OF TESTOSTERONE ON THE BEHAVIOUR OF THE DOMESTIC 

CHICK. II. EFFECTS PRESENT IN BOTH SEXES. 

245713 04-04 
DOMINAL 

TREATMENT OF ENDOGENOUS PSYCHOSES WITH DOMINAL AND 
DOMINAL FORTE IN COMBINATION WITH HIGHLY ACTIVE 
NEUROLEPTICS. 

235305 02-11 
DOMINANCE 

MEDICAL DOMINANCE: PSYCHOACTIVE DRUGS AND MENTAL-HEALTH 
POLICY. 

239298 03-17 
DOMINANT 

THE EFFECTS OF AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE 

BUTYROPHENONE SERIES, ON DOMINANT SUBORDINATE BEHAVIOUR 
IN WISTAR RATS COMPETING FOR FOOD. 

225571 01-04 
DOPA 

NEW PATHWAY FOR METABOLISM OF DOPA. 

246286 04-03 
REVERSAL BY A CENTRAL ANTIACETYLCHOLINE DRUG OF PIMOZIDE- 
INDUCED INHIBITION OF MOUSE JUMPING IN AMPHETAMINE DOPA 
TREATED MICE. 

250656 04-03 
ALTERED PATTERN OF DOPA METABOLISM, 

251185 04-03 
DOPA-OECARBOXYLASE 

TREATMENT OF SYDENHAMS CHOREA WITH A COMBINATION OF L-DOPA 
AND A PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR. 

237733 02-11 
COMPARISON OF DOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 
COMBINED WITH LEVODOPA AND LEVODOPA ALONE IN PARKINSONS 
DISEASE. 

248612 04-11 
COMPARISON OF DOPA-DECARBOXYLASE INHIBITOR (CARBIDOPA) 

COMBINED WITH LEVODOPA AND LEVODOPA ALONE ON THE 
CARDIOVASCULAR SYSTEM OF PATIENTS WITH PARKINSONS DISEASE. 

248613 04-11 
DOPA-INDUCED 

EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

237107 02-04 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

248960 04-02 
DOPAMINE 

THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE- 
HYDROXYLASE AND THE ROLE OF POSTSYNAPTIC DOPAMINE 
RECEPTORS. 

226185 01-04 
LSD AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN VARIOUS RAT 
BRAIN AREAS. 

226406 01-03 



5-112 



UME 14, SUBJECT INDEX 



Subject Index 



)OPAMINE RECEPTOR BLOCKADE AND THE NEUROLEPTICS, A 
CRYSTALLOGRAPHIC STUDY, 

226761 01-03 
XUTE AND SUBACUTE EFFECTS OF NEUROLEPTICS ON DOPAMINE 
SYNTHESIS AND RELEASE IN THE RAT STRIATUM. 

226858 01-03 
HE EFFECTS OF PROTRIPTYLINE AND CLOMIPRAMINE IN VITRO ON THE 
UPTAKE OF 5-HYDROXYTRYPTAMINE AND DOPAMINE IN HUMAN 
PLATELET-RICH PLASMA. 

227139 01-03 
AIL PINCH INDUCES EATING IN SATED RATS WHICH APPEARS TO 
DEPEND ON NIGROSTRIATAL DOPAMINE. 

227343 01-03 
:OMPARISON OF CENTRAL EFFECTS OF NORADRENALINE AND DOPAMINE 
INJECTED INTO THE LATERAL BRAIN VENTRICLE IN RATS. 

227636 01-04 
k DOPAMINE RECEPTOR STIMULATOR IN DEPRESSION. (UNPUBLISHED 
PAPER). 

227785 01-09 
lAPID AND DISSOCIATED CHANGES IN SENSITIVITIES OF DIFFERENT 
DOPAMINE RECEPTORS IN MOUSE BRAIN. 

227996 01-03 
SD AND DOPAMINE RECEPTORS. 

228050 01-03 
SD AND DOPAMINE RECEPTORS - PIERI REPLY. 

228051 01-03 
HE EFFECTS OF ACETYLCHOLINE AND DOPAMINE ON THE CAUDATE- 
NUCLEUS DEPLETED OF BIOGENIC AMINES. 

230457 01-03 

:hemistry of dopamine receptors. 

230600 01-03 
)0PAMINE SENSITIVE ADENYLATE-CYCLASE IN MAMMALIAN BRAIN: A 
POSSIBLE SITE OF ACTION OF ANTIPSYCHOTIC DRUGS. 

230602 01-13 
)XOTREMORINE AND ATROPINE-INDUCED CHANGES OF DOPAMINE 
METABOLISM IN THE RAT STRIATUM. 

230854 01-03 
;ABA AND THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA. 

231019 01-17 
\ DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN ANTERIOR LIMBIC 
CORTEX AND MESOLIMBIC REGION OF PRIMATE BRAIN. 

231304 01-03 
FUNCTIONAL SIGNIFICANCE OF CENTRAL-NERVOUS-SYSTEM 
NOREPINEPHRINE AND DOPAMINE: A PSYCHOPHARAAACOLOGICAL 
STUDY. (PH.D. DISSERTATION). 

231437 01-04 
:FFECTS of INTRAVENTRICULAR 6-HYDROXYDOPAMINE AND 
REPLACEMENT THERAPY WITH NOREPINEPHRINE, DOPAMINE, AND 
SEROTONIN ON SELF-STIMULATION IN DIENCEPHALIC AND 
MESENCEPHALIC REGIONS IN THE RAT. 

232332 01-04 
)OPAMINE AND PSYCHOTIC STATES: PRELIMINARY REMARKS. 

233961 02-13 
:ENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM 
PRECURSORS, ENZYME INHIBITORS, AND STUDIES OF CENTRAL 
DOPAMINE TURNOVER. 

233964 02-14 
)OPAMINE, PSYCHOMOTOR STIMULANTS, AND SCHIZOPHRENIA: 
EFFECTS OF METHYLPHENIDATE AND THE STEREOISOMERS OF 
AMPHETAMINE IN SCHIZOPHRENICS. 

233967 02-08 
rHE EFFECT OF CATECHOL-0-METHYLTRANSFERASE INHIBITORS ON 
BEHAVIOR AND DOPAMINE METABOLISM. 

233969 02-03 
RELATIONSHIP OF DOPAMINE NEURAL SYSTEMS TO THE BEHAVIORAL 

ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION 
INTO BRAIN. 

233970 0203 
)ISRUPTION OF BRAIN STIMULATION-INDUCED FEEDING BY DOPAMINE 

RECEPTOR BLOCKADE. 

235587 02-04 
)OPAMINE AND SCHIZOPHRENIA. 

235802 02-08 
>ARTICIPATION OF ADRENO, DOPAMINE, AND SEROTONERGIC 
MECHANISMS OF THE SEPTUM IN CONDITIONED REFLEX REACTIONS 
TO VARIOUS BIOLOGICAL MODALITIES IN RATS. 

236828 02-04 
ONOPHORES X573A AND A23187: EFFECTS ON THE PERMEABILITY OF 
LIPID BIMOLECULAR MEMBRANES TO DOPAMINE AND CALCIUM. 
(UNPUBLISHED PAPER). 

236873 02-03 
EXCITATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 
RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL, 
FUNCTIONAL AND CLINICAL DATA. 

237104 02-03 



EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

237107 02-04 
EFFECT OF NOMIFENSINE ON MOTOR ACTIVITY, DOPAMINE TURNOVER 
RATE AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE 
CONCENTRATIONS OF RAT STRIATUM. 

237156 02-04 
RESPONSE OF NIGRAL DOPAMINE NEURONS TO ACUTE AND PROLONGED 
MORPHINE TREATMENT: EFFECT OF EXPOSURE TO COLD, 
PHYSOSTIGMINE AND NICOTINE. 

237158 02-03 
ACTIONS OF PHENOTHIAZINE ANALOGS ON DOPAMINE SENSITIVE 

ADENYLATE-CYCLASE IN NEURONAL AND GLIAL ENRICHED FRACTIONS 
FROM RAT BRAIN. 

237241 02-03 
MORPHINE-INDUCED INHIBITION OF DIFFERENT PAIN RESPONSES IN 
RELATION TO THE REGIONAL TURNOVER OF RAT BRAIN 
NORADRENALINE AND DOPAMINE. 

237697 02-04 
CLINICAL STUDIES WITH DOPAMINE RECEPTOR STIMULANTS. 

237725 02-08 
BRAIN DOPAMINE AND JUMPING BEHAVIOUR IN MICE. 

237746 02-03 
SELECTIVE BLOCKING ACTION OF LSD ON INHIBITORY DOPAMINE 
RECEPTORS. 

237782 02-03 
UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF NIGROSTRIATAL OR 
MESOLIMBIC DOPAMINE CONTAINING TERMINALS AND THE DRUG- 
INDUCED ROTATION OF RATS. 

237866 02-03 
STUDIES ON THE MECHANISM OF DEPLETION OF STRIATAL DOPAMINE 
BY ALPHA-METHYL-M-TYROSINE. 

237873 02-03 
EFFECTS OF METHAMPHETAMINE AND CHLORPROMAZINE ON NIGRAL 
AND STRIATAL TYROSINE-HYDROXYLASE ACTIVITY AND ON STRIATAL 
DOPAMINE LEVELS. (PH.D. DISSERTATION). 

238079 02-03 
3,4 DIHYDROXYPHENYLAMINO 2 IMIDAZOLINE (DPI), A NEW POTENT 
AGONIST AT DOPAMINE RECEPTORS MEDIATING NEURONAL 
INHIBITION. 

238321 02-03 
SCHIZOPHRENIA: RELATIONSHIPS TO DOPAMINE TRANSMISSION, MOTOR 
CONTROL, AND FEATURE EXTRACTION. 

238464 02-08 
CYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN 
THE CAUDATE-NUCLEUS. (UNPUBLISHED PAPER). 

238471 02-03 
PITUITARY HORMONE LEVELS IN SCHIZOPHRENIA BEFORE AND AFTER 
DOPAMINE BLOCKADE. (UNPUBLISHED PAPER) 

238491 02-13 
CHANGES IN THE SELF-STIMULATION BEHAVIOR BY INTRAVENTRICULAR 
INJECTION OF EPINEPHRINE, NOREPINEPHRINE, ISOPROTERENOL AND 
DOPAMINE. 

238566 02-04 
DOPAMINE AGONIST INDUCED ASYMMETRY AFTER LESIONS OF 
SUPERIOR COLLICULUS IN RATS. 

238699 03-03 
EFFECTS OF DOPAMINE (DA) DERIVATIVES ON CENTRAL DOPAMINERGIC 

MECHANISMS. 

238700 03-03 
ENDOGENOUS DOPAMINE RELEASE DEPENDENT AND INDEPENDENT 

ACTIVATION OF DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL 
SYNAPTOSOMES. 

238729 03-03 
AMFONELIC-ACID FACILITATION OF IMPULSE-INDUCED STRIATAL 

DOPAMINE RELEASE. 

238730 03-03 
EVIDENCE FOR A DOPAMINE RECEPTOR ANTIBODY. 

238736 03 03 
THE ROLE OF DOPAMINE (DA) AND SEROTONIN (5-HT) IN THE 

PROLONGATION OF POST-DECAPITATION CONVULSIONS (PDC) IN MICE. 

238737 03-03 
EFFECTS OF MORPHINE ON DOPAMINE STIMULATED ADENYLATE- 
CYCLASE AND ON CYCLIC-GMP FORMATION IN MONKEY BRAIN 
AMYGDALA. 

238739 03 03 
THE DYNAMICS OF DOPAMINE METABOLISM IN VARIOUS REGIONS OF 
RAT BRAIN. 

238761 03-03 
DOPAMINE AND PSYCHOACTIVE DRUG ACTION: A FURTHER 
EVALUATION. 

238768 03-04 
NONSPECIFIC SUPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS 
AFTER 6-HYDROXYDOPAMINE LESION OF THE NIGROSTRIATAL 
PATHWAY. 

240063 03 03 



00 
pa 

* 



I 

I 



S-113 



Subject Index 



THE AMPHETAMINE-INDUCED INHIBITION OF DOPAMINE BIOSYNTHESIS 
IN RAT STRIATUM. 

240065 03-03 

THE BRAINS DOPAMINE RECEPTOR: LABELING WITH 3H-D0PAMINE AND 
3H-HAL0PERID0L . 

240077 03-03 

CYCLIC ADENOSINE MONOPHOSPHATE IN CEREBROSPINAL FLUID: 
EFFECTS OF THEOPHYLLINE, L-DOPA AND A DOPAMINE RECEPTOR 
STIMULANT IN RATS 

240447 03-03 

NEUROCHEMICAL CORRELATES OF BEHAVIOUR - CONTENT OF 
TRYPTOPHAN, 5-HYDROXYTRYPTOPHAN, SEROTONIN, 5- 
HYDROXYINDOLEACETICACID, TYROSINE, DOPAMINE AND 
NOREPINEPHRINE IN FOUR BRAIN PARTS OF THE PIGEON DURING 
BEH.AVIOURAL DEPRESSION FOLLOWING AN INJECTION. 

241205 03-04 
A STUDY OF THE METABOLISM AND RELEASE OF DOPAMINE AND 

AMINO-ACIDS FROM NERVE ENDINGS ISOLATED FROM SHEEP CORPUS- 
STRIATUM, 

241206 03-03 
EFFECTS OF ELECTRICAL STIMULATION OF THE NIGROSTRIATAL 

PATHWAY OF THE RAT ON DOPAMINE METABOLISM. 

241207 03-03 
DETERMINATIONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESIS IN 
A SINGLE MOUSE BRAIN: BIPHASIC EFFECTS OF ( -h ) AMPHETAMINE. 

241257 03-03 
DOPAMINERGIC NEURONS - ALTERATION IN THE SENSITIVITY OF 

TYROSINE-HYDROXYLASE TO INHIBITION BY ENDOGENOUS DOPAMINE 
AFTER CESSATION OF IMPULSE FLOW. 

241295 03-03 
EFFECTS OF SOME DOPAMINE ANALOGS AND HALOPERIDOL ON 
RESPONSE TO STIMULATION OF ADRENERGIC NERVES USING CAT 
ATRIA IN VITRO. 

241313 03-03 
EFFECTS OF THE D-ISOMERS AND L ISOMERS OF AMPHETAMINE ON 
UPTAKE, RELEASE AND CATABOLISM OF NOREPINEPHRINE, DOPAMINE 
AND 5-HYDROXYTRYPTAMINE IN SEVERAL REGIONS OF RAT BRAIN. 

241345 03-03 
COMPARISON OF THE INHIBITORY EFFECTS OF NEUROLEPTIC DRUGS ON 
ADENYLATE CYCLASE IN RAT TISSUES STIMULATED BY DOPAMINE 
NORADRENALINE AND Gi UCAGON. 

241347 03-03 
ALTERATIONS IN DOPAMINE UPTAKE IN RAT CORPUS-STRIATUM 
INDUCED BY COMBINATIONS OF STRESS AND DELTA8- 
TETRAHYDR0CANNA8IN0L (DELTA8-THC). 

241926 03-03 
CF-25-397, DIDEHYORO METHYL 8BETAPYRIDYLTHI0METHYLERG0LINE A 

NEW CENTRAL DOPAMINE RECEPTOR AGONIST. 

241927 03-04 
IS METOCLOPRAMIDE A DIRECTLY ACTING DOPAMINE RECEPTOR 

ANTAGONIST?. 

241929 03-03 
EFFECTS OF DOPAMINE RECEPTOR BLOCKADE ON SELF-STIMULATION IN 
THE MONKEY. 

242748 04-04 
REINSTATEMENT OF EATING BY DOPAMINE AGONISTS IN APHAGIC 
DOPAMINE DENERVATED RATS. 

243348 04-04 
A PRELIMINARY REPORT: NEUROENDOCRINE EFFECTS OF DOPAMINE AND 
NOREPINEPHRINE RECEPTOR STIMULATORS. 

243440 04-03 
DOPAMINE RECEPTOR BINDING PREDICTS CLINICAL AND 

PHARMACOLOGICAL POTENCIES OF ANTISCHIZOPHRENIC DRUGS. 

243483 04-03 
NEONATAL HYPERTHYROIDISM: ALTERATIONS IN BEHAVIOURAL 
ACTIVITY AND THE METABOLISM OF BRAIN NOREPINEPHRINE AND 
DOPAMINE. 

243792 04-03 
RESPONSES OF NEURONES IN THE CEREBRAL CORTEX AND CAUDATE- 
NUCLEUS TO AMANTADINE, AMPHETAMINE AND DOPAMINE. 

243805 04-03 
THE EFFECT OF AMPHETAMINE STEREOISOMERS ON THE FUNCTION OF 
DOPAMINE SYNAPSES IN VITRO 

244043 04-03 
EFFECT OF METHADONE AND DEXTROMORAMIDE ON DOPAMINE 
METABOLISM: COMPARISON WITH HALOPERIDOL AND 
AMPHETAMINE. 

244513 04-03 
ACTION OF OPIATES, ANTIPSYCHOTICS, AMPHETAMINE AND 

APOMORPHINE ON DOPAMINE RECEPTORS IN RAT STRIATUM: IN VIVO 
CHANGES OF 3,5 CYCLIC-AMP CONTENT AND ACETYLCHOLINE 
TURNOVER RATE 

244514 04-03 
ISOLATION AND RADIOENZYMIC ESTIMATION OF PICOGRAM QUANTITIES 

OF DOPAMINE AND NOREPINEPHRINE IN BIOLOGICAL SAMPLES. 

244636 04-06 



Psychopharmacology Abstrad 

DEMONSTRATION OF AN INVERSELY PROPORTIONAL RELATIONSHIP 
BETWEEN DOPAMINE AND SEROTONIN IN CERTAIN CEREBRAL 
STRUCTURES: NEUROCHEMICAL AND MORPHOLOGICAL ASPECTS. 

244638 04-1 
ASSESSMENT OF CEREBROSPINAL FLUID LEVELS OF DOPAMINE 
METABOLITES BY GAS CHROAAATOGRAPHY. 

245300 04j 
BENZTROPINE-INDUCED RELEASE OF DOPAMINE FROM BRAIN IN VIVO. 

245598 04^ 
TETRAHYDROCANNABINOL ATTENUATED ABSTINENCE AND INDUCED 
ROTATION IN MORPHINE-DEPENDENT RATS: POSSIBLE INVOLVEMENT 
OF DOPAMINE. 

245601 04j 
ESTERS OF APOMORPHINE AND N,N DIMETHYLDOPAMINE AS AGONIST: 
OF DOPAMINE RECEPTORS IN THE RAT BRAIN IN VIVO. 

2461 .SO 04-^ 
CLOZAPINE AND THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA, A 
CRITICAL APPRAISAL. 

246671 04^ 
INVOLVEMENT OF CENTRAL DOPAMINE IN THE HYPERTHERMIA IN RAT: 
PRODUCED BY D-AMPHETAMINE. 

246820 04-1 
EFFECT OF MORPHINE ON A DEPOLARISING DOPAMINE RESPONSE. 

246998 04J 
ANTIDEPRESSANT DRUGS AFFECT DOPAMINE UPTAKE. 

247021 04j 
THE SEARCH FOR THE DOPAMINE RECEPTOR: TRIBULATIONS. 

247215 04J 
NEURAL AND NEUROENDOCRINE FUNCTIONS OF DOPAMINE. 

247690 04- 
THE DOPAMINE RECEPTOR: DIFFERENTIAL BINDING OF D-LSD AND 
RELATED AGENTS TO AGONIST AND ANTAGONIST STATES. 

247862 04-1 
EFFECTS OF CHEMICAL STIMULATION OF THE MESOLIMBIC DOPAMINE 
SYSTEM UPON LOCOMOTOR ACTIVITY. 

248285 04^ 
THE EFFECT OF MEPIPRAZOLE ON CENTRAL MONOAMINE NEURONS. 
EVIDENCE FOR INCREASED 5-HYDROXYTRYPTAMINE AND DOPAMINE 
RECEPTOR ACTIVITY. 

248288 04-1 
ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE APPLIE[ 
INTRACEREBRALLY TO THE NUCLEUS-ACCUMBENS SEPTI BY TYPICAL 
NEUROLEPTICS AND BY CLOZAPINE, SULPIRIDE AND THIORIDAZINE. 

248290 04-( 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEEN CLINICAL 
POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS. 

248466 QA4 
POTENTIATION OF ETHANOL NARCOSIS BY DOPAMINE AND L-DOPA 
BASED ISOQUINOLINES. 

248513 04-( 
RADIOPHARAAACEUTICALS. 16. HALOGENATED DOPAMINE ANALOGS. 
SYNTHESIS AND RADIOLABELING OF 6-IODODOPAMINE AND TISSUE 
DISTRIBUTION STUDIES IN ANIMALS. 

248537 04-( 
EFFECT OF THIORIDAZINE, CLOZAPINE AND OTHER ANTIPSYCHOTICS OK 
THE KINETIC STATE OF TYROSINE-HYDROXYLASE AND ON THE 
TURNOVER RATE OF DOPAMINE IN STRIATUM AND NUCLEUS- 
ACCUMBENS. 

248698 04-C 
EFFECTS OF THYMOLEPTICS ON BEHAVIOUR ASSOCIATED WITH 

CHANGES IN BRAIN DOPAMINE: I. POTENTIATION OF DOPA-INDUCED 
GNAWING OF MICE. 

248960 04-C 
DEPRESSION OF DOPAMINE RELEASE DURING THE ETHANOL 
WITHDRAWAL SYNDROME. 

249293 04-C 
STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE 
RECEPTORS IN COMPARISON TO APOMORPHINE, ( -I- ) AMPHETAMINE 
AND L-DOPA. 

249419 O4-0 
EFFECT OF METOCLOPRAMIDE ON TURNOVER OF BRAIN DOPAMINE 
NORADRENALINE AND 5-HYDROXYTRYPTAMINE. 

249628 04-0 
A FUNCTIONAL EFFECT OF DOPAMINE IN THE NUCLEUS-ACCUMBENS AN 
IN SOME OTHER DOPAMINE RICH PARTS OF THE RAT BRAIN. 

249669 04-0 
THE EFFECT OF LONG-TERM PENFLURIDOL TREATMENT ON THE 

SENSITIVITY OF THE DOPAMINE RECEPTORS IN THE NUCLEUS- 
ACCUMBENS AND IN THE CORPUS-STRIATUM. 

249670 04-0 
LSD AS AN AGONIST AT MESOLIMBIC DOPAMINE RECEPTORS. 

249680 04-0 
SPECIFICITY OF DOPAMINERGIC NEURONAL DEGENERATION INDUCED BY 
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE IN THE 
NIGROSTRIATAL DOPAMINE SYSTEM. 

249899 04-0: 
DOPAMINE RELEASE IN SUBSTANTIA-NIGRA?. 

249984 04-0: 



S-114 



UME 14, SUBJECT INDEX 



Subject Index 



^ COMPARISON BETWEEN A MELANOCYTE STIMULATING HORMONE 
INHIBITORY FACTOR (MIF-I) AND SUBSTANCES KNOWN TO ACTIVATE 
CENTRAL DOPAMINE RECEPTORS. 

250082 04-03 
AUTOMATIC REGISTRATION OF BEHAVIOUR RELATED TO DOPAMINE AND 
NORADRENALINE TRANSMISSION. 

250086 04-04 
'HE EFFECT OF CARBON DISULFIDE ON THE STEREOTYPIC EFFECT OF 
DOPAMINE AGONISTS. 

250090 04-04 
.OCALIZATION OF DOPAMINE RECEPTORS IN THE RAT CEREBRAL 
CORTEX. 

250356 04-03 
IMITING FACTORS IN THE ANTAGONISM OF NEUROLEPTICS ON 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE. 

250359 04-03 
riME-DEPENDENT EFFECTS OF PHENOTHIAZINES ON DOPAMINE 
TURNOVER IN PSYCHIATRIC PATIENTS. 

250389 04-13 
;FFECT of ETHANOL on dopamine synthesis and RELEASE FROM RAT 
CORPUS-STRIATUM. 

251178 04-03 
'REFERENTIAL DEAMINATION OF DOPAMINE BY AN A TYPE 
MONOAMINE-OXIDASE IN RAT BRAIN. 

251225 04-03 
WESOLIMBIC AREA AND C. STRIATUM: RELATIVE INCREASES IN 
DOPAMINE TURNOVER BY NEUROLEPTIC AND RELATED COMPOUNDS 
DEVOID OF ANTIPSYCHOTIC ACTIVITY. 

251395 04-03 
\LTERATION OF DOPAMINE METABOLISM IN RAT BRAIN BY BACLOFEN 
(LIORESAL (R)). 

251398 04-03 
EFFECT OF DOPAMINE AGONISTS AND ANTAGONISTS ON ASYMMETRIC 
BEHAVIOUR OCCURRING DURING PRECIPITATED MORPHINE 
WITHDRAWAL AFTER UNILATERAL INACTIVATION OF THE STRIATUM 
IN RATS. 

251402 04-04 
ON THE ACTIONS OF COMPOUNDS RELATED TO DOPAMINE AT A 
NEUROSECRETORY SYNAPSE. 

251703 04-03 
THE TOXICITY OF DIRECT ACTING DOPAMINE AGONISTS: IMPLICATIONS 
FOR THE THERAPY OF PARKINSONISM. 

251959 04-05 
INFLUENCE OF METHAMPHETAMINE ON NIGRAL AND STRIATAL 
TYROSINE-HYDROXYLASE ACTIVITY AND ON STRIATAL DOPAMINE 
LEVELS. 

252027 04-03 
EFFECTS OF TETRAHYDROPAPAVEROLINE ON DOPAMINE AND 5- 
HYDROXYTRYPTAMINE METABOLISM IN RAT BRAIN IN VIVO. 

252220 04-03 
EFFECT OF NARCOTIC DEPENDENCE AND WITHDRAWAL ON STRIATAL 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND SYNAPTOSOMAL 
CYCLIC-AMP METABOLISM. 

253135 04-03 
THE ROLE OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE 
IN THE HYPERACTIVITY RESPONSE RESULTING FROM THE 
ADMINISTRATION OF TRANYLCYPROMINE TO RATS PRETREATED WITH 
LITHIUM OR RUBIDIUM 

253593 04-04 
^MINE-BETA-HYDROXYLASE 

DOPAMINE-BETA-HYDROXYLASE IN NERVE FUNCTION AND MENTAL- 
ILLNESS. 

225869 01-17 
EFFECTS OF A DOPAMINE-BETA-HYDROXYLASE INHIBITOR ON 
AMPHETAMINE-INDUCED HYPERACTI\'ITY IN RATS. 

226766 01-03 
EFFECTS OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND 
DOPAMINE-BETA-HYDROXYLASE ON RAT SELF-STIMULATION AFTER 
RESERPINE TREATMENT. 

237103 02-04 
RELEASE OF NOREPINEPHRINE (NE) AND DOPAMINE-BETA-HYDROXYLASE 
(DBH): EFFECT OF PHENOXYBENZAMINE (PBZ) ALONE AND IN 
COMBINATION WITH 8-BROMO-CGMP AND DIBUTYRYL-CAMP. 

238690 03-03 
INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY SOME ANALOGS OF 

METHIMA20LE. 

238691 03-03 
RATE OF BIOSYNTHESIS OF DOPAMINE-BETA-HYDROXYLASE IN LOCUS- 

COERULEUS OF RAT BRAIN AFTER RESERPINE. 

238759 03-03 
REDUCED PLASMA NOREPINEPHRINE AND DOPAMINE-BETA- 
HYDROXYLASE DURING FENFLURAMINE (PONDIMIN) TREATMENT IN 
MAN. (UNPUBLISHED PAPER). 

239305 03-13 
SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDICATOR OF 
SYMPATHETIC ACTIVITY AND PRIMARY HYPERTENSION. 

241294 03-13 



ENDOGENOUS INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE IN RAT 

ORGANS. 

244315 04-03 
THE EFFECTS OF GANGLIONIC BLOCKADE, RESERPINE AND VINBLASTINE 

ON PLASAAA CATECHOLAMINES AND DOPAMINE-BETA-HYDROXYLASE 

IN THE RAT. 

246843 04-03 
RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY 

NERVE STIMULATION. V. ENHANCED RELEASE ASSOCIATED WITH A 
GRANULAR EFFECT OF A BENZOQUINOLIZINE DERIVATIVE WITH 
RESERPINE-LIKE PROPERTIES. 

246844 04-03 
EFFECTS OF RESERPINE ON ACTIVITIES AND AMOUNTS OF TYROSINE- 
HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE IN 
CATECHOLAMINE NEURONAL SYSTEMS IN RAT BRAIN. 

246845 04-03 
INHIBITION BY CYCLOPROPANE OF RELEASE OF NOREPINEPHRINE, BUT 

NOT OF DOPAMINE-BETA-HYDROXYLASE FROM GUINEA-PIG VAS- 
DEFERENS (UNPUBLISHED PAPER). 

247028 04-03 
MODIFICATION OF THE L-DOPA REVERSAL OF RESERPINE AKINESIA BY 
INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE. 

248289 04-04 
EFFECTS OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND 
DOPAMINE-BETA-HYDROXYLASE ON RAT SELF-STIMULATION AFTER 
RESERPINE TREATMENT. 

248964 04-04 
MECHANISMS OF TRANS- SYNAPTIC INDUCTION OF TYROSINE- 
HYDROXYLASE (TH) AND DOPAMINE-BETA-HYDROXYLASE (DBH) IN 
ORGAN CULTURES OF RAT SYMPATHETIC GANGLIA: ROLE OF 
DEPOLARIZATION OF THE POSTSYNAPTIC MEMBRANE. 

251393 04-03 
BEHAVIORAL DEPRESSION IN SIDMAN AVOIDANCE LEARNING INDUCED 
BY DOPAMINE-BETA-HYDROXYLASE INHIBITORS 

253450 04-04 
DOPAMINE-DEPENDENT 

EFFECTS OF DRUGS ACTING ON CEREBRAL 5-HYDROXYTRYPTAMINE 
MECHANISMS ON DOPAMINE-DEPENDENT TURNING BEHAVIOUR IN 
MICE. 

243803 04-04 
DOPAMINE-INDUCED 

THE INFLUENCE OF IMIPRAMINE ON DOPAMINE-INDUCED GANGLIONIC 
INHIBITION AND NEUROGENIC VASODILATION IN THE OOG. 

237160 02-03 
DOPAMINE-INDUCED INCREASES IN CYCLIC-AMP, AND CYCLIC-AMP 
DEPENDENT PROTEIN PHOSPHORYLATION, IN THE RAT CAUDATE- 
NUCLEUS. (PH.D. DISSERTATION). 

238080 02-13 
A DOPAMINE-INDUCED NEURONAL MEMORY TRACE, MEDIATED BY 
CYCLIC-AMP AND DISRUPTABLE BY CYCLIC-GMP 

238717 03-04 
IMPORTANCE OF O-METHYLATION IN DOPAMINE-INDUCED MOTOR AND 
BEHAVIORAL PHENOMENA. 

251143 04-04 
DOPAMINERGIC 

DOPAMINERGIC AND CHOLINERGIC INFLUENCES ON MORPHINE SELF- 
ADMINISTRATION IN RATS. 

227703 01-04 
BEHAVIOURAL SEQUELAE OF DOPAMINERGIC DEGENERATION: 
POSTSYNAPTIC SUPERSENSITIVITY? 

229434 01 03 
DIFFERENTIAL SENSITIVITY OF TWO DOPAMINERGIC STRUCTURES IN RAT 
BRAIN TO HALOPERIDOL AND TO CLOZAPINE. 

233291 02-03 
EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER 
METABOLISM IN CENTRAL DOPAMINERGIC NEURONES. 

233971 02-03 
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC 
AGONISTS. 

233973 02-03 
THE USE OF A DOPAMINERGIC RECEPTOR STIMULATING AGENT 

(PIRIBEDIL, ET-495) IN PARKINSONS DISEASE. 

233974 02-11 
CLINICAL STUDIES OF DOPAMINERGIC MECHANISMS. 

233975 02-11 
EFFECTS OF MOLINDONE ON CENTRAL DOPAMINERGIC NEURONAL 

ACTIVITY AND METABOLISM: SIMILARITY TO OTHER NEUROLEPTICS 

236519 02-03 
DOPAMINERGIC EFFECTS OF PHENCYCLIDINE IN RATS WITH 
NIGROSTRIATAL LESIONS 

236523 02-04 
EFFECTS OF DOPAMINERGIC AGONISTS AND ELECTRICAL STIMULATION 
OF THE MIDBRAIN RAPHE ON THE RELEASE OF 5- 
HYDROXYTRYPTAMINE FROM THE CAT BRAIN IN VIVO. 

237154 02-03 
EFFECTS OF DOPAMINE (DA) DERIVATIVES ON CENTRAL DOPAMINERGIC 
MECHANISMS. 

238700 03-03 



Off 
7^ 










S-115 



Subject Index 



Psychopharnacology Abstrac 



DOPAMINERGIC NEURONS - ALTERATION IN THE SENSITIVITY OF 

TYROSINE-HYDROXYLASE TO INHIBITION BY ENDOGENOUS DOPAMINE 
AFTER CESSATION OF IMPULSE FLOW. 

241295 03-03 
DOPAMINERGIC NEURONS - ALTERATION IN THE KINETIC PROPERTIES OF 

TYROSINE-HYDROXYLASE AFTER CESSATION OF IMPULSE FLOW. 

241296 03-03 
CYCLIC-AMP AS A POSSIBLE MEDIATOR IN DOPAMINERGIC 

STIMULATION-INDUCED ROTATIONAL BEHAVIOR OF RATS LESIONED 
UNILATERALLY IN SUBSTANTIA-NIGRA. 

241382 03-04 
D-AMPHETAMINE-INDUCED INHIBITION OF CENTRAL DOPAMINERGIC 
NEURONS: MEDIATION BY A STRIATO-NIGRAL FEEDBACK PATHWAY. 

243882 04-03 
DOPAMINERGIC CHOLINERGIC INTERACTIONS IN THE CENTRAL-NERVOUS- 
SYSTEM: BIOCHEMICAL PHARMACOLOGICAL ASPECTS. 

244038 04-17 
EEG SYNCHRONIZING EFFECT OF GAMMA-HYDROXYBUTYRATE AND 1- 
HYDROXY-3-AMINO-PYRROLIDONE-2 (HA-966) IN RELATION OF 
DOPAMINERGIC BRAIN FUNCTION. 

245599 04-03 
D-AMPHETAMINE AND L-AMPHETAMINE STEREOISOMERS: COMPARATIVE 
POTENCIES IN AFFECTING THE FIRING OF CENTRAL DOPAMINERGIC 
AND NORADRENERGIC NEURONS 

247211 04-03 
APOMORPHINE-INDUCED STEREOTYPED BITING IN THE TORTOISE IN 
RELATION TO DOPAMINERGIC MECHANISMS. 

247875 04-04 
APORPHINES 15: ACTION OF APORPHINE ALKALOIDS ON DOPAMINERGIC 
MECHANISMS IN RAT BRAIN. 

248286 04-03 
DOPAMINERGIC NATURE OF AMPHETAMINE-INDUCED PECKING IN 
PIGEONS. 

248408 04-03 
DECREASE IN RAT STRIATAL ACETYLCHOLINE LEVELS BY SOME DIRECT 
AND INDIRECT ACTING DOPAMINERGIC ANTAGONISTS. 

248410 04-03 
SYNTHESIS AND DOPAMINERGIC ACTIVITY OF (+ OR -)-, (-1^)-, AND (-) 2- 
DIPROPYLAMINO-5-HYDROXYTETRAHYDRONAPHTHALENE. 

248650 04-02 
ENHANCEMENT OF RESERPINE-ELICITED DOPAMINERGIC 

SUPERSENSITIVITY BY REPEATED TREATMENT WITH APOMORPHINE 
AND ALPHA-METHYL-P-TYROSINE. 

249002 04-03 
A COMPARISON OF NARCOTIC ANALGESICS WITH NEUROLEPTICS ON 
BEHAVIORAL MEASURES OF DOPAMINERGIC ACTIVITY. 

249139 04-04 
EFFECT OF METACLOPRAMIDE ON LIMBIC NORADRENERGIC AND 
STRIATAL AND LIMBIC DOPAMINERGIC MECHANISMS. 

249305 04-06 
INHIBITION OF TURNING BEHAVIOUR BY CLOZAPINE IN MICE WITH 
UNILATERAL DESTRUCTION OF DOPAMINERGIC NERVE TERMINALS. 

249629 04-04 
SPECIFICITY OF DOPAMINERGIC NEURONAL DEGENERATION INDUCED BY 
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE IN THE 
NIGROSTRIATAL DOPAMINE SYSTEM. 

249899 04-03 
POSTNATAL DEVELOPMENT OF DOPAMINERGIC AND CHOLINERGIC 
CATALEPSY IN THE RAT. 

250084 04-03 
CENTRAL DOPAMINERGIC NEURONS: EFFECTS OF ALTERATIONS IN 

IMPULSE FLOW ON THE ACCUMULATION OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085 04-03 
MODIFICATION OF CONDITIONED AVOIDANCE AND TURNING BEHAVIOUR 

BY BACLOFEN AND IIS INFLUENCE ON CHOLINERGIC DOPAMINERGIC 
NERVOUS SYSTEM. 

251397 04-03 
INTERACTION OF BENZODIAZEPINES WITH NEUROLEPTICS AT CENTRAL 
DOPAMINERGIC SYSTEMS: INVOLVEMENT OF GABA. 

251399 04-03 
EFFECTS OF DOPAMINERGIC STIMULANTS ON CYCLIC NUCLEOTIDE 
LEVELS IN MOUSE BRAIN IN VIVO. 

251432 04-03 
DIRECT DOPAMINERGIC ACTION OF LISURIDE HYDROGEN MALEATE, AN 
ERGOT DERIVATIVE, IN MICE. 

252028 04-04 
DORSAL 

DEPRESSIVE EFFECTS OF MORPHINE UPON LAMINA V CELLS ACTIVITIES 
IN THE DORSAL HORN OF THE SPINAL CAT. 

232328 01-03 
D-AMPHETAMINE AND L-AMPHETAMINE DIFFERENTIALLY MEDIATES 
SELF-STIMULATION IN RAT DORSAL MIDBRAIN AREA. 

239272 03-04 
THE EFFECT OF DIAZEPAM AND PICROTOXIN ON BRAINSTEM EVOKED 
DORSAL ROOT POTENTIALS 

239982 03-03 



AROUSAL AND ACTIVITY LEVEL OF RATS WITH LESIONS IN THE DORS/ 
HIPPOCAMPUS. 

247420 04 
INTRACRANIAL SELF-STIMULATION FROM THE DORSAL RAPHE NUCLEU 
OF THE RAT: EFFECTS OF THE INJECTION OF P-CHLOROPHENYLALANI 
AND OF ALPHA-METHYL-P-TYROSINE. 

250982 04 
DORSALIS 

EFFECTS OF MORPHINE ON SINGLE UNIT ACTIVITY OF NEURONS IN THI 
NUCLEUS RAPHE DORSALIS. 

249249 04 
DORSET 

REPORT OF A SYMPOSIUM ON BETA-ADRENERGIC RECEPTOR BLOCKAC 
IN PSYCHIATRY, HELD IN FERNDOWN, DORSET, ON JUNE 21ST 1975 
BETA-ADRENERGIC BLOCKING DRUGS IN ANXIETY. 

251156 04 
DORSOLATERAL 

BEHAVIORAL EFFECTS OF AMPHETAMINE IN A GROUP OF RHESUS 
MONKEYS WITH LESIONS OF DORSOLATERAL FRONTAL CORTEX. 

244684 04 
DOSAGE 

FLUPENTHIXOL-DECANOATE - CONTROLLED INVESTIGATION CONCERNI 
DOSAGE. 

226408 01 
VERY HIGH DOSAGE VS STANDARD DOSAGE FLUPHENAZINE IN 
SCHIZOPHRENIA: A DOUBLE-BLIND STUDY OF NONCHRONIC 
TREATMENT REFRACTORY PATIENTS. 

228223 01 
INFLUENCE OF PSYCHOTROPIC DRUGS ON CHRONIC SCHIZOPHRENIC 
SYNDROMES - WITH SPECIAL EMPHASIS ON THE CHANGE IN CLINK 
PROCESS WITH A RELATIVELY HIGH DOSAGE OF SPIROPERIDOL. 

229761 01 
PROBENECID: DOSAGE, LEVELS IN PLASMA AND CEREBROSPINAL FLUII 
(CSF) AND INFLUENCE UPON CSF LEVELS OF HOMOVANILLIC-ACID 
(HVA) AND 5-HYDROXYINDOLEACETIC-ACID (5-HIAA) IN THE RABBIT 

230877 01 
PHARMACOLOGICAL RESPONSE DATA FOR COMPARATIVE 

BIOAVAILABILITY STUDIES OF CHLORPROMAZINE ORAL DOSAGE 
FORMS IN HUMANS: I. PUPILOMETRY. 

232623 02 
PLASMA CORTICOIDS AND BRAIN TRYPTOPHAN AFTER ACUTE AND 
TOLERANCE DOSAGE OF LSD. 

23431 1 02 
HIGH DOSAGE AND VERSATILE DRUG THERAPY WITH TREATMENT 
RESISTANT PSYCHOTIC PATIENTS. 

235419 02 
HIGHER UNIT DOSAGE OF PSYCHOTROPIC DRUGS. 

239679 03 
HIGHER UNIT DOSAGE OF PSYCHOTROPIC DRUGS. 

239680 03 
OBSTACLES IN IMPLEMENTATION OF HIGHER UNIT DOSAGE OF 

PSYCHOTROPICS DRUGS. 

239681 03 
DOSAGE OF ANTIPSYCHOTIC DRUGS. 

242269 03 
IMIPRAMINE DOSAGE IN CHILDREN: A COMMENT ON IMIPRAMINE AN 
ELECTROCARDIOGRAPHIC ABNORAAALITIES IN HYPERACTIVE 
CHILDREN. 

245001 04 
BUTAPERAZINE PHARMACOKINETICS: EFFECT OF DOSAGE REGIMEN Oh 
STEADY-STATE BLOOD LEVELS. 

245842 04 
COMBINATION DRUG THERAPY FOR THE PSYCHOGERIATRIC PATIENT: 
COMPARISON OF DOSAGE LEVELS OF THE SAME PSYCHOTROPIC 
DRUGS, USED SINGLY AND IN COMBINATION. 

246694 04 
CORRELATION BETWEEN DISSOLUTION CHARACTERISTICS AND 
ABSORPTION OF METHAQUALONE FROM SOLID DOSAGE FORMS. 

250332 04 
RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM 
PROPHYLAXIS IN RECURRENT DEPRESSION. 

252954 04 
PAVOR-NOCTURNUS: A COMPLICATION OF SINGLE DAILY TRICYCLIC 01 

NEUROLEPTIC DOSAGE. 

252955 04 
DOSAGE OF ANTIPSYCHOTIC DRUGS. 

253018 04 
DOSE 

A SINGLE DOSE ANTIANXIETY DRUG: A REPORT FROM THE GENERAL 
PRACTITIONER RESEARCH GROUP. 

227914 01- 
LOSS OF INHIBITORY MOTOR CONTROL FOLLOWING A SUBANESTHETIC 
DOSE OF THIOBARBITURATE IN RHESUS MONKEYS. 

228139 01- 
PLASMA LEVELS OF MESORIDAZINE AND ITS METABOLITES AND 
CLINICAL RESPONSES IN ACUTE SCHIZOPHRENIA AFTER A SINGLE 
INTRAMUSCULAR DRUG DOSE. 

229446 01- 



5-116 



UME 14, SUBJECT INDEX 

IMPLIFIEO LITHIUM DOSE ADJUSTMENT BY LOAD TEST. 

230866 01 16 
lEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AND AMPHETAMINE 
AFTER CHRONIC HIGH DOSE HALOPERIDOL TREATMEN 

232616 02-04 
PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER- 
DISCHARGES IN RATS: INCREMENTAL DOSE, HIPPOCAMPAL EEG AND 
BEHAVIORAL ACTIVITY CORRELATES. 

239858 03-03 
IICOTINE-LIKE BEHAVIORAL EFFECT AFTER SMALL DOSE OF 
MECAMYLAMINE IN ROMAN HIGH-AVOIDANCE RATS. 

239865 03-04 
1 MULTIPLE DOSE, CONTROLLED STUDY OF PHENELZINE IN DEPRESSION 
ANXIETY STATES. 

239938 03-10 
ONCURRENT SCHEDULES OF COCAINE INJECTION IN RHESUS MONKEYS: 
DOSE VARIATIONS UNDER INDEPENDENT AND NON-INDEPENDENT 
VARIABLE-INTERVAL PROCEDURES. 

240015 03-04 
lALOXONE AS A NEGATIVE REINFORCER IN RHESUS MONKEYS: EFFECTS 
OF DOSE, SCHEDULE, AND NARCOTIC REGIMEN. 

240018 03-04 
I CONTROLLED COMPARATIVE TRIAL OF A COMBINATION OF 
OPIPRAMOL AND CLOMIPRAMINE AND A HIGHER DOSE OF 
CLOMIPRAMINE ALONE. 

245468 04-09 
ilNGLE DOSE IMIPRAMINE PAMOATE IN THE TREATMENT OF DEPRESSIVE 
NEUROSIS. 

246300 04-10 
'ARAMETHADIONE AND METABOLITE SERUM LEVELS IN HUMANS AFTER 
A SINGLE ORAL PARAMETHADIONE DOSE. 

246969 04-17 
VHAT IS THE PROPER DOSE OF STIMULANT DRUGS IN CHILDREN?. 

247376 04-17 
JALOXONE BLOCKADE OF MORPHINE ANALGESIA - A DOSE EFFECT 
STUDY OF DURATION AND MAGNITUDE. 

249271 04-02 
;TUDIES on single dose tolerance DEVELOPMENT TO MORPHINE IN 
MICE. 

249288 04-04 
lAETHADONE DURING PREGNANCY IN THE RAT: DOSE LEVEL EFFECTS ON 
MATERNAL AND PERINATAL MORTALITY AND GROWTH IN THE 
OFFSPRING. 

251428 04-05 
■RELATED 
)OSE-RELATED EFFECTS OF METRAZOL ON RETENTION AND EEG. 

242733 03-04 
)OSE-RELATED EFFECTS OF CENTRAL NORADRENALINE STIMULATION ON 
BEHAVIOURAL AROUSAL IN RATS. 

247206 04-04 
-RESPONSE 

\NGIOTENSIN-INDUCED DRINKING IN THE CAT: A DOSE-RESPONSE AND 
BIOCHEMICAL ANALYSIS. (PH.D. DISSERTATION). 

227106 01-04 
)OSE-RESPONSE RELATIONS IN DRUG-INDUCED INAPPROPRIATE 
SECRETION OF ADH: EFFECTS OF CLOFIBRATE AND CARBAMAZEPINE. 

232638 02-13 
)OSE-RESPONSE EFFECTS OF SCOPOLAMINE ON ACTIVITY IN AN OPEN- 
FIELD. 

237728 02-04 
:aRBACHOL elicited mouse-killing BY RATS: CIRCADIAN RHYTHM 
AND DOSE-RESPONSE. 

238006 02-04 
\N INVESTIGATION ON THE DOSE-RESPONSE RELATIONSHIP BETWEEN 
CONVENTIONAL ANTIOXIDANT FOOD ADDITIVES AND 
NEUROTRANSMITTER METABOLISM. 

238745 03-03 
)OSE-RESPONSE STUDIES ON EFFECTS OF AMPHETAMINE ON ACTIVITY 
AND OXYGEN CONSUMPTION IN DOG AND CAT MODELS OF 
HYPERKINESIS (HYPOINHIBITORY SYNDROME). 

238825 03-03 
FASTE AVERSIONS INDUCED BY D-AMPHETAMINE: DOSE-RESPONSE 
RELATIONSHIP. 

242882 04-04 
)OSE-RESPONSE EFFECTS OF D-AMPHETAMINE ON PASSIVE AVOIDANCE 
LEARNING IN THE RAT. 

246313 04-04 
S 

FHE LONG-TERM USE OF HIGH DOSES OF FLUPHENAZINE-ENANTHATE 
AND FLUPHENAZINE-DECANOATE. 

225936 01-08 
FHE DEPENDENCE OF THE MAGNITUDE OF CONDITIONED SALIVATION IN 
DOGS ON DOSES OF CAFFEINE. 

236249 02-03 
VOVANTAGES OF THE INITIAL THERAPY OF ACUTE SCHIZOPHRENIA WITH 
LARGE DOSES OF DROPERIDOL: A COMPARATIVE STUDY. 

237124 02-08 



Subject Index 



ANTAGONISM OF APOMORPHINE AND D-AMPHETAMINE-INDUCED 
STEREOTYPED BEHAVIOUR BY INJECTION OF LOW DOSES OF 
HALOPERIDOL INTO THE CAUDATE-NUCLEUS AND THE NUCLEUS- 
ACCUMBENS. 

237704 02-04 
THERAPEUTIC DOSES OF CYPROHEPTADINE DO NOT INHIBIT 
MONOAMINE-OXIDASE IN MAN. 

237927 02-13 
THE ANXIOLYTIC EFFECT OF SMALL CUMULATIVE DOSES OF OXYPERTIN 
IN RATS IN AN ANXIETY TEST AND THE POSSIBLE NEUROCHEMICAL 
CORRELATES IN THE HYPOTHALAMUS AND STRIATUM. 

239834 03-04 
EFFECTS OF REPEATED DOSES OF SCOPOLAMINE ON THE 
ELECTROENCEPHALOGRAPHIC STAGES OF SLEEP IN NORAAAL 
VOLUNTEERS. 

248629 04-13 
MYELOID HYPERPLASIA IN GROWING RATS AFTER CHRONIC TREATMENT 
WITH DELTA9-THC AT BEHAVIORAL DOSES. 

248915 04-05 
PLASMA RENIN ACTIVITY IN DEPRESSED PATIENTS TREATED WITH 
INCREASING DOSES OF LITHIUM CARBONATE. 

249673 04-13 
SENSITIVITY TO LOW DOSES OF ETHANOL AND PENTOBARBITAL IN MICE 
SELECTED FOR SENSITIVITY TO HYPNOTIC DOSES OF ETHANOL. 

250284 04-04 
PHARAAACOKINETICS OF METHOTRIMEPRAZINE AFTER SINGLE AND 
MULTIPLE DOSES. 

250422 04-07 
COMPARISON OF LOW DOSES OF HALOPERIDOL AND DIAZEPAM IN 
ANXIETY STATES. 

250491 04 10 
INHIBITION AND ENHANCEMENT OF PHOTICALLY EVOKED RESPONSES BY 
DIFFERENT DOSES OF L-DOPA. 

251214 04-03 
THE EFFECTS OF HIGH DOSES OF OXPRENOLOL AND OF PROPRANOLOL 
ON PURSUIT ROTOR PERFORMANCE, REACTION TIME AND CRITICAL 
FLICKER FREQUENCY. 

251986 04-14 
DOTHIEPIN 

SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH PARTICULAR 
REFERENCE TO DOTHIEPIN. 

226897 CM 5 
THE HAMILTON RATING SCALE. AN ASSESSMENT BASED ON A 

DOTHIEPIN (PROTHIADEN) VERSUS IMIPRAAAINE (TOFRANIL) CLINICAL 
TRIAL. 

226899 01-09 
THE USE OF DOTHIEPIN IN THE TREATMENT OF PSYCHONEUROTIC 
ANXIETY WITH DEPRESSIVE FEATURES. 

237774 02-10 
A RETROSPECTIVE ASSESSMENT OF THE LONG-TERM EFFECTS OF 
DOTHIEPIN. 

239820 03-09 
DOUBLE-BUND 

LOXAPINE SUCCINATE: A CONTROLLED DOUBLE-BLIND STUDY IN 
CHRONIC SCHIZOPHRENIA. 

225867 01-08 
A DOUBLE-BLIND COMPARISON BETWEEN DOXEPIN AND DIAZEPAM IN 
THE TREATMENT OF STATES OF ANXIETY. 

226410 01-10 
SHORT-TERM EFFECTS OF VILOXAZINE (VIVALAN) COMPARED WITH 
PLACEBO IN DEPRESSION: A DOUBLE-BLIND STUDY 

227214 01-09 
EFFECTS OF A PROCAINE PREPARATION (GER0VITAL-H3) IN 
HOSPITALIZED GERIATRIC PATIENTS: A DOUBLE-BLIND STUDY. 

227330 01-11 
A DOUBLE-BLIND TRIAL OF LITHIUM CARBONATE AND HALOPERIDOL IN 
HUNTINGTONS-CHOREA. 

227550 01-11 
CAFFEINE VERSUS METHYLPHENIDATE AND D-AMPHETAMINE IN 
MINIMAL-BRAIN-DYSFUNCTION: A DOUBLE-BLIND COMPARISON. 

227571 01-11 
VERY HIGH DOSAGE VS STANDARD DOSAGE FLUPHENAZINE IN 
SCHIZOPHRENIA: A DOUBLE-BLIND STUDY OF NONCHRONIC 
TREATMENT REFRACTORY PATIENTS 

228223 01-08 
THERAPY OF ANXIETY IN PATIENTS WITH RHEUMATIC DISEASE: 
CROSSOVER DOUBLE-BLIND STUDY COMPARING LORAZEPAM WITH 
PLACEBO. 

228241 01-11 
A DOUBLE-BLIND CONTROLLED COMPARISON OF CLOMIPRAMINE 
(ANAFRANIL) AND IMIPRAMINE ON DEPRESSION. 

228327 01-09 
A DOUBLE-BLIND COMPARISON OF PENFLURIDOL (EASER) WITH 
PIMOZIDE IN SCHIZOPHRENIA. 

229026 01-07 
DOUBLE-BLIND CONTROLLED STUDY OF L-DOPA THERAPY IN 
SCHIZOPHRENIA. 

229064 01-08 



iS" 



I 



s-n7 



Subject Index 



Psychopharmacology Abstrac 



DISCOURSE ON THE DOUBLE-BLIND METHOD. INSTITUTION AND 
EXPERIMENTATION: )9366-RP. 

229078 0116 
EFFECTS OF DISCONTINUITY OF MEDICATION ON THE RESULTS OF A 
DOUBLE-BLIND DRUG STUDY IN OUTPATIENT ALCOHOLICS. 

229091 01-11 
DOUBLE-BLIND EVALUATION OF NAFTIDROFURYL IN TREATING ELDERLY 
CONFUSED HOSPITALISED PATIENTS 

229368 01-11 
THE CLINICAL EVALUATION OF A NEW MINOR TRANQUILIZER 
CLORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOMATIC DISEASE, NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BUND CLINICAL STUDY. 

229504 01-11 
A DOUBLE-BLIND TRIAL OF INTRAVENOUS THYROTROPIN-RELEASING 
HORMONE IN THE TREATMENT OF REACTIVE DEPRESSION. 

229693 01-09 
THE EFFECT OF L-DOPA ON YOUNG PATIENTS WITH SIMPLE 

SCHIZOPHRENIA, TREATED WITH NEUROLEPTIC DRUGS. A DOUBLE- 
BLIND CROSSOVER TRIAL WITH MADOPAR AND PLACEBO. 

230823 01-08 
DOUBLE-BLIND TRIAL OF SINTAMIL IN DEPRESSION. 

231603 01-10 
THE ASSESSMENT OF THIOTHIXENE IN CHRONIC SCHIZOPHRENIA: A 
DOUBLE BLIND CONTROLLED TRIAL. 

231609 01-08 
RESPONSES OF CHRONIC SCHIZOPHRENIC FEMALES TO A COMBINATION 
OF DIPHENYLHYDANTOIN AND NEUROLEPTICS: A DOUBLE-BLIND 
STUDY. 

232781 02-08 
ALLEVIATING AGITATION, APPREHENSION, AND RELATED SYMPTOMS IN 
GERIATRIC PATIENTS: A DOUBLE-BLIND COMPARISON OF A 
PHENOTHIAZINE AND A BENZODIAZEPINE. 

234114 02-11 
LITHIUM CARBONATE IN AFFECTIVE DISORDERS: IV. A DOUBLE-BLIND 
STUDY OF PROPHYLAXIS IN UNIPOLAR RECURRENT DEPRESSION. 

234203 02-09 
LORAZEPAM AND DIAZEPAM IN THE TREATMENT OF NEUROTIC 
ANXIETY: DOUBLE-BLIND TRIAL 

236658 02-10 
CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY OF THE COMPARATIVE 
EFFECTIVENESS OF MEPIPRAZOL (EMD-16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 02-10 
A DOUBLE-BLIND COMPARISON OF LOXAPINE SUCCINATE AND 

TRIFLUOPERAZINE IN NEWLY ADMITTED SCHIZOPHRENIC PATIENTS. 

237828 02-08 
A DOUBLE-BLIND TRIAL OF MAPROTILINE (LUDIOMIL) AND 
AMITRIPTYLINE IN DEPRESSED OUTPATIENTS. 

238981 03-10 
PIPAMPERONE (DIPIPERON, R-3-345) IN TROUBLESOME MENTAL 

RETARDATES: A DOUBLE-BLIND PLACEBO CONTROLLED CROSSOVER 
STUDY WITH LONG-TERM FOLLOW-UP. 

238982 03-11 
A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE-DECANOATE AND 

FLUPENTHIXOLDECANOATE IN THE TREATMENT OF ACUTE 
SCHIZOPHRENIA. 

238996 03-08 
PERORAL AND PARENTERAL ADMINISTRATION OF LONG-ACTING 

NEUROLEPTICS: A DOUBLE-BLIND STUDY OF PENFLURIDOL COMPARED 
TO FLUPENTHIXOL-DECANOATE IN THE TREATMENT OF 
SCHIZOPHRENIA. 

239023 03-08 
TREATMENT WITH RESERPINE OF PATIENTS RESISTANT TO TRICYCLIC 
ANTIDEPRESSANTS: A DOUBLE-BLIND TRIAL. 

239348 03-09 
DOUBLE-BLIND COMPARISON OF MAPROTILINE WITH AMITRIPTYLINE IN 
THE TREATMENT OF DEPRESSIVE ILLNESS, 

239818 03-10 
DOUBLE-BLIND TRIAL OF DIFFUCAPS AMITRIPTYLINE AND ORDINARY 
AMITRIPTYLINE IN SLEEP DISORDERS OF DEPRESSIVE ORIGIN, 

240032 03-09 
TRIAL OF A NEW THERAPEUTIC AGENT, PERVINCAMINE, IN THE 

POSTCONCUSSION SYNDROME OF CRANIAL TRAUMAS: APPLICATION 
OF A DOUBLE-BLIND CONTROL AND SEQUENTIAL ANALYSIS. 

240033 03-11 
THE QUALITY OF INTELLECTUAL LIFE IN THE ELDERLY: DOUBLE-BLIND 

STUDY OF HYDROSARPAN-711 IN 80 SUBJECTS. 

240166 03-11 
LORAZEPAM IN THE MANAGEMENT OF ANXIETY ASSOCIATED WITH 
CHRONIC GASTROINTESTINAL DISEASE: A DOUBLE-BLIND STUDY. 

241274 03-14 
CAMAZEPAM (SB-5833) IN PREPARATION FOR ENDOSCOPY INSPECTION: 
OPEN AND DOUBLE-BLIND STUDY VERSUS DIAZEPAM. 

241276 03-14 
MAPROTILINE (LUDIOMIL, CIBA-34276-BA) AND IMIPRAMINE IN 
DEPRESSED OUTPATIENTS: A DOUBLE-BLIND CLINICAL STUDY. 

242248 03-09 



A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL WITH MAPROTILINE 
(LUDIOMIL) AND IMIPRAMINE IN NEWLY-ADMITTED DEPRESSED 
PATIENTS. 

242249 03 

THE QUALITY OF INTELLECTUAL LIFE: DOUBLE-BLIND STUDY OF 
HYDROSARPAN-711 INVOLVING 80 SUBJECTS. 

242899 04 
BEHAVIOR AND INTELLECTUAL ACTIVITY OF THE ELDERLY: DOUBLE- 
BLIND STUDY OF HYDROSARPAN-711 IN A HOSPICE ENVIRONMENT. 

242900 04 
THE CLINICAL EFFECTIVENESS OF A CAVAIN-MAGNESIUM-OROTATE 

COMBINATION IN NURSING HOME PATIENTS IN A DOUBLE-BLIND 
STUDY. 

243180 04 
A DOUBLE-BLIND COMPARISON OF LOXITANE: LOXAPINE SUCCINATE 
AND TRIFLUOPERAZINE HYDROCHLORIDE IN CHRONIC SCHIZOPHREh 
PATIENTS. 

245014 04 
ANXIETY/DEPRESSION IN ELDERLY PATIENTS: A DOUBLE-BLIND 
COMPARATIVE STUDY OF FLUPHENAZINE/NORTRIPTYLINE AND 
PROMAZINE, 

247030 04 
LITHIUM CARBONATE AND AFFECTIVE DISORDERS. V: A DOUBLE-BLINI 
STUDY OF PROPHYLAXIS OF DEPRESSION IN BIPOLAR ILLNESS. 

247582 04 
DOUBLE-BLIND PLACEBO CONTROLLED EFFICACY STUDY OF KETAZOLA 
(U-28774). 

248532 04 
SELF-INHIBITING ACTION OF NORTRIPTYLINE ANTIDEPRESSIVE EFFECT, 
HIGH PLASMA LEVELS: A RANDOMIZED, DOUBLE-BUND STUDY 
CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION. 

248955 04 

OXAZEPAM PROTRIPTYLINE: A DOUBLE-BLIND PHASE II EVALUATION ( 

THE EFFICACY AND SAFETY OF THE COMBINATION VERSUS PLACEBI 

IN NEUROTIC, DEPRESSED AND ANXIOUS PSYCHIATRIC OUTPATIENT 

248975 04 
A DOUBLE-BUND EVALUATION OF METIAPINE IN HOSPITALIZED ACUTI 

SCHIZOPHRENICS. 

248976 04 
LORAZEPAM IN GASTROINTESTINAL DISORDERS WITH ANXIETY OVERl 

(A DOUBLE-BLIND CROSSOVER STUDY). 

250193 04 
THE OBJECTIVE MEASUREMENT OF MENTAL PERFORMANCE IN 

CEREBROVASCULAR DISEASE: A DOUBLE-BLIND CONTROLLED STUDV 
USING A GRADED-RELEASE PREPARATION OF ISOXSUPRINE. 

250414 04 
COMPARISON OF A NEW ANTIDEPRESSIVE, LOFEPRAMINE WITH 
IMIPRAMINE IN A DOUBLE-BLIND MULTICENTRE TRIAL. 

251118 04 
POTENTIATION BY METYROSINE OF THIORIDAZINE EFFECTS IN CHRONI 
SCHIZOPHRENICS: A LONG-TERM TRIAL USING DOUBLE-BLIND 
CROSSOVER TECHNIQUE, 

251374 04 
SUSTAINED-RELEASE LITHIUM CARBONATE IN A DOUBLE-BLIND STUDY 
SERUM LITHIUM LEVELS, SIDE-EFFECTS, AND PLACEBO RESPONSE. 

251826 04 
CARBAMAZEPINE (TEGRETOL) - A DOUBLE-BLIND COMPARISON WITH 
PHENYTOIN (DILANTIN). 

251937 04 
A THREE- YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS 
FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA. 

253048 04 
A CONTROLLED DOUBLE-BLIND COMPARISON BETWEEN LOXAPINE ANC 
HALOPERIDOL IN ACUTE NEWLY HOSPITALIZED SCHIZOPHRENIC 
PATIENTS, 

253051 04 
DOUBLE-PULSE 

AN ANALYSIS OF THE DOUBLE-PULSE TECHNIQUES USE IN MEASURING 
HYPOTHALAMIC REFRACTORY PERIODS IN REWARD NEURONS. (PH.( 
DISSERTATION), 

241129 03 
USES OF DOUBLE-PULSE STIMULATION BEHAVIORALLY TO INFER 
REFRACTORINESS, SUMMATION, CONVERGENCE, AND TRANSMITTER 
CHARACTERISTICS OF HYPOTHALAMIC REWARD SYSTEMS. 

250278 04 
DOWNS-SYNDROME 

REVIEW OF DRUG TREATMENT FOR DOWNS-SYNDROME PERSONS. 

239074 03- 
DOXEPIN 

A DOUBLE-BLIND COMPARISON BETWEEN DOXEPIN AND DIAZEPAM IN 
THE TREATMENT OF STATES OF ANXIETY. 

226410 01 
DOXEPIN, A NEW ANTIDEPRESSANT DRUG FOR PATIENTS IN THE 
INTERNAL MEDICINE CLINIC. 

229515 01- 
EFFECTIVENESS OF SINEQUAN (DOXEPIN) IN THE TREATMENT OF 
NEUROTIC AND PSEUDONEUROTIC SYNDROMES. 

230818 01- 



S-118 



>LUME 14, SUBJECT INDEX 



Subject Index 



OOXEPIN IN THE TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS. 

235826 02-10 
EFFICACY AND TOLERANCE OF INJECTABLE DOXEPIN. 

237775 02-10 

EFFECT OF 5,5 DIPHENYLHYDANTOIN (DPH) ON LEARNING AND MEMORY 
IN CATS. 

229680 01-04 
DPH-INTOXICATION - CLINICAL AND NEUROPSYCHOLOGICAL 
EVALUATION OF A SLOW DPH ELIMINATION. 

240692 03-15 
(.INTOXICATION 
DPH-INTOXICATION - CLINICAL AND NEUROPSYCHOLOGICAL 
EVALUATION OF A SLOW DPH ELIMINATION. 

240692 03-15 

3,4 DIHYDROXYPHENYIAMINO 2 IMIDAZOLINE (DPI), A NEW POTENT 
AGONIST AT DOPAMINE RECEPTORS MEDIATING NEURONAL 
INHIBITION. 

238321 02-03 
■ASSISTED 

COUNSELING, PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH: AN EMPIRICAL STUDY OF THE EFFICACY OF DPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH.D. 
DISSERTATION) 

228686 01-11 
\W-A-MAN 
DEPRESSIVE STATE AND DIMENSIONS OF THE MAN ON GOODENOUGHS 
DRAW-A-MAN TEST IN CHILDREN. 

235998 02-10 
■AMS 
SEROTONIN: THE CRUCIAL SUBSTANCE THAT TURNS DREAMS ON AND 
OFF. 

241505 03-12 
NK 
SUBJECTIVE RATINGS OF SLEEP QUALITY AND ANXIETY AFTER PLACEBO, 
DRUG AND A FOOD DRINK. 

239059 03-14 
INKING 
ANGIOTENSIN-INDUCED DRINKING IN THE CAT: A DOSE-RESPONSE AND 
BIOCHEMICAL ANALYSIS. (PH.D. DISSERTATION). 

227106 01-04 
PHENYLPROPANOLAMINE INHIBITS FEEDING, BUT NOT DRINKING, 
INDUCED BY HYPOTHALAMIC STIMULATION. 

231700 01-03 
PITRESSIN-INDUCEO INHIBITION OF DRINKING FOLLOWING WATER 
DEPRIVATION IN THE SWR-J MOUSE. 

242746 04-04 
ANALYSIS OF HORMONAL MEDIATION OF DRINKING BEHAVIOR. 

244469 04-04 
PATTERN OF DRINKING AND FEEDING PRODUCED BY HYPOTHALAMIC 
NOREPINEPHRINE INJECTION IN THE SATIATED RAT. 

245929 04-02 
EFFECT OF HYDROXYLAMINE ON THE CONSEQUENCES OF LONG-LASTING 
ADMINISTRATION OF MORPHINE IN MICE: III. EFFECT ON PREFERRED 
DRINKING OF MORPHINE SOLUTION. 

249032 04-04 
THE EFFECT OF SUBFORNICAL ORGAN LESIONS AND VENTRICULAR 
BLOCKADE ON DRINKING INDUCED BY ANGIOTENSIN-II. 

252170 04-03 
IVE 
STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOUR) BY P- 
CHIOROPHENYLALANINE (PCPA) IN THE RAT. 

246674 04-04 
IVERS 
THE EFFECT OF GRANDAXIN ON LORRY DRIVERS. 

252446 04-14 
IVING 
EFFECT OF TWO WEEKS TREATMENT WITH CHLORDIAZEPOXIDE OR 
FLUPENTHIXOL, ALONE OR IN COMBINATION WITH ALCOHOL, ON 
PSYCHOMOTOR SKILLS RELATED TO DRIVING. 

229907 01-14 
EFFECT OF SUBACUTE TREATMENT WITH HYPNOTICS, ALONE OR IN 
COMBINATION WITH ALCOHOL, ON PSYCHOMOTOR SKILLS RELATED 
TO DRIVING, 

241417 03-15 
MENTAL ILLNESS AND SIMULATED DRIVING: BEFORE AND DURING 
TREATMENT. 

241425 03-15 
THE INTERACTION BETWEEN DRUGS, ALCOHOL AND DRIVING AN 
AUTOMOBILE. 

244453 04-15 
I 
CHOLINERGIC BLOCKADE, SEPTAL LESIONS, AND DRL PERFORMANCE IN 
THE RAT. 

226305 01-04 



COMBINED EFFECTS OF METHAMPHETAMINE, CAFFEINE, DIAZEPAM, AND 
PENTOBARBITAL ON DRL PERFORMANCE IN RATS. 

241400 03-04 
CHOLINERGIC MODIFICATION OF DRL PERFORMANCE IN NORAAAL RATS 
AND RATS WITH LESIONS OF THE SEPTUM. (PH.D. DISSERTATION). 

241681 03-04 
DROPERIDOL 

THE EFFECT OF DIAZEPAM, FLUNITRAZEPAM AND DROPERIDOL WITH AN 
ANALGESIC ON BLOOD-PRESSURE AND HEARTRATE IN MAN. 

232531 01-13 
THE ACTION OF CHLORPROAAAZINE, TRIFLUOPERAZINE AND DROPERIDOL 
ON THE CAPTURE AND ACCUMULATION OF EXOGENOUS 
NOREPINEPHRINE. 

236713 02-03 
ADVANTAGES OF THE INITIAL THERAPY OF ACUTE SCHIZOPHRENIA WITH 
LARGE DOSES OF DROPERIDOL: A COMPARATIVE STUDY. 

237124 02-08 
DROWSINESS 

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE 
SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG 
SURVEILLANCE PROGRAM. 

225722 01-15 
DRUG 

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE 
SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG 
SURVEILLANCE PROGRAM, 

225722 01-15 
DRUG ACTION IN MANAGEMENT OF HYPERTENSION, 

225766 01-11 
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON DRUG METABOLISM. 

226829 01-13 
DIAZEPAM, ETHANOL AND DRUG METABOLIZING ENZYMES IN RAT 
LIVER. 

226927 01-03 
OPERANT ANALYSIS OF BEHAVIOR ASSOCIATED WITH ORAL SELF- 
ADMINISTRATION OF DRUG SOLUTIONS IN RATS. (PHD. 
DISSERTATION), 

226992 01-04 
VIVALAN: DRUG PROFILE, 

227227 01-07 
HANDBOOK OF DRUG AND CHEMICAL STIMULATION OF THE BRAIN: 
BEHAVIORAL, PHARMACOLOGICAL AND PHYSIOLOGICAL ASPECTS, 

227382 01-06 
DRUG INTERACriONS. 

227412 01-17 
INHIBITION OF DRUG METABOLIZING ENZYMES BY DIAZEPAM IN RAT 
LIVER. 

227696 01-03 
GUIDELINES FOR ANTIPSYCHOTIC DRUG USE. 

227731 01-17 
A SINGLE DOSE ANTIANXIETY DRUG: A REPORT FROM THE GENERAL 
PRACTITIONER RESEARCH GROUP, 

227914 01-10 
ANTINUCLEAR ANTIBODIES IN PSYCHIATRIC ILLNESS: THEIR 
RELATIONSHIP TO DIAGNOSIS AND DRUG TREATMENT, 

228208 01-15 
NEW DRUG THERAPY IN THE FIELD OF PSYCHIATRY. 

228211 01-17 
ISSUES CONCERNING DRUG THERAPY IN THE MENTAL HOSPITAL. 

228322 01-17 
AN INVESTIGATION OF THE SELECTION PROCESS AND DRUG TREATMENT 
OF EXPLOSIVELY AGGRESSIVE ADOLESCENT FEMALES. (PH.D, 
DISSERTATION), 

228726 01-11 
DRUG TREATMENT IN A REHABILITATION CENTER FOR CHRONIC 
ALCOHOLICS. 

228908 01-11 
THE USE OF TRANQUILIZERS IN THE TREATMENT OF MIXED DRUG 
ABUSE. 

229044 01-11 
EFFECTS OF DISCONTINUITY OF MEDICATION ON THE RESULTS OF A 
DOUBLE-BLIND DRUG STUDY IN OUTPATIENT ALCOHOLICS. 

229091 01-11 
EVIDENCE FOR DRUG ACTIONS ON BOTH PRE- AND POSTSYNAPTIC 
CATECHOLAMINE RECEPTORS IN THE CNS. 

229431 01-03 
A CONTRIBUTION TO PSYCHOACTIVE DRUG MEASUREMENT TECHNIQUES. 

229442 01-16 
PLASMA LEVELS OF MESORIDAZINE AND ITS METABOLITES AND 
CLINICAL RESPONSES IN ACUTE SCHIZOPHRENIA AFTER A SINGLE 
INTRAMUSCULAR DRUG DOSE. 

229446 01-08 
PREDICTION OF RESPONSE TO DRUG AND GROUP PSYCHOTHERAPY IN 
DEPRESSED OUTPATIENTS, 

229449 01-09 
CONCEPTUAL IMPLICATIONS OF DRUG AND NONSOMATIC TREATMENT 
INTERACTION STUDIES. 

229452 01-17 



as 









s-n9 



Subject Index 



Psychopharmacoiogy Abstrac 



A SURVEY OF PSYCHOACTIVE DRUG USE IN ^HE AGED IN VETERANS 
ADMINISTRATION HOSPITALS. 

229458 01-11 
DRUG SCHEDULE INTERACTIONS AND INTERCURRENT BEHAVIOR. 

229479 01-04 
DOXEPIN, A NEW ANTIDEPRESSANT DRUG FOR PATIENTS IN THE 
INTERNAL MEDICINE CLINIC. 

229515 01-10 
HEREDITY OF HEXOBARBITAL SLEEPING TIME AND EFFICIENCY OF DRUG 
METABOLISM IN WISTAR AND SPRAGUE-DAWLEY RATS. 

230007 01-04 
EFFECTS OF DRUG EXPERIENCE ON DRUG-INDUCED CONDITIONED TASTE 
AVERSIONS: STUDIES WITH AMPHETAMINE AND FENFLURAMINE. 

230829 01-04 
A CLINICAL TRIAL WITH NOMIFENSIN, A NEW ANTIDEPRESSANT DRUG. 

231035 01-09 
DRUG TREATMENT OF MENTAL DISORDERS. 

23111301-17 
PHARMACOLOGICAL STUDIES OF DRUG ACTION ON CNS, WITH SPECIAL 
REFERENCE TO EFFECTS OF MAPROTILINE. 

231316 01-04 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAAAATE 
APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. I. THEORETICAL 
CONSIDERATIONS AND LITERATURE REVIEW. 

232517 01-17 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. II. FIVE 
EXPERIMENTS. 

232518 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. Ill THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAMATE IN THE BLOOD 
AND THEIR EFFECTS ON PERFORMANCE; APPLICATION OF 
MATHEMATICAL MODELS. 

232519 01-14 
DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. IV. THE 
CONCENTRATIONS OF ALCOHOL AND MEPROBAMATE IN THE BLOOD. 

232520 01-13 
DRUG INTERACTIONS: THE EFFECT OF ALCOHOL AND MEPROBAMATE 

APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. V. SUMMARY 
AND CONCLUSIONS. 

232521 01-14 
NUTRITION AND DRUG THERAPY FOR PERSONS WITH DEVELOPMENTAL 

DISABILITIES. 

232815 02-15 
INPATIENT AND OUTPATIENT PATTERNS OF PSYCHOTROPIC DRUG 
PRESCRIBING BY NONPSYCHIATRIST PHYSICIANS. 

232838 02-17 
CONDITIONED AVERSION BY PSYCHOACTIVE DRUGS: DOES IT HAVE 
SIGNIFICANCE FOR AN UNDERSTANDING OF DRUG DEPENDENCE 

233488 02- 14 
ANALYSIS OF VARIANCE STUDY OF A SLEEP INDUCING DRUG. 

233698 02-07 
ABUSE OF PSYCHOPHARMACEUTICAL AGENTS IN DRUG DEPENDENCE 
(ANALYSIS OF CASES HOSPITALIZED IN A PSYCHIATRIC DEPARTMENT 
IN THE YEARS 1970 TO 1973). 

234653 02-17 
DIFFERENTIAL DRUG EFFECTS ON BRAIN SEROTONERGIC SYSTEMS. 

234805 02-03 
GOOD TRIP OR BAD TRIP: THE ROLES OF TOLERANCE AND STRESS IN 
HALLUCINOGENIC DRUG ACTION. 

234811 02- 12 
HIGH DOSAGE AND VERSATILE DRUG THERAPY WITH TREATMENT 
RESISTANT PSYCHOTIC PATIENTS. 

235419 02-17 
IMPACT OF PSYCHOSOCIAL FACTORS ON THE CONDUCT OF COMBINED 
DRUG AND PSYCHOTHERAPY RESEARCH. 

235534 02-17 
METHODS OF ASSESSMENT OF DRUG ADMINISTRATION IN A 
PSYCHIATRIC HOSPITAL. 

235545 02-17 
CHANGES IN SERUM TRYPTOPHAN AND ALBUMIN BINDING OF 
TRYPTOPHAN IN CHLORPROMAZINE TREATED CHRONIC 
SCHIZOPHRENICS ON WITHDRAWAL AND RESTORATION OF DRUG 
THERAPY. 

235629 02-08 
CHANGES IN PSYCHOACTIVE DRUG USE AMONG ADULTS IN 
METROPOLITAN TORONTO - 1971-1974. 

236046 02-17 
RECENT DEVELOPMENTS IN THE DRUG TREATMENT OF SCHIZOPHRENIA. 

236751 02-08 
ASSISTING MULTIPLE DRUG ADDICTS. PSYCHOTHERAPY AND 
PSYCHOPHARMACOLOGY. 

237095 02-11 
DRUG DISSOCIATION OF NEUROELECTRICAL AND BEHAVIORAL 
RESPONSES IN MICE (PH.D. DISSERTATION). 

238159 02-03 



1 



DRUG PERMEATION THROUGH MEMBRANES V: INTERACTION OF 
DIAZEPAM WITH COMMON EXCIPIENTS. 

238485 02 
DOPAMINE AND PSYCHOACTIVE DRUG ACTION: A FURTHER 
EVALUATION. 

238768 03 
CONDITIONED AND UNCONDITIONED DRUG EFFECTS IN A CLASSICAL 
CONDITIONING PARADIGM. 

238787 03 
THERAPEUTIC ATTEMPTS WITH LITHIUM IN YOUNG DRUG ADDICTS. 

238988 03 
SUBJECTIVE RATINGS OF SLEEP QUALITY AND ANXIETY AFTER PLACES 
DRUG AND A FOOD DRINK. 

239059 03 
REVIEW OF DRUG TREATMENT FOR DOWNS- SYNDROME PERSONS. 

239074 03 
DRUG EFFECTS ON LEARNING: A TWO STAGE DRUG SCREEN UTILIZING 
FIXED-RATIO AND SERIAL DISCRIMINATION REVERSAL LEARNING. 
(PH.D. DISSERTATION). 

239533 03 
DEPRESSED 5-HYDROXYINDOLE LEVELS ASSOCIATED WITH HYPERACTI' 
AND AGGRESSIVE BEHAVIOR: RELATIONSHIP TO DRUG RESPONSE. 

239936 03 
INTRODUCTION: THE CONTROL OF BEHAVIOR BY CONSEQUENT DRUG 
INJECTIONS. 

240009 03 
STIMULI ASSOCIATED WITH DRUG INJECTIONS AS EVENTS THAT 
CONTROL BEHAVIOR. 

24001 1 03 
INTRODUCTION: COMPLEX SCHEDULES OF DRUG INJECTION. 

240012 03 
PHARAAACOLOGICAL AND ENVIRONMENTAL VARIABLES AFFECTING 

DRUG PREFERENCE IN RHESUS MONKEYS. 

240013 03 
DRUG EFFECTS AND CONCURRENT PERFORMANCES. 

240016 03 
INTRODUCTION: SCHEDULES OF TERMINATION OF DRUG INJECTIONS. 

240017 03 
DRUG EFFECTS AND THE ENVIRONMENTAL CONTROL OF BEHAVIOR. 

240021 03 
DRUG INJECTIONS AS NEGATIVE REINFORCERS. 

240022 03 
DRUG TREATMENT IN PSYCHIATRY. 

240086 03 
EXPERIMENTAL HUAAAN DRUG SELF-ADMINISTRATION: METHODOLOO 
AND APPLICATION TO THE STUDY OF SEDATIVE ABUSE. 

240831 03 
DRUG RECEPTOR INTERACTIONS OF MORPHINE AND NALORPHINE: 
COMPETITIVE DUALISM VERSUS RECEPTOR DUALISM. (PH.D. 
DISSERTATION). 

240934 03 
THEORETICAL AND METHODOLOGICAL CONSIDERATIONS ON DRUG 
DISCRIMINATION LEARNING. 

241228 03 
AN INTEGRATED APPROACH FOR THE VALUATION OF PSYCHOTROPIC 
DRUG IN MAN: I. STUDIES ON AMPHETAMINE. RELATIONSHIP 
BETWEEN DRUG LEVELS AND PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241234 03 
INFLUENCE OF DIURNAL CYCLES ON BIOCHEMICAL PARAMETERS OF 
DRUG SENSITIVITY: THE PINEAL GLAND AS A MODEL. 

241471 03 
DRUG DISCRIMINATION IN RATS: EFFECTS OF MIXTURES OF DITRAN A 
CHOLINESTERASE INHIBITORS. 

242737 03 
RATE DEPENDENT DRUG EFFECTS: POSSIBLE STATE-DEPENDENCY. 

242739 03 
DRUG-INDUCED CONDITIONED SUPPRESSION: SPECIFICITY DUE TO DRU 
EMPLOYED AS UCS. 

242750 04 
IN VIVO AND IN VITRO EFFECTS OF DELTA9-TETRAHYDROCANNABIN0L 
ON RAT LIVER MICROSOMAL DRUG METABOLIZING ENZYMES. 

243182 04 
DEATH AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL. 

243716 04 
DRUG THERAPY IN CHILD CARE. 

243897 04 
PSYCHOPHARMACOLOGIC AGENTS: EFFECT ON DRUG METABOLISM. 

244060 04 
DEVELOPMENT OF DRUG SENSITIVE SYMPTOM RATING SCALES. 

244063 04 
PSYCHOTOGENIC DRUG ACTION ON CHEMICALLY DEFINED NEURONS. 

244072 04 
PERSONALITY FACTORS AND DRUG EFFECTS IN A CONTROLLED STUDY 
OF CYCLAZOCINE. 

244298 04- 



S-120 



/OLUME 14, SUBJECT INDEX 



Subject Index 



THE DRUG TREATMENT OF MOOD DISORDERS. PART II; ANTIMANIC AND 
ANTIDEPRESSANT AGENTS, MAINTENANCE TREATMENT, AND RECENT 
ADVANCES. (UNPUBLISHED PAPER). 

244574 04-09 
EFFECTS OF DRUG STATE CHANGE ON DISCRIMINATION PERFORMANCE. 

244679 04-04 
THE BEHAVIORAL PHARMACOLOGY OF BUTACLAMOL HYDROCHLORIDE 
(AY-23028), A NEW POTENT NEUROLEPTIC DRUG, 

245295 04-04 
DRUG DISCRIMINATION IN RATS: THE EFFECTS OF PHENCYCLIDINE AND 
DITRAN. 

245297 04-04 
LONG-TERM EFFECTS OF BARBITAL ON SPONTANEOUS ACTIVITY OF RATS 
TRAINED TO USE THE DRUG AS A DISCRIMINATIVE STIMULUS. 

245299 04-04 
DRUG THERAPY: SULFASALAZINE. 

245307 04-13 
DEPRESSION, DELUSION AND DRUG RESPONSE. 

245784 04-09 
OSTEOMALACIA ASSOCIATED WITH ANTICONVULSANT DRUG THERAPY 
IN MENTALLY RETARDED CHILDREN. 

245806 04-15 
DRUG THERAPY: NEUROLOGIC SYNDROMES ASSOCIATED WITH 
ANTIPSYCHOTIC DRUG USE. 

246061 04-15 
DRUG INTERACTIONS. 

246296 04-15 
COMBINATION DRUG THERAPY FOR THE PSYCHOGERIATRIC PATIENT: 
COMPARISON OF DOSAGE LEVELS OF THE SAME PSYCHOTROPIC 
DRUGS, USED SINGLY AND IN COMBINATION. 

246694 04-11 
GLC DETERMINATION OF PLASMA DRUG LEVELS AFTER ORAL 
ADMINISTRATION OF CLORAZEPATE POTASSIUM SALTS. 

246968 04-03 
METABOLIC FATE OF FLURAZEPAM II: A NEW POTENT METABOLITE 
OBTAINED BY IN VITRO LIVER DRUG METABOLIZING ENZYME SYSTEM. 

246971 04-03 
OPIATE RECEPTOR IN NORMAL AND DRUG ALTERED BRAIN FUNCTION. 

246996 04-03 
EFFECTS OF A CHOLINE-DEFICIENT DIET ON THE INDUCTION OF DRUG 
AND ETHANOL METABOLIZING ENZYMES AND ON THE ALTERATION OF 
RATES OF ETHANOL DEGRADATION BY ETHANOL AND 
PHENOBARBITAL, 

247032 04-03 
DRUGS AND PUNISHED RESPONDING VI: BODY WEIGHT AS A 
DETERMINANT OF DRUG EFFECTS. 

247845 04-04 
NEW METHOD FOR DETECTING AND QUANTITATING PHARMACOKINETIC 

DRUG DRUG INTERACTIONS APPLIED TO ETHANOL PROPRANOLOL. 

247846 04-06 
THIRD PSYCHOACTIVE DRUG USAGE GUIDE. 

247880 04-17 
CONNERS TEACHER RATING SCALE FOR USE IN DRUG STUDIES WITH 
CHILDREN - AN EMPIRICAL STUDY. 

248593 04-11 
INHIBITION OF DRUG METABOLISM BY FLUOXETINE, 

248605 04-02 
A PRACTICAL CLASSIFICATION OF UNTOWARD DRUG EFFECTS. 

248909 04-15 
THE PERIAQUEDUCTAL GRAY AND ANALGESIA: FURTHER STUDIES OF 
DRUG AND TEST SPECIFICITY 

249248 04-03 
DRUG THERAPY IN MENTAL HANDICAP. 

249525 04-17 
DEVELOPMENT OF THE INFLUENCES OF SODIUM, CATECHOLAMINE AND 
TRICYCLIC ANTIDEPRESSANT DRUG ON THE UPTAKE OF 3H-5- 
HYDROXYTRYPTAMINE BY RAT BRAIN SYNAPTOSOMES. 

249667 04-03 
COMPENDIUM OF PHARMACOLOGY DRUG CHARTS. 

249768 04-17 
EXTINCTION-INDUCED MIRROR RESPONDING AS A BASELINE FOR 
STUDYING DRUG EFFECTS ON AGGRESSION. 

250073 04-06 
DRUG ANTAGONISM AND REVERSIBILITY OF THE BINDING OF 
INOOLEAMINES IN BRAIN. 

250081 04-03 
REVERSAL BY A CENTRAL ANTIACETYLCHOLINE DRUG OF PIMOZIDE- 
INDUCED INHIBITION OF MOUSE JUMPING IN AMPHETAMINE DORA 
TREATED MICE. 

250656 04-03 
BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF THIOTHIXENE: RELATION 
TO TISSUE LEVELS OF THE DRUG 

251131 04-03 
SOME EFFECTS OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A 
PURPORTED HASHISH AND LSD ANTAGONIST, ON BRAIN 
NORADRENERGIC AND SEROTONERGIC SYSTEMS. 

251534 04-03 
SOME PHARMACOLOGICAL ASPECTS OF DRUG DEPENDENCE. 

251561 0413 



URGENT PHARMACOTHERAPY FOR DRUG ABUSE. 

251755 04-17 
THE RELATIONSHIP BETWEEN ACETYLATOR STATUS AND INHIBITION OF 
MONOAMINE-OXIDASE, EXCRETION OF FREE DRUG AND 
ANTIDEPRESSANT RESPONSE IN DEPRESSED PATIENTS ON PHENELZINE. 

251985 04-10 
DRUG RESEARCH AND THE QUESTION OF CONSENT. 

252314 04-17 
RECENT ADVANCES IN THE DRUG TREATMENT OF THE FUNCTIONAL 
PSYCHOSES. 

252653 04-09 
DRUG AND PSYCHOTHERAPY INTERACTIONS IN DEPRESSION. 

252941 04-09 
PATTERNS AND PROBLEMS OF DRUG CONSUMPTION IN A DEVELOPING 
COUNTRY. 

252990 04-17 
DIGITALIS: CLINICAL IMPLICATIONS OF NEW FACTS ABOUT AN OLD 
DRUG. 

253495 04-15 
OUTPATIENT PHENOTHIAZINE USE AND BONE MARROW DEPRESSION: A 
REPORT FROM THE DRUG EPIDEMIOLOGY UNIT AND THE BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM. 

253661 04-15 
INTERACTIONS BETWEEN DRUGS AND SALIVA STIMULATING PARAFILM 
AND THEIR IMPLICATIONS IN MEASUREMENTS OF SALIVA DRUG 
LEVELS. 

253693 04-03 
DRUG-INDUCED 

EFFECTS OF DRUG EXPERIENCE ON DRUG-INDUCED CONDITIONED TASTE 
AVERSIONS: STUDIES WITH AMPHETAMINE AND FENFLURAMINE. 

230829 01-04 
INVOLVEMENT OF BIOGENIC AMINES IN DRUG-INDUCED AGGRESSIVE 
PECKING IN CHICKS. 

230878 01-04 
DOSE-RESPONSE RELATIONS IN DRUG-INDUCED INAPPROPRIATE 

SECRETION OF ADH: EFFECTS OF CLOFIBRATE AND CARBAAAAZEPINE. 

232638 02-13 
DRUG-INDUCED STEREOTYPED BEHAVIOR: SIMILARITIES AND 
DIFFERENCES. 

233963 02-03 
DRUG-INDUCED RHYTHMICAL ACTIVITY IN THE INFERIOR OLIVARY 
COMPLEX OF THE RAT. 

235866 02-03 
EFFECT OF MORPHINE ANTAGONISTS ON DRUG-INDUCED HYPOTHERMIA 
IN MICE AND RATS, 

237100 02-03 
INHIBITION OF DRUG-INDUCED ANOREXIA IN RATS BY METHYSERGIDE 

237745 02-04 
UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF NIGROSTRIATAL OR 
MESOLIMBIC DOPAMINE CONTAINING TERMINALS AND THE DRUG- 
INDUCED ROTATION OF RATS. 

237866 02-03 
CORTICAL DISINHIBITION: A POSSIBLE MECHANISM FOR DRUG-INDUCED 
HALLUCINATIONS. 

238830 03-03 
ANTIDOPAMINERGIC AND ANTIMUSCARINIC EFFECTS OF 
DIBENZODIAZEPINES: RELATIONSHIP TO DRUG INDUCED 
PARKINSONISM. 

241248 03-03 
SPONTANEOUS AND DRUG-INDUCED ROTATION (CIRCLING BEHAVIOR) IN 
THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS). 

241311 03-04 
THE POTENTIATING EFFECT OF LICL ON ADRENERGIC DRUG-INDUCED 
AGGRESSIVE BEHAVIOR IN MICE. 

241364 03-04 
DRUG-INDUCED CHANGES IN BODY TEMPERATURE AND 5 

HYDROXYTRYPTAMINE (5-HT) TURNOVER RATE IN THE RAT BRAIN. 

241395 03-03 
PSYCHOPHARMACOLOGICAL CHARACTERIZATION OF A DRUG-INDUCED 
GROOMING BEHAVIOR IN THE CRICKET, ACHETA-DOMESTICUS 
(INSECTA, ORTHOPTERA). (PH.D. DISSERTATION). 

241994 03-04 
DRUG-INDUCED CONDITIONED SUPPRESSION: SPECIFICITY DUE TO DRUG 
EMPLOYED AS UCS. 

242750 04-04 
DRUG-INDUCED PARKINSONISM IN THE RAT - A MODEL FOR 

BIOCHEMICAL INVESTIGATION OF THE PARKINSON SYNDROME: III: 
THE INCORPORATION OF D GLUC0SE-14C(U) IN AMINO-ACIDS OF 
BRAIN AND LIVER FROM RATS PRETREATED WITH RESERPINE OR 
WITH PHENOTHIAZINES. 

244692 04-03 
A CONTROLLED TRIAL OF AMANTADINE IN DRUG-INDUCED 
EXTRAPYRAMIDAL DISORDERS. 

244701 04-15 
DRUG-INDUCED CHANGES IN BEHAVIOUR AND GANGLIONIC 
ACETYLCHOLINE CONCENTRATION OF THE LEECH. 

245595 04-03 
DRUG-INDUCED EXTRAPYRAMIDAL EFFECTS -■ A REVIEW. 

246187 04-15 






'•n 



SSL 

^:. 



;??. 



S-121 



Subject Index 



Psychopharmacology Abstracts 



DRUG INDUCED ALTERATIONS OF SLOW POTENTIAL RESPONSES IN THE 
RAT 

249250 04-03 
EFFECTS OF DIAZEPAM ON SIX DRUG-INDUCED LOCOMOTOR 
HYPERACTIVITIES IN MICE. 

249677 0404 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACIDS 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG-INDUCED 
BEHAVIORAL EXCITATION. 

250067 04-04 
HYPOTHALAMIC LESIONS AND DRUG-INDUCED ANOREXIA 

250938 04-03 
MANAGEMENT OF PATIENTS WITH SUSPECTED DRUG-INDUCED 
PSYCHOSES 

252733 04-15 
DRUG-INFORAAATION-CENTER 

TOXICOLOGY UPDATE OF THE ARKANSAS POISON CONTROL DRUG- 
INFORMATION-CENTER; THE TRICYCLIC ANTIDEPRESSANTS. 

245822 04-13 
DRUG-NAIVE 

EFFECTS OF BENZODIAZEPINE ANTIANXIETY AGENTS ON PUNISHED 
(CONFLICT) AND UNPUNISHED BEHAVIOR IN DRUG-NAIVE RATS. 

238697 03-04 
DRUG-REINFORCED 

FOOD AND DRUG-REINFORCED RESPONDING: EFFECTS OF DITA AND D- 
AMPHETAMINE 

227127 01-04 
DRUGGING 

DRUGGING TO SUPPRESS BEHAVIOR. 

252315 04-17 
DRUGS 

ACUTE SEDATIVE PROPERTIES OF SKF-525-A IN RATS: IMPLICATIONS FOR 
ITS USE AS A METABOLISM INHIBITOR IN THE STUDY OF 
PSYCHOACTIVE DRUGS. 

225572 01-03 
DRUGS IN THE MANAGEMENT OF LEARNING AND BEHAVIOR DISORDERS 
IN SCHOOL CHILDREN. 

225783 01-14 
fSYCHOTROPIC DRUGS AND GENDER AS MODIFIERS OF THE ROLE OF 
PLASMA TRYPTOPHAN AND SEROTONIN IN SCHIZOPHRENIA. 

225935 01-08 
PSYCHOTROPIC DRUGS AND THE HUMAN EEG 

226725 01-16 
INFLUENCE OF DRUGS ON STRIATAL AND LIMBIC HOMOVANILLIC-ACID 
CONCENTRATION IN THE RAT BRAIN. 

226727 01-03 
DEPLETION OF S-ADENOSYL-L-METHIONINE IN MOUSE BRAIN BY 
ANTIDEPRESSIVE DRUGS. 

226850 01-03 
RATE-DEPENDENT EFFECTS OF DRUGS ON THE VARIABLE-INTERVAL 
BEHAVIOR OF RATS. 

226854 01-04 
SIDE EFFECTS OF TRICYCLIC ANTIDEPRESSANT DRUGS WITH PARTICULAR 
REFERENCE TO DOTHIEPIN. 

226897 01-15 
PSYCHOTROPIC DRUGS AND IMPARIMENT OF PSYCHOMOTOR 
FUNCTIONS 

227136 01-15 
TESTING PSYCHOTROPIC DRUGS IN GENERAL PRACTICE. 

227223 01-16 
TRANSPLACENTAL EFFECTS OF DRUGS ON HEARING, VISION, AND 
BEHAVIOUR 

227391 01-05 
THE NONCONTRIBUTION OF DRUGS TO THE DISCHARGE OF THE LONG- 
STAY PSYCHIATRIC PATIENT. 

227461 0117 
OPHTHALMOLOGICAL FINDINGS ON NEUROPSYCHIATRIC PATIENTS 
DURING PSYCHOPHARMACOTHERAPY: II. SEVEN CASES DUE 10 
ANTIPSYCHOTIC DRUGS 

227808 01-15 
A COMBINATION OF ANTIANXIETY DRUGS: REPORT FROM THE GENERAL 
PRACTITIONER RESEARCH GROUP, 

228207 01 10 
HOW DRUGS ACT -11 DRUGS AND SLEEP. 

228997 01-13 
SELECTED BIBLIOGRAPHY ON DETECTION OF DEPENDENCE PRODUCING 
DRUGS IN BODY FLUIDS. 

22911201-17 
ATTEMPTS AT A NEUROCHEMICAL INTERPRETATION OF NATURAL 
BEHAVIOR AND BEHAVIOR MODIFIED BY NEUROLEPTIC DRUGS. 

229113 01-14 
DRUGS FOR MENTAL DISORDERS OF OLD AGE. 

229315 01-11 
THE IMPORTANCE OF REINFORCEMENT SCHEDULES IN DETERMINING 
EFFECTS OF DRUGS. 

229428 01-04 
STRATEGIES OF BASIC RESEARCH IN DEVELOPMENT OF DRUGS. 

229429 01-06 



STRUCTURE-ACTIVITY RELATIONSHIPS FOR AGONIST AND ANTAGONIST 
DRUGS AT PRESYNAPTIC AND POSTSYNAPTIC RECEPTOR SITES IN RAT 
BRAIN. 

229435 01-03 
A NOVEL APPROACH TO QUANTITATIVE DETERMINATION OF 
SUBNANOMOLES OF PSYCHOACTIVE DRUGS IN BLOOD. 

229441 01-16 
DRUGS AND PSYCHOTHERAPY IN DEPRESSION REVISITED: ISSUES IN THE 
ANALYSIS OF LONG-TERM TRIALS. 

229450 01-09 
RESPONSE OF THE ELDERLY TO PSYCHOTROPIC DRUGS: PREDICTABLE OR 
IDIOSYNCRATIC 

229457 01-11 
DRUGS, BEHAVIOR, AND THE CHOLINERGIC NERVOUS SYSTEM. 

229485 01-04 
ANALYSIS OF DRUGS AND PSYCHOACTIVE PHENOLIC AMINES. 

229486 01-03 
MODIFICATION OF THE FRUSTRATION EFFECT WITH DRUGS. 

229487 01-04 
DRUGS, AGGRESSION, AND NEUROCHEMISTRY. 

229488 01-04 
EFFECTS OF PSYCHOTROPIC DRUGS ON BRAIN NUCLEAR RNA. 

229494 01-03 
THE POSITION OF LONG-ACTING DRUGS IN THE ECONOMY OF 
PSYCHIATRIC INSTITUTIONS. 

229558 01-17 

FLUPHENAZINE-DECANOATE IN ASSOCIATION WITH OTHER 
PSYCHOTROPIC DRUGS (PRELIMINARY NOTE). 

229561 01-17 
THE EFFECTS OF DRUGS ON PSYCHIATRIC PATIENTS PERFORAAANCE ON 
THE HALSTEAD-REITAN NEUROPSYCHOLOGICAL TEST BATTERY. 

229650 01-14 
AN ELECTROENCEPHALOGRAPHIC STUDY ON PSYCHOTROPIC DRUGS. 

229725 01-14 
INFLUENCE OF PSYCHOTROPIC DRUGS ON CHRONIC SCHIZOPHRENIC 
SYNDROMES - WITH SPECIAL EMPHASIS ON THE CHANGE IN CLINICAL 
PROCESS WITH A RELATIVELY HIGH DOSAGE OF SPIROPERIDOL. 

229761 01-08 
CLINICAL EXPERIENCES WITH ANTIDEPRESSANT DRUGS IN THE 
TREATMENT OF ANXIOUS PHOBIC PATIENTS. 

230015 01-10 
CLINICAL USE OF DRUGS FOR SLEEP DISTURBANCES. 

230119 01-17 
BEHAVIORAL EFFECTS OF ANTIEPILEPTIC DRUGS. 

230368 01-11 
DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN MAMMALIAN BRAIN: A 
POSSIBLE SITE OF ACTION OF ANTIPSYCHOTIC DRUGS. 

230602 01-13 
POISONING BY TRICYCLIC ANTIDEPRESSANT DRUGS: GENERAL AND 
PHARMACOKINETIC CONSIDERATIONS. 

230820 0) -15 
THE EFFECT OF L-DOPA ON YOUNG PATIENTS WITH SIMPLE 

SCHIZOPHRENIA, TREATED WITH NEUROLEPTIC DRUGS: A DOUBLE- 
BLIND CROSSOVER TRIAL WITH AAADOPAR AND PLACEBO. 

230823 01 08 
STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 
EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT. 

230860 01 03 
MODIFICATION OF THE BEHAVIORAL RESPONSE TO DRUGS IN RATS 
EXPOSED PRENATALLY TO CHLORPROMAZINE. 

230864 01-04 
PSYCHOACTIVE DRUGS AND SOCIAL JUDGMENT: THEORY AND 
RESEARCH. 

231066 01-14 

THE EFFECT OF PSYCHOTROPIC DRUGS ON CONDITIONED REFLEXES 
AFTER AN EMOTIONAL STRESS IN CATS. 

231069 01-04 
DRUGS AND BEHAVIOR: A PRIMER IN NEUROPSYCHOPHARMACOLOGY. 

23122701 17 
THE USE OF ANTIDEPRESSANT DRUGS IN SCHIZOPHRENIA. 

231277 01-08 
CARDIOVASCULAR SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS -■ A 
RISK IN THE USE OF THESE DRUGS. 

23131701-15 
STUDIES ON THE MECHANISM OF ACTION OF TRICYCLIC 
ANTIDEPRESSANT DRUGS, USING IPRINDOLE AS A TOOL. (PH.D. 
DISSERTATION). 

231438 01-03 
SIDE-EFFECT'= OF PSYCHOTROPIC DRUGS. 

231991 01-15 
ADVERSE REACTIONS ASSOCIATED WITH MOOD-ALTERING DRUGS. 

231995 01 15 
THE THERAPY OF AUTONOMIC REGULATORY DISTURBANCES THROUGH 
DRUGS 

232260 01 15 
BEHAVIORAL AND BIOCHEMICAL INTERACTIONS OF 5,7 
DIHYDROXYTRYPTAMINE WITH VARIOUS DRUGS WHEN 



S-122 



4 



HUME 14, SUBJECT INDEX 



Subject Index 



ADMINISTERED INTRACISTERNALLY TO ADULT AND DEVELOPING 
RATS. 

232609 02-04 
ANXIOLYTIC DRUGS. 

232704 02-10 
EFFECTS OF PSYCHOTROPIC DRUGS ON THE PGO ACTIVITIES (PGO 
ACTIVITY IN THE REM SLEEP AND RESERPINEINDUCED PGO ACTIVITY). 

233077 02-04 
THE INFLUENCE OF ALCOHOL AND OTHER DRUGS ON MENTAL TASK 
PERFORMANCES UNDER THEIR COMBINED ADMINISTRATION. 

233281 02- 14 
INDIVIDUAL DIFFERENCES AND SETTING AS DETERMINANTS OF ACUTE 
ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS. 

233377 02-12 
CONDITIONED AVERSION BY PSYCHOACTIVE DRUGS: DOES IT HAVE 
SIGNIFICANCE FOR AN UNDERSTANDING OF DRUG DEPENDENCE 

233488 02-14 
DRUGS FOR EMOTIONAL DISORDERS: CURRENT PROBLEMS. 

233514 02-17 
CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
BIOCHEMICAL MECHANISMS OF ACTION AND PHARMACOKINETICS OF 

PSYCHOTROPIC DRUGS. 

233682 02-17 
PHARMACOPSYCHOLOGICAL STUDIES IN NORMAL SUBJECTS WITH A 

VIEW TO PREDICTING THE THERAPEUTIC EFFICIENCY OF 
PSYCHOTROPIC DRUGS. 

233683 02-17 
THE ROLE OF CLINICAL PSYCHIATRY IN THE DEVELOPMENT OF NEW 

PSYCHOTROPIC DRUGS. 

233684 02-17 
THE DYSTONIC HYPERKINETIC SYNDROME: A CASUISTICAL 

CONTRIBUTION TO THE UNDERSTANDING OF THE ACTIONS OF DRUGS 
IN CHILDREN. 

233717 02-11 
XEROSTOMIA AND ASIALIA CAUSED BY PSYCHOTROPIC DRUGS AND 

THEIR TREATMENT WITH TPMP (TRITHIO-P-METHOXYPHENYLPROPENE). 

233718 02-15 
THE USE OF SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS TO 

MODIFY AMINE METABOLISM IN BRAIN. 

233947 02-03 
CATECHOLAMINES, DRUGS, AND BEHAVIOR: MUTUAL INTERACTIONS. 

233968 02-04 
DRUGS IN COMBINATION WITH OTHER THERAPIES. 

234378 02-17 
EXPERIMENTAL STUDIES ON THE EFFECT OF SOME PSYCHOTROPIC 
DRUGS AND PYRAZOLE ON THE RATE OF ETHANOL OXIDATION IN 
VIVO AND IN THE PERFUNDATED RAT LIVER IN VITRO. 

234522 02-03 
CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
PSYCHOTROPIC DRUGS. 

234797 02-09 
NOREPINEPHRINE METABOLISM AFTER SHORT-TERM AND LONG-TERM 
ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANT DRUGS AND 
ELECTROCONVULSIVE SHOCK. 

234804 02-03 
ADAPTIVE CHANGES IN BEHAVIOR AFTER REPEATED ADMINISTRATION 
OF VARIOUS PSYCHOACTIVE DRUGS, 

234810 0204 
INTRODUCTION TO THE SYMPOSIUM ON SYSTEMATIC STUDIES WITH 
PSYCHOACTIVE DRUGS - NEW METHODS IN THE ASSESSMENT OF 
CHANGE. 

235355 02-17 
HOW DRUGS ACT - 26: DRUGS AND THE MENTAL STATE. 

235638 02-17 
A CLINICAL CONTRIBUTION ON THE EFFECTS OF SUSPENDING 
ANTIPARKINSONIAN DRUGS IN PROLONGED TREATMENT WITH 
NEUROLEPTIC DRUGS, 

235992 02-11 
THE NATURE OF BACKGROUND SPIKE ACTIVITY OF CORTICAL NEURONS 
UNDER THE ACTION OF PSYCHOTROPIC DRUGS, 

236265 02-03 
PRACTICAL CONSIDERATIONS ON TREATMENT WITH ANTIPSYCHOTIC 
DRUGS 

236359 02-08 
EFFECT OF PSYCHOTROPIC DRUGS ON (H3) GAMMA-AMINOBUTYRIC- 
ACID UPTAKE BY SYNAPTOSOMES OF THE RAT BRAIN, 

236370 0203 
TESTING OF NEW PSYCHOTROPIC DRUGS ON OUTPATIENTS, 

236811 02-17 
CLINICAL USE OF ANTIANXIETY DRUGS, 

237165 02-10 
METABOLISM OF 5-HYDR0XYTRYPT0PHAN-14C AFTER INTRACISTERNAL 
INJECTION WITH AND WITHOUT THE INFLUENCE OF DRUGS IN THE 
RAT BRAIN, 

237700 02-03 



A DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR BY INTRAVENOUS 
ADMINISTRATION OF DRUGS IN RATS, 

237701 02-04 
EFFECTS OF SCOPOLAMINE, D-AMPHETAMINE AND OTHER DRUGS 
AFFECTING CATECHOLAMINES ON SPONTANEOUS ALTERNATION AND 
LOCOMOTOR ACTIVITY IN MICE, 

237703 02-04 
THE POTENTIATION OF CONDITIONED REINFORCEMENT BY 

PSYCHOMOTOR STIMULANT DRUGS. A TEST OF HILLS HYPOTHESIS. 

237711 02-04 
SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS AS AIDS IN 
EVALUATING THE ROLE OF TYPE A AND B ENZYMES. 

237776 02-03 
BA,RBITURATE REINFORCED RESPONDING IN RHESUS MONKEYS: 
COMPARISONS OF DRUGS WITH DIFFERENT DURATIONS OF ACTION 

237874 02-04 
THE INCREASE IN BRAIN TRYPTOPHAN CAUSED BY AMPHETAMINE-LIKE 
DRUGS: CORRELATION WITH AN INCREASE IN BODY TEMPERATURE. 

237891 02-03 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE- BIOCHEMICAL AND 

PHARMACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE AS 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINE 
AND OTHER PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION). 

238077 02-03 
EFFECTS OF PSYCHOTROPIC DRUGS ON PROSTAGLANDIN BIOSYNTHESIS 
IN \'ITRO. 

238320 0203 
ANALYTICAL STUDY OF ACQUISITION ON FREE-OPERANT AVOIDANCE 
RESPONSE FOR EVALUATION OF PSYCHOTROPIC DRUGS IN RATS. 

238564 02-04 
MODIFICATION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS BY 
DRUGS WHICH ALTER BRAIN CATECHOLAMINE LEVELS OR STIMULATE 
CATECHOLAMINE RECEPTORS, 

238734 03-03 
LONG-TERM CONSUMPTION OF A TRYPTOPHAN POOR DIET ALTERS THE 
BEHAVIORAL RESPONSE TO DRUGS 

238741 03-03 
EFFECTS OF SOME PSYCHOTROPIC DRUGS ON AGGRESSIVE BEHAVIOR IN 
RATS, 

238754 03-04 
EFFECTS OF TRANQUILIZER DRUGS ON GABA RELEASE IN VITRO, 

238779 03-03 
EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONOAMINE 
METABOLISM, 

238838 03-03 
SLEEP AND HYPNOTIC DRUGS: THE PHYSIOLOGY, PHARMACOLOGY AND 
CLINICAL ASPECTS OF SLEEP. 

239029 03-14 
EFFECT OF ANTIDIURETIC DRUGS IN RATS WITH LITHIUM-INDUCED 
POLYURIA. 

239041 03-05 
EFFECT OF CONVULSIONS AND ANTICONVULSIVE DRUGS ON 
CEREBROSPINAL FLUID CYCLIC-AMP IN RABBITS. 

239090 03-03 
EFFECT OF SOME INTRACEREBRALLY ADMINISTERED DRUGS ON A 
CONDITIONED REFLEX IN THE CAT 

239275 03-04 
MEDICAL DOMINANCE: PSYCHOACTIVE DRUGS AND MENTAL HEALTH 
POLICY 

239298 03-17 
CONDITIONED SUPPRESSION OF AN OPERANT RESPONSE USING DRUGS 
AS CONDITIONED STIMULI. (PH.D. DISSERTATION). 

239523 03-04 
REFLECTIONS ON PSYCHIATRIC ASSISTANCE IN AN OUTPATIENT 
GERIATRIC CENTER: THE USE OF PSYCHOTROPIC DRUGS 

239641 03-11 
EFFECTS IF SOME DRUGS ON PSYCHOSEXUAL RESPONSE IN MAN. 

239646 03-14 
HIGHER UNIT DOSAGE OF PSYCHOTROPIC DRUGS. 

239679 03- 1 7 
HIGHER UNIT DOSAGE OF PSYCHOTROPIC DRUGS. 

239680 03 17 
OBSTACLES IN IMPLEMENTATION OF HIGHER UNIT DOSAGE OF 

PSYCHOTROPICS DRUGS. 

239681 03-17 
OPEN WITHDRAWAL OF ANTIPARKINSON DRUGS IN THE NEUROLEPTIC- 

INDUCED PARKINSON SYNDROME 

239822 03-15 
ALTERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS AFTER CHRONIC HALOPERIDOL: INDIRECT EVIDENCE FOR 
CHOLINERGIC HYPOSENSITIVITY. 

239826 03-04 
EVALUATION OF PSYCHOTROPIC DRUGS: A SYMPOSIUM. 

239846 03-17 
DUAL ACTION OF MORPHINE AND RELATED DRUGS ON COMPULSIVE 
GNAWING OF RATS. 

239860 03-04 






ftmrna 

ClKU 

31SB" 
t 



4 "I' 

285 



S-123 



Subject Index 



CHARACTERISTICS OF BEHAVIOR CONTROLLED BY SCHEDULED 
INJECTIONS OF DRUGS 

240010 03-04 

PSYCHOTROPIC DRUGS AS NEGATIVE REINFORCERS. 

240020 0304 
TREATMENT OF DEPRESSION WITH TRICYCLIC DRUGS - 
PHARMACOKINETIC AND PHARMACODYNAMIC ASPECTS, 

240216 03-09 
CHANGES IN THE PHARMACODYNAMICS AND PHARMACOKINETICS OF 
PSYCHOLEPTIC DRUGS IN RADIATION SICKNESS, EFFECT OF X-RAY 
RADIATION ON PHARMACODYNAMIC ACTIVITY OF NITRAZEPAM IN 
ANIMALS, 

240237 03-04 
PSYCHOTROPIC DRUGS AND THE ANTIDEPRESSED PERSONALITY. 

240251 03-15 
ASTONIN-H IN THE TREATMENT OF ARTERIAL HYPERTENSION DUE TO 
PSYCHOTROPIC DRUGS, 

240261 03-15 
THE USE AND MISUSE OF PSYCHOTROPIC DRUGS IN CHILDREN. 

240522 03-17 
STIMULANT DRUGS FOR HYPERACTIVITY: SOME ADDITIONAL 
DISTURBING QUESTIONS. 

240599 03-17 
PHARMACOLOGY OF PSYCHOACTIVE DRUGS. 

240704 03-17 
EFFICIENCY PROFILES OF TRANQUILIZERS AND BROAD SPECTRUM 
PSYCHOSOMATIC DRUGS. 

240706 03-17 
PSYCHOPHARMACOLOGICAL DRUGS IN NEUROLOGY. 

240708 03- 17 
DO ANORECTIC DRUGS PRODUCE WEIGHT LOSS BY APPETITE 
SUPPRESSION^. 

240802 03-13 
A PRIMER ON THE CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS. 

240838 03-17 
EFFECTS OF CHOLINERGIC DRUGS ON ABNORMAL SOCIAL BEHAVIOR IN 
THE RHESUS MONKEY. (PH D, DISSERTATION), 

241109 03-04 
EFFECTS OF STIMULATORY AND DEPRESSANT DRUGS ON CYCLIC 
GUANOSINE 3,5 MONOPHOSPHATE AND ADENOSINE 3.5 
MONOPHOSPHATE LEVELS IN MOUSE BRAIN, 

241246 03-03 
INFLUENCE OF DRUGS AND CHEMICALS UPON HEPATIC ENZYMES AND 
PROTEINS - I, STRUCTURE-ACTIVITY RELATIONSHIP BETWEEN 
VARIOUS BARBITURATES AND MICROSOMAL ENZYME INDUCTION IN 
RAT LIVER, 

241297 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 
CURARIZED CAT: I, PGO WAVE ACTIVITY INDUCED BY RO-4-1284 AND 
BY P-CHLOROPHENYLALANINE (PCPA) AS A BASIS FOR 
NEUROPHARMACOLOGICAL STUDIES, 

241315 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: II, PGO WAVE ACTIVITY AND BRAIN 5- 
HYDROXYTRYPTAMINE, 

241316 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: III, PGO WAVE ACTIVITY AND BRAIN 
CATECHOLAMINES 

241317 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: IV, THE EFFECTS OF ACETYLCHOLINE, GABA AND 
BENZODIAZEPINES ON PGO WAVE ACTIVITY, 

241318 03-03 
DRUGS AND PGO WAVES IN THE LATERAL GENICULATE BODY OF THE 

CURARIZED CAT: V. MISCELLANEOUS COMPOUNDS. SYNOPSIS OF THE 
ROLE OF CENTRAL NEUROTRANSMITTERS ON PGO WAVE ACTIVITY. 

241319 03-03 
COMPARISON OF THE INHIBITORY EFFECTS OF NEUROLEPTIC DRUGS ON 

ADENYLATE-CYCLASE IN RAT TISSUES STIMULATED BY DOPAMINE, 
NORADRENALINE AND GLUCAGON. 

241347 03-03 
INFLUENCE OF PSYCHOTROPIC DRUGS AND BETADIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE (SKF-525-A) ON MESCALINE-INDUCED 
BEHAVIOR AND ON TISSUE LEVELS OF MESCALINE IN MICE, 

241349 03-04 
EFFECTS OF DRUGS INJECTED INTO THE HYPOTHALAMUS ON MURICIDE 
AND EEG IN THE OLFACTORY BULBECTOMIZED RATS, 

241367 03-04 
STUDIES ON THE CORRELATION BETWEEN BEHAVIOR AND BRAIN AMINES 
WITH PSYCHOTROPIC DRUGS, 

241378 03-04 
EFFECTS OF DRUGS ON TREMORINE-INDUCED TREMOR, 

241379 03-04 
CHANGES IN CARDIOVASCULAR RESPONSES TO BRAIN STIMULATION 

FOLLOWING OLFACTORY BULBECTOMY AND THE EFFECTS OF 
PSYCHOTROPIC DRUGS IN RATS, 

241389 03-03 



Psychopharmacology Abstracts 

EFFECTS OF ANTIANXIETY DRUGS ON CEREBRAL MONOAMINE 
TURNOVER. 

241392 03-03 
EFFECTS OF CHOLINERGIC DRUGS ON 5-HYDROXYTRYPTAMINE (5-HT) 
TURNOVER RATE IN THE RAT BRAIN. 

241396 03-03 
EFFECTS OF VARIOUS DRUGS ON LEARNING BEHAVIOR OF ANIAAALS 4TH 
REPORT. COMPARISON OF GABA AND ITS DERIVATIVES WITH 
ADRENERGIC AND CHOLINERGIC DRUGS. 

241401 03-04 
MODIFICATIONS OF EFFECTS OF CHLORPROMAZINE ON ADRENERGIC 
DRUGS AND BARBITURATES BY REPEATED ADMINISTRATION TO RATS. 

241406 03-03 
THERAPEUTIC USEFULNESS OF HALLUCINOGENIC DRUGS AS A FUNCTION, 
OF THEIR CHEMICAL STRUCTURE, 

241428 03-12 
VARIATIONS IN EFFECT OF MEMORY ALTERING DRUGS AS A FUNCTION 
OF THE STRENGTH OF THE LEARNED RESPONSE, (PH,D, DISSERTATION), 

241689 030' 
ARE NEUROLEPTIC DRUGS ANTICARCINOGENIC?. 

241736 03-1; 
COMPARISON TRIAL OF TWO ANTIPSYCHOTIC DRUGS: 
CHLORPROMAZINE AND CLOZAPINE. 

241760 03-0f 
ELECTROCONVULSIVE SHOCK INCREASES THE BEHAVIOURAL RESPONSES 
OF RATS TO BRAIN S-HYDROXYTRYPTAMINE ACCUMULATION AND 
CENTRAL NERVOUS SYSTEM STIMULANT DRUGS, 

241979 03-0' 
BRAIN, BEHAVIOUR AND DRUGS. 

242265 03-1; 
DOSAGE OF ANTIPSYCHOTIC DRUGS. 

242269 03-1: 
PSYCHOTROPIC DRUGS FROM THE PRACTITIONERS POINT OF VIEW. 

242720 03-1: 
DOPAMINE RECEPTOR BINDING PREDICTS CLINICAL AND 

PHARMACOLOGICAL POTENCIES OF ANTISCHIZOPHRENIC DRUGS 

243483 04-0: 
EFFECTS OF ANTICONVULSANT AND CONVULSANT DRUGS ON THE 
ATPASE ACTIVITIES OF SYNAPTOSOMES AND THEIR COMPONENTS. 

243801 04-0: 
EFFECTS OF DRUGS ACTING ON CEREBRAL 5-HYDROXYTRYPTAMINE 
MECHANISMS ON DOPAMINE-DEPENDENT TURNING BEHAVIOUR IN 
MICE. 

243803 04-0. 
SKELETAL MUSCLE NECROSIS FOLLOWING MEMBRANE ACTIVE DRUGS 
PLUS SEROTONIN. 

243813 04-0: 

CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
PSYCHOTROPIC DRUGS. 

243819 04-1 

ANORECTIC DRUGS. 

243869 04-1 
DRUGS AROUSAL, AND BRAIN STEADY POTENTIAL RESPONSES. 

243953 04-1 
COURSE AND RESULTS OF TREATMENT WITH THREE ACTIVATING 
NEUROLEPTIC DRUGS. 

244049 04-0 

CENTRAL ACTIONS OF HALLUCINOGENIC DRUGS. 

244071 04-1 
INTRACAUDATE NEUROTRANSMITTER PROCESSES IN RELATION TO 
RAPHE NEUROTRANSMITTER PROCESSES: A BEHAVIOURAL ANALYSIS 
OF INTRACEREBRALLY APPLIED DRUGS IN ACUTE AND LONG-TERM 
MORPHINE TREATED CATS 

244215 04-0 
THE INTERACTION BETWEEN DRUGS, ALCOHOL AND DRIVING AN 
AUTOMOBILE. 

244453 04-1 
A METHOD FOR BIOASSAY OF PHYSICAL DEPENDENCE ON SEDATIVE 
DRUGS IN DOG. 

244674 04-0 

MEDICAL PRACTICE WITHOUT ANTIANXIETY DRUGS. 

245524 04-1 
DEPRESSION AND ANTIDEPRESSANT DRUGS. 

245646 04-0 
EFFECTIVENESS OF HYPNOTIC DRUGS WITH PROLONGED USE: 
FLURAZEPAM AND PENTOBARBITAL. 

245652 04-1 
EFFECTS OF DRUGS ON EPILEPTIC PATIENTS, 

245884 04-1 
A STUDY OF THE CENTRAL EFFECTS OF SYMPATHOMIMETIC DRUGS: EEC 
AND BEHAVIOURAL INVESTIGATIONS ON CLONIDINE AND 
NAPHAZOLINE, 

246148 O4-0 
THE EFFECTS OF TRANQUILLIZING DRUGS ON TIMING BEHAVIOUR IN 

RATS, 

246306 04-0 
LIPID PEROXIDATION AS THE CAUSE OF THE ASCORBIC-ACID INDUCED 
DECREASE OF ADENOSINE TRIPHOSPHATASE ACTIVITIES OF RAT BRAII 



S-124 



>LUME 14, SUBJECT INDEX 

MICROSOMES AND ITS INHIBITION BY BIOGENIC AMINES AND 
PSYCHOTROPIC DRUGS 

246318 04-04 
EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 

AND CIRCULATION RELATED TO EEG -■ DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE. 

246319 04-03 
COMBINATION DRUG THERAPY FOR THE PSYCHOGERIATRIC PATIENT: 

COMPARISON OF DOSAGE LEVELS OF THE SAME PSYCHOTROPIC 
DRUGS, USED SINGLY AND IN COMBINATION. 

246694 04-11 
REVERSAL OF THE 6-HYDROXYDOPAMINE-INDUCED SUPPRESSION OF A 
CAR BY DRUGS FACILITATING CENTRAL CATECHOLAMINERGIC 
MECHANISMS- 

246818 04-04 
EFFECTS OF SELECTED DRUGS ON AN AUDITORY OR THALAMIC 
CONDITIONED STIMULUS ELICITING RECRUITMENT IN THE CAT. 

246967 04-04 
PLASMA PROTEIN BINDING OF DRUGS AS A FUNCTION OF AGE IN ADULT 
HUMAN SUBJECTS. 

246970 04-13 
AN ANALYSIS OF THE DRUGS ACTING ON CEREBRAL ENERGY 
METABOLISM. 

247012 04-03 
EFFECTS OF VARIOUS DRUGS ON SERUM FREE AND TOTAL TRYPTOPHAN 

LEVELS AND BRAIN TRYPTOPHAN METABOLISM IN RATS. 

247013 04-03 
ANTIDEPRESSANT DRUGS AFFECT DOPAMINE UPTAKE. 

247021 04-03 
EFFECTS OF ANTIDEPRESSANT DRUGS ON AMYGDALOID AFTER- 
DISCHARGE IN RATS. 

247039 04-03 
DRUGS HELP, BUT WONT CURE, MOST HYPERACTIVE CHILDREN. 

247143 04-17 
MEASUREMENT OF THE EFFECTS OF DRUGS ON ACTIVITY OF PERMANENT 
GROUPS OF RATS. 

247207 04-04 
SHOULD PATIENTS RECEIVING MAJOR TRANQUILIZER THERAPY RECEIVE 
ANTIPARKINSON DRUGS PROPHYLACTICALLY?. 

247359 04-15 
WHAT IS THE PROPER DOSE OF STIMULANT DRUGS IN CHILDREN?. 

247376 04-17 
EFFICACY AND TOLERANCE LIMITS IN THE USE OF ANTIDEPRESSANT 
DRUGS. 

247543 04-09 
ANTIDEPRESSANT DRUGS AND ANESTHESIA. 

247544 04-15 
CARDIOTOXIC EFFECTS OF PSYCHOTROPIC DRUGS. 

247784 04-15 
DRUGS AND PUNISHED RESPONDING VI: BODY WEIGHT AS A 
DETERMINANT OF DRUG EFFECTS. 

247845 04-04 
THE ANTINICOTINIC EFFECTS OF DRUGS WITH CLINICALLY USEFUL 
SEDATIVE ANTIANXIETY PROPERTIES. 

248009 04-03 
ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED WITH THREE OTHER DRUGS, 

248283 04-02 
ANTIPSYCHOTIC DRUGS: DIRECT CORRELATION BETWEEN CLINICAL 
POTENCY AND PRESYNAPTIC ACTION ON DOPAMINE NEURONS. 

248466 04-03 
CHANGES IN THE ARTERIAL BLOOD-PRESSURE RESPONSES OF 

HYPERTENSIVE RATS TO SOME DRUGS ACTING ON THE CENTRAL 
SYMPATHETIC MECHANISMS. 

248551 04-03 
DRUGS DERIVED FROM CANNABINOIDS. 1. NITROGEN ANALOGS, 
BENZOPYRANOPYRIDINES AND BENZOPYRANOPYRROLES. 

248646 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 2. BASIC ESTERS OF NITROGEN 

AND CARBOCYCLIC ANALOGS, 

248647 04-02 
DRUGS DERIVED FROM CANNABINOIDS 5, DELTA 

TETRAHYDROCANNABINOL AND HETEROCYCLIC ANALOGS 
CONTAINING AROMATIC SIDE CHAINS 

248648 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 3. SULFUR ANALOGS, 

IHIOPYRANOBENZOPYRANS AND THIENOBENZOPYRANS. 

248651 04-02 
DRUGS DERIVED FROM CANNABINOIDS. 4. EFFECT OF ALKYL 

SUBSTITUTION IN SULFUR AND CARBOCYCLIC ANALOGS. 

248652 04-02 
SIDE EFFECTS OF DRUGS AS MODELS OF ILLNESSES. 

248850 04 15 
COMPLICATIONS OF PSYCHOACTIVE DRUGS AS SEEN BY FAMILY 

PRACTITIONERS. 

248851 04 15 
INTRAGASTRIC SELF ADMINISTRATION OF PSVCHOACTIVE DRUGS BY 

THE RHESUS MONKEY 

249004 04 06 



Subject Index 

EEG AND BEHAVIORAL EFFECTS OF NARCOTIC ANTAGONISTS ALONE AND 
IN COMBINATION WITH OTHER PSYCHOACTIVE DRUGS IN MORPHINE- 
DEPENDENT MACACA-MULATTA. 

249267 04-04 
ACTION OF PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE 
CEREBRAL CORTEX AND LUNG FOLLOWING MICROWAVE 
IRRADIATION 

249286 04-03 
CORRELATION OF THE INCREASE IN BRAIN TRYPTOPHAN PRODUCED BY 
AMPHETAMINE-LIKE DRUGS WITH AN INCREASE IN BODY 
TEMPERATURE. 

249316 04 03 
INTER-GROUP AGGRESSION IN MICE: A NEW METHOD FOR TESTING THE 
EFFECTS OF CENTRALLY ACTIVE DRUGS. 

249668 04-04 
EFFECTS OF ANTIANXIETY DRUGS ON FOOD INTAKE IN TRAINED AND 
UNTRAINED RATS AND MICE. 

249678 04-04 

INHIBITION OF CIRCLING BEHAVIOR BY NEUROLEPTIC DRUGS IN MICE 
WITH UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF THE STRIATUM. 

249679 04-04 
SELF-ADMINISTRATION OF PSYCHOMOTOR STIMULANT DRUGS: THE 

EFFECTS OF UNLIMITED ACCESS. 

250066 04-04 
RATE-DEPENDENT EFFECTS OF DRUGS: A REVIEW OF THE LITERATURE. 

250070 04-04 
A CRITIQUE OF OBSTETRICAL PAIN RELIEVING DRUGS AS PREDICTORS OF 
INFANT BEHAVIOR VARIABILITY. 

250175 04-15 
ANTIPSYCHOTIC PHENOTHIAZINE DRUGS AND THE SIGNIFICANCE OF THE 
X-RAY STRUCTURE OF PROMAZINE HCL. 

250357 04-01 
ANTIACETYLCHOLINE ACTIVITIES OF PSYCHOACTIVE DRUGS: A 

COMPARISON OF THE (3H)QUINUCLIDINYL BENZILATE BINDING ASSAY 
WITH CONVENTIONAL METHODS. 

250360 04-02 
INAPPROPRIATE PRESCRIBING OF PSYCHOACTIVE DRUGS. 

250711 04-17 
THE ENDOGENOUS NEUROTIC DISTINCTION AS A PREDICTOR OF 
RESPONSE TO ANTIDEPRESSANT DRUGS. 

250726 04-11 

PSYCHOTROPIC DRUGS IN SOMATIC DISORDERS. 

250856 04 17 

BETA-ADRENERGIC BLOCKING DRUGS FOR ANXIETY. 

251155 04-14 
REPORT OF A SYMPOSIUM ON BETA-ADRENERGIC RECEPTOR BLOCKADE 

IN PSYCHIATRY, HELD IN FERNDOWN, DORSET, ON JUNE 21 ST 1975. 
BETA-ADRENERGIC BLOCKING DRUGS IN ANXIETY. 

251156 04-10 
SOME STUDIES OF BETA-RECEPTOR BLOCKING DRUGS ON THE CENTRAL 

NERVOUS-SYSTEM IN MAN. 

251162 04-13 
INTERACTION OF ATROPINE OR METHYLATROPINIUM WITH FOUR 
EFFECTS OF TWO CHOLINERGIC DRUGS. 

251217 04-03 
EFFECTS OF ALPHA-RECEPTOR BLOCKERS AND ANTIDEPRESSANT DRUGS 
ON THE PRESYNAPTIC ALPHA RECEPTOR OF RAT CEREBRAL CORTEX. 

251394 04-03 
INFLUENCE OF AGE AND DRUGS ON BEHAVIORAL THERMOREGULATION 
IN RATS. 

251409 04-04 
EFFECTS OF CENTRALLY ACTING DRUGS ON STRESS-INDUCED INCREASE 
OF CGMP IN MOUSE BRAIN. 

251416 04-03 
DELTA9-TETRAHYDR0CANNABIN0L, ETHANOL, AND AMPHETAAAINE AS 
DISCRIMINATIVE STIMULI GENERALIZATION TESTS WITH OTHER 
DRUGS. 

251977 04-04 
DIFFERENTIAL BEHAVIORAL RESPONSES OF MALE AND FEMALE ADULT 
RATS TREATED WITH FIVE PSYCHOTROPIC DRUGS IN THE NEONATAL 
STAGE. 

251981 04 04 
THE USE OF PSYCHOTROPIC DRUGS IN RHEUMATOLOGY 

252135 04-17 
THE USE OF PSYCHOTROPIC DRUGS IN OTHER PAINFUL CONDITIONS. 

252142 04-17 
THE USE OF PSYCHOTROPIC DRUGS IN A PAIN CLINIC 

252144 04 17 
COMPARISONS BETWEEN THE ANTIANESTHETIC ACTION OF DIBUTYRYL- 
CYCLIC-AMP AND ANALEPTIC DRUGS ON AMOBARBITAL-INDUCED 
NARCOSIS IN THE RAT 

252221 04 03 
SLEEP LABORATORY STUDIES OF FLURAZEPAM: A MODEL FOR 
EVALUATING HYPNOTIC DRUGS. 

252230 04-11 
INTERACTION OF DIET AND DRUGS IN THE REGULATION OF BRAIN 5- 
HYDROXYINDOLES AND THE RESPONSE TO PAINFUL ELECTRIC SHOCK. 

252516 04-03 



as 






S-125 



Subject Index 



Psychopharmacology Abstract* 



ANTICHOLINERGIC ACTIVITY Of ANTIPSYCHOTIC DRUGS IN RELATION TO 
THEIR EXTRAPYRAMIDAL EFFECTS 

252520 0405 
ACCIDENTAL POISONING WITH PSYCHOTROPIC DRUGS IN CHILDREN, 

252656 04-15 
THE INFLUENCE OF ANTICONVULSANT DRUGS ON CEREBRAL ASPARTATE 
AMINOTRANSFERASE ACTIVITY IN MICE WITH PREDISPOSITION TO 
AUDIOGENIC SEIZURES, 

252711 04-03 
MAINTENANCE ANTIPSYCHOTIC DRUGS DO PREVENT RELAPSE: A REPLY 
TO TOBIAS AND MACDONALD 

252847 04-08 
CULTURE, MORBIDITY, AND THE EFFECTS OF DRUGS, 

252991 04-17 
DOSAGE OF ANTIPSYCHOTIC DRUGS, 

253018 04-08 
NEW PSYCHOACTIVE DRUGS IN PSYCHOGERIATRICS. 

253060 04-11 
STRATEGIES AND TACTICS IN THE USE OF ANTIOBESITY DRUGS, 

253315 04-11 
DISCRIMINATIVE STIMULUS PROPERTIES OF ANALGESIC DRUGS: 
NARCOTIC VERSUS NONNARCOTIC ANALGESICS, 

253394 04-04 
METHAQUALONE WITH PSYCHOTROPIC DRUGS: ADVERSE INTERACTION. 

253531 04-15 
INTERACTIONS BETWEEN DRUGS AND SALIVA STIMULATING PARAFILM 
AND THEIR IMPLICATIONS IN MEASUREMENTS OF SALIVA DRUG 
LEVELS, 

253693 04-03 
ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE 
DRUGS TO PREPUBERTAL MALE RATS, II. LSD. 

253700 04-03 
DUAL 

DUAL ACTION OF MORPHINE AND RELATED DRUGS ON COMPULSIVE 
GNAWING OF RATS. 

239860 03-04 
DUALISM 

DRUG RECEPTOR INTERACTIONS OF MORPHINE AND NALORPHINE: 
COMPETITIVE DUALISM VERSUS RECEPTOR DUALISM. (PH.D. 
DISSERTATION), 

240934 03-03 
DUODENAL 

EXTRANEURONAL UPTAKE AND METABOLISM OF (3H)L-N0REPINEPHRINE 
BY THE RAT DUODENAL MUCOSA. 

241299 03-03 
DURATION 

DELTA9-TETRAHYDR0CANNABIN0L (DELTA9-THC) AND 1 1-0H-DELTA9- 
THC: ONSET, PATTERN AND DURATION OF BEHAVIORAL EFFECTS AND 
TOLERANCE IN RATS. 

238813 03-04 
RELATIONSHIP BETWEEN THE SUBCELLULAR DISTRIBUTION OF DELTA9- 
TETRAHYDROCANNABINOL AND ITS METABOLITES IN RAT BRAIN AND 
THE DURATION OF THE EFFECT ON MOTOR ACTIVITY. 

241242 03-03 
DIFFERENTIAL SENSITIVITY OF THE RESPONSE DURATION AND RESPONSE 
RATE TO IMIPRAMINE DURING OPERANT BEHAVIOR IN RATS, 

241377 03-04 
THE DURATION OF TOLERANCE TO THE ANOREXIGENIC EFFECT OF 
AMPHETAMINE IN RATS, 

245298 04-03 
PENFLURIDOL BLOCKADE OF APOMORPHINE: DEPENDENCE OF DURATION 
ON SPECIES AND ENDPOINT, 

248406 04-02 
DISTRIBUTION STUDIES OF (14C)DELTA9TETRAHYDR0CANNABIN0L IN 
MICE: EFFECT OF VEHICLE, ROUTE OF ADMINISTRATION, AND 
DURATION OF TREATMENT. 

249223 04-03 
NALOXONE BLOCKADE OF MORPHINE ANALGESIA - A DOSE EFFECT 
STUDY OF DURATION AND MAGNITUDE. 

249271 04-02 
COMPARISON OF DEPOT FLUPHENAZINES: DURATION OF ACTION AND 
INCIDENCE OF SIDE-EFFECTS. 

252006 04-08 
THE DURATION OF MAINTENANCE THERAPY IN CHRONIC 
SCHIZOPHRENIA. 

252763 04-08 
DURATIONS 

BARBITURATE REINFORCED RESPONDING IN RHESUS MONKEYS: 
COMPARISONS OF DRUGS WITH DIFFERENT DURATIONS OF ACTION. 

237874 02-04 
DYNAMIC 

EFFECTS OF ALCOHOL AND MARIJUANA ON DYNAMIC VISUAL ACUITY: I. 
THRESHOLD MEASUREMENTS. 

235759 02-14 
DYNAMICS 

THE DYNAMICS OF DOPAMINE METABOLISM IN VARIOUS REGIONS OF 
RAT BRAIN. 

238761 0303 



DYSFUNCTION 

BRAIN DYSFUNCTION IN CHRONIC SEDATIVE USERS. 

VIOLENT BEHAVIOR, BRAIN DYSRHYTHMIA, AND GLUCOSE 
DYSFUNCTION: A NEW SYNDROME. 

THIORIDAZINE AND SEXUAL DYSFUNCTION. 



226922 01-1: 

233870 02-1 
236318 02- 1 



DYSFUNCTIONS 

DOES PIRACETAM COUNTERACT THE ECT-INDUCED MEMORY 
DYSFUNCTIONS IN DEPRESSED PATIENTS?. 

239002 03-0 
DYSKINESIA 

MECHANISMS OF A DYSKINESIA INDUCTION BY 1-3,4 
DIHYDROXYPEHNYLPIPERAZINE IN THE RAT. 

239964 03-0 
TREATMENT OF PHENOTHIAZINE-INDUCED DYSKINESIA. 

253038 04-1 
DYSKINESIAS 

ANTIDOPAMINERGIC EFFECTS OF APOMORPHINE IN PATIENTS WITH 
DYSKINESIAS. 

251958 04-1 
DISSOCIATION OF STEREOTYPED BITING RESPONSES AND ORO-BUCCO- 
LINGUAL DYSKINESIAS. 

252031 04-0 
COMPARATIVE ANALYSIS OF PERSISTENT DYSKINESIAS OF LONG-TERM 
USAGE WITH NEUROLEPTICS IN FRANCE AND IN JAPAN. 

252181 04-1 
DYSKINETIC 

NEUROLEPTIC ANTAGONISM OF DYSKINETIC PHENOMENA. 

248407 04-0 
A METHOD FOR EXPLAINING DYSKINETIC MOVEMENTS - A FILM 
PRESENTATION. y 

253034 04-1 
DYSMENORRHOEA 

ISOXSUPRINE IN PRIMARY DYSMENORRHOEA: ITS EFFECTIVENESS IN 
PREMENSTRUAL TENSION. 

245136 04-1 
DYSPHORIC 

DYSPHORIC RESPONSE TO NEUROLEPTIC TREATMENT IN SCHIZOPHRENI/: 
AND ITS PROGNOSTIC SIGNIFICANCE. 

250989 04-1 
DYSRHYTHMIA 

SCHIZOPHRENIFORM PSYCHOSIS OF EPILEPSY: TWO CASES WITH 
PAROXYSMAL DYSRHYTHMIA ON EEG. 

228068 01 -C 
VIOLENT BEHAVIOR, BRAIN DYSRHYTHMIA, AND GLUCOSE 
DYSFUNCTION: A NEW SYNDROME. 

233870 02-1 
DYSTONIA 

LONG-TERM LEVODOPA THERAPY FOR TORSION DYSTONIA. 

249367 04-1 
PHENYTOIN-INDUCED DYSTONIA AND CHOREOATHETOSIS IN TWO 
RETARDED EPILEPTIC CHILDREN. 

251654 04-1 
DYSTONIC 

THE DYSTONIC HYPERKINETIC SYNDROME: A CASUISTICAL 
CONTRIBUTION TO THE UNDERSTANDING OF THE ACTIONS OF DRUGS 
IN CHILDREN. 

233717 02-1 
A PRIMATE MODEL OF ACUTE DYSTONIC REACTION TO NEUROLEPTICS. 

241934 03-C 
D14S 

NEUROPHARMACOLOGICAL STUDIES ON D145 (1,3 DIMETHYL-5- 
AMINOADAMANTAN). 

227133 Ol-O 
EASER 

A DOUBLE-BLIND COMPARISON OF PENFLURIDOL (EASER) WITH 
PIMOZIDE IN SCHIZOPHRENIA. 

229026 01 -C 
EATING 

TAIL PINCH INDUCES EATING IN SATED RATS WHICH APPEARS TO 
DEPEND ON NIGROSTRIATAL DOPAMINE. 

227343 Ol-O 
REINSTATEMENT OF EATING BY DOPAMINE AGONISTS IN APHAGIC 
DOPAMINE DENERVATED RATS. 

243348 04-C 
ECLAMPSIA 

ROLE OF DIAZEPAM IN THE AAANAGEMENT OF ECLAMPSIA. 

237898 02-1 
ECONOMY 

THE POSITION OF LONG-ACTING DRUGS IN THE ECONOMY OF 
PSYCHIATRIC INSTITUTIONS. 

229558 01-1 



ECT 



EFFECT OF ECT AND IMIPRAMINE TREATMENT ON THE CONCENTRATION 
OF 5-HYDROXYINDOLEACETIC-ACID (5-HIAA) AND HOMOVANILLIC- 
ACID (HVA) IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS. 

230827 01 -C 



S-126 



VOLUME 14, SUBJECT INDEX 

INTRAVENOUS TRANQUILI IZATION WITH ECT. 



Subject Index 



249537 04- 16 



CT-INOUCED 

DOES PIRACETAM COUNTERACT THE ECT-INDUCED MEMORY 
DYSFUNCTIONS IN DEPRESSED PATIENTS?. 



EG 



239002 03-09 

PSYCHOTROPIC DRUGS AND THE HUMAN EEC. 

226725 01 16 
EFFECTS OF CLONIDINE AND BS-100141 ON THE EEG SLEEP PATTERN IN 
RATS 

226728 01-03 
THE EFFECTS OF LOW-LEVEL DIELDRIN EXPOSURE ON THE EEG AND 
LEARNING ABILITY OF THE SQUIRREL-MONKEY. 

227385 01-04 
SCHIZOPHRENIFORM PSYCHOSIS OF EPILEPSY: TWO CASES WITH 
PAROXYSMAL DYSRHYTHMIA ON EEG. 

228068 01-08 
STUDY OF THE ACTION OF SOME CENTRALLY ACTING DRUGS ON THE 
EEG AND ON A CONDITIONED AVOIDANCE REFLEX IN THE RABBIT. 

230860 01-03 
BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF 
PSYCHOSIS. 

233965 02-03 
CYCLIC EEG CHANGES IN SUBACUTE SPONGIFORM AND ANOXIC 
ENCEPHALOPATHY. 

235563 02- 13 
ROLE OF BIOGENIC AMINES IN THE EFFECTS OF MARIJUANA ON EEG 

PATTERNS IN CATS. 

235564 02-03 
ALTERATIONS OF THE EEG OF EXTRAPYRAMIDAL NUCLEI FOLLOWING 6- 

HYDROXYDOPAMINE LESIONS. 

238735 03-03 
EFFECT OF DELTA9-THC ON PHYSICAL SYMPTOMS AND EEG IN THE 
NATURALLY EPILEPTIC BEAGLE. 

238811 03-04 
ANXIETY AND EEG ALPHA ACTIVITY IN NEUROTIC PATIENTS. 

239022 03-10 
EEG SLEEP STUDIES OF INSOMNIACS UNDER FLUNITRAZEPAM 
TREATMENT. 

239819 03-14 
PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER- 
DISCHARGES IN RATS: INCREMENTAL DOSE, HIPPOCAMPAL EEG AND 
BEHAVIORAL ACTIVITY CORRELATES. 

239858 03-03 
CONTROLLED CLINICAL AND QUANTITATIVE EEG STUDIES OF 

TRIFLUBAZAM (0RF-8063) IN PATIENTS WITH ANXIETY SYNDROME 

241275 03-10 
THE EFFECT OF MORPHINE ON THE EEG OF THE HYPOTHALAMUS IN THE 
RAT. 

241328 03-03 
EFFECTS OF DRUGS INJECTED INTO THE HYPOTHALAMUS ON MURICIDE 
AND EEG IN THE OLFACTORY BULBECTOMIZED RATS. 

241367 03-04 
PHARMACOLOGICAL STUDIES ON THE MIDBRAIN RAPHE SYSTEM {III). 
EFFECTS OF MIDBRAIN RAPHE STIMULATION AND LESION ON EEG 
ACTIVITY IN RATS. 

241390 03-03 
DOSE-RELATED EFFECTS OF METRAZOL ON RETENTION AND EEG 

242733 03-04 
THE MORNING AFTER: RESIDUAL EEG EFFECTS OF TRIAZOLAM AND 
FLURAZEPAM, ALONE AND IN COMBINATION WITH ALCOHOL. 

244960 04- 1 3 
EEG SYNCHRONIZING EFFECT OF GAMMA-HYDROXYBUTYRATE AND 1- 
HYDROXY-3-AMINO-PYRROLIDONE-2 (HA-966) IN RELATION OF 
DOPAMINERGIC BRAIN FUNCTION. 

245599 04-03 
A STUDY OF THE CENTRAL EFFECTS OF SYMPATHOMIMETIC DRUGS: EEG 
AND BEHAVIOURAL INVESTIGATIONS ON CLONIDINE AND 
NAPHAZOLINE. 

246148 04-04 
EFFECTS OF PSYCHOTROPIC DRUGS ON CANINE CEREBRAL METABOLISM 
AND CIRCULATION RELATED TO EEG - DIAZEPAM, CLOMIPRAMINE, 
AND CHLORPROMAZINE. 

246319 04-03 
CHARACTERIZATION OF EEG EFFECTS PRODUCED BY THE INTERACTION 
OF SECOBARBITAL WITH PSYCHOMOTOR STIMULANTS USING 
SPECTRAL ANALYSIS TECHNIQUES. 

249251 04-03 
EEG AND BEHAVIORAL EFFECTS OF NARCOTIC ANTAGONISTS ALONE AND 
IN COMBINATION WITH OTHER PSYCHOACTIVE DRUGS IN MORPHINE- 
DEPENDENT MACACA-MULATTA. 

249267 04-04 
EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVEAU ISOLE AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT. 

249307 04-03 



THE NEUROLOGISTS USE OF RATING SCALES, EEG, AND TRANQUILIZERS 
IN DEALING WITH HYSTERICAL SYMPTOMS. 

249771 04- 10 
EEL 

SERUM LITHIUM MEASUREMENT OF THE EEL FLAMEPHOTOMETER. 

241777 03-16 
EFFECTIVENESS 

EFFECTIVENESS OF SINEQUAN (DOXEPIN) IN THE TREATMENT OF 
NEUROTIC AND PSEUDONEUROTIC SYNDROMES. 

230818 01-10 
ON THE EFFECTIVENESS OF PSYCHIATRIC AMBULATORY STATIONS. 

234289 02-1 1 
CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY OF THE COMPARATIVE 
EFFECTIVENESS OF MEPIPRAZOL (EMD-16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 02-10 
AMITRIPTYLINE IN THE PROPHYLAXIS OF MIGRAINE: EFFECTIVENESS AND 
RELATIONSHIP ON ANTIMIGRAINE AND ANTIDEPRESSANT EFFECTS. 

237138 02-11 
EFFECTIVENESS OF MORPHINE AND INEFFECTIVENESS OF DIAZEPAM AND 
PHENOBARBITAL ON THE MOTIVATIONAI PROPERTIES OF 
HYPOTHALAMIC SELF-STIMULATION BEHAVIOUR. 

239981 03-04 
METHODOLOGY OF THERAPEUTIC EFFECTIVENESS TRIALS IN 
PSYCHOPHARMACOLOGY. 

240444 03-17 
THE CLINICAL EFFECTIVENESS OF A CAVAIN-AMGNESIUM-OROTATE 
COMBINATION IN NURSING HOME PATIENTS IN A DOUBLE-BLIND 
STUDY. 

243180 04-11 
PROPHYLACTIC EFFECTIVENESS OF LITHIUM IN PATIENTS WITH 
AFFECTIVE DISTURBANCES. 

243985 04-09 
DIFFERENTIAL PHARMACOTHERAPY FOR NEUROTIC STATES 
(COMPARATIVE EFFECTIVENESS OF BENZODIAZEPINE DERIVATIVES). 

244349 04-10 
TRAZODONE: THERAPEUTIC EFFECTIVENESS IN ENDOGENOUS 
DEPRESSION, COMPARED WITH BLOOD LEVELS. 

244588 04-09 
ISOXSUPRINE IN PRIMARY DYSMENORRHOEA: ITS EFFECTIVENESS IN 
PREMENSTRUAL TENSION. 

245136 04-11 
EFFECTIVENESS OF HYPNOTIC DRUGS WITH PROLONGED USE: 
FLURAZEPAM AND PENTOBARBITAL. 

245652 04-11 
THE EFFECTIVENESS OF DIPHENHYDRAMINE HCL IN PEDIATRIC SLEEP 
DISORDERS 

251827 04-14 
EFFICIENCY 

HEREDITY OF HEXOBARBITAL SLEEPING TIME AND EFFICIENCY OF DRUG 
METABOLISM IN WISTAR AND SPRAGUE-DAWLEY RATS. 

230007 01-04 
PHARMACOPSYCHOLOGICAL STUDIES IN NORMAL SUBJECTS WITH A 
VIEW TO PREDICTING THE THERAPEUTIC EFFICIENCY OF 
PSYCHOTROPIC DRUGS. 

233683 02-17 
EFFICIENCY PROFILES OF TRANQUILIZERS AND BROAD SPECTRUM 
PSYCHOSOMATIC DRUGS. 

240706 03-17 
PSYCHOMETRIC ASSESSMENT OF THE THERAPEUTIC EFFICIENCY OF 
ANTIDEPRESSANT AGENTS. 

251004 04 10 
EFFLUX 

ALTERATIONS IN CA45 UPTAKE AND EFFLUX IN RAT CORTEX. STRIATUM 
AND HYPOTHALAMUS SLICES 

238714 03-03 
EFFECTS OF CHLORIMIPRAMINE AND LYSERGIC-ACID-DIETHYLAMIDE ON 
EFFLUX OF PRECURSOR FORMED 3H-SER0T0NIN: CORRELATIONS WITH 
SEROTONERGIC IMPULSE FLOW. 

246846 04-03 
EGYT-341 

THE MAIN PHARMACOLOGICAL CHARACTERISTICS OF GRANDAXIN 
(TOFIZOPAM, EGYT-341) 

252445 04-02 
EJACULATORY 

INHIBITION OF THE EJACULATORY REFLEX IN B6D2F1 MICE BY 
TESTOSTERONE PROPIONATE. 

250984 04 04 
ELDERLY 

PROVIDERS AS PRESCRIBERS ATTITUDES TOWARD ASPECTS OF 
PRESCRIBING AND THEIR RELATIONSHIP TO MANAGEMENT OF 
HYPERTENSION IN THE ELDERLY. • 

227923 01-11 
MANAGEMENT OF THE ELDERLY HYPERTENSIVE IN FOUR PRACTICE 

SETTINGS. 

227924 01-11 
DOUBLE-BLIND EVALUATION OF NAFTIDROFURYL IN TREATING ELDERLY 

CONFUSED HOSPITALISED PATIENTS 

229368 01-11 






as 



S-127 



Subject Index 



Psychopharmacology Abstracts 



RESPONSE OF THE ELDERLY TO PSYCHOTROPIC DRUGS: PREDICTABLE OR 
IDIOSYNCRATIC 

229457 CM 1 
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN ELDERLY VOLUNTEERS: 
EFFECT OF DIAZEPAM IN MALES 

229840 01 11 
CLINICAL PSYCHOPHARMACOLOGY AND THE ELDERLY PATIENT. 

236300 02- 17 
UTILIZATION OF PIRACETAM (NOOTROPIL) IN ELDERLY WITH 
NEURASTHENIC STATES 

236794 02-11 
THE QUALITY OF INTELLECTUAL LIFE IN THE ELDERLY: DOUBLE-BLIND 
STUDY OF HYDROSARPAN-711 IN 80 SUBJECTS. 

240166 03-11 
ADAPTIVENESS AND BEHAVIOR OF THE ELDERLY SUBJECT. 

242898 04-11 
BEHAVIOR AND INTELLECTUAL ACTIVITY OF THE ELDERLY: DOUBLE- 
BLIND STUDY OF HYDROSARPAN-711 IN A HOSPICE ENVIRONMENT. 

242900 04-11 
CLINICAL FINDINGS IN DISEASES IN THE ELDERLY WITH A CLEAR 
PSYCHOGENIC COMPONENT WITH PARTICULAR RESPECT TO THEIR 
PHARMACOLOGICAL TREATMENT. 

244476 04-11 
EFFECTS OF PROPRANOLOL HYDROCHLORIDE ON LEARNING IN ELDERLY 
SUBJECTS. 

246440 04-14 
ANXIETY/DEPRESSION IN ELDERLY PATIENTS: A DOUBLE-BLIND 
COMPARATIVE STUDY OF FLUPHENAZINE/NORTRIPTYLINE AND 
PROMAZINE. 

247030 04-11 

ELECTRIC 

THE USE OF INJECTABLE LORAZEPAM IN PREPARATION FOR ELECTRIC 
CARDIOVERSION. 

244451 04-11 
THE SUPPRESSION OF BEHAVIOUR IN RATS BY PREVIOUS EXPERIENCE 
AND ELECTRIC SHOCK AND ITS ANTAGONISM BY ATROPINE. 

245305 04-04 
INTERACTION OF DIET AND DRUGS IN THE REGULATION OF BRAIN 5- 
HYDROXYINDOLES AND THE RESPONSE TO PAINFUL ELECTRIC SHOCK. 

252516 04-03 
ELECTRICAL 

COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS 

232483 01-04 
EFFECTS OF DOPAMINERGIC AGONISTS AND ELECTRICAL STIMULATION 
OF THE MIDBRAIN RAPHE ON THE RELEASE OF 5- 
HYOROXYTRYPTAMINE FROM THE CAT BRAIN IN VIVO. 

237154 02-03 
THE MECHANISM BY WHICH DELTA9-TETRAHYDR0CANNABIN0L (THC) 
PRODUCES A DECREASE IN SALIVARY FLOW FOLLOWING ELECTRICAL 
STIMULATION. 

238815 03-03 
INTRASPECIES AGGRESSION INDUCED BY ELECTRICAL SHOCK AND 
REACTIVITY AFTER RAPHE LESIONS IN THE RAT. EFFECTS OF 
PHYSOSTIGMINE. 

239829 03-04 
EFFECTS OF ELECTRICAL STIMULATION OF THE NIGROSTRIATAL 
PATHWAY OF THE RAT ON DOPAMINE METABOLISM. 

241207 03-03 
ELECTRICALLY-INDUCED 

INTERACTION OF 0ELTA9-TETRAHYDR0CANNABIN0L AND CANNABIDIOL 
WITH PHENOBARBITONE IN PROTECTING MICE FROM ELECTRICALLY- 
INDUCED CONVULSIONS. 

244894 04-04 
ELECTRICALLY-INDUCED HIPPOCAMPAL AND CORTICAL SEIZURES AND 
THEIR EFFECTS ON OPERANT BEHAVIOR. 

249241 04-06 
GAMMA AMINOBUTYRICACID: SELECTIVE INHIBITION OF ELECTRICALLY- 
INDUCED HEAD TURNING FOLLOWING INTRACAUDATE 
ADMINISTRATION. 

253392 04-04 
ELECTROCARDIOGRAM 

CHLORPROMAZINE INDUCED ELECTROCARDIOGRAM ABNORMALITIES. 

231037 01-08 
ELECTROCARDIOGRAMS 

EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON THE 

ELECTROCARDIOGRAMS OF PATIENTS WITH ENDOGENOUS DEPRESSION 
(INTRODUCTORY REPORT), 

234046 0209 
ELECTROCARDIOGRAPHIC 

IMIPRAMINE DOSAGE IN CHILDREN: A COMMENT ON IMIPRAMINE AND 
ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE 
CHILDREN 

245001 04-14 

ELECTROCLINICAl 

ElECTROCLINICAL CORRELATIONS IN PSYCHOPATHIES, 

236793 02-14 



ELECTROCONVULSIVE 

NOREPINEPHRINE METABOLISM AFTER SHORT-TERM AND LONG-TERM 
ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANT DRUGS AND 
ELECTROCONVULSIVE SHOCK. 

234804 02-03 
EFFECTS OF ELECTROCONVULSIVE SHOCK AND CYCLOHEXIMIDE ON THE 
INCORPORATION OF AMINO-ACIDS INTO PROTEINS OF MOUSE BRAIN 
SUBCELLULAR FRACTIONS. 

237155 02-03 
ELECTROCONVULSIVE SHOCK RAISES PROSTAGLANDINS-F IN RAT 
CEREBRAL CORTEX 

237921 02-03 
ELECTROCONVULSIVE SHOCK INCREASES THE BEHAVIOURAL RESPONSES 
OF RATS TO BRAIN 5-HYDROXYTRYPTAMINE ACCUMULATION AND 
CENTRAL NERVOUS SYSTEM STIMULANT DRUGS. 

241979 0304 
ELECTROCORTICAL 

BLOCKADE OF THE ELECTROCORTICAL CHANGES INDUCED BY PERFUSION 
OF AMPHETAMINE IN THE BRAINSTEM RETICULAR FORAAATION. 

241930 03-03 
EFFECT OF CHLORPROMAZINE ON THE INTERACTION BETWEEN PHASIC 
AND TONIC ELECTROCORTICAL AROUSAL MECHANISMS. 

24631 1 04-03 
BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS OF 
CHOLERA TOXIN. 

252034 04-03 

ELECTRODERMAL 

THE ACTION OF CHLORPROMAZINE ON THE ELECTRODERAAAL RESPONSE 
IN THE CAT, 

239963 03-03 

ELECTRODES 

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF 
VARIOUS STIMULUS PARAMETERS: VI, INFLUENCE OF FENTANYL, 
PIRITRAMIDE, AND MORPHINE ON MEDICAL FOREBRAIN BUNDLE 
STIMULATION WITH MONOPOLAR ELECTRODES. 

241229 03-04 
ELECTROENCEPHALOGRAM 

CHANGES IN THE ELECTROENCEPHALOGRAM AND REM SLEEP TIME 
DURING MORPHINE ABSTINENCE IN PELLET IMPLANTED RATS. 

227701 01-03 
COMPUTERIZED ELECTROENCEPHALOGRAM: A MODEL OF 

UNDERSTANDING THE BRAIN FUNCTION IN CHILDHOOD PSYCHOSIS 
AND ITS TREATMENT. 

232635 02-11 
EPILEPTIFORM ACTIVITY IN THE ELECTROENCEPHALOGRAM INDUCED BY 
LITHIUM CARBONATE. 

233499 02-15 
EFFECT OF AZAFEN ON THE ELECTROENCEPHALOGRAM. 

234430 02-13 
EFFECTS OF ALPHA-METHYL-P-TYROSINE (AMPT) ON THE 

ELECTROENCEPHALOGRAM (EEG) OF THE CERVEAU ISOLE AND SLEEP 
OF THE CHRONIC MESENCEPHALIC CAT. 

249307 04-03 

ELECTROENCEPHALOGRAPHIC 

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL CHANGES ASSOCIATED 
WITH PAPAVERINE ADMINISTRATION IN HEALTHY GERIATRIC 
SUBJECTS. 

226478 01-11 
SIMILARITY IN CNS SENSITIVITY TO HEXOBARBITAL IN THE RAT AND 
MOUSE AS DETERMINED BY AN ANALYTICAL, A PHARMACOKINETIC, 
AND AN ELECTROENCEPHALOGRAPHIC MEASURE. 

226865 01-03 
AN ELECTROENCEPHALOGRAPHIC STUDY OF THE VALUE OF ACTIVATION 
BY MEGIMID IN PSYCHIATRIC DISEASES. 

22911501-13 
AN ELECTROENCEPHALOGRAPHIC STUDY ON PSYCHOTROPIC DRUGS. 

229725 01 14 
THE EFFECT OF DIAZEPAM AND FENTANYL ON MENTAL, PSYCHOMOTOR 
AND ELECTROENCEPHALOGRAPHIC FUNCTIONS AND THEIR RATE OF 
RECOVERY. 

230830 01-14 
ELECTROENCEPHALOGRAPHIC STUDIES ON THE DEVELOPMENT OF 
TOLERANCE AND CROSS-TOLERANCE TO MESCALINE IN THE RAT. 

230880 01-04 
ELECTROENCEPHALOGRAPHIC STUDIES IN PATIENTS WITH AFFECTIVE 
DISORDERS DURING PROPHYLACTIC TREATMENT WITH LITHIUM 
CARBONATE. 

234044 02-09 
REGIONAL ROLE OF CATECHOLAMINES IN ALPHA METHYL-M TYROSINE 
INDUCED ELECTROENCEPHALOGRAPHIC AROUSAL 

234067 02-03 
ELECTROENCEPHALOGRAPHIC FINDINGS IN PHENCYCLIDINE 
INTOXICATION. 

236667 02 15 
THE EFFECTS OF AMOXAPINE ON ELECTROENCEPHALOGRAPHIC STAGES 
OF SLEEP IN NORMAL HUMAN SUBJECTS. 

237696 02-14 



S-128 



JME 14, SUBJECT INDEX 

\MMA-HYDROXYBUTYRATE: CORRELATION OF SERUM AND 
CEREBROSPINAL FLUID LEVELS WITH ELECTROENCEPHALOGRAPHIC 
AND BEHAVIORAL EFFECTS- 

237826 02-03 
CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF A NEW 
ANTIDEPRESSANT AGENT, MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
AOIENE CHLORHYDRATE (CIBA-34276-BA). 

247554 04-09 
FECTS OF REPEATED DOSES OF SCOPOLAMINE ON THE 
ELECTROENCEPHALOGRAPHIC STAGES OF SLEEP IN NORMAL 
VOLUNTEERS. 

248629 04-13 
LATERAL ELECTROENCEPHALOGRAPHIC RESPONSE AND UNILATERAL 
TOLERANCE TO UNILATERAL INTRACEREBRAL MORPHINE INJECTIONS. 

249484 04-03 
■LATIONSHIP BETWEEN THE BEHAVIORAL AND 
ELECTROENCEPHALOGRAPHIC EFFECTS OF CHLORPROMAZINE AND 
FLUPHENAZINE IN RATS. 

249623 04-02 
lOENCEPHALOGRAPHICAl 

LINICAL AND ELECTROENCEPHALOGRAPHICAL STUDIES OF THE 
THIOXANTHENES. 

227765 01-08 
LINICAL AND ELECTROENCEPHALOGRAPHICAL STUDIES OF THE NEW 
HYPNOSEDATIVE K-2004. 

243198 04-11 

ROLYTIC 

CTIVITY AVOIDANCE LEARNING AND REGIONAL 5- 
HYDROXYTRYPTAMINE FOLLOWING INTRABRAIN STEM 5,7 
OIHYDROXYTRYPTAMINE AND ELECTROLYTIC MIDBRAIN RAPHE 
LESIONS IN THE RAT. 

252173 04-03 
ROMETRY 

ENMETRAZOLE (DH-524): EUPHORIANT CLASSIFIED BY CEREBRAL 
ELECTROMETRY. 

230781 01-14 
RON 

LECTRON BEAM IONIZATION MASS FRAGMENTOGRAPHIC ANALYSIS OF 
TRICYCLIC ANTIDEPRESSANTS IN HUMAN PLASMA. 

238486 02-16 
ROPHORETIC 

LECTROPHORETIC APPLICATION OF LIGNOCAINE TO THE CERVICAL AREA 
FOR THE TREATMENT OF VEGETATIVE NEUROSES. 

244467 04-10 
ROPHYSIOLOGICAL 

;\ETHADONE-INDUCED BEHAVIORAL CHANGES: CIRCULAR MOVEMENTS, 
AGGRESSION, AND ELECTROPHYSIOLOGICAL ASPECTS. 

229286 01-04 
>ROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF 
ACTION OF BENZODIAZEPINES 

232512 01-03 
;XCITATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 
RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL, 
FUNCTIONAL AND CLINICAL DATA. 

237104 02 03 
lYTOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES OF DOPAMINE IN 
THE CAUDATE-NUCLEUS. (UNPUBLISHED PAPER). 

238471 02-03 
ELECTROPHYSIOLOGICAL EVIDENCE FOR A NEUROHORMONAL 
DEPENDENCE IN THE CHANGES OF THE LATE GLABELLAR RESPONSE IN 
MAN. 

246992 04-13 
CLONAZEPAM IN FACIAL NEURALGIA AND CLUSTER HEADACHE: 
CLINICAL AND ELECTROPHYSIOLOGICAL STUDY. 

246995 04-11 
ELECTROPHYSIOLOGICAL EFFECTS OF TRIIODOTHYRONINE AND 
PROPRANOLOL. 

251984 04-13 

TROPHYSIOLOGY 

SLEEP AND ITS DISTURBANCES IN THE CHILD: CONTRIBUTIONS OF 
ELECTROPHYSIOLOGY. 

228091 01-11 
TROSHOCK 

INJECTIONS OF AMINO-ACIDS THAT ALTER BRAIN SEROTONIN INCREASE 
THE SENSITIVITY TO ELECTROSHOCK IN RATS. 

238783 03-03 
INHIBITORY EFFECTS IF 6 HYDROXYDOPAMINE ON THE CLONIC 
CONVULSIONS INDUCED BY ELECTROSHOCK AND DECAPITATION. 

245597 04-03 
SUSCEPTIBILITY TO ELECTROSHOCK CONVULSION AFTER BARBITURATE 
PELLET IMPLANTATION IN THE MOUSE. 

249254 04-05 
ATED 

INERT GAS NARCOSIS: AVOIDANCE BEHAVIOR IN RATS BREATHING 
ELEVATED PRESSURES OF NITROGEN AND HELIUM. 

23551 1 02 04 



Subject Index 

OLFACTORY BULB REMOVAL RESULTS IN ELEVATED SPONTANEOUS 
LOCOMOTOR ACTIVITY IN MICE. 

239284 03-04 
EFFECT OF LSD ON RAT BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AT 
ELEVATED ENVIRONMENTAL TEMPERATURE. 

241925 03-03 

ELEVATION 

CHLORPROMAZINE AND HORMONAL ELEVATION OF CYCLIC-AMP 
CONTENTS IN TURKEY ERYTHROCYTES AND PERFUSED RAT HEART 
AND LIVER. 

239044 03-03 

POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY, 
WITHOUT CONCURRENT INCREASES IN STEADY-STATE 
CATECHOLAMINE LEVELS, RESULTING FROM DL ALPHA-METHYL P 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT. 

248697 04-03 
ELEVATION OF AMPHETAMINE LEVELS IN RAT BRAIN AFTER 

ADMINISTRATION OF THE CHOLINE ACETYLTRANSFERASE INHIBITOR 4- 
1-NAPHTHYLVINYLPYRIDINE (NVP). 

249027 04-03 

EUCITATION 

ELICITATION OF MOUSE JUMPING BY COMBINED TREATMENT WITH 
AMPHETAMINE AND L-DOPA: BLOCKADE BY KNOWN NEUROLEPTICS. 

249272 04-04 

ELICITING 

EFFECTS OF SELECTED DRUGS ON AN AUDITORY OR THALAMIC 
CONDITIONED STIMULUS ELICITING RECRUITMENT IN THE CAT. 

246967 04-04 

ELICITS 

CHOLECYSTOKININ ELICITS THE COMPLETE BEHAVIORAL SEQUENCE OF 
SATIETY IN RATS. 

245612 04-02 

ELIMINATION 

SERUM CONCENTRATION AND ELIMINATION OF THIORIDAZINE IN 
PSYCHIATRIC PATIENTS. 

238552 02-13 
DPH-INTOXICATION - CLINICAL AND NEUROPSYCHOLOGICAL 
EVALUATION OF A SLOW DPH ELIMINATION. 

240692 03 15 
MATERNAL AND NEONATAL ELIMINATION OF AMOBARBITAL AFTER 
TREATMENT OF THE MOTHER WITH BARBITURATES DURING LATE 
PREGNANCY. 

243085 04-15 

BILIARY ELIMINATION OF DIAZEPAM IN MAN. 

250423 04-13 

EMBRYO 

ONTOGENY OF BEHAVIORAL SENSITIVITY TO STRYCHNINE IN THE CHICK 
EMBRYO EVIDENCE FOR THE EARLY ONSET OF CNS INHIBITION 

228630 01-04 
EFFECTS OF DIAZEPAM ON THE ISOLATED CHICK EMBRYO HEART. 

230862 01 03 

EMBRYOGENESIS 

EFFECTS OF P-CHLOROPHENYLALANINE ON TIME OF NEURONAL ORIGIN 
DURING EMBRYOGENESIS IN THE RAT. 

252018 04 03 

EMBRYONIC 

POSTNATAL ELEVATION Of BRAIN TYROSINE-HYDROXYLASE ACTIVITY, 
WITHOUT CONCURRENT INCREASES IN STEADY STATE 
CATECHOLAMINE LEVELS, RESULTING FROM DL-ALPHA METHYL-P 
TYROSINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT 

248697 04 03 
EMD-I6923 

CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY OF THE COMPARATIVE 
EFFECTIVENESS OF MEPIPRAZOL (EMD 16923) AND DIAZEPAM IN 
TREATING NEUROTIC DISORDERS. 

237025 02 10 

EMERGENCY 

PSYCHIATRIC EMERGENCY CAUSED BY ACUTE INTOXICATION AND 
DETOXIFICATION SYNDROMES 

242751 04 17 

EMOTIONAL 

THE EFFECT OF PSYCHOTROPIC DRUGS ON CONDITIONED REFLEXES 
AFTER AN EMOTIONAL STRESS IN CATS 

231069 01 04 
DRUGS FOR EMOTIONAL DISORDERS CURRENT PROBLEMS 

233514 02-17 

MENTAL AND EMOTIONAL DISTURBANCE WITH PENTAZOCINE (TALWIN) 

USE. 

233828 02-15 

SYMPOSIUM II. PHARMACOLOGY ON BRAIN MONOAMINES: 

4) 
THE ROLE OF BRAIN SEROTONIN IN EMOTIONAL BEHAVIOR OF THE RAT 

241363 03 04 
PARTICIPATION OF THE SEROTONERGIC SYSTEM OF THE BRAIN IN THE 
REGULATION OF EMOTIONAL REACTIVITY 

242544 03-03 
EFFECTS OF L-DOPA ON EMOTIONAL REACTIONS AND METABOLISM OF 
SEROTONIN IN THE RAT BRAIN 

244455 04 04 



pa 



5© 



S-129 



Subject Index 



Psychopharmacology Abstra 



ANTIDEPRESSANT TREATMENT WITH MAPROTILINE IN THE 

MANAGEMENT OF EMOTIONAL DISTURBANCES IN PATIENTS WITH 
ACUTE MYOCARDIAL INFARCTION: A CONTROLLED STUDY. 

253684 04-11 
EMOTIONALITY 

EFFECTS OF HANDLING BEFORE CENTRAL 6 HYDROXYDOPAMINE 

TREATMENT ON SUBSEQUENT EMOTIONALITY AND NEUROCHEMICAL 
CHANGES IN RATS, 

228142 01-04 
STUDIES ON BIOGENIC AMINES AND BEHAVIOR (II). RELATIONSHIP 
BETWEEN EMOTIONALITY AND DEFECATION. 

241371 03-04 
EMPHASIS 

INFLUENCE OF PSYCHOTROPIC DRUGS ON CHRONIC SCHIZOPHRENIC 
SYNDROMES - WITH SPECIAL EMPHASIS ON THE CHANGE IN CLINICAL 
PROCESS WITH A RELATIVELY HIGH DOSAGE OF SPIROPERIDOL. 

229761 01-08 
EMPIRICAL 

COUNSELING, PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH: AN EMPIRICAL STUDY OF THE EFFICACY OF DPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH.D. 
DISSERTATION). 

228686 01-11 
CONNERS TEACHER RATING SCALE FOR USE IN DRUG STUDIES WITH 
CHILDREN - AN EMPIRICAL STUDY. 

248593 04-11 
EMPLOYED 

DRUG-INDUCED CONDITIONED SUPPRESSION; SPECIFICITY DUE TO DRUG 
EMPLOYED AS UCS. 

242750 04-04 
EMPLOYING 

HEROIN ADDICTION. SEQUENTIAL TREATMENT EMPLOYING 
PHARMACOLOGIC SUPPORTS 

239939 03-11 
ENAMINE 

NEW TRICYCLIC ENAMINE DERIVATIVES WITH CNS DEPRESSANT 
PROPERTIES. 

232528 01-02 
ENCEPHALOPATHY 

THE USE OF CLONAZEPAM IN TREATING CONVULSIVE MANIFESTATIONS 
WITH ENCEPHALOPATHY IN CHILDREN; STUDY OF 28 CASES. 

229083 01-11 
COGNITIVE DEFICITS ASSOCIATED WITH CHRONIC HEPATIC 
ENCEPHALOPATHY AND THEIR RESPONSE TO LEVODOPA. 

230580 01-15 
CYCLIC EEG CHANGES IN SUBACUTE SPONGIFORM AND ANOXIC 
ENCEPHALOPATHY, 

235563 02-13 
ENCEPHALOPATHY SUBSEQUENT TO ACCIDENTAL POISONING WITH 
CHLORPROMAZINE. 

239089 03-05 
ENCOUNTER 

COUNSELING, PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH; AN EMPIRICAL STUDY OF THE EFFICACY OF DPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH.D. 
DISSERTATION) 

228686 01 11 
ENDINGS 

CHARACTERISTICS OF TYROSINE HYDROXYLATION IN ISOLATED NERVE 
ENDINGS. 

237244 02-03 
A STUDY OF THE METABOLISM AND RELEASE OF DOPAMINE AND 

AMINO-ACIDS FROM NERVE ENDINGS ISOLATED FROM SHEEP CORPUS- 
STRIATUM. 

241206 03-03 
ENDOCRINE 

ENDOCRINE EFFECTS OF CHRONIC INTRAVENTRICULAR ADMINISTRATION 
OF DELTA9-TETRAHYDR0CANNABIN0L TO PREPUBERAL AND ADULT 
MALE RATS. 

248275 04-05 
BEHAVIOR AND ENDOCRINE EFFECTS OF 3,4,5 
TRIMETHOXYAMPHETAMINE IN MALE MICE. 

251215 04-04 
ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE 
DRUGS TO PREPUBERTAL MALE RATS. II. LSD. 

253700 04-03 
ENDOCRINOLOGICAL 

THYROTROPIN-RELEASING HORMONE IN DEPRESSION; CLINICAL AND 
ENDOCRINOLOGICAL FINDINGS. 

235370 02-09 
ENDOGENOUS 

AN EVALUATION OF THE USE OF INTRAVENTRICULARLY ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE AS A MARKER FOR ENDOGENOUS BRAIN 
5-HYDROXYTRYPTAMINE. 

226400 01-03 



ISOLATION OF AN ENDOGENOUS COMPOUND FROM THE BRAIN WITH 
PHARMACOLOGICAL PROPERTIES SIMILAR TO MORPHINE. 

227774 
EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON THE 

ELECTROCARDIOGRAMS OF PATIENTS WITH ENDOGENOUS DEPRESS 
(INTRODUCTORY REPORT). 

234046 
DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON ENDOGENOU 
NEUROTRANSMITTERS. 

234798 0, 
TREATMENT OF ENDOGENOUS PSYCHOSES WITH DOMINAL AND 
DOMINAL FORTE IN COMBINATION WITH HIGHLY ACTIVE 
NEUROLEPTICS. 

235305 O; 
ENDOGENOUS BRAIN 2-PHENYLETHYLAMINE; BIOCHEMICAL AND 
PHARMACOLOGICAL STUDIES ON ITS ORIGIN AND POSSIBLE ROLE . 
A MAJOR MEDIATOR OF THE CENTRAL ACTIONS OF AMPHETAMINi 
AND OTHER PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION). 

238077 
THE EFFECT OF PARGYLINE ON THE RELEASE OF ENDOGENOUS 

NOREPINEPHRINE BY N-ETHYLAMPHETAMINE AND FENFLURAMINE. 

238688 

NALOXONE ANTAGONISM OF CONDITIONAL REVERSAL OF NARCOTIC 

WITHDRAWAL SIGNS AND CONDITIONAL MORPHINE HYPERTHERM 

AN INDIRECT EVIDENCE FOR RELEASE OF ENDOGENOUS OPIOID-LIKI 

SUBSTANCE IN THE RAT. 

238713 
ENDOGENOUS DOPAMINE RELEASE DEPENDENT AND INDEPENDENT 
ACTIVATION OF DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL 
SYNAPTOSOMES. 

238729 
EFFECT OF DIPHENYLHYDANTOIN ON THE ENDOGENOUS 
PHOSPHORYLATION OF BRAIN PROTEIN. 

240746 
ON THE ROLE OF ENDOGENOUS OPIOID PEPTIDES; FAILURE OF NALOX 
TO INFLUENCE SHOCK ESCAPE THRESHOLD IN THE RAT. 

241244 
DETERMINATIONS OF ENDOGENOUS CONCENTRATIONS OF 

NOREPINEPHRINE AND DOPAMINE AND THEIR RATES OF SYNTHESI! 
A SINGLE MOUSE BRAIN; 8IPHASIC EFFECTS OF ( O AMPHETAMINI 

241257 
DOPAMINERGIC NEURONS - ALTERATION IN THE SENSITIVITY OF 
TYROSINE-HYDROXYLASE TO INHIBITION BY ENDOGENOUS DOPAMI 
AFTER CESSATION OF IMPULSE FLOW. 

241295 
ENDOGENOUS INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE IN RAT 
ORGANS. 

244315 
TRAZODONE; THERAPEUTIC EFFECTIVENESS IN ENDOGENOUS 
DEPRESSION, COMPARED WITH BLOOD LEVELS. 

244588 
MORPHINES PROCONVULSANT ACTION; IMPORTANCE OF ENDOGENOl 
NOREPINEPHRINE. 

248880 
SELF-INHIBITING ACTION OF NORTRIPTYLINE ANTIOEPRESSIVE EFFECT 
HIGH PLASMA LEVELS; A RANDOMIZED, DOUBLE-BLIND STUDY 
CONTROLLED BY PLASMA CONCENTRATIONS IN PATIENTS WITH 
ENDOGENOUS DEPRESSION. 

248955 
EFFECT OF LABELLED ACETYLCHOLINE (ACCH) UPTAKE BY RAT BRAIN 
SLICES ON ENDOGENOUS LEVELS OF ACCH AND CHOLINE (CH). 

249298 
THE ENDOGENOUS NEUROTIC DISTINCTION AS A PREDICTOR OF 
RESPONSE TO ANTIDEPRESSANT DRUGS. 

250726 
EFFECT OF OXOTREMORINE ON ENDOGENOUS ACETYLCHOLINE AND 
UPTAKE AND BIOTRANSFORMATION OF RADIOACTIVE CHOLINE IN 
DISCRETE REGIONS OF MOUSE BRAIN IN VIVO. 

251175 
ENDOSCOPY 

CAMAZEPAM (SB-5833) IN PREPARATION FOR ENDOSCOPY INSPECTIC 
OPEN AND DOUBLE-BLIND STUDY VERSUS DIAZEPAM. 

241276 0: 
ENDPOINT 

PENFLURIDOL BLOCKADE OF APOMORPHINE; DEPENDENCE OF DURATI 
ON SPECIES AND ENDPOINT. 

248406 0. 
ENERGY 

COCAINE AND AMPHETAMINE MODIFICATION OF CEREBRAL ENERGY 
METABOLISM IN VIVO. 

230834 
AN ANALYSIS OF THE DRUGS ACTING ON CEREBRAL ENERGY 
METABOLISM. 

247012 0- 
ENHANCEMENT 

MORPHINE ENHANCEMENT OF SHUTTLE AVOIDANCE PREVENTED BY 
ALPHA-METHYLTYROSINE. 

230825 



S-130 



LUME 14, SUBJECT INDEX 



Subject index 



RETROGRADE ENHANCEMENT OF MEMORY BY MILD FLUROTHYL 
TREATMENT IN THE CHICK 

237260 02-04 

PERFORMANCE ENHANCEMENT EFFECTS OF D-AMPHETAMINE, 
METHYLPHENIDATE, PIPRADROL AND PHENINDAMINE IN RATS. 

239857 03-04 
FENFLURAMINE-INDUCED ENHANCEMENT OF CONFINEMENT MOTOR 
ACTIVITY- AN INDIRECT 5-HYDROXYTRYPTAMINE LIKE ACTION?. 

24491 1 04-04 
ENHANCEMENT BY CHLORPROMAZINE OF HYPERGYLCEMIC ACTION OF 

OIAZOXIDE. 

247715 04-15 
ENHANCEMENT OF RESERPINE-ELICITED DOPAMINERGIC 

SUPERSENSITIVITY BY REPEATED TREATMENT WITH APOMORPHINE 
AND ALPHA-METHYL-P-TYROSINE. 

249002 04-03 
IMIPRAMINE ENHANCEMENT OF PENTOBARBITAL TOXICITY IN RATS. 

249929 04-05 
OPIATE RECEPTOR BINDING - ENHANCEMENT BY OPIATE 
ADMINISTRATION IN VIVO. 

250378 04-03 
INHIBITION AND ENHANCEMENT OF PHOTICALLY EVOKED RESPONSES BY 
DIFFERENT DOSES OF L-DOPA 

251214 04-03 
ANCING 

COUNSELING, PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH: AN EMPIRICAL STUDY OF THE EFFICACY OF OPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH.D. 
DISSERTATION). 

228686 01-11 
TOLERANCE TO THE ACTIVITY ENHANCING EFFECT OF D-AMPHETAMINE. 
(PH.D. DISSERTATION). 

241575 03-03 
EPHAUN 

THE REGIONAL DISTRIBUTION OF A MORPHINE-LIKE FACTOR ENKEPHALIN 
IN MONKEY BRAIN. 

252219 04-03 
ICHED 

ACTIONS OF PHENOTHIAZINE ANALOGS ON DOPAMINE SENSITIVE 
ADENYLATE-CYCLASE IN NEURONAL AND GLIAL ENRICHED FRACTIONS 
FROM RAT BRAIN. 

237241 02-03 

EROHEPATIC 

INTESTINAL ABSORPTION, DEMETHYLATION, AND ENTEROHEPATIC 
CIRCULATION OF IMIPRAMINE. 

252231 04-13 
ORHINAl 

INTRACRANIAL SELF-STIMULATION DERIVED FROM ENTORHINAL CORTEX. 

238757 03-04 
JRESIS 
PSYCHOLOGICAL TEST INVESTIGATIONS OF PATIENTS TREATED WITH 
CARBAMAZEPINE FOR NOCTURNAL ENURESIS AND TICS. 

229684 01-14 
IMIPRAMINE IN ENURESIS -■ PSYCHOLOGICAL AND PHYSIOLOGICAL 

EFFECTS. 

247743 04-11 

/IRONMENT 

THE EFFECTS OF TEST ENVIRONMENT AND REARING CONDITION ON 
AMPHETAMINE-INDUCED STEREOTYPY IN THE GUINEA-PIG. 

237712 02-04 
THE EFFECTS OF SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS ON 
RETENTION OF HABITUATION TO A NOVEL ENVIRONMENT 

24 1 546 03-04 
BEHAVIOR AND INTELLECTUAL ACTIVITY OF THE ELDERLY: DOUBLE- 
BLIND STUDY OF HYDR0SARPAN-71I IN A HOSPICE ENVIRONMENT. 

242900 04-11 
l/IRONMENTAl 
ENVIRONMENTAL INFLUENCES ON THE BEHAVIORAL RESPONSE TO ACUTE 
AND CHRONIC AMPHETAMINE ADMINISTRATION. 

238843 03 04 
PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES AFFECTING 
DRUG PREFERENCE IN RHESUS MONKEYS. 

240013 03-04 
DRUG EFFECTS AND THE ENVIRONMENTAL CONTROL OF BEHAVIOR 

240021 03-04 
EFFECTS OF ENVIRONMENTAL TEMPERATURE ON 5- 
HYDROXYTRYPTAMINE (5-HT) TURNOVER RATE IN THE RAT BRAIN (III) 

241394 03-03 
EFFECT OF LSD ON RAT BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AT 
ELEVATED ENVIRONMENTAL TEMPERATURE. 

241925 03-03 
ZYMATIC 
ENZYMATIC CONVERSION OF MORPHINE TO PSEUDOMORPHINE. 

243780 04-03 



ENZYME 

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM 
PRECURSORS, ENZYME INHIBITORS, AND STUDIES OF CENTRAL 
DOPAMINE TURNOVER. 

233964 02 14 

INFLUENCE OF DRUGS AND CHEMICALS UPON HEPATIC ENZYMES AND 
PROTEINS - I STRUCTURE-ACTIVITY RELATIONSHIP BETWEEN 
VARIOUS BARBITURATES AND MICROSOMAL ENZYME INDUCTION IN 

RAT LIVER. 

241297 03-03 

HISTOTOPOGRAPHY OF THE CHANGES IN ENZYME ACTIVITY IN THE RAT 
BRAIN UNDER THE EFFECT OF FLUOROPHENAZINE. 

241989 03-03 
EFFECTS OF PASSIVE IMMUNIZATION WITH RABBIT 

ANTIPHENOBARBITAL IGG ON CYCLOBARBITALINDUCED SLEEPING 
TIME AND HEPATIC ENZYME ACTIVITIES OF C3H MICE. 

242201 03-03 
EFFECTS OF AXOTOMY ON THE TRANS-SYNAPTIC REGULATION OF 
ENZYME ACTIVITY IN ADULT RAT SUPERIOR CERVICAL GANGLIA. 

244200 04 03 
METABOLIC FATE OF FLURAZEPAM II: A NEW POTENT METABOLITE 

OBTAINED BY IN VITRO LIVER DRUG METABOLIZING ENZYME SYSTEM. 

246971 04-03 
EXTRAPINEAL AMINE N-ACETYLATION IN RAT BRAIN: REGIONAL AND 
SUBCELLULAR DISTRIBUTION AND ENZYME KINETICS. 

250377 04 01 

USE OF 300-MSEC MICROWAVE IRRADIATION FOR ENZYME 

INACTIVATION: A STUDY OF EFFECTS OF SODIUM PENTOBARBITAL ON 
ACETYLCHOLINE CONCENTRATION IN MOUSE BRAIN REGIONS. 

253106 04-03 
ENZYMES 

UTILIZATION OF CELLULAR STUDIES OF NEUROTRANSMITTER RELATED 
ENZYMES AND TRANSPORT PROCESSES IN MAN FOR THE 
INVESTIGATION OF BIOLOGICAL FACTORS IN BEHAVIORAL DISORDERS. 
(UNPUBLISHED PAPER). 

226731 01-13 

DIAZEPAM, ETHANOL AND DRUG METABOLIZING ENZYMES IN RAT 
LIVER. 

226927 01-03 

INHIBITION OF DRUG METABOLIZING ENZYMES BY DIAZEPAM IN RAT 
LIVER. 

227696 01-03 

NEUROPSYCHOPHARAAACOLOGY OF MONOAMINES AND I HEIR 
REGULATORY ENZYMES. 

233941 02-03 
INDUCTION OF HEPATIC ENZYMES BY METHAQUALONE AND EFFECT ON 
WARFARIN-INDUCED HYPOPROTHROMBINEMIA 

237760 02-03 
SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS AS AIDS IN 
EVALUATING THE ROLE OF TYPE A AND B ENZYMES, 

237776 02-03 
NEUROPSYCHOPHARAAACOLOGY OF MONOAMINES AND THEIR 
REGULATORY ENZYMES. 

237829 02- r/ 
INFLUENCE OF DRUGS AND CHEMICALS UPON HEPATIC ENZYMES AND 
PROTEINS - I STRUCTURE ACTIVITY RELATIONSHIP BETWEEN 
VARIOUS BARBITURATES AND MICROSOMAL ENZYME INDUCTION IN 
RAT LIVER. 

241297 03-03 
IN VIVO AND IN VITRO EFFECTS OF DELTA9 TETRAHYDROCANNABINOL 
ON RAT LIVER MICROSOMAL DRUG METABOLIZING ENZYMES. 

243182 04-03 
EFFECTS OF A CHOLINE-DEFICIENT DIET ON THE INDUCTION OF DRUG 
AND ETHANOL METABOLIZING ENZYMES AND ON THE ALTERATION OF 
RATES OF ETHANOL DEGRADATION BY ETHANOL AND 
PHENOBARBITAL. 

247032 04-03 
ENZYMOLOGICAL 

TRYPTOLINES: PHARMACOLOGICAL AND ENZYMOLOGICAL STUDIES 
PH.D. DISSERTATION). 

242002 03-02 
EPHEDRINE 

ACCUMULATION OF LABELED EPHEDRINE, NOREPHEDRINE, 

AMPHETAMINE AND TYRAMINE IN PIGMENTED AND NONPIGMENTED 
EYES OF BLACK AND WHITE RATS. 

230450 01-05 
L-DOPA, AMINOPHYLLINE, EPHEDRINE ANTAGONISTIC INTERACTION 
WITH ETHANOL IN HUMANS, 

238748 03-13 
EPIDEMIOLOGY 

EPIDEMIOLOGY OF TARDIVE-DYSKINESIA PART II 

244497 04-15 
EPIDEMIOLOGY OF TARDIVE-DYSKINESIA: PART I. 

250991 04-15 
OUTPATIENT PHENOTHIAZINE USE AND BONE MARROW DEPRESSION: A 
REPORT FROM THE DRUG EPIDEMIOLOGY UNIT AND THE BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM 

253661 04 15 



::SS 



S-131 



Subject Index 



Psychopharmacology Abstrac 



EPILEPSY 

NEUROCHEMICAL AND MORPHOLOGICAL CHANGES DURING THE 
DEVELOPMENT OF COBALT-INDUCED EPILEPSY IN THE RAT. 

226399 01-03 
BIOCHEMICAL OBSERVATIONS FOLLOWING ADMINISTRATION OF 
TAURINE TO PATIENTS WITH EPILEPSY. 

226737 01-13 
SCHIZOPHRENIFORM PSYCHOSIS OF EPILEPSY: TWO CASES WITH 
PAROXYSMAL DYSRHYTHMIA ON EEG. 

228068 01-08 
APPEARANCE OF WET DOG SHAKE BEHAVIOR DURING COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT AND ITS SUPPRESSION BY 
RESERPINE 

230836 01-04 
FUGUE STATES - EPILEPSY - MEDICATION - HELD COMPETENT TO 
STAND TRIAL: PEOPLE V. PARSONS, 371 N.Y.S.2D 840, (NEW-YORK), 
NASSAU COUNTY COURT. AUGUST 1, 1975. 

237476 02- 17 
DIPHENYLHYDANTOIN SERUM LEVELS, TOXICITY, AND 

NEUROPSYCHOLOGICAL PERFORMANCE IN PATIENTS WITH EPILEPSY. 

240473 03-15 
STUDY OF THE TOLERANCE AND CLINICAL EFFECT OF CARBAMAZEPINE 
IN A NEW SUSPENSION IN 38 CHILDREN AND ADOLESCENTS FROM 2- 
18 YEARS OLD, AFFECTED WITH EPILEPSY SOMETIMES ASSOCIATED 
WITH BEHAVIOR AND CHARACTER. 

244958 04-11 
SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE CHILDHOOD 
EPILEPSY. 

245344 04-11 
SCHIZOPHRENIA, EPILEPSY, CANCER, METHIONINE, AND FOLATE 
METABOLISM: PATHOGENESIS OF SCHIZOPHRENIA. 

248543 04-16 
FENFLURAMINE WITHDRAWAL AND EPILEPSY. 

250944 04-11 
EFFECT OF CARBAMAZEPINE (TEGRETOL) ON ATTENTIONAL AND 
PERCEPTUAL FUNCTIONS OF CHILDREN WITH EPILEPSY. 

251949 04-11 
EPIIEPTIC 

INVOLUNTARY MOVEMENTS CAUSED BY PHENYTOIN INTOXICATION IN 
EPILEPTIC PATIENTS 

225890 01-15 
EFFECT OF DELTA9-THC ON PHYSICAL SYMPTOMS AND EEG IN THE 
NATURALLY EPILEPTIC BEAGLE. 

23881 1 03-04 
PLASMA CONCENTRATION OF DIPHENYLHYDANTOIN IN THE EPILEPTIC: 
ITS INTEREST FOR THE CLINICIAN. 

240762 03-11 
BIOAVAILABILITY OF TWO CARBAMAZEPINE PREPARATIONS DURING 
CHRONIC ADMINISTRATION TO EPILEPTIC PATIENTS, 

242212 03 11 
EFFECTS OF DRUGS ON EPILEPTIC PATIENTS. 

245884 04-11 
PHENYTOIN-INDUCED DYSTONIA AND CHOREOATHETOSIS IN TWO 
RETARDED EPILEPTIC CHILDREN. 

251654 04 15 
EPILEPTICS 

EFFECTS OF SULTHIAME UPON INTELLECTUAL NEUROPSYCHOLOGICAL, 
AND SOCIAL FUNCTIONING ABILITIES AMONG ADULT EPILEPTICS: 
COMPARISON WITH DIPHENYLHYDANTOIN. 

240475 03 14 
EPILEPTIFORM 

EPILEPTIFORM ACTIVITY IN THE ELECTROENCEPHALOGRAM INDUCED BY 
LITHIUM CARBONATE. 

233499 02-15 
EPINEPHRINE 

CHANGES IN THE SELF STIMULATION BEHAVIOR BY INTRAVENTRICULAR 
INJECTION OF EPINEPHRINE, NOREPINEPHRINE, ISOPROTERENOL AND 
DOPAMINE 

238566 02-04 
ULTRASENSITIVE CHEMOSENSORY RESPONSES BY A PROTOZOAN TO 
EPINEPHRINE AND OTHER NEUROCHEMICALS. 

248163 04-02 
EPISODE 

APPLICATION OF LITHIUM SALTS NOT ONLY IN MANIC-DEPRESSIVE 
PSYCHOSIS WITH FREQUENT PHASES, BUT ALSO FOR TREATMENT OF 
EVERY PHASE (EPISODE) OF PSYCHOSIS 

236732 02-09 
EPITHALAMIN 

INCREASE IN HYPOTHALAMIC SENSITIVITY TO THE INHIBITORY ACTION 
OF ESTROGENS CAUSED BY THE USE OF L DOPA, DILANTIN, 
EPITHALAMIN, AND PHENOFORMIN IN OLD RATS 

241983 03-05 
EPOXIDE 

KINETICS OF CARBAMAZEPINE AND ITS 10,1 1 EPOXIDE METABOLITE IN 
CHILDREN 

243086 04-13 



EQUIPMENT 

INEXPENSIVE EQUIPMENT FOR HIGH PRESSURE LIQUID 

CHROMATOGRAPHY: APPLICATION TO ASSAYS FOR TAURINE, 
GAMMA-AMINOBUTYRIC-ACID AND 5-HYDROXYTRYPTOPHAN. 
(UNPUBLISHED PAPER). 

231278 01- 
ERGOCORNINE 

EFFECTS OF ERGOCORNINE AND CI-628 ON FOOD INTAKE AND TASTE 
PREFERENCES. 

239290 03- 
ERGOT 

DIRECT DOPAMINERGIC ACTION OF LISURIDE HYDROGEN MALEATE, AN 
ERGOT DERIVATIVE, IN MICE. 

252028 04- 
ERGOTAMINE 

THE EFFECT OF ERGOTAMINE AND METHYSERGIDE ON SEROTONIN 
METABOLISM IN THE RAT BRAIN. 

226826 01- 
ERYTHROCYTE 

REGULATION OF PROTEIN PHOSPHORYLATION AND MEMBRANE 

PERMEABILITY BY BETA-ADRENERGIC AGENTS AND CYCLIC ADENOSI 
3:5-MONOPHOSPHATE IN THE AVIAN ERYTHROCYTE. 

231014 01- 
PLASMA AND ERYTHROCYTE MAGNESIUM LEVELS IN PATIENTS WITH 
PRIAAARY AFFECTIVE DISORDER DURING CHRONIC LITHIUM 
TREATMENT. 

238977 03 
THE RELATIONSHIP OF PLASMA TO ERYTHROCYTE LITHIUM LEVELS IN 
PATIENTS TAKING LITHIUM CARBONATE. 

249535 04 
INCREASED ERYTHROCYTE NA + PUMP AND NAK-ATPASE ACTIVITY 
DURING LITHIUM THERAPY. 

253137 04 
ERYTHROCYTES 

RESPONSES OF ISOLATED HUMAN BASILAR ARTERIES TO 5- 

HYROXYTRYPAMINE, NORADRENALINE, SERUM, PLATELETS, AND 
ERYTHROCYTES. 

230739 01 
CHLORPROMAZINE AND HORMONAL ELEVATION OF CYCLIC-AMP 
CONTENTS IN TURKEY ERYTHROCYTES AND PERFUSED RAT HEART 
AND LIVER. 

239044 03- 
IN VITRO AND IN VIVO TRANSPORT OF LITHIUM BY HUMAN 
ERYTHROCYTES. 

246275 04 
THE EFFECTS OF HARMALINE ON SODIUM TRANSPORT IN HUMAN 
ERYTHROCYTES: EVIDENCE IN FAVOR OF ACTION AT INTERIOR 
SODIUM SENSITIVE SITES. 

246856 04 
ESCAPE 

5 METHOXY N,N:DIMETHYLTRYPTAMINE (5-MEO-DMT) SHARES 

INHIBITORY EFFECTS WITH MESCALINE BUT NOT EXCITATORY EFFEC 
ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS. (UNPUBLISHED PARE 

227802 01 
ON THE ROLE OF ENDOGENOUS OPIOID PEPTIDES: FAILURE OF NALOXO 
TO INFLUENCE SHOCK ESCAPE THRESHOLD IN THE RAT. 

241244 03 
THE EFFECTS OF NOREPINEPHRINE BIOSYNTHESIS INHIBITION ON THE 
CONSOLIDATION OF TWO DISCRIMINATED ESCAPE RESPONSES. 

241301 03 
EFFECTS OF CHLORPROMAZINE ON AVOIDANCE AND ESCAPE 
RESPONDING IN HUMANS. 

250076 04 
ESTABLISH 

AN ATTEMPT TO ESTABLISH QUALITY CONTROL IN DETERMINATION 01 
PLASMA CHLORPROMAZINE BY A MULTILABORATORY 
COLLABORATION. 

229439 01 
ESTAZOLAM 

CONTROLLED COMPARISON OF ESTAZOLAM AND NITRAZEPAM AS 
HYPNOTICS ON THE PREOPERATIVE NIGHT SLEEP. 

241273 03 
ESTERS 

ESTERS OF APOMORPHINE AND N,N DIMETHYLDOPAMINE AS AGONIST 
OF DOPAMINE RECEPTORS IN THE RAT BRAIN IN VIVO. 

246150 04 
DRUGS DERIVED FROM CANNABINOIDS. 2. BASIC ESTERS OF NITROGEf 
AND CARBOCYCLIC ANALOGS. 

248647 04 
ESTIMATING 

USE OF THE MOUSE JUMPING TEST FOR ESTIMATING ANTAGONISTIC 
POTENCIES OF MORPHINE ANTAGONISTS 

250354 04 
ESTIMATION 

ISOLATION AND RADIOENZYMIC ESTIMATION OF PICOGRAM QUANTITl 
OF DOPAMINE AND NOREPINEPHRINE IN BIOLOGICAL SAMPLES. 

244636 04 



S-132 



UME 14, SUBJECT INDEX 

PPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE 
ESTIMATION OF BRAIN ACETYLCHOLINE TURNOVER RATE: EFFECTS OF 
OXOTREMORINE AND PHYSOSTIGMINE. 

248700 04-03 

DIOL 

FFECT OF CANNABIS EXTRACT ON THE UTERINE MONOAMINE-OXIDASE 
ACTIVITY OF NORMAL AND ESTRADIOL TREATED RATS. 

241343 03-03 
FFECT OF ESTROGEN TREATMENT ON ESTRADIOL BINDING CAPACITY IN 
UTERI OF AGING RATS, 

247588 04-03 
STRADIOL BENZOATE, NOREPINEPHRINE, AND WEIGHT REGULATORY 
BEHAVIOR IN FEMALE RATS. 

250012 04-04 

)GEN 

FFECT OF ESTROGEN TREATMENT ON ESTRADIOL BINDING CAPACITY IN 

UTERI OF AGING RATS. 

247588 04-03 
FFECTS OF ESTROGEN AND ANDROGEN ON THE SEXUAL BEHAVIOUR OF 

THE OVARIECTOMIZED EWE. 

248223 04-04 
>GENS 

NCREASE IN HYPOTHALAMIC SENSITIVITY TO THE INHIBITORY ACTION 
OF ESTROGENS CAUSED BY THE USE OF L-DOPA, DILANTIN, 
EPITHALAMIN, AND PHENOFORMIN IN OLD RATS. 

241983 03-05 

NFLUENCE OF CHLORPROMAZINE ON THE POSITIVE AND NEGATIVE 
FEEDBACK MECHANISM OF ESTROGENS IN MAN. 

248224 04-13 
JUDIES ON SULFATE CONJUGATION OF ESTROGENS IN BRAIN AND 

LIVER. 

249245 04-03 

'5 

FHE USE OF A DOPAMINERGIC RECEPTOR STIMULATING AGENT 
(PIRIBEDIL, ET-495) IN PARKINSONS DISEASE. 

233974 02-11 
ENOXIN 

ITAFENOXIN IN THE TREATMENT OF NEUROSIS - AN UNCONTROLLED 
CLINICAL STUDY. 

235357 02-07 
NOl 

NTERACTIONS OF DELTA9-TETRAHYDR0CANNABIN0L, ADRENAL 
STEROIDS, AND ETHANOL. 

226763 01-03 
3IAZEPAM, ETHANOL AND DRUG METABOLIZING ENZYMES IN RAT 
LIVER. 

226927 01-03 
ETHANOL AS A REINFORCER FOR RATS: EFFECTS OF CONCURRENT 
ACCESS TO WATER AND ALTERNATE POSITIONS OF WATER AND 
ETHANOL. 

227128 01 04 
EFFECT OF ETHANOL ON DIAZEPAM DISTRIBUTION IN RAT. 

231007 01-03 
EFFECT OF ETHANOL INTAKE ON PHENYTOIN METABOLISM IN 
VOLUNTEERS. 

233280 02-13 
EXPERIMENTAL STUDIES ON THE EFFECT OF SOME PSYCHOTROPIC 
DRUGS AND PYRAZOLE ON THE RATE OF ETHANOL OXIDATION IN 
VIVO AND IN THE PERFUNDATED RAT LIVER IN VITRO. 

234522 02-03 
THE DISTRIBUTION AND METABOLISM OF ETHANOL AND BARBITURATES 
IN THE ORGANISM DURING THEIR COMBINED USE (LITERATURE 
SURVEY). 

236717 02-03 

EFFECT OF P-CHLOROPHENYLALANINE ON THE ACQUISITION OF 

TOLERANCE TO ETHANOL AND PENTOBARBITAL 

237720 02-04 
L-DOPA, AMINOPHYLLINE, EPHEDRINE: ANTAGONISTIC INTERACTION 

WITH ETHANOL IN HUMANS. 

238748 03-13 
ETHANOL, WATER AND FOOD INTAKE UNDER A FIXED-INTERVAL (Fl) 

SCHEDULE OF FOOD PELLET PRESENTATION. 

238749 03-04 
ETHANOL PREFERENCE IN RATS: POSSIBLE UNDERLYING MECHANISMS. 

238750 03-04 
EFFECTS OF ACUTE ETHANOL ADMINISTRATION ON BRAIN BIOGENIC 

AMINES. 

238751 03-03 
RESPONSE TO DELTA9-TETRAHYDR0CANNABIN0L, BARBITURATES AND 

ETHANOL IN LACTATING, VIRGIN FEMALE, AND MALE MICE. 

238766 03-03 
EFFECTS OF LITHIUM ON CHRONIC ETHANOL CONSUMPTION AND 
BEHAVIOR. 

238849 03-03 

THE EFFECT OF ETHANOL STRESS IN COMBINATION ON THE 

PHARMACOLOGIC ACTION OF HEXOBARBITAL (PH.D. DISSERTATION) 

240933 03-03 



Subject Index 

THE MODIFICATION OF THE ETHANOL WITHDRAWAL SYNDROME IN 
RATS BY DIN PROPYLACETATE. 

241222 03-03 
PHARMACOLOGICAL ASPECTS OF PHYSICAL DEPENDENCE ON ETHANOL. 

241240 03- 17 
CHANGE IN ETHANOL CONSUMPTION BY ALBINO RATS UNDER THE 
EFFECT OF NEUROLEPTICS AND TRANQUILIZERS. 

241987 03-03 
EFFECTS OF FRONTAL POLAR CORTICAL ABLATION AND CYCLOHEXIMIDE 
ON ETHANOL TOLERANCE IN RATS. 

242741 03-03 

DIAGNOSIS AND MANAGEMENT OF ETHANOL WITHDRA.WAL 

SYNDROMES. 

244107 04-11 

ETHANOL NARCOSIS IN MICE: EFFECTS OF L-DOPA, ITS METABOLITES 
AND OTHER EXPERIMENTAL VARIABLES. 

246821 04-05 
EFFECTS OF ETHANOL ON NEUROTRANSMITTER RELEASE BY RAT BRAIN 
CORTICAL SLICES. 

246850 04-03 
EFFECTS OF A CHOLINE-DEFICIENT DIET ON THE INDUCTION OF DRUG 
AND ETHANOL METABOLIZING ENZYMES AND ON THE ALTERATION OF 
RATES OF ETHANOL DEGRADATION BY ETHANOL AND 
PHENOBARBITAL. 

247032 04-03 
NEW METHOD FOR DETECTING AND QUANTITATING PHARMACOKINETIC 
DRUG DRUG INTERACTIONS APPLIED TO ETHANOL PROPRANOLOL. 

247846 04-06 
POTENTIATION OF ETHANOL NARCOSIS BY DOPAMINE AND L-DOPA 
BASED ISOQUINOLINES. 

248513 04-03 
EFFECTS OF PENTOBARBITAL IN MICE SELECTIVELY BRED FOR DIFFERENT 
SENSITIVITIES TO ETHANOL. 

249261 04-04 
DISCRIMINATIVE STIMULUS PROPERTIES OF ETHANOL AND BARBITAL. 

249262 04-04 
DEVELOPMENT OF CROSS-TOLERANCE BETWEEN DELTA9- 

TETRAHYDROCANNABINOL AND ETHANOL. 

249263 04-03 
THE CONTRIBUTION OF LEARNING TO THE DEVELOPMENT OF CHRONIC 

ETHANOL TOLERANCE IN THE RAT 

249264 04-04 
DEPRESSION OF DOPAMINE RELEASE DURING THE ETHANOL 

WITHDRAWAL SYNDROME. 

249293 04-03 
CHRONIC ETHANOL FEEDING AND BRAIN ADENYLCYCLASE AND 

PHOSPHODIESTERASE LEVELS IN MICE. 

249294 04-03 
THE EFFECT OF CAFFEINE ON HUMAN PERFORMANCE, ALONE AND IN 

COMBINATION WITH ETHANOL. 

249674 04-14 
INVESTIGATIONS INTO THE MECHANISM OF REDUCTION OF ETHANOL 
SLEEP BY THYROTROPIN-RELEASING HORMONE (TRH) 

250110 04-03 
SENSITIVITY TO LOW DOSES OF ETHANOL AND PENTOBARBITAL IN MICE 
SELECTED FOR SENSITIVITY TO HYPNOTIC DOSES OF ETHANOL. 

250284 04-04 
EFFECT OF ETHANOL ON DOPAMINE SYNTHESIS AND RELEASE FROM RAT 
CORPUS-STRIATUM. 

251178 04-03 
EFFECT OF PROPRANOLOL ON ETHANOL METABOLISM EVIDENCE FOR 

THE ROLE OF MITOCHONDRIAL NADH OXIDATION 

251179 04-03 
DELTA9-TETRAHYDR0CANNABIN0L, ETHANOL, AND AMPHETAMINE AS 

DISCRIMINATIVE STIMULI GENERALIZATION TESTS WITH OTHER 
DRUGS. 

251977 04-04 
EFFECTS OF CAFFEINE AND ETHANOL ON THE BLOOD-BRAIN BARRIER IN 
RATS. 

252222 04-03 
DIFFERENTIAL EFFECTS OF ETHANOL AND MANNITOL ON CONTRACTION 
OF ARTERIAL SMOOTH MUSCLE 

253113 04-03 

ETHER 

THE EFFECT OF DELTA9-TETRAHYDR0CANNABIN0L, CANNABIDIOL AND 
CANNABINOL ON ETHER ANAESTHESIA IN MICE. 

226764 01-04 
ETHERS 

SUBSTITUTED CYCLOALKANOL ETHERS OF PSYCHOSTIMULANT ACTIVITY: 
STUDIES ON QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS. 

231008 01-03 
ETHICAL 

ETHICAL AND LEGAL IMPLICATIONS OF INVESTIGATIONS INTO THE 
EFFICACY OF PSYCHIATRIC TREATMENTS. 

235354 02-17 
ETHYLAICOHOI 

DIFFERENTIAL EFFECTS OF ETHYLALCOHOL ON CONTRACTION OF 
ARTERIAL SMOOTH MUSCLE. 

251905 04-03 



es 






S-133 



Subject Index 



Psychopharmacology Abstract 



ETIFOXINE 

tVAlUATION OF THE PSYCHOTROPIC EFFECT OF ETIFOXINE THROUGH 
PURSUIT ROTOR PERFORMANCE AND GSR. 

237)02 02-14 
ETIIEFRINE 

ON HYPOTENSION AS A RESULT OF PSYCHOTROPIC MEDICATION: 
COMPARATIVE STUDY OF TWO CORRECTIVES (ETILEFRINE AND 
DIHYDROERGOTAMINE). 

241763 03-15 
ETORPHINE 

STEREOSPECIFIC BINDING OF ETORPHINE IN ISOLATED NEURAL CELLS 
AND IN RETINA, DETERMINED BY A SENSITIVE MICROASSAY. 

252178 04-03 
EUFLAVINE 

EUFLAVINE EFFECT ON BRAIN HEAVY METAL CONTENT AND STAINING 
PATTERN, AND ON SHUTTLEBOX BEHAVIOR IN GOLDFISH. 

241221 03-04 
EUPHORIANT 

FENMETRAZOLE (DH 524): EUPHORIANT CLASSIFIED BY CEREBRAL 
ELECTROMETRY. 

230781 01-14 
ATTENUATION OF THE EUPHORIANT AND ACTIVATING EFFECTS OF D- 
AMPHETAMINE AND AND L-AMPHETAMINE BY LITHIUM CARBONATE 
TREATMENT 

237716 02-14 
POSSIBLE MEDIATION OF THE EUPHORIANT AND SEDATIVE EFFECT OF 
MARIHUANA BY 2-PHENYLETHYLAMINE AND BY PHENYLACETIC-ACID. 

238820 03-03 
EUROPEAN 

AN EXAMPLE OF EUROPEAN MULTICENTER TRIALS: MULTISPECTRAL 
ANALYSIS OF CLOZAPINE. 

253052 04-08 
EUROPIUM 

NMR STUDY OF AMPHETAMINES USING EUROPIUM SHIFT REAGENTS. 

239660 03-01 
EVALUATING 

EVALUATING POTENTIAL ANTIDEPRESSANTS IN ANIMALS. 

227207 OT -06 
A SIMPLE METHOD OF EVALUATING THE COMPETITIVE INTERACTION OF 
REVERSIBLE INHIBITORS WITH CHOLINESTERASES. 

231072 OT -06 
SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS AS AIDS IN 
EVALUATING THE ROLE OF TYPE A AND B ENZYMES. 

237776 02-03 
A BRIEF ANXIETY RATING SCALE IN EVALUATING ANXIOLYTICS. 

237926 02-11 
RELAY TOXICITY A NEW APPROACH TO A METHODOLOGY OF 

EVALUATING THE TOXICITY OF AODITIVFS TO FARM ANIMAL FEED. 

245T14 04-06 
SIEEP LABORATORY STUDIES OF FLURAZEPAM: A MODEL FOR 
EVALUATING HYPNOTIC DRUGS 

252230 04 11 
EVALUATION 

EVALUATION OF SIDE EFFECTS ON NEUROTICS - A TEST USING 
MESORIDAZINE AND PLACEBO. 

225686 01-15 
AN EVAIUATION OF THE USE OF INTRAVENTRICULARLY ADMINISTERED 
(3H)5 HYDROXYTRYPTAMINE AS A MARKER FOR ENDOGENOUS BRAIN 
5-HYDROXYTRYPTAMINE 

226400 01-03 
COMPARATIVE EVALUATION OF FIURAZEPAM AND NITRAZEPAM FOR 
OCCASIONAL INSOMNIACS 

228315 01-11 
DOUBLE BLIND EVALUATION OF NAFTIDROFURYL IN TREATING ELDERLY 
CONFUSED HOSPITALISED PATIENTS 

229368 01 11 
FVAIUATION OF NEW COMPOUNDS FOR PSYCHOTROPIC ACTIVITY 

229477 01-04 
lilt CIINICAI EVALUATION OF A NEW MINOR TRANQUILIZER 
(lORAZEPATE DIPOTASSIUM (MENDON) IN THE TREATMENT OF 
PATIENTS WITH PSYCHOSOMATIC DISEASE. NEUROSES AND 
DEPRESSIVE STATE IN A DOUBLE-BLIND CLINICAL STUDY. 

229504 01 11 
PSYCHOMETRIC CLINICAL EVAIUATION, THROUGH OVERALL AND 
GORHAMS TEST, OF THERAPY WITH FLUPHENAZINE DECANOATE. 

229555 01-17 
A CONTROLLED EVAIUATION OF LORAZEPAM AND DIAZEPAM IN 
ANXIETY NEUROSIS 

230907 01-08 
IFFFCr OF I .') HYDROXYTRYPTOPHAN ON BRAIN MONOAMINE 
METABOLISM AND EVALUATION OF ITS CLINICAL EFFECT IN 
DEPRESSED PATIENTS. 

234673 02-09 
EVAttlATiON OT COMBINED PHARMACOLOGICAL AND 

PSYCHOIHERAPEUTIC TREATMENT IN PATIENTS WITH FUNCTIONAL 
ABDOMINAL DISORDERS. 

235782 02 11 



CLINICAL EVALUATION OF THE ANTIDEPRESSIVE ACTION OF THE . « 
PREPARATION AZAFEN. ■ ^ 

236429 02-i 
EVALUATION OF DISULFIRAM TREATMENT OF CHRONIC ALCOHOLISM. 

237026 02-; 
EVALUATION OF THE PSYCHOTROPIC EFFECT OF ETIFOXINE THROUGH 
PURSUIT ROTOR PERFORMANCE AND GSR. 

237102 02-; 
EVALUATION OF LORAZEPAM AND PENTOBARBITAL AS SURGICAL 
PREMEDICANTS. 

237734 02-! 
LENPERONE: A CONTROLLED EVALUATION IN CHRONIC SCHIZOPHRENIC 
PATIENTS. 

237899 02-(' 
ANALYTICAL STUDY OF ACQUISITION ON FREE-OPERANT AVOIDANCE 
RESPONSE FOR EVALUATION OF PSYCHOTROPIC DRUGS IN RATS. 

238564 02-{ 
DOPAMINE AND PSYCHOACTIVE DRUG ACTION: A FURTHER 
EVALUATION. 

238768 03-( 
EVALUATION OF CESIUM CHLORIDE AS ANTIDEPRESSANT. 

238836 03-( 
EVALUATION OF PSYCHOTROPIC DRUGS: A SYMPOSIUM. 

239846 03-; 
A BEHAVIORAL PARADIGM FOR THE EVALUATION OF NARCOTIC 
ANTAGONISTS. 

239941 03-1 
DPH-INTOXICATION - CLINICAL AND NEUROPSYCHOLOGICAL 
EVALUATION OF A SLOW DPH ELIMINATION. 

240692 03-1 
A PRIMER ON THE CLINICAL EVALUATION OF PSYCHOTROPIC DRUGS, 

240838 03-1 
BEHAVIORAL TERATOGENESIS: A CRITICAL EVALUATION. 

242744 03-1 
A CONTROLLED EVALUATION OF LOXITANE IN SEVENTY-FIVE 
ADOLESCENT SCHIZOPHRENIC PATIENTS. 

247483 04-( 
CLINICAL EVALUATION OF CDP-CHOLINE (NICHOLIN): EFFICACY AS 
ANTIDEPRESSANT TREATMENT. 

247969 04-( 
APOMORPHINE-INDUCED AGGRESSION: AN EVALUATION OF POSSIBLE 
SENSITIZING FACTORS IN THE RAT. 

248008 04-C 
AMPHETAMINE: EVALUATION OF D-ISOMERS AND L-ISOMERS AS 

RELEASING AGENTS AND UPTAKE INHIBITORS FOR 3H-D0PAMINE ANI 
3H-N0REPINEPHRINE IN SLICES OF RAT NEOSTRIATUM AND CEREBRAI 
CORTEX. 

248699 04-C 

OXAZEPAM PROTRIPTYLINE: A DOUBLE-BLIND PHASE II EVALUATION OF 

THE EFFICACY AND SAFETY OF THE COMBINATION VERSUS PLACEBO 

IN NEUROTIC. DEPRESSED AND ANXIOUS PSYCHIATRIC OUTPATIENTS. 

248975 04-1 
A DOUBLE-BLIND EVALUATION OF METIAPINE IN HOSPITALIZED ACUTE 

SCHIZOPHRENICS. 

248976 04-C 
CLORAZEPATE DIPOTASSIUM (TRANXENE): A CONTROLLED EVALUATION 

IN ALCOHOLIC PATIENTS AFTER WITHDRAWAL. 

251718 04-1 
AN EVALUATION OF PAPAVERINE IN TARDIVE-DYSKINESIA. 

251830 04-1 
EVALUATION OF THE ANTINOCICEPTIVE EFFECTS OF 4,ALPHA-DIMETHYL 
M-TRYAMINE (H77-77) IN THE RAT 

252026 04-C 
THE CLINICAL EVALUATION OF GRANDAXIN USED IN THE TREATMENT C 
OUTPATIENTS (A MULTICENTRIC STUDY). 

252448 04-C 
EVENTS 

STIMULI ASSOCIATED WITH DRUG INJECTIONS AS EVENTS THAT 
CONTROL BEHAVIOR. 

24001 1 03-C 
EVIDENCE 

THE EVIDENCE OF THE RELEASE OF PROSTAGLANDIN-LIKE MATERIAL 
FROM RABBIT KIDNEY AND GUINEA-PIG LUNG BY (-) TRANS-DELTA9- 
TETRAHYDROCANNABINOL. 

226762 01 -C 
EVIDENCE FOR AN INVOLVEMENT OF GABA IN THE MEDIATION OF THE 
CEREBELLAR CGMP DECREASE AND THE ANTICONVULSANT ACTION 
DIAZEPAM 

226857 01 -C 
ONTOGENY OF BEHAVIORAL SENSITIVITY TO STRYCHNINE IN THE CHICK 
EMBRYO: EVIDENCE FOR THE EARLY ONSET OF CNS INHIBITION 

228630 01 -C 
EVIDENCE FOR DRUG ACTIONS ON BOTH PRE- AND POSTSYNAPTIC 
CATECHOLAMINE RECEPTORS IN THE CNS. 

229431 01-0 
INHIBITION OF CENTRALLY EVOKED PRESSOR RESPONSES BY DIAZEPAM 
EVIDENCE FOR AN EXCLUSIVELY SUPRAMEDULLARY ACTION. 

231039 01-0 



S-134 



AB 14, SUBJECT INDEX 



Subject Index 



lence for gaba involvement in the action of diazepam on 
iesynaptic nerve terminals in bullfrog sympathetic 
;nglia 

232513 01 03 
lENCE FOR INVOLVEMENT OF GABA IN THE ACTION OF 
^NZOOIAZEPINES; STUDIES ON RAT CEREBELLUM. 

232514 01-03 
FRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS; EVIDENCE FROM 
iECURSORS, ENZYME INHIBITORS, AND STUDIES OF CENTRAL 
3PAMINE TURNOVER. 

233964 02-14 
ICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
iYCHOTROPIC DRUGS 

234797 02-09 
lEASE OF TYROSINE-HYDROXYLASE ACTIVITY AFTER RESERPINE: 
^IDENCE FOR THE SELECTIVE RESPONSE OF NORADRENERGIC 
^URONS. 

237881 0203 
WIORAL EVIDENCE OF THE INTERACTION OF PHENCYCLIDINE WITH 
UECHOLAMINES IN PRIMATE SOCIAL COLONIES. 

238696 03-04 
OXONE ANTAGONISM OF CONDITIONAL REVERSAL OF NARCOTIC 
'ITHDRAWAL SIGNS AND CONDITIONAL MORPHINE HYPERTHERMIA: 
H INDIRECT EVIDENCE FOR RELEASE OF ENDOGENOUS OPIOID-LIKE 
JBSTANCE IN THE RAT. 

238713 03-04 
)ENCE FOR A BETA-ADRENERGIC RECEPTOR MEDIATED POSITIVE 
:EDBACK MECHANISM REGULATING RELEASE OF NOREPINEPHRINE. 

238727 03-03 
)ENCE FOR A DOPAMINE RECEPTOR ANTIBODY. 

238736 03-03 
NIOBARBITAL (PB) DISPOSITION IN MAN: PRESUMPTIVE EVIDENCE 
)R SEVERAL METABOLITES. 

238796 03-13 
ERATION IN THE ACTION OF CHOLINERGIC AND ANTICHOLINERGIC 
RUGS AFTER CHRONIC HALOPERIDOL: INDIRECT EVIDENCE FOR 
HOLINERGIC HYPOSENSITIVITY. 

239826 03-04 
'HETAMINE AND THE REWARD SYSTEM: EVIDENCE FOR TOLERANCE 
ND POST-DRUG DEPRESSION. 

239850 03-04 
3ENCE THAT DIPHENYLHYDANTOIN DOES NOT AFFECT ADENOSINE 
RIPHOSPHATASES FROM BRAIN. 

239962 03-03 
3ENCE FOR THE ROLE OF BRAIN BIOGENIC AMINES IN DEPRESSED 
\OTOR ACTIVITY SEEN IN CHEMICALLY THYROIDECTOMIZED RATS 

241203 03 03 
JICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO 
SYCHOTROPIC DRUGS. 

243819 04-13 
REASED INTRACRANIAL SELF-STIMULATION AFTER NEUROLEPTICS OR 
•HYDROXYDOPAMINE: EVIDENCE FOR MEDIATION BY MOTOR 
EFICITS RATHER THAN BY REDUCED REWARD. 

244676 04-04 
F-STIMULATION AND NORADRENALINE: EVIDENCE THAT INHIBITION 
iF SYNTHESIS ABOLISHES RESPONDING ONLY IF THE RESERVE POOL IS 
ilSPERSED FIRST. 

246774 04-03 
EFFECTS OF HARMALINE ON SODIUM TRANSPORT IN HUMAN 
RYTHROCYTES: EVIDENCE IN FAVOR OF ACTION AT INTERIOR 
ODIUM SENSITIVE SITES. 

246856 04-13 
CTROPHYSIOLOGICAL EVIDENCE FOR A NEUROHORMONAL 
lEPENDENCE IN THE CHANGES OF THE LATE GLABELLAR RESPONSE IN 
/\AN 

246992 04-13 
FLURAMINE: EVIDENCE FOR A NEUROTOXIC ACTION ON MIDBRAIN 
iND A LONG-TERM DEPLETION OF SEROTONIN. 

247214 04-05 
; EFFECT OF MEPIPRAZOLE ON CENTRAL MONOAMINE NEURONS. 
VIDENCE FOR INCREASED 5-HYDROXYTRYPTAMINE AND DOPAMINE 
lECEPTOR ACTIVITY. 

248288 04-03 
iTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 
'REFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
IIVENTER CERVICIS MUSCLE. 

248409 0403 
tTHER EVIDENCE FOR CHOLINERGIC HABENULO-INTERPEDUNCULAR 
lEURONS: PHARMACOLOGIC AND FUNCTIONAL CHARACTERISTICS. 

249074 04-03 
DENCE FOR ALPHA, BETA AND PHENYLETHYLAMINIC ADRENERGIC 
iECEPTORS IN ISOLATED FROG SCIATIC NERVE 

249257 04-03 
DENCE FOR 2-PHENYLETHYLAMINE (PEA) AS A MEDIATOR FOR THE 
:ENTRAL stimulant and ANTITREMORGENIC ACTIONS OF DELTA9- 
ETRAHYOROCANNABINOL (THC). 

249309 0403 



BEHAVIORAL EVIDENCE FOR THE RAPID RELEASE OF CNS SEROTONIN BY 
PCA AND FENFLURAMINE. 

250083 04-04 
EFFECT OF PROPRANOLOL ON ETHANOL METABOLISM - EVIDENCE FOR 
THE ROLE OF MITOCHONDRIAL NADH OXIDATION. 

251179 04-03 
EVIDENCE CONCERNING THE INVOLVEMENT OF 5 HYDROXYTRYPTAMINE 
IN THE LOCOMOTOR ACTIVITY PRODUCED BY AMPHETAMINE OR 
TRANYLCYPROMINE PLUS L-DOPA 

251704 04-04 
EFFECTS OF LILLY-HOMO, A SPECIFIC INHIBITOR OF 5- 

HYDROXYTRYPTAMINE UPTAKE, ON FOOD INTAKE AND ON 5- 
HYDROXYTRYPTOPHAN-INDUCED ANOREXIA. EVIDENCE FOR 
SEROTONINERGIC inhibition of FEEDING. 

252522 04-03 
PHARMACOLOGICAL EVIDENCE FOR THE CENTRAL SEROTONERGIC 
EFFECTS OF MONOMETHOXYAMPHETAMINES. 

253108 04-04 

EVOCATION 

EXPOSURE IN VIVO OF AGORAPHOBICS: CONTRIBUTIONS OF DIAZEPAM, 
GROUP EXPOSURE, AND ANXIETY EVOCATION. 

250727 04-10 
EVOKED 

THE EFFECT OF D,L-AMPHETAMINE ON THE REACTION OF CORTICAL 
NEURONS EVOKED BY STIMULATION OF MESODIENCEPHALIC 
STRUCTURES. 

228546 01-03 
INHIBITION OF CENTRALLY EVOKED PRESSOR RESPONSES BY DIAZEPAM: 
FVIDENCE FOR AN EXCLUSIVELY SUPRAMEDULLARY ACTION. 

231039 01-03 
COMPARISON OF DEFENSIVE BEHAVIOR EVOKED BY CHEMICAL AND 
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 

232483 01-04 
ARE HORMONES PSYCHOACTIVE'' EVOKED POTENTIAL INVESTIGATIONS 
IN AAAN. 

232532 0114 
THE EFFECT OF SMALL CONCENTRATIONS OF SODIUM PENTOBARBITAL 
ON AUDITORY EVOKED RESPONSES. 

234682 02-03 
THE EFFECT OF NEUROTROPIC AGENTS ON EVOKED POTENTIALS OF THE 
ASSOCIATIVE AND PROJECTION AREAS OF THE CAT NEOCORTEX. 

236261 02-03 
LOCAL ANESTHETICS AND BARBITURATES EFFECTS ON EVOKED 
POTENTIALS IN ISOLATED MAMMALIAN CORTEX 

237875 02-03 
REDUCED SPONTANEOUS LOCOMOTOR ACTIVITY EVOKED BY L- 
TRYPTOPHAN & PREVENTED BY D TRYPTOPHAN. 

238698 03-04 
THE TRANSCALLOSALLY EVOKED POTENTIAL (TEP) FOLLOWING 
ADMINISTRATION OF LSD, MESCALINE, DMT, APOMORPHINE AND 
METHOXAMINE IN THE DOG. 

238703 03-03 
PHARMACOLOGICAL SUPPRESSION OF PHOTICALLY EVOKED AFTER- 
DISCHARGES IN RATS: INCREMENTAL DOSE, HIPPOCAMPAL EEG AND 
BEHAVIORAL ACTIVITY CORRELATES 

239858 03-03 
EFFECTS OF DIPHENYLHYDANTOIN AND DIAZEPAM ON HIPPOCAMPAL 
EVOKED RESPONSES, 

239961 03-03 
THE EFFECT OF DIAZEPAM AND PICROTOXIN ON BRAINSTEM EVOKED 
DORSAL ROOT POTENTIALS. 

239982 03-03 
THE INVOLVEMENT OF METHYSERGID SENSITIVE RECEPTORS AND 
PROSTAGLANDINS IN THE HYPERTHERMIA EVOKED BY 5-HT IN THE 
CAT. 

241255 03-03 
INTRAVENOUS L-DOPA PLUS CARBIDOPA IN DEPRESSED PATIENTS: 

AVERAGE EVOKED RESPONSE, LEARNING, AND BEHAVIORAL CHANGES. 

244664 04-09 
EFFECTS OF DELTA9-TETRAHYDR0CANNABIN0L AND PENTOBARBITAL ON 
A CORTICAL RESPONSE EVOKED DURING CONDITIONING. 

244693 04-03 
PHARMACOLOGICAL APPROACHES TO THE FUNCTION OF CERTAIN 
NONSPECIFIC SUBCORTICAL STRUCTURES PARTICIPATING IN THE 
GENESIS OF THE VISUAL EVOKED POTENTIAL APPLICATIONS TO THE 
STUDY OF SEVERAL PSYCHOTROPICS 

244874 04-03 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
0-METHYLTRANSFERASE, AND FAMILY HISTORY 

246629 04-09 
INHIBITION AND ENHANCEMENT OF PHOTICALLY EVOKED RESPONSES BY 
DIFFERENT DOSES OF L-DOPA. 

251214 0403 



U9 



OB 



3b: 



EWE 



EFFECTS OF ESTROGEN AND ANDROGEN ON THE SEXUAL BEHAVIOUR OF 
THE OVARIECTOMIZED EWE 

248223 04-04 



S-135 



Subject Index 



Psychopharmacology Abstra< 



EX-1I-582A 

AN EARLY CLINICAL AND TOXICITY TRIAL GF EX-n-5a2A IN CHRONIC 
SCHIZOPHRENIA. 

247481 04-07 
EXAMINATION 

OXPRENOLOL IN THE TREATMENT OF EXAMINATION NERVES. 

251160 04-10 
EXAMPLE 

AN EXAMPLE OF EUROPEAN MULTICENTER TRIALS, MULTISPECTRAL 
ANALYSIS OF CLOZAPINE. 

253052 04-08 
EXCIPIENTS 

DRUG PERMEATION THROUGH MEMBRANES V- INTERACTION OF 
DIAZEPAM WITH COMMON EXCIPIENTS. 

238485 02-02 
EXCITABILITY 

CHANGES IN EXCITABILITY OF THE HIPPOCAMPUS AFTER STIMULATION 
OF SEROTONERGIC SYSTEMS IN RABBITS OF DIFFERENT AGES. 

231119 01-04 
EXCITABILITY OF THE HYPOTHALAMUS AND LIMBIC BRAIN STRUCTURES 
OF RABBITS UNDER THE EFFECT OF GLUCOCORTICOIDS AND ACTH. 

236716 02-03 
LACK OF A RELATION BETWEEN THE ANTIPSYCHOTIC AND THE 

EXCITABILITY DEPRESSANT PROPERTIES OF MAJOR TRANQUILIZERS. 

238710 03-03 
CHANGES IN EXCITABILITY OF AMYGDALOID AND SEPTAL NUCLEI 
INDUCED BY MEDAZEPAM HYDROCHLORIDE. 

241232 03-03 
EXCITATION 

THE EFFECT OF TRIFLUOPERAZINE ON THE TRANSMISSION OF 
EXCITATION IN THE RABBIT BRAIN DURING PROLONGED 
ADMINISTRATION OF THE PREPARATION 

231070 01-03 
DIPHENYLHYDANTOIN INHIBITS IONIC EXCITATION OF MOUSE 
NEUROBLASTOMA CELLS. 

23291 7 02-03 
THYROTROPIN-RELEASING HORMONE TRH-INDUCED HYPERTHERMIA AND 
BEHAVIORAL EXCITATION IN RABBITS. 

236524 02-04 
EXCITATION MEDIATING AND INHIBITION MEDIATING DOPAMINE 

RECEPTORS: A NEW CONCEPT TOWARDS A BETTER UNDERSTANDING 
OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL, 
FUNCTIONAL AND CLINICAL DATA 

237104 02-03 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY. 

237458 02-10 
ALPHA BUNGAROTOXIN, COBRA NEUROTOXIN AND EXCITATION OF 
RENSHAW CELLS BY ACETYLCHOLINE. 

244203 04-03 
NEUROCHEMICAL CORRELATES OF BEHAVIOR: LEVELS OF AMINO-ACIDS 
IN FOUR AREAS OF THE BRAIN OF THE RAT DURING DRUG-INDUCED 
BEHAVIORAL EXCITATION. 

250067 04-04 
EXCITATORY 

INHIBITORY AND EXCITATORY EFFECTS OF CNS DEPRESSANTS ON 
INVERTEBRATE SYNAPSES. 

226398 01-03 
5 METHOXY N,N:DIMETHYLTRYPTAMINE (5-MEO-DMT) SHARES 

INHIBITORY EFFECTS WITH MESCALINE BUT NOT EXCITATORY EFFECTS 
ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS. (UNPUBLISHED PAPER). 

227802 01-04 
EXCITATORY EFFECTS OF 5-HYDROXYTRYPTAMINE, HISTAMINE AND 
POTASSIUM IONS ON MUSCULAR GROUP IV AFFERENT UNITS: A 
COMPARISON WITH BRADYKININ. 

241798 03-03 
EXCITEMENT 

THE PLACEBO EFFECT IN PSYCHOPHARMACOTHERAPY IN 

CONSIDERATION OF THE EFFECT OF MEPIPRAZOL ON EXCITEMENT IN 
PSYCHOTICS. 

234217 02-08 
EXCRETION 

BIOTRANSFORMATION AND BILIARY EXCRETION OF IMIPRAMINE IN 
RATS UNDER VARIOUS EXPERIMENTAL CONDITIONS 

226928 01-03 
EFFECT OF VILOXAZINE (VIVALAN) ON THE URINARY EXCRETION OF 
CATECHOLAMINES AND THEIR METABOLITES. 

227212 01-07 
CHLORPROMAZINE EXCRETION: ISOTOPE VERSUS CHEMICAL ASSAY. 

229481 01-03 
COMPARISON OF SERUM LEVELS AND URINARY EXCRETION OF THREE 
MAJOR ANTICONVULSANTS BETWEEN CHILDREN AND ADULTS. 

233832 02-13 
PHARMACOKINETIC STUDIES IN ABSORPTION AND EXCRETION OF 
OXAZEPAM IN COMBINATION WITH ALCOHOL. 

237123 02-13 



THE EFFECTS OF ASCORBIC-ACID (AA) PRETREATMENT ON 
AMPHETAMINE (A) EXCRETION IN MAN. 

238797 03 
URINARY EXCRETION OF METABOLITES OF CHLORPROMAZINE: CLINICf 
CHEMICAL CORRELATIONS 

244050 04 
RENAL LITHIUM, SODIUM, POTASSIUM, AND WATER EXCRETION AND 
PLASMA RENIN ACTIVITY IN RATS IN THE COLD. 

246673 04 
ABSORPTION, DISTRIBUTION AND EXCRETION OF TRIFLUOPERAZINE IN 
RATS. 

249036 04 
THE EFFECT OF LITHIUM ON UNSTIMULATED AND GLUCAGON 

STIMULATED URINARY CYCLIC AMP EXCRETION IN RAT AND MAN. 

251129 0-! 
THE RELATIONSHIP BETWEEN ACETYLATOR STATUS AND INHIBITION C 
MONOAMINE-OXIDASE, EXCRETION OF FREE DRUG AND 
ANTIDEPRESSANT RESPONSE IN DEPRESSED PATIENTS ON PHENELZI 

251985 0^ 
ABSORPTION AND EXCRETION OF A NEW ANTIDEPRESSIVE {SQ-10996) 
HUAAANS. 

253323 0^ 
EXERTION 

METHYLPHENIDATE IN CHILDREN: EFFECTS UPON CARDIORESPIRATOR' 
FUNCTION ON EXERTION. 

247378 0^ 
EXOCYTOTIC 

INHIBITION BY HALOTHANE OF EXOCYTOTIC RELEASE OF 

NOREPINEPHRINE FROM GUINEA-PIG VAS-DEFERENS. (UNPUBLISHED 
PAPER). 

227777 01 
EXOGENOUS 

THE CAPACITY OF ADRENERGIC NERVES TO ACCUMULATE EXOGENOU: 
NOREPINEPHRINE UNDER THE INFLUENCE OF SOME 
PHARMACOLOGICAL AGENTS. 

228551 01 
THE ACTION OF CHLORPROMAZINE, TRIFLUOPERAZINE AND OROPERIC 
ON THE CAPTURE AND ACCUMULATION OF EXOGENOUS 
NOREPINEPHRINE. 

236713 0; 
EXPERIENCE 

CLINICAL EXPERIENCE IN USING SULPIRIDE FOR INTERNAL 
PSYCHOSOMATIC ILLNESS. 

227806 01 
CLINICAL EXPERIENCE IN USING SULPIRIDE (FK-880) FOR DEPRESSION 

228334 01 
CLINICAL EXPERIENCE IN USING CLOXAZOLAM (SEPAZON). 

229025 01 
CLINICAL EXPERIENCE IN USING MENDON (DIPOTASSIUM CLORAZEPA' 

229626 01 
CLINICAL EXPERIENCE IN USING AAAPROTILINE, A NEW ANTIDEPRESSI\ 
MEDICINE. 

229760 01 
EFFECTS OF DRUG EXPERIENCE ON DRUG-INDUCED CONDITIONED TAS 
AVERSIONS: STUDIES WITH AMPHETAMINE AND FENFLURAMINE. 

230829 01 
EFFECTS OF PRIOR EXPERIENCE ON DIFFERENTIAL LEARNING UNDER 
AMPHETAMINE. 

230868 01 
CLINICAL EXPERIENCE WITH CLOZAPINE. 

234419 0; 
EFFECTS OF TESTING AGE AND FOSTERING EXPERIENCE ON SEIZURE 
SUSCEPTIBILITY OF RATS TREATED PRENATALLY WITH 
CHLORPROMAZINE. 

234739 O; 
PRELIMINARY EXPERIENCE WITH PARENTERAL SINTAMIL IN TREATMEI 
OF DEPRESSION. 

235348 O; 
FIVE YEARS EXPERIENCE IN OUTPATIENT PSYCHIATRIC PRACTICE WITI 
NEW TRANQUILIZER, LEXOTANIL (RO-5-3350). 

239748 O; 
CLINICAL EXPERIENCE WITH RO-5-3350 (BROMAZEPAM). 

245138 0' 
THE SUPPRESSION OF BEHAVIOUR IN RATS BY PREVIOUS EXPERIENCE 
AND ELECTRIC SHOCK AND ITS ANTAGONISM BY ATROPINE. 

245305 0' 
RECENT CLINICAL EXPERIENCE WITH TREATMENT OF DEPRESSION WIT 
GER0VITAL-H3 TABLETS. 

246425 0' 
CLINICAL EXPERIENCE WITH BETA-BLOCKERS IN CONSULTANT 
PSYCHIATRIC PRACTICE. 

251165 0' 
EXPERIENCED 

MARIJUANA PRODUCED CHANGES IN PAIN TOLERANCE. EXPERIENCED 
AND NONEXPERIENCED SUBJECTS. 

226903 01 



S-136 



HUME 14, SUBJECT INDEX 



Subject Index 



•ERIENCES 

COUNSELING PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH: AN EMPIRICAL STUDY OF THE EFFICACY OF DPTASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH.D. 
DISSERTATION). 

228686 01-11 
CLINICAL EXPERIENCES WITH ANTIDEPRESSANT DRUGS IN THE 
TREATMENT OF ANXIOUS PHOBIC PATIENTS. 

230015 01-10 
CLINICAL EXPERIENCES WITH THE BENZODIAZEPINE DERIVATIVE 
BROMAZEPAM IN CONNECTION WITH AN ACUTE STATES OF 
RESTLESSNESS AND EXCITATION IN PSYCHIATRY 

237458 02-10 
EXPERIENCES WITH A DEPOT NEUROLEPTIC (DAPOTUM-D). 

242503 03-08 
CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, ICI-58834. 

244189 04-07 
l>ERIMENTAL 
BIOTRANSFORAAATION AND BILIARY EXCRETION OF IMIPRAMINE IN 
RATS UNDER VARIOUS EXPERIMENTAL CONDITIONS. 

226928 01-03 
AN EXPERIMENTAL THERAPY AND RE-EDUCATION PROGRAM FOR 
ALCOHOLICS INCLUDING CHEMOTHERAPY WITH PROPRANOLOL 
HYDROCHLORIDE. (PH.D. DISSERTATION). 

228750 01-11 
THE CLINICAL APPLICATION OF LABORATORY ANIMAL EXPERIMENTAL 
FINDINGS: TREATMENT OF HYPERSEXUALIZED BEHAVIOR IN A MALE. 

229037 01-11 
APPEARANCE OF WET DOG SHAKE BEHAVIOR DURING COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT AND ITS SUPPRESSION BY 
RESERPINE. 

230836 01-04 
EXPERIMENTAL STUDIES ON THE EFFECT OF SOME PSYCHOTROPIC 
DRUGS AND PYRAZOLE ON THE RATE OF ETHANOL OXIDATION IN 
VIVO AND IN THE PERFUNDATED RAT LIVER IN VITRO. 

234522 02-03 
AN EXPERIMENTAL STUDY OF THE SPECTRUM OF INDIVIDUAL 
PSYCHOTROPIC ACTIVITY OF CLOZAPINE (LEPONEX). 

236174 02-04 
PROFILE OF TRH IN EXPERIMENTAL PSYCHOPHARMACOLOGY. 

237708 02-04 
NEUROHUMORAL MECHANISMS RELATING TO CIRCADIAN SLEEP- 
WAKEFULNESS CYCLES OF HUMORAL EXPERIMENTAL ANIMALS. 

238971 03-03 
EXPERIMENTAL HUMAN DRUG SELF-ADMINISTRATION: METHODOLOGY 
AND APPLICATION TO THE STUDY OF SEDATIVE ABUSE. 

240831 03-14 
IDENTIFICATION AND QUANTIFICATION OF CHLORPROMAZINE AND ITS 
METABOLITES IN ACUTE EXPERIMENTAL INTOXICATION. 

244462 04-06 
LOGICAL ANALYSIS OF THE RESPECTIVE INFLUENCE OF THREE 
EXPERIMENTAL VARIABLES BY MEANS OF A DIAGRAM OF L. CARROLL. 
APPLICATION OF THIS METHOD TO A CLINICAL TRIAL OF TWO FORMS 
OF NOVERIL. 

245971 04-06 
INFLUENCE OF DESMETHYLIMIPRAMINE ON SOME NEUROCHEMICAL 
ALTERATIONS DURING EXPERIMENTAL HYPOTHYROIDISM. 

246152 04-03 
ETHANOL NARCOSIS IN MICE: EFFECTS OF L-DOPA, ITS METABOLITES 
AND OTHER EXPERIMENTAL VARIABLES. 

246821 04-05 
TREATMENT OF EXPERIMENTAL IMIPRAMINE AND DESIPRAMINE 
POISONING IN THE RAT. 

251419 04-03 
(PERIMENTAllY-INDUCED 

RELATIONSHIP BETWEEN OBJECTIVE AND SUBJECTIVE ASSESSMENT OF 
EXPERIMENTALLY-INDUCED FATIGUE, 

253587 04-12 
(PERIMENTATION 

DISCOURSE ON THE DOUBLE-BLIND METHOD INSTITUTION AND 
EXPERIMENTATION: 19366-RP. 

229078 01-16 
CLINICAL EXPERIMENTATION OF THE LONG-ACTING NEUROLEPTICS: 
METHODOLOGICAL PROBLEMS. 

229554 01-16 
FLUPHENAZINE: DIFFICULTIES AND LIMITATIONS IN ANIMAL 
EXPERIMENTATION WITH NEUROLEPTIC SUBSTANCES. 

247151 04-04 
KPERIMENTS 

CLINICAL THERAPEUTIC EXPERIMENTS ON PSYCHOTIC PATIENTS WITH 
LONG-ACTING FLUPHENAZINE. 

229550 01-11 
CLINICAL EXPERIMENTS WITH FLUPHENAZINE-DECANOATE IN 

HOSPITALIZED PATIENTS 

229551 0111 
CLINICAL THERAPEUTIC EXPERIMENTS WITH FLUPHENAZINE-DECANOATE 

IN TREATING DISSOCIATIVE SYNDROMES. 

229560 01-1 1 



DRUG INTERACTIONS: THE EFFECTS OF ALCOHOL AND MEPROBAMATE 
APPLIED SINGLY AND JOINTLY IN HUMAN SUBJECTS. II. FIVE 
EXPERIMENTS. 

232518 0114 
CHANCES OF DETECTING AND DIFFERENTIATION CENTRAL NERVOUS 
EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS WITH SPECIAL 
CONSIDERATION OF BEHAVIORAL PHARMACOLOGICAL METHODS. 

233681 02-06 
SERUM LITHIUM CURVE AND CLINICAL PSYCHOMETRIC VARIABLES: 
PRELIMINARY EXPERIMENTS. 

244591 04-13 
EXPLAINING 

A METHOD FOR EXPLAINING DYSKINETIC MOVEMENTS - A FILM 
PRESENTATION. 

253034 04-15 
EXPLANTS 

BIOELECTRIC EFFECTS OF ISOPROTERENOL AND PROPRANOLOL ON NERVE 
CELLS IN EXPLANTS OF RAT CEREBELLUM. 

237880 02-03 
INHIBITORY ACTION OF NORADRENALINE AND CYCLIC-AMP IN EXPLANTS 
OF RAT CEREBELLUM. 

239836 03-03 
DIAZEPAM AND CHLORDIAZEPOXIDE: POWERFUL GABA ANTAGONISTS IN 
EXPLANTS OF RAT CEREBELLUM. 

244205 04-03 
EXPLORATION 

EXPLORATION OF THE ANTIDEPRESSANT POTENTIAL OF IPRINDOLE. 

241241 03-04 
ARE CENTRAL CHOLINERGIC PATHWAYS INVOLVED IN THE HABITUATION 
OF EXPLORATION AND DISTRACTION? 

241932 03-04 

EXPLORATORY 

EFFECTS OF SCOPOLAMINE ON HABITUATION OF EXPLORATORY 
ACTIVITY IN RATS. 

235509 02-04 

EXPLOSIVELY 

AN INVESTIGATION OF THE SELECTION PROCESS AND DRUG TREATMENT 
OF EXPLOSIVELY AGGRESSIVE ADOLESCENT FEMALES. (PH.D. 
DISSERTATION). 

228726 01-11 
EXPOSED 

MODIFICATION OF THE BEHAVIORAL RESPONSE TO DRUGS IN RATS 
EXPOSED PRENATALLY TO CHLORPROMAZINE. 

230864 01-04 
CEREBRAL AND CEREBELLAR NEUROCHEMICAL CHANGES AND 

BEHAVIORAL MANIFESTATIONS IN RATS CHRONICALLY EXPOSED TO 
MARIJUANA SMOKE. 

243181 04-04 
EXPOSURE 

BEHAVIORAL CHANGES IN 2-MONTH-OLD RATS FOLLOWING PRENATAL 
EXPOSURE TO ANTIBODIES AGAINST SYNAPTIC MEMBRANES. 

226186 01 04 
THE EFFECTS OF LOW-LEVEL DIELDRIN EXPOSURE ON THE EEG AND 
LEARNING ABILITY OF THE SQUIRREL-MONKEY. 

227385 01-04 
ASSOCIATION BETWEEN CLEFT LIP WITH OR WITHOUT CLEFT PALATE 
AND PRENATAL EXPOSURE TO DIAZEPAM. 

229349 01-17 
RESPONSE OF NIGRAL DOPAMINE NEURONS TO ACUTE AND PROLONGED 
MORPHINE TREATMENT: EFFECT OF EXPOSURE TO COLD, 
PHYSOSTIGMINE AND NICOTINE. 

237158 02-03 
THE INTERACTIVE EFFECTS OF PRENATAL IMIPRAMINE EXPOSURE AND 
POSTNATAL REARING CONDITIONS ON BEHAVIOUR AND HISTOLOGY. 

237721 02-05 
PROTECTION AGAINST STRESS-INDUCED DEPLETION OF BRAIN 
NOREPINEPHRINE AFTER PRIOR EXPOSURE TO CHRONIC STRESSES. 

238718 03-04 
EFFECTS ON OFFSPRING OF CHRONIC MATERNAL METHAMPHETAMINE 
EXPOSURE. 

245405 04-05 
EXPOSURE IN VIVO OF AGORAPHOBICS: CONTRIBUTIONS OF DIAZEPAM, 
GROUP EXPOSURE, AND ANXIETY EVOCATION. 

250727 04-10 
EXPRESSION 

THE EFFECTS OF LSD ON THE EXPRESSION OF AFFECT IN 
PSYCHOTHERAPY (PH.D. DISSERTATION). 

231480 01-12 
EXTENSION 

RATE-DEPENDENT EFFECT OF AMPHETAMINE IN RATS: EXTENSION TO 
BETWEEN SUBJECTS EFFECT. 

251988 04-04 
EXTINCTION 

THE EFFECTS OF NEONATAL 6-HYDROXYDOPAMINE-INDUCED 
SYMPATHECTOMY ON RESPONSE INHIBITION IN EXTINCTION. 

226871 01-03 
PIMOZIDE-INDUCED EXTINCTION OF INTRACRANIAL SELF-STIMULATION: 
RESPONSE PATTERNS RULE OUT MOTOR OR PERFORMANCE DEFICITS. 

249749 04-03 






ISO, 



S-137 



M^ssm 



Subject Index 



Psychopharmacology Abstrac 



EXTINCTION RESPONDING FOLLOWING AMPHETAMINE SELF- 
ADMINISTRATION: DETERMINATION OF REINFORCEMENT MAGNITUD 

250010 04-04 
HORMONAL INFLUENCES ON THE EXTINCTION OF CONDITIONED TASTE 
AVERSION 

251980 04-04 
EXTINCTION-INDUCED 

EXTINCTION-INDUCED MIRROR RESPONDING AS A BASELINE FOR 
STUDYING DRUG EFFECTS ON AGGRESSION. 

250073 04-06 
EXTRACEUUIAR 

CEREBRAL ARTERIAL SPASM PART 4: IN VITRO EFFECTS OF 

TEMPERATURE, SEROTONIN ANALOGUES, LARGE NONPHYSIOLOGICAL 
CONCENTRATIONS OF SEROTONIN, AND EXTRACELLULAR CALCIUM 
AND MAGNESIUM ON SEROTONIN-INDUCED CONTRACTIONS OF THE 
CANINE BASILAR ARTERY. 

243797 04-03 
DIPSOGENIC EFFECTS OF INTRACELLULAR AND EXTRACELLULAR THIRST 
STIMULI BEFORE AND AFTER CHRONIC DFP TREATMENT. 

247209 04-04 
EXTRACT 

N-HYDROXYAMPHETAMINE A MAJOR METABOIITE OF AMPHETAMINE IN 
RABBIT LIVER EXTRACT 

238682 03-03 
EFFECT OF CANNABIS EXTRACT ON THE UTERINE MONOAMINE-OXIDASE 
ACTIVITY OF NORMAL AND ESTRADIOL TREATED RATS. 

241343 03-03 
EXTRACTION 

SCHIZOPHRENIA: RELATIONSHIPS TO DOPAMINE TRANSMISSION, MOTOR 
CONTROL, AND FEATURE EXTRACTION. 

238464 02-08 
EXTRACTS 

IDENTIFICATION AND DISTRIBUTION OF BENZYLAMINE IN TISSUE 
EXTRACTS ISOLATED FROM RATS PRETREATED WITH PARGYLINE. 

250379 04-03 
EXTRAJUNCTIONAl 

FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCLE. 

248409 04-03 
EXTRANEURONAL 

EXTRANEURONAL UPTAKE AND METABOLISM OF (3H)L-N0REPmEPHRINE 
BY THE RAT DUODENAt MUCOSA. 

24)299 03-03 
EXTRAPINEAl 

EXTRAPINEAL AMINE N-ACETYLATION IN RAT BRAIN: REGIONAL AND 
SUBCELLULAR DISTRIBUTION AND ENZYME KINETICS. 

250377 04-01 
EXTRAPYRAMIDAL 

ON THE DIFFERENTIAL DIAGNOSIS OF ACUTE EXTRAPYRAMIDAL MOTOR 
DISTURBANCES IN CHILDHOOD: CASUISTIC ACCOUNT. 

234291 02-11 
ALTERATIONS OF THE EEG OF EXTRAPYRAMIDAL NUCLEI FOLLOWING 6 
HYOROXYDOPAMINE LESIONS. 

238735 03-03 
2-PHENYLETHYLAMINE (PEA) IN D-AMPHETAMINE-INDUCED 
EXTRAPYRAMIDAL DISORDERS 

238841 03-03 
EXTRAPYRAMIDAL SYMPTOMS UNDER CLOZAPINE: A CASUISTIC 
CONTRIBUTION. 

238855 03-15 
EXTRAPYRAMIDAL SYMPTOMS IN A COMBINATION OF LITHIUM LONG- 
TERM THERAPY WITH NORTRIPTYLINE: A CAUSISTIC REPORT ON 
PATHOGENESIS AND HYPOTHESIS FORMULATION. 

239835 03-15 
THE RELEVANCE TO DIFFERENTIAL DIAGNOSIS OF THE DISTRIBUTION OF 
EXTRAPYRAMIDAL SYMPTOMS RESULTING FROM NEUROLEPTIC 
THERAPY IN PSYCHIATRIC PRACTICE. 

244355 04-15 
A CONTROILED TRIAL OF AMANTADINE IN DRUG-INDUCED 
EXTRAPYRAMIDAl DISORDERS. 

244701 04-15 
DELAYED SEVERE EXTRAPYRAMIDAL DISTURBANCE FOLLOWING 
FREQUENT DEPOT PHENOTHIAZINE ADMINISTRATION 

245789 04-15 
DRUG-INDUCED EXTRAPYRAMIDAL EFFECTS A REVIEW 

246187 04-15 
ANTICHOLINERGIC ACTIVITY OF ANTIPSYCHOTIC DRUGS IN RELATION TO 
THEIR EXTRAPYRAMIDAL EFFECTS, 

252520 04-05 
EXTRINSIC 

FURTHER EVIDENCE THAT EXTRINSIC ACETYLCHOLINE ACTS 

PREFERENTIALLY ON EXTRAJUNCTIONAL RECEPTORS IN THE CHICK 
BIVENTER CERVICIS MUSCIE 

248409 04-03 



I 



EYES 



F-l 



SMOOTH PURSUIT EYE MOVEMENTS, AND DIAZEPAM, CPZ, AND 
SECOBARBITAL. 

246303 04-14 
INHIBITION OF SLOW WAVE SLEEP AND RAPID EYE MOVEMENT SLEEP BY 
THYROTROPIN-RELEASING HORMONE IN CATS. 

249281 04-02' 
EYE COLOR AND TARDIVE-DYSKINESIA. 

253037 04-15 

ACCUMULATION OF LABELED EPHEDRINE, NOREPHEDRINE, 

AMPHETAMINE AND TYRAMINE IN PIGMENTED AND NONPIGMENTED 
EYES OF BLACK AND WHITE RATS. 

230450 01-03 



EYE 



DEPOSITS IN THE LENS AND CORNEA OF THE EYE DURING LONG-TERM 
CHLORPROMAZINE MEDICATION 

240048 03-15 



EFFECTS OF D-AMPHETAMINE ON F-l SHOCK PRESENTATION WITH 
SDELTA PROBE. 

237699 02-04 
FACIAL 

CLONAZEPAM IN FACIAL NEURALGIA AND CLUSTER HEADACHE: 
CLINICAL AND ELECTROPHYSIOLOGICAL STUDY. 

246995 04-11 
FACILITATED 

LITHIUM DIFFERENTIALLY ANTAGONISES SELF-STIAAULATION 
FACILITATED BY MORPHINE AND ( f ) AMPHETAMINE. 

249486 04 03 
FACILITATING 

REVERSAL OF THE 6-HYDROXYDOPAMINE-INDUCED SUPPRESSION OF A 
CAR BY DRUGS FACILITATING CENTRAL CATECHOLAMINERGIC 
MECHANISMS. 

246818 04-04 
FACILITATION 

FACILITATION AND DISRUPTION BY MESCALINE OF SHUTTLEBOX 
AVOIDANCE IN RATS. (PH.D. DISSERTATION). 

226991 01)2 
DOES INCREASING STRESS CHANGE THE BEHAVIORAL ACTION OF 
MESCALINE FROM DISRUPTION TO FACILITATION?. 

237732 02-04 
AMFONELIC-ACID FACILITATION OF IMPULSE-INDUCED STRIATAL 
DOPAMINE RELEASE. 

238730 03-03 
PIRACETAM-INDUCED FACILITATION OF INTERHEMISPHERIC TRANSFER 
OF VISUAL INFORMATION IN RATS. 

239861 03-04 
DIPHENYLHYDANTOIN FACILITATION OF LABILE, PROTEIN INDEPENDENT 
MEMORY, 

253290 04-04 
FACT 

FACT AND FICTION OF MENOPAUSE. 

249975 04-17 
FAILS 

6-HYDROXYDOPAMINE (6-OHDA) ADMINISTRATION TO NEONATAL RATS 
FAILS TO AFFECT THE DEVELOPMENT OF TYROSINE-HYDROXYLASE 
(TH), CHOLINE ACETYLTRANSFERASE (CAT) AND GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) IN THE CNS. 

238826 03-03 
FAILURE 

FAILURE OF DEPLETION OF RAT BRAIN 5-HYDROXYTRYPTAMINE TO 
ALTER FENFLURAMINE-INDUCED ANOREXIA. 

237748 0203 
ON THE ROLE OF ENDOGENOUS OPIOID PEPTIDES: FAILURE OF NALOXONE 
TO INFLUENCE SHOCK ESCAPE THRESHOLD IN THE RAT 

241244 03-04 
UNWANTED CORTICOSTEROID EFFECTS IN CHILDHOOD BONE MARROW 
FAILURE, RENAL FAILURE AND BRAIN DAMAGE: CASE REPORT. 

245856 04-13 
FAILURE OF INCREASED BRAIN GAMMA-AMINOBUTYRIC-ACID LEVELS TO 
INFLUENCE AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR. 

247730 04-03 
CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 
ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
FAILURE OF PHENOBARBITONE TO PREVENT FEBRILE CONVULSIONS. 

251103 04-11 
FAILURES 

LITHIUM IN TREATMENT FAILURES 

230562 01-11 
MENTAL-HEALTH PROGRAMS: PROMISES?. FULFILLMENT?. FAILURES';'. 

236911 02-15 
FAMIUAL 

THE SOCIAL FAMILIAL REINSERTION OF THE PSYCHOTIC PATIENT 
THROUGH THE USE OF LONG-ACTING NEUROLEPTICS. 

229552 01-17 
FAMILY 

COUNSELING, PEAK EXPERIENCES AND THE HUMAN ENCOUNTER WITH 
DEATH: AN EMPIRICAL STUDY OF THE EFFICACY OF DPT-ASSISTED 
COUNSELING IN ENHANCING THE QUALITY OF LIFE OF PERSONS WITH 
TERMINAL CANCER AND THEIR CLOSEST FAMILY MEMBERS. (PH D 
DISSERTATION). 

228686 0111 



S-138 



HUME 14, SUBJECT INDEX 

lEVOAMPHETAMINE VS DEXTROAMPHETAMINE IN MINIMAL-BRAIN- 
DYSFUNCTION: REPLICATION, TIME RESPONSE, AND DIFFERENTIAL 
EFFECT BY DIAGNOSTIC GROUP AND FAMILY RATING. 

239932 03-11 
TRIAZOLAM IN INSOMNIAC FAMILY PRACTICE PATIENTS. 

245649 04-11 
LITHIUM CARBONATE RESPONSE IN DEPRESSION: PREDICTION BY 

UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL- 
0-METHYLTRANSFERASE. AND FAMILY HISTORY. 

246629 04-09 
COMPLICATIONS OF PSYCHOACTIVE DRUGS AS SEEN BY FAMILY 
PRACTITIONERS. 

248851 04-15 
RM 
RELAY TOXICITY: A NEW APPROACH TO A METHODOLOGY OF 

EVALUATING THE TOXICITY OF ADDITIVES TO FARM ANIMAL FEED. 

245114 04-06 
ST 
MONOAMINES AS POSSIBLE MEDIATORS IN THE REGULATION OF FAST 
AXOPLASMIC FLOW. 

253407 04-03 
TAl 
FATAL PARALYTIC ILEUS COMPLICATING PHENOTHIAZINE THERAPY. 

235286 02-15 
TAUTIES 

PHENCYCLIDINE - STATES OF ACUTE INTOXICATION AND FATALITIES. 

247147 04-15 
TE 
METABOLIC FATE OF FLURAZEPAM II: A NEW POTENT METABOLITE 

OBTAINED BY IN VITRO LIVER DRUG METABOLIZING ENZYME SYSTEM. 

246971 04-03 
TIGUE 

RELATIONSHIP BETWEEN OBJECTIVE AND SUBJECTIVE ASSESSMENT OF 
EXPERIMENTALLY-INDUCED FATIGUE. 

253587 04-12 
,TTY-ACIDS 

THE ROLE OF ADRENAL CATECHOLAMINES IN THE RELEASE OF 
CORTICOSTERONE AND FATTY-ACIDS BY NICOTINE IN THE RAT. 

247731 04-03 
iVOR 

THE EFFECTS OF HARMALINE ON SODIUM TRANSPORT IN HUMAN 
ERYTHROCYTES: EVIDENCE IN FAVOR OF ACTION AT INTERIOR 
SODIUM SENSITIVE SITES. 

246856 04-13 
AR 

EFFECTS OF CHLORPROMAZINE ON FEAR MOTIVATED BEHAVIOR, 
URINARY CORTISOL, URINARY VOLUME, AND HEARTRATE IN THE 
DOG. 

240916 03-04 

ATURE 

SCHIZOPHRENIA: RELATIONSHIPS TO DOPAMINE TRANSMISSION, MOTOR 
CONTROL, AND FEATURE EXTRACTION. 

238464 02-08 
IBRILE 

FAILURE OF PHENOBARBITONE TO PREVENT FEBRILE CONVULSIONS. 

251103 04-11 

;eo 

relay toxicity: a new approach to a methodology of 
evaluating the toxicity of additives to farm animal feed, 

245114 04-06 
:EOBACK 

EVIDENCE FOR A BETA-ADRENERGIC RECEPTOR MEDIATED POSITIVE 
FEEDBACK MECHANISM REGULATING RELEASE OF NOREPINEPHRINE. 

238727 03-03 
A QUANTITATIVE COMPARISON OF RELATIONSHIPS BETWEEN PLASMA 
TESTOSTERONE (T) AND TWO CENTRAL FUNCTIONS: LH FEEDBACK 
AND SEX BEHAVIOR 

238800 03-04 
ANALYSIS OF THE DISCREPANCY IN MAN-MACHINE TRACKING SYSTEMS 
UNDER CONDITIONS OF DELAYED FEEDBACK. 

242702 03-14 
D AMPHETAMINE-INDUCED INHIBITION OF CENTRAL DOPAMINERGIC 
NEURONS MEDIATION BY A STRIATO-NIGRAL FEEDBACK PATHWAY. 

243882 04-03 
INFLUENCE OF CHLORPROMAZINE ON THE POSITIVE AND NEGATIVE 
FEEDBACK MECHANISM OF ESTROGENS IN MAN. 

248224 04 13 
EEDING 

GLUCOREGULATORY FEEDING BY RATS AFTER INTRAVENTRICULAR 6 
HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS. 

227125 01-04 
THE EFFECTS OF SEROTONIN ON FEEDING IN THE RABBIT. 

230872 01-04 
PHENYLPROPANOLAMINE INHIBITS FEEDING, BUT NOT DRINKING, 
INDUCED BY HYPOTHALAMIC STIMULATION. 

231700 01 03 
EFFECT OF VENTROMEDIAL HYPOTHALAMIC PROCAINE INJECTIONS ON 
FEEDING, LEVER PRESSING, AND OTHER BEHAVIOR IN RATS 

231707 01-04 



Subject Index 

DISRUPTION OF BRAIN STIMULATION INDUCED FEEDING BY DOPAMINE 
RECEPTOR BLOCKADE. 

235587 0204 

MARIJUANA-INDUCED ALTERATIONS IN FEEDING BEHAVIOR AND 
HYPOTHALAMIC CONCENTRATIONS OF NOREPINEPHRINE AND 
SEROTONIN IN THE RAT, 

238720 03-04 

HYPOTHALAMIC NORADRENALINE TURNOVER IS INCREASED DURING 
GLUCOPRIVIC FEEDING. 

238804 03-04 

VENTROMEDIAL HYPOTHALAMUS AND SHORT-TERM FEEDING 
SUPPRESSION BY CAERULEIN IN MALE RATS. 

244311 04-04 
PATTERN OF DRINKING AND FEEDING PRODUCED BY HYPOTHALAMIC 
NOREPINEPHRINE INJECTION IN THE SATIATED RAT. 

245929 04-02 
BEHAVIOURAL CHANGES IN LABORATORY MICE DURING CANNABIS 
FEEDING AND WITHDRAWAL. 

246310 04-04 

CHRONIC ETHANOL FEEDING AND BRAIN ADENYLCYCLASE AND 
PHOSPHODIESTERASE LEVELS IN MICE. 

249294 04-03 
CYCLIC-AMP AND CENTRAL NORADRENALINE RECEPTORS: FAILURE TO 
ACTIVATE DIENCEPHALIC ADRENERGIC FEEDING PATHWAYS. 

250075 04-04 
EFFECTS OF LILLY-1 10140, A SPECIFIC INHIBITOR OF 5 

HYDROXYTRYPTAMINE UPTAKE, ON FOOD INTAKE AND ON 5- 
HYDROXYTRYPTOPHAN INDUCED ANOREXIA, EVIDENCE FOR 
SEROTONINERGIC INHIBITION OF FEEDING, 

252522 04-03 

FELINE 

EFFECTS OF ANTIHISTAMINIC DRUGS ON FELINE BRAIN MONO